<SEC-DOCUMENT>0001628280-26-031661.txt : 20260507
<SEC-HEADER>0001628280-26-031661.hdr.sgml : 20260507
<ACCEPTANCE-DATETIME>20260507065417
ACCESSION NUMBER:		0001628280-26-031661
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		65
CONFORMED PERIOD OF REPORT:	20260331
FILED AS OF DATE:		20260507
DATE AS OF CHANGE:		20260507

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Shattuck Labs, Inc.
		CENTRAL INDEX KEY:			0001680367
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				812575858
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39593
		FILM NUMBER:		26950732

	BUSINESS ADDRESS:	
		STREET 1:		500 W. 5TH STREET
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78701
		BUSINESS PHONE:		512-900-4690

	MAIL ADDRESS:	
		STREET 1:		500 W. 5TH STREET
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78701
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>sttk-20260331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019ce397-05b9-74d0-8227-66267d5910e2,g:518bbadf-25d7-41ee-8c01-9003cd0ed70a,d:2d8e618db7b2478ba6efdb70e68630b1-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:sttk="http://www.shattucklabs.com/20260331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sttk-20260331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-26">0001680367</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-27">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-28">2026</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-29">Q1</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-30">December 31</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="f-79">http://fasb.org/us-gaap/2025#LicenseMember</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="f-80">http://fasb.org/us-gaap/2025#LicenseMember</ix:nonNumeric><ix:nonNumeric contextRef="c-105" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-479">513</ix:nonNumeric><ix:nonNumeric contextRef="c-107" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-480">361</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sttk-20260331.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="vote"><xbrli:measure>sttk:vote</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>sttk:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sttk:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sttk:CommonStockWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sttk:CommonStockWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sttk:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">sttk:OperatingAccountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">sttk:OperatingAccountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sttk:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sttk:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">sttk:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sttk:KayakAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-01</xbrli:startDate><xbrli:endDate>2025-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sttk:KayakAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sttk:KayakAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sttk:KayakAgreementContingentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sttk:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sttk:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sttk:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-01</xbrli:startDate><xbrli:endDate>2025-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sttk:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-01</xbrli:startDate><xbrli:endDate>2025-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sttk:CommonStockWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-01</xbrli:startDate><xbrli:endDate>2025-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sttk:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sttk:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sttk:BeneficialOwnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-01</xbrli:startDate><xbrli:endDate>2025-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sttk:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sttk:CommonStockWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sttk:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sttk:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sttk:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sttk:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sttk:BlackScholesOptionPricingModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sttk:BlackScholesOptionPricingModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sttk:BlackScholesOptionPricingModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sttk:BlackScholesOptionPricingModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sttk:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sttk:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sttk:SL325Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sttk:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sttk:SL325Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sttk:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sttk:OtherResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sttk:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sttk:OtherResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sttk:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sttk:OtherResearchAndDevelopmentSL172154Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sttk:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sttk:OtherResearchAndDevelopmentSL172154Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sttk:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">sttk:ArunthathyNirmaliniLiniPanditeM.B.Ch.B.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">sttk:ArunthathyNirmaliniLiniPanditeM.B.Ch.B.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">sttk:AbhinavShuklaPhDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">sttk:AbhinavShuklaPhDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i2d8e618db7b2478ba6efdb70e68630b1_1"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14.5pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14.5pt;font-weight:700;line-height:115%">SECURITIES AND EXCHANGE COMMISSION </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:700;line-height:115%">WASHINGTON, DC 20549 </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.365%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14.5pt;font-weight:700;line-height:115%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.365%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.717%"><tr><td style="width:1.0%"/><td style="width:13.997%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:83.803%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">March&#160;31, 2026</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">OR</span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.057%"><tr><td style="width:1.0%"/><td style="width:16.218%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.582%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">For the transition period from      to      </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:85%">Commission File Number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-39593</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.198%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:20.5pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">Shattuck Labs, Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.198%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.352%"><tr><td style="width:1.0%"/><td style="width:34.362%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.168%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.170%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">81-2575858</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Identification Number)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">500 W. 5th Street</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-10">Suite 1200</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Austin</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-12">TX</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">78701</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">512</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">900-4690</ix:nonNumeric> </span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.673%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">(Address of principal executive offices including zip code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:85%">Former name, former address and former fiscal year, if changed since last report: N/A</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.429%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:85%">Securities registered pursuant to Section 12(b) of the Exchange Act:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:700;line-height:85%"> </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.720%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.946%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:85%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:85%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:85%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:85%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:85%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">STTK</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:85%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:85%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-19">Yes</ix:nonNumeric>  &#9746;    No &#9744;</span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:85%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-20">Yes</ix:nonNumeric>  &#9746;    No  &#9744;</span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:85%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:18.482%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:56.845%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.370%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Large accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#9744;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-21">Non-accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#9746;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Smaller reporting company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-22">&#9746;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Emerging growth company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-23">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:85%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  &#9744; </span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:85%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  <ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-24">&#9744;</ix:nonNumeric>    No  &#9746;</span></div><div style="text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:85%">As of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:85%">April&#160;30, 2026</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:85%"> the registrant </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:85%">had <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-25">76,680,517</ix:nonFraction> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:85%">shares of common stock, $0.0001 par value per share, outstanding.</span></div><div style="margin-top:3pt;text-align:center;text-indent:24.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i2d8e618db7b2478ba6efdb70e68630b1_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SHATTUCK LABS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:1pt;margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.433%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">PART I</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i2d8e618db7b2478ba6efdb70e68630b1_16">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Item 1.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i2d8e618db7b2478ba6efdb70e68630b1_16">Condensed Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i2d8e618db7b2478ba6efdb70e68630b1_16">Condensed Balance Sheets as</a></span><span style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i2d8e618db7b2478ba6efdb70e68630b1_16"> of </a>March&#160;31, 2026<a style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i2d8e618db7b2478ba6efdb70e68630b1_16"> and </a>December&#160;31, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i2d8e618db7b2478ba6efdb70e68630b1_19">Condensed Statements of Operations and Comprehensive Loss for the Three Months Ended</a></span><span style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i2d8e618db7b2478ba6efdb70e68630b1_19"> </a>March&#160;31, 2026<a style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i2d8e618db7b2478ba6efdb70e68630b1_19"> and </a>2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i2d8e618db7b2478ba6efdb70e68630b1_22">Condensed Statements of Changes in Stockholders&#8217; Equity for the Three Months Ended </a></span><span style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">March&#160;31, 2026<a style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i2d8e618db7b2478ba6efdb70e68630b1_22"> and </a>2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i2d8e618db7b2478ba6efdb70e68630b1_25">Condensed Statements of Cash Flows for the Three Months End</a></span><span style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i2d8e618db7b2478ba6efdb70e68630b1_25">ed </a>March&#160;31, 2026<a style="color:#0e32e1;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i2d8e618db7b2478ba6efdb70e68630b1_25"> and </a>2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i2d8e618db7b2478ba6efdb70e68630b1_28">Notes to the Unaudited Interim Condensed Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2d8e618db7b2478ba6efdb70e68630b1_61">Item 2</a>.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i2d8e618db7b2478ba6efdb70e68630b1_61">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i2d8e618db7b2478ba6efdb70e68630b1_91">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">28</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i2d8e618db7b2478ba6efdb70e68630b1_94">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">28</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">PART II</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i2d8e618db7b2478ba6efdb70e68630b1_97">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">29</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i2d8e618db7b2478ba6efdb70e68630b1_100">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">29</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2d8e618db7b2478ba6efdb70e68630b1_103">Item 1</a>A.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i2d8e618db7b2478ba6efdb70e68630b1_103">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">29</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2d8e618db7b2478ba6efdb70e68630b1_106">Item </a>2.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i2d8e618db7b2478ba6efdb70e68630b1_106">Unregistered Sales of Equity Securities and Use of Proceeds </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">29</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i2d8e618db7b2478ba6efdb70e68630b1_109">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">29</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i2d8e618db7b2478ba6efdb70e68630b1_112">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">29</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i2d8e618db7b2478ba6efdb70e68630b1_115">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">29</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2d8e618db7b2478ba6efdb70e68630b1_118">Item&#160;</a>6.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i2d8e618db7b2478ba6efdb70e68630b1_118">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">30</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i2d8e618db7b2478ba6efdb70e68630b1_121">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">31</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i2d8e618db7b2478ba6efdb70e68630b1_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE ABOUT FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains &#8220;forward-looking statements&#8221; within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts, including statements concerning our plans, objectives, goals, strategies, future events, future revenues or performance, financing needs, plans or intentions relating to products and markets, and business trends and other information referred to under the sections entitled &#8220;Risk Factors,&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221;  are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;objective,&#8221; &#8220;intend,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;can,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;design,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;plan,&#8221; &#8220;develop,&#8221; or the negative of these terms, and similar expressions intended to identify forward-looking statements. Forward-looking statements are not historical facts, and reflect our current views with respect to future events, outcomes or results. Given the significant risks and uncertainties, you should not place undue reliance on these forward-looking statements. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of risks, uncertainties and other factors that could cause our actual results or outcomes, or the timing of our results or outcomes, to differ materially from the forward-looking statements expressed or implied in this Quarterly Report on Form 10-Q. Such risks, uncertainties and other factors include, among others, the following: </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the timing of the initiation, progress, and expected results of our nonclinical studies, our clinical trials, and our research and development programs; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to enroll patients in our clinical trials;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the costs related to our nonclinical studies, our clinical trials, our research and development programs, and the impact of inflationary pressures on such costs;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to retain the continued service of our key executives and to identify, hire, and retain additional qualified professionals; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to advance product candidates into, and successfully complete, nonclinical studies and clinical trials; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the timing or likelihood of regulatory filings and approvals;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the commercialization of our product candidates, if approved; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the pricing, coverage, and reimbursement of our product candidates, if approved;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the implementation of our business model, strategic plans for our business, and product candidates;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our technology;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our potential need to obtain additional licenses of third-party technology that may not be available to us or are available only on commercially unreasonable terms, and which may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to enter into strategic arrangements and/or collaborations and to realize the potential benefits of such arrangements; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our estimates regarding the market opportunity for our product candidates, if approved;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our estimates regarding expenses, capital requirements, and needs for additional financing and our ability to obtain additional capital; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our financial performance; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">developments relating to our competitors and our industry, including competing product candidates and therapies; and</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">economic downturns, inflation, fluctuating interest rates, changes in trade policies, including tariffs or other trade restrictions or the threat of such actions, natural disasters, public health crises, such as pandemics, political crises, government shutdowns, geopolitical events, or other macroeconomic conditions.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There may be other risks, uncertainties, and other factors that may cause our actual results or outcomes, or the timing of our results or outcomes, to differ materially from the forward-looking statements expressed or implied in this Quarterly Report on Form 10-Q, including factors disclosed in &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;. You should evaluate all forward-looking statements made in this Quarterly Report on Form 10-Q in the context of these risks, uncertainties and other factors. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We caution you that the risks, uncertainties, and other factors referred to above and elsewhere in this Quarterly Report on Form 10-Q may not contain all of the risks, uncertainties and other factors that may affect our future results and operations. Moreover, new risks will emerge from time to time. It is not possible for our management to predict all risks. In addition, we cannot assure you that we will realize the results, outcomes, benefits or developments that we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our business in the way we expect.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any forward-looking statements contained in this Quarterly Report on Form 10-Q speak only as of the date hereof and not of any future date, and we expressly disclaim any intent to update any forward-looking statements, whether as a result of new information, future developments, future events, changes in assumptions or otherwise.</span></div><div id="i2d8e618db7b2478ba6efdb70e68630b1_13"></div><div style="margin-top:3pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i2d8e618db7b2478ba6efdb70e68630b1_16"></div><hr style="page-break-after:always"/><div style="min-height:22.5pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART I - FINANCIAL INFORMATION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Condensed Financial Statements</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SHATTUCK LABS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share amounts)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"/><td style="width:70.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.447%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.655%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">March 31,<br/>2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">December 31,<br/>2025</span></td><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-31">90,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-32">54,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="f-33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="f-34">23,873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-35">3,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-36">4,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-37">93,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-38">82,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-39">5,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-40">6,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investment in related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-41">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-42">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-43">2,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-44">1,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-45">102,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-46">91,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-47">1,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-48">2,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="sttk:AccruedLiabilitiesAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-49">2,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="sttk:AccruedLiabilitiesAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-50">4,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-51">4,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-52">7,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Non-current operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">2,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-54">1,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-55">6,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-56">8,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commitments and contingencies (Note 5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-57"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-58"></ix:nonFraction></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-59"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-60">0.0001</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-61"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-62">300,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-63"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-64">75,581,787</ix:nonFraction></ix:nonFraction> shares issued and outstanding at March&#160;31, 2026 and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-65"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-66">63,279,843</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-67">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-68">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-69">541,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-70">512,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive income </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="3" id="f-71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-72">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-73">445,296</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-74">430,529</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-75">95,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-76">82,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-77">102,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-78">91,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited interim condensed financial statements</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i2d8e618db7b2478ba6efdb70e68630b1_19"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SHATTUCK LABS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share amounts) </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"/><td style="width:70.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.330%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.447%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.449%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-79"><span style="-sec-ix-hidden:f-80">Revenue</span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-83">10,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-84">9,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-85">4,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-86">4,470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Expense from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-87">15,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-88">14,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-89">15,545</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-90">14,389</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="f-91">779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="f-92">689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-93">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-94">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total other income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="f-95">778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="f-96">687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-97">14,767</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-98">13,702</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized loss on investments</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-99">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-100">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-101">14,773</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-102">13,704</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share &#8211; basic and diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-103"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-104">0.13</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-105"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-106">0.27</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding &#8211; basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-107"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-108">112,234,551</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-109"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-110">50,965,815</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited interim condensed financial statements</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i2d8e618db7b2478ba6efdb70e68630b1_22"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SHATTUCK LABS, INC. </span></div><div style="padding-right:-18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</span></div><div style="padding-right:-11.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share amounts)</span></div><div style="padding-right:-6.75pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:35.866%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.178%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.767%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2026</span></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Additional Paid-In Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive (Loss) Income</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total Stockholders&#8217; Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Balance at December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-111">63,279,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-112">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-113">512,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-114">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-115">430,529</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-116">82,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Proceeds from sale of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-117">5,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-118">20,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-119">20,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Exercise of pre-funded warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="sttk:StockIssuedDuringPeriodSharesWarrantExercises" format="ixt:num-dot-decimal" scale="0" id="f-120">6,928,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 4pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;Exercise of common stock warrants into common stock and pre-funded warrants </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="sttk:StockIssuedDuringPeriodSharesWarrantExercises" format="ixt:num-dot-decimal" scale="0" id="f-121">153,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="sttk:StockIssuedDuringPeriodValueWarrantExercises" format="ixt:num-dot-decimal" scale="3" id="f-122">5,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="sttk:StockIssuedDuringPeriodValueWarrantExercises" format="ixt:num-dot-decimal" scale="3" id="f-123">5,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Exercise of stock options and purchases pursuant to employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-124">68,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-125">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-126">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock upon settlement of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-127">206,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Taxes paid related to net share settlement of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-128">56,040</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-129">262</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-130">262</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Unrealized gain on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-131">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-132">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-133">2,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-134">2,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-135">14,767</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-136">14,767</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Balance at March 31, 2026</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-137">75,581,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-138">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-139">541,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-140">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-141">445,296</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-142">95,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2025</span></td></tr><tr style="height:29pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Additional Paid-In Capital</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive (Loss) Income</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Deficit</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total Stockholders&#8217; Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Balance at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-143">47,714,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-144">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-145">461,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-146">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-147">381,720</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-148">79,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Exercise of stock options and purchases pursuant to employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-149">6,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-150">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-151">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock upon settlement of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-152">232,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Taxes paid related to net share settlement of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-153">54,403</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-154">65</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-155">65</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-156">1,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-157">1,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Unrealized loss on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-158">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-159">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-160">13,702</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-161">13,702</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Balance at March 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-162">47,899,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-163">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-164">463,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-165">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-166">395,422</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-167">67,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited interim condensed financial statements</span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i2d8e618db7b2478ba6efdb70e68630b1_25"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SHATTUCK LABS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF CASH FLOWS </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:77.070%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.493%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.495%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Cash flows used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Net loss </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-168">14,767</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-169">13,702</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Adjustments to reconcile net loss to net cash used in operating activities: </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-170">2,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-171">1,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-172">891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-173">936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash operating lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="f-174">132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="f-175">118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net amortization of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="f-176">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="f-177">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-178">1,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-179">723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="f-180">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="f-181">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-182">911</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-183">886</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-184">1,955</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="f-185">716</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Non-current operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-186">225</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-187">240</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Net cash used in operating activities </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-188">13,424</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-189">12,032</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-190">23,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-191">15,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="f-192">67</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="f-193">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Net cash provided by investing activities </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-194">23,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-195">15,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from sale of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-196">20,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-197">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from exercise of common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="3" id="f-198">5,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:fixed-zero" scale="3" id="f-199">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from the exercises of stock options and purchases pursuant to employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="f-200">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="f-201">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-202">262</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-203">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Net cash provided by (used in) financing activities </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-204">25,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-205">57</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Increase in cash and cash equivalents </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-206">36,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-207">3,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents, beginning of period </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-208">54,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-209">57,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents, end of period </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-210">90,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-211">60,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental disclosures of non-cash financial activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized gain on investments</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="f-212">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:fixed-zero" scale="3" id="f-213">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unpaid amounts related to purchase of property and equipment</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-214">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-215">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Changes in lease balances resulting from lease modification</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="sttk:IncreaseDecreaseInOperatingLeasesRightOfUseAssetsLiability" scale="3" id="f-216">678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="sttk:IncreaseDecreaseInOperatingLeasesRightOfUseAssetsLiability" format="ixt:fixed-zero" scale="3" id="f-217">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited interim condensed financial statements</span></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i2d8e618db7b2478ba6efdb70e68630b1_28"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SHATTUCK LABS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS</span></div><div id="i2d8e618db7b2478ba6efdb70e68630b1_31"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:NatureOfOperations" id="f-218" continuedAt="f-218-1" escape="true">Organization and Description of Business </ix:nonNumeric></span></div><ix:continuation id="f-218-1"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Shattuck Labs, Inc. (the &#8220;Company&#8221;) was incorporated in 2016 in the State of Delaware and is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. Shattuck is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease and other inflammatory and immune-mediated diseases. Shattuck&#8217;s expertise in protein engineering and the development of novel tumor necrosis factor receptor agonist and antagonist therapeutics come together in its lead program, SL-325, which it believes could be a first-in-class death receptor 3 ("DR3") antagonist antibody designed to achieve best-in-class clinical remission rates due to a more complete and durable blockade of the clinically validated tumor necrosis factor like ligand 1A ("TL1A")/DR3 pathway.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="f-219">445.3</ix:nonFraction> million as of March&#160;31, 2026. The Company anticipates incurring additional losses and negative cash flows from operations until such time, if ever, that it can generate significant sales of its product candidates currently in development, and is highly dependent on its ability to find additional sources of funding in the form of licensing of its technology, collaboration agreements and/or public and private debt and equity financings. Adequate additional funding may not be available to the Company on acceptable terms, or at all. The failure to raise funds as and when needed could have a negative impact on the Company&#8217;s financial condition and ability to pursue its clinical operations, research and development and commercialization of its product candidates. Management believes that the Company&#8217;s cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="f-220">90.4</ix:nonFraction> million as of March&#160;31, 2026 are sufficient to fund projected operations of the Company for at least the next twelve months following the date these financial statements are issued. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Global Economic Considerations</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The global macroeconomic environment is uncertain and could be negatively affected by, among other things, inflation, slower growth or recession, changes in trade policies, including tariffs or other trade restrictions or the threat of such actions, instability, or volatility in the global capital and credit markets, supply chain weaknesses, financial institution instability, changes to fiscal and monetary policy or government budget dynamics, and instability in the geopolitical environment. Such challenges have caused, and may continue to cause, recession fears, high interest rates, foreign exchange volatility, and inflationary pressures. At this time, the Company is unable to quantify the potential effects of this economic instability on its future operations.</span></div></ix:continuation><div id="i2d8e618db7b2478ba6efdb70e68630b1_34"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="f-221" continuedAt="f-221-1" escape="true">Basis of Presentation and Summary of Significant Accounting Policies </ix:nonNumeric></span></div><ix:continuation id="f-221-1" continuedAt="f-221-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-222" escape="true"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Condensed Financial Statements </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying interim financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company&#8217;s financial position, its results of operations, statements of changes in stockholders&#8217; equity and cash flows for the interim periods presented. Operating results for interim periods presented are not necessarily indicative of the results that may be expected for the year ending December 31, 2026. The interim financial statements presented herein do not contain all required disclosures under GAAP for annual financial statements. The accompanying unaudited interim condensed financial statements should be read in conjunction with the annual audited financial statements and related notes in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2025.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-223" continuedAt="f-223-1" escape="true"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-221-2" continuedAt="f-221-3"><ix:continuation id="f-223-1"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition, the accrual of research and development expenses, and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates, if any, are recorded in the period in which they become known and actual results could differ from management&#8217;s estimates.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-224" escape="true"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received upon the sale of an asset or paid upon the transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. Fair value measurements are classified and disclosed in one of the following categories: </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level&#160;1: Observable inputs such as quoted prices in active markets for identical assets the reporting entity has the ability to access as of the measurement date; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level&#160;2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level&#160;3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are classified based on the lowest level of input that is significant to the measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of the assets and liabilities and their placement within the fair value hierarchy levels. The determination of the fair values takes into account the market for its financial assets and liabilities, the associated credit risk and other factors as required. The Company considers active markets as those in which transactions for the assets or liabilities occur with sufficient frequency and volume to provide pricing information on an ongoing basis. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that the carrying amounts of the Company&#8217;s financial instruments, including short-term investments and accounts payable, approximate fair value due to the short-term nature of those instruments.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-225" escape="true"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risk </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and short-term investments. The Company maintains its cash and cash equivalents at an accredited financial institution in amounts that exceed federally-insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company&#8217;s short term investments consist of U.S. Treasury securities that management believes protects the Company from risk of default and impairment of value. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is highly dependent on a limited number of contract development and manufacturing organizations (&#8220;CDMOs&#8221;) to supply drug products for its research and development activities of its programs, including nonclinical studies. The Company is highly dependent on a single CDMO for the supply of cGMP drug product for its clinical trials. These programs could be adversely affected by a significant interruption in the supply of such drug products. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is highly dependent on a limited number of contract research organizations (&#8220;CROs&#8221;) and third-party service providers to manage and support its clinical trials. These programs could be adversely affected by a significant disruption in services provided by these CROs and third parties.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" id="f-226" continuedAt="f-226-1" escape="true"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents </span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-226-1">The Company considers all demand deposits with financial institutions and all highly liquid investments with original maturities of 90 days or less at the date of purchase to be cash and cash equivalents.</ix:continuation> Cash and cash equivalents consisted of $<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-227">1.6</ix:nonFraction>&#160;million held in operating accounts and $<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-228">88.9</ix:nonFraction> million held in money market funds as of March&#160;31, 2026, and $<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-229">1.9</ix:nonFraction>&#160;million held in operating accounts and $<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-230">52.3</ix:nonFraction>&#160;million held in money market funds as of December&#160;31, 2025. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-221-3" continuedAt="f-221-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentPolicyTextBlock" id="f-231" continuedAt="f-231-1" escape="true"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company's short-term investments consist of highly-rated U.S. Treasury securities and have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices. Management determines the appropriate classification of its investment securities at the time of purchase. The Company may hold securities with stated maturities greater than one year. All available-for-sale securities are considered available to support current operations and are classified as current assets. Credit impairments for available-for-sale securities are recorded through an allowance rather than a direct write-down of the security and are recorded through a charge to the statements of operations and comprehensive loss. Unrealized gains or losses not related to credit impairments are recorded in accumulated other comprehensive income, a component of stockholders&#8217; equity, until realized. The Company reviews available-for-sale debt securities for impairments related to credit losses and other factors each quarter. </span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:27pt"><ix:continuation id="f-231-1" continuedAt="f-231-2"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a long-term related party investment in preferred stock of a privately held company. The investment is accounted for under Accounting Standards Codification ("ASC") 321, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in Equity Securities</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-231-2"> and is classified as a long-term asset in the accompanying balance sheet as it is not expected to be liquidated within one year. For investments that do not have a readily determinable fair value, the Company applies the measurement alternative, whereby the investment is carried at cost, adjusted for observable price changes in orderly transactions for identical or similar securities of the same issuer and impairment losses, if any.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="sttk:PrepaidExpenseAndOtherAssetsPolicyPolicyTextBlock" id="f-232" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets include prepaid expenses for general business purposes and services used in research projects, which are stated at cost and amortized on a straight-line basis over the related period of benefit. Supplies and materials that have multiple applications for alternative future use are expensed as they are consumed.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-233" escape="true"><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life of the asset. Expenditures for repairs and maintenance that do not extend the estimated useful life or improve an asset are expensed as incurred. Upon retirement or sale, the cost and related accumulated depreciation and amortization of assets disposed of are removed from the accounts, and any resulting gain or loss is included in the statement of operations and comprehensive loss.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-234" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation periods are as follows:</span></div><div style="margin-top:6pt;text-align:center;text-indent:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.333%"><tr><td style="width:1.0%"/><td style="width:62.938%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.862%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Office equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-40" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-235">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-41" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-236">5</ix:nonNumeric>&#160;to&#160;<ix:nonNumeric contextRef="c-42" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-237">10</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Lab equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-43" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-238">5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Shorter&#160;of&#160;lease&#160;term&#160;or <ix:nonNumeric contextRef="c-44" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-239">15</ix:nonNumeric> years</span></div></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" id="f-240" continuedAt="f-240-1" escape="true"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-240-1">Long-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstance indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable and the carrying amount exceeds the projected discounted future cash flows arising from these assets.</ix:continuation> There were no impairments of long-lived assets for the three months ended March&#160;31, 2026 and 2025.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-241" continuedAt="f-241-1" escape="true"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception. Right-of-use (&#8220;ROU&#8221;) assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. The classification of the Company's leases as operating or finance leases, along with the initial measurement and recognition of the associated ROU assets and lease liabilities, are performed at the lease commencement date. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. As the Company's leases do not provide an implicit rate, the Company </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-221-4" continuedAt="f-221-5"><ix:continuation id="f-241-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. The ROU asset is based on the measurement of the lease liability and also includes any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company's operating leases is recognized on a straight-line basis over the lease term. Operating lease ROU assets and long-term operating lease liabilities are presented separately and operating lease liabilities payable in the next 12 months are recorded in accrued expenses and other current liabilities. The Company has elected to not apply the recognition requirement of ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> of the Financial Accounting Standards Board (&#8220;FASB&#8221;) to leases with a term of 12 months or less for all classes of assets.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="f-242" escape="true"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments and Contingencies</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows ASC 450-20, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to report accounting for contingencies. Certain conditions may exist as of the date the condensed financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company&#8217;s condensed financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-243" continuedAt="f-243-1" escape="true"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue is recognized in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;). Arrangements with collaborators may include licenses to intellectual property, research and development services, manufacturing services for clinical and commercial supply, and participation on joint steering committees. The Company evaluates the promised goods or services in the contract to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, the Company considers the stage of development of the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property and whether the promised goods or services are integral to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Upon the amendment of an existing agreement, the Company evaluates whether the amendment represents a modification to an existing contract that would be recorded through a cumulative catch-up to revenue, prospective modification, or a separate contract. If it is determined that it is a separate contract, the Company will evaluate the necessary revenue recognition through the five-step process described below. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">When the Company concludes that a contract should be accounted for as a combined performance obligation and recognized over time, the Company must then determine the period over which revenue should be recognized and the method by which to measure revenue. The Company generally recognizes revenue using a cost-based input method. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes collaboration revenue in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services when its customer or collaborator obtains control of </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-243-1" continuedAt="f-243-2"><ix:continuation id="f-221-5" continuedAt="f-221-6"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">promised goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the following five steps are performed: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.73pt">identify the contract(s) with a customer;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.96pt">identify the performance obligations in the contract; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">iii.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.19pt">determine the transaction price; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">iv.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.73pt">allocate the transaction price to the performance obligations within the contract; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">v.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">recognize revenue when (or as) the entity satisfies a performance obligation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company only applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company&#8217;s arrangements may consist of a license of, or options to license, the Company&#8217;s intellectual property and research, development and manufacturing services. The Company may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i)&#160;the customer can benefit from on its own or together with other readily available resources and (ii)&#160;are separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most-likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes variable consideration in the transaction price to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations that consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company&#8217;s accompanying balance sheet. Deferred revenues expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability. Deferred revenues not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as non-current liabilities. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Company&#8217;s collaboration revenue arrangements may include the following: </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Up-front License Fees: If a license is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, up-front fees allocated to the </span></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-221-6" continuedAt="f-221-7"><ix:continuation id="f-243-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Milestone Payments: At the inception of an agreement that includes research and development milestone payments, the Company evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company first estimates the amount of the milestone payment that the Company could receive using either the expected value or the most-likely amount approach. The Company primarily uses the most-likely amount approach as that approach is generally most predictive for milestone payments with a binary outcome. The Company then considers whether any portion of that estimated amount is subject to the variable consideration constraint (that is, whether it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty). The Company updates the estimate of variable consideration included in the transaction price at each reporting date which includes updating the assessment of the likely amount of consideration and the application of the constraint to reflect current facts and circumstances. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Royalties: For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not granted a development and commercialization license nor recognized any revenue related to sales-based royalties or milestone payments based on the level of sales. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and Development Services: The Company will record costs associated with development and process optimization activities as research and development expenses in the statements of operations and comprehensive loss consistent with ASC 730, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> The Company considered the guidance in ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 808&#8221;) and will recognize the payments received from these agreements as revenue when the related costs are incurred. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">License Revenue: License revenue is generated from granting third parties rights to certain of the Company&#8217;s intellectual property, including research, development, and commercialization of specified product candidates. The Company evaluates each licensing arrangement to determine whether the license is distinct from other promised goods or services and whether the arrangement includes multiple performance obligations. If an arrangement includes multiple performance obligations, the transaction price is allocated to each performance obligation based on relative standalone selling prices. Upfront payments, including nonrefundable license fees, are recognized as revenue when the underlying performance obligation is satisfied. Milestone payments that are contingent on the occurrence of a future event are included in the transaction price only when it is probable that a significant reversal of cumulative revenue will not occur. Sales-based royalties, including milestone payments based on a level of sales, are recognized as revenue when the subsequent sales occur.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company may also enter into arrangements that include non-cash consideration, such as equity instruments. In such cases, the Company measures the transaction price at the estimated fair value of the non-cash consideration received at contract inception and recognizes revenue when the performance obligation is satisfied.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-244" continuedAt="f-244-1" escape="true"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred, and include salaries, stock-based compensation and other personnel-related costs, equipment and supplies, depreciation, nonclinical studies, clinical trials and manufacturing development activities. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of the Company&#8217;s ongoing research and development activities are conducted by third-party service providers, including CROs and CDMOs. The Company accrues for expenses resulting from obligations under agreements with CROs, CDMOs and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with CROs, CDMOs and other outside </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-221-7" continuedAt="f-221-8"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-244-1">service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through an evaluation of the progress or stage of completion of the services. In the event advance payments are made to a CRO, CDMO or outside service provider, the payments will be recorded as a prepaid asset which will be amortized as the contracted services are performed. As actual costs become known, the Company adjusts its accruals and prepaid assets accordingly. Inputs, such as the services performed, the number of patients enrolled or the study duration, may vary from the Company&#8217;s estimates, resulting in adjustments to research and development expenses in future periods. The Company makes significant judgments and estimates in determining the accrual and/or prepaid balance in each reporting period and changes in these estimates may result in material changes to the Company&#8217;s accruals that could materially affect the Company&#8217;s results of operations.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="sttk:WarrantsPolicyTextBlock" id="f-245" continuedAt="f-245-1" escape="true"><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants and Pre-Funded Warrants</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-245-1">The Company&#8217;s common stock warrants and pre-funded warrants are classified as a component of permanent stockholders&#8217; equity within additional paid-in capital. The common stock warrants and pre-funded warrants are equity classified because they, (i) are freestanding financial instruments, (ii) are immediately exercisable, (iii) do not embody an obligation for the Company to repurchase its shares, (iv) permit the holders to receive a fixed number of shares of common stock upon exercise, (v) are indexed to the Company&#8217;s common stock and, (vi) meet the equity classification criteria. In addition, such common stock warrants and pre-funded warrants do not provide any guarantee of value or return.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-246" escape="true"><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the cost of stock-based awards issued to employees and nonemployees as compensation expense on a straight-line basis over the vesting period of the award, net of estimated forfeitures. Forfeiture estimates are based on historical cancellation data. The Company uses the Black-Scholes option pricing model to determine the grant-date fair value of stock options. The fair values of restricted stock units (&#8220;RSUs&#8221;) are based on the fair value of the Company&#8217;s common stock on the date of the grant. The Company also grants stock options that vest upon achievement of certain market-based conditions. The Company uses the Monte Carlo pricing model to estimate the fair value of options that have market-based conditions. The Company adjusts expense for forfeitures in the periods they occur.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-247" escape="true"><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statements and the tax bases of assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in tax rates on deferred tax assets and liabilities will be recognized in the period that includes the enactment date. Additionally, any changes in income tax laws are immediately recognized in the year of enactment.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is established against the deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. The deferred tax assets and liabilities are classified as noncurrent along with the related valuation allowance. Due to a lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on the technical merits, as the largest amount of benefits that is more likely than not to be realized upon the ultimate settlement. The Company&#8217;s policy is to recognize interest and penalties related to the unrecognized tax benefits as a component of income tax expense.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-248" continuedAt="f-248-1" escape="true"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Basic shares outstanding includes the weighted average effect of the Company&#8217;s outstanding <ix:nonFraction unitRef="shares" contextRef="c-45" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-249">38,448,034</ix:nonFraction> pre-funded warrants as of March&#160;31, 2026, the exercise of which requires nominal consideration for the delivery of an equal number of shares of common stock. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock or convertible notes, if any, </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-221-8"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-248-1">stock options and unvested shares of restricted stock, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-250" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding as they would be anti-dilutive:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.484%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">As of March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-46" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-251">47,487,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-47" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-252">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-48" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-253">13,064,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-49" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-254">8,458,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-50" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-255">589,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-51" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-256">527,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-257">61,141,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-258">8,986,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-259" escape="true"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Comprehensive Income (Loss) </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Other comprehensive income (loss) is comprised of unrealized gains and losses on short-term investments.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-260" escape="true"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in this update are intended to enhance the transparency and decision usefulness of income tax disclosures primarily through changes to the rate reconciliation and income taxes paid information. This update is effective for annual periods beginning after December 15, 2024, and may be applied prospectively or retrospectively. The Company has retrospectively adopted this ASU in the financial statements for the year ending December&#160;31, 2025. </span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (&#8220;ASU 2024-03&#8221;), which is intended to provide more detailed information about specified categories of expenses (employee compensation, depreciation, and amortization) included in certain expense captions presented on the statement of operations. The guidance in this ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either, (i) prospectively to financial statements issued for periods after the effective date of this ASU or, (ii) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its financial statements and disclosures.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i2d8e618db7b2478ba6efdb70e68630b1_40"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="f-261" continuedAt="f-261-1" escape="true">Investments </ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="f-262" continuedAt="f-262-1" escape="true"><ix:continuation id="f-261-1" continuedAt="f-261-2"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the Company&#8217;s investments by major security type (amounts in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.483%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.613%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2026</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Gain</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-263">88,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-264">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-265">88,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-266">88,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-267">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-268">88,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-261-2"><ix:continuation id="f-262-1"><div style="margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.483%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.613%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-269">23,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" scale="3" id="f-270">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-271">23,873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market fund</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-272">52,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-273">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-274">52,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-275">76,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" scale="3" id="f-276">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-277">76,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:1pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company's money market funds are calculated using level 1 inputs and the Company's U.S. government securities are valued using level 2 inputs. U.S. government securities outstanding as of December&#160;31, 2025 matured in January 2026. There were <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal" format="ixt:fixed-zero" scale="0" id="f-278"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal" format="ixt:fixed-zero" scale="0" id="f-279">no</ix:nonFraction></ix:nonFraction> impairments of U.S. government securities or money market funds for the three months ended March&#160;31, 2026 and the year ended</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2025.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a related party investment in a private company&#8217;s preferred stock. The Company did not identify any impairment indicators or observable price changes for this investment as of March&#160;31, 2026. The Company had no other investments held at March&#160;31, 2026 other than those included in the table above.</span></div></ix:continuation><div id="i2d8e618db7b2478ba6efdb70e68630b1_43"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="f-280" continuedAt="f-280-1" escape="true">Accrued Expenses and Other Current Liabilities</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-281" escape="true"><ix:continuation id="f-280-1"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following (amounts in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.925%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development contract costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="sttk:AccruedResearchAndDevelopmentContractCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-282">1,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="sttk:AccruedResearchAndDevelopmentContractCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-283">1,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-284">852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-285">837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Compensation and related benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="f-286">752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-287">2,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-288">335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-289">236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="sttk:AccruedLiabilitiesAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-290">2,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="sttk:AccruedLiabilitiesAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-291">4,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="i2d8e618db7b2478ba6efdb70e68630b1_46"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-292" continuedAt="f-292-1" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><ix:continuation id="f-292-1" continuedAt="f-292-2"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain office space, laboratory facilities, and equipment. These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain of these leases also include renewal options at the election of the Company to renew or extend the lease. These optional periods have not been considered in the determination of the ROU assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options. The Company performed evaluations of its contracts and determined it has operating leases. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In February 2026, the Company entered into an amendment to extend the term of its lease for the Austin, Texas office location. The amendment extended the non-cancelable lease term to December 31, 2029 and increased the total contractual lease payments due over the revised lease term. In accordance with ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, the Company remeasured the existing lease liability as of the modification date and as a result, recorded an increase to the ROU asset and liability of approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="sttk:IncreaseDecreaseInOperatingLeasesRightOfUseAssetsLiability" scale="6" id="f-293">0.7</ix:nonFraction>&#160;million during the three months ended March 31, 2026.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There have been no other material changes in the Company's operating leases as compared to the operating leases disclosed in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2025.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may become involved in various legal actions arising in the ordinary course of business. As of March&#160;31, 2026, the Company was not aware of any existing, pending, or threatened legal actions that would have a material impact on the financial position, results of operations, or cash flows of the Company.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-292-2"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Contractual obligations represent future cash commitments and liabilities under agreements with third parties, and exclude contingent liabilities for which the Company cannot reasonably predict future payment. The Company&#8217;s contractual obligations result primarily from obligations for various CDMOs and CROs, which include potential payments that may be required under its agreements. The contracts also contain variable costs and milestones that are hard to predict, as they are based on such things as patients enrolled and clinical trial sites. The timing of payments and actual amounts paid under CDMO and CRO agreements may be different depending on the timing of receipt of goods or services or changes to agreed-upon terms or amounts for some obligations. Such agreements are cancellable upon written notice by the Company and, therefore, are not long-term liabilities.</span></div></ix:continuation><div id="i2d8e618db7b2478ba6efdb70e68630b1_49"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-294" continuedAt="f-294-1" escape="true">Related Party License Revenue</ix:nonNumeric></span></div><ix:continuation id="f-294-1" continuedAt="f-294-2"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In August 2025, the Company granted Kayak Therapeutics, Inc. ("Kayak") an exclusive license (the "Kayak Agreement") to its oncology-focused TRIM7 program. Pursuant to the Kayak Agreement, as the upfront consideration, the Company received preferred stock in Kayak with a fair market value of $<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-295">1.0</ix:nonFraction>&#160;million and recognized that consideration as license revenue. The Company also subleases certain lab space, office space, and lab equipment to Kayak for one year for total consideration of $<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" name="sttk:SubleaseAgreementConsideration" scale="6" id="f-296">0.3</ix:nonFraction>&#160;million. In November 2025, an officer of the Company was elected to the board of directors of Kayak and as a result, Kayak became a related party. Payments received pursuant to the sublease for the three months ended March&#160;31, 2026 were $<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="us-gaap:SubleaseIncome" scale="6" id="f-297">0.1</ix:nonFraction>&#160;million and recorded as a reduction to research and development expenses. </span></div></ix:continuation><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-294-2">Pursuant to the Kayak Agreement, the Company is also eligible to receive future payments contingent upon the achievement of specified development, regulatory, and commercial milestones of up to $<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-5" name="us-gaap:AccountsReceivableNet" scale="6" id="f-298">86.0</ix:nonFraction> million, and tiered royalties on net sales of any commercialized products subject to the Kayak Agreement in the low single digits. Such future payments are considered variable consideration and will be recognized as revenue only when the underlying contingencies are resolved and it is probable that a significant reversal of revenue will not occur.</ix:continuation> </span></div><div id="i2d8e618db7b2478ba6efdb70e68630b1_52"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-299" continuedAt="f-299-1" escape="true">Equity</ix:nonNumeric></span></div><ix:continuation id="f-299-1" continuedAt="f-299-2"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue up to <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-300">300,000,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">shares of common stock and <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-301">10,000,000</ix:nonFraction> shares of preferred stock, all with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-302"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-303">0.0001</ix:nonFraction></ix:nonFraction> per share. The holders of the Company&#8217;s common stock are entitled to <ix:nonFraction unitRef="vote" contextRef="c-3" decimals="INF" name="sttk:CommonStockNumberOfVotesPerCommonShare" format="ixt-sec:numwordsen" scale="0" id="f-304">one</ix:nonFraction> vote per share on all matters submitted to a vote of stockholders. The Company&#8217;s common stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking fund provisions. Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of the Company&#8217;s common stock will receive ratably any dividends declared by the Company&#8217;s board of directors (the &#8220;Board&#8221;) out of funds legally available. In the event of the Company&#8217;s liquidation, dissolution or winding-up, the holders of the Company&#8217;s common stock will be entitled to share ratably in all assets remaining after payment of or provision for any liabilities. As of the periods presented, no common stock dividends had been declared by the Board. As of March&#160;31, 2026, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-305">none</ix:nonFraction> of the <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-306">10,000,000</ix:nonFraction> shares of preferred stock were outstanding, and the Company has no present plans to issue any shares of preferred stock.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Company sold <ix:nonFraction unitRef="usd" contextRef="c-59" decimals="INF" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-307">4,651,163</ix:nonFraction> shares of common stock through an underwritten public offering, and concurrently completed a private placement of <ix:nonFraction unitRef="shares" contextRef="c-60" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-308">3,100,823</ix:nonFraction> pre-funded warrants. The purchase price per share of common stock was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-61" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-309">6.45</ix:nonFraction>, and the purchase price per pre-funded warrant was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-62" decimals="INF" name="sttk:ClassOfWarrantOrRightPriceOfPreFundedWarrants" scale="0" id="f-310">6.4499</ix:nonFraction>, which was the purchase price per share of common stock minus the $<ix:nonFraction unitRef="usdPerShare" contextRef="c-62" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-311">0.0001</ix:nonFraction> per share exercise price of the pre-funded warrant. Each pre-funded warrant may be exercised for <ix:nonFraction unitRef="shares" contextRef="c-62" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-312">one</ix:nonFraction> share of common stock, is immediately exercisable, does not expire, and is subject to a beneficial ownership limitation of <ix:nonFraction unitRef="number" contextRef="c-62" decimals="INF" name="sttk:ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise" scale="-2" id="f-313">9.99</ix:nonFraction>% on a post-exercise basis. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In August 2025, the Company issued and sold <ix:nonFraction unitRef="shares" contextRef="c-63" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-314">15,225,158</ix:nonFraction> shares of common stock, pre-funded warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-64" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-315">37,410,188</ix:nonFraction> shares of common stock, and accompanying common stock warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-65" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-316">52,635,346</ix:nonFraction> shares of common stock or pre-funded warrants in a private placement offering with certain institutional accredited investors. The purchase price of each share of common stock and accompanying common stock warrant was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-66" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-317">0.8677</ix:nonFraction>, and the purchase price of each pre-funded warrant and accompanying common stock warrant was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-67" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-318">0.8676</ix:nonFraction>, which was the purchase price per share of common stock and accompanying common stock warrant, minus the $<ix:nonFraction unitRef="usdPerShare" contextRef="c-67" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-319">0.0001</ix:nonFraction> per share exercise price of the pre-funded warrants. Each pre-funded warrant may be exercised for <ix:nonFraction unitRef="shares" contextRef="c-67" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-320">one</ix:nonFraction> share of common stock, is immediately exercisable, does not expire, and is subject to a beneficial ownership </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-299-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">limitations of up to <ix:nonFraction unitRef="number" contextRef="c-68" decimals="INF" name="sttk:ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise" scale="-2" id="f-321">9.99</ix:nonFraction>% on a post-exercise basis.  Two beneficial owners of 10% or more of our common stock participated in the private placement offering with the same terms as all other participants in the offering. Together, the beneficial owners purchased <ix:nonFraction unitRef="shares" contextRef="c-69" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-322">8,963,785</ix:nonFraction> pre-funded warrants in lieu of common stock and received accompanying common stock warrants to purchase an additional <ix:nonFraction unitRef="shares" contextRef="c-69" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-323">8,963,785</ix:nonFraction> shares of common stock.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2026, <ix:nonFraction unitRef="shares" contextRef="c-70" decimals="INF" name="sttk:ClassOfWarrantOrRightWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="f-324">6,929,032</ix:nonFraction> pre-funded warrants were exercised and as of March&#160;31, 2026, <ix:nonFraction unitRef="shares" contextRef="c-45" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-325">38,448,034</ix:nonFraction> pre-funded warrants remain outstanding.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Each common stock warrant has an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-71" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-326">1.0846</ix:nonFraction> and is exercisable at any time after the date of issuance for <ix:nonFraction unitRef="shares" contextRef="c-71" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-327">one</ix:nonFraction> share of common stock or pre-funded warrant in lieu thereof. The common stock warrants will expire on the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Company&#8217;s Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2026, <ix:nonFraction unitRef="shares" contextRef="c-15" decimals="INF" name="sttk:ClassOfWarrantOrRightWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="f-328">5,019,719</ix:nonFraction> common stock warrants were exercised for gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="6" id="f-329">5.4</ix:nonFraction> million in exchange for <ix:nonFraction unitRef="shares" contextRef="c-45" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-330">4,866,055</ix:nonFraction> pre-funded warrants with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-45" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-331">0.0001</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="sttk:StockIssuedDuringPeriodSharesWarrantExercises" format="ixt:num-dot-decimal" scale="0" id="f-332">153,664</ix:nonFraction> shares of common stock. As of March&#160;31, 2026, <ix:nonFraction unitRef="shares" contextRef="c-72" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-333">47,487,573</ix:nonFraction> common stock warrants remain outstanding.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In January 2026, the Company entered into a sales agreement (the &#8220;Sales Agreement&#8221;) with Leerink Partners, LLC (the &#8220;Sales Agent&#8221;), pursuant to which it may offer and sell up to $<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-5" name="sttk:SaleOfStockMaximumAggregateSalesPrice" scale="6" id="f-334">75.0</ix:nonFraction> million of shares of its common stock from time to time through an at the market offering facility (the &#8220;ATM Facility&#8221;). The Sales Agent is generally entitled to compensation at a commission equal to up to <ix:nonFraction unitRef="number" contextRef="c-73" decimals="INF" name="sttk:SaleOfStockCommissionPercentage" scale="-2" id="f-335">3</ix:nonFraction>% of the aggregate gross sales price per share sold under the Sales Agreement. For the three months ended March 31, 2026, the Company sold <ix:nonFraction unitRef="shares" contextRef="c-74" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-336">5,000,000</ix:nonFraction> shares of common stock for $<ix:nonFraction unitRef="usdPerShare" contextRef="c-75" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-337">4.28</ix:nonFraction> per share for gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-338">21.4</ix:nonFraction>&#160;million through the ATM Facility.</span></div></ix:continuation><div id="i2d8e618db7b2478ba6efdb70e68630b1_55"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-339" continuedAt="f-339-1" escape="true">Stock-Based Compensation and Employee Benefit Plans</ix:nonNumeric></span></div><ix:continuation id="f-339-1" continuedAt="f-339-2"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Equity Incentive Plan</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company adopted the 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;) which, as of the adoption date, replaced the 2016 Stock Incentive Plan. Under the 2020 Plan, the share reserve automatically increases on January 1st of each year beginning in 2021 and ending with a final increase on January 1, 2030 in an amount equal to <ix:nonFraction unitRef="number" contextRef="c-76" decimals="INF" name="sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage" scale="-2" id="f-340">4</ix:nonFraction>% of the Company&#8217;s outstanding shares of common stock on December 31st of the preceding calendar year. The Board may provide that there will be no increase in the share reserve for any such year or that the increase in the share reserve may be smaller than would otherwise occur. On January 1, 2026, the share reserve automatically increased by <ix:nonFraction unitRef="shares" contextRef="c-77" decimals="INF" name="sttk:CommonStockAdditionalCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-341">2,531,194</ix:nonFraction> shares. As of March&#160;31, 2026, there were <ix:nonFraction unitRef="shares" contextRef="c-78" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-342">1,559,581</ix:nonFraction> shares available for future grants. The 2020 Plan permits the granting of options, stock appreciation rights, restricted stock units (&#8220;RSUs&#8221;), performance stock and performance cash awards. The terms of the agreements under the 2020 Plan are determined by the Board. The Company&#8217;s awards generally vest over <ix:nonNumeric contextRef="c-79" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-343">four years</ix:nonNumeric> and have a term of <ix:nonNumeric contextRef="c-79" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="f-344">10</ix:nonNumeric> years. Periodically, the Company also grants awards that vest based on the Company's stock achieving certain closing share prices for a specified number of consecutive trading days.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Employee Stock Purchase Plan (the &#8220;2020 ESPP&#8221;) became effective in October 2020. Eligible employees may purchase shares of common stock under the 2020 ESPP at <ix:nonFraction unitRef="number" contextRef="c-80" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-345">85</ix:nonFraction>% of the lower of the fair market value of the Company&#8217;s common stock as of the first or the last day of each offering period. Employees are limited to contributing <ix:nonFraction unitRef="number" contextRef="c-81" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="f-346">15</ix:nonFraction>% of the employee&#8217;s eligible compensation and may not purchase more than $<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue" format="ixt:num-dot-decimal" scale="3" id="f-347">25,000</ix:nonFraction> of stock during any calendar year or more than <ix:nonFraction unitRef="shares" contextRef="c-80" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" format="ixt:num-dot-decimal" scale="0" id="f-348">2,000</ix:nonFraction> shares during any one purchase period. The 2020 ESPP share reserve automatically increases on January 1st of each calendar year, for <ix:nonNumeric contextRef="c-80" name="sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm" format="ixt-sec:durwordsen" id="f-349">ten years</ix:nonNumeric>, commencing on January 1, 2021, in an amount equal to <ix:nonFraction unitRef="number" contextRef="c-81" decimals="INF" name="sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage" scale="-2" id="f-350">1</ix:nonFraction>% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year. The Board may act prior to January 1st of a given year to provide that there will be no January 1st increase of the share reserve for such year or that the increase in the share reserve for such year will be a smaller number of shares of common stock than would otherwise occur pursuant to the preceding sentence. The Board elected not to increase the share reserve for the ESPP on January 1, 2026. As of March&#160;31, 2026, there were <ix:nonFraction unitRef="shares" contextRef="c-82" decimals="INF" name="sttk:CommonStockAdditionalCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-351">1,660,870</ix:nonFraction> shares available for future purchases. There were <ix:nonFraction unitRef="shares" contextRef="c-82" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-352">30,916</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-83" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-353">6,859</ix:nonFraction> shares issued under the Company&#8217;s 2020 ESPP during the three months ended March&#160;31, 2026 and 2025, respectively, in each case for aggregate proceeds of less than $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-5" name="us-gaap:ProceedsFromStockPlans" scale="6" id="f-354"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-5" name="us-gaap:ProceedsFromStockPlans" scale="6" id="f-355">0.1</ix:nonFraction></ix:nonFraction>&#160;million.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-339-2" continuedAt="f-339-3"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Stock-Based Compensation Expense</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-356" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following expense categories of its accompanying unaudited interim condensed statements of operations and comprehensive loss (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.153%"><tr><td style="width:1.0%"/><td style="width:58.134%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.044%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.044%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.702%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-357">1,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-358">687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-359">1,379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-360">1,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-361">2,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-362">1,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-363" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes option activity under the 2020 Plan for the three months ended March&#160;31, 2026:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:48.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.886%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.023%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.023%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Exercise&#160;Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Remaining&#160;Life</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December&#160;31, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-364">8,648,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-365">5.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-55" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-366">7.06</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-367">4,642,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-368">4.75</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-369">38,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-370">0.86</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-371">188,616</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-372">7.15</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Balance at March&#160;31, 2026</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-373">13,064,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-374">5.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-375">7.89</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-376">7,106,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-377">3.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-378">9.29</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at the end of the period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-379">5,096,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-380">6.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-381">5.67</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Options granted during the three months ended March&#160;31, 2026 and 2025 had weighted-average grant-date fair values of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-382">4.02</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-383">0.96</ix:nonFraction> per share, respectively. As of March&#160;31, 2026, the unrecognized compensation cost for options issued was $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="f-384">24.6</ix:nonFraction> million and will be recognized over an estimated weighted-average amortization period of <ix:nonNumeric contextRef="c-88" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-385">1.69</ix:nonNumeric> years. The total intrinsic value of options exercised during the three months ended March&#160;31, 2026 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-386">0.2</ix:nonFraction> million. There were <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:fixed-zero" scale="0" id="f-387">no</ix:nonFraction> options exercised during the three months ended March 31, 2025. The aggregate intrinsic value of options outstanding and exercisable as of March&#160;31, 2026 was $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="f-388">11.7</ix:nonFraction> million.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" id="f-389" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes employee RSU activity for the three months ended March&#160;31, 2026:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.455%"><tr><td style="width:1.0%"/><td style="width:67.780%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.080%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.081%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December&#160;31, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-89" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-390">481,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-89" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-391">8.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-90" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-392">316,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-90" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-393">4.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-90" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-394">206,513</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-90" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-395">7.69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-90" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="f-396">861</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-90" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-397">8.67</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Balance at March&#160;31, 2026</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-91" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-398">589,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-91" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-399">6.49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-400">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-401">0.3</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of stock-based compensation cost related to RSUs for the three months ended March&#160;31, 2026 and 2025, respectively. As of March&#160;31, 2026, the unrecognized compensation cost for RSUs issued was $<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-402">3.5</ix:nonFraction> million and will be recognized over an estimated weighted-average amortization period of <ix:nonNumeric contextRef="c-90" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-403">2.60</ix:nonNumeric> years. The fair values of RSUs are based on the fair value of the Company&#8217;s common stock on the date of the grant.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-339-3" continuedAt="f-339-4"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Stock Options and Shares Issued</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation by measuring and recognizing as compensation expense the fair value of all share-based payment awards made to employees, including employee stock options and restricted stock awards. The Company uses the Black-Scholes option pricing model to estimate the fair value of employee stock options that only have service or performance conditions. The inputs to the Black-Scholes option  pricing model require a number of management estimates such as the expected term, volatility, risk-free interest rate and dividend yield. The fair value of stock options was determined using the methods and assumptions discussed below.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The expected term of employee stock options with service-based vesting is determined using the &#8220;simplified&#8221; method, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company&#8217;s lack of sufficient historical data.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The expected stock price volatility assumption is based on the historical volatilities of the common stock of a peer group of publicly traded companies as well as the historical volatility of the Company&#8217;s common stock since the Company began trading subsequent to the Company&#8217;s initial public offering (&#8220;IPO&#8221;) in October 2020 over the period corresponding to the expected life as of the grant date. The historical volatility data was computed using the daily closing prices during the equivalent period of the calculated expected term of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of the Company&#8217;s stock price becomes available, or until circumstances change, such that the identified entities are no longer comparable companies. In the latter case, other suitable, similar entities whose share prices are publicly available would be utilized in the calculation.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the expected term. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The expected dividend yield is <ix:nonFraction unitRef="number" contextRef="c-88" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-404">0</ix:nonFraction>% because the Company has not historically paid, and does not expect, for the foreseeable future, to pay dividends on its common stock. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Prior to the Company&#8217;s IPO, the Board periodically estimated the fair value of the Company&#8217;s common stock considering, among other things, contemporaneous valuations of its common stock prepared by an unrelated third-party valuation firm. Subsequent to the Company&#8217;s IPO, options are issued with a strike price no less than the market price on date of grant.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-405" continuedAt="f-405-1" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of options calculated using the Black-Scholes option pricing model granted under the Company&#8217;s 2020 Plan were estimated using the following weighted-average assumptions:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.673%"><tr><td style="width:1.0%"/><td style="width:59.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.175%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2020 Plan</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Expected term - years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-93" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-406">6.08</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-94" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-407">6.00</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-93" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-408">110.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-94" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-409">101.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-93" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-410">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-94" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-411">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-93" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-412">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-94" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-413">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-indent:27pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-405-1"><ix:continuation id="f-339-4"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of shares issued calculated using the Black-Scholes option pricing model under the Company&#8217;s 2020 ESPP were estimated using the following weighted-average assumptions:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.352%"><tr><td style="width:1.0%"/><td style="width:59.720%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.711%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.035%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2020 ESPP</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Expected term - years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-95" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-414">0.50</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-96" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-415">0.50</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-95" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-416">109.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-96" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-417">107.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-95" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-418">3.92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-96" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-419">4.70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-95" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-420">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-96" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-421">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div id="i2d8e618db7b2478ba6efdb70e68630b1_58"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-422" continuedAt="f-422-1" escape="true">Segment Reporting</ix:nonNumeric></span></div><ix:continuation id="f-422-1" continuedAt="f-422-2"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-423"><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-424">one</ix:nonFraction></ix:nonFraction> reportable and operating segment, which is engaged in the business of drug discovery and development. The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) is the Company&#8217;s chief executive officer. The CODM uses the Company&#8217;s net loss to monitor actual results versus the budget in assessing segment performance and the allocation of resources. The measure of segment assets is reported on the balance sheets as total assets. Accounting policies for segment reporting are the same as the accounting policies disclosed in Note 2.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-425" escape="true"><ix:continuation id="f-422-2"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information about the Company&#8217;s single reportable segment and the significant expenses reviewed by the CODM, including a reconciliation to net loss (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:60.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.680%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.681%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-426">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-427">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">SL-325</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-428">2,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-429">2,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other research and development</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2,3</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-430">4,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-431">4,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development non-equity compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="sttk:ResearchAndDevelopmentNonEquityCompensation" format="ixt:num-dot-decimal" scale="3" id="f-432">2,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="sttk:ResearchAndDevelopmentNonEquityCompensation" format="ixt:num-dot-decimal" scale="3" id="f-433">2,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development equity compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="sttk:ResearchAndDevelopmentEquityCompensation" format="ixt:num-dot-decimal" scale="3" id="f-434">1,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="sttk:ResearchAndDevelopmentEquityCompensation" scale="3" id="f-435">687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total research and development</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-436">10,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-437">9,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative non-equity compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="sttk:GeneralAndAdministrativeNonEquityCompensation" format="ixt:num-dot-decimal" scale="3" id="f-438">1,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="sttk:GeneralAndAdministrativeNonEquityCompensation" format="ixt:num-dot-decimal" scale="3" id="f-439">1,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative equity compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="sttk:GeneralAndAdministrativeEquityCompensation" format="ixt:num-dot-decimal" scale="3" id="f-440">1,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="sttk:GeneralAndAdministrativeEquityCompensation" format="ixt:num-dot-decimal" scale="3" id="f-441">1,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other general and administrative including legal and accounting fees, facilities, insurance, travel and depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:OtherGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-442">1,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:OtherGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-443">2,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total general and administrative</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-444">4,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-445">4,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Expense from operations</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-446">15,545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-447">14,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-448">15,545</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-449">14,389</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other Income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-450">778</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-451">687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net Loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-452">14,767</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-453">13,702</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">1 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Expenses for SL-325 that were incurred prior to it being nominated a product candidate are included in &#8220;other research and development&#8221;. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"> Other research and development expense includes technical operations expense of $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="sttk:OtherResearchAndDevelopmentExpenseTechnicalOperations" scale="6" id="f-454">1.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="sttk:OtherResearchAndDevelopmentExpenseTechnicalOperations" scale="6" id="f-455">2.4</ix:nonFraction> million, research activities for other pipeline compounds and facility expenses of $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="6" id="f-456">1.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="6" id="f-457">1.3</ix:nonFraction> million and depreciation expense of $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-458">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-459">0.9</ix:nonFraction> million for the three months ended March 31, 2026 and 2025, respectively.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">3</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Other research and development expense includes a gain of $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" sign="-" name="sttk:OtherResearchAndDevelopmentExpenseTechnicalOperations" scale="6" id="f-460">0.7</ix:nonFraction> million due to a change in estimate and expense of $<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="sttk:OtherResearchAndDevelopmentExpenseTechnicalOperations" scale="6" id="f-461">2.0</ix:nonFraction> million for the three months ended March 31, 2026 and 2025, respectively, related to SL-172154 which was discontinued in October 2024.</span></div></ix:continuation></ix:nonNumeric><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i2d8e618db7b2478ba6efdb70e68630b1_61"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed financial statements and related notes appearing in this Quarterly Report on Form 10-Q, as well as the audited financial statements, notes and Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December&#160;31, 2025. This discussion and other parts of this Quarterly Report on Form 10-Q contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the &#8220;Risk Factors&#8221; section of this Quarterly Report on Form 10-Q. You should carefully read the &#8220;Cautionary Note About Forward-Looking Statements&#8221; of this Quarterly Report on Form 10-Q and the &#8220;Risk Factors&#8221; section of our Annual Report on Form 10-K for the year ended December 31, 2025 to gain an understanding of the important factors that could cause actual results to differ materially from the results described below. </span></div><div id="i2d8e618db7b2478ba6efdb70e68630b1_64"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific Death Receptor 3 (&#8220;DR3&#8221;) blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases. Our expertise in protein engineering and the development of novel tumor necrosis factor (&#8220;TNF&#8221;) receptor therapeutics come together in our lead program, SL-325, a potentially first-in-class DR3 blocking antibody designed to achieve a more complete blockade of the clinically validated DR3/TL1A pathway than TL1A blocking antibodies. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">SL-325 is a high-affinity DR3 blocking monoclonal antibody. DR3 is the sole known receptor for tumor necrosis factor like ligand 1A ("TL1A"). In our head-to-head preclinical studies, SL-325 blocked TL1A binding to DR3 better than sequence equivalents of leading TL1A blocking antibodies. We believe that the underlying biological differences in the expression of DR3 and TL1A, and the design characteristics of SL-325, may allow SL-325 to achieve best-in-class clinical remission rates in patients with inflammatory bowel disease ("IBD") due to a more complete and durable blockade of the clinically validated DR3/TL1A pathway. Additionally, we expect that SL-325 has the potential to demonstrate a superior immunogenicity profile in comparison to TL1A blocking antibodies. By targeting DR3 instead of TL1A, we expect to avoid the formation of immune complexes, which we believe are the primary source of immunogenicity for all TL1A blocking antibodies, and lead to high rates of anti-drug antibody (&#8220;ADA&#8221;) formation toward TL1A targeting antibodies. ADA to TL1A targeting antibodies has been shown to reduce efficacy in IBD patients. We are currently conducting a single ascending dose (&#8220;SAD&#8221;) and multiple ascending dose (&#8220;MAD&#8221;) Phase 1 clinical trial evaluating SL-325 in healthy volunteers. We expect this Phase 1 clinical trial to be completed in the second quarter of 2026. We expect to initiate a randomized, placebo-controlled Phase 2 clinical trial evaluating SL-325 in patients with Crohn&#8217;s Disease (&#8220;CD&#8221;) in the third quarter of 2026.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">TL1A is the sole known signaling ligand for DR3, and TL1A does not signal through any other receptors. Thus, we believe that the clinical safety profile of TL1A blocking antibodies generated to date in clinical trials conducted by other parties derisks the clinical safety profile for DR3 blockade. The lack of toxicity of SL-325 in our recently completed non-human primate (&#8220;NHP&#8221;) acute toxicology study also suggests a potentially favorable clinical safety profile. We engineered SL-325 to lack any Fc gamma receptor binding function, and SL-325 has not shown any evidence in our preclinical studies to date of antibody dependent cellular cytotoxicity or cellular phagocytosis, which further supports a potentially derisked safety profile. We have demonstrated that SL-325 binds an epitope on DR3 that does not trigger receptor-mediated endocytosis, and the binding of SL-325 to DR3 was shown to be highly durable in our preclinical assays and in our NHP studies. Because DR3 is expressed on circulating, peripheral blood lymphocytes, we are able to directly measure DR3 receptor occupancy (&#8220;RO&#8221;), and our nonclinical studies suggest that blockade is durable for at least two months as a result of the properties of SL-325 and the stable expression of DR3. In our preclinical studies, including our acute NHP toxicology study, the RO and pharmacokinetic (&#8220;PK&#8221;) profile of SL-325 suggest extended dosing intervals, which are being further characterized in our ongoing Phase 1 clinical trial. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">DR3 has a distinct expression pattern from TL1A, and, consequently, blocking the receptor may allow a more complete and durable blockade of the axis, which we believe will translate to improved efficacy in patients with IBD. DR3 and TL1A have distinct expression patterns within the gastrointestinal tract (&#8220;GI&#8221;) of patients with IBD, including both ulcerative colitis (&#8220;UC&#8221;) and Crohn&#8217;s disease (&#8220;CD&#8221;). The cells within the GI tract that are capable of expressing TL1A include tissue resident antigen presenting cells and other non-hematopoietic cells. While TL1A is not usually expressed, when antigen presenting cells are exposed to inflammatory signals, a wave of TL1A mRNA expression begins, which peaks within 12 hours and ceases within 24 hours. In contrast, DR3 is stably expressed, primarily by lymphocytes both in the peripheral blood and in tissues. Direct comparison of TL1A and DR3 expression in the GI tracts of patients with IBD shows that TL1A is only upregulated in the actively inflamed areas of the GI tract. In contrast, DR3 is more abundant than TL1A and is upregulated in both actively inflamed parts of the GI tissue and in the adjacent non-inflamed tissue. The absence of TL1A in the non-inflamed areas of the bowel eliminates the mechanism through which TL1A blocking antibodies would be retained in non-inflamed areas of the GI tract. Because inflammation observed in UC and CD can wax and wane in different areas of the bowel over time, stable blockade of DR3 may reduce the spread of inflammation and may contribute to higher rates of clinical and endoscopic remission than what TL1A blocking antibodies have achieved to date. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A source of immunogenicity shared by all TL1A blocking antibodies is the formation of immune complexes between soluble TL1A in the blood and the anti-TL1A antibodies. Binding of soluble TL1A in the blood by anti-TL1A antibodies leads to a significant increase in the concentration of total TL1A in the blood. These immune complexes have contributed to ADA formation in more than 64% of subjects treated with afimkibart, tulisokibart, or duvakitug in third-party clinical trials. A third-party Phase 2 trial testing the efficacy of afimkibart in CD patients demonstrated that ADA caused accelerated clearance of afimkibart, which reduced efficacy in an ADA titer dependent manner. Because DR3 is a membrane-restricted receptor, and SL-325 was engineered to bind an epitope on DR3 that is not found on DcR3, immune complex formation is not expected with SL-325. Data generated from our GLP acute NHP toxicology study, along with </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in silico</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> assessment of immunogenicity risk, consistently suggest that SL-325 may have single digit ADA rates in humans. Thus, we expect that SL-325 has the potential to demonstrate a best-in-mechanism immunogenicity profile, and we expect that this superior immunogenicity profile alone will lead to improved efficacy as a monotherapy, at both the induction and maintenance time points.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, there is a high degree of sequence identity between certain third-party anti-TL1A antibodies, including tulisokibart, afimkibart, and duvakitug, and potential third-party combination agents, including vedolizumab, risankizumab, mirikizumab, and guselkumab. This overlap in sequence identity introduces a risk that ADAs generated against TL1A antibodies may cross-bind to these potential combination agents and could cause accelerated clearance of both the anti-TL1A antibody and other antibodies included in a coformulation, and that this may impact the efficacy of each agent. Because of this, we believe that SL-325 may allow for improved efficacy in combination with other agents, compared to TL1A targeting antibodies.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are planning initial clinical development of SL-325 in patients with CD. The clinical success of several TL1A blocking antibodies to date suggests that SL-325 may have monotherapy disease modifying activity early in clinical development. As described above, we believe that targeting DR3 may be more efficacious than targeting TL1A in patients with IBD. We have completed enrollment in the ongoing Phase 1 clinical trial for SL-325 in healthy volunteers in the second quarter of 2026, with participant follow-up, data collection, and data analysis ongoing. We expect to initiate our Phase 2 clinical trial in patients with CD in the third quarter of 2026. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We also plan to evaluate SL-325 in other inflammatory and immune-mediated diseases where the DR3/TL1A axis is implicated. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition to SL-325 and SL-425 (a half-life extended version of SL-325), we are developing bispecific antibodies which co-target DR3 and other clinically validated targets in immune mediated and inflammatory diseases. Inhibition of the TL1A/DR3 axis may be mechanistically distinct from the IL-23/IL-23R, IL-17/IL-17R, TSLP/TSLP-R or &#945;4&#946;7/MADCAM-1 axes (as examples). Thus, dual inhibition of the TL1A/DR3 axis with coformulated or bispecific antibodies may provide additive clinical benefit in a variety of immune mediated and inflammatory diseases. As seen with TL1A directed antibodies, two third-party TL1A-directed bispecific antibodies, AMG966 and RO7837195, have also demonstrated nearly 100% ADA formation following a single dose in Phase 1 clinical trials. The mechanism of ADA formation was reported to be secondary to large immune complex formation for AMG966, which we believe is also true for RO7837195. The emerging clinical data from TL1A-directed </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">bispecific antibodies is similar to the prior failure of TNF&#945;-directed bispecific antibodies, which we believe is because both TNF&#945; and TL1A are soluble trimeric proteins found in the blood, and cause immunogenicity secondary to large immune complex formation. We expect that our DR3-directed bispecific antibodies to be less immunogenic than TL1A-directed bispecifics. DR3 may thus provide a differentiated target in a bispecific antibody format, providing advantages over TL1A-directed bispecific antibodies. Additionally, development of bispecific antibodies may enable more efficient clinical development than is expected for multi-antibody coformulations, and may avoid some of the challenges associated with potential immunogenicity in certain coformulations, as described above. </span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Research Programs</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a strong research organization that has developed a diverse pipeline of preclinical compounds. One of our guiding principles for considering additional pipeline candidates is a preference for compounds that we expect to have monotherapy activity early in clinical development. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DR3 Bispecific Antibodies</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition to SL-325 and SL-425, we are developing a series of bispecific antibodies targeting DR3 and other clinically validated targets. The future of biologic therapy for both UC and CD is widely believed to include blockade of multiple inflammatory pathways, and the mechanism of DR3/TL1A inhibition is known to be non-redundant with the mechanism of other clinically validated targets. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Several attempts have been made to develop bispecific antibodies targeting TL1A, including a TL1A and TNF&#945; blocking antibody known as AMG966. As discussed above, TL1A blocking antibodies stabilize serum TL1A as a result of immune complex formation between soluble TL1A and anti-TL1A antibodies. These immune complexes are believed to contribute to the high rates of ADA formation with TL1A blocking monoclonal antibodies. In the case of AMG966, the bispecific antibody was shown to stabilize both soluble TL1A and TNF&#945;, which led to large immune complex formation and the rapid development of high-titer neutralizing ADA responses in patients treated in a third-party Phase 1 clinical trial. AMG966 was discontinued as a result of this immunogenicity. A second TL1A directed bispecific antibody, RO7837195, targets TL1A and IL-23 p40. This antibody was also tested in a third-party Phase 1 clinical trial in healthy volunteers. Like AMG966, RO7837195 also induced ADA in nearly 100% of treated subjects after a single dose, and most of these ADA were also neutralizing. These two clinical trials suggest high rates of ADA may be unavoidable for TL1A-directed bispecific antibodies. The emerging clinical data for TL1A-directed bispecific antibodies is similar to the prior failure of multiple TNF&#945;-directed bispecific antibodies. Both TNF&#945; and TL1A are soluble trimeric proteins, and binding of bispecific antibodies to these proteins is known to cause large immune complex formation which results in the formation of ADA in nearly all treated subjects. Because DR3 is a membrane-restricted target, immune complex formation is not expected either for SL-325, SL-425, or DR3 directed bispecific antibodies.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Overview of Operations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2026 and 2025, our net loss was $14.8 million and $13.7 million, respectively. We have not been profitable since inception, and as of March&#160;31, 2026, we had an accumulated deficit of $445.3&#160;million&#160;and $90.4&#160;million&#160;in cash and cash equivalents. We expect to continue to incur significant expenses and operating losses in the near term in connection with our ongoing activities, as we: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue Phase 1 clinical development of our lead product candidate, SL-325;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiate nonclinical studies and clinical trials for additional product candidates that we may identify in the future, including potential DR3 based bispecific antibodies targeting DR3 together with another biologically relevant target; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacture sufficient quantities of bulk drug substance and drug product to support our ongoing and planned nonclinical studies and clinical trials; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain our operational, financial, and management systems;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">retain key personnel and infrastructure to support our nonclinical development, research and manufacturing, and future clinical development efforts;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">utilize our in-house process development and manufacturing capabilities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to develop, perfect, and defend our intellectual property portfolio; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur additional legal, accounting, or other expenses in operating our business, including the additional costs associated with operating as a public company and expenses incurred in connection with ongoing and future litigation, if any.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect to generate significant product revenue unless and until we successfully complete development and obtain regulatory and marketing approval of, and begin to sell, one or more of our product candidates, if ever, which we expect will take several years. We expect to spend a significant amount in development and marketing costs prior to such time. We may never succeed in achieving regulatory and marketing approval for our product candidates. We may obtain unexpected results from our nonclinical studies and clinical trials. We may elect to discontinue, delay, or modify nonclinical studies and clinical trials of our product candidates. We may be adversely affected by inflationary pressures and the macroeconomic environment, which are beyond our control. A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. Accordingly, until such time as we can generate significant product revenue, if ever, we expect to continue to seek private or public equity and debt financing, and/or additional collaborations with third parties, to meet our capital requirements. There can be no assurance that such funding may be available to us on acceptable terms, or at all, or that we will be able to commercialize our product candidates. In addition, we may not be profitable even if we commercialize any of our product candidates.</span></div><div id="i2d8e618db7b2478ba6efdb70e68630b1_67"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Global Economic Considerations </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The global macroeconomic environment is uncertain, and could be negatively affected by, among other things, inflation, slower growth or recession, changes in trade policies, including tariffs or other trade restrictions or the threat of such actions, instability or volatility in the global capital and credit markets, supply chain weaknesses, financial institution instability, changes to fiscal and monetary policy or government budget dynamics and instability in the geopolitical environment. Such challenges have caused, and may continue to cause, recession fears, high interest rates, foreign exchange volatility, and inflationary pressures. At this time, we are unable to quantify the potential effects of this economic instability on our future operations.</span></div><div id="i2d8e618db7b2478ba6efdb70e68630b1_70"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Components of our Results of Operations </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Related Party License Revenue</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized in 2025 was a result of an exclusive license agreement (the "Kayak Agreement") with Kayak Therapeutics, Inc. (&#8220;Kayak&#8221;) for our oncology-focused TRIM7 program, which we entered into in August 2025. Pursuant to the Kayak Agreement, we received preferred stock of Kayak with a fair market value of $1.0 million as upfront consideration for entering into the agreement and recognized the consideration as license revenue.</span><span style="color:#008080;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expense </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses consist primarily of costs incurred in connection with the discovery and development of our current and potential future product candidates. These expenses include: </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred to conduct our clinical trials, including expenses associated with clinical trials of SL-325 and any potential product candidates we may advance in the future;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of manufacturing nonclinical study and clinical trial materials, including the costs of raw materials required for manufacturing;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">process development activities to optimize manufacturing processes, including the development and validation of Phase 3 and commercial manufacturing processes and analytical methods;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred to conduct our nonclinical studies;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, including salaries, benefits, and stock-based compensation;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">laboratory materials and supplies used to support our research activities;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fees paid to third parties who assist with research and development activities;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses relating to regulatory activities, including filing fees paid to regulatory agencies; and</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">allocated expenses for facility-related costs.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our research and development expenses by product candidate: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.521%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">(in thousands)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">SL-325</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,861&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other pipeline compounds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Internal costs, including personnel related benefits, facilities and depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total research and development costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,946&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9,919&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Expenses for SL-325 that were incurred prior to it being nominated as a product candidate are included in "other pipeline compounds&#8221; in the table above.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are central to our business model. We are focused on the preclinical and clinical development of SL-325 and other DR3 targeted assets, and conducting additional research on other potential product candidates. Product candidates in earlier stages of development generally have lower development costs than those in later stages of development. In 2026, we anticipate initiating Phase 2 clinical trial(s) for SL-325. Accordingly, we expect an increase in research and development and expense year-over-year, as we incur incremental clinical trial expenses and additional costs associated with commensurate increases in our workforce to support these efforts. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The process of conducting the necessary nonclinical and clinical research to obtain regulatory approval is costly and time consuming. The actual probability of success for our product candidates may be affected by a variety of factors including: </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the safety and efficacy of our product candidates; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">nonclinical data for our product candidates; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">investment in our pipeline; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing capability; and </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercial viability. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may never succeed in achieving regulatory approval for any of our product candidates due to the uncertainties discussed above. We are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of our product candidates, if ever. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expense </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense consists primarily of personnel expenses, including salaries, benefits, and stock-based compensation expense, for employees and consultants in executive, finance, accounting, legal, information technology, business development, and human resource functions. General and administrative expense also includes corporate facility costs, including rent, utilities, depreciation, and maintenance, not otherwise included in research and development expenses, as well as legal fees related to intellectual property, corporate, and litigation matters and fees for accounting and tax services. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If any of our current or future product candidates, including SL-325, continues to advance through clinical development, or obtains regulatory approval, we expect that we would incur increased expenses associated with </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">building the appropriate general and administrative support for our increased research and development activities, or building a sales and marketing team.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other income consists of interest earned on our cash, cash equivalents and short-term investments, which consists of amounts held in a money market fund and government obligations as well as investment fees and realized gain or losses on short-term investments (if any). </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have not recorded any income tax benefits for the net operating losses ("NOLs") we have incurred or for our research and development tax credits, as we believe, based upon the weight of available evidence, that it is more likely than not that all of our NOLs and tax credits will not be realized. Our capital loss and tax credit carryforwards as of December 31, 2025 began to expire in 2026. We have recorded a full valuation allowance against our deferred tax assets at each balance sheet date.</span></div><div id="i2d8e618db7b2478ba6efdb70e68630b1_73"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended March&#160;31, 2026 and 2025</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth our results of operations for the three months ended March&#160;31, 2026 and 2025: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.993%"><tr><td style="width:1.0%"/><td style="width:46.479%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.923%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.923%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.085%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.089%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Dollar</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Percentage</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,946&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(15,545)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(14,389)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,156)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other income:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(14,767)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(13,702)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,065)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by $1.0&#160;million, or 10.4%, to $10.9&#160;million for the three months ended March&#160;31, 2026 from $9.9&#160;million for the three months ended March&#160;31, 2025. The increase in research and development expenses was primarily due to an increase of $0.6 million in SL-325 expenses primarily as a result of moving SL-325 into clinical development in 2025, an increase in personnel related costs of $0.7 million partially offset by a decrease of $0.3 million in other pipeline compounds cost.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expense </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses remained relatively unchanged for the three months ended March&#160;31, 2026 as compared to the three months ended March&#160;31, 2025.&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other income increased by $0.1 million, or 13.2%, to $0.8 million for the three months ended March&#160;31, 2026 from $0.7 million for the three months ended March&#160;31, 2025 primarily as a result of an increase in our average investment balance.</span></div><div id="i2d8e618db7b2478ba6efdb70e68630b1_76"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, our primary sources of liquidity have been generated by sales of our common stock, pre-funded warrants, common stock warrants, convertible preferred stock, and convertible notes, and through </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">collaboration agreements. As of March&#160;31, 2026, we had an accumulated deficit of $445.3 million and $90.4 million of cash and cash equivalents.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In August 2025, we issued and sold 15,225,158 shares of common stock, pre-funded warrants to purchase up to 37,410,188 shares of common stock, and accompanying common stock warrants to purchase up to 52,635,346 shares of common stock for gross proceeds of $45.7 million. In 2026, 5,019,719 common stock warrants have been exercised for gross proceeds of $5.4 million and we may receive an additional $51.5 million in gross proceeds if the remaining common stock warrants are exercised.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In January 2026, we entered into a sales agreement (the &#8220;Sales Agreement&#8221;) with Leerink Partners LLC (the &#8220;Sales Agent&#8221;), pursuant to which we may offer and sell up to $75.0 million of shares of our common stock from time to time through our ATM Facility. The Sales Agent is generally entitled to compensation at a commission equal to up to 3.0% of the aggregate gross sales price per share sold under the Sales Agreement. For the three months ended March 31, 2026, we sold 5,000,000 shares of common stock at $4.28 per share for gross proceeds of $21.4&#160;million.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capital Resources and Funding Requirements </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our primary uses of cash, cash equivalents and short-term investments are to fund our operations, which consist primarily of research and development expenditures related to our programs, product development costs, research expenses, administrative support, capital expenditures related to bringing in-house certain process development and manufacturing capabilities, and working capital requirements. We anticipate incurring additional net losses and negative cash flows from operations in the near future until such time, if ever, that we can generate significant sales of our product candidates currently in development. Our future funding requirements will depend on many factors, including: </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, timing, progress and results of discovery, nonclinical development, laboratory testing, and clinical trials for our product candidates; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of process development and scale up of a commercially ready manufacturing process to support registrational clinical trials;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of manufacturing our product candidates for clinical trials and in preparation for marketing approval and commercialization;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we enter into collaborations or other arrangements with additional third parties in order to further develop our product candidates; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights, and defending other intellectual property-related claims; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and fees associated with the discovery, acquisition or in-license of additional product candidates or technologies; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of future commercialization activities, if any, including establishing sales, marketing, manufacturing, distribution and storage capabilities, for any of our product candidates for which we receive marketing approval; and </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Until we obtain regulatory approval to market our product candidates, if ever, we cannot generate revenues from sales of our products. Even if we are able to sell our products, we may not generate a sufficient amount of product revenues to finance our cash requirements. Accordingly, it will be necessary for us to seek to raise additional capital through equity offerings and/or debt financings or from other potential sources of liquidity, which may include new collaborations, licensing or other commercial agreements for one or more of our development programs or patent portfolios. There can be no assurance that such funding may be available to us on acceptable terms, or at all. The issuance of equity securities may result in dilution to stockholders and the issuance of debt securities may have rights, preferences and privileges senior to those of our common stock and the terms of any such debt securities could impose significant restrictions on our operations. The failure to raise funds as and when needed </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">could have a negative impact on our financial condition and ability to pursue our business strategies. Additionally, if additional funding is not secured when required, we may need to delay or curtail our operations until such funding is received, which would have a material and adverse impact on our business prospects and results of operations.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our cash and cash equivalents as of March&#160;31, 2026, and assuming the full exercise of the outstanding common stock warrants, are sufficient to fund projected operations into 2029.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a summary of our cash flows for the periods indicated: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.938%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.560%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.561%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">(in thousands)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(13,424)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(12,032)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">23,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">25,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net increase in cash and cash equivalents</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">36,227&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,511&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Used in Operating Activities </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2026, net cash used in operating activities was $13.4&#160;million and primarily reflected our net loss of $14.8 million and a $2.0 million decrease in our operating assets and liabilities partially offset by net non-cash operating charges of $3.4 million for stock-based compensation, depreciation expense, accretion of investments and non-cash operating lease expense. We expect to continue to use cash in our operating activities as we conduct our clinical trials and nonclinical studies, incur costs of manufacturing clinical trial and nonclinical study materials and continue process development activities to optimize our manufacturing processes.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2025, net cash used in operating activities was $12.0&#160;million and primarily reflected our net loss of $13.7 million and a $1.1 million decrease in our operating assets and liabilities partially offset by non-cash operating charges of $2.8 million for stock-based compensation, depreciation expense, accretion of investments and non-cash operating lease expense.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Provided by Investing Activities </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2026, net cash provided by investing activities was $23.8 million as a result of investment maturities.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2025, net cash provided by investing activities was $15.6 million, as a result of investment maturities.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Provided by (Used in) Financing Activities </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2026, net cash provided by financing activities was $25.8 million and was primarily a result of proceeds from the sale of common stock and exercise of common stock warrants for $26.0 million.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2025, minimal cash was used in financing activities.</span></div><div id="i2d8e618db7b2478ba6efdb70e68630b1_79"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Other Commitments </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See Note 5 to our condensed financial statements found elsewhere in this Quarterly Report on Form 10-Q for additional disclosures. There have been no other material changes from the Contractual Obligations and Other Commitments disclosed in Note 6 and 7 of our Annual Report on Form 10-K for the year ended December&#160;31, 2025.</span></div><div id="i2d8e618db7b2478ba6efdb70e68630b1_82"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these condensed financial statements requires us to make estimates </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and judgments that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to revenue recognition, the accrual for research and development expenses, and the valuation of stock-based awards. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our critical accounting policies are those policies which require the most significant judgments and estimates in the preparation of our financial statements. We believe that the assumptions and estimates associated with our most critical accounting policies are those relating to revenue, accrued research and development costs and stock-based compensation.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in our critical accounting policies and estimates as compared to the critical accounting policies and estimates disclosed in Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December&#160;31, 2025.</span></div><div id="i2d8e618db7b2478ba6efdb70e68630b1_85"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2 to our condensed financial statements found elsewhere in this Quarterly Report on Form 10-Q for a description of recent accounting pronouncements applicable to our financial statements.</span></div><div id="i2d8e618db7b2478ba6efdb70e68630b1_88"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company and Smaller Reporting Company Status</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We were previously an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, as amended ("JOBS Act"). The JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2025, we ceased to qualify as an emerging growth company. We continue to qualify as a &#8220;smaller reporting company&#8221; as defined in Rule 12b-2 under the 1934 Securities and Exchange Act (the "Exchange Act") and thus will continue to be permitted to make certain reduced disclosures in the Annual Report on Form 10-K and other periodic reports.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to be a smaller reporting company so long as (i)&#160;the market value of our stock held by non-affiliates is less than $250.0&#160;million or (ii)&#160;our annual revenue is less than $100.0&#160;million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700.0&#160;million. As long as we remain a smaller reporting company we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of financial statements in our Annual Report on Form&#160;10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </span></div><div id="i2d8e618db7b2478ba6efdb70e68630b1_91"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are a smaller reporting company, as defined by Rule 12b-2 under the Exchange Act and in Item 10(f)(1) of Regulation S-K, and are not required to provide the information under this item.</span></div><div id="i2d8e618db7b2478ba6efdb70e68630b1_94"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and our principal financial officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures. Based on this evaluation of our disclosure controls and procedures as of March&#160;31, 2026, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures as of such date are effective at the reasonable assurance level. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act means controls and other </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act are recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the first quarter of the year ending December&#160;31, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i2d8e618db7b2478ba6efdb70e68630b1_97"></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART II - OTHER INFORMATION</span></div><div id="i2d8e618db7b2478ba6efdb70e68630b1_100"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i2d8e618db7b2478ba6efdb70e68630b1_103"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to various risks, including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025. There have been no material changes from the risk factors disclosed in Item 1A of our Annual Report on Form 10-K.</span></div><div style="text-indent:27pt"><span><br/></span></div><div id="i2d8e618db7b2478ba6efdb70e68630b1_106"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i2d8e618db7b2478ba6efdb70e68630b1_109"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i2d8e618db7b2478ba6efdb70e68630b1_112"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div id="i2d8e618db7b2478ba6efdb70e68630b1_115"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information</span></div><ix:nonNumeric contextRef="c-105" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-462" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-105" name="ecd:TrdArrAdoptionDate" id="f-463">February 2, 2026</ix:nonNumeric>, <ix:nonNumeric contextRef="c-105" name="ecd:TrdArrIndName" id="f-464">Arunthathy Nirmalini (Lini) Pandite, M.B.Ch.B.,</ix:nonNumeric> the Company's <ix:nonNumeric contextRef="c-105" name="ecd:TrdArrIndTitle" id="f-465">Chief Medical Officer</ix:nonNumeric>, <ix:nonNumeric contextRef="c-105" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-466">adopted</ix:nonNumeric> a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act (a &#8220;10b5-1 Plan&#8221;). Dr. Pandite&#8217;s 10b5-1 Plan provides for the potential sale of up to <ix:nonFraction unitRef="shares" contextRef="c-106" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-467">83,514</ix:nonFraction> shares of the Company&#8217;s common stock and will expire on the earlier of <ix:nonNumeric contextRef="c-105" name="ecd:TrdArrExpirationDate" id="f-468">June 30, 2027</ix:nonNumeric> or the date when all shares under Dr. Pandite&#8217;s 10b5-1 Plan are sold.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-107" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-469" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-107" name="ecd:TrdArrAdoptionDate" id="f-470">February 2, 2026</ix:nonNumeric>, <ix:nonNumeric contextRef="c-107" name="ecd:TrdArrIndName" id="f-471">Abhinav Shukla, PhD.,</ix:nonNumeric> the Company's <ix:nonNumeric contextRef="c-107" name="ecd:TrdArrIndTitle" id="f-472">Chief Technical Officer</ix:nonNumeric>, <ix:nonNumeric contextRef="c-107" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-473">adopted</ix:nonNumeric> a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. Dr. Shukla&#8217;s 10b5-1 Plan provides for the potential exercise of stock options to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-108" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-474">168,659</ix:nonFraction> shares of the Company's common stock and subsequent sale of a portion of the exercised options to cover the exercise price and estimated income taxes associated with the exercise. The 10b5-1 Plan will expire on the earlier of <ix:nonNumeric contextRef="c-107" name="ecd:TrdArrExpirationDate" id="f-475">January 29, 2027</ix:nonNumeric> or the date when all shares under Dr. Shuckla&#8217;s 10b5-1 Plan are exercised.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The adoption of Dr. Pandite and Dr. Shukla's 10b5-1 plans were in accordance with both the Company's insider trading policy and SEC rules and regulations, on the date of adoption.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other than as described above, during the three months ended March 31, 2026, none of our directors or Section 16 officers (as defined in Rule 16a-1(f) under the Exchange Act) <ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-476">adopted</ix:nonNumeric> or <ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-477"><ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-478">terminated</ix:nonNumeric></ix:nonNumeric> a &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as each term is defined in Item 408(a) of Regulation S-K.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i2d8e618db7b2478ba6efdb70e68630b1_118"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6. Exhibits</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth below.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.156%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.003%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Description of Exhibit</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520269417/d72237dex31.htm">Amended and Restated Certificate of Incorporation of Shattuck Labs, Inc. (incorporated by reference from Exhibit 3.1 to Shattuck&#8217;s Current Report on Form 8-K filed on October 14, 2020 (Commission File No. 001-39593))</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520269417/d72237dex32.htm">Amended and Restated Bylaws of Shattuck Labs, Inc. (incorporated by reference from Exhibit 3.2 to Shattuck&#8217;s Current Report on Form 8-K filed on October 14, 2020 (Commission File No. 001-39593))</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520263321/d69956dex41.htm">Form of common stock certificate of Shattuck (incorporated by reference from Exhibit 4.1 of Shattuck&#8217;s Amendment No. 2 to Registration Statement on Form S-1 filed on October 8, 2020 (Commission File No. 333-248918))</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520249204/d69956dex42.htm">Second Amended and Restated Investors&#8217; Rights Agreement, dated as of June 12, 2020, by and among Shattuck Labs, Inc. and certain of its stockholders (incorporated by reference from Exhibit 4.2 of Shattuck&#8217;s Amendment No. 2 to Registration Statement on Form S-1 filed on October 8, 2020 (Commission File No. 333-248918))</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">10.1*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="ibc-shattucklabs_1stamen.htm">First </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="ibc-shattucklabs_1stamen.htm">A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="ibc-shattucklabs_1stamen.htm">mendment to Texas Lease Agreement</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">10.2*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="ibcbankplazasecondamendm.htm">S</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="ibcbankplazasecondamendm.htm">econd Amendment to Texas Lease Agreement</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">31.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="sub-certxsection302xceoxq1.htm">Certification of the principal executive officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">31.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="sub-certxsection302xcfoxq1.htm">Certification of the principal financial officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">32.1* (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="sub-certxsection906ofthesa.htm">Certification of the principal executive officer and principal financial officer pursuant to 18 U.S.C. Section 1350 and Rule 13a-14(b) under the Securities Exchange Act of 1934</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Inline XBRL Instance Document </span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Definition</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">104*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">The cover page for this report, formatted in Inline XBRL (included in Exhibit 101)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">______________</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The certifications on Exhibit 32 hereto are deemed not &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section. Such certifications will not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i2d8e618db7b2478ba6efdb70e68630b1_121"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.380%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.094%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Shattuck Labs, Inc.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date: May&#160;07, 2026</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Dr. Taylor Schreiber</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Dr.&#160;Taylor Schreiber</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chief Executive Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(principal executive officer)</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date: May&#160;07, 2026</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Andrew R. Neill</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:104%">Andrew R. Neill</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:104%">Chief Financial Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(principal financial and accounting officer)</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ibc-shattucklabs_1stamen.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>ibc-shattucklabs_1stamen</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- ibc-shattucklabs_1stamen001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ibc-shattucklabs_1stamen001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ibc-shattucklabs_1stamen002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ibc-shattucklabs_1stamen002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ibc-shattucklabs_1stamen003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ibc-shattucklabs_1stamen003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ibc-shattucklabs_1stamen004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ibc-shattucklabs_1stamen004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ibc-shattucklabs_1stamen005.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ibc-shattucklabs_1stamen005.jpg" title="slide5" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ibcbankplazasecondamendm.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>ibcbankplazasecondamendm</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- ibcbankplazasecondamendm001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ibcbankplazasecondamendm001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ibcbankplazasecondamendm002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ibcbankplazasecondamendm002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ibcbankplazasecondamendm003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ibcbankplazasecondamendm003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ibcbankplazasecondamendm004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ibcbankplazasecondamendm004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>sub-certxsection302xceoxq1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ia2e6788c8e8940f8b9941e3b49fb75f2_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:167%">Exhibit 31.1</font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:125%">CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES</font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:125%">EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO </font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:125%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, Taylor Schreiber, certify that&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">1.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">I have reviewed this Quarterly Report on Form&#160;10-Q of Shattuck Labs, Inc.&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">2.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">3.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">4.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.767%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">a.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.461%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">b.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.461%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">c.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.461%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">d.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">5.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.767%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">a.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.461%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">b.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.074%"><tr><td style="width:1.0%"></td><td style="width:62.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.054%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58; May&#160;7, 2026</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47; Taylor Schreiber</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">Dr.&#160;Taylor Schreiber</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Chief Executive Officer</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">(principal executive officer)</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>sub-certxsection302xcfoxq1.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i47c4b01043b74874854de68f812edaf3_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:167%">Exhibit 31.2</font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:125%">CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES</font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:125%">EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO </font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:125%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, Andrew R. Neill, certify that&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.000%"><tr><td style="width:1.0%"></td><td style="width:3.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">1.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">I have reviewed this Quarterly Report on Form&#160;10-Q of Shattuck Labs, Inc.&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">2.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">3.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">4.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.767%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">a.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.461%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">b.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.461%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">c.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.114%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">d.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">5.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.767%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">a.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.461%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">b.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.305%"><tr><td style="width:1.0%"></td><td style="width:62.652%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.769%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58; May&#160;7, 2026</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47; Andrew R. Neill</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:104%">Andrew R. Neill</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:104%">Chief Financial Officer</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(principal financial and accounting officer)</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>sub-certxsection906ofthesa.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i6510bee2eb9147ebaf8264e3b730cfce_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:167%">Exhibit 32.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:7pt;margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Shattuck Labs, Inc. (the &#8220;Company&#8221;) for the period ended March&#160;31, 2026</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:3.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.162%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">(1)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:3.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.162%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">(2)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:35.501%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.162%"></td><td style="width:0.1%"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58; May&#160;7, 2026</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47; Dr. Taylor Schreiber</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">Dr. Taylor Schreiber</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;padding-left:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%">Chief Executive Officer</font></div><div style="margin-top:2pt;padding-left:2pt;padding-right:2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">(principal executive officer)</font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2pt;padding-right:2pt"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58; May&#160;7, 2026</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47; Andrew R. Neill</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">Andrew R. Neill</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;padding-left:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%">Chief Financial Officer</font></div><div style="margin-top:2pt;padding-left:2pt;padding-right:2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">(principal financial and accounting officer)</font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2pt;padding-right:2pt"><font><br></font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167;1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Note&#58; A signed original of this written statement required by &#167;906 has been provided to Shattuck Labs, Inc. and will be retained by Shattuck Labs, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>sttk-20260331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019ce397-05b9-74d0-8227-66267d5910e2,g:518bbadf-25d7-41ee-8c01-9003cd0ed70a-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sttk="http://www.shattucklabs.com/20260331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.shattucklabs.com/20260331">
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sttk-20260331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sttk-20260331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sttk-20260331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sttk-20260331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.shattucklabs.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDBALANCESHEETS" roleURI="http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS">
        <link:definition>9952151 - Statement - CONDENSED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDBALANCESHEETSParenthetical" roleURI="http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETSParenthetical">
        <link:definition>9952152 - Statement - CONDENSED BALANCE SHEETS - Parenthetical</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>9952153 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" roleURI="http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
        <link:definition>9952154 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS">
        <link:definition>9952155 - Statement - CONDENSED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandDescriptionofBusiness" roleURI="http://www.shattucklabs.com/role/OrganizationandDescriptionofBusiness">
        <link:definition>9952156 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPolicies" roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies">
        <link:definition>9952157 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.shattucklabs.com/role/Investments">
        <link:definition>9952158 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilities" roleURI="http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilities">
        <link:definition>9952159 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.shattucklabs.com/role/CommitmentsandContingencies">
        <link:definition>9952160 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyLicenseRevenue" roleURI="http://www.shattucklabs.com/role/RelatedPartyLicenseRevenue">
        <link:definition>9952161 - Disclosure - Related Party License Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.shattucklabs.com/role/Equity">
        <link:definition>9952162 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationandEmployeeBenefitPlans" roleURI="http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlans">
        <link:definition>9952163 - Disclosure - Stock-Based Compensation and Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://www.shattucklabs.com/role/SegmentReporting">
        <link:definition>9952164 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9955511 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>9955512 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.shattucklabs.com/role/InvestmentsTables">
        <link:definition>9955513 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesTables" roleURI="http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables">
        <link:definition>9955514 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationandEmployeeBenefitPlansTables" roleURI="http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansTables">
        <link:definition>9955515 - Disclosure - Stock-Based Compensation and Employee Benefit Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://www.shattucklabs.com/role/SegmentReportingTables">
        <link:definition>9955516 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandDescriptionofBusinessDetails" roleURI="http://www.shattucklabs.com/role/OrganizationandDescriptionofBusinessDetails">
        <link:definition>9955517 - Disclosure - Organization and Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>9955518 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails" roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails">
        <link:definition>9955519 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of property and equipment depreciation and amortization periods (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails" roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails">
        <link:definition>9955520 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of anti-dilutive securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsScheduleofInvestmentsDetails" roleURI="http://www.shattucklabs.com/role/InvestmentsScheduleofInvestmentsDetails">
        <link:definition>9955521 - Disclosure - Investments - Schedule of Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsNarrativeDetails" roleURI="http://www.shattucklabs.com/role/InvestmentsNarrativeDetails">
        <link:definition>9955522 - Disclosure - Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesDetails" roleURI="http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails">
        <link:definition>9955523 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.shattucklabs.com/role/CommitmentsandContingenciesDetails">
        <link:definition>9955524 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyLicenseRevenueDetails" roleURI="http://www.shattucklabs.com/role/RelatedPartyLicenseRevenueDetails">
        <link:definition>9955525 - Disclosure - Related Party License Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityDetails" roleURI="http://www.shattucklabs.com/role/EquityDetails">
        <link:definition>9955526 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationandEmployeeBenefitPlansNarrativeDetails" roleURI="http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansNarrativeDetails">
        <link:definition>9955527 - Disclosure - Stock-Based Compensation and Employee Benefit Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationandEmployeeBenefitPlansScheduleofstockbasedcompensationexpenseDetails" roleURI="http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofstockbasedcompensationexpenseDetails">
        <link:definition>9955528 - Disclosure - Stock-Based Compensation and Employee Benefit Plans - Schedule of stock-based compensation expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationandEmployeeBenefitPlansScheduleofoptionactivityDetails" roleURI="http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofoptionactivityDetails">
        <link:definition>9955529 - Disclosure - Stock-Based Compensation and Employee Benefit Plans - Schedule of option activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationandEmployeeBenefitPlansScheduleofrestrictedstockactivityDetails" roleURI="http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofrestrictedstockactivityDetails">
        <link:definition>9955530 - Disclosure - Stock-Based Compensation and Employee Benefit Plans - Schedule of restricted stock activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationandEmployeeBenefitPlansScheduleof2020PlanoptionvaluationassumptionsDetails" roleURI="http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020PlanoptionvaluationassumptionsDetails">
        <link:definition>9955531 - Disclosure - Stock-Based Compensation and Employee Benefit Plans - Schedule of 2020 Plan option valuation assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationandEmployeeBenefitPlansScheduleof2020ESPPvaluationassumptionsDetails" roleURI="http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020ESPPvaluationassumptionsDetails">
        <link:definition>9955532 - Disclosure - Stock-Based Compensation and Employee Benefit Plans - Schedule of 2020 ESPP valuation assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingDetails" roleURI="http://www.shattucklabs.com/role/SegmentReportingDetails">
        <link:definition>9955533 - Disclosure - Segment Reporting (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent" abstract="false" name="AccruedLiabilitiesAndOtherLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_PreFundedWarrantsMember" abstract="true" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sttk_CommonStockWarrantsMember" abstract="true" name="CommonStockWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sttk_StockIssuedDuringPeriodSharesWarrantExercises" abstract="false" name="StockIssuedDuringPeriodSharesWarrantExercises" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sttk_StockIssuedDuringPeriodValueWarrantExercises" abstract="false" name="StockIssuedDuringPeriodValueWarrantExercises" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_IncreaseDecreaseInOperatingLeasesRightOfUseAssetsLiability" abstract="false" name="IncreaseDecreaseInOperatingLeasesRightOfUseAssetsLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_PrepaidExpenseAndOtherAssetsPolicyPolicyTextBlock" abstract="false" name="PrepaidExpenseAndOtherAssetsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="sttk_WarrantsPolicyTextBlock" abstract="false" name="WarrantsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="sttk_OperatingAccountMember" abstract="true" name="OperatingAccountMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sttk_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sttk_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrentMember" abstract="true" name="DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sttk_AccruedResearchAndDevelopmentContractCostsCurrent" abstract="false" name="AccruedResearchAndDevelopmentContractCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_KayakAgreementMember" abstract="true" name="KayakAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sttk_KayakAgreementContingentMilestonesMember" abstract="true" name="KayakAgreementContingentMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sttk_SubleaseAgreementConsideration" abstract="false" name="SubleaseAgreementConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_UnderwrittenPublicOfferingMember" abstract="true" name="UnderwrittenPublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sttk_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sttk_BeneficialOwnersMember" abstract="true" name="BeneficialOwnersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sttk_CommonStockNumberOfVotesPerCommonShare" abstract="false" name="CommonStockNumberOfVotesPerCommonShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sttk_ClassOfWarrantOrRightPriceOfPreFundedWarrants" abstract="false" name="ClassOfWarrantOrRightPriceOfPreFundedWarrants" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="sttk_ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise" abstract="false" name="ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="sttk_ClassOfWarrantOrRightWarrantsExercised" abstract="false" name="ClassOfWarrantOrRightWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sttk_SaleOfStockMaximumAggregateSalesPrice" abstract="false" name="SaleOfStockMaximumAggregateSalesPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_SaleOfStockCommissionPercentage" abstract="false" name="SaleOfStockCommissionPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sttk_A2020StockIncentivePlanMember" abstract="true" name="A2020StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sttk_A2020EmployeeStockPurchasePlanMember" abstract="true" name="A2020EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" abstract="false" name="CommonStockAdditionalCapitalSharesReservedForFutureIssuance" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sttk_BlackScholesOptionPricingModelMember" abstract="true" name="BlackScholesOptionPricingModelMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sttk_ReportableSegmentMember" abstract="true" name="ReportableSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sttk_SL325Member" abstract="true" name="SL325Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sttk_OtherResearchAndDevelopmentMember" abstract="true" name="OtherResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sttk_OtherResearchAndDevelopmentSL172154Member" abstract="true" name="OtherResearchAndDevelopmentSL172154Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sttk_ResearchAndDevelopmentNonEquityCompensation" abstract="false" name="ResearchAndDevelopmentNonEquityCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_ResearchAndDevelopmentEquityCompensation" abstract="false" name="ResearchAndDevelopmentEquityCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_GeneralAndAdministrativeNonEquityCompensation" abstract="false" name="GeneralAndAdministrativeNonEquityCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_GeneralAndAdministrativeEquityCompensation" abstract="false" name="GeneralAndAdministrativeEquityCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_OtherResearchAndDevelopmentExpenseTechnicalOperations" abstract="false" name="OtherResearchAndDevelopmentExpenseTechnicalOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_ArunthathyNirmaliniLiniPanditeM.B.Ch.B.Member" abstract="true" name="ArunthathyNirmaliniLiniPanditeM.B.Ch.B.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sttk_AbhinavShuklaPhDMember" abstract="true" name="AbhinavShuklaPhDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>sttk-20260331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019ce397-05b9-74d0-8227-66267d5910e2,g:518bbadf-25d7-41ee-8c01-9003cd0ed70a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item"/>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS" xlink:type="simple" xlink:href="sttk-20260331.xsd#CONDENSEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019ce397-05ba-703a-8bca-8d731771e1da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_019ce397-05ba-707d-af58-c60e9ddae4bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019ce397-05ba-703a-8bca-8d731771e1da" xlink:to="loc_us-gaap_AccountsPayableCurrent_019ce397-05ba-707d-af58-c60e9ddae4bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_019ce397-05ba-75be-b1a3-a0e78bd8f7ac" xlink:href="sttk-20260331.xsd#sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019ce397-05ba-703a-8bca-8d731771e1da" xlink:to="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_019ce397-05ba-75be-b1a3-a0e78bd8f7ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_019ce397-05ba-7672-9c62-1b1cc0d48ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019ce397-05ba-70c9-add9-099bbd3f367a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019ce397-05ba-7672-9c62-1b1cc0d48ca4" xlink:to="loc_us-gaap_AssetsCurrent_019ce397-05ba-70c9-add9-099bbd3f367a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_019ce397-05ba-7d59-87e9-75fab1fec487" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019ce397-05ba-7672-9c62-1b1cc0d48ca4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_019ce397-05ba-7d59-87e9-75fab1fec487" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent_019ce397-05ba-7638-b6d8-4b3df916bd10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019ce397-05ba-7672-9c62-1b1cc0d48ca4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent_019ce397-05ba-7638-b6d8-4b3df916bd10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_019d09f6-1697-7eb0-a1d7-43e1dcaacbf6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019ce397-05ba-7672-9c62-1b1cc0d48ca4" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_019d09f6-1697-7eb0-a1d7-43e1dcaacbf6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019ce397-05ba-78a1-8131-9680815f8dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019ce397-05ba-7c43-95f7-d2ea66581ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019ce397-05ba-78a1-8131-9680815f8dbf" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019ce397-05ba-7c43-95f7-d2ea66581ccc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019ce397-05ba-7a7d-92f3-aeb84100cef2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019ce397-05ba-78a1-8131-9680815f8dbf" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019ce397-05ba-7a7d-92f3-aeb84100cef2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_019ce397-05ba-770a-b098-f56fde8978d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019ce397-05ba-78a1-8131-9680815f8dbf" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_019ce397-05ba-770a-b098-f56fde8978d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_019ce397-05ba-7dad-991c-28761754d317" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_019ce397-05ba-7f31-a6bf-1c4c07d1f337" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019ce397-05ba-7dad-991c-28761754d317" xlink:to="loc_us-gaap_CommitmentsAndContingencies_019ce397-05ba-7f31-a6bf-1c4c07d1f337" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_019ce397-05ba-77b9-8cbd-ba588c827f55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019ce397-05ba-7dad-991c-28761754d317" xlink:to="loc_us-gaap_Liabilities_019ce397-05ba-77b9-8cbd-ba588c827f55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019ce397-05ba-736a-a8ff-9585cd93b0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019ce397-05ba-7dad-991c-28761754d317" xlink:to="loc_us-gaap_StockholdersEquity_019ce397-05ba-736a-a8ff-9585cd93b0ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019ce397-05ba-7377-b787-9358f02480ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019ce397-05ba-77ee-b028-e709349e334e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019ce397-05ba-7377-b787-9358f02480ca" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019ce397-05ba-77ee-b028-e709349e334e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_019ce397-05ba-7d8f-8576-cab38f7ecd85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019ce397-05ba-7377-b787-9358f02480ca" xlink:to="loc_us-gaap_AdditionalPaidInCapital_019ce397-05ba-7d8f-8576-cab38f7ecd85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019ce397-05ba-756f-9b6a-3e209494de10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019ce397-05ba-7377-b787-9358f02480ca" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019ce397-05ba-756f-9b6a-3e209494de10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_019ce397-05ba-7992-bb28-a7e1d5eeed36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019ce397-05ba-7377-b787-9358f02480ca" xlink:to="loc_us-gaap_CommonStockValue_019ce397-05ba-7992-bb28-a7e1d5eeed36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_019ce397-05ba-7fef-82e0-f8eb25913b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019ce397-05ba-7cf8-9dec-f6aebc948ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019ce397-05ba-7fef-82e0-f8eb25913b1a" xlink:to="loc_us-gaap_LiabilitiesCurrent_019ce397-05ba-7cf8-9dec-f6aebc948ca8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_019ce397-05ba-72c1-bd13-8a51417e3a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019ce397-05ba-7fef-82e0-f8eb25913b1a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_019ce397-05ba-72c1-bd13-8a51417e3a1c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="sttk-20260331.xsd#CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019ce397-05ba-764e-ab1f-cb181dee3d13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_019ce397-05ba-7821-886e-42b21b928f48" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_019ce397-05ba-764e-ab1f-cb181dee3d13" xlink:to="loc_us-gaap_OperatingExpenses_019ce397-05ba-7821-886e-42b21b928f48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019ce397-05ba-793b-a959-c886061b77e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_019ce397-05ba-764e-ab1f-cb181dee3d13" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019ce397-05ba-793b-a959-c886061b77e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019ce397-05ba-728c-8305-4cc3a673737a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019ce397-05ba-7658-a48e-15ceb098b150" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019ce397-05ba-728c-8305-4cc3a673737a" xlink:to="loc_us-gaap_OperatingIncomeLoss_019ce397-05ba-7658-a48e-15ceb098b150" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_019ce397-05ba-7021-aa3f-919acdfd252b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019ce397-05ba-728c-8305-4cc3a673737a" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_019ce397-05ba-7021-aa3f-919acdfd252b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_019ce397-05ba-79ac-b0ff-d3efdd362781" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019ce397-05ba-774e-a669-3c22a143f902" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_019ce397-05ba-79ac-b0ff-d3efdd362781" xlink:to="loc_us-gaap_NetIncomeLoss_019ce397-05ba-774e-a669-3c22a143f902" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_019ce397-05ba-7803-aacf-ca2f2c81e33c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_019ce397-05ba-79ac-b0ff-d3efdd362781" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_019ce397-05ba-7803-aacf-ca2f2c81e33c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_019ce397-05ba-795d-bcb9-245d63aea168" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019ce397-05ba-7ff8-8283-bee3f147e027" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_019ce397-05ba-795d-bcb9-245d63aea168" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019ce397-05ba-7ff8-8283-bee3f147e027" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_019ce397-05ba-790f-a1ed-77201b503689" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_019ce397-05ba-795d-bcb9-245d63aea168" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_019ce397-05ba-790f-a1ed-77201b503689" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_019d4dc2-6fe5-74e4-8b0f-3574f48a7ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_019d4dc2-6fe5-7e3d-92fe-cdf1dac38369" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_019d4dc2-6fe5-74e4-8b0f-3574f48a7ab8" xlink:to="loc_us-gaap_InvestmentIncomeInterest_019d4dc2-6fe5-7e3d-92fe-cdf1dac38369" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_019d4dc2-6fe5-79c6-8efe-7508df533caa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_019d4dc2-6fe5-74e4-8b0f-3574f48a7ab8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_019d4dc2-6fe5-79c6-8efe-7508df533caa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sttk-20260331.xsd#CONDENSEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019ce397-05ba-745e-92c7-3a489abdefff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_019ce397-05ba-7705-8cce-72b1365eb92e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019ce397-05ba-745e-92c7-3a489abdefff" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_019ce397-05ba-7705-8cce-72b1365eb92e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_019ce397-05ba-7a47-8b6a-fce194ed2695" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019ce397-05ba-745e-92c7-3a489abdefff" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_019ce397-05ba-7a47-8b6a-fce194ed2695" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019ce397-05ba-75d3-bf35-3d7ae03f0411" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019ce397-05ba-730c-9bf0-5d8c26f723c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019ce397-05ba-75d3-bf35-3d7ae03f0411" xlink:to="loc_us-gaap_NetIncomeLoss_019ce397-05ba-730c-9bf0-5d8c26f723c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_019ce397-05ba-73b7-a530-8274801f9304" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019ce397-05ba-75d3-bf35-3d7ae03f0411" xlink:to="loc_us-gaap_ShareBasedCompensation_019ce397-05ba-73b7-a530-8274801f9304" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_019ce397-05ba-76b2-a2fa-27e3f55069db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019ce397-05ba-75d3-bf35-3d7ae03f0411" xlink:to="loc_us-gaap_Depreciation_019ce397-05ba-76b2-a2fa-27e3f55069db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_019ce397-05ba-7575-ba16-237dabba024a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019ce397-05ba-75d3-bf35-3d7ae03f0411" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_019ce397-05ba-7575-ba16-237dabba024a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_019ce397-05ba-7b7e-99fb-2154600823c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019ce397-05ba-75d3-bf35-3d7ae03f0411" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_019ce397-05ba-7b7e-99fb-2154600823c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019ce397-05ba-7b74-9c48-1064c5cd744c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019ce397-05ba-75d3-bf35-3d7ae03f0411" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019ce397-05ba-7b74-9c48-1064c5cd744c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_019ce397-05ba-7c7b-8745-45cdd6ce4579" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019ce397-05ba-75d3-bf35-3d7ae03f0411" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_019ce397-05ba-7c7b-8745-45cdd6ce4579" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_019ce397-05ba-710c-b8d7-52d55f0df7e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019ce397-05ba-75d3-bf35-3d7ae03f0411" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_019ce397-05ba-710c-b8d7-52d55f0df7e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_019ce397-05ba-7201-9952-93907b6eb6a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019ce397-05ba-75d3-bf35-3d7ae03f0411" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_019ce397-05ba-7201-9952-93907b6eb6a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_019ce397-05ba-7182-8f82-49d9c0396e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019ce397-05ba-75d3-bf35-3d7ae03f0411" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_019ce397-05ba-7182-8f82-49d9c0396e2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019ce397-05ba-7049-9e0c-b384c4812d01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019ce397-05ba-75f4-aa71-09fcec8c6d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019ce397-05ba-7049-9e0c-b384c4812d01" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019ce397-05ba-75f4-aa71-09fcec8c6d9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019ce397-05ba-7277-9231-e4c8535fa854" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019ce397-05ba-7049-9e0c-b384c4812d01" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019ce397-05ba-7277-9231-e4c8535fa854" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019ce397-05ba-7f39-a0fa-1ad3a857e01f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019ce397-05ba-7049-9e0c-b384c4812d01" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019ce397-05ba-7f39-a0fa-1ad3a857e01f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019ce397-05ba-740f-8023-78e690e42b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019ce397-05ba-7560-84bf-aebab6675027" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019ce397-05ba-740f-8023-78e690e42b8f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019ce397-05ba-7560-84bf-aebab6675027" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_019ce397-05ba-7e59-b6af-22c51fe8c7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019ce397-05ba-740f-8023-78e690e42b8f" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_019ce397-05ba-7e59-b6af-22c51fe8c7b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_019ce397-05ba-73a8-bd9a-2d925a87ea6c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019ce397-05ba-740f-8023-78e690e42b8f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_019ce397-05ba-73a8-bd9a-2d925a87ea6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_019d8b2a-3be7-72aa-b963-d5d6275167df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019ce397-05ba-740f-8023-78e690e42b8f" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_019d8b2a-3be7-72aa-b963-d5d6275167df" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/InvestmentsScheduleofInvestmentsDetails" xlink:type="simple" xlink:href="sttk-20260331.xsd#InvestmentsScheduleofInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.shattucklabs.com/role/InvestmentsScheduleofInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_019d0595-e040-7d5a-9dd1-0b640f04b0bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_019d0595-e040-7b28-92b1-50498fdeec41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_019d0595-e040-7d5a-9dd1-0b640f04b0bd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_019d0595-e040-7b28-92b1-50498fdeec41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019d0595-e040-77ae-88be-7e57e2f45142" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_019d0595-e040-7d5a-9dd1-0b640f04b0bd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019d0595-e040-77ae-88be-7e57e2f45142" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="sttk-20260331.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_019d059f-961a-785d-894d-048275162c0a" xlink:href="sttk-20260331.xsd#sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AccruedResearchAndDevelopmentContractCostsCurrent_019d059f-961a-7418-881f-39317eae0587" xlink:href="sttk-20260331.xsd#sttk_AccruedResearchAndDevelopmentContractCostsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_019d059f-961a-785d-894d-048275162c0a" xlink:to="loc_sttk_AccruedResearchAndDevelopmentContractCostsCurrent_019d059f-961a-7418-881f-39317eae0587" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019d059f-961a-7196-9479-57230830a640" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_019d059f-961a-785d-894d-048275162c0a" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019d059f-961a-7196-9479-57230830a640" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_019d059f-961a-7521-81d2-0e6ac81c0f39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_019d059f-961a-785d-894d-048275162c0a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_019d059f-961a-7521-81d2-0e6ac81c0f39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_019d059f-961a-70af-acea-500ca716367c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_019d059f-961a-785d-894d-048275162c0a" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_019d059f-961a-70af-acea-500ca716367c" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>sttk-20260331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019ce397-05b9-74d0-8227-66267d5910e2,g:518bbadf-25d7-41ee-8c01-9003cd0ed70a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sttk-20260331.xsd#CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019ce397-05ba-7f45-8699-885202b65958" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019ce397-05ba-748c-b439-7495f2bd0ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_019ce397-05ba-7f45-8699-885202b65958" xlink:to="loc_us-gaap_StatementTable_019ce397-05ba-748c-b439-7495f2bd0ac1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_019ce397-05ba-715a-8cef-60884953020f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_019ce397-05ba-748c-b439-7495f2bd0ac1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_019ce397-05ba-715a-8cef-60884953020f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019ce397-05ba-715a-8cef-60884953020f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019ce397-05ba-715a-8cef-60884953020f" xlink:to="loc_us-gaap_EquityComponentDomain_019ce397-05ba-715a-8cef-60884953020f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019ce397-05ba-7f76-9c20-c2f02205c93a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019ce397-05ba-715a-8cef-60884953020f" xlink:to="loc_us-gaap_EquityComponentDomain_019ce397-05ba-7f76-9c20-c2f02205c93a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019ce397-05ba-7f58-aa9d-aa34ad60ef0b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019ce397-05ba-7f76-9c20-c2f02205c93a" xlink:to="loc_us-gaap_CommonStockMember_019ce397-05ba-7f58-aa9d-aa34ad60ef0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_019ce397-05ba-7a07-ae04-2f767b96b213" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019ce397-05ba-7f76-9c20-c2f02205c93a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_019ce397-05ba-7a07-ae04-2f767b96b213" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019ce397-05ba-703f-ad97-fb63fd6863c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019ce397-05ba-7f76-9c20-c2f02205c93a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019ce397-05ba-703f-ad97-fb63fd6863c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_019ce397-05ba-7c34-a0e1-341de210be4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019ce397-05ba-7f76-9c20-c2f02205c93a" xlink:to="loc_us-gaap_RetainedEarningsMember_019ce397-05ba-7c34-a0e1-341de210be4f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_019dace2-a7d2-7641-95c2-06ca46738b70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_019ce397-05ba-748c-b439-7495f2bd0ac1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_019dace2-a7d2-7641-95c2-06ca46738b70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019dace2-a7d2-7641-95c2-06ca46738b70_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019dace2-a7d2-7641-95c2-06ca46738b70" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019dace2-a7d2-7641-95c2-06ca46738b70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019dace2-a7d2-7b1a-a4af-d7f32b508075" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019dace2-a7d2-7641-95c2-06ca46738b70" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019dace2-a7d2-7b1a-a4af-d7f32b508075" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_PreFundedWarrantsMember_019dace2-c3e9-7844-84d7-d277d78824d8" xlink:href="sttk-20260331.xsd#sttk_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019dace2-a7d2-7b1a-a4af-d7f32b508075" xlink:to="loc_sttk_PreFundedWarrantsMember_019dace2-c3e9-7844-84d7-d277d78824d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_CommonStockWarrantsMember_019dace2-ed75-705d-9aaa-e6693ac97eba" xlink:href="sttk-20260331.xsd#sttk_CommonStockWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019dace2-a7d2-7b1a-a4af-d7f32b508075" xlink:to="loc_sttk_CommonStockWarrantsMember_019dace2-ed75-705d-9aaa-e6693ac97eba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019ce397-05ba-7915-b759-77911a9aa0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019ce397-05ba-7f45-8699-885202b65958" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019ce397-05ba-7915-b759-77911a9aa0c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_019ce397-05ba-77b1-be2a-b96c0e1699f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019ce397-05ba-7915-b759-77911a9aa0c0" xlink:to="loc_us-gaap_SharesOutstanding_019ce397-05ba-77b1-be2a-b96c0e1699f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019ce397-05ba-782b-aeb2-3caa2f5afa83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019ce397-05ba-7915-b759-77911a9aa0c0" xlink:to="loc_us-gaap_StockholdersEquity_019ce397-05ba-782b-aeb2-3caa2f5afa83" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_019d8fa1-4a10-7b04-91b8-dae3aea64432" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019ce397-05ba-7915-b759-77911a9aa0c0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_019d8fa1-4a10-7b04-91b8-dae3aea64432" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_019d0a04-50df-7153-b599-fc034c013702" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019ce397-05ba-7915-b759-77911a9aa0c0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_019d0a04-50df-7153-b599-fc034c013702" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_StockIssuedDuringPeriodSharesWarrantExercises_019d8f41-5a55-7458-8745-4c0e10dadc3e" xlink:href="sttk-20260331.xsd#sttk_StockIssuedDuringPeriodSharesWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019ce397-05ba-7915-b759-77911a9aa0c0" xlink:to="loc_sttk_StockIssuedDuringPeriodSharesWarrantExercises_019d8f41-5a55-7458-8745-4c0e10dadc3e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_StockIssuedDuringPeriodValueWarrantExercises_019d229d-c09e-7e6f-9518-38b389e86cab" xlink:href="sttk-20260331.xsd#sttk_StockIssuedDuringPeriodValueWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019ce397-05ba-7915-b759-77911a9aa0c0" xlink:to="loc_sttk_StockIssuedDuringPeriodValueWarrantExercises_019d229d-c09e-7e6f-9518-38b389e86cab" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_019ce397-05ba-7cbf-aa9a-f5e735fb120c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019ce397-05ba-7915-b759-77911a9aa0c0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_019ce397-05ba-7cbf-aa9a-f5e735fb120c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_019ce397-05ba-7330-9b3b-2d7640574797" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019ce397-05ba-7915-b759-77911a9aa0c0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_019ce397-05ba-7330-9b3b-2d7640574797" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_019ce397-05ba-7286-b8f1-58d1e463b699" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019ce397-05ba-7915-b759-77911a9aa0c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_019ce397-05ba-7286-b8f1-58d1e463b699" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_019ce397-05ba-72de-b1fc-d3b9e9659827" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019ce397-05ba-7915-b759-77911a9aa0c0" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_019ce397-05ba-72de-b1fc-d3b9e9659827" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_019ce397-05ba-7606-94d1-700397fc45f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019ce397-05ba-7915-b759-77911a9aa0c0" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_019ce397-05ba-7606-94d1-700397fc45f1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019ce397-05ba-78d5-ae9a-069e644b8513" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019ce397-05ba-7915-b759-77911a9aa0c0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019ce397-05ba-78d5-ae9a-069e644b8513" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_019ce397-05ba-775c-a23a-a95ced9cf246" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019ce397-05ba-7915-b759-77911a9aa0c0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_019ce397-05ba-775c-a23a-a95ced9cf246" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019ce397-05ba-7e28-a9e5-0f394dce64c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019ce397-05ba-7915-b759-77911a9aa0c0" xlink:to="loc_us-gaap_NetIncomeLoss_019ce397-05ba-7e28-a9e5-0f394dce64c5" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_019ce397-05ba-70ae-a13a-7029fda415b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019ce397-05ba-7b22-bf61-dba6bf51b55a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="sttk-20260331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_019ce397-05ba-75f2-a7cb-52729b0eb8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_019ce397-05ba-77fd-9a0e-20023f42c022" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_019ce397-05ba-75f2-a7cb-52729b0eb8e5" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_019ce397-05ba-77fd-9a0e-20023f42c022" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_019ce397-05ba-79b1-9524-fb6d2fd92d89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_019ce397-05ba-77fd-9a0e-20023f42c022" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_019ce397-05ba-79b1-9524-fb6d2fd92d89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019ce397-05ba-79b1-9524-fb6d2fd92d89_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_019ce397-05ba-79b1-9524-fb6d2fd92d89" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019ce397-05ba-79b1-9524-fb6d2fd92d89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019ce397-05ba-773e-a09f-4dd7d432cb48" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_019ce397-05ba-79b1-9524-fb6d2fd92d89" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019ce397-05ba-773e-a09f-4dd7d432cb48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_OperatingAccountMember_019ce397-05ba-7eaf-9fda-b2f52d5a3f83" xlink:href="sttk-20260331.xsd#sttk_OperatingAccountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019ce397-05ba-773e-a09f-4dd7d432cb48" xlink:to="loc_sttk_OperatingAccountMember_019ce397-05ba-7eaf-9fda-b2f52d5a3f83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_019ce397-05ba-7303-b6af-4bbc50c6cde2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019ce397-05ba-773e-a09f-4dd7d432cb48" xlink:to="loc_us-gaap_MoneyMarketFundsMember_019ce397-05ba-7303-b6af-4bbc50c6cde2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_019dd03d-2b67-7357-9e4c-6e5b209355ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_019ce397-05ba-77fd-9a0e-20023f42c022" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_019dd03d-2b67-7357-9e4c-6e5b209355ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019dd03d-2b67-7357-9e4c-6e5b209355ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019dd03d-2b67-7357-9e4c-6e5b209355ce" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019dd03d-2b67-7357-9e4c-6e5b209355ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019dd03d-2b67-7391-b3ed-fa63b1ca0e08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019dd03d-2b67-7357-9e4c-6e5b209355ce" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019dd03d-2b67-7391-b3ed-fa63b1ca0e08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_PreFundedWarrantsMember_019dd03d-5058-75a4-8131-67244664b77b" xlink:href="sttk-20260331.xsd#sttk_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019dd03d-2b67-7391-b3ed-fa63b1ca0e08" xlink:to="loc_sttk_PreFundedWarrantsMember_019dd03d-5058-75a4-8131-67244664b77b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019ce397-05ba-71c2-85ec-8b0aa55088b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_019ce397-05ba-75f2-a7cb-52729b0eb8e5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019ce397-05ba-71c2-85ec-8b0aa55088b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_019dd03d-0947-71b7-88ca-d1d37c6db8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_019ce397-05ba-75f2-a7cb-52729b0eb8e5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_019dd03d-0947-71b7-88ca-d1d37c6db8a0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails" xlink:type="simple" xlink:href="sttk-20260331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019d055a-cd2e-7a21-91ff-cedde35d7e85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019d055a-cd2e-75c1-b5ce-ffd38ac0065e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019d055a-cd2e-7a21-91ff-cedde35d7e85" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019d055a-cd2e-75c1-b5ce-ffd38ac0065e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019d055a-cd2e-7e96-abb1-2e9514cd6798" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019d055a-cd2e-75c1-b5ce-ffd38ac0065e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019d055a-cd2e-7e96-abb1-2e9514cd6798" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019d055a-cd2e-7e96-abb1-2e9514cd6798_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019d055a-cd2e-7e96-abb1-2e9514cd6798" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019d055a-cd2e-7e96-abb1-2e9514cd6798_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019d055a-cd2e-7933-a9c0-a303c19d9ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019d055a-cd2e-7e96-abb1-2e9514cd6798" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019d055a-cd2e-7933-a9c0-a303c19d9ba0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_019d055a-cd2e-7f56-8487-16bc77691dda" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019d055a-cd2e-7933-a9c0-a303c19d9ba0" xlink:to="loc_us-gaap_OfficeEquipmentMember_019d055a-cd2e-7f56-8487-16bc77691dda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_019d055a-cd2e-76a2-9dbf-2c6bdce688d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019d055a-cd2e-7933-a9c0-a303c19d9ba0" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_019d055a-cd2e-76a2-9dbf-2c6bdce688d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_LaboratoryEquipmentMember_019d4dbf-e1f7-718e-b88f-20fe15411d5a" xlink:href="sttk-20260331.xsd#sttk_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019d055a-cd2e-7933-a9c0-a303c19d9ba0" xlink:to="loc_sttk_LaboratoryEquipmentMember_019d4dbf-e1f7-718e-b88f-20fe15411d5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_019d055a-cd2e-7579-b536-b2d7a1f9baec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019d055a-cd2e-7933-a9c0-a303c19d9ba0" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_019d055a-cd2e-7579-b536-b2d7a1f9baec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019d055a-cd2e-7441-afae-4a2dd7ec110d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019d055a-cd2e-75c1-b5ce-ffd38ac0065e" xlink:to="loc_srt_RangeAxis_019d055a-cd2e-7441-afae-4a2dd7ec110d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019d055a-cd2e-7441-afae-4a2dd7ec110d_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_019d055a-cd2e-7441-afae-4a2dd7ec110d" xlink:to="loc_srt_RangeMember_019d055a-cd2e-7441-afae-4a2dd7ec110d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019d055a-cd2e-795b-9689-3d87886fd4d5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_019d055a-cd2e-7441-afae-4a2dd7ec110d" xlink:to="loc_srt_RangeMember_019d055a-cd2e-795b-9689-3d87886fd4d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019d055a-cd2e-7145-bbf5-4719c25a3399" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019d055a-cd2e-795b-9689-3d87886fd4d5" xlink:to="loc_srt_MinimumMember_019d055a-cd2e-7145-bbf5-4719c25a3399" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019d055a-cd2e-7b6b-b53e-c36f521380c8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019d055a-cd2e-795b-9689-3d87886fd4d5" xlink:to="loc_srt_MaximumMember_019d055a-cd2e-7b6b-b53e-c36f521380c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_019d055a-cd2e-7c19-86aa-9f2cb6824fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019d055a-cd2e-7a21-91ff-cedde35d7e85" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_019d055a-cd2e-7c19-86aa-9f2cb6824fa5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails" xlink:type="simple" xlink:href="sttk-20260331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019d055a-f26d-7562-b331-59ae01a453b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019d055a-f26d-7789-9f69-8fd7c7517f13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019d055a-f26d-7562-b331-59ae01a453b5" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019d055a-f26d-7789-9f69-8fd7c7517f13" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019d055a-f26d-7abe-ab98-6877eff503b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019d055a-f26d-7789-9f69-8fd7c7517f13" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019d055a-f26d-7abe-ab98-6877eff503b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019d055a-f26d-7abe-ab98-6877eff503b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019d055a-f26d-7abe-ab98-6877eff503b7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019d055a-f26d-7abe-ab98-6877eff503b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019d055a-f26d-72f4-b632-533912ede80b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019d055a-f26d-7abe-ab98-6877eff503b7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019d055a-f26d-72f4-b632-533912ede80b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_019d055a-f26d-763a-9055-5550658a8f30" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019d055a-f26d-72f4-b632-533912ede80b" xlink:to="loc_us-gaap_WarrantMember_019d055a-f26d-763a-9055-5550658a8f30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019d8b3b-6e9a-7c8f-bac5-7f7a540b9878" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019d055a-f26d-72f4-b632-533912ede80b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019d8b3b-6e9a-7c8f-bac5-7f7a540b9878" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_019d055a-f26d-749c-852b-afacf585b7ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019d055a-f26d-72f4-b632-533912ede80b" xlink:to="loc_us-gaap_RestrictedStockMember_019d055a-f26d-749c-852b-afacf585b7ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019d055a-f26d-790e-92e5-497dc5b7756a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019d055a-f26d-7562-b331-59ae01a453b5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019d055a-f26d-790e-92e5-497dc5b7756a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/InvestmentsScheduleofInvestmentsDetails" xlink:type="simple" xlink:href="sttk-20260331.xsd#InvestmentsScheduleofInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/InvestmentsScheduleofInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019d0563-e4b0-7864-b5df-91c73ee74681" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019d0563-e4b0-74b5-b470-09c254ecbc36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019d0563-e4b0-7864-b5df-91c73ee74681" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019d0563-e4b0-74b5-b470-09c254ecbc36" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019d0563-e4b0-733f-b0e7-c6e7b333ad33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019d0563-e4b0-74b5-b470-09c254ecbc36" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019d0563-e4b0-733f-b0e7-c6e7b333ad33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d0563-e4b0-733f-b0e7-c6e7b333ad33_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019d0563-e4b0-733f-b0e7-c6e7b333ad33" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d0563-e4b0-733f-b0e7-c6e7b333ad33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d0563-e4b0-7bad-a1d1-ab53788d2908" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019d0563-e4b0-733f-b0e7-c6e7b333ad33" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d0563-e4b0-7bad-a1d1-ab53788d2908" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_019d0563-e4b0-7e84-89e1-c148acb5c9c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d0563-e4b0-7bad-a1d1-ab53788d2908" xlink:to="loc_us-gaap_MoneyMarketFundsMember_019d0563-e4b0-7e84-89e1-c148acb5c9c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_019d0563-e4b0-7c64-b7c5-0bbb05169c05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d0563-e4b0-7bad-a1d1-ab53788d2908" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_019d0563-e4b0-7c64-b7c5-0bbb05169c05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_019d0563-e4b0-7109-9a6c-f3be63b1fa33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019d0563-e4b0-74b5-b470-09c254ecbc36" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_019d0563-e4b0-7109-9a6c-f3be63b1fa33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_019d0563-e4b0-7109-9a6c-f3be63b1fa33_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_019d0563-e4b0-7109-9a6c-f3be63b1fa33" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_019d0563-e4b0-7109-9a6c-f3be63b1fa33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_019d0563-e4b0-70e5-828e-81504668f40c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_019d0563-e4b0-7109-9a6c-f3be63b1fa33" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_019d0563-e4b0-70e5-828e-81504668f40c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_019d0563-e4b0-7183-90ae-f017628986f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_019d0563-e4b0-70e5-828e-81504668f40c" xlink:to="loc_us-gaap_CashEquivalentsMember_019d0563-e4b0-7183-90ae-f017628986f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrentMember_019d0563-e4b0-7224-bd6b-147fd7d4414b" xlink:href="sttk-20260331.xsd#sttk_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_019d0563-e4b0-70e5-828e-81504668f40c" xlink:to="loc_sttk_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrentMember_019d0563-e4b0-7224-bd6b-147fd7d4414b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAbstract_019d0563-e4b0-75d3-882f-f024b0b4cafe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019d0563-e4b0-7864-b5df-91c73ee74681" xlink:to="loc_us-gaap_DebtSecuritiesAbstract_019d0563-e4b0-75d3-882f-f024b0b4cafe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_019d0563-e4b0-750e-8b89-bb25a2cf1aac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAbstract_019d0563-e4b0-75d3-882f-f024b0b4cafe" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_019d0563-e4b0-750e-8b89-bb25a2cf1aac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_019d0563-e4b0-746b-9c52-0f9fffd4f6b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAbstract_019d0563-e4b0-75d3-882f-f024b0b4cafe" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_019d0563-e4b0-746b-9c52-0f9fffd4f6b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019d0563-e4b0-75da-b393-39551b3126c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAbstract_019d0563-e4b0-75d3-882f-f024b0b4cafe" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019d0563-e4b0-75da-b393-39551b3126c1" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/RelatedPartyLicenseRevenueDetails" xlink:type="simple" xlink:href="sttk-20260331.xsd#RelatedPartyLicenseRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/RelatedPartyLicenseRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019d0602-80ed-7958-94a1-7c1363229551" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019d0602-80ec-773b-ab07-cfbd9b7a9f85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019d0602-80ed-7958-94a1-7c1363229551" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019d0602-80ec-773b-ab07-cfbd9b7a9f85" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_019d0602-80ec-726f-8850-74242b892a20" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019d0602-80ec-773b-ab07-cfbd9b7a9f85" xlink:to="loc_srt_CounterpartyNameAxis_019d0602-80ec-726f-8850-74242b892a20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019d0602-80ec-726f-8850-74242b892a20_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_019d0602-80ec-726f-8850-74242b892a20" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019d0602-80ec-726f-8850-74242b892a20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019d0602-80ed-7042-9f56-faeab369227d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_019d0602-80ec-726f-8850-74242b892a20" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019d0602-80ed-7042-9f56-faeab369227d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_KayakAgreementMember_019d0602-80ed-7bbc-bde6-7416f2a62d80" xlink:href="sttk-20260331.xsd#sttk_KayakAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019d0602-80ed-7042-9f56-faeab369227d" xlink:to="loc_sttk_KayakAgreementMember_019d0602-80ed-7bbc-bde6-7416f2a62d80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_019d0602-80ed-7680-890f-842fc449b272" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019d0602-80ec-773b-ab07-cfbd9b7a9f85" xlink:to="loc_us-gaap_TypeOfArrangementAxis_019d0602-80ed-7680-890f-842fc449b272" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019d0602-80ed-7680-890f-842fc449b272_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_019d0602-80ed-7680-890f-842fc449b272" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019d0602-80ed-7680-890f-842fc449b272_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019d0602-80ed-7a88-86f1-cb77961de30f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_019d0602-80ed-7680-890f-842fc449b272" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019d0602-80ed-7a88-86f1-cb77961de30f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_KayakAgreementContingentMilestonesMember_019d0602-80ed-7617-9c51-098e9b88acf8" xlink:href="sttk-20260331.xsd#sttk_KayakAgreementContingentMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019d0602-80ed-7a88-86f1-cb77961de30f" xlink:to="loc_sttk_KayakAgreementContingentMilestonesMember_019d0602-80ed-7617-9c51-098e9b88acf8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019d0602-80ed-733e-967a-c20811ca1f63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019d0602-80ed-7958-94a1-7c1363229551" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019d0602-80ed-733e-967a-c20811ca1f63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_SubleaseAgreementConsideration_019d0602-80ed-78d0-bba4-69455deb7b4c" xlink:href="sttk-20260331.xsd#sttk_SubleaseAgreementConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019d0602-80ed-7958-94a1-7c1363229551" xlink:to="loc_sttk_SubleaseAgreementConsideration_019d0602-80ed-78d0-bba4-69455deb7b4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_019d0602-80ed-794b-8cbd-752207ba6636" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubleaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019d0602-80ed-7958-94a1-7c1363229551" xlink:to="loc_us-gaap_SubleaseIncome_019d0602-80ed-794b-8cbd-752207ba6636" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_019d0602-80ed-78b6-a942-0d53eb50d20c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019d0602-80ed-7958-94a1-7c1363229551" xlink:to="loc_us-gaap_AccountsReceivableNet_019d0602-80ed-78b6-a942-0d53eb50d20c" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/EquityDetails" xlink:type="simple" xlink:href="sttk-20260331.xsd#EquityDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/EquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_019d1e8b-c8fe-7a33-9678-b4df3d7723be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_019d1e8b-c8fe-7a33-9678-b4df3d7723be" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_019d1e8b-c8fe-7c85-af00-fe14c6646c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019d1e8b-c8fe-7a33-9678-b4df3d7723be" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_019d1e8b-c8fe-7c85-af00-fe14c6646c2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019d1e8b-c8fe-7c85-af00-fe14c6646c2e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019d1e8b-c8fe-7c85-af00-fe14c6646c2e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019d1e8b-c8fe-7c85-af00-fe14c6646c2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019d1e8b-c8fe-75d2-b02d-1233f921e879" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019d1e8b-c8fe-7c85-af00-fe14c6646c2e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019d1e8b-c8fe-75d2-b02d-1233f921e879" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_UnderwrittenPublicOfferingMember_019d1e8b-c8fe-79be-986f-efd533dc550f" xlink:href="sttk-20260331.xsd#sttk_UnderwrittenPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019d1e8b-c8fe-75d2-b02d-1233f921e879" xlink:to="loc_sttk_UnderwrittenPublicOfferingMember_019d1e8b-c8fe-79be-986f-efd533dc550f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_019d1e8b-c8fe-77c8-aebf-cb09168c96ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019d1e8b-c8fe-75d2-b02d-1233f921e879" xlink:to="loc_us-gaap_PrivatePlacementMember_019d1e8b-c8fe-77c8-aebf-cb09168c96ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AtTheMarketOfferingMember_019d1e8b-c8fe-7211-948f-d170bdd41142" xlink:href="sttk-20260331.xsd#sttk_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019d1e8b-c8fe-75d2-b02d-1233f921e879" xlink:to="loc_sttk_AtTheMarketOfferingMember_019d1e8b-c8fe-7211-948f-d170bdd41142" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_019d1e8b-c8fe-7431-9628-a6ecdd005c25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019d1e8b-c8fe-7a33-9678-b4df3d7723be" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_019d1e8b-c8fe-7431-9628-a6ecdd005c25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019d1e8b-c8fe-7431-9628-a6ecdd005c25_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019d1e8b-c8fe-7431-9628-a6ecdd005c25" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019d1e8b-c8fe-7431-9628-a6ecdd005c25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019d1e8b-c8fe-7b1a-8fa0-7e010fcc26fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019d1e8b-c8fe-7431-9628-a6ecdd005c25" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019d1e8b-c8fe-7b1a-8fa0-7e010fcc26fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_PreFundedWarrantsMember_019d1e8b-c8fe-751f-9be2-d1e09bfdd9fa" xlink:href="sttk-20260331.xsd#sttk_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019d1e8b-c8fe-7b1a-8fa0-7e010fcc26fb" xlink:to="loc_sttk_PreFundedWarrantsMember_019d1e8b-c8fe-751f-9be2-d1e09bfdd9fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_CommonStockWarrantsMember_019d1e8b-c8fe-73cb-bfa5-825a8fe08e41" xlink:href="sttk-20260331.xsd#sttk_CommonStockWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019d1e8b-c8fe-7b1a-8fa0-7e010fcc26fb" xlink:to="loc_sttk_CommonStockWarrantsMember_019d1e8b-c8fe-73cb-bfa5-825a8fe08e41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019d1e8b-c8fe-768d-a9ab-2ce552307f85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019d1e8b-c8fe-7a33-9678-b4df3d7723be" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019d1e8b-c8fe-768d-a9ab-2ce552307f85" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019d1e8b-c8fe-768d-a9ab-2ce552307f85_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019d1e8b-c8fe-768d-a9ab-2ce552307f85" xlink:to="loc_us-gaap_ClassOfStockDomain_019d1e8b-c8fe-768d-a9ab-2ce552307f85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019d1e8b-c8fe-7a3a-b3b3-1de48a780370" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019d1e8b-c8fe-768d-a9ab-2ce552307f85" xlink:to="loc_us-gaap_ClassOfStockDomain_019d1e8b-c8fe-7a3a-b3b3-1de48a780370" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019d1e8b-c8fe-78c4-b54b-4e050bd8bb81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019d1e8b-c8fe-7a3a-b3b3-1de48a780370" xlink:to="loc_us-gaap_CommonStockMember_019d1e8b-c8fe-78c4-b54b-4e050bd8bb81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_019d1e8b-c8fe-7bb4-b5cc-5e9f1ca43fd4" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019d1e8b-c8fe-7a33-9678-b4df3d7723be" xlink:to="loc_srt_CounterpartyNameAxis_019d1e8b-c8fe-7bb4-b5cc-5e9f1ca43fd4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019d1e8b-c8fe-7bb4-b5cc-5e9f1ca43fd4_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_019d1e8b-c8fe-7bb4-b5cc-5e9f1ca43fd4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019d1e8b-c8fe-7bb4-b5cc-5e9f1ca43fd4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019d1e8b-c8fe-7b05-af36-e2628eb213dc" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_019d1e8b-c8fe-7bb4-b5cc-5e9f1ca43fd4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019d1e8b-c8fe-7b05-af36-e2628eb213dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_BeneficialOwnersMember_019d1e8b-c8fe-7537-8ac7-8e7b2c964cc3" xlink:href="sttk-20260331.xsd#sttk_BeneficialOwnersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019d1e8b-c8fe-7b05-af36-e2628eb213dc" xlink:to="loc_sttk_BeneficialOwnersMember_019d1e8b-c8fe-7537-8ac7-8e7b2c964cc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_019dd04a-105c-7f01-b9b8-1abc6524d640" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019d1e8b-c8fe-7a33-9678-b4df3d7723be" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_019dd04a-105c-7f01-b9b8-1abc6524d640" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019dd04a-105c-7f01-b9b8-1abc6524d640_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019dd04a-105c-7f01-b9b8-1abc6524d640" xlink:to="loc_us-gaap_EquityComponentDomain_019dd04a-105c-7f01-b9b8-1abc6524d640_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019dd04a-105c-7d84-84f1-95d1e54a484c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019dd04a-105c-7f01-b9b8-1abc6524d640" xlink:to="loc_us-gaap_EquityComponentDomain_019dd04a-105c-7d84-84f1-95d1e54a484c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019dd04a-105c-74db-8c46-7b1bac0cfe0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019dd04a-105c-7d84-84f1-95d1e54a484c" xlink:to="loc_us-gaap_CommonStockMember_019dd04a-105c-74db-8c46-7b1bac0cfe0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_019d1e8b-c8fe-767f-99b2-16f82e1a9733" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_019d1e8b-c8fe-767f-99b2-16f82e1a9733" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_019d1e8b-c8fe-7c09-a9ca-605dfb5a1d87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_019d1e8b-c8fe-7c09-a9ca-605dfb5a1d87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_019d1e8b-c8fe-753e-b926-80a1a4794722" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_019d1e8b-c8fe-753e-b926-80a1a4794722" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_019d1e8b-c8fe-78cc-a624-2873b6dc0d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_019d1e8b-c8fe-78cc-a624-2873b6dc0d8c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_CommonStockNumberOfVotesPerCommonShare_019d1e8b-c8fe-7419-a7ad-95a7c04100f4" xlink:href="sttk-20260331.xsd#sttk_CommonStockNumberOfVotesPerCommonShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_sttk_CommonStockNumberOfVotesPerCommonShare_019d1e8b-c8fe-7419-a7ad-95a7c04100f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_019d1e8b-c8fe-722b-9e67-73ab28277fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_019d1e8b-c8fe-722b-9e67-73ab28277fa3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_019d1e8b-c8fe-7219-b896-a921abdb054f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_019d1e8b-c8fe-7219-b896-a921abdb054f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_019d1e8b-c8fe-797b-9eea-8b95d871f8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_019d1e8b-c8fe-797b-9eea-8b95d871f8fb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_019d1e8b-c8fe-7fbc-a2c5-f1a20705174e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_019d1e8b-c8fe-7fbc-a2c5-f1a20705174e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ClassOfWarrantOrRightPriceOfPreFundedWarrants_019d1e8b-c8fe-780a-8fc3-5e51a1644cb9" xlink:href="sttk-20260331.xsd#sttk_ClassOfWarrantOrRightPriceOfPreFundedWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_sttk_ClassOfWarrantOrRightPriceOfPreFundedWarrants_019d1e8b-c8fe-780a-8fc3-5e51a1644cb9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019d1e8b-c8fe-7306-8533-cff8f96820e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019d1e8b-c8fe-7306-8533-cff8f96820e0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_019d1e8b-c8fe-72a5-a107-28470b6df0d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_019d1e8b-c8fe-72a5-a107-28470b6df0d5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise_019d1e8b-c8fe-77f3-ae27-eceb9a0a8bad" xlink:href="sttk-20260331.xsd#sttk_ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_sttk_ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise_019d1e8b-c8fe-77f3-ae27-eceb9a0a8bad" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019d1e8b-c8fe-7486-89d6-d9256251e063" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019d1e8b-c8fe-7486-89d6-d9256251e063" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ClassOfWarrantOrRightWarrantsExercised_019dcead-b0a6-741a-bed8-3dc63700a0a4" xlink:href="sttk-20260331.xsd#sttk_ClassOfWarrantOrRightWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_sttk_ClassOfWarrantOrRightWarrantsExercised_019dcead-b0a6-741a-bed8-3dc63700a0a4" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_019dcead-b0a6-7c3d-b7fc-2d60cc07caf2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_019dcead-b0a6-7c3d-b7fc-2d60cc07caf2" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019dcead-b0a6-7ab4-bf65-93d009ec0902" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019dcead-b0a6-7ab4-bf65-93d009ec0902" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_SaleOfStockMaximumAggregateSalesPrice_019d1e8b-c8fe-71bd-8023-f20fe121baad" xlink:href="sttk-20260331.xsd#sttk_SaleOfStockMaximumAggregateSalesPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_sttk_SaleOfStockMaximumAggregateSalesPrice_019d1e8b-c8fe-71bd-8023-f20fe121baad" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_SaleOfStockCommissionPercentage_019d1e8b-c8fe-7bfd-977b-aacc7c6d9802" xlink:href="sttk-20260331.xsd#sttk_SaleOfStockCommissionPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_sttk_SaleOfStockCommissionPercentage_019d1e8b-c8fe-7bfd-977b-aacc7c6d9802" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019d1e8b-c8fe-7fc0-ba9f-6ebffbcf40b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019d1e8b-c8fe-7fc0-ba9f-6ebffbcf40b1" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_StockIssuedDuringPeriodSharesWarrantExercises_019dd04a-105c-7315-b58a-b2f425ef170d" xlink:href="sttk-20260331.xsd#sttk_StockIssuedDuringPeriodSharesWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_sttk_StockIssuedDuringPeriodSharesWarrantExercises_019dd04a-105c-7315-b58a-b2f425ef170d" xlink:type="arc" order="20"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="sttk-20260331.xsd#StockBasedCompensationandEmployeeBenefitPlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09ba-29af-7b6c-9ea2-048f4bccaf91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09ba-29af-7b6c-9ea2-048f4bccaf91" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_019d09ba-29af-7055-8fce-65df0109e7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09ba-29af-7b6c-9ea2-048f4bccaf91" xlink:to="loc_us-gaap_PlanNameAxis_019d09ba-29af-7055-8fce-65df0109e7b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019d09ba-29af-7055-8fce-65df0109e7b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_019d09ba-29af-7055-8fce-65df0109e7b4" xlink:to="loc_us-gaap_PlanNameDomain_019d09ba-29af-7055-8fce-65df0109e7b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019d09ba-29af-762e-9269-94ef273b8159" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_019d09ba-29af-7055-8fce-65df0109e7b4" xlink:to="loc_us-gaap_PlanNameDomain_019d09ba-29af-762e-9269-94ef273b8159" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020StockIncentivePlanMember_019d09ba-29af-74d5-976a-23c9c0e130e4" xlink:href="sttk-20260331.xsd#sttk_A2020StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_019d09ba-29af-762e-9269-94ef273b8159" xlink:to="loc_sttk_A2020StockIncentivePlanMember_019d09ba-29af-74d5-976a-23c9c0e130e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020EmployeeStockPurchasePlanMember_019d09ba-29af-7ece-b082-3f2d48d19bd6" xlink:href="sttk-20260331.xsd#sttk_A2020EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_019d09ba-29af-762e-9269-94ef273b8159" xlink:to="loc_sttk_A2020EmployeeStockPurchasePlanMember_019d09ba-29af-7ece-b082-3f2d48d19bd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019d09ba-29af-72ea-90f4-e57e8066701e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09ba-29af-7b6c-9ea2-048f4bccaf91" xlink:to="loc_us-gaap_AwardTypeAxis_019d09ba-29af-72ea-90f4-e57e8066701e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d09ba-29af-72ea-90f4-e57e8066701e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019d09ba-29af-72ea-90f4-e57e8066701e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d09ba-29af-72ea-90f4-e57e8066701e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d09ba-29af-7dfa-a921-f5cab5ec56c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019d09ba-29af-72ea-90f4-e57e8066701e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d09ba-29af-7dfa-a921-f5cab5ec56c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019d09ba-29af-7503-8350-e3b675917740" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d09ba-29af-7dfa-a921-f5cab5ec56c2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019d09ba-29af-7503-8350-e3b675917740" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019d09ba-29af-7188-9f31-e0fdd66494e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d09ba-29af-7dfa-a921-f5cab5ec56c2" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019d09ba-29af-7188-9f31-e0fdd66494e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage_019d09ba-29af-77d9-a8cd-6bfa2ad513b2" xlink:href="sttk-20260331.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage_019d09ba-29af-77d9-a8cd-6bfa2ad513b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019d09ba-29af-72cb-aabb-4cafc4cc2be4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019d09ba-29af-72cb-aabb-4cafc4cc2be4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_019d09ba-29af-7173-86c8-0ccaf87a833a" xlink:href="sttk-20260331.xsd#sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_019d09ba-29af-7173-86c8-0ccaf87a833a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019d09ba-29af-7d84-8f03-1338835f0b50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019d09ba-29af-7d84-8f03-1338835f0b50" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_019d09ba-29af-7d9b-9c54-7686f4f9a4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_019d09ba-29af-7d9b-9c54-7686f4f9a4c8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_019d09ba-29af-7b08-a976-31ff78459da1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_019d09ba-29af-7b08-a976-31ff78459da1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_019d09ba-29af-7303-a0ec-0732de2cf04d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_019d09ba-29af-7303-a0ec-0732de2cf04d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue_019d09ba-29af-717a-8392-492b9213783a" xlink:href="sttk-20260331.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue_019d09ba-29af-717a-8392-492b9213783a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_019d09ba-29af-74b4-9f9b-e0a0e9dd8ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_019d09ba-29af-74b4-9f9b-e0a0e9dd8ac9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm_019d09ba-29af-74f9-a8fc-dfe9011940a9" xlink:href="sttk-20260331.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm_019d09ba-29af-74f9-a8fc-dfe9011940a9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_019d09ba-29af-76c3-9504-724a4f1ea178" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_019d09ba-29af-76c3-9504-724a4f1ea178" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_019d8fca-5307-78c7-a16c-0683284be3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_us-gaap_ProceedsFromStockPlans_019d8fca-5307-78c7-a16c-0683284be3a7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019d09ba-29af-76d4-8882-a81fa0326242" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019d09ba-29af-76d4-8882-a81fa0326242" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_019d09ba-29af-7bb7-bb69-b81eab3d547b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_019d09ba-29af-7bb7-bb69-b81eab3d547b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019d09ba-29af-7898-a09a-0e6a0b0e1d13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019d09ba-29af-7898-a09a-0e6a0b0e1d13" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_019d09ba-29af-7d79-b8ae-80dfa24267e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_019d09ba-29af-7d79-b8ae-80dfa24267e3" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_019d8fce-e604-76b4-809d-ecee0d491314" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_019d8fce-e604-76b4-809d-ecee0d491314" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019d09ba-29af-7de9-a84f-c4a20fbdee82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019d09ba-29af-7de9-a84f-c4a20fbdee82" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_019d09ba-29af-7eb9-9b16-450ec9acbaac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_019d09ba-29af-7eb9-9b16-450ec9acbaac" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019d09ba-29af-7a4c-8404-1c0fb865d7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019d09ba-29af-7a4c-8404-1c0fb865d7e8" xlink:type="arc" order="19"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofstockbasedcompensationexpenseDetails" xlink:type="simple" xlink:href="sttk-20260331.xsd#StockBasedCompensationandEmployeeBenefitPlansScheduleofstockbasedcompensationexpenseDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofstockbasedcompensationexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09c5-750a-7dfc-979a-3b4ac03e2cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09c5-750a-7448-9f9e-71aaf62ca806" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09c5-750a-7dfc-979a-3b4ac03e2cf5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09c5-750a-7448-9f9e-71aaf62ca806" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_019d09c5-750a-7b3a-92cc-5111a6ef42c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09c5-750a-7448-9f9e-71aaf62ca806" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_019d09c5-750a-7b3a-92cc-5111a6ef42c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_019d09c5-750a-7b3a-92cc-5111a6ef42c2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_019d09c5-750a-7b3a-92cc-5111a6ef42c2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_019d09c5-750a-7b3a-92cc-5111a6ef42c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_019d09c5-750a-7ea2-a8d7-2b8a6a94bbde" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_019d09c5-750a-7b3a-92cc-5111a6ef42c2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_019d09c5-750a-7ea2-a8d7-2b8a6a94bbde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019d09c5-750a-76da-aadc-3a699c423707" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019d09c5-750a-7ea2-a8d7-2b8a6a94bbde" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019d09c5-750a-76da-aadc-3a699c423707" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_019d09c5-750a-7c0b-93c2-d5dba75233c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019d09c5-750a-7ea2-a8d7-2b8a6a94bbde" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_019d09c5-750a-7c0b-93c2-d5dba75233c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019d09c5-750a-7a51-88e4-e0a98845b564" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09c5-750a-7dfc-979a-3b4ac03e2cf5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019d09c5-750a-7a51-88e4-e0a98845b564" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofrestrictedstockactivityDetails" xlink:type="simple" xlink:href="sttk-20260331.xsd#StockBasedCompensationandEmployeeBenefitPlansScheduleofrestrictedstockactivityDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofrestrictedstockactivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ce-82bd-740f-8792-a619ee5b4973" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09ce-82bd-72c3-8ecb-610586354b18" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ce-82bd-740f-8792-a619ee5b4973" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09ce-82bd-72c3-8ecb-610586354b18" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019d09ce-82bd-7e01-a245-c33987ef44bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09ce-82bd-72c3-8ecb-610586354b18" xlink:to="loc_us-gaap_AwardTypeAxis_019d09ce-82bd-7e01-a245-c33987ef44bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d09ce-82bd-7e01-a245-c33987ef44bc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019d09ce-82bd-7e01-a245-c33987ef44bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d09ce-82bd-7e01-a245-c33987ef44bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d09ce-82bd-7bc4-97ee-5499f10be31c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019d09ce-82bd-7e01-a245-c33987ef44bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d09ce-82bd-7bc4-97ee-5499f10be31c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019d09ce-82bd-752c-ad57-fee348ca7710" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d09ce-82bd-7bc4-97ee-5499f10be31c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019d09ce-82bd-752c-ad57-fee348ca7710" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019d09ce-82bd-744c-9307-14fd005c2ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ce-82bd-740f-8792-a619ee5b4973" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019d09ce-82bd-744c-9307-14fd005c2ff3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019d09ce-82bd-7690-bae7-3106b55cc7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019d09ce-82bd-744c-9307-14fd005c2ff3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019d09ce-82bd-7690-bae7-3106b55cc7cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019d09ce-82bd-78f9-aa12-1f214f9dfe53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019d09ce-82bd-744c-9307-14fd005c2ff3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019d09ce-82bd-78f9-aa12-1f214f9dfe53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_019d09ce-82bd-7819-954f-b024e0491a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019d09ce-82bd-744c-9307-14fd005c2ff3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_019d09ce-82bd-7819-954f-b024e0491a1d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_019d09ce-82bd-7eee-93e8-bc5d7b93fd84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019d09ce-82bd-744c-9307-14fd005c2ff3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_019d09ce-82bd-7eee-93e8-bc5d7b93fd84" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019d09ce-82bd-7f7c-b36e-cdc0ce6daa33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019d09ce-82bd-722c-8a0c-5769497abe08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ce-82bd-740f-8792-a619ee5b4973" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019d09ce-82bd-722c-8a0c-5769497abe08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019d09ce-82bd-749b-b8e6-c4ad24398ece" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019d09ce-82bd-722c-8a0c-5769497abe08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019d09ce-82bd-749b-b8e6-c4ad24398ece" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019d09ce-82bd-7dd7-81c6-fbd4dc398b01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019d09ce-82bd-722c-8a0c-5769497abe08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019d09ce-82bd-7dd7-81c6-fbd4dc398b01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_019d09ce-82bd-71dc-b9dc-aaea77ea0393" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019d09ce-82bd-722c-8a0c-5769497abe08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_019d09ce-82bd-71dc-b9dc-aaea77ea0393" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_019d09ce-82bd-7961-a911-f56c1e85300f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019d09ce-82bd-722c-8a0c-5769497abe08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_019d09ce-82bd-7961-a911-f56c1e85300f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019d09ce-82bd-71bf-945f-5abfe263b6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020PlanoptionvaluationassumptionsDetails" xlink:type="simple" xlink:href="sttk-20260331.xsd#StockBasedCompensationandEmployeeBenefitPlansScheduleof2020PlanoptionvaluationassumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020PlanoptionvaluationassumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09d2-371f-78b5-a41b-00ace77607b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09d2-371f-74c3-ada3-f2e44ad501e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09d2-371f-78b5-a41b-00ace77607b2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09d2-371f-74c3-ada3-f2e44ad501e8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019d09d2-371f-7146-908e-4f3165fde830" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09d2-371f-74c3-ada3-f2e44ad501e8" xlink:to="loc_us-gaap_AwardTypeAxis_019d09d2-371f-7146-908e-4f3165fde830" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d09d2-371f-7146-908e-4f3165fde830_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019d09d2-371f-7146-908e-4f3165fde830" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d09d2-371f-7146-908e-4f3165fde830_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d09d2-371f-71fe-b377-eebb351f2060" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019d09d2-371f-7146-908e-4f3165fde830" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d09d2-371f-71fe-b377-eebb351f2060" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019d09d2-371f-7042-af3e-471df17f889c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d09d2-371f-71fe-b377-eebb351f2060" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019d09d2-371f-7042-af3e-471df17f889c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_019d09d2-371f-77fd-8df7-06302438b635" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09d2-371f-74c3-ada3-f2e44ad501e8" xlink:to="loc_us-gaap_PlanNameAxis_019d09d2-371f-77fd-8df7-06302438b635" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019d09d2-371f-77fd-8df7-06302438b635_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_019d09d2-371f-77fd-8df7-06302438b635" xlink:to="loc_us-gaap_PlanNameDomain_019d09d2-371f-77fd-8df7-06302438b635_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019d09d2-371f-79e1-90d3-87841957d143" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_019d09d2-371f-77fd-8df7-06302438b635" xlink:to="loc_us-gaap_PlanNameDomain_019d09d2-371f-79e1-90d3-87841957d143" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020StockIncentivePlanMember_019d09d2-371f-719e-a656-e07812f73531" xlink:href="sttk-20260331.xsd#sttk_A2020StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_019d09d2-371f-79e1-90d3-87841957d143" xlink:to="loc_sttk_A2020StockIncentivePlanMember_019d09d2-371f-719e-a656-e07812f73531" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_019d09d2-371f-78e8-a2d9-4034336a3105" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09d2-371f-74c3-ada3-f2e44ad501e8" xlink:to="loc_us-gaap_ValuationTechniqueAxis_019d09d2-371f-78e8-a2d9-4034336a3105" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_019d09d2-371f-78e8-a2d9-4034336a3105_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_019d09d2-371f-78e8-a2d9-4034336a3105" xlink:to="loc_us-gaap_ValuationTechniqueDomain_019d09d2-371f-78e8-a2d9-4034336a3105_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_019d09d2-371f-74c6-8927-fd9df8cfcd26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_019d09d2-371f-78e8-a2d9-4034336a3105" xlink:to="loc_us-gaap_ValuationTechniqueDomain_019d09d2-371f-74c6-8927-fd9df8cfcd26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_BlackScholesOptionPricingModelMember_019d09d2-371f-7b52-8a7f-c008899ab738" xlink:href="sttk-20260331.xsd#sttk_BlackScholesOptionPricingModelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_019d09d2-371f-74c6-8927-fd9df8cfcd26" xlink:to="loc_sttk_BlackScholesOptionPricingModelMember_019d09d2-371f-7b52-8a7f-c008899ab738" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019d09d2-371f-731a-8f48-ad0ce98c394b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09d2-371f-78b5-a41b-00ace77607b2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019d09d2-371f-731a-8f48-ad0ce98c394b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_019d09d2-371f-7c46-8c08-04bd97dbca14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09d2-371f-78b5-a41b-00ace77607b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_019d09d2-371f-7c46-8c08-04bd97dbca14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019d09d2-371f-7482-a1a4-7d567be063db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09d2-371f-78b5-a41b-00ace77607b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019d09d2-371f-7482-a1a4-7d567be063db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019d09d2-371f-7868-adc3-abd36e8f7c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09d2-371f-78b5-a41b-00ace77607b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019d09d2-371f-7868-adc3-abd36e8f7c1b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020ESPPvaluationassumptionsDetails" xlink:type="simple" xlink:href="sttk-20260331.xsd#StockBasedCompensationandEmployeeBenefitPlansScheduleof2020ESPPvaluationassumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020ESPPvaluationassumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09d2-4517-7ff2-bc89-ce0501c59db5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09d2-4517-7aac-a21c-7aaddca54513" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09d2-4517-7ff2-bc89-ce0501c59db5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09d2-4517-7aac-a21c-7aaddca54513" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019d09d2-4517-739b-ac11-a3ad2ed03435" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09d2-4517-7aac-a21c-7aaddca54513" xlink:to="loc_us-gaap_AwardTypeAxis_019d09d2-4517-739b-ac11-a3ad2ed03435" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d09d2-4517-739b-ac11-a3ad2ed03435_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019d09d2-4517-739b-ac11-a3ad2ed03435" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d09d2-4517-739b-ac11-a3ad2ed03435_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d09d2-4517-7705-ae25-f60a62fc9a32" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019d09d2-4517-739b-ac11-a3ad2ed03435" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d09d2-4517-7705-ae25-f60a62fc9a32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_019d09d2-4517-780c-8e28-cf0c7f3ac5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d09d2-4517-7705-ae25-f60a62fc9a32" xlink:to="loc_us-gaap_EmployeeStockMember_019d09d2-4517-780c-8e28-cf0c7f3ac5c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_019d09d2-4517-79bb-8cf5-453128b1d500" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09d2-4517-7aac-a21c-7aaddca54513" xlink:to="loc_us-gaap_PlanNameAxis_019d09d2-4517-79bb-8cf5-453128b1d500" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019d09d2-4517-79bb-8cf5-453128b1d500_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_019d09d2-4517-79bb-8cf5-453128b1d500" xlink:to="loc_us-gaap_PlanNameDomain_019d09d2-4517-79bb-8cf5-453128b1d500_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019d09d2-4517-7b6c-9dc3-0f6dc15656cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_019d09d2-4517-79bb-8cf5-453128b1d500" xlink:to="loc_us-gaap_PlanNameDomain_019d09d2-4517-7b6c-9dc3-0f6dc15656cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020EmployeeStockPurchasePlanMember_019d09d2-4517-78b1-9ba7-32bbf04f8af1" xlink:href="sttk-20260331.xsd#sttk_A2020EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_019d09d2-4517-7b6c-9dc3-0f6dc15656cc" xlink:to="loc_sttk_A2020EmployeeStockPurchasePlanMember_019d09d2-4517-78b1-9ba7-32bbf04f8af1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_019d09d2-4517-7413-b41c-4819f49a8712" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09d2-4517-7aac-a21c-7aaddca54513" xlink:to="loc_us-gaap_ValuationTechniqueAxis_019d09d2-4517-7413-b41c-4819f49a8712" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_019d09d2-4517-7413-b41c-4819f49a8712_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_019d09d2-4517-7413-b41c-4819f49a8712" xlink:to="loc_us-gaap_ValuationTechniqueDomain_019d09d2-4517-7413-b41c-4819f49a8712_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_019d09d2-4517-772b-ae83-1c64c7c85322" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_019d09d2-4517-7413-b41c-4819f49a8712" xlink:to="loc_us-gaap_ValuationTechniqueDomain_019d09d2-4517-772b-ae83-1c64c7c85322" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_BlackScholesOptionPricingModelMember_019d09d2-4517-7a66-8c58-a46e1bc2e82f" xlink:href="sttk-20260331.xsd#sttk_BlackScholesOptionPricingModelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_019d09d2-4517-772b-ae83-1c64c7c85322" xlink:to="loc_sttk_BlackScholesOptionPricingModelMember_019d09d2-4517-7a66-8c58-a46e1bc2e82f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019d09d2-4517-7f76-b54b-ee9dcaa7e95e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09d2-4517-7ff2-bc89-ce0501c59db5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019d09d2-4517-7f76-b54b-ee9dcaa7e95e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_019d09d2-4517-79c2-938b-45c58ecf3aca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09d2-4517-7ff2-bc89-ce0501c59db5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_019d09d2-4517-79c2-938b-45c58ecf3aca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019d09d2-4517-7095-9be6-e167345a0d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09d2-4517-7ff2-bc89-ce0501c59db5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019d09d2-4517-7095-9be6-e167345a0d8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019d09d2-4517-7b77-861c-092d92906613" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09d2-4517-7ff2-bc89-ce0501c59db5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019d09d2-4517-7b77-861c-092d92906613" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/SegmentReportingDetails" xlink:type="simple" xlink:href="sttk-20260331.xsd#SegmentReportingDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/SegmentReportingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_019ce397-0676-7ec3-abd8-decd87541585" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_019ce397-0676-73c9-be02-eb7b2f8f5492" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_019ce397-0676-7ec3-abd8-decd87541585" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_019ce397-0676-73c9-be02-eb7b2f8f5492" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019ce397-0676-7324-8df7-3862e1e0d348" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_019ce397-0676-73c9-be02-eb7b2f8f5492" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019ce397-0676-7324-8df7-3862e1e0d348" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019ce397-0676-7324-8df7-3862e1e0d348_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019ce397-0676-7324-8df7-3862e1e0d348" xlink:to="loc_us-gaap_SegmentDomain_019ce397-0676-7324-8df7-3862e1e0d348_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019ce397-0676-70bb-85a8-971a49003e76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019ce397-0676-7324-8df7-3862e1e0d348" xlink:to="loc_us-gaap_SegmentDomain_019ce397-0676-70bb-85a8-971a49003e76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ReportableSegmentMember_019ce397-0676-7663-aa95-a48dbac54c64" xlink:href="sttk-20260331.xsd#sttk_ReportableSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_019ce397-0676-70bb-85a8-971a49003e76" xlink:to="loc_sttk_ReportableSegmentMember_019ce397-0676-7663-aa95-a48dbac54c64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019ce397-0676-781b-9051-509f931cf06a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_019ce397-0676-73c9-be02-eb7b2f8f5492" xlink:to="loc_srt_ProductOrServiceAxis_019ce397-0676-781b-9051-509f931cf06a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019ce397-0676-781b-9051-509f931cf06a_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_019ce397-0676-781b-9051-509f931cf06a" xlink:to="loc_srt_ProductsAndServicesDomain_019ce397-0676-781b-9051-509f931cf06a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019ce397-0676-74d7-9b35-9bdbbe88664f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_019ce397-0676-781b-9051-509f931cf06a" xlink:to="loc_srt_ProductsAndServicesDomain_019ce397-0676-74d7-9b35-9bdbbe88664f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_SL325Member_019ce397-0676-726c-b4e6-9c493c8fc4f1" xlink:href="sttk-20260331.xsd#sttk_SL325Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019ce397-0676-74d7-9b35-9bdbbe88664f" xlink:to="loc_sttk_SL325Member_019ce397-0676-726c-b4e6-9c493c8fc4f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_OtherResearchAndDevelopmentMember_019ce397-0676-74cf-99f7-679025489cc1" xlink:href="sttk-20260331.xsd#sttk_OtherResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019ce397-0676-74d7-9b35-9bdbbe88664f" xlink:to="loc_sttk_OtherResearchAndDevelopmentMember_019ce397-0676-74cf-99f7-679025489cc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_OtherResearchAndDevelopmentSL172154Member_019dd056-9de5-7217-a70d-d170c9d68611" xlink:href="sttk-20260331.xsd#sttk_OtherResearchAndDevelopmentSL172154Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sttk_OtherResearchAndDevelopmentMember_019ce397-0676-74cf-99f7-679025489cc1" xlink:to="loc_sttk_OtherResearchAndDevelopmentSL172154Member_019dd056-9de5-7217-a70d-d170c9d68611" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_019ce397-0676-7bbf-8445-7ba65029d3c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_019ce397-0676-7ec3-abd8-decd87541585" xlink:to="loc_us-gaap_NumberOfReportableSegments_019ce397-0676-7bbf-8445-7ba65029d3c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_019ce397-0676-75fd-9730-1ac384650241" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_019ce397-0676-7ec3-abd8-decd87541585" xlink:to="loc_us-gaap_NumberOfOperatingSegments_019ce397-0676-75fd-9730-1ac384650241" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019ce397-0676-7413-921c-a07a41f1b65a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_019ce397-0676-7ec3-abd8-decd87541585" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019ce397-0676-7413-921c-a07a41f1b65a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019ce397-0676-70b1-b23a-263d5c66c4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_019ce397-0676-7ec3-abd8-decd87541585" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019ce397-0676-70b1-b23a-263d5c66c4e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ResearchAndDevelopmentNonEquityCompensation_019ce397-0676-7785-a5e2-1b9c41ab88a7" xlink:href="sttk-20260331.xsd#sttk_ResearchAndDevelopmentNonEquityCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_019ce397-0676-7ec3-abd8-decd87541585" xlink:to="loc_sttk_ResearchAndDevelopmentNonEquityCompensation_019ce397-0676-7785-a5e2-1b9c41ab88a7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ResearchAndDevelopmentEquityCompensation_019ce397-0676-75e8-8a71-9abe217fd087" xlink:href="sttk-20260331.xsd#sttk_ResearchAndDevelopmentEquityCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_019ce397-0676-7ec3-abd8-decd87541585" xlink:to="loc_sttk_ResearchAndDevelopmentEquityCompensation_019ce397-0676-75e8-8a71-9abe217fd087" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_GeneralAndAdministrativeNonEquityCompensation_019ce397-0676-79e7-a047-06a50c5e878a" xlink:href="sttk-20260331.xsd#sttk_GeneralAndAdministrativeNonEquityCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_019ce397-0676-7ec3-abd8-decd87541585" xlink:to="loc_sttk_GeneralAndAdministrativeNonEquityCompensation_019ce397-0676-79e7-a047-06a50c5e878a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_GeneralAndAdministrativeEquityCompensation_019ce397-0676-7b74-abb8-72767965c5f2" xlink:href="sttk-20260331.xsd#sttk_GeneralAndAdministrativeEquityCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_019ce397-0676-7ec3-abd8-decd87541585" xlink:to="loc_sttk_GeneralAndAdministrativeEquityCompensation_019ce397-0676-7b74-abb8-72767965c5f2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_019ce397-0676-717a-9952-65392ae0d22c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_019ce397-0676-7ec3-abd8-decd87541585" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_019ce397-0676-717a-9952-65392ae0d22c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_019ce397-0676-73ff-a2e1-f89dd9530686" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_019ce397-0676-7ec3-abd8-decd87541585" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_019ce397-0676-73ff-a2e1-f89dd9530686" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_019ce397-0676-7258-9b2a-68639356a776" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_019ce397-0676-7ec3-abd8-decd87541585" xlink:to="loc_us-gaap_OperatingExpenses_019ce397-0676-7258-9b2a-68639356a776" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019ce397-0676-77d9-ad4e-113561c059bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_019ce397-0676-7ec3-abd8-decd87541585" xlink:to="loc_us-gaap_OperatingIncomeLoss_019ce397-0676-77d9-ad4e-113561c059bf" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_019ce397-0676-74db-aea3-40d1bd8fab74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_019ce397-0676-7ec3-abd8-decd87541585" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_019ce397-0676-74db-aea3-40d1bd8fab74" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019ce397-0676-75d9-b7f7-f183f9e7ef74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_019ce397-0676-7ec3-abd8-decd87541585" xlink:to="loc_us-gaap_NetIncomeLoss_019ce397-0676-75d9-b7f7-f183f9e7ef74" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_OtherResearchAndDevelopmentExpenseTechnicalOperations_019ce397-0676-746a-9111-393dfd1c0a71" xlink:href="sttk-20260331.xsd#sttk_OtherResearchAndDevelopmentExpenseTechnicalOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_019ce397-0676-7ec3-abd8-decd87541585" xlink:to="loc_sttk_OtherResearchAndDevelopmentExpenseTechnicalOperations_019ce397-0676-746a-9111-393dfd1c0a71" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_019ce397-0676-7572-887b-1603c0ac6095" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_019ce397-0676-7ec3-abd8-decd87541585" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_019ce397-0676-7572-887b-1603c0ac6095" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_019ce397-0676-7516-93fc-18d5b42facf6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_019ce397-0676-7ec3-abd8-decd87541585" xlink:to="loc_us-gaap_Depreciation_019ce397-0676-7516-93fc-18d5b42facf6" xlink:type="arc" order="16"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#IndividualsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ArunthathyNirmaliniLiniPanditeM.B.Ch.B.Member_019db3bc-0aa8-78a3-b480-ff582e9d438d" xlink:href="sttk-20260331.xsd#sttk_ArunthathyNirmaliniLiniPanditeM.B.Ch.B.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_sttk_ArunthathyNirmaliniLiniPanditeM.B.Ch.B.Member_019db3bc-0aa8-78a3-b480-ff582e9d438d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AbhinavShuklaPhDMember_019db3bc-d6a6-7e9e-b515-fdaba6d1d2c4" xlink:href="sttk-20260331.xsd#sttk_AbhinavShuklaPhDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_sttk_AbhinavShuklaPhDMember_019db3bc-d6a6-7e9e-b515-fdaba6d1d2c4" xlink:type="arc" order="3"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>sttk-20260331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019ce397-05b9-74d0-8227-66267d5910e2,g:518bbadf-25d7-41ee-8c01-9003cd0ed70a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_019d8b22-3a35-70c6-8276-3f01f55f5305_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain on investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_019ce397-0676-7fed-a0d2-c70323334889_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_019ce397-071d-7301-8a66-1052efddd703_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_019ce397-0676-7d9a-8915-bdb3657947de_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_CommonStockWarrantsMember_019d08f8-8961-7cf7-bb85-ebfa610c1339_terseLabel_en-US" xlink:label="lab_sttk_CommonStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock warrants</link:label>
    <link:label id="lab_sttk_CommonStockWarrantsMember_label_en-US" xlink:label="lab_sttk_CommonStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Warrants [Member]</link:label>
    <link:label id="lab_sttk_CommonStockWarrantsMember_documentation_en-US" xlink:label="lab_sttk_CommonStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_CommonStockWarrantsMember" xlink:href="sttk-20260331.xsd#sttk_CommonStockWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_CommonStockWarrantsMember" xlink:to="lab_sttk_CommonStockWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_019ce397-071d-7b26-bcfb-48a470f61613_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_019ce397-0676-735e-8793-69f1db9743e5_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_019ce397-071d-7fad-aae6-d0ed24b353e6_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_A2020EmployeeStockPurchasePlanMember_019ce397-071d-7c49-a112-f8a941c612d3_terseLabel_en-US" xlink:label="lab_sttk_A2020EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_sttk_A2020EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_sttk_A2020EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2020 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_sttk_A2020EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_sttk_A2020EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2020 Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020EmployeeStockPurchasePlanMember" xlink:href="sttk-20260331.xsd#sttk_A2020EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_A2020EmployeeStockPurchasePlanMember" xlink:to="lab_sttk_A2020EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_019ce397-071d-7f96-a59b-b53df1f2f678_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Adopted Accounting Pronouncements/Recently Issued Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_LaboratoryEquipmentMember_019ce397-071d-7b40-8026-09fa17587cbb_terseLabel_en-US" xlink:label="lab_sttk_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_sttk_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_sttk_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_sttk_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_sttk_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Laboratory Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_LaboratoryEquipmentMember" xlink:href="sttk-20260331.xsd#sttk_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_LaboratoryEquipmentMember" xlink:to="lab_sttk_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_019ce397-0676-71de-92e2-f0c12da026b1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_019ce397-0676-7be3-ab15-4878d1d373ab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Taxes paid related to net share settlement of restricted stock units</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_019ce397-0676-7f6f-8694-412247fc0746_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_019ce397-0676-7dc2-af4c-9921c5e20b3a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share &#8211; basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019ce397-071e-7233-924d-26dfcaa8c851_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise_019ce397-0676-7a74-8cf2-04b950f6d3fc_terseLabel_en-US" xlink:label="lab_sttk_ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-funded warrants, ownership limitation post-exercise</link:label>
    <link:label id="lab_sttk_ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise_label_en-US" xlink:label="lab_sttk_ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Pre-Funded Warrants, Ownership Limitation Post-Exercise</link:label>
    <link:label id="lab_sttk_ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise_documentation_en-US" xlink:label="lab_sttk_ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Pre-Funded Warrants, Ownership Limitation Post-Exercise</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise" xlink:href="sttk-20260331.xsd#sttk_ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise" xlink:to="lab_sttk_ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_019ce397-0676-7a58-8243-ee93b7c9519e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_019ce397-0676-70f5-a0a8-a4dfe690e38f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_019ce397-0676-7bae-af48-ed6da9ae8db8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued under ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_019ce397-0676-71a2-a9d7-bf0b30f4e6c9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_019ce397-071d-71f4-a418-2ef437b403fb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_ResearchAndDevelopmentNonEquityCompensation_019ce397-0676-7002-a438-c17e44646812_terseLabel_en-US" xlink:label="lab_sttk_ResearchAndDevelopmentNonEquityCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development non-equity compensation</link:label>
    <link:label id="lab_sttk_ResearchAndDevelopmentNonEquityCompensation_label_en-US" xlink:label="lab_sttk_ResearchAndDevelopmentNonEquityCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Non-Equity Compensation</link:label>
    <link:label id="lab_sttk_ResearchAndDevelopmentNonEquityCompensation_documentation_en-US" xlink:label="lab_sttk_ResearchAndDevelopmentNonEquityCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development Non-Equity Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ResearchAndDevelopmentNonEquityCompensation" xlink:href="sttk-20260331.xsd#sttk_ResearchAndDevelopmentNonEquityCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_ResearchAndDevelopmentNonEquityCompensation" xlink:to="lab_sttk_ResearchAndDevelopmentNonEquityCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_019ce397-0676-7e3e-af36-34b8b6fb74dc_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherGeneralAndAdministrativeExpense_019ce397-071d-732d-9cd8-8948224cd846_terseLabel_en-US" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other general and administrative including legal and accounting fees, facilities, insurance, travel and depreciation</link:label>
    <link:label id="lab_us-gaap_OtherGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019ce397-0676-7ff6-be2b-11013d97d252_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_019ce397-0676-7db3-a940-a7fdd2acabd3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019ce397-071d-7c29-9521-a25dba5fd2a4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_019ce397-0677-7b1c-9bfc-dddbcb56409a_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_019ce397-0677-731d-a22f-ba0c642834a1_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_019ce397-0677-75ee-b114-e3b25388c845_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_019ce397-0676-78f7-a75d-4bff86adcafd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_019ce397-071d-782c-8fb0-d44be5755166_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_019ce397-0676-75c4-ba33-99a9db87ce08_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of property and equipment depreciation periods</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_019ce397-0677-7e05-985f-1a49e93d7a5b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_019ce397-0676-7397-8498-095e753462b3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of common stock, net of offering costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_019ce397-071e-74f7-9b26-3d9fc02d15eb_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_019ce397-071e-7119-a4f9-140d8c96439c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Options, granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_019ce397-071e-759e-adc4-a058b93f5b0a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019ce397-0676-7f65-922b-13e3e61d8bfc_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019ce397-0676-710c-a4e7-03cf4decb5d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_019ce397-071d-78e0-a886-23b6e8784463_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019ce397-071d-7034-87da-45426acfe17f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_019ce397-0676-7085-9dfe-61e4e5a42128_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_019ce397-071d-733e-8e65-ef79eba0820f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_019ce397-071d-7f32-bb4d-7c0de85c7c8d_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_ResearchAndDevelopmentEquityCompensation_019ce397-0676-7042-9211-44b236fdcb30_terseLabel_en-US" xlink:label="lab_sttk_ResearchAndDevelopmentEquityCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development equity compensation</link:label>
    <link:label id="lab_sttk_ResearchAndDevelopmentEquityCompensation_label_en-US" xlink:label="lab_sttk_ResearchAndDevelopmentEquityCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Equity Compensation</link:label>
    <link:label id="lab_sttk_ResearchAndDevelopmentEquityCompensation_documentation_en-US" xlink:label="lab_sttk_ResearchAndDevelopmentEquityCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development Equity Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ResearchAndDevelopmentEquityCompensation" xlink:href="sttk-20260331.xsd#sttk_ResearchAndDevelopmentEquityCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_ResearchAndDevelopmentEquityCompensation" xlink:to="lab_sttk_ResearchAndDevelopmentEquityCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_019ce397-071d-7a43-865f-f6ecab91961d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019ce397-0676-79ee-9fe4-c13380565ac5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_019d08f8-8961-7323-bb70-dcf55321f37d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_StockIssuedDuringPeriodSharesWarrantExercises_019d229d-875f-7e9f-b0fb-97276c955201_terseLabel_en-US" xlink:label="lab_sttk_StockIssuedDuringPeriodSharesWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of common stock warrants into common stock and pre-funded warrants (in shares)</link:label>
    <link:label id="lab_sttk_StockIssuedDuringPeriodSharesWarrantExercises_label_en-US" xlink:label="lab_sttk_StockIssuedDuringPeriodSharesWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrant Exercises</link:label>
    <link:label id="lab_sttk_StockIssuedDuringPeriodSharesWarrantExercises_documentation_en-US" xlink:label="lab_sttk_StockIssuedDuringPeriodSharesWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_StockIssuedDuringPeriodSharesWarrantExercises" xlink:href="sttk-20260331.xsd#sttk_StockIssuedDuringPeriodSharesWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_StockIssuedDuringPeriodSharesWarrantExercises" xlink:to="lab_sttk_StockIssuedDuringPeriodSharesWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_019ce397-0676-7ac4-8e18-8e7653be1d9b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gain</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_019ce397-071d-746f-9738-2501a3fc2967_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_019ce397-071d-760c-8b62-8ce15f6a5fb7_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent_019d04cf-5280-7fc4-aee1-3ce727dfd6e6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in related party</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_KayakAgreementContingentMilestonesMember_019d0602-80ed-7933-b95a-38fafcf60d30_terseLabel_en-US" xlink:label="lab_sttk_KayakAgreementContingentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kayak Agreement, Contingent Milestones</link:label>
    <link:label id="lab_sttk_KayakAgreementContingentMilestonesMember_label_en-US" xlink:label="lab_sttk_KayakAgreementContingentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kayak Agreement, Contingent Milestones [Member]</link:label>
    <link:label id="lab_sttk_KayakAgreementContingentMilestonesMember_documentation_en-US" xlink:label="lab_sttk_KayakAgreementContingentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kayak Agreement, Contingent Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_KayakAgreementContingentMilestonesMember" xlink:href="sttk-20260331.xsd#sttk_KayakAgreementContingentMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_KayakAgreementContingentMilestonesMember" xlink:to="lab_sttk_KayakAgreementContingentMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_019ce397-0676-7cfc-972c-d85e6ce86312_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_019ce397-071d-735a-a7ea-69342104cab3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_019ce397-071e-7abb-8af6-3dd440654cd7_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_019ce397-0676-7255-b265-f3ac4e633718_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_019ce397-071d-7b4c-9e8e-15d6f4917eaf_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_019ce397-0676-725a-98aa-73ef3c9c6b24_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_019ce397-0676-7c26-a7f2-a38f5f267723_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_019ce397-0676-7a98-a0ef-6a4ea04a5df7_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019ce397-071e-702e-87b6-046ed12ad561_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_019d4dbb-0446-7279-9dbf-51d45aaa9241_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_019ce397-0676-7cb9-925b-f7e6698706aa_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_019ce397-0676-72db-a0af-48e0f912c45f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Released (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_019d4dba-8adb-7183-8eea-51abd6eb8f37_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_019ce397-071e-7c89-a77f-c673fc8f11cf_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options and purchases pursuant to employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_019ce397-0676-7178-b5cc-ab9142dcd7de_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019ce397-0676-767f-8c8a-72bd32be9aaa_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operations:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_019ce397-071e-7b89-8119-78293b123629_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_019ce397-0677-7a3d-825d-87f117f90721_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_019ce397-0676-7ae5-a483-619a2bf537b0_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_019ce397-0676-7027-ba96-308ef295a676_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_019d055a-f26d-7e02-b8c8-01354222f550_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_019ce397-0677-77f7-a4f0-5347b58c8a30_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019ce397-0676-74ee-ad7b-4b058b6da29c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019ce397-071d-78e8-aefc-66c50e272d24_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019ce397-071d-7b7b-a866-4736212a5873_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_019ce397-071e-7088-9034-9557dcde2c4f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_019ce397-071e-78b5-97bc-a45d64868e4e_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_019ce397-0676-7265-bb96-21aa13d61e99_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_AbhinavShuklaPhDMember_label_en-US" xlink:label="lab_sttk_AbhinavShuklaPhDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Abhinav Shukla, PhD [Member]</link:label>
    <link:label id="lab_sttk_AbhinavShuklaPhDMember_documentation_en-US" xlink:label="lab_sttk_AbhinavShuklaPhDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Abhinav Shukla, PhD</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AbhinavShuklaPhDMember" xlink:href="sttk-20260331.xsd#sttk_AbhinavShuklaPhDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_AbhinavShuklaPhDMember" xlink:to="lab_sttk_AbhinavShuklaPhDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_019d228f-43f0-73f3-91ce-918c170cb047_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019ce397-071d-79b6-9c21-cb6089b0b55f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_019ce397-071e-7afc-9086-0a17ebd3d30b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_019ce397-071e-7dd3-a64a-b8919f44c06b_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019ce397-0677-70ad-a5ab-985c9ae19fa1_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019ce397-071d-7df6-bef2-7a7e694e9d00_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_019ce397-0676-7cdd-ab0d-ed2fbb335b27_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of accrued expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_019ce397-0676-78ce-8fc4-7bddcc07ebbf_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019ce397-0676-7f11-b383-f54cf3b8e70c_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019ce397-0676-71e3-86e7-76b19289f433_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_019ce397-0676-781b-acc2-87303756c795_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_019ce397-0676-76f6-aa21-2edaeef3deff_terseLabel_en-US" xlink:label="lab_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_019ce397-0676-7027-8eb7-e378559365ee_totalLabel_en-US" xlink:label="lab_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses and other current liabilities</link:label>
    <link:label id="lab_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_label_en-US" xlink:label="lab_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities and Other Liabilities, Current</link:label>
    <link:label id="lab_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_documentation_en-US" xlink:label="lab_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Liabilities and Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:href="sttk-20260331.xsd#sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="lab_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_PreFundedWarrantsMember_019d08f8-8961-7f65-b7fe-597dd07da7fb_terseLabel_en-US" xlink:label="lab_sttk_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrants</link:label>
    <link:label id="lab_sttk_PreFundedWarrantsMember_label_en-US" xlink:label="lab_sttk_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
    <link:label id="lab_sttk_PreFundedWarrantsMember_documentation_en-US" xlink:label="lab_sttk_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_PreFundedWarrantsMember" xlink:href="sttk-20260331.xsd#sttk_PreFundedWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_PreFundedWarrantsMember" xlink:to="lab_sttk_PreFundedWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_019ce397-0677-73f2-a72e-f9e422599cdb_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_019ce397-0676-73a2-9dd1-89d7376b1c02_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_019ce397-071d-7efa-ae0e-f5dcabc6c828_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_019ce397-0676-727c-80c5-acd95c72d45d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_019ce397-071d-703c-b388-593b3cc321bc_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted&#160;average remaining contract life, vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_019ce397-071d-7117-9d9d-3dbcc4b70eeb_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019ce397-0676-781d-9529-1a53d0be49df_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Awards, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019ce397-0676-7b62-9305-2d1ba1fd3096_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Awards, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019ce397-071d-7a37-811f-8f53fbfcba97_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_019ce397-071e-7130-b8ca-c7303c36a473_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_019ce397-0676-79f9-aacc-d5ee4a077a0a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_019ce397-0676-7f47-b418-6c824687e498_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019ce397-0676-72e7-99c9-fc57ab8177a5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_019ce397-0676-7b05-8ede-4cbae4583f78_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_019ce397-071d-7ad6-bfc3-a1a424e01b8d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment depreciation and amortization periods</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_019ce397-0676-72e1-888c-ac1c8e39418b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of valuation assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_019ce397-0676-7fc2-b381-200877cce3dd_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_019ce397-0676-7cce-b343-94d8723f1ca7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_019ce397-071d-714a-9f58-a442612f92f0_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money Market Funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_019d0563-e4b0-7362-97ba-f50935812e2d_netLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Money market fund</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_BlackScholesOptionPricingModelMember_019ce397-0677-72b6-a625-fdb2567486c6_terseLabel_en-US" xlink:label="lab_sttk_BlackScholesOptionPricingModelMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Black-Scholes Option Pricing Model</link:label>
    <link:label id="lab_sttk_BlackScholesOptionPricingModelMember_label_en-US" xlink:label="lab_sttk_BlackScholesOptionPricingModelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Black-Scholes Option Pricing Model [Member]</link:label>
    <link:label id="lab_sttk_BlackScholesOptionPricingModelMember_documentation_en-US" xlink:label="lab_sttk_BlackScholesOptionPricingModelMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Black-Scholes Option Pricing Model</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_BlackScholesOptionPricingModelMember" xlink:href="sttk-20260331.xsd#sttk_BlackScholesOptionPricingModelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_BlackScholesOptionPricingModelMember" xlink:to="lab_sttk_BlackScholesOptionPricingModelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_019ce397-071d-7d73-be33-246d10100b3b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_019ce397-0677-735d-8a93-31f486969fb9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_019d0602-80ed-7b33-8bdb-752758f2c9e6_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_019ce397-0676-7c09-87cd-0514c2731cc4_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization and Description of Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_019ce397-071e-7097-bc54-0cd489efdd00_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_019ce397-071e-7514-a46c-42b91f418abc_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosures of non-cash financial activities:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019ce397-0676-7a92-9054-0c2e0b35f90f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise&#160;Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_019ce397-071d-7bbe-a196-5126e1022f46_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019ce397-071d-7024-8262-1cc725adcd79_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_019ce397-071d-7531-91c1-78e1af5cf07e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_019ce397-0676-73fd-be9b-a2d6417a90e9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_019ce397-0676-7527-852e-426dba124d4b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible List]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_019ce397-0676-7cd4-ac32-07fb82389e2c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_019ce397-071d-7c95-ae42-ded210269327_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_019ce397-071e-7332-aff7-074954ad5db2_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_019ce397-0676-76fb-a282-38f30a08c849_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Unaudited Interim Condensed Financial Statements</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_019ce397-0676-7742-944d-f072cb7de19b_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_019ce397-071e-746a-91d9-9fa84a206b07_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019ce397-0676-787f-95b0-7a3e8a39a335_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average amortization period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019ce397-071d-731f-af45-0fa9c77b1cfa_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Options, granted (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_019ce397-0676-7f1f-b915-ee6eb4de2876_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_019ce397-0676-7bd7-986a-24dd331d4361_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value of options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_019ce397-0677-7a2a-8b62-244e6ada4101_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019ce397-0677-7459-87ac-8e8e0a56d23b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019ce397-0676-71d4-a590-96407f1dea92_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_019ce397-0676-7b0c-9d40-61a8412cc8e8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_019ce397-0677-715b-a56d-cab5aec8bed6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_019ce397-071d-7a40-90d2-11c964920392_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019ce397-0676-73ae-b5f4-5bdc961bb154_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, proceeds received</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_019ce397-0676-7bd4-b259-0d4c442488a3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019ce397-0676-7b3b-aaba-f8f4a07da48a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price of warrants or rights (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019ce397-0676-7e64-a35a-ee0ffa7ae5a1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_019ce397-071d-7a0f-b238-9e1d1c272241_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_019ce397-0676-7b08-9a9a-7d2cabeceef6_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_019ce397-0676-73e1-8197-e0b8c5d4c128_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_BeneficialOwnersMember_019d08f8-8961-77d7-b62c-007f59aaee0e_terseLabel_en-US" xlink:label="lab_sttk_BeneficialOwnersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Beneficial Owners</link:label>
    <link:label id="lab_sttk_BeneficialOwnersMember_label_en-US" xlink:label="lab_sttk_BeneficialOwnersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Beneficial Owners [Member]</link:label>
    <link:label id="lab_sttk_BeneficialOwnersMember_documentation_en-US" xlink:label="lab_sttk_BeneficialOwnersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Beneficial Owners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_BeneficialOwnersMember" xlink:href="sttk-20260331.xsd#sttk_BeneficialOwnersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_BeneficialOwnersMember" xlink:to="lab_sttk_BeneficialOwnersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019ce397-0676-74f4-a0c6-0a8fc13e4a4a_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_019ce397-0677-7ab4-9930-cb95b3ba6c5f_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation and Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_IncreaseDecreaseInOperatingLeasesRightOfUseAssetsLiability_019dd040-6c4d-7e06-8749-abf4ea5002e0_terseLabel_en-US" xlink:label="lab_sttk_IncreaseDecreaseInOperatingLeasesRightOfUseAssetsLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in lease balances resulting from lease modification</link:label>
    <link:label id="lab_sttk_IncreaseDecreaseInOperatingLeasesRightOfUseAssetsLiability_label_en-US" xlink:label="lab_sttk_IncreaseDecreaseInOperatingLeasesRightOfUseAssetsLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Operating Leases, Right of Use Assets (Liability)</link:label>
    <link:label id="lab_sttk_IncreaseDecreaseInOperatingLeasesRightOfUseAssetsLiability_documentation_en-US" xlink:label="lab_sttk_IncreaseDecreaseInOperatingLeasesRightOfUseAssetsLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Operating Leases, Right of Use Assets (Liability)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_IncreaseDecreaseInOperatingLeasesRightOfUseAssetsLiability" xlink:href="sttk-20260331.xsd#sttk_IncreaseDecreaseInOperatingLeasesRightOfUseAssetsLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_IncreaseDecreaseInOperatingLeasesRightOfUseAssetsLiability" xlink:to="lab_sttk_IncreaseDecreaseInOperatingLeasesRightOfUseAssetsLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_019ce397-0676-7f9d-99b3-6151922044ed_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_019ce397-0676-7b01-a11e-25325bd62e2d_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_019d08f8-8961-7c99-8aa9-4696f55bb96d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_SaleOfStockCommissionPercentage_019d08f8-8961-7910-9409-b2dddd5ca9cf_terseLabel_en-US" xlink:label="lab_sttk_SaleOfStockCommissionPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock commission</link:label>
    <link:label id="lab_sttk_SaleOfStockCommissionPercentage_label_en-US" xlink:label="lab_sttk_SaleOfStockCommissionPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Commission Percentage</link:label>
    <link:label id="lab_sttk_SaleOfStockCommissionPercentage_documentation_en-US" xlink:label="lab_sttk_SaleOfStockCommissionPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Commission Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_SaleOfStockCommissionPercentage" xlink:href="sttk-20260331.xsd#sttk_SaleOfStockCommissionPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_SaleOfStockCommissionPercentage" xlink:to="lab_sttk_SaleOfStockCommissionPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_019ce397-071e-7a31-a5a8-cb35038875fc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_019ce397-0676-7693-98c2-27419e9ae071_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_019ce397-071d-7927-8f30-6b00a3d39af2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_019ce397-0676-7aba-929f-d18217a152f4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_019ce397-0676-71ff-97e6-157aedca66a1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019ce397-0676-7a04-a34b-acd9dbac1095_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_WarrantsPolicyTextBlock_019d4dbb-7465-7874-b148-1dd07a369b12_terseLabel_en-US" xlink:label="lab_sttk_WarrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock Warrants and Pre-Funded Warrants</link:label>
    <link:label id="lab_sttk_WarrantsPolicyTextBlock_label_en-US" xlink:label="lab_sttk_WarrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants [Policy Text Block]</link:label>
    <link:label id="lab_sttk_WarrantsPolicyTextBlock_documentation_en-US" xlink:label="lab_sttk_WarrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_WarrantsPolicyTextBlock" xlink:href="sttk-20260331.xsd#sttk_WarrantsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_WarrantsPolicyTextBlock" xlink:to="lab_sttk_WarrantsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_019ce397-071d-7f27-a74e-1ea3928647d3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Taxes paid related to net share settlement of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_019ce397-071d-729b-a8a3-24c577155980_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_019d0602-80ed-7e59-8049-bccc2fdbc42d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Account receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_019ce397-071d-726c-9a56-4f93090b03f5_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_019ce397-071d-72e5-9581-118874bc90ca_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_019d0a0d-de7e-7456-86d7-f6e4994a3fd9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of common stock warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019ce397-0676-77ce-bb7e-0fad6ca6cd0b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_OperatingAccountMember_019ce397-071d-79c0-bbe6-ba203944a4e8_terseLabel_en-US" xlink:label="lab_sttk_OperatingAccountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Account</link:label>
    <link:label id="lab_sttk_OperatingAccountMember_label_en-US" xlink:label="lab_sttk_OperatingAccountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Account [Member]</link:label>
    <link:label id="lab_sttk_OperatingAccountMember_documentation_en-US" xlink:label="lab_sttk_OperatingAccountMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Account</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_OperatingAccountMember" xlink:href="sttk-20260331.xsd#sttk_OperatingAccountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_OperatingAccountMember" xlink:to="lab_sttk_OperatingAccountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_019ce397-0676-7759-ac74-2ba2b6892f3a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_019d09ba-29af-7da5-a39d-1ca36b02ea57_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_019ce397-071d-7da1-813e-7df28d37dbbe_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_019ce397-071d-726a-af2d-c2d04e82f1a0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of RSU activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_019ce397-0676-731e-864d-25f4c2d4f75c_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_019ce397-0676-7d13-9262-ffdbbb0c672c_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_019ce397-0677-70e0-8c92-33903e22530d_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. government securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage_019ce397-0677-76ae-aa6f-6dcf66d44ec0_terseLabel_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in number of shares authorized, percentage of capital stock outstanding</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage_label_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized, Annual Increase Percentage</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage_documentation_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized, Annual Increase Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage" xlink:href="sttk-20260331.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage" xlink:to="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_019ce397-0676-7490-8e26-c3253d641720_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net amortization of investments</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_019ce397-071d-7416-aa16-0fef9498be8e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted&#160;average remaining contract life, outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_KayakAgreementMember_019d0602-80ed-7040-88cf-2ab15dc36a2b_terseLabel_en-US" xlink:label="lab_sttk_KayakAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kayak Agreement</link:label>
    <link:label id="lab_sttk_KayakAgreementMember_label_en-US" xlink:label="lab_sttk_KayakAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kayak Agreement [Member]</link:label>
    <link:label id="lab_sttk_KayakAgreementMember_documentation_en-US" xlink:label="lab_sttk_KayakAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kayak Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_KayakAgreementMember" xlink:href="sttk-20260331.xsd#sttk_KayakAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_KayakAgreementMember" xlink:to="lab_sttk_KayakAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019ce397-0676-7cf8-b3f8-d5cf3ad32f2a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal_019ce397-0676-7caf-82b2-2dff5cc450dd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment impairment</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest, Allowance for Credit Loss, Not to Sell before Recovery, Credit Loss, Previously Recorded, Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_019ce397-0676-7ebd-aca8-ac77015ca2c5_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_019ce397-0676-76ac-b88b-0380fcae7d48_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options and purchases pursuant to employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_019ce397-071d-7d63-97f1-96c9a8b2c9e6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019ce397-0676-78e8-8822-dace582d70d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_019ce397-0676-77c6-88c0-f9148e789529_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019ce397-0676-75ba-81b6-e98dbfa8ef60_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividends</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019d09d2-4517-783a-bb46-2cd35336ba43_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected dividends</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_ArunthathyNirmaliniLiniPanditeM.B.Ch.B.Member_label_en-US" xlink:label="lab_sttk_ArunthathyNirmaliniLiniPanditeM.B.Ch.B.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arunthathy Nirmalini (Lini) Pandite, M.B.Ch.B., [Member]</link:label>
    <link:label id="lab_sttk_ArunthathyNirmaliniLiniPanditeM.B.Ch.B.Member_documentation_en-US" xlink:label="lab_sttk_ArunthathyNirmaliniLiniPanditeM.B.Ch.B.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Arunthathy Nirmalini (Lini) Pandite, M.B.Ch.B.,</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ArunthathyNirmaliniLiniPanditeM.B.Ch.B.Member" xlink:href="sttk-20260331.xsd#sttk_ArunthathyNirmaliniLiniPanditeM.B.Ch.B.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_ArunthathyNirmaliniLiniPanditeM.B.Ch.B.Member" xlink:to="lab_sttk_ArunthathyNirmaliniLiniPanditeM.B.Ch.B.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019ce397-071d-70f2-9ecd-fbb3bc1c9100_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019ce397-071d-7ffe-93e0-5a8274fd3f27_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_019ce397-071d-7e47-a2f8-c7449d638252_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_019ce397-071d-72ea-8d59-c1c61689ebec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum number of shares per employee during any one purchase period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019ce397-0676-71dc-88d9-5253f6ca4843_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019ce397-0676-75aa-84e1-b8f0a4c42228_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019ce397-0676-78b1-8534-e64e9b649bce_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_019ce397-0677-7207-8972-2c3a100596da_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_019d8faa-c01f-769f-a48b-c7f8cdb04688_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_019ce397-0676-76ce-9600-0b72c8826b9e_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_019ce397-071e-7839-9882-242e1ff5f1f6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_019ce397-0676-7d1f-a2d7-cdf03e0c937b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalent [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_019ce397-071d-751a-9fa6-a35b9584f774_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrentMember_019ce397-0676-7208-b6b1-509d2c696226_terseLabel_en-US" xlink:label="lab_sttk_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments:</link:label>
    <link:label id="lab_sttk_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrentMember_label_en-US" xlink:label="lab_sttk_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale Excluding Accrued Interest, Current [Member]</link:label>
    <link:label id="lab_sttk_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrentMember_documentation_en-US" xlink:label="lab_sttk_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale Excluding Accrued Interest, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrentMember" xlink:href="sttk-20260331.xsd#sttk_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrentMember" xlink:to="lab_sttk_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_019ce397-0676-708b-9b6c-7a88906d6944_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019ce397-0676-759c-a55a-8416713736a3_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of securities called by warrants or rights (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_019ce397-0676-7162-881c-2a69cd468870_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_019ce397-071e-7ef9-92cf-1d2a389c39db_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_019ce397-0676-7c16-acb3-5a5ca6b79876_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_019ce397-071d-7ed2-b949-0134d17ecfef_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_019ce397-071e-7dc1-880d-64d0330331a5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from ESPP</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_019ce397-0676-733c-9589-5cf60def3442_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.0001 par value: 300,000,000 shares authorized; 75,581,787 shares issued and outstanding at March&#160;31, 2026 and 63,279,843 shares issued and outstanding at December&#160;31, 2025</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_A2020StockIncentivePlanMember_019ce397-071d-74db-9d58-df63c67507e6_terseLabel_en-US" xlink:label="lab_sttk_A2020StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020 Stock Incentive Plan</link:label>
    <link:label id="lab_sttk_A2020StockIncentivePlanMember_label_en-US" xlink:label="lab_sttk_A2020StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2020 Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_sttk_A2020StockIncentivePlanMember_documentation_en-US" xlink:label="lab_sttk_A2020StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2020 Stock Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020StockIncentivePlanMember" xlink:href="sttk-20260331.xsd#sttk_A2020StockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_A2020StockIncentivePlanMember" xlink:to="lab_sttk_A2020StockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_019ce397-0676-7905-af70-029bf9ae5c41_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019ce397-071d-7cf4-b6a8-6cbe74b1f436_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares outstanding &#8211; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_019ce397-0676-7021-98b3-0a14c088e31d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 5)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_019ce397-0676-7a02-b113-033c91158e5d_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_019ce397-0676-75c1-9c27-67ef0739964c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_019ce397-0676-7bcf-9d48-d63324321566_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_019ce397-0676-714f-98fd-d0f35fc5961a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_019ce397-0677-7a72-9e76-0e4e9d6644df_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019ce397-071d-7a5e-ba2f-3df9eabf7adb_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_019ce397-0677-713b-addf-8fb84a0815f1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining contract life, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_019ce397-0676-73cb-aa3c-2dcfb8e02eb7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm_019ce397-071d-7dda-8aed-43c80568819d_terseLabel_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual increase in number of shares authorized, term</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm_label_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase In Number of Shares Authorized, Term</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm_documentation_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase In Number of Shares Authorized, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm" xlink:href="sttk-20260331.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm" xlink:to="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_019ce397-071d-7454-924d-159b0258c530_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_019ce397-071e-7770-b2d0-a8078927be10_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_019ce397-0676-7ad2-bc82-6358db2e0f7b_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_019ce397-071e-72c8-bf0a-4d39314bb77c_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_019d0a0d-de7e-7d47-bd7a-7d3b647010d6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019ce397-0676-71bb-b65a-86b72cb3734a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019d0602-80ed-7ad7-9dfc-dbfdc6d24c73_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">License and collaboration revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_019ce397-0676-7c82-bef2-010abb959ec4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_OtherResearchAndDevelopmentExpenseTechnicalOperations_019ce397-0676-73a6-ad41-5ad4b6aa56c0_terseLabel_en-US" xlink:label="lab_sttk_OtherResearchAndDevelopmentExpenseTechnicalOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other research and development expense (income), technical operations</link:label>
    <link:label id="lab_sttk_OtherResearchAndDevelopmentExpenseTechnicalOperations_label_en-US" xlink:label="lab_sttk_OtherResearchAndDevelopmentExpenseTechnicalOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Research And Development Expense, Technical Operations</link:label>
    <link:label id="lab_sttk_OtherResearchAndDevelopmentExpenseTechnicalOperations_documentation_en-US" xlink:label="lab_sttk_OtherResearchAndDevelopmentExpenseTechnicalOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Research And Development Expense, Technical Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_OtherResearchAndDevelopmentExpenseTechnicalOperations" xlink:href="sttk-20260331.xsd#sttk_OtherResearchAndDevelopmentExpenseTechnicalOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_OtherResearchAndDevelopmentExpenseTechnicalOperations" xlink:to="lab_sttk_OtherResearchAndDevelopmentExpenseTechnicalOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_019ce397-0676-7359-977d-e3bc3f95e0d5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation, expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_019ce397-0676-7996-89ab-487f9e68edb7_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_019ce397-0676-77a3-92d1-1cc047def43a_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_019ce397-071d-744e-82f5-84805dedfa51_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the exercises of stock options and purchases pursuant to employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_019ce397-0676-721b-948d-ba38b5686a08_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price of common stock in percent</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_019ce397-0676-7266-a1ed-e246e39dc896_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_019ce397-071d-77bf-af37-c36a08bbf4d5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_019ce397-0676-7aec-8693-0509dff50097_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_019ce397-071e-70f1-b4bb-23b65a2a5d83_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_019ce397-0676-7c2b-aaf8-7cc2c1cfd9a4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining&#160;Life (Years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_GeneralAndAdministrativeEquityCompensation_019ce397-0676-7e7c-9787-f473136d0684_terseLabel_en-US" xlink:label="lab_sttk_GeneralAndAdministrativeEquityCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative equity compensation</link:label>
    <link:label id="lab_sttk_GeneralAndAdministrativeEquityCompensation_label_en-US" xlink:label="lab_sttk_GeneralAndAdministrativeEquityCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General And Administrative Equity Compensation</link:label>
    <link:label id="lab_sttk_GeneralAndAdministrativeEquityCompensation_documentation_en-US" xlink:label="lab_sttk_GeneralAndAdministrativeEquityCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">General And Administrative Equity Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_GeneralAndAdministrativeEquityCompensation" xlink:href="sttk-20260331.xsd#sttk_GeneralAndAdministrativeEquityCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_GeneralAndAdministrativeEquityCompensation" xlink:to="lab_sttk_GeneralAndAdministrativeEquityCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_019ce397-071d-7345-93a1-bec52322293e_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Expense from operations</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_019ce397-071d-7842-b3f5-8fd469c77625_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense from operations</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_019ce397-071d-7279-8e26-ced35cfc0d06_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_019ce397-071d-7d9e-bbc4-38d15a1c6796_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_019ce397-0676-7530-9511-432d2dc37a76_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_019ce397-071d-7739-8721-828bf15ea1f9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share &#8211; diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_019ce397-0676-72a8-9330-131371f5a276_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_019ce397-0676-7a5d-a365-a6278a26cd09_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019ce397-071d-7d34-9424-886a02f3e50f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_019ce397-0677-771c-8cf0-9558a8102892_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_019d4dc2-6fe5-7ad5-b62b-8c5adc199696_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_AtTheMarketOfferingMember_019d08f8-8961-7307-b26f-5db2c19059d9_terseLabel_en-US" xlink:label="lab_sttk_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At The Market Offering</link:label>
    <link:label id="lab_sttk_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_sttk_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:label id="lab_sttk_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_sttk_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At The Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AtTheMarketOfferingMember" xlink:href="sttk-20260331.xsd#sttk_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_AtTheMarketOfferingMember" xlink:to="lab_sttk_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_OtherResearchAndDevelopmentSL172154Member_019dd056-9de5-72b9-a786-ab153041a0f8_terseLabel_en-US" xlink:label="lab_sttk_OtherResearchAndDevelopmentSL172154Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Research And Development, SL-172154</link:label>
    <link:label id="lab_sttk_OtherResearchAndDevelopmentSL172154Member_label_en-US" xlink:label="lab_sttk_OtherResearchAndDevelopmentSL172154Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Research And Development, SL-172154 [Member]</link:label>
    <link:label id="lab_sttk_OtherResearchAndDevelopmentSL172154Member_documentation_en-US" xlink:label="lab_sttk_OtherResearchAndDevelopmentSL172154Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Research And Development, SL-172154</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_OtherResearchAndDevelopmentSL172154Member" xlink:href="sttk-20260331.xsd#sttk_OtherResearchAndDevelopmentSL172154Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_OtherResearchAndDevelopmentSL172154Member" xlink:to="lab_sttk_OtherResearchAndDevelopmentSL172154Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_019ce397-071d-7521-96c0-c3a262413aa8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of antidilutive securities excluded from computation of net loss per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_019ce397-0676-785f-a952-1ebfbbea5a21_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_019ce397-0677-7191-8c25-1ca4bbc423f2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_019ce397-0677-7691-8584-f3f477049625_terseLabel_en-US" xlink:label="lab_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, additional capital shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Additional Capital Shares Reserved for Future Issuance</link:label>
    <link:label id="lab_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_documentation_en-US" xlink:label="lab_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Additional Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:href="sttk-20260331.xsd#sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:to="lab_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_019ce397-071d-718d-adf4-0b821a2bde77_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_019ce397-071e-78c3-bfa7-49c661b367d1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsMember_019ce397-071d-7061-b0c1-000301da1bcb_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember" xlink:to="lab_us-gaap_CashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019ce397-071d-749b-ba74-a1918a37ea16_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_019ce397-071d-711d-b423-a4703d01e655_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_019ce397-0676-76fe-a9c5-d781ab2ce91c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation and related benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherResearchAndDevelopmentExpense_019ce397-0676-79b6-b0b1-6f4036c8bce6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other research and development expense</link:label>
    <link:label id="lab_us-gaap_OtherResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_OtherResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_OtherResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_019ce397-071d-7caf-8858-54f291b1498b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_019ce397-0676-7726-8375-f37c18540dc3_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_019ce397-0676-7c4c-84c6-690d0489b6de_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_019d059e-6470-77cd-90c4-bdcdabec5a0c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019ce397-0676-7cc2-9b19-3cc82f8a2f29_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation, vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_019ce397-0676-728f-9340-2b85c90d98a9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_019ce397-0676-7417-ad81-4b79c19f6928_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_019ce397-071d-75d2-bcc8-daa2dbade0ab_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_019ce397-071d-7bbf-8777-b65f754de91d_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_019ce397-071d-7562-859a-71790189eb9c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_019ce397-0676-75cb-8397-bedff1adfd38_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_019d04ea-c842-744c-b330-68e24a04f40f_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_019ce397-0676-77e6-ad65-9116b7b56e64_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_UnderwrittenPublicOfferingMember_019d08f8-8961-7052-a8f5-517fbf835f14_terseLabel_en-US" xlink:label="lab_sttk_UnderwrittenPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underwritten Public Offering</link:label>
    <link:label id="lab_sttk_UnderwrittenPublicOfferingMember_label_en-US" xlink:label="lab_sttk_UnderwrittenPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underwritten Public Offering [Member]</link:label>
    <link:label id="lab_sttk_UnderwrittenPublicOfferingMember_documentation_en-US" xlink:label="lab_sttk_UnderwrittenPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Underwritten Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_UnderwrittenPublicOfferingMember" xlink:href="sttk-20260331.xsd#sttk_UnderwrittenPublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_UnderwrittenPublicOfferingMember" xlink:to="lab_sttk_UnderwrittenPublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_019ce397-0676-748b-b235-ff1634f1fb9d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_019ce397-071e-7525-b5c0-a076166bf09d_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_019ce397-0676-74fd-89ae-5baef4ffd2f9_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of securities called by each warrant or right (in share per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019ce397-071d-70ca-bd67-93f60811a5ab_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term - years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue_019ce397-0676-7e82-91d2-1e9c501fd159_terseLabel_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum value of shares per employee during any calendar year</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue_label_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Shares Per Employee, Value</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue_documentation_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Shares Per Employee, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue" xlink:href="sttk-20260331.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue" xlink:to="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019ce397-0676-7794-8b7b-76c1dfd63632_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_019ce397-071d-7c08-87a8-6691de275855_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_019ce397-0676-7cb1-9eb8-a3662bb4cd23_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other expense</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_019ce397-0676-7fdf-8820-d61137d4858f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contribution limit in percentage of employee's eligible compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019ce397-0676-7275-a823-e959025b5700_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_019ce397-0676-763d-8e61-3a3c689b691b_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party License Revenue</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019ce397-0677-7945-bb1f-eed4a9df9557_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019ce397-0676-7cce-a9fc-46f80544a703_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_ClassOfWarrantOrRightWarrantsExercised_019d08f8-8961-7477-8209-bebed17fdae3_terseLabel_en-US" xlink:label="lab_sttk_ClassOfWarrantOrRightWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock warrants exercised (in shares)</link:label>
    <link:label id="lab_sttk_ClassOfWarrantOrRightWarrantsExercised_label_en-US" xlink:label="lab_sttk_ClassOfWarrantOrRightWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Warrants Exercised</link:label>
    <link:label id="lab_sttk_ClassOfWarrantOrRightWarrantsExercised_documentation_en-US" xlink:label="lab_sttk_ClassOfWarrantOrRightWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ClassOfWarrantOrRightWarrantsExercised" xlink:href="sttk-20260331.xsd#sttk_ClassOfWarrantOrRightWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_ClassOfWarrantOrRightWarrantsExercised" xlink:to="lab_sttk_ClassOfWarrantOrRightWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_CommonStockNumberOfVotesPerCommonShare_019ce397-0677-7949-9038-c4ec52202df3_terseLabel_en-US" xlink:label="lab_sttk_CommonStockNumberOfVotesPerCommonShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, number of votes per common share</link:label>
    <link:label id="lab_sttk_CommonStockNumberOfVotesPerCommonShare_label_en-US" xlink:label="lab_sttk_CommonStockNumberOfVotesPerCommonShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Number Of Votes Per Common Share</link:label>
    <link:label id="lab_sttk_CommonStockNumberOfVotesPerCommonShare_documentation_en-US" xlink:label="lab_sttk_CommonStockNumberOfVotesPerCommonShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Number Of Votes Per Common Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_CommonStockNumberOfVotesPerCommonShare" xlink:href="sttk-20260331.xsd#sttk_CommonStockNumberOfVotesPerCommonShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_CommonStockNumberOfVotesPerCommonShare" xlink:to="lab_sttk_CommonStockNumberOfVotesPerCommonShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019ce397-0676-7891-9e06-9bf3251b953a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_019ce397-071d-7f95-9322-81dc4530a8f2_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_019ce397-071d-788f-808d-7da2e2d463bb_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of preferred stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_019ce397-0676-7269-8c2d-5486dedab7ea_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_ReportableSegmentMember_019ce397-0677-721e-b525-617b4b0bea4d_terseLabel_en-US" xlink:label="lab_sttk_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:label id="lab_sttk_ReportableSegmentMember_label_en-US" xlink:label="lab_sttk_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reportable Segment [Member]</link:label>
    <link:label id="lab_sttk_ReportableSegmentMember_documentation_en-US" xlink:label="lab_sttk_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ReportableSegmentMember" xlink:href="sttk-20260331.xsd#sttk_ReportableSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_ReportableSegmentMember" xlink:to="lab_sttk_ReportableSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_019ce397-0676-7882-94fa-a8c7d7f0851c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_019ce397-071e-7ff4-aa8e-d5738ab1aee5_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_019ce397-0676-7516-adb6-f3835be261d8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of option activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_StockIssuedDuringPeriodValueWarrantExercises_019d229d-c09e-762f-8408-dabd5fb9fb9a_terseLabel_en-US" xlink:label="lab_sttk_StockIssuedDuringPeriodValueWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of common stock warrants into common stock and pre-funded warrants</link:label>
    <link:label id="lab_sttk_StockIssuedDuringPeriodValueWarrantExercises_label_en-US" xlink:label="lab_sttk_StockIssuedDuringPeriodValueWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Warrant Exercises</link:label>
    <link:label id="lab_sttk_StockIssuedDuringPeriodValueWarrantExercises_documentation_en-US" xlink:label="lab_sttk_StockIssuedDuringPeriodValueWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_StockIssuedDuringPeriodValueWarrantExercises" xlink:href="sttk-20260331.xsd#sttk_StockIssuedDuringPeriodValueWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_StockIssuedDuringPeriodValueWarrantExercises" xlink:to="lab_sttk_StockIssuedDuringPeriodValueWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_019ce397-0676-7a0e-a30a-3380ee1311c0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019ce397-0676-7b42-97c9-0b9d04b9dfc2_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares outstanding &#8211; basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_019ce397-0676-73df-82f9-0eff61936549_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019ce397-0676-7385-9150-7bf29273bca9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_019d228e-9d63-798a-8ff8-14a4d5defb98_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_019ce397-0676-78de-bb65-44e65b6a880e_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_SaleOfStockMaximumAggregateSalesPrice_019ce397-071d-7eab-b46d-b2f5f9de8657_terseLabel_en-US" xlink:label="lab_sttk_SaleOfStockMaximumAggregateSalesPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock maximum aggregate sales price</link:label>
    <link:label id="lab_sttk_SaleOfStockMaximumAggregateSalesPrice_label_en-US" xlink:label="lab_sttk_SaleOfStockMaximumAggregateSalesPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock Maximum Aggregate Sales Price</link:label>
    <link:label id="lab_sttk_SaleOfStockMaximumAggregateSalesPrice_documentation_en-US" xlink:label="lab_sttk_SaleOfStockMaximumAggregateSalesPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock Maximum Aggregate Sales Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_SaleOfStockMaximumAggregateSalesPrice" xlink:href="sttk-20260331.xsd#sttk_SaleOfStockMaximumAggregateSalesPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_SaleOfStockMaximumAggregateSalesPrice" xlink:to="lab_sttk_SaleOfStockMaximumAggregateSalesPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_GeneralAndAdministrativeNonEquityCompensation_019ce397-0676-7e77-8376-841883b0febc_terseLabel_en-US" xlink:label="lab_sttk_GeneralAndAdministrativeNonEquityCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative non-equity compensation</link:label>
    <link:label id="lab_sttk_GeneralAndAdministrativeNonEquityCompensation_label_en-US" xlink:label="lab_sttk_GeneralAndAdministrativeNonEquityCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General And Administrative Non-Equity Compensation</link:label>
    <link:label id="lab_sttk_GeneralAndAdministrativeNonEquityCompensation_documentation_en-US" xlink:label="lab_sttk_GeneralAndAdministrativeNonEquityCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">General And Administrative Non-Equity Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_GeneralAndAdministrativeNonEquityCompensation" xlink:href="sttk-20260331.xsd#sttk_GeneralAndAdministrativeNonEquityCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_GeneralAndAdministrativeNonEquityCompensation" xlink:to="lab_sttk_GeneralAndAdministrativeNonEquityCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019ce397-0676-7370-bdac-52cfff8d48db_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019ce397-0676-7b55-848f-ec6f410aa98a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019ce397-071d-717e-b7ec-4dcaee4aa311_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_019ce397-0676-7bd7-9504-0d6385ba8dd4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_SL325Member_019ce397-0676-743e-8048-2315a3f9d90f_terseLabel_en-US" xlink:label="lab_sttk_SL325Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SL-325</link:label>
    <link:label id="lab_sttk_SL325Member_label_en-US" xlink:label="lab_sttk_SL325Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SL-325 [Member]</link:label>
    <link:label id="lab_sttk_SL325Member_documentation_en-US" xlink:label="lab_sttk_SL325Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SL-325</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_SL325Member" xlink:href="sttk-20260331.xsd#sttk_SL325Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_SL325Member" xlink:to="lab_sttk_SL325Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_019ce397-0676-7264-a134-67e1c00ca143_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019ce397-071d-78d2-8c54-645afd8e7d06_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_PrepaidExpenseAndOtherAssetsPolicyPolicyTextBlock_019dda41-f8a5-7c29-8751-14a10c4dc3c2_terseLabel_en-US" xlink:label="lab_sttk_PrepaidExpenseAndOtherAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_sttk_PrepaidExpenseAndOtherAssetsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_sttk_PrepaidExpenseAndOtherAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets Policy [Policy Text Block]</link:label>
    <link:label id="lab_sttk_PrepaidExpenseAndOtherAssetsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_sttk_PrepaidExpenseAndOtherAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_PrepaidExpenseAndOtherAssetsPolicyPolicyTextBlock" xlink:href="sttk-20260331.xsd#sttk_PrepaidExpenseAndOtherAssetsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_PrepaidExpenseAndOtherAssetsPolicyPolicyTextBlock" xlink:to="lab_sttk_PrepaidExpenseAndOtherAssetsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_019ce397-0676-7b69-8720-9817d932133f_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_OtherResearchAndDevelopmentMember_019ce397-071e-706f-80ec-f6e5e7c1d73e_terseLabel_en-US" xlink:label="lab_sttk_OtherResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Research And Development</link:label>
    <link:label id="lab_sttk_OtherResearchAndDevelopmentMember_label_en-US" xlink:label="lab_sttk_OtherResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Research And Development [Member]</link:label>
    <link:label id="lab_sttk_OtherResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_sttk_OtherResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_OtherResearchAndDevelopmentMember" xlink:href="sttk-20260331.xsd#sttk_OtherResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_OtherResearchAndDevelopmentMember" xlink:to="lab_sttk_OtherResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_019d08f8-8961-7f51-8269-51a77a67bd69_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_019ce397-071d-76ac-bed8-f776fef74917_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_019ce397-0677-7c2a-b788-a783c23e8b8d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_AccruedResearchAndDevelopmentContractCostsCurrent_019d059d-67f3-7d95-b1b8-654127d6caa0_terseLabel_en-US" xlink:label="lab_sttk_AccruedResearchAndDevelopmentContractCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development contract costs</link:label>
    <link:label id="lab_sttk_AccruedResearchAndDevelopmentContractCostsCurrent_label_en-US" xlink:label="lab_sttk_AccruedResearchAndDevelopmentContractCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Contract Costs, Current</link:label>
    <link:label id="lab_sttk_AccruedResearchAndDevelopmentContractCostsCurrent_documentation_en-US" xlink:label="lab_sttk_AccruedResearchAndDevelopmentContractCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Contract Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AccruedResearchAndDevelopmentContractCostsCurrent" xlink:href="sttk-20260331.xsd#sttk_AccruedResearchAndDevelopmentContractCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_AccruedResearchAndDevelopmentContractCostsCurrent" xlink:to="lab_sttk_AccruedResearchAndDevelopmentContractCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_019ce397-0676-7014-a5eb-b747e43c6355_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_019ce397-0677-7664-83d2-163ecb372274_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_019ce397-0676-7b1a-bf20-49a5029c86a7_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_019d8b1e-3fd9-7f6f-85ed-8159e637df41_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unpaid amounts related to purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_019ce397-071d-7302-9d57-ddb7b5879f68_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_019ce397-071d-7208-9e54-bf2f2be4ad35_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_019ce397-0677-7cb4-aca9-c51efa70280f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_019d08f8-8961-76ca-9dbe-60987a363cb5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_019ce397-071d-7c3f-8e4b-f12b5642e77f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_019ce397-0676-7930-97b6-995874a259b0_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_019ce397-0677-7541-b169-a84bee8db659_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_SubleaseAgreementConsideration_019d0602-80ed-74b7-9e72-9164016e936e_terseLabel_en-US" xlink:label="lab_sttk_SubleaseAgreementConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sublease consideration</link:label>
    <link:label id="lab_sttk_SubleaseAgreementConsideration_label_en-US" xlink:label="lab_sttk_SubleaseAgreementConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sublease Agreement, Consideration</link:label>
    <link:label id="lab_sttk_SubleaseAgreementConsideration_documentation_en-US" xlink:label="lab_sttk_SubleaseAgreementConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sublease Agreement, Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_SubleaseAgreementConsideration" xlink:href="sttk-20260331.xsd#sttk_SubleaseAgreementConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_SubleaseAgreementConsideration" xlink:to="lab_sttk_SubleaseAgreementConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAbstract_019ce397-0676-76b2-af9a-fa0dc0531994_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAbstract" xlink:to="lab_us-gaap_DebtSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_019ce397-0676-7576-be26-db1de87c1894_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_019ce397-0676-74fb-8c3c-5935914c07d9_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon settlement of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_019ce397-0676-7e6f-8fe8-9551d6c49aed_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Released (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_ClassOfWarrantOrRightPriceOfPreFundedWarrants_019ce397-0676-72fb-aa95-596767dfa35a_terseLabel_en-US" xlink:label="lab_sttk_ClassOfWarrantOrRightPriceOfPreFundedWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price of pre-funded warrants (in dollars per share)</link:label>
    <link:label id="lab_sttk_ClassOfWarrantOrRightPriceOfPreFundedWarrants_label_en-US" xlink:label="lab_sttk_ClassOfWarrantOrRightPriceOfPreFundedWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Price of Pre-Funded Warrants</link:label>
    <link:label id="lab_sttk_ClassOfWarrantOrRightPriceOfPreFundedWarrants_documentation_en-US" xlink:label="lab_sttk_ClassOfWarrantOrRightPriceOfPreFundedWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Price of Pre-Funded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ClassOfWarrantOrRightPriceOfPreFundedWarrants" xlink:href="sttk-20260331.xsd#sttk_ClassOfWarrantOrRightPriceOfPreFundedWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_ClassOfWarrantOrRightPriceOfPreFundedWarrants" xlink:to="lab_sttk_ClassOfWarrantOrRightPriceOfPreFundedWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_019ce397-0676-737e-8403-fd3eb2707e29_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019d0a0d-de7e-71c5-ad30-acb282e42c30_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>sttk-20260331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019ce397-05b9-74d0-8227-66267d5910e2,g:518bbadf-25d7-41ee-8c01-9003cd0ed70a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.shattucklabs.com/role/Cover" xlink:type="simple" xlink:href="sttk-20260331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_019ce397-05ba-7152-85fe-cdebee674e46" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_019ce397-05ba-7775-8c06-21abd15b57a3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce397-05ba-7152-85fe-cdebee674e46" xlink:to="loc_dei_DocumentType_019ce397-05ba-7775-8c06-21abd15b57a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_019ce397-05ba-7007-9068-e3b1d965c6e6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce397-05ba-7152-85fe-cdebee674e46" xlink:to="loc_dei_DocumentQuarterlyReport_019ce397-05ba-7007-9068-e3b1d965c6e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_019ce397-05ba-73e7-91ca-cb5574a9efca" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce397-05ba-7152-85fe-cdebee674e46" xlink:to="loc_dei_DocumentPeriodEndDate_019ce397-05ba-73e7-91ca-cb5574a9efca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_019ce397-05ba-74f9-a4d6-b248d370b089" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce397-05ba-7152-85fe-cdebee674e46" xlink:to="loc_dei_DocumentTransitionReport_019ce397-05ba-74f9-a4d6-b248d370b089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_019ce397-05ba-7f37-a688-0efacceb92d3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce397-05ba-7152-85fe-cdebee674e46" xlink:to="loc_dei_EntityFileNumber_019ce397-05ba-7f37-a688-0efacceb92d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_019ce397-05ba-789b-b03e-69cd385ab5dd" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce397-05ba-7152-85fe-cdebee674e46" xlink:to="loc_dei_EntityRegistrantName_019ce397-05ba-789b-b03e-69cd385ab5dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_019ce397-05ba-764a-a533-df6b643f8536" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce397-05ba-7152-85fe-cdebee674e46" xlink:to="loc_dei_EntityIncorporationStateCountryCode_019ce397-05ba-764a-a533-df6b643f8536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_019ce397-05ba-7200-be77-5d159f237941" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce397-05ba-7152-85fe-cdebee674e46" xlink:to="loc_dei_EntityTaxIdentificationNumber_019ce397-05ba-7200-be77-5d159f237941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_019ce397-05ba-7cbd-a1bb-fa7eb4d3334c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce397-05ba-7152-85fe-cdebee674e46" xlink:to="loc_dei_EntityAddressAddressLine1_019ce397-05ba-7cbd-a1bb-fa7eb4d3334c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_019ce397-05ba-7dea-b0ae-c8a0109ecbcb" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce397-05ba-7152-85fe-cdebee674e46" xlink:to="loc_dei_EntityAddressAddressLine2_019ce397-05ba-7dea-b0ae-c8a0109ecbcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_019ce397-05ba-72ce-b323-c1e9cc1afe97" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce397-05ba-7152-85fe-cdebee674e46" xlink:to="loc_dei_EntityAddressCityOrTown_019ce397-05ba-72ce-b323-c1e9cc1afe97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_019ce397-05ba-71e2-b913-a2d0b47b3cb6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce397-05ba-7152-85fe-cdebee674e46" xlink:to="loc_dei_EntityAddressStateOrProvince_019ce397-05ba-71e2-b913-a2d0b47b3cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_019ce397-05ba-76dc-b5b6-34c7cf88e7b1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce397-05ba-7152-85fe-cdebee674e46" xlink:to="loc_dei_EntityAddressPostalZipCode_019ce397-05ba-76dc-b5b6-34c7cf88e7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_019ce397-05ba-7889-b4a7-dd587536fe4a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce397-05ba-7152-85fe-cdebee674e46" xlink:to="loc_dei_CityAreaCode_019ce397-05ba-7889-b4a7-dd587536fe4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_019ce397-05ba-77db-9741-a3ce7c278fb3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce397-05ba-7152-85fe-cdebee674e46" xlink:to="loc_dei_LocalPhoneNumber_019ce397-05ba-77db-9741-a3ce7c278fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_019ce397-05ba-75cb-b395-cdc3a3994f3c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce397-05ba-7152-85fe-cdebee674e46" xlink:to="loc_dei_Security12bTitle_019ce397-05ba-75cb-b395-cdc3a3994f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_019ce397-05ba-73d1-9a74-1612a42ba549" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce397-05ba-7152-85fe-cdebee674e46" xlink:to="loc_dei_TradingSymbol_019ce397-05ba-73d1-9a74-1612a42ba549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_019ce397-05ba-71a1-8fda-703d8d3bfdac" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce397-05ba-7152-85fe-cdebee674e46" xlink:to="loc_dei_SecurityExchangeName_019ce397-05ba-71a1-8fda-703d8d3bfdac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_019ce397-05ba-79b7-abec-85dbeaefb8dd" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce397-05ba-7152-85fe-cdebee674e46" xlink:to="loc_dei_EntityCurrentReportingStatus_019ce397-05ba-79b7-abec-85dbeaefb8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_019ce397-05ba-734f-b695-02cfc44b4b8d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce397-05ba-7152-85fe-cdebee674e46" xlink:to="loc_dei_EntityInteractiveDataCurrent_019ce397-05ba-734f-b695-02cfc44b4b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_019ce397-05ba-7013-87fd-4f964fa370db" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce397-05ba-7152-85fe-cdebee674e46" xlink:to="loc_dei_EntityFilerCategory_019ce397-05ba-7013-87fd-4f964fa370db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_019ce397-05ba-7ce2-aaa0-0e1bbb3a3f2b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce397-05ba-7152-85fe-cdebee674e46" xlink:to="loc_dei_EntitySmallBusiness_019ce397-05ba-7ce2-aaa0-0e1bbb3a3f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_019ce397-05ba-71b5-9171-dee8fbe4a3ae" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce397-05ba-7152-85fe-cdebee674e46" xlink:to="loc_dei_EntityEmergingGrowthCompany_019ce397-05ba-71b5-9171-dee8fbe4a3ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_019ce397-05ba-75a5-bf24-5236bbc749ac" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce397-05ba-7152-85fe-cdebee674e46" xlink:to="loc_dei_EntityShellCompany_019ce397-05ba-75a5-bf24-5236bbc749ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_019ce397-05ba-7c33-b21c-f25b72ca4771" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce397-05ba-7152-85fe-cdebee674e46" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_019ce397-05ba-7c33-b21c-f25b72ca4771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_019ce397-05ba-7952-8bc2-0a61d3945805" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce397-05ba-7152-85fe-cdebee674e46" xlink:to="loc_dei_EntityCentralIndexKey_019ce397-05ba-7952-8bc2-0a61d3945805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_019ce397-05ba-796c-b90e-b6152ba153e5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce397-05ba-7152-85fe-cdebee674e46" xlink:to="loc_dei_AmendmentFlag_019ce397-05ba-796c-b90e-b6152ba153e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_019ce397-05ba-7d5d-8af3-64cebb206fb1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce397-05ba-7152-85fe-cdebee674e46" xlink:to="loc_dei_DocumentFiscalYearFocus_019ce397-05ba-7d5d-8af3-64cebb206fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_019ce397-05ba-7da8-9d63-0d7b55be7366" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce397-05ba-7152-85fe-cdebee674e46" xlink:to="loc_dei_DocumentFiscalPeriodFocus_019ce397-05ba-7da8-9d63-0d7b55be7366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_019ce397-05ba-7ebf-8e19-6fa65226d16b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce397-05ba-7152-85fe-cdebee674e46" xlink:to="loc_dei_CurrentFiscalYearEndDate_019ce397-05ba-7ebf-8e19-6fa65226d16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS" xlink:type="simple" xlink:href="sttk-20260331.xsd#CONDENSEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_019ce397-05ba-7a0a-a83a-c0934f1fe4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_019ce397-05ba-7a95-a48f-926e35b115c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019ce397-05ba-7a0a-a83a-c0934f1fe4ee" xlink:to="loc_us-gaap_AssetsAbstract_019ce397-05ba-7a95-a48f-926e35b115c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_019ce397-05ba-77f4-ac38-d3d384512e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019ce397-05ba-7a95-a48f-926e35b115c1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_019ce397-05ba-77f4-ac38-d3d384512e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019ce397-05ba-75fa-b240-46a6c9ce737c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019ce397-05ba-77f4-ac38-d3d384512e6a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019ce397-05ba-75fa-b240-46a6c9ce737c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_019ce397-05ba-784f-8add-2fbada5b8717" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019ce397-05ba-77f4-ac38-d3d384512e6a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_019ce397-05ba-784f-8add-2fbada5b8717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019ce397-05ba-7db9-99ec-98637d90e887" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019ce397-05ba-77f4-ac38-d3d384512e6a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019ce397-05ba-7db9-99ec-98637d90e887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019ce397-05ba-7895-9d2e-64a2901ffabf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019ce397-05ba-77f4-ac38-d3d384512e6a" xlink:to="loc_us-gaap_AssetsCurrent_019ce397-05ba-7895-9d2e-64a2901ffabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_019ce397-05ba-75fa-8b0e-251c38cdaf56" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019ce397-05ba-7a95-a48f-926e35b115c1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_019ce397-05ba-75fa-8b0e-251c38cdaf56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent_019d09d4-a23b-7550-8dbe-3eb4158fc6ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019ce397-05ba-7a95-a48f-926e35b115c1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent_019d09d4-a23b-7550-8dbe-3eb4158fc6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_019ce397-05ba-7196-af34-d14d5e410f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019ce397-05ba-7a95-a48f-926e35b115c1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_019ce397-05ba-7196-af34-d14d5e410f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_019ce397-05ba-73e8-846c-8d94c00b4375" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019ce397-05ba-7a95-a48f-926e35b115c1" xlink:to="loc_us-gaap_Assets_019ce397-05ba-73e8-846c-8d94c00b4375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019ce397-05ba-7ddb-b9af-7beff5ab3d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019ce397-05ba-7a0a-a83a-c0934f1fe4ee" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019ce397-05ba-7ddb-b9af-7beff5ab3d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_019ce397-05ba-7c60-84c3-58dce92af53f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019ce397-05ba-7ddb-b9af-7beff5ab3d1b" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_019ce397-05ba-7c60-84c3-58dce92af53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_019ce397-05ba-7c09-a28e-11e2ea311746" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019ce397-05ba-7c60-84c3-58dce92af53f" xlink:to="loc_us-gaap_AccountsPayableCurrent_019ce397-05ba-7c09-a28e-11e2ea311746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_019ce397-05ba-7f0a-a4fd-8f8d0b08ad52" xlink:href="sttk-20260331.xsd#sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019ce397-05ba-7c60-84c3-58dce92af53f" xlink:to="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_019ce397-05ba-7f0a-a4fd-8f8d0b08ad52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019ce397-05ba-7aee-bf8b-cd24f1a40962" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019ce397-05ba-7c60-84c3-58dce92af53f" xlink:to="loc_us-gaap_LiabilitiesCurrent_019ce397-05ba-7aee-bf8b-cd24f1a40962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_019ce397-05ba-71a6-9d1e-93c1338f1098" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019ce397-05ba-7ddb-b9af-7beff5ab3d1b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_019ce397-05ba-71a6-9d1e-93c1338f1098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_019ce397-05ba-75fb-abd2-0976a8c0427e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019ce397-05ba-7ddb-b9af-7beff5ab3d1b" xlink:to="loc_us-gaap_Liabilities_019ce397-05ba-75fb-abd2-0976a8c0427e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_019ce397-05ba-70a9-a286-3f30b941bec8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019ce397-05ba-7ddb-b9af-7beff5ab3d1b" xlink:to="loc_us-gaap_CommitmentsAndContingencies_019ce397-05ba-70a9-a286-3f30b941bec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_019ce397-05ba-73f8-8ba6-bf8464b88eea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019ce397-05ba-7ddb-b9af-7beff5ab3d1b" xlink:to="loc_us-gaap_StockholdersEquityAbstract_019ce397-05ba-73f8-8ba6-bf8464b88eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_019ce397-05ba-7be5-816a-7ea27e49e78d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019ce397-05ba-73f8-8ba6-bf8464b88eea" xlink:to="loc_us-gaap_CommonStockValue_019ce397-05ba-7be5-816a-7ea27e49e78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_019ce397-05ba-7034-bb3b-4c7ad8005efc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019ce397-05ba-73f8-8ba6-bf8464b88eea" xlink:to="loc_us-gaap_AdditionalPaidInCapital_019ce397-05ba-7034-bb3b-4c7ad8005efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019ce397-05ba-793b-883f-c22283475d13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019ce397-05ba-73f8-8ba6-bf8464b88eea" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019ce397-05ba-793b-883f-c22283475d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019ce397-05ba-713c-9546-efdc31a0153a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019ce397-05ba-73f8-8ba6-bf8464b88eea" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019ce397-05ba-713c-9546-efdc31a0153a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019ce397-05ba-7131-bd2e-aa13ae503b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019ce397-05ba-73f8-8ba6-bf8464b88eea" xlink:to="loc_us-gaap_StockholdersEquity_019ce397-05ba-7131-bd2e-aa13ae503b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_019ce397-05ba-724a-9398-f3dc3bc8ed72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019ce397-05ba-7ddb-b9af-7beff5ab3d1b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_019ce397-05ba-724a-9398-f3dc3bc8ed72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="sttk-20260331.xsd#CONDENSEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_019ce397-05ba-7db4-94f9-394888e9a0d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_019ce397-05ba-7967-940e-9d4eae5e909c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019ce397-05ba-7db4-94f9-394888e9a0d7" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_019ce397-05ba-7967-940e-9d4eae5e909c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_019ce397-05ba-7771-94c5-3c03316266c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019ce397-05ba-7db4-94f9-394888e9a0d7" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_019ce397-05ba-7771-94c5-3c03316266c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_019ce397-05ba-79af-beab-7c488fc41b25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019ce397-05ba-7db4-94f9-394888e9a0d7" xlink:to="loc_us-gaap_CommonStockSharesIssued_019ce397-05ba-79af-beab-7c488fc41b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019ce397-05ba-7717-9d84-8f12b345ae35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019ce397-05ba-7db4-94f9-394888e9a0d7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019ce397-05ba-7717-9d84-8f12b345ae35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="sttk-20260331.xsd#CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_019ce397-05ba-7fcc-bc01-347ab60a3068" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_019ce397-05ba-730c-b09f-aa9d6d58d034" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019ce397-05ba-7fcc-bc01-347ab60a3068" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_019ce397-05ba-730c-b09f-aa9d6d58d034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019ce397-05ba-70c2-a18d-b59d1f55c39b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019ce397-05ba-7fcc-bc01-347ab60a3068" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019ce397-05ba-70c2-a18d-b59d1f55c39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_019ce397-05ba-760a-871b-805f1ee210a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019ce397-05ba-7fcc-bc01-347ab60a3068" xlink:to="loc_us-gaap_OperatingExpensesAbstract_019ce397-05ba-760a-871b-805f1ee210a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019ce397-05ba-708b-b7f0-f5e37089d63a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019ce397-05ba-760a-871b-805f1ee210a5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019ce397-05ba-708b-b7f0-f5e37089d63a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_019ce397-05ba-7b92-9811-ce842e097a68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019ce397-05ba-760a-871b-805f1ee210a5" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_019ce397-05ba-7b92-9811-ce842e097a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_019ce397-05ba-7e8d-85d3-8a72c8511213" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019ce397-05ba-760a-871b-805f1ee210a5" xlink:to="loc_us-gaap_OperatingExpenses_019ce397-05ba-7e8d-85d3-8a72c8511213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019ce397-05ba-773d-a19b-a3423c81248f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019ce397-05ba-7fcc-bc01-347ab60a3068" xlink:to="loc_us-gaap_OperatingIncomeLoss_019ce397-05ba-773d-a19b-a3423c81248f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_019d228e-9d63-7a34-bd6b-83e1a7a4256b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019ce397-05ba-7fcc-bc01-347ab60a3068" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_019d228e-9d63-7a34-bd6b-83e1a7a4256b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_019d228f-43f0-7028-8278-ccca1f59871c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_019d228e-9d63-7a34-bd6b-83e1a7a4256b" xlink:to="loc_us-gaap_InvestmentIncomeInterest_019d228f-43f0-7028-8278-ccca1f59871c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_019ce397-05ba-700e-95df-d0ef5f9b704e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_019d228e-9d63-7a34-bd6b-83e1a7a4256b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_019ce397-05ba-700e-95df-d0ef5f9b704e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_019d228a-d0a0-7dea-9dd0-bdb6418e9280" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_019d228e-9d63-7a34-bd6b-83e1a7a4256b" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_019d228a-d0a0-7dea-9dd0-bdb6418e9280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019ce397-05ba-7ecd-a053-b1dec3a404a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019ce397-05ba-7fcc-bc01-347ab60a3068" xlink:to="loc_us-gaap_NetIncomeLoss_019ce397-05ba-7ecd-a053-b1dec3a404a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_019ce397-05ba-7f08-8377-227308280e46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019ce397-05ba-7fcc-bc01-347ab60a3068" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_019ce397-05ba-7f08-8377-227308280e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_019ce397-05ba-7721-81b1-c43410239f13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019ce397-05ba-7fcc-bc01-347ab60a3068" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_019ce397-05ba-7721-81b1-c43410239f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_019ce397-05ba-7a89-a94a-6ff0d2b21a48" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019ce397-05ba-7fcc-bc01-347ab60a3068" xlink:to="loc_us-gaap_EarningsPerShareBasic_019ce397-05ba-7a89-a94a-6ff0d2b21a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_019ce397-05ba-7e77-a2d0-7189439c59eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019ce397-05ba-7fcc-bc01-347ab60a3068" xlink:to="loc_us-gaap_EarningsPerShareDiluted_019ce397-05ba-7e77-a2d0-7189439c59eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019ce397-05ba-7aee-9724-c354d70d94c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019ce397-05ba-7fcc-bc01-347ab60a3068" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019ce397-05ba-7aee-9724-c354d70d94c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019ce397-05ba-778f-b065-23cab83cf1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019ce397-05ba-7fcc-bc01-347ab60a3068" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019ce397-05ba-778f-b065-23cab83cf1f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sttk-20260331.xsd#CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_019ce397-05ba-793b-ac48-9fdd216d7d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019ce397-05ba-748c-b439-7495f2bd0ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_019ce397-05ba-793b-ac48-9fdd216d7d0a" xlink:to="loc_us-gaap_StatementTable_019ce397-05ba-748c-b439-7495f2bd0ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_019ce397-05ba-715a-8cef-60884953020f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019ce397-05ba-748c-b439-7495f2bd0ac1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_019ce397-05ba-715a-8cef-60884953020f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019ce397-05ba-7f76-9c20-c2f02205c93a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019ce397-05ba-715a-8cef-60884953020f" xlink:to="loc_us-gaap_EquityComponentDomain_019ce397-05ba-7f76-9c20-c2f02205c93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019ce397-05ba-7f58-aa9d-aa34ad60ef0b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019ce397-05ba-7f76-9c20-c2f02205c93a" xlink:to="loc_us-gaap_CommonStockMember_019ce397-05ba-7f58-aa9d-aa34ad60ef0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_019ce397-05ba-7a07-ae04-2f767b96b213" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019ce397-05ba-7f76-9c20-c2f02205c93a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_019ce397-05ba-7a07-ae04-2f767b96b213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019ce397-05ba-703f-ad97-fb63fd6863c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019ce397-05ba-7f76-9c20-c2f02205c93a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019ce397-05ba-703f-ad97-fb63fd6863c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_019ce397-05ba-7c34-a0e1-341de210be4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019ce397-05ba-7f76-9c20-c2f02205c93a" xlink:to="loc_us-gaap_RetainedEarningsMember_019ce397-05ba-7c34-a0e1-341de210be4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_019dace2-a7d2-7641-95c2-06ca46738b70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019ce397-05ba-748c-b439-7495f2bd0ac1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_019dace2-a7d2-7641-95c2-06ca46738b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019dace2-a7d2-7b1a-a4af-d7f32b508075" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019dace2-a7d2-7641-95c2-06ca46738b70" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019dace2-a7d2-7b1a-a4af-d7f32b508075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_PreFundedWarrantsMember_019dace2-c3e9-7844-84d7-d277d78824d8" xlink:href="sttk-20260331.xsd#sttk_PreFundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019dace2-a7d2-7b1a-a4af-d7f32b508075" xlink:to="loc_sttk_PreFundedWarrantsMember_019dace2-c3e9-7844-84d7-d277d78824d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_CommonStockWarrantsMember_019dace2-ed75-705d-9aaa-e6693ac97eba" xlink:href="sttk-20260331.xsd#sttk_CommonStockWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019dace2-a7d2-7b1a-a4af-d7f32b508075" xlink:to="loc_sttk_CommonStockWarrantsMember_019dace2-ed75-705d-9aaa-e6693ac97eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019ce397-05ba-7f45-8699-885202b65958" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019ce397-05ba-748c-b439-7495f2bd0ac1" xlink:to="loc_us-gaap_StatementLineItems_019ce397-05ba-7f45-8699-885202b65958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019ce397-05ba-7915-b759-77911a9aa0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019ce397-05ba-7f45-8699-885202b65958" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019ce397-05ba-7915-b759-77911a9aa0c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_019ce397-05ba-77b1-be2a-b96c0e1699f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019ce397-05ba-7915-b759-77911a9aa0c0" xlink:to="loc_us-gaap_SharesOutstanding_019ce397-05ba-77b1-be2a-b96c0e1699f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019ce397-05ba-782b-aeb2-3caa2f5afa83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019ce397-05ba-7915-b759-77911a9aa0c0" xlink:to="loc_us-gaap_StockholdersEquity_019ce397-05ba-782b-aeb2-3caa2f5afa83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_019d8fa1-4a10-7b04-91b8-dae3aea64432" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019ce397-05ba-7915-b759-77911a9aa0c0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_019d8fa1-4a10-7b04-91b8-dae3aea64432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_019d0a04-50df-7153-b599-fc034c013702" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019ce397-05ba-7915-b759-77911a9aa0c0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_019d0a04-50df-7153-b599-fc034c013702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_StockIssuedDuringPeriodSharesWarrantExercises_019d8f41-5a55-7458-8745-4c0e10dadc3e" xlink:href="sttk-20260331.xsd#sttk_StockIssuedDuringPeriodSharesWarrantExercises"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019ce397-05ba-7915-b759-77911a9aa0c0" xlink:to="loc_sttk_StockIssuedDuringPeriodSharesWarrantExercises_019d8f41-5a55-7458-8745-4c0e10dadc3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_StockIssuedDuringPeriodValueWarrantExercises_019d229d-c09e-7e6f-9518-38b389e86cab" xlink:href="sttk-20260331.xsd#sttk_StockIssuedDuringPeriodValueWarrantExercises"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019ce397-05ba-7915-b759-77911a9aa0c0" xlink:to="loc_sttk_StockIssuedDuringPeriodValueWarrantExercises_019d229d-c09e-7e6f-9518-38b389e86cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_019ce397-05ba-7cbf-aa9a-f5e735fb120c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019ce397-05ba-7915-b759-77911a9aa0c0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_019ce397-05ba-7cbf-aa9a-f5e735fb120c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_019ce397-05ba-7330-9b3b-2d7640574797" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019ce397-05ba-7915-b759-77911a9aa0c0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_019ce397-05ba-7330-9b3b-2d7640574797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_019ce397-05ba-7286-b8f1-58d1e463b699" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019ce397-05ba-7915-b759-77911a9aa0c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_019ce397-05ba-7286-b8f1-58d1e463b699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_019ce397-05ba-72de-b1fc-d3b9e9659827" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019ce397-05ba-7915-b759-77911a9aa0c0" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_019ce397-05ba-72de-b1fc-d3b9e9659827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_019ce397-05ba-7606-94d1-700397fc45f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019ce397-05ba-7915-b759-77911a9aa0c0" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_019ce397-05ba-7606-94d1-700397fc45f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019ce397-05ba-78d5-ae9a-069e644b8513" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019ce397-05ba-7915-b759-77911a9aa0c0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019ce397-05ba-78d5-ae9a-069e644b8513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_019ce397-05ba-775c-a23a-a95ced9cf246" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019ce397-05ba-7915-b759-77911a9aa0c0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_019ce397-05ba-775c-a23a-a95ced9cf246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019ce397-05ba-7e28-a9e5-0f394dce64c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019ce397-05ba-7915-b759-77911a9aa0c0" xlink:to="loc_us-gaap_NetIncomeLoss_019ce397-05ba-7e28-a9e5-0f394dce64c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_019ce397-05ba-70ae-a13a-7029fda415b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019ce397-05ba-7915-b759-77911a9aa0c0" xlink:to="loc_us-gaap_SharesOutstanding_019ce397-05ba-70ae-a13a-7029fda415b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019ce397-05ba-7b22-bf61-dba6bf51b55a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019ce397-05ba-7915-b759-77911a9aa0c0" xlink:to="loc_us-gaap_StockholdersEquity_019ce397-05ba-7b22-bf61-dba6bf51b55a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sttk-20260331.xsd#CONDENSEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_019ce397-05ba-7277-843a-ad82dd061c78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019ce397-05ba-7204-9501-23f388af1f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019ce397-05ba-7277-843a-ad82dd061c78" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019ce397-05ba-7204-9501-23f388af1f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019ce397-05ba-70ad-9c84-c381bf1bbd87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019ce397-05ba-7204-9501-23f388af1f9a" xlink:to="loc_us-gaap_NetIncomeLoss_019ce397-05ba-70ad-9c84-c381bf1bbd87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019ce397-05ba-783d-8076-eb5f4b6f0eba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019ce397-05ba-7204-9501-23f388af1f9a" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019ce397-05ba-783d-8076-eb5f4b6f0eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_019ce397-05ba-7899-b635-083abdeb7415" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019ce397-05ba-783d-8076-eb5f4b6f0eba" xlink:to="loc_us-gaap_ShareBasedCompensation_019ce397-05ba-7899-b635-083abdeb7415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_019ce397-05ba-7861-b5c1-748e938ffa3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019ce397-05ba-783d-8076-eb5f4b6f0eba" xlink:to="loc_us-gaap_Depreciation_019ce397-05ba-7861-b5c1-748e938ffa3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_019ce397-05ba-7946-920f-3873fa9aae95" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019ce397-05ba-783d-8076-eb5f4b6f0eba" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_019ce397-05ba-7946-920f-3873fa9aae95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_019ce397-05ba-7e66-980b-4590aceaba32" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019ce397-05ba-783d-8076-eb5f4b6f0eba" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_019ce397-05ba-7e66-980b-4590aceaba32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019ce397-05ba-788b-b81f-5d94cf03c7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019ce397-05ba-783d-8076-eb5f4b6f0eba" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019ce397-05ba-788b-b81f-5d94cf03c7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019ce397-05ba-7cdc-9cd4-8b9a7e104672" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019ce397-05ba-788b-b81f-5d94cf03c7bb" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019ce397-05ba-7cdc-9cd4-8b9a7e104672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_019ce397-05ba-71d6-8785-29b331147987" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019ce397-05ba-788b-b81f-5d94cf03c7bb" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_019ce397-05ba-71d6-8785-29b331147987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_019ce397-05ba-7177-826c-52d9df34efe7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019ce397-05ba-788b-b81f-5d94cf03c7bb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_019ce397-05ba-7177-826c-52d9df34efe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_019ce397-05ba-751d-93dc-4b83dfc143f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019ce397-05ba-788b-b81f-5d94cf03c7bb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_019ce397-05ba-751d-93dc-4b83dfc143f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_019ce397-05ba-7ea2-84e3-24ecd7e6408f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019ce397-05ba-788b-b81f-5d94cf03c7bb" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_019ce397-05ba-7ea2-84e3-24ecd7e6408f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019ce397-05ba-7a8e-be0a-f1f8904d757d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019ce397-05ba-788b-b81f-5d94cf03c7bb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019ce397-05ba-7a8e-be0a-f1f8904d757d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019ce397-05ba-7aaf-8bab-3acbd3935f91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019ce397-05ba-7277-843a-ad82dd061c78" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019ce397-05ba-7aaf-8bab-3acbd3935f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_019ce397-05ba-73a8-9064-af71cedb4a65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019ce397-05ba-7aaf-8bab-3acbd3935f91" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_019ce397-05ba-73a8-9064-af71cedb4a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_019ce397-05ba-76c5-b96c-05a6b95acde4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019ce397-05ba-7aaf-8bab-3acbd3935f91" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_019ce397-05ba-76c5-b96c-05a6b95acde4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019ce397-05ba-7768-927c-ad247e289932" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019ce397-05ba-7aaf-8bab-3acbd3935f91" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019ce397-05ba-7768-927c-ad247e289932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019ce397-05ba-7076-b593-0a4a112b8fce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019ce397-05ba-7277-843a-ad82dd061c78" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019ce397-05ba-7076-b593-0a4a112b8fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019d8b27-6d58-7960-aac4-f62381e23618" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019ce397-05ba-7076-b593-0a4a112b8fce" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019d8b27-6d58-7960-aac4-f62381e23618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_019d8b28-e663-726a-8e71-75f6a7810a31" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019ce397-05ba-7076-b593-0a4a112b8fce" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_019d8b28-e663-726a-8e71-75f6a7810a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_019ce397-05ba-79ee-a60e-8ed27e272623" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019ce397-05ba-7076-b593-0a4a112b8fce" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_019ce397-05ba-79ee-a60e-8ed27e272623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_019ce397-05ba-764c-902c-e39ac02132d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019ce397-05ba-7076-b593-0a4a112b8fce" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_019ce397-05ba-764c-902c-e39ac02132d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019ce397-05ba-7d55-b71f-ff8da3531e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019ce397-05ba-7076-b593-0a4a112b8fce" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019ce397-05ba-7d55-b71f-ff8da3531e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019ce397-05ba-76b6-82b6-d4faf57f71ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019ce397-05ba-7277-843a-ad82dd061c78" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019ce397-05ba-76b6-82b6-d4faf57f71ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019ce397-05ba-7cdf-942c-6ddb0013b0fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019ce397-05ba-7277-843a-ad82dd061c78" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019ce397-05ba-7cdf-942c-6ddb0013b0fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019ce397-05ba-7b43-b403-6eedc3317d54" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019ce397-05ba-7277-843a-ad82dd061c78" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019ce397-05ba-7b43-b403-6eedc3317d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_019ce397-05ba-7a91-8d3f-8c4a3e15d13e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019ce397-05ba-7277-843a-ad82dd061c78" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_019ce397-05ba-7a91-8d3f-8c4a3e15d13e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_019ce397-05ba-7daf-8449-b504b324492a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_019ce397-05ba-7a91-8d3f-8c4a3e15d13e" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_019ce397-05ba-7daf-8449-b504b324492a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_019d8b1e-3fd9-7824-88a2-e73098706c97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_019ce397-05ba-7a91-8d3f-8c4a3e15d13e" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_019d8b1e-3fd9-7824-88a2-e73098706c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_IncreaseDecreaseInOperatingLeasesRightOfUseAssetsLiability_019dd538-860d-7213-aa72-d188218c8971" xlink:href="sttk-20260331.xsd#sttk_IncreaseDecreaseInOperatingLeasesRightOfUseAssetsLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_019ce397-05ba-7a91-8d3f-8c4a3e15d13e" xlink:to="loc_sttk_IncreaseDecreaseInOperatingLeasesRightOfUseAssetsLiability_019dd538-860d-7213-aa72-d188218c8971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/OrganizationandDescriptionofBusiness" xlink:type="simple" xlink:href="sttk-20260331.xsd#OrganizationandDescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/OrganizationandDescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019ce397-05ba-7482-ba24-4ee80cffbc04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_019ce397-05ba-7edf-a042-08999fc5150f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019ce397-05ba-7482-ba24-4ee80cffbc04" xlink:to="loc_us-gaap_NatureOfOperations_019ce397-05ba-7edf-a042-08999fc5150f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="sttk-20260331.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019ce397-05ba-74ac-9ab8-1ee0d99817c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_019ce397-05ba-72a2-bbae-16132f27de13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019ce397-05ba-74ac-9ab8-1ee0d99817c0" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_019ce397-05ba-72a2-bbae-16132f27de13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/Investments" xlink:type="simple" xlink:href="sttk-20260331.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_019ce397-0676-75ca-ab29-a77c7b572857" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_019ce397-0676-7eac-8867-a99bcb444b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_019ce397-0676-75ca-ab29-a77c7b572857" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_019ce397-0676-7eac-8867-a99bcb444b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="simple" xlink:href="sttk-20260331.xsd#AccruedExpensesandOtherCurrentLiabilities"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_019ce397-0676-7866-afe8-2858312af4f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_019ce397-0676-7e58-9ba6-edc561a34fde" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019ce397-0676-7866-afe8-2858312af4f8" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_019ce397-0676-7e58-9ba6-edc561a34fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="sttk-20260331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019ce397-0676-78a2-9e80-4630a3b04772" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_019ce397-0676-76b4-b418-d5a6871258c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019ce397-0676-78a2-9e80-4630a3b04772" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_019ce397-0676-76b4-b418-d5a6871258c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/RelatedPartyLicenseRevenue" xlink:type="simple" xlink:href="sttk-20260331.xsd#RelatedPartyLicenseRevenue"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/RelatedPartyLicenseRevenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019ce397-0676-73e4-88a2-26a8b991ce40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_019ce397-0676-7a68-aaa1-6b9feddda788" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019ce397-0676-73e4-88a2-26a8b991ce40" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_019ce397-0676-7a68-aaa1-6b9feddda788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/Equity" xlink:type="simple" xlink:href="sttk-20260331.xsd#Equity"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/Equity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_019ce397-0676-7e28-bb34-b9505a83b720" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_019ce397-0676-74fd-94d3-7af96e0643ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_019ce397-0676-7e28-bb34-b9505a83b720" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_019ce397-0676-74fd-94d3-7af96e0643ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlans" xlink:type="simple" xlink:href="sttk-20260331.xsd#StockBasedCompensationandEmployeeBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019ce397-0676-797a-b394-26a423bdfa45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_019ce397-0676-702d-976e-e79d902701ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019ce397-0676-797a-b394-26a423bdfa45" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_019ce397-0676-702d-976e-e79d902701ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/SegmentReporting" xlink:type="simple" xlink:href="sttk-20260331.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019ce397-0676-7a73-8ee1-fd4bf46faf28" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_019ce397-0676-72b4-826b-5aefa47fe38b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019ce397-0676-7a73-8ee1-fd4bf46faf28" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_019ce397-0676-72b4-826b-5aefa47fe38b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="sttk-20260331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019ce397-05ba-74cc-af21-121fc8e57051" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_019ce397-05ba-7fb4-8e2d-3e6ae79884a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019ce397-05ba-74cc-af21-121fc8e57051" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_019ce397-05ba-7fb4-8e2d-3e6ae79884a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_019ce397-05ba-7dc2-ab34-c4e9293d5bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019ce397-05ba-74cc-af21-121fc8e57051" xlink:to="loc_us-gaap_UseOfEstimates_019ce397-05ba-7dc2-ab34-c4e9293d5bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_019ce397-05ba-7c85-b837-fd593a657e15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019ce397-05ba-74cc-af21-121fc8e57051" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_019ce397-05ba-7c85-b837-fd593a657e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_019ce397-05ba-73fc-bc88-6dba2a95c2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019ce397-05ba-74cc-af21-121fc8e57051" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_019ce397-05ba-73fc-bc88-6dba2a95c2c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_019ce397-05ba-7926-b404-cb4ed6d819e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019ce397-05ba-74cc-af21-121fc8e57051" xlink:to="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_019ce397-05ba-7926-b404-cb4ed6d819e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_019ce397-05ba-7900-9174-dc5655286a94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019ce397-05ba-74cc-af21-121fc8e57051" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_019ce397-05ba-7900-9174-dc5655286a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_PrepaidExpenseAndOtherAssetsPolicyPolicyTextBlock_019dda41-f8a5-755a-8df6-109ee46780e5" xlink:href="sttk-20260331.xsd#sttk_PrepaidExpenseAndOtherAssetsPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019ce397-05ba-74cc-af21-121fc8e57051" xlink:to="loc_sttk_PrepaidExpenseAndOtherAssetsPolicyPolicyTextBlock_019dda41-f8a5-755a-8df6-109ee46780e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_019ce397-05ba-7ad2-bbf3-3f0169f1c0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019ce397-05ba-74cc-af21-121fc8e57051" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_019ce397-05ba-7ad2-bbf3-3f0169f1c0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_019ce397-05ba-7c91-aeff-7e1d8bc83d48" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019ce397-05ba-74cc-af21-121fc8e57051" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_019ce397-05ba-7c91-aeff-7e1d8bc83d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_019ce397-05ba-7b35-9e35-ce3d098c5f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019ce397-05ba-74cc-af21-121fc8e57051" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_019ce397-05ba-7b35-9e35-ce3d098c5f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_019ce397-05ba-724a-888e-ca4a5e2aeaea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019ce397-05ba-74cc-af21-121fc8e57051" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_019ce397-05ba-724a-888e-ca4a5e2aeaea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_019ce397-05ba-7691-a8cf-4ac50c43f3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019ce397-05ba-74cc-af21-121fc8e57051" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_019ce397-05ba-7691-a8cf-4ac50c43f3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_019ce397-05ba-7329-a87e-19df41860efd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019ce397-05ba-74cc-af21-121fc8e57051" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_019ce397-05ba-7329-a87e-19df41860efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_WarrantsPolicyTextBlock_019d4dbb-7465-7b80-bcff-8fa68ccc5bb3" xlink:href="sttk-20260331.xsd#sttk_WarrantsPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019ce397-05ba-74cc-af21-121fc8e57051" xlink:to="loc_sttk_WarrantsPolicyTextBlock_019d4dbb-7465-7b80-bcff-8fa68ccc5bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_019d4dbb-0446-79b4-acb3-f79469cfb9e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019ce397-05ba-74cc-af21-121fc8e57051" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_019d4dbb-0446-79b4-acb3-f79469cfb9e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_019d4dba-8adb-7ace-bce1-0cba7bee0a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019ce397-05ba-74cc-af21-121fc8e57051" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_019d4dba-8adb-7ace-bce1-0cba7bee0a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_019ce397-05ba-7a9c-aa3b-d619f9dfb753" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019ce397-05ba-74cc-af21-121fc8e57051" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_019ce397-05ba-7a9c-aa3b-d619f9dfb753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_019ce397-05ba-7f59-aac8-c21e0c045da8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019ce397-05ba-74cc-af21-121fc8e57051" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_019ce397-05ba-7f59-aac8-c21e0c045da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_019ce397-05ba-7da2-8434-324c1e82830f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019ce397-05ba-74cc-af21-121fc8e57051" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_019ce397-05ba-7da2-8434-324c1e82830f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="sttk-20260331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019ce397-05ba-75e6-bf9c-02326cc04555" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_019d4dbd-83dc-7ae1-8521-b3b0f50d714e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019ce397-05ba-75e6-bf9c-02326cc04555" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_019d4dbd-83dc-7ae1-8521-b3b0f50d714e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_019ce397-05ba-7551-a9ba-6a20f9d254e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019ce397-05ba-75e6-bf9c-02326cc04555" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_019ce397-05ba-7551-a9ba-6a20f9d254e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/InvestmentsTables" xlink:type="simple" xlink:href="sttk-20260331.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_019ce397-0676-743d-bac3-9e114d2af598" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_019ce397-0676-7933-bfee-5e7ea849f199" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_019ce397-0676-743d-bac3-9e114d2af598" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_019ce397-0676-7933-bfee-5e7ea849f199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="sttk-20260331.xsd#AccruedExpensesandOtherCurrentLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_019ce397-0676-7d95-b877-11c2b85285fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_019ce397-0676-7800-8bc9-3e791efb3832" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019ce397-0676-7d95-b877-11c2b85285fa" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_019ce397-0676-7800-8bc9-3e791efb3832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansTables" xlink:type="simple" xlink:href="sttk-20260331.xsd#StockBasedCompensationandEmployeeBenefitPlansTables"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019ce397-0676-7a77-9245-09907c9d3f48" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_019ce397-0676-724c-8f14-7ea7a6519926" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019ce397-0676-7a77-9245-09907c9d3f48" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_019ce397-0676-724c-8f14-7ea7a6519926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_019ce397-0676-7afe-9f54-6f820e5931f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019ce397-0676-7a77-9245-09907c9d3f48" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_019ce397-0676-7afe-9f54-6f820e5931f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_019ce397-0676-735f-acca-1bef5ee8bb70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019ce397-0676-7a77-9245-09907c9d3f48" xlink:to="loc_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_019ce397-0676-735f-acca-1bef5ee8bb70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_019ce397-0676-7126-a446-9a93d7ab027f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019ce397-0676-7a77-9245-09907c9d3f48" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_019ce397-0676-7126-a446-9a93d7ab027f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="sttk-20260331.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019ce397-0676-7b95-87ec-686bb8388398" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_019ce397-0676-7b74-9fda-877d8ed51b58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019ce397-0676-7b95-87ec-686bb8388398" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_019ce397-0676-7b74-9fda-877d8ed51b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/OrganizationandDescriptionofBusinessDetails" xlink:type="simple" xlink:href="sttk-20260331.xsd#OrganizationandDescriptionofBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/OrganizationandDescriptionofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019ce397-05ba-757d-8a5f-33e54d906fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019ce397-05ba-7cdd-8e82-a1b45f5ac891" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019ce397-05ba-757d-8a5f-33e54d906fcf" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019ce397-05ba-7cdd-8e82-a1b45f5ac891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_019ce397-05ba-79e3-b865-6bf6ef3be655" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019ce397-05ba-757d-8a5f-33e54d906fcf" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_019ce397-05ba-79e3-b865-6bf6ef3be655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="sttk-20260331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019ce397-05ba-7104-8855-08a8d2f3d230" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_019ce397-05ba-77fd-9a0e-20023f42c022" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019ce397-05ba-7104-8855-08a8d2f3d230" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_019ce397-05ba-77fd-9a0e-20023f42c022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_019ce397-05ba-79b1-9524-fb6d2fd92d89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_019ce397-05ba-77fd-9a0e-20023f42c022" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_019ce397-05ba-79b1-9524-fb6d2fd92d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019ce397-05ba-773e-a09f-4dd7d432cb48" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_019ce397-05ba-79b1-9524-fb6d2fd92d89" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019ce397-05ba-773e-a09f-4dd7d432cb48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_OperatingAccountMember_019ce397-05ba-7eaf-9fda-b2f52d5a3f83" xlink:href="sttk-20260331.xsd#sttk_OperatingAccountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019ce397-05ba-773e-a09f-4dd7d432cb48" xlink:to="loc_sttk_OperatingAccountMember_019ce397-05ba-7eaf-9fda-b2f52d5a3f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_019ce397-05ba-7303-b6af-4bbc50c6cde2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019ce397-05ba-773e-a09f-4dd7d432cb48" xlink:to="loc_us-gaap_MoneyMarketFundsMember_019ce397-05ba-7303-b6af-4bbc50c6cde2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_019dd03d-2b67-7357-9e4c-6e5b209355ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_019ce397-05ba-77fd-9a0e-20023f42c022" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_019dd03d-2b67-7357-9e4c-6e5b209355ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019dd03d-2b67-7391-b3ed-fa63b1ca0e08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019dd03d-2b67-7357-9e4c-6e5b209355ce" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019dd03d-2b67-7391-b3ed-fa63b1ca0e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_PreFundedWarrantsMember_019dd03d-5058-75a4-8131-67244664b77b" xlink:href="sttk-20260331.xsd#sttk_PreFundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019dd03d-2b67-7391-b3ed-fa63b1ca0e08" xlink:to="loc_sttk_PreFundedWarrantsMember_019dd03d-5058-75a4-8131-67244664b77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_019ce397-05ba-75f2-a7cb-52729b0eb8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_019ce397-05ba-77fd-9a0e-20023f42c022" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_019ce397-05ba-75f2-a7cb-52729b0eb8e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019ce397-05ba-71c2-85ec-8b0aa55088b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_019ce397-05ba-75f2-a7cb-52729b0eb8e5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019ce397-05ba-71c2-85ec-8b0aa55088b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_019dd03d-0947-71b7-88ca-d1d37c6db8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_019ce397-05ba-75f2-a7cb-52729b0eb8e5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_019dd03d-0947-71b7-88ca-d1d37c6db8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails" xlink:type="simple" xlink:href="sttk-20260331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019d055a-cd2e-799b-ad6f-27ba36b3aa82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019d055a-cd2e-75c1-b5ce-ffd38ac0065e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019d055a-cd2e-799b-ad6f-27ba36b3aa82" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019d055a-cd2e-75c1-b5ce-ffd38ac0065e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019d055a-cd2e-7e96-abb1-2e9514cd6798" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019d055a-cd2e-75c1-b5ce-ffd38ac0065e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019d055a-cd2e-7e96-abb1-2e9514cd6798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019d055a-cd2e-7933-a9c0-a303c19d9ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019d055a-cd2e-7e96-abb1-2e9514cd6798" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019d055a-cd2e-7933-a9c0-a303c19d9ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_019d055a-cd2e-7f56-8487-16bc77691dda" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019d055a-cd2e-7933-a9c0-a303c19d9ba0" xlink:to="loc_us-gaap_OfficeEquipmentMember_019d055a-cd2e-7f56-8487-16bc77691dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_019d055a-cd2e-76a2-9dbf-2c6bdce688d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019d055a-cd2e-7933-a9c0-a303c19d9ba0" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_019d055a-cd2e-76a2-9dbf-2c6bdce688d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_LaboratoryEquipmentMember_019d4dbf-e1f7-718e-b88f-20fe15411d5a" xlink:href="sttk-20260331.xsd#sttk_LaboratoryEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019d055a-cd2e-7933-a9c0-a303c19d9ba0" xlink:to="loc_sttk_LaboratoryEquipmentMember_019d4dbf-e1f7-718e-b88f-20fe15411d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_019d055a-cd2e-7579-b536-b2d7a1f9baec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019d055a-cd2e-7933-a9c0-a303c19d9ba0" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_019d055a-cd2e-7579-b536-b2d7a1f9baec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019d055a-cd2e-7441-afae-4a2dd7ec110d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019d055a-cd2e-75c1-b5ce-ffd38ac0065e" xlink:to="loc_srt_RangeAxis_019d055a-cd2e-7441-afae-4a2dd7ec110d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019d055a-cd2e-795b-9689-3d87886fd4d5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_019d055a-cd2e-7441-afae-4a2dd7ec110d" xlink:to="loc_srt_RangeMember_019d055a-cd2e-795b-9689-3d87886fd4d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019d055a-cd2e-7145-bbf5-4719c25a3399" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019d055a-cd2e-795b-9689-3d87886fd4d5" xlink:to="loc_srt_MinimumMember_019d055a-cd2e-7145-bbf5-4719c25a3399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019d055a-cd2e-7b6b-b53e-c36f521380c8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019d055a-cd2e-795b-9689-3d87886fd4d5" xlink:to="loc_srt_MaximumMember_019d055a-cd2e-7b6b-b53e-c36f521380c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019d055a-cd2e-7a21-91ff-cedde35d7e85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019d055a-cd2e-75c1-b5ce-ffd38ac0065e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019d055a-cd2e-7a21-91ff-cedde35d7e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_019d055a-cd2e-7c19-86aa-9f2cb6824fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019d055a-cd2e-7a21-91ff-cedde35d7e85" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_019d055a-cd2e-7c19-86aa-9f2cb6824fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails" xlink:type="simple" xlink:href="sttk-20260331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019d055a-f26d-7bec-8139-4b2e58088d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019d055a-f26d-7789-9f69-8fd7c7517f13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019d055a-f26d-7bec-8139-4b2e58088d3b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019d055a-f26d-7789-9f69-8fd7c7517f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019d055a-f26d-7abe-ab98-6877eff503b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019d055a-f26d-7789-9f69-8fd7c7517f13" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019d055a-f26d-7abe-ab98-6877eff503b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019d055a-f26d-72f4-b632-533912ede80b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019d055a-f26d-7abe-ab98-6877eff503b7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019d055a-f26d-72f4-b632-533912ede80b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_019d055a-f26d-763a-9055-5550658a8f30" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019d055a-f26d-72f4-b632-533912ede80b" xlink:to="loc_us-gaap_WarrantMember_019d055a-f26d-763a-9055-5550658a8f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019d8b3b-6e9a-7c8f-bac5-7f7a540b9878" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019d055a-f26d-72f4-b632-533912ede80b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019d8b3b-6e9a-7c8f-bac5-7f7a540b9878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_019d055a-f26d-749c-852b-afacf585b7ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019d055a-f26d-72f4-b632-533912ede80b" xlink:to="loc_us-gaap_RestrictedStockMember_019d055a-f26d-749c-852b-afacf585b7ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019d055a-f26d-7562-b331-59ae01a453b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019d055a-f26d-7789-9f69-8fd7c7517f13" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019d055a-f26d-7562-b331-59ae01a453b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019d055a-f26d-790e-92e5-497dc5b7756a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019d055a-f26d-7562-b331-59ae01a453b5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019d055a-f26d-790e-92e5-497dc5b7756a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/InvestmentsScheduleofInvestmentsDetails" xlink:type="simple" xlink:href="sttk-20260331.xsd#InvestmentsScheduleofInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/InvestmentsScheduleofInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_019d0563-e4b0-71ac-8924-22b1452eff38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019d0563-e4b0-74b5-b470-09c254ecbc36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_019d0563-e4b0-71ac-8924-22b1452eff38" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019d0563-e4b0-74b5-b470-09c254ecbc36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019d0563-e4b0-733f-b0e7-c6e7b333ad33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019d0563-e4b0-74b5-b470-09c254ecbc36" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019d0563-e4b0-733f-b0e7-c6e7b333ad33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d0563-e4b0-7bad-a1d1-ab53788d2908" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019d0563-e4b0-733f-b0e7-c6e7b333ad33" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d0563-e4b0-7bad-a1d1-ab53788d2908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_019d0563-e4b0-7e84-89e1-c148acb5c9c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d0563-e4b0-7bad-a1d1-ab53788d2908" xlink:to="loc_us-gaap_MoneyMarketFundsMember_019d0563-e4b0-7e84-89e1-c148acb5c9c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_019d0563-e4b0-7c64-b7c5-0bbb05169c05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d0563-e4b0-7bad-a1d1-ab53788d2908" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_019d0563-e4b0-7c64-b7c5-0bbb05169c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_019d0563-e4b0-7109-9a6c-f3be63b1fa33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019d0563-e4b0-74b5-b470-09c254ecbc36" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_019d0563-e4b0-7109-9a6c-f3be63b1fa33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_019d0563-e4b0-70e5-828e-81504668f40c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_019d0563-e4b0-7109-9a6c-f3be63b1fa33" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_019d0563-e4b0-70e5-828e-81504668f40c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_019d0563-e4b0-7183-90ae-f017628986f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_019d0563-e4b0-70e5-828e-81504668f40c" xlink:to="loc_us-gaap_CashEquivalentsMember_019d0563-e4b0-7183-90ae-f017628986f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrentMember_019d0563-e4b0-7224-bd6b-147fd7d4414b" xlink:href="sttk-20260331.xsd#sttk_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_019d0563-e4b0-70e5-828e-81504668f40c" xlink:to="loc_sttk_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrentMember_019d0563-e4b0-7224-bd6b-147fd7d4414b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019d0563-e4b0-7864-b5df-91c73ee74681" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019d0563-e4b0-74b5-b470-09c254ecbc36" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019d0563-e4b0-7864-b5df-91c73ee74681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAbstract_019d0563-e4b0-75d3-882f-f024b0b4cafe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019d0563-e4b0-7864-b5df-91c73ee74681" xlink:to="loc_us-gaap_DebtSecuritiesAbstract_019d0563-e4b0-75d3-882f-f024b0b4cafe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_019d0563-e4b0-750e-8b89-bb25a2cf1aac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAbstract_019d0563-e4b0-75d3-882f-f024b0b4cafe" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_019d0563-e4b0-750e-8b89-bb25a2cf1aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_019d0563-e4b0-746b-9c52-0f9fffd4f6b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAbstract_019d0563-e4b0-75d3-882f-f024b0b4cafe" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_019d0563-e4b0-746b-9c52-0f9fffd4f6b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019d0563-e4b0-75da-b393-39551b3126c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAbstract_019d0563-e4b0-75d3-882f-f024b0b4cafe" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019d0563-e4b0-75da-b393-39551b3126c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/InvestmentsNarrativeDetails" xlink:type="simple" xlink:href="sttk-20260331.xsd#InvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/InvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_019d0564-001e-70c8-ab07-e580c851f021" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal_019d0564-001e-7d28-9db3-ebdb3ef697f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_019d0564-001e-70c8-ab07-e580c851f021" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal_019d0564-001e-7d28-9db3-ebdb3ef697f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="sttk-20260331.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_019d059e-fbce-79ca-8a3a-355034edb04d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AccruedResearchAndDevelopmentContractCostsCurrent_019d059e-fbce-7fbf-b617-b0a89068041c" xlink:href="sttk-20260331.xsd#sttk_AccruedResearchAndDevelopmentContractCostsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019d059e-fbce-79ca-8a3a-355034edb04d" xlink:to="loc_sttk_AccruedResearchAndDevelopmentContractCostsCurrent_019d059e-fbce-7fbf-b617-b0a89068041c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_019d059e-fbce-7cd1-a71e-958d27b28562" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019d059e-fbce-79ca-8a3a-355034edb04d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_019d059e-fbce-7cd1-a71e-958d27b28562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019d059e-fbce-766d-ac87-642133c6d296" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019d059e-fbce-79ca-8a3a-355034edb04d" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019d059e-fbce-766d-ac87-642133c6d296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_019d059e-fbce-71ac-baac-58cf934a80bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019d059e-fbce-79ca-8a3a-355034edb04d" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_019d059e-fbce-71ac-baac-58cf934a80bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_019d059e-fbce-7685-817c-9ec235df5850" xlink:href="sttk-20260331.xsd#sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019d059e-fbce-79ca-8a3a-355034edb04d" xlink:to="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_019d059e-fbce-7685-817c-9ec235df5850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="sttk-20260331.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019ce397-0676-781e-b953-fc393261755b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_IncreaseDecreaseInOperatingLeasesRightOfUseAssetsLiability_019dd040-6c4d-7415-82ac-c6937fdf00ac" xlink:href="sttk-20260331.xsd#sttk_IncreaseDecreaseInOperatingLeasesRightOfUseAssetsLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019ce397-0676-781e-b953-fc393261755b" xlink:to="loc_sttk_IncreaseDecreaseInOperatingLeasesRightOfUseAssetsLiability_019dd040-6c4d-7415-82ac-c6937fdf00ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/RelatedPartyLicenseRevenueDetails" xlink:type="simple" xlink:href="sttk-20260331.xsd#RelatedPartyLicenseRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/RelatedPartyLicenseRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019d0602-80ec-7abf-bcf5-e2198b3b5c13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019d0602-80ec-773b-ab07-cfbd9b7a9f85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019d0602-80ec-7abf-bcf5-e2198b3b5c13" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019d0602-80ec-773b-ab07-cfbd9b7a9f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_019d0602-80ec-726f-8850-74242b892a20" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019d0602-80ec-773b-ab07-cfbd9b7a9f85" xlink:to="loc_srt_CounterpartyNameAxis_019d0602-80ec-726f-8850-74242b892a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019d0602-80ed-7042-9f56-faeab369227d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_019d0602-80ec-726f-8850-74242b892a20" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019d0602-80ed-7042-9f56-faeab369227d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_KayakAgreementMember_019d0602-80ed-7bbc-bde6-7416f2a62d80" xlink:href="sttk-20260331.xsd#sttk_KayakAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019d0602-80ed-7042-9f56-faeab369227d" xlink:to="loc_sttk_KayakAgreementMember_019d0602-80ed-7bbc-bde6-7416f2a62d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_019d0602-80ed-7680-890f-842fc449b272" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019d0602-80ec-773b-ab07-cfbd9b7a9f85" xlink:to="loc_us-gaap_TypeOfArrangementAxis_019d0602-80ed-7680-890f-842fc449b272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019d0602-80ed-7a88-86f1-cb77961de30f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_019d0602-80ed-7680-890f-842fc449b272" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019d0602-80ed-7a88-86f1-cb77961de30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_KayakAgreementContingentMilestonesMember_019d0602-80ed-7617-9c51-098e9b88acf8" xlink:href="sttk-20260331.xsd#sttk_KayakAgreementContingentMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019d0602-80ed-7a88-86f1-cb77961de30f" xlink:to="loc_sttk_KayakAgreementContingentMilestonesMember_019d0602-80ed-7617-9c51-098e9b88acf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019d0602-80ed-7958-94a1-7c1363229551" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019d0602-80ec-773b-ab07-cfbd9b7a9f85" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019d0602-80ed-7958-94a1-7c1363229551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019d0602-80ed-733e-967a-c20811ca1f63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019d0602-80ed-7958-94a1-7c1363229551" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019d0602-80ed-733e-967a-c20811ca1f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_SubleaseAgreementConsideration_019d0602-80ed-78d0-bba4-69455deb7b4c" xlink:href="sttk-20260331.xsd#sttk_SubleaseAgreementConsideration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019d0602-80ed-7958-94a1-7c1363229551" xlink:to="loc_sttk_SubleaseAgreementConsideration_019d0602-80ed-78d0-bba4-69455deb7b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_019d0602-80ed-794b-8cbd-752207ba6636" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019d0602-80ed-7958-94a1-7c1363229551" xlink:to="loc_us-gaap_SubleaseIncome_019d0602-80ed-794b-8cbd-752207ba6636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_019d0602-80ed-78b6-a942-0d53eb50d20c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019d0602-80ed-7958-94a1-7c1363229551" xlink:to="loc_us-gaap_AccountsReceivableNet_019d0602-80ed-78b6-a942-0d53eb50d20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/EquityDetails" xlink:type="simple" xlink:href="sttk-20260331.xsd#EquityDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/EquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_019d1e8b-c8fe-72ba-a284-a541952a39bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_019d1e8b-c8fe-7a33-9678-b4df3d7723be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_019d1e8b-c8fe-72ba-a284-a541952a39bd" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_019d1e8b-c8fe-7a33-9678-b4df3d7723be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_019d1e8b-c8fe-7c85-af00-fe14c6646c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019d1e8b-c8fe-7a33-9678-b4df3d7723be" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_019d1e8b-c8fe-7c85-af00-fe14c6646c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019d1e8b-c8fe-75d2-b02d-1233f921e879" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019d1e8b-c8fe-7c85-af00-fe14c6646c2e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019d1e8b-c8fe-75d2-b02d-1233f921e879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_UnderwrittenPublicOfferingMember_019d1e8b-c8fe-79be-986f-efd533dc550f" xlink:href="sttk-20260331.xsd#sttk_UnderwrittenPublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019d1e8b-c8fe-75d2-b02d-1233f921e879" xlink:to="loc_sttk_UnderwrittenPublicOfferingMember_019d1e8b-c8fe-79be-986f-efd533dc550f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_019d1e8b-c8fe-77c8-aebf-cb09168c96ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019d1e8b-c8fe-75d2-b02d-1233f921e879" xlink:to="loc_us-gaap_PrivatePlacementMember_019d1e8b-c8fe-77c8-aebf-cb09168c96ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AtTheMarketOfferingMember_019d1e8b-c8fe-7211-948f-d170bdd41142" xlink:href="sttk-20260331.xsd#sttk_AtTheMarketOfferingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019d1e8b-c8fe-75d2-b02d-1233f921e879" xlink:to="loc_sttk_AtTheMarketOfferingMember_019d1e8b-c8fe-7211-948f-d170bdd41142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_019d1e8b-c8fe-7431-9628-a6ecdd005c25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019d1e8b-c8fe-7a33-9678-b4df3d7723be" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_019d1e8b-c8fe-7431-9628-a6ecdd005c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019d1e8b-c8fe-7b1a-8fa0-7e010fcc26fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019d1e8b-c8fe-7431-9628-a6ecdd005c25" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019d1e8b-c8fe-7b1a-8fa0-7e010fcc26fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_PreFundedWarrantsMember_019d1e8b-c8fe-751f-9be2-d1e09bfdd9fa" xlink:href="sttk-20260331.xsd#sttk_PreFundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019d1e8b-c8fe-7b1a-8fa0-7e010fcc26fb" xlink:to="loc_sttk_PreFundedWarrantsMember_019d1e8b-c8fe-751f-9be2-d1e09bfdd9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_CommonStockWarrantsMember_019d1e8b-c8fe-73cb-bfa5-825a8fe08e41" xlink:href="sttk-20260331.xsd#sttk_CommonStockWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019d1e8b-c8fe-7b1a-8fa0-7e010fcc26fb" xlink:to="loc_sttk_CommonStockWarrantsMember_019d1e8b-c8fe-73cb-bfa5-825a8fe08e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019d1e8b-c8fe-768d-a9ab-2ce552307f85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019d1e8b-c8fe-7a33-9678-b4df3d7723be" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019d1e8b-c8fe-768d-a9ab-2ce552307f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019d1e8b-c8fe-7a3a-b3b3-1de48a780370" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019d1e8b-c8fe-768d-a9ab-2ce552307f85" xlink:to="loc_us-gaap_ClassOfStockDomain_019d1e8b-c8fe-7a3a-b3b3-1de48a780370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019d1e8b-c8fe-78c4-b54b-4e050bd8bb81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019d1e8b-c8fe-7a3a-b3b3-1de48a780370" xlink:to="loc_us-gaap_CommonStockMember_019d1e8b-c8fe-78c4-b54b-4e050bd8bb81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_019d1e8b-c8fe-7bb4-b5cc-5e9f1ca43fd4" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019d1e8b-c8fe-7a33-9678-b4df3d7723be" xlink:to="loc_srt_CounterpartyNameAxis_019d1e8b-c8fe-7bb4-b5cc-5e9f1ca43fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019d1e8b-c8fe-7b05-af36-e2628eb213dc" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_019d1e8b-c8fe-7bb4-b5cc-5e9f1ca43fd4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019d1e8b-c8fe-7b05-af36-e2628eb213dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_BeneficialOwnersMember_019d1e8b-c8fe-7537-8ac7-8e7b2c964cc3" xlink:href="sttk-20260331.xsd#sttk_BeneficialOwnersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019d1e8b-c8fe-7b05-af36-e2628eb213dc" xlink:to="loc_sttk_BeneficialOwnersMember_019d1e8b-c8fe-7537-8ac7-8e7b2c964cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_019dd04a-105c-7f01-b9b8-1abc6524d640" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019d1e8b-c8fe-7a33-9678-b4df3d7723be" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_019dd04a-105c-7f01-b9b8-1abc6524d640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019dd04a-105c-7d84-84f1-95d1e54a484c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019dd04a-105c-7f01-b9b8-1abc6524d640" xlink:to="loc_us-gaap_EquityComponentDomain_019dd04a-105c-7d84-84f1-95d1e54a484c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019dd04a-105c-74db-8c46-7b1bac0cfe0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019dd04a-105c-7d84-84f1-95d1e54a484c" xlink:to="loc_us-gaap_CommonStockMember_019dd04a-105c-74db-8c46-7b1bac0cfe0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019d1e8b-c8fe-7a33-9678-b4df3d7723be" xlink:to="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_019d1e8b-c8fe-767f-99b2-16f82e1a9733" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_019d1e8b-c8fe-767f-99b2-16f82e1a9733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_019d1e8b-c8fe-7c09-a9ca-605dfb5a1d87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_019d1e8b-c8fe-7c09-a9ca-605dfb5a1d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_019d1e8b-c8fe-753e-b926-80a1a4794722" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_019d1e8b-c8fe-753e-b926-80a1a4794722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_019d1e8b-c8fe-78cc-a624-2873b6dc0d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_019d1e8b-c8fe-78cc-a624-2873b6dc0d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_CommonStockNumberOfVotesPerCommonShare_019d1e8b-c8fe-7419-a7ad-95a7c04100f4" xlink:href="sttk-20260331.xsd#sttk_CommonStockNumberOfVotesPerCommonShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_sttk_CommonStockNumberOfVotesPerCommonShare_019d1e8b-c8fe-7419-a7ad-95a7c04100f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_019d1e8b-c8fe-722b-9e67-73ab28277fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_019d1e8b-c8fe-722b-9e67-73ab28277fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_019d1e8b-c8fe-7219-b896-a921abdb054f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_019d1e8b-c8fe-7219-b896-a921abdb054f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_019d1e8b-c8fe-797b-9eea-8b95d871f8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_019d1e8b-c8fe-797b-9eea-8b95d871f8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_019d1e8b-c8fe-7fbc-a2c5-f1a20705174e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_019d1e8b-c8fe-7fbc-a2c5-f1a20705174e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ClassOfWarrantOrRightPriceOfPreFundedWarrants_019d1e8b-c8fe-780a-8fc3-5e51a1644cb9" xlink:href="sttk-20260331.xsd#sttk_ClassOfWarrantOrRightPriceOfPreFundedWarrants"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_sttk_ClassOfWarrantOrRightPriceOfPreFundedWarrants_019d1e8b-c8fe-780a-8fc3-5e51a1644cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019d1e8b-c8fe-7306-8533-cff8f96820e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019d1e8b-c8fe-7306-8533-cff8f96820e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_019d1e8b-c8fe-72a5-a107-28470b6df0d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_019d1e8b-c8fe-72a5-a107-28470b6df0d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise_019d1e8b-c8fe-77f3-ae27-eceb9a0a8bad" xlink:href="sttk-20260331.xsd#sttk_ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_sttk_ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise_019d1e8b-c8fe-77f3-ae27-eceb9a0a8bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019d1e8b-c8fe-7486-89d6-d9256251e063" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019d1e8b-c8fe-7486-89d6-d9256251e063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ClassOfWarrantOrRightWarrantsExercised_019dcead-b0a6-741a-bed8-3dc63700a0a4" xlink:href="sttk-20260331.xsd#sttk_ClassOfWarrantOrRightWarrantsExercised"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_sttk_ClassOfWarrantOrRightWarrantsExercised_019dcead-b0a6-741a-bed8-3dc63700a0a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_019dcead-b0a6-7c3d-b7fc-2d60cc07caf2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_019dcead-b0a6-7c3d-b7fc-2d60cc07caf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019dcead-b0a6-7ab4-bf65-93d009ec0902" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019dcead-b0a6-7ab4-bf65-93d009ec0902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_SaleOfStockMaximumAggregateSalesPrice_019d1e8b-c8fe-71bd-8023-f20fe121baad" xlink:href="sttk-20260331.xsd#sttk_SaleOfStockMaximumAggregateSalesPrice"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_sttk_SaleOfStockMaximumAggregateSalesPrice_019d1e8b-c8fe-71bd-8023-f20fe121baad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_SaleOfStockCommissionPercentage_019d1e8b-c8fe-7bfd-977b-aacc7c6d9802" xlink:href="sttk-20260331.xsd#sttk_SaleOfStockCommissionPercentage"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_sttk_SaleOfStockCommissionPercentage_019d1e8b-c8fe-7bfd-977b-aacc7c6d9802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019d1e8b-c8fe-7fc0-ba9f-6ebffbcf40b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019d1e8b-c8fe-7fc0-ba9f-6ebffbcf40b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_StockIssuedDuringPeriodSharesWarrantExercises_019dd04a-105c-7315-b58a-b2f425ef170d" xlink:href="sttk-20260331.xsd#sttk_StockIssuedDuringPeriodSharesWarrantExercises"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019d1e8b-c8fe-748a-a4e8-9859dcfb8aef" xlink:to="loc_sttk_StockIssuedDuringPeriodSharesWarrantExercises_019dd04a-105c-7315-b58a-b2f425ef170d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="sttk-20260331.xsd#StockBasedCompensationandEmployeeBenefitPlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d09ba-29af-72ea-8da5-aeaf4438cc15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09ba-29af-7b6c-9ea2-048f4bccaf91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d09ba-29af-72ea-8da5-aeaf4438cc15" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09ba-29af-7b6c-9ea2-048f4bccaf91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_019d09ba-29af-7055-8fce-65df0109e7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09ba-29af-7b6c-9ea2-048f4bccaf91" xlink:to="loc_us-gaap_PlanNameAxis_019d09ba-29af-7055-8fce-65df0109e7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019d09ba-29af-762e-9269-94ef273b8159" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_019d09ba-29af-7055-8fce-65df0109e7b4" xlink:to="loc_us-gaap_PlanNameDomain_019d09ba-29af-762e-9269-94ef273b8159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020StockIncentivePlanMember_019d09ba-29af-74d5-976a-23c9c0e130e4" xlink:href="sttk-20260331.xsd#sttk_A2020StockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_019d09ba-29af-762e-9269-94ef273b8159" xlink:to="loc_sttk_A2020StockIncentivePlanMember_019d09ba-29af-74d5-976a-23c9c0e130e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020EmployeeStockPurchasePlanMember_019d09ba-29af-7ece-b082-3f2d48d19bd6" xlink:href="sttk-20260331.xsd#sttk_A2020EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_019d09ba-29af-762e-9269-94ef273b8159" xlink:to="loc_sttk_A2020EmployeeStockPurchasePlanMember_019d09ba-29af-7ece-b082-3f2d48d19bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019d09ba-29af-72ea-90f4-e57e8066701e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09ba-29af-7b6c-9ea2-048f4bccaf91" xlink:to="loc_us-gaap_AwardTypeAxis_019d09ba-29af-72ea-90f4-e57e8066701e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d09ba-29af-7dfa-a921-f5cab5ec56c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_019d09ba-29af-72ea-90f4-e57e8066701e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d09ba-29af-7dfa-a921-f5cab5ec56c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019d09ba-29af-7503-8350-e3b675917740" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d09ba-29af-7dfa-a921-f5cab5ec56c2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019d09ba-29af-7503-8350-e3b675917740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019d09ba-29af-7188-9f31-e0fdd66494e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d09ba-29af-7dfa-a921-f5cab5ec56c2" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019d09ba-29af-7188-9f31-e0fdd66494e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09ba-29af-7b6c-9ea2-048f4bccaf91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage_019d09ba-29af-77d9-a8cd-6bfa2ad513b2" xlink:href="sttk-20260331.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage_019d09ba-29af-77d9-a8cd-6bfa2ad513b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019d09ba-29af-72cb-aabb-4cafc4cc2be4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019d09ba-29af-72cb-aabb-4cafc4cc2be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_019d09ba-29af-7173-86c8-0ccaf87a833a" xlink:href="sttk-20260331.xsd#sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_019d09ba-29af-7173-86c8-0ccaf87a833a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019d09ba-29af-7d84-8f03-1338835f0b50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019d09ba-29af-7d84-8f03-1338835f0b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_019d09ba-29af-7d9b-9c54-7686f4f9a4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_019d09ba-29af-7d9b-9c54-7686f4f9a4c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_019d09ba-29af-7b08-a976-31ff78459da1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_019d09ba-29af-7b08-a976-31ff78459da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_019d09ba-29af-7303-a0ec-0732de2cf04d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_019d09ba-29af-7303-a0ec-0732de2cf04d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue_019d09ba-29af-717a-8392-492b9213783a" xlink:href="sttk-20260331.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue_019d09ba-29af-717a-8392-492b9213783a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_019d09ba-29af-74b4-9f9b-e0a0e9dd8ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_019d09ba-29af-74b4-9f9b-e0a0e9dd8ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm_019d09ba-29af-74f9-a8fc-dfe9011940a9" xlink:href="sttk-20260331.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm_019d09ba-29af-74f9-a8fc-dfe9011940a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_019d09ba-29af-76c3-9504-724a4f1ea178" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_019d09ba-29af-76c3-9504-724a4f1ea178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_019d8fca-5307-78c7-a16c-0683284be3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_us-gaap_ProceedsFromStockPlans_019d8fca-5307-78c7-a16c-0683284be3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019d09ba-29af-76d4-8882-a81fa0326242" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019d09ba-29af-76d4-8882-a81fa0326242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_019d09ba-29af-7bb7-bb69-b81eab3d547b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_019d09ba-29af-7bb7-bb69-b81eab3d547b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019d09ba-29af-7898-a09a-0e6a0b0e1d13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019d09ba-29af-7898-a09a-0e6a0b0e1d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_019d09ba-29af-7d79-b8ae-80dfa24267e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_019d09ba-29af-7d79-b8ae-80dfa24267e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_019d8fce-e604-76b4-809d-ecee0d491314" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_019d8fce-e604-76b4-809d-ecee0d491314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019d09ba-29af-7de9-a84f-c4a20fbdee82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019d09ba-29af-7de9-a84f-c4a20fbdee82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_019d09ba-29af-7eb9-9b16-450ec9acbaac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_019d09ba-29af-7eb9-9b16-450ec9acbaac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019d09ba-29af-7a4c-8404-1c0fb865d7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ba-29af-734a-a30c-a2fdbd262490" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019d09ba-29af-7a4c-8404-1c0fb865d7e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofstockbasedcompensationexpenseDetails" xlink:type="simple" xlink:href="sttk-20260331.xsd#StockBasedCompensationandEmployeeBenefitPlansScheduleofstockbasedcompensationexpenseDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofstockbasedcompensationexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d09c5-750a-701f-b802-a3858d752ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09c5-750a-7448-9f9e-71aaf62ca806" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d09c5-750a-701f-b802-a3858d752ed4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09c5-750a-7448-9f9e-71aaf62ca806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_019d09c5-750a-7b3a-92cc-5111a6ef42c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09c5-750a-7448-9f9e-71aaf62ca806" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_019d09c5-750a-7b3a-92cc-5111a6ef42c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_019d09c5-750a-7ea2-a8d7-2b8a6a94bbde" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_019d09c5-750a-7b3a-92cc-5111a6ef42c2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_019d09c5-750a-7ea2-a8d7-2b8a6a94bbde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019d09c5-750a-76da-aadc-3a699c423707" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019d09c5-750a-7ea2-a8d7-2b8a6a94bbde" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019d09c5-750a-76da-aadc-3a699c423707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_019d09c5-750a-7c0b-93c2-d5dba75233c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019d09c5-750a-7ea2-a8d7-2b8a6a94bbde" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_019d09c5-750a-7c0b-93c2-d5dba75233c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09c5-750a-7dfc-979a-3b4ac03e2cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09c5-750a-7448-9f9e-71aaf62ca806" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09c5-750a-7dfc-979a-3b4ac03e2cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019d09c5-750a-7a51-88e4-e0a98845b564" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09c5-750a-7dfc-979a-3b4ac03e2cf5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019d09c5-750a-7a51-88e4-e0a98845b564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofoptionactivityDetails" xlink:type="simple" xlink:href="sttk-20260331.xsd#StockBasedCompensationandEmployeeBenefitPlansScheduleofoptionactivityDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofoptionactivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d09c6-2f0f-73e0-8e5d-59d9678c171c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019d09c6-2f0f-7af8-aba8-d9f4fe35e5e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d09c6-2f0f-73e0-8e5d-59d9678c171c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019d09c6-2f0f-7af8-aba8-d9f4fe35e5e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019d09c6-2f0f-7688-8393-88e2104b6050" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019d09c6-2f0f-7af8-aba8-d9f4fe35e5e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019d09c6-2f0f-7688-8393-88e2104b6050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019d09c6-2f0f-7cf6-a121-bcfa632a3796" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019d09c6-2f0f-7af8-aba8-d9f4fe35e5e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019d09c6-2f0f-7cf6-a121-bcfa632a3796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019d09c6-2f0f-79a7-a2a1-0ade067f7891" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019d09c6-2f0f-7af8-aba8-d9f4fe35e5e9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019d09c6-2f0f-79a7-a2a1-0ade067f7891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_019d09c6-2f0f-7c75-98d4-ddf91b44e83a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019d09c6-2f0f-7af8-aba8-d9f4fe35e5e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_019d09c6-2f0f-7c75-98d4-ddf91b44e83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019d09c6-2f0f-7a46-9e84-6aa023a89c82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019d09c6-2f0f-7af8-aba8-d9f4fe35e5e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019d09c6-2f0f-7a46-9e84-6aa023a89c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_019d09c6-2f0f-7f3f-95b9-8c6e349855ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019d09c6-2f0f-7af8-aba8-d9f4fe35e5e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_019d09c6-2f0f-7f3f-95b9-8c6e349855ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_019d09c6-2f0f-7b03-9826-9cd80f03ce19" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019d09c6-2f0f-7af8-aba8-d9f4fe35e5e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_019d09c6-2f0f-7b03-9826-9cd80f03ce19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019d09c6-2f0f-742c-a924-fe73b5791be0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d09c6-2f0f-73e0-8e5d-59d9678c171c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019d09c6-2f0f-742c-a924-fe73b5791be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019d09c6-2f0f-75ec-a4fb-63492408c826" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019d09c6-2f0f-742c-a924-fe73b5791be0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019d09c6-2f0f-75ec-a4fb-63492408c826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_019d09c6-2f0f-74dc-a8d0-2ede816a65a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019d09c6-2f0f-742c-a924-fe73b5791be0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_019d09c6-2f0f-74dc-a8d0-2ede816a65a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_019d09c6-2f0f-7b4d-b36a-75e1d68f75a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019d09c6-2f0f-742c-a924-fe73b5791be0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_019d09c6-2f0f-7b4d-b36a-75e1d68f75a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_019d09c6-2f0f-7896-a00b-5d25d6b531f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019d09c6-2f0f-742c-a924-fe73b5791be0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_019d09c6-2f0f-7896-a00b-5d25d6b531f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019d09c6-2f0f-7536-9240-87f833a39da1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019d09c6-2f0f-742c-a924-fe73b5791be0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019d09c6-2f0f-7536-9240-87f833a39da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_019d09c6-2f0f-7f7d-bdd7-8ab4ccbaa451" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019d09c6-2f0f-742c-a924-fe73b5791be0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_019d09c6-2f0f-7f7d-bdd7-8ab4ccbaa451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_019d09c6-2f0f-7f67-9599-ec0e7eb48dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019d09c6-2f0f-742c-a924-fe73b5791be0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_019d09c6-2f0f-7f67-9599-ec0e7eb48dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_019d09c6-2f0f-7f3b-81bf-997b19143798" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d09c6-2f0f-73e0-8e5d-59d9678c171c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_019d09c6-2f0f-7f3b-81bf-997b19143798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_019d09c6-2f0f-7c71-8e2e-ed5b7ce82346" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_019d09c6-2f0f-7f3b-81bf-997b19143798" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_019d09c6-2f0f-7c71-8e2e-ed5b7ce82346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_019d09c6-2f0f-7707-a41c-5b7bea90f8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_019d09c6-2f0f-7f3b-81bf-997b19143798" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_019d09c6-2f0f-7707-a41c-5b7bea90f8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_019d09c6-2f0f-7b83-8d37-dc86eba68f95" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_019d09c6-2f0f-7f3b-81bf-997b19143798" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_019d09c6-2f0f-7b83-8d37-dc86eba68f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofrestrictedstockactivityDetails" xlink:type="simple" xlink:href="sttk-20260331.xsd#StockBasedCompensationandEmployeeBenefitPlansScheduleofrestrictedstockactivityDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofrestrictedstockactivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d09ce-82bd-70ec-8ed9-0d4c1bab328c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09ce-82bd-72c3-8ecb-610586354b18" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d09ce-82bd-70ec-8ed9-0d4c1bab328c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09ce-82bd-72c3-8ecb-610586354b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019d09ce-82bd-7e01-a245-c33987ef44bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09ce-82bd-72c3-8ecb-610586354b18" xlink:to="loc_us-gaap_AwardTypeAxis_019d09ce-82bd-7e01-a245-c33987ef44bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d09ce-82bd-7bc4-97ee-5499f10be31c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_019d09ce-82bd-7e01-a245-c33987ef44bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d09ce-82bd-7bc4-97ee-5499f10be31c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019d09ce-82bd-752c-ad57-fee348ca7710" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d09ce-82bd-7bc4-97ee-5499f10be31c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019d09ce-82bd-752c-ad57-fee348ca7710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ce-82bd-740f-8792-a619ee5b4973" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09ce-82bd-72c3-8ecb-610586354b18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ce-82bd-740f-8792-a619ee5b4973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019d09ce-82bd-744c-9307-14fd005c2ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ce-82bd-740f-8792-a619ee5b4973" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019d09ce-82bd-744c-9307-14fd005c2ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019d09ce-82bd-7690-bae7-3106b55cc7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019d09ce-82bd-744c-9307-14fd005c2ff3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019d09ce-82bd-7690-bae7-3106b55cc7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019d09ce-82bd-78f9-aa12-1f214f9dfe53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019d09ce-82bd-744c-9307-14fd005c2ff3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019d09ce-82bd-78f9-aa12-1f214f9dfe53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_019d09ce-82bd-7819-954f-b024e0491a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019d09ce-82bd-744c-9307-14fd005c2ff3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_019d09ce-82bd-7819-954f-b024e0491a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_019d09ce-82bd-7eee-93e8-bc5d7b93fd84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019d09ce-82bd-744c-9307-14fd005c2ff3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_019d09ce-82bd-7eee-93e8-bc5d7b93fd84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019d09ce-82bd-7f7c-b36e-cdc0ce6daa33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019d09ce-82bd-744c-9307-14fd005c2ff3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019d09ce-82bd-7f7c-b36e-cdc0ce6daa33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019d09ce-82bd-722c-8a0c-5769497abe08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09ce-82bd-740f-8792-a619ee5b4973" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019d09ce-82bd-722c-8a0c-5769497abe08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019d09ce-82bd-749b-b8e6-c4ad24398ece" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019d09ce-82bd-722c-8a0c-5769497abe08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019d09ce-82bd-749b-b8e6-c4ad24398ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019d09ce-82bd-7dd7-81c6-fbd4dc398b01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019d09ce-82bd-722c-8a0c-5769497abe08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019d09ce-82bd-7dd7-81c6-fbd4dc398b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_019d09ce-82bd-71dc-b9dc-aaea77ea0393" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019d09ce-82bd-722c-8a0c-5769497abe08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_019d09ce-82bd-71dc-b9dc-aaea77ea0393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_019d09ce-82bd-7961-a911-f56c1e85300f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019d09ce-82bd-722c-8a0c-5769497abe08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_019d09ce-82bd-7961-a911-f56c1e85300f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019d09ce-82bd-71bf-945f-5abfe263b6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019d09ce-82bd-722c-8a0c-5769497abe08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019d09ce-82bd-71bf-945f-5abfe263b6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020PlanoptionvaluationassumptionsDetails" xlink:type="simple" xlink:href="sttk-20260331.xsd#StockBasedCompensationandEmployeeBenefitPlansScheduleof2020PlanoptionvaluationassumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020PlanoptionvaluationassumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d09d2-371f-738c-a240-425adc10ec09" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09d2-371f-74c3-ada3-f2e44ad501e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d09d2-371f-738c-a240-425adc10ec09" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09d2-371f-74c3-ada3-f2e44ad501e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019d09d2-371f-7146-908e-4f3165fde830" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09d2-371f-74c3-ada3-f2e44ad501e8" xlink:to="loc_us-gaap_AwardTypeAxis_019d09d2-371f-7146-908e-4f3165fde830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d09d2-371f-71fe-b377-eebb351f2060" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_019d09d2-371f-7146-908e-4f3165fde830" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d09d2-371f-71fe-b377-eebb351f2060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019d09d2-371f-7042-af3e-471df17f889c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d09d2-371f-71fe-b377-eebb351f2060" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019d09d2-371f-7042-af3e-471df17f889c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_019d09d2-371f-77fd-8df7-06302438b635" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09d2-371f-74c3-ada3-f2e44ad501e8" xlink:to="loc_us-gaap_PlanNameAxis_019d09d2-371f-77fd-8df7-06302438b635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019d09d2-371f-79e1-90d3-87841957d143" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_019d09d2-371f-77fd-8df7-06302438b635" xlink:to="loc_us-gaap_PlanNameDomain_019d09d2-371f-79e1-90d3-87841957d143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020StockIncentivePlanMember_019d09d2-371f-719e-a656-e07812f73531" xlink:href="sttk-20260331.xsd#sttk_A2020StockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_019d09d2-371f-79e1-90d3-87841957d143" xlink:to="loc_sttk_A2020StockIncentivePlanMember_019d09d2-371f-719e-a656-e07812f73531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_019d09d2-371f-78e8-a2d9-4034336a3105" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09d2-371f-74c3-ada3-f2e44ad501e8" xlink:to="loc_us-gaap_ValuationTechniqueAxis_019d09d2-371f-78e8-a2d9-4034336a3105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_019d09d2-371f-74c6-8927-fd9df8cfcd26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_019d09d2-371f-78e8-a2d9-4034336a3105" xlink:to="loc_us-gaap_ValuationTechniqueDomain_019d09d2-371f-74c6-8927-fd9df8cfcd26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_BlackScholesOptionPricingModelMember_019d09d2-371f-7b52-8a7f-c008899ab738" xlink:href="sttk-20260331.xsd#sttk_BlackScholesOptionPricingModelMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_019d09d2-371f-74c6-8927-fd9df8cfcd26" xlink:to="loc_sttk_BlackScholesOptionPricingModelMember_019d09d2-371f-7b52-8a7f-c008899ab738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09d2-371f-78b5-a41b-00ace77607b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09d2-371f-74c3-ada3-f2e44ad501e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09d2-371f-78b5-a41b-00ace77607b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019d09d2-371f-731a-8f48-ad0ce98c394b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09d2-371f-78b5-a41b-00ace77607b2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019d09d2-371f-731a-8f48-ad0ce98c394b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_019d09d2-371f-7c46-8c08-04bd97dbca14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09d2-371f-78b5-a41b-00ace77607b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_019d09d2-371f-7c46-8c08-04bd97dbca14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019d09d2-371f-7482-a1a4-7d567be063db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09d2-371f-78b5-a41b-00ace77607b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019d09d2-371f-7482-a1a4-7d567be063db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019d09d2-371f-7868-adc3-abd36e8f7c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09d2-371f-78b5-a41b-00ace77607b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019d09d2-371f-7868-adc3-abd36e8f7c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020ESPPvaluationassumptionsDetails" xlink:type="simple" xlink:href="sttk-20260331.xsd#StockBasedCompensationandEmployeeBenefitPlansScheduleof2020ESPPvaluationassumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020ESPPvaluationassumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d09d2-4517-71bf-9463-a824920be294" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09d2-4517-7aac-a21c-7aaddca54513" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d09d2-4517-71bf-9463-a824920be294" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09d2-4517-7aac-a21c-7aaddca54513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019d09d2-4517-739b-ac11-a3ad2ed03435" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09d2-4517-7aac-a21c-7aaddca54513" xlink:to="loc_us-gaap_AwardTypeAxis_019d09d2-4517-739b-ac11-a3ad2ed03435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d09d2-4517-7705-ae25-f60a62fc9a32" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_019d09d2-4517-739b-ac11-a3ad2ed03435" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d09d2-4517-7705-ae25-f60a62fc9a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_019d09d2-4517-780c-8e28-cf0c7f3ac5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d09d2-4517-7705-ae25-f60a62fc9a32" xlink:to="loc_us-gaap_EmployeeStockMember_019d09d2-4517-780c-8e28-cf0c7f3ac5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_019d09d2-4517-79bb-8cf5-453128b1d500" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09d2-4517-7aac-a21c-7aaddca54513" xlink:to="loc_us-gaap_PlanNameAxis_019d09d2-4517-79bb-8cf5-453128b1d500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019d09d2-4517-7b6c-9dc3-0f6dc15656cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_019d09d2-4517-79bb-8cf5-453128b1d500" xlink:to="loc_us-gaap_PlanNameDomain_019d09d2-4517-7b6c-9dc3-0f6dc15656cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020EmployeeStockPurchasePlanMember_019d09d2-4517-78b1-9ba7-32bbf04f8af1" xlink:href="sttk-20260331.xsd#sttk_A2020EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_019d09d2-4517-7b6c-9dc3-0f6dc15656cc" xlink:to="loc_sttk_A2020EmployeeStockPurchasePlanMember_019d09d2-4517-78b1-9ba7-32bbf04f8af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_019d09d2-4517-7413-b41c-4819f49a8712" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09d2-4517-7aac-a21c-7aaddca54513" xlink:to="loc_us-gaap_ValuationTechniqueAxis_019d09d2-4517-7413-b41c-4819f49a8712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_019d09d2-4517-772b-ae83-1c64c7c85322" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_019d09d2-4517-7413-b41c-4819f49a8712" xlink:to="loc_us-gaap_ValuationTechniqueDomain_019d09d2-4517-772b-ae83-1c64c7c85322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_BlackScholesOptionPricingModelMember_019d09d2-4517-7a66-8c58-a46e1bc2e82f" xlink:href="sttk-20260331.xsd#sttk_BlackScholesOptionPricingModelMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_019d09d2-4517-772b-ae83-1c64c7c85322" xlink:to="loc_sttk_BlackScholesOptionPricingModelMember_019d09d2-4517-7a66-8c58-a46e1bc2e82f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09d2-4517-7ff2-bc89-ce0501c59db5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d09d2-4517-7aac-a21c-7aaddca54513" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09d2-4517-7ff2-bc89-ce0501c59db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019d09d2-4517-7f76-b54b-ee9dcaa7e95e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09d2-4517-7ff2-bc89-ce0501c59db5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019d09d2-4517-7f76-b54b-ee9dcaa7e95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_019d09d2-4517-79c2-938b-45c58ecf3aca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09d2-4517-7ff2-bc89-ce0501c59db5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_019d09d2-4517-79c2-938b-45c58ecf3aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019d09d2-4517-7095-9be6-e167345a0d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09d2-4517-7ff2-bc89-ce0501c59db5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019d09d2-4517-7095-9be6-e167345a0d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019d09d2-4517-7b77-861c-092d92906613" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d09d2-4517-7ff2-bc89-ce0501c59db5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019d09d2-4517-7b77-861c-092d92906613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/SegmentReportingDetails" xlink:type="simple" xlink:href="sttk-20260331.xsd#SegmentReportingDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/SegmentReportingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019ce397-0676-77be-808c-727b944fdfc7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_019ce397-0676-73c9-be02-eb7b2f8f5492" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019ce397-0676-77be-808c-727b944fdfc7" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_019ce397-0676-73c9-be02-eb7b2f8f5492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019ce397-0676-7324-8df7-3862e1e0d348" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_019ce397-0676-73c9-be02-eb7b2f8f5492" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019ce397-0676-7324-8df7-3862e1e0d348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019ce397-0676-70bb-85a8-971a49003e76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019ce397-0676-7324-8df7-3862e1e0d348" xlink:to="loc_us-gaap_SegmentDomain_019ce397-0676-70bb-85a8-971a49003e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ReportableSegmentMember_019ce397-0676-7663-aa95-a48dbac54c64" xlink:href="sttk-20260331.xsd#sttk_ReportableSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_019ce397-0676-70bb-85a8-971a49003e76" xlink:to="loc_sttk_ReportableSegmentMember_019ce397-0676-7663-aa95-a48dbac54c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019ce397-0676-781b-9051-509f931cf06a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_019ce397-0676-73c9-be02-eb7b2f8f5492" xlink:to="loc_srt_ProductOrServiceAxis_019ce397-0676-781b-9051-509f931cf06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019ce397-0676-74d7-9b35-9bdbbe88664f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_019ce397-0676-781b-9051-509f931cf06a" xlink:to="loc_srt_ProductsAndServicesDomain_019ce397-0676-74d7-9b35-9bdbbe88664f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_SL325Member_019ce397-0676-726c-b4e6-9c493c8fc4f1" xlink:href="sttk-20260331.xsd#sttk_SL325Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019ce397-0676-74d7-9b35-9bdbbe88664f" xlink:to="loc_sttk_SL325Member_019ce397-0676-726c-b4e6-9c493c8fc4f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_OtherResearchAndDevelopmentMember_019ce397-0676-74cf-99f7-679025489cc1" xlink:href="sttk-20260331.xsd#sttk_OtherResearchAndDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019ce397-0676-74d7-9b35-9bdbbe88664f" xlink:to="loc_sttk_OtherResearchAndDevelopmentMember_019ce397-0676-74cf-99f7-679025489cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_OtherResearchAndDevelopmentSL172154Member_019dd056-9de5-7217-a70d-d170c9d68611" xlink:href="sttk-20260331.xsd#sttk_OtherResearchAndDevelopmentSL172154Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sttk_OtherResearchAndDevelopmentMember_019ce397-0676-74cf-99f7-679025489cc1" xlink:to="loc_sttk_OtherResearchAndDevelopmentSL172154Member_019dd056-9de5-7217-a70d-d170c9d68611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_019ce397-0676-7ec3-abd8-decd87541585" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_019ce397-0676-73c9-be02-eb7b2f8f5492" xlink:to="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_019ce397-0676-7ec3-abd8-decd87541585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_019ce397-0676-7bbf-8445-7ba65029d3c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_019ce397-0676-7ec3-abd8-decd87541585" xlink:to="loc_us-gaap_NumberOfReportableSegments_019ce397-0676-7bbf-8445-7ba65029d3c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_019ce397-0676-75fd-9730-1ac384650241" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_019ce397-0676-7ec3-abd8-decd87541585" xlink:to="loc_us-gaap_NumberOfOperatingSegments_019ce397-0676-75fd-9730-1ac384650241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019ce397-0676-7413-921c-a07a41f1b65a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_019ce397-0676-7ec3-abd8-decd87541585" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019ce397-0676-7413-921c-a07a41f1b65a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019ce397-0676-70b1-b23a-263d5c66c4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_019ce397-0676-7ec3-abd8-decd87541585" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019ce397-0676-70b1-b23a-263d5c66c4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ResearchAndDevelopmentNonEquityCompensation_019ce397-0676-7785-a5e2-1b9c41ab88a7" xlink:href="sttk-20260331.xsd#sttk_ResearchAndDevelopmentNonEquityCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_019ce397-0676-7ec3-abd8-decd87541585" xlink:to="loc_sttk_ResearchAndDevelopmentNonEquityCompensation_019ce397-0676-7785-a5e2-1b9c41ab88a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ResearchAndDevelopmentEquityCompensation_019ce397-0676-75e8-8a71-9abe217fd087" xlink:href="sttk-20260331.xsd#sttk_ResearchAndDevelopmentEquityCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_019ce397-0676-7ec3-abd8-decd87541585" xlink:to="loc_sttk_ResearchAndDevelopmentEquityCompensation_019ce397-0676-75e8-8a71-9abe217fd087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_GeneralAndAdministrativeNonEquityCompensation_019ce397-0676-79e7-a047-06a50c5e878a" xlink:href="sttk-20260331.xsd#sttk_GeneralAndAdministrativeNonEquityCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_019ce397-0676-7ec3-abd8-decd87541585" xlink:to="loc_sttk_GeneralAndAdministrativeNonEquityCompensation_019ce397-0676-79e7-a047-06a50c5e878a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_GeneralAndAdministrativeEquityCompensation_019ce397-0676-7b74-abb8-72767965c5f2" xlink:href="sttk-20260331.xsd#sttk_GeneralAndAdministrativeEquityCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_019ce397-0676-7ec3-abd8-decd87541585" xlink:to="loc_sttk_GeneralAndAdministrativeEquityCompensation_019ce397-0676-7b74-abb8-72767965c5f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_019ce397-0676-717a-9952-65392ae0d22c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_019ce397-0676-7ec3-abd8-decd87541585" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_019ce397-0676-717a-9952-65392ae0d22c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_019ce397-0676-73ff-a2e1-f89dd9530686" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_019ce397-0676-7ec3-abd8-decd87541585" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_019ce397-0676-73ff-a2e1-f89dd9530686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_019ce397-0676-7258-9b2a-68639356a776" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_019ce397-0676-7ec3-abd8-decd87541585" xlink:to="loc_us-gaap_OperatingExpenses_019ce397-0676-7258-9b2a-68639356a776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019ce397-0676-77d9-ad4e-113561c059bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_019ce397-0676-7ec3-abd8-decd87541585" xlink:to="loc_us-gaap_OperatingIncomeLoss_019ce397-0676-77d9-ad4e-113561c059bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_019ce397-0676-74db-aea3-40d1bd8fab74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_019ce397-0676-7ec3-abd8-decd87541585" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_019ce397-0676-74db-aea3-40d1bd8fab74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019ce397-0676-75d9-b7f7-f183f9e7ef74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_019ce397-0676-7ec3-abd8-decd87541585" xlink:to="loc_us-gaap_NetIncomeLoss_019ce397-0676-75d9-b7f7-f183f9e7ef74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_OtherResearchAndDevelopmentExpenseTechnicalOperations_019ce397-0676-746a-9111-393dfd1c0a71" xlink:href="sttk-20260331.xsd#sttk_OtherResearchAndDevelopmentExpenseTechnicalOperations"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_019ce397-0676-7ec3-abd8-decd87541585" xlink:to="loc_sttk_OtherResearchAndDevelopmentExpenseTechnicalOperations_019ce397-0676-746a-9111-393dfd1c0a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_019ce397-0676-7572-887b-1603c0ac6095" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_019ce397-0676-7ec3-abd8-decd87541585" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_019ce397-0676-7572-887b-1603c0ac6095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_019ce397-0676-7516-93fc-18d5b42facf6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_019ce397-0676-7ec3-abd8-decd87541585" xlink:to="loc_us-gaap_Depreciation_019ce397-0676-7516-93fc-18d5b42facf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ArunthathyNirmaliniLiniPanditeM.B.Ch.B.Member" xlink:href="sttk-20260331.xsd#sttk_ArunthathyNirmaliniLiniPanditeM.B.Ch.B.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_sttk_ArunthathyNirmaliniLiniPanditeM.B.Ch.B.Member" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AbhinavShuklaPhDMember" xlink:href="sttk-20260331.xsd#sttk_AbhinavShuklaPhDMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_sttk_AbhinavShuklaPhDMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ibc-shattucklabs_1stamen001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibc-shattucklabs_1stamen001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0L 0#WI:CD^\GUJ2@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (Y/OQ_P"]_2I!44OW
MXO\ >_I4@H 6BBB@ HHHH ***QO$7B*'PY;VDDME>7DEW<BVAAM%5G9RK-_$
MRC&$/>@#9HK#T7Q/;ZQ<SVCV-_IUY HD:VOX@CE"2 ZD$JRY!&0>*TX-1L;J
M"2:WO+>:*(D2/'*K*A'4$@\4 6:*JVFI6%_#'-9WMM<12,51X95=6(Z@$'DC
M%-N]7TVPC62\U&TMD:3RE::94!?^Z,GK[4 7**SCK$$=Y?1W&VWM[2&.9KJ6
M11&0V[WXQMY)P.1CO2#Q#HK6_GKK&GF$''F"Y3;G;NZYQ]WYOIS0!I457LK^
MSU*V%S8W<%U Q($L$@=21UY'%<EI'CK4M=LXK[3?!VI3V,KLB3_:K90=KE&.
MUI W53V[4 =K16:/$.BF_%@-7L#>%BHMQ<IYA()!&W.<@@C'L:F_M73_ ";>
M;[?;>5<_ZA_-7;+P3\ISSP">.PH N45RFK?$#0[+P[J&KZ=>6VJBQ:)98K6X
M4D&20(,D9P,G]#6Q+XBT:#5X](FU2S34I,;;5IE$AR,@;>O2@#3HK*MO$VA7
MFI?V=;:O937OS?Z/',I?Y20W&<\$'/THL_$^A:CJ<NF6>K6<]]%NWP1S N-I
MPW'L>OI0!JT5R7B;QNGAO4I[5[!IUBTJ74BZR[2?+8+LQCONZ_I3K7Q;?K=Z
M:NK:']@M-1(2"Z2[651(5W(CC (W#(!YY '>@#JZ*JP:E975I)=V]S'+!&75
MY(SN *DAAQW&#7,Z)X[.IW%F+W29=/M]0LI+^RD:42-+$A7.Y5&5;:ZMCG@^
MHH ["BN-TOQ^NL:9KU[9:)J$ATR80QVVS;-<$JI!V'[H^;OVY]J2+QKJ2IJ=
MI<^&YCK5E'!(ME:7 G$HE8A?G"@+C:=V1P!D9H [.BN7TKQE!-INKW6L+;Z>
M=)E\NZ>.X\Z'[JL"KX!/# 8P#GC%9UE\09]8\/Z+?Z5HC27>KW,T$-M<3^6(
MUC9PSR,%..$S@ ]<4 =S17#S>.[Z6[T:PL-)MC?W[7D4L=W>-&D,ELRJZAEC
M?=G)(.!P/4XIL'CZ]NK>"W@T6)]6FU*33TB^V9MF,:>8TBS!"2FW_9SD$8XH
M [JBL;PWKW]O6%Q)) L%U:74MG<PI)YBI+&<'#8&0>""0.#TK-D\>6"^,)M!
MCC9X[6SFN;J\#?NXVCV9C'JP#@L,C&5]> #JZ*X#0?B+/JZSW$FFVIMUL7O1
M%9WJSW$(4!@DL> 59@1@#.#D'!J+3OB<;C0]6U.XM+%TL]+34D%G>><!N4_N
M9&VC9)N7T/7VY /1**YSPAXDF\36<US(-*V(54?V??FYPQ&2KY1=I''KG)_&
MMXM\<VWAF_TS3HX?M=_>W$*-$K8\F)Y AE8]ADX'J?H: .LHKB_$'BK7-$EO
M+PZ79II-K<10@SSL)[O=MR8E (SEL $Y)4]*6/Q1J-UJ&JQ+=Z%90V=R]NOV
MJ5O,.T*=Q&0,<^O:@#LZ*\[U+XB7,'B&?3;(Z3(;.:*WEBGG,4EU(RJ6$1/R
MIC< -Q^8\<=^E\::]<>&O"MWJMM DTD)0?O"=B!G"EVQSM4')QZ4 ;]%>;6O
MC_5+G18E@.EW=_<:N-+MKZ /]CD!02>;C.[@94J&Y93S4.I?$+58;ZPTQ+G1
M+&=M0NK&[OKK<UNIBB60%?G7&=X7!/!R.: /3\T5P\FM^(X]"2\AU/PW>1-*
MWFZI$&6UM8E7DLOF$N2W'##&>:VO"&NRZ_X2LM6NQ"DDJMO:+(C;:Q7>N>0I
MQD9YP: -ZBO-_"OQ OO$.LVC/<Z.EC>"5ULQO%Q$B@E6,F2CM@990 5S_LFH
M/"7Q%OM:M[G4K_4=%6UCMI[M+&&WE6?RDSAB[L%/&,X'?M0!Z?FBO*M*^(^J
MR>%[[5[VZTBXN8;&*X6PAM9H&B:1E 9G=B&C7=RRC'7FM&Y\::QI+W>DW5QI
M%[J[)9FSE@1XX2;B4Q .NYB=I&[@C*D=.M 'HE%< ?%7B"VNKGP]*VFS:Z+R
M""&X6)UA\N5'D#LF[.56*3@-V'-,A\3^(YO^*?!LEUX:I)8M>&%O)$2Q+,9O
M+!Z['4!2V-QZXH ]"HKE2/&EIIVHP!].U"[ C-E=[#"#N.'#Q[C]P988;YNG
M%<S-X]U32H=5L+N]L[J>#4(+"VU2.U81L\@W2+Y2L2[Q@'Y5.22HH ]0HKSZ
MV\;7</@O6-0:\L]3O+.?[+;&*"2W>25L*B2PN-R-N8< G(YK5T'7]7N_#M\L
M]I%>Z]IUR]K-#$PA25@PV.-Q.U2C*W?OC/2@#K**XS0/$/B"_P#A\NJR65K<
MZSYT\3Q+)Y<*%)WCR3R=JA<\ DXX'-:G@G5KK7?!>DZI>LC7-S 'D9%VJ3D]
M!VH WZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** (9_O1?[_\ 0U,*AG.&A_W_ .AJ84 %%%% !111
M0 5R'CKS8I/#=XEI=W,5IJZ33"UMWG=4\J4;MJ G&2!T[UU]% 'E_B.#4_%D
MFK7VFZ/J,$,6DM:)]HC-M+>;YD=T4-AE&R-ER0.7_/,U30)+ZSUJ7PUX>N;'
M2GM[))K)K(V[7;1S%Y L; 9/ED G'S=,GFO8Z* /,V:VM=7L-9TSPKJ5IIL.
MIF6<Q64@EE+6KQEQ;[=RJ"4!('/)QW.%JNEZAJ=DMQ)I&JV<SZE?O&YTY;L(
MLNW"R0D'*N!]\<+@@GFO::* /%%T;6(K6UN=3TE(8UCT836!(VW(B,^^%%8X
M9AN1MF3R .:IZ-HK:[XWFN(?#[1:9#XEWS6\D*[8@+;JRC@$L5..Q;UKVW4=
M-LM6LI++4+6*YMI,;HY5R"0<@_4'D'M3=,TG3]&M/LFFV<-K!N+%(EP"QZD^
MI/J: ,3P=I;Z2_B&+[)]EMY=7DFMT"[5,9CCY4#L6#?CFN)\':9!I>CV4.IZ
M%XM74(IG9_(GN5@SYK%2$64)C&,C&.N17KM% 'FA\*R+:VTZZ0/MI\627DLG
ME#?Y)N7(<GKMV;?PK)N?!.N7@UK1(K62"QTNTO$T67S-JRM<_,%'(QM7?'ST
M#5[#10!X;J7@[6-2T:\6UL/$4EU'86]N%U">W5"1<1.8D5%&X*$)#;L=AG-;
M]UX;UN1M1TG^RY7DN_$4>IQ:JKQA(X0R/DY.X.JJ8P-O<<D9KU.B@#QK0K'5
M-:LK33[/1)+>*W\17=XVK[XPFT2RJ2!DMOYVX*XPHYQ6CX,\.:G87WAVUO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!!<_>@_ZZ#^1J>JUW_RQ_ZZC^1JS0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% %6]^[#_ -=5_K5JJM\<)#_UV6K5 !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5-0XBB/_ $V3^=6Q
M5+4CB"(_]-D_]"JX* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** *&KG%HA_P"FT?\ Z$*OBL_6?^/$'TEC_P#0A5\=* %HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** ,[6SC32?^FL?_H8K0'2L[7>-*<_
M]-(__0Q6B.E "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &
M9K__ "!Y3Z.A_P#'Q6D.E9OB#_D"S?[R?^ABM)?NB@!:*** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ K'\4:Q/X?\/7>K06<=V+1#+)$\QB)0
M DX.ULGIQQ]:V*YKXA_\DZ\0_P#7A+_Z": ,#2_B'KNL>%(O$5EX5MWM9ED:
M*(ZJ!*_EE@P"^5R?D8XST%3:C\1+RP\9:5X=71()7U2-9H)Q?$*$;/WAY?!^
M4\#/;FN2^$^A:M/HG@O5DU"6;3+62]5[)D15B+&4!P1RW)QSG&[C JUXS_Y.
M"\'_ /7L/_0I: .GOO']];?$2'P=%HEO)<W$1FBN'OF1"H5FY'E$@_*>F?K4
MV@>/X]4\8:IX5U+3SIVJ6">:0)Q+')'A3N#84]&4X(Z&N*\66E\W[0^CC2KJ
M*VOIM*=XY9HO,0,$F'*Y'!V_K5?X5W44WCCQ)<^*HYQXUCCQ,LI4(T( !$:J
M .@3/7C!'4T =E9_$'4-5\+ZAXFTG2+6ZTRU,VR/[85G=(\_-MV$#."=N>G?
MM6CK7B_4=,AU*Z@T2*XL;"T2YDG>\,>\L"2B 1MD@ <D@<BO)M0\'7.AZ,_Q
M%^'6N/;6$D(NY=/=N%3JR==K8.<HW3& 2:]6U:^FUGX/WNH7,36\]SH;W$D8
MXVL82Q'TS^E %?0/'.K:[IFDZLF@0QZ;?W7V<LMX7DAY9=S+Y8&-R@=>]=S7
MGOP3G$WPPL ,YCEF4_\ ?PG^M=GK6J1:+H]UJ$HW"%,JF>7<\*@]V8@#W- &
M+9^.=.O/B%?^#T&+JTMEF\S>,.QP60#U 93_ -]<<52^(OC+4_!6GV]_9:3%
MJ,,C,KH9BCIM1G+8VD%0JG->4^*--U[P?J'A[QK/H,EK/I\^W4[M;I)3=&1B
M6)"_=SN=<G. RCL*]8\2SV.M7'A!D\N[T_4;R1<G.V2)[2;^8/>@"]I_C.UU
M'P##XHABW++;AQ;JV3YI.WR\COO.VL+P;\0-6\6Z!J^IKI=E:_8,JD9N&;S&
M"[CD[1@8[\UR7PQT?5]-\4ZGX-N8F?2-$U WXG<_?+*1"N,="?WF1W2I?@N^
M[P%XI..DTG_HJ@#I?#?C_7/$WAE]7M=+TN*0SO;PVLUZX::14W[5.SJ1G ]J
MK>,/B+KWAKPGH&NV^EVER=1B1I[4B0-&WE&1L'^Z .XXVGUXY;X2:7=7.@:3
MK4=\4M=.U6X:[@DD"Q+&8,>9V^8$@<G&":[S6-1L-?U7P5<QA);*YU"Z10^"
MLJ"WG3..ZMU'J"* $'CJ?7?#VBZSX9GL?)OKN.TGBNXF=X7<XP=KC!'H>H((
M('6GJGB_Q79_$FS\)P?V*R7D)FCN'MY<H,.0"HDY^YC.>_2N.N?".H^ ?B;I
M5MIA9_"^LZG#+Y>TE;>56R%SVX) /<<=1FMOQ1=+:?M"^&G<*%:U"9+@?>\U
M?Z_C0!U&A^.YKOQA?>#]8LX;+6;>,21/%*9(;@;0V5R 1P<X]CSQ6%HWQ.U5
M?B6?"OB"VLH[:9Y8;6[MT=1)*C8 .YCC.",=<E>QK(6U;Q1^T>NI:6Q:PTB!
M1=7<!RC/L(V;AP2=X4CT!]*I>.]$EU#PKJ'B72F#7^A>(+BY1D.3LW+NQCT(
M5OH#0!U7Q*^)6J>$=2M;31[.SN <+<R7.XA';E5&TCG )/U6E\<>-?$_A#7-
M"L(CI-TNK/Y6Y[:1?*8%%)P)#D9?/X5Q7Q3@N;7P=X;N=00)J6H7DE[=KD_*
M[JIV\\X1=J?\!%:OQME@?Q7X)!G55\]F9E?!52\7S9[#@\^U 'H>EW_B277I
M+:ZGTNZTUH9@MU9VTB&&X1D78P+L".6[]5(XQ7&Z-\4M6L/B!+X>\70VL-G/
M*\%A?PQ-&DCI(4.=S'@D$=>#]<UT?AJ\TWPJ+3PRNHPWMS=WMS+#MN1)((27
ME\R0GN/NGU/.>N,K4_"VD_$CP1J%A%<0/>VNHWK6UQ&P8Q2&>1@"1_"P(S^!
M["@#0AU;QA/_ ,)';V]UIUQ=6%]!96V+)P,/Y+-(X\PY"I(W Q]W.>U84'BW
MQO-\3KKP6-0T8-!")?M?]GO@G8KXV>;_ +6.O:K/P2&KKI.O1:Z)!J4.HB&<
M2G+92")1D]^%'/?KWK(M)H4_:=OG:>';);!5/F Y;R4&WKUR#QUH ]4T2XU6
M70(Y-5AC34T$B2K&I5&96(!4$YVG (]C7F_B?Q;X]\+Z7H,]W<:,;O4Y-DL
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#-\0<Z%=?[H_F*OQ?ZI?H*H:_\ \@*[_P!T?S%7XO\ 5+]!0 ^BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S=?_P"0%=_[G]15^+_5
M+]*HZ]SH5Y_USJ]%_J4^@H ?1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !169JECJ-[<V@L]5ET^W3>9_)CC9Y.!M
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M$4<@'.<;M[ #U^E1_%C6]3+V>F:3=2V\$%U!_:,D3E&82MA(LCU4.Q_X#ZT
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M2\$LB_\ +0HQ7=]3CGWS]*Q[>9?&'Q6UK3=2B6;2] AB$-K(,H\T@R9&7HQ
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M6P3@<] *S=-\8>+M=AT_6M&TVXN+"ZO"&MWAB6(6NXKN$F_?O&,G*XYQCC)
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M0DVG;YRG!0G& 2>!GKVK8KG+KPQ:P^%-<TR G%^;J<LQ^[)*6;(],$C'TI/
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MJZ,JQKDDL<=@35'0/&NJ>(=+\&6#79M=1U>*::[NXHT8[8200H8%07('."
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M/]DVLENJW.]VFWJ%+,?7\\U>N=.\5W4LTPU2PMV%LT5O%%$Y19&(_>/EOFP
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M:G]BU&$Q6*",2.-BD[6PQ.X[>O3G)( ..PUJ&6YT/4(((S)-);2(B @%F*D
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M!R#CJ,\<_?\ PVUZ[\/Z]X<BU73HM)U"]:[B8P.9OFF60JYSC  .,<DXY44
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MWD?FVMS$T4J9(W*PP1D<C@UDZ?X3L--FL[@R7=Y)I\;1V0N9=_D*1@A>F3C
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M<$$D$>M '9R310[/,D1-[!%W,!N8] /4TRZN[:RMGN;NXBMX$^]+*X15^I/
MKROXIWTE_-.NGZU%97/AY4O88FG1/M%SD-MPQYVQY..YE'I@]E=:Q;>(OAA>
M:M:,##=Z5+(,'.TF-LK]0<@_2@#H;.]M-0MEN;*ZAN8&SMEAD#J<=<$<5/7-
M_#Y0GP^T$#_GRC_E724 %8DGC'PU#(8Y=>TU&#%6#7*#8PZAN?E/7@XK;KRC
M0=3N],UCQU;V?A:]U:%]6D9Q#)$$):-25(=P3GV!Z_A0!ZE;W$%W;I<6TT<T
M,@RDD;!E8>H(X-)]KM_MGV/SD^T^7YOE;OFV9QNQZ9XKSWX)F&'X=B,7RS&*
MZE,L)5E^QL<,82& Z9R>,9)^M<G/XJT^#QII'CJWUJ*1=0NVT^ZLO.!:*S;B
M)BHY4 KYASW<"@#V2^US2],N[>UOKZ"WGN6"PI*^WS"3@ 9[YJ>^U"UTRS>[
MO9U@MTY>1^B_6L+QUH]KK_AZ/3;O=Y,]Y;J6C.&7,@Y4]C[UQKZ[?Z?X;UOP
M;XFESJMM92&RNWX&H0 'YQ_M*!R,Y[^IH ](EUS3(-4M],EO(TOKE=\-N<[Y
M%[D#N!CGTH.MZ<-7_LG[2IO]H<P*I+!3G#' X7@\GC/'6O-_B5?W^E?$7PO?
MZ98-?WL%E?M%;KU8^7U]P.N!R<8'-=AX&N-)U30QK&G7GVZ>].ZZNW4+(T@X
MVLO\(7H%Z >N<D ZBBBLCQ5?W6E^$M7O[) US;V<LL0/0,%)!_#KCVH ;<^*
M]$M9)T>]WFW;;.T$3RK">X=D!"'V)%6+K7=+L]%.L37D9TX('^TQYD3:>C97
M/'O6%\,K2WMOASHIA(<W%N)YY#UDE?ERQ[G)(_"O-["66/X;_$W2QN^PZ?J=
MS#:*<XC3?]P>PP#CWH ]=B\5:1+<6T FN$>Z8) 9;2:-9"1D ,R@=!ZULURF
MB3ZI?-I=IJ&AP1Z<MD)UN#,)3YR&+R^,#:<%C_P&NKH *PG\8:*))5CGGN$A
M8K++:VDL\2$=0712H(SR,\57^(.H7FE^ -;O=/9DNHK5BCKU3L6'T!)_"G>
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M%OP6FGW$-O<FWO=DDT)E0?NQG*AE)X]Q78Z1'JUI-.FMZA:W,DT@%LT$)@7
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M;_D#WG_7%_Y&I+$YL+<_],U_E0!8HHHH **** "BBB@ HHHH **** "BBB@
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MV.#V.:CNO#NJ>)]8TRZ\0Q6-O8:9,+F*RMY&F,TX! 9V*J JYR !R>IKL:*
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MU337D>SGSY;O&4W '&<'GJ#4EEK%CJ-]J%G:SK)/82K%<*/X&*AA^A_,$=J
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M DD<9MZ+K$>MV#74=K<VQ25X7AN4"NK(Q4Y )'4>M "+ILX\0RZF;L&&2W6
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MI-X/^F#_ /H)HTPYTNU/_3)?Y4 6Z*** "BBB@ HHHH **** "BBB@ HHHH
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M8A*&A=D#-.VW]V268*,@G P#UKK?".GZOINDRV^LZE-J$OGLT4\RA7,9 QN
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MU<5S-Y@BZ\+QP#GI3-1\(V&I:X-9DN+Z*_6 V\4L%P4\I#U"@<<GG)![>@H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** *VH?\ (-NO^N3_ ,C46C_\@:S_ .N2_P JFO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@""]_X\9_^N;?RJ'2/^0/:?]<E_E4UY_QY3_\
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MRT:I\GR<XVYYQUQ[UW5% !7.>+O"J^)+>SG@G^RZKILXN;"Y()5)!@X8=U.
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M2^U$3F)Y5A40Q%R68X&>P_$BGZ_K]OX>LXYIK:\NY97\N&VLH3+-(V"3A?0
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MA5QQV8D$XQG% %'6?"VE#QEX2MM!TZVM+O3IC<3RVZ!/*M54C8V.N]F &?\
M;/K77>*=5N-#\+:GJMK#%/-9VSSB.5BJL%&3R >P/_UJYS2O#?C#3YY&?6='
MS=7"S7EREE(9Y #R 6<@<<+QA1T%=+XETN;6_#.IZ5!*D4EY;/;B1P2%##:3
M@>Q- '+?\)IKMKH]G>:EIMI VJR6Z:<L)DG/SHSOYB*N[*JN<+G.<9ZFJFI?
M$'7=-T'Q!=OHA:33#$T%S+;S6\-RDA"_*)!NW*3R.GO6OK?@R\U?PCI&GPZF
M+'5M*:*6VO(DW*)(U*YVGL03Q[]^\&J>$_$?B#PEJ&G:OK%F]]>B-!Y$+)!
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M>-QQDX#,0.P&!BU;^&;:U\577B&.ZNQ=742Q31%E\IU7[O&W/';F@#;HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** (KG_CUE_P!QOY4RQ_X\+?\
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M^S.,_3->4JWB#QK<^(+FPU:'3[K3=2:V@D>YEC^RI%@@F(?(RN-Q);.<D=
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M8;W5=)31HOMMO8WCQW<<CJ#YX"D>9TQ@GU/K5F\U-;GQ/\-Y-.U.ZN+"]AN
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M&\1ZU"GA/3=:L]4O'N[:_F>-3:M)RRRA@6(!Y^7/3WX]'FU?3+>0QS:C:1N
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MC\Z ,#PWX03PYJFKWR:G=W9U.59I5G"<.%P6RH')]!@#TKI*P?#'B5?$G]J
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M'ABQU>ZMX[=[N,2B&-BVP'L2>I_"MAY$CV[W5=QVC<<9/I0!B6/A#2=.U_\
MMJV6=;S[/]F),S,#'G."#U.[YB3R2<U3N/AWX8N?$+ZW)IQ%Y*XDFVS.L<K
MY!= =K<C/(KII[B&VC\R>:.),@;I&"C)Z<FB>>&UA::XECBB7[SR,%4=N2:
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MDL404GU^F>^.M:]% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MTO449H9,%70X>-QRKJ>S ]#6-I_@&TM-;M]8N]6U/4KR&U:TW7LB.'C/9@%
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M30BARX4;B,%L<FG4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML>_#A6*X)!&#M/&3F@#T2BH;N[AL+.:[N7V0PH7=L$X &3P.37FNM?$'^V_
M?]LZ!?2V<T5_"CJ(^6B:?RP&++@97G /'3- 'J%%8^D>*]"UZ[N[72]3@NIK
M3'GK&3\N>AST(XZC--LO%NA:CJ::=:Z@CW4B&2)"C*)5'4HQ #C_ '2: -JB
MJ6L-.FC7KVTQ@G6!VCD"AMK $@X((-9/@2_OM6\$Z7J.I7)N+NZA$LC[549/
M8!0!B@#HZ*Q]7\4Z-H3R+J-YY31Q>=(%B>3RTS@,VT':,YY.,X/H:34/%6C:
M8(C/>;O-@-RGD1M-^Y&,R?(#A/F'S=.: -FBL:Z\5:/:6EA<M<M*FH(7M!;P
MO*\RA=Q*JH)P%Y/%$OBK1X;"RO#<N\=\2+5(X'>27')VH!NX YXXH V:*H:/
MK6GZ_IRW^FW GMV8KG:5*L#@J5(!!![$5C7?C*WM?'=KX8%M</+);-/+(L#L
M%Y4+C Y'+9;H,=: .HHK!NO&6AV4S1SW,JHEP+62?[/(88Y2<;6DV[1R0.3@
M$XJ[-KNG6^O6NB23D:A=1--#&$8AD7J=V,#\30!HT53U74K?1](O-2NFVP6L
M+3/]%&<#W/2N1U.X2#P9:ZCK^M:CI\M]<6\SR61;]TS$%85P#A/X23U/)ZXH
M [JBN9U+49?#_B?3S-/))INL3?9=KG/V>XVY3;WVL%8$=C@C'-=#<W$=I:S7
M,N[RXD+ML0L< 9. .2?84 2T5QMG\4?"U]>6%O#=3[+\A8+AK=UA+GHA<C ;
MIQ[@=:LI\0= DUK^R$DNS=BZ^R.IM) $DQD;B1P#V/0]N 30!U-%<XOC?1B;
M:0M<+9W5Q]F@O6A(@DEW%0H;W((!(P>QJS9^)["]U[4M%1)TO=/19)ED0*"K
M?=*G/(/_ .O% &U17'7>J:1JNK^$+^2XU6VDN6E>QA3*1S;H\_O0,C&T9 SW
M^M4?B-XGBB\&^)+>R2^>:V@,3W5J&"0RD @%U(((RN<<#//&: ._HKE8/%-K
MI>D:=;R0WEY=C3([N6.WCWLL84#>Q) Y.<<Y.#Z5N:-K%AK^D6VJ:9.)[.X7
M='(!C/8@@]""""/:@"]17GNNWIUCXC0^';RWU$Z>NFO+Y4#[!([2!/,)# D*
M,X/8G.*T[;Q5I.A:1#&\FI7&EV;_ &.35[C#IO5@F7;(8_,<;@NW.>: .OHK
MDM7^(>DZ/K=QI$EIJ5Q=V\232+:VWF (QQNX/09Y/]>*ZFXN(K2VEN9W"0Q(
M9'8_PJ!DG\J )**YK2?&MAJU_86HM+VV.HVQNK&2X10MQ&,$E=K$C@@X8 X(
MK5US6+;P_HMUJMX)#;6J>9)Y2[FQ["@#0HKE(/'VFW%JT\=CJ85GA2V$EOL^
MUF52R^5N(!& <DD 8SG'-.MO'VCS6FK2S">VFTID6YMI0IDRX!CV[6*MOR N
M#R30!U-%>;G4KFZ^,NF^9IVH6FS1IR(;@IASO4Y7:[+GMU':N@7QSI[>&M/U
MX6E[]DO;I;0+L3?&YD,0+#=C&X8X)ZB@#J**YG4O&EI8/?F*QO;RWTUU2]FM
MD5A"S8.,9W,0&!(4' /KQ56#Q3J4_P 1Y="&ERC3X[!+A9=R9;<^-Y!((488
M8^]GJ.E '845Q.A:YH.D:)JUW96E[#&NKRV\D$AWRRW3,%*H"Q'+' Y ^E:T
M'BE&U2XTJ[T^YM=1CMS=10,R-]IC'7RV#8)!X(..H[<T =!17$6'Q,L;Z/1+
MG^RM1AL-8G%M;W<H0+YIW84C=NYVXR!CWKM7=8T9W("J,DGL* '4UY$B7=(Z
MH,XRQQ7*GQY9QV5CJ=Q87D&CWLBQQ7TFS;\QPC%0Q8*W&#CN,XK%U".37OB?
M>Z3J>E"\TU=*5%BDD4J@DE8-* 3P2 !Q\PQ0!Z-15>PLH=.T^WLK??Y-O&L2
M;W+-M P,D\D^YJQ0 4444 %%%% !1110 4444 %%%% !1110 4444 -?[C?2
MJ>C_ /((M?\ KF*N/]T_2J6BG.CVI_V* +]%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 <E\4/^28^(O^O)ZX7QC9ZS
M)\&=.NKC4K*ZT>&TM9KNTCA,+SQ@)M02;F'7!Z<X'2O5];T:T\0:1<:7?B0V
MMPNV58W*%E],CG%8B?#O0#9Q65R-0O;.'9Y=K=ZA-)$NS[OR%MI ]""* -W1
M[ZWO]&T^[MT\F*YMHYHHC@%4900,>P(J]69<>'],N==L=:EM\W]C&\5O('8!
M%<88;0<'CU%:= !1110 4444 <!X<&/C+XT/K;67_HNM#QSJ=@VD/IKW]Q'/
M)=VT!AM"!)*TCY6'<2 NX YY&%.>A&;EUX%\/7NH7-_/:7!N[D@S2I>SH7P,
M#[KC@#H.@I7\"^&Y=(N-*ETQ9;2XF%Q*LDLCN\F -Y<MNS@ 9S0!YG&]Y!I_
MQ4L/,-I':10S6]M:W3E+5S&S'8V 1RH)  ';I706>EIHWB_P7>6MS>-/J5I/
M'>F6X9Q.%@#KD$X&"!C& .E=6G@+PM&LRIHEJHFA6"3:"-Z#L>>??U[YK0/A
M_2S<:?.;0>;IR[+1M[9B&,8'/IQ]* /(+M;#Q3\$-9\0ZI)YFML)I)I#(5>"
M17(6(#/RJ% &WH<YQDUVU_)-%\1--DMH_,G3P[=-&G]YA)%@?G6W<^!/"UYJ
M%U?W&AVDES= B=V3[^1@Y'3.._6KR>'=)BU"TOH[&-+FTA\BW="0(X^FT '
M'MB@#RR2-;KX.VOBZR^;Q3&R3B]5 9FN#-M:,\<KEF79TQ@8J_9^&+#Q#\4/
M&*:DDTHLGT^Y@B6Y<(DIC+$]1GD8&>@9L8S7?Q^%="BU1]232[=;MY/-:0+U
MD_OXZ;O?&:L0:'I=MJ<VI0V,*7TW^MN O[Q_8MU(]!VH \,\07.GZS\#-2UW
M41:R^)6N_P#2';'FQO\ :-HC'< 1XPO3'-?0",#$K Y&T'(K%O/!?AC4+ZXO
M;S0=/GN;E0LTDD"DR $$9]>0/R%;<<:11K'&BI&BA551@ #H * /#+NXT^:^
MT;6+*>QC1_%*C[3<2@W\V9BK@XQLB X"G=\H4G&:O/H6DZUX@^* OK7[0+=(
MIH0TAV(QMV;<JCC=D'YNO/;)SZ>?"?AUFN&.A:<6N)!+,3;)^\<'(9N.3GG-
M2?\ "-:'YM[)_9-EOO@5NF\E<S@G.'X^;\: /+]%UA=0U[P/9^(WB?3)?#ZS
MV_VD_NY;S(4DYX9@F<9[MZFMWX3)8P/XO@TT0BS379O)6$@H$VIC;CM78R^%
M] GTN+3)M&L)+"%MT=L]NIC0^H7&!U-6[+2]/TUIFL;*WMC.^^4PQA-[>IQU
MH 35CC1K[_KWD_\ 037*?#1Y?^%3Z4;;#3"VD\L<?>WM@?G79W%O#=V[P7$2
M2PN,.CC(8>A%1V=A9Z?&\=E:PVZ.V]EB0*"V ,X'?@?E0!XWX/3P[J^F^&+R
M7Q$4UZUN49[2&.%+IIR=LJN-N]D.6+$]N<\54NM#TE_AKX]O?LL/VJTUJ\-M
M,/O6Y652NP_P=N!C->TQ:+I=OJ<FIPZ=:1W\J[7N4A42,/0MC)IW]DZ;Y$D'
M]GVODR-N>/R5VLWJ1C!- 'D_CZ[T^?7O$L2R6L5Y#H.R634GW*RLK%4MD)'S
MD]6R<$*,$YJAI,%AK_B'X7_;%@O5;1I5F#88,R1C"MZX(Z'WKV@Z7I[2Q2FQ
MMC)$ACC8Q+E%/50<<#VI$TK3HI8Y8["U22(8C=85!0>@..* /"=6CBC^'OC"
M-(HUM;'Q8RQ(J@)!'YJ# _NKD_3FO>=/N+*YLDET^2&2UR0C0XV'!(.,<=0>
ME-32]/CBFB2QMECF_P!:@A4"3_>&.?QJRB)&BHBJJ*,!5& !0!X[>:K8-X?^
M)5AK\MM%K9:Z,<5P<,\/DX@\O=@L!CC'0\]\FCI>JPZ9/X3.MZNVFZ1<>&H8
M;.Z1(V3S0!YJ.9$=02 /3H!7M<ME:SRB6:VADD"E [Q@D*>HR>QI9K2VN(1#
M-;Q21#&$= 5&.G!H \GCTNQL;30%\+>(S;W5HEV^FIK.UH;N)F4.HP%(4G!4
M@9P<CBK#ZE;ZAH/PZOI+..PD;5T582V0J^7*#L)).PD*1[%?:O4I+>&4 20Q
MN%Z!E!Q0T$3;=T2';]W*CCZ4 >7:1H^F:KXN\?M%!8S:O!=Q2V;_ "EH9! "
MKKS\IWYR1C)'/2LKP._AK4K'P]IU[>:J?$.E3I_Q+'!5[>=<[V(VCY#\S,23
MZ=2 ?9TABC8LD:*QZD* 32B- Y<(H<]6 Y- &;XDC>;PMJ\<2,\CV4RJBC)8
ME#@ =S7F&D^(;9=,^'&I_: ^B:=;?9=0F&1':W)MU1"YQC@[UST&[W&?8Z;Y
M:;-FQ=G]W'% '$^&;<S?$;Q-JNGRQOI%Q#;HSQ'*2W*@[F4C@X4J"1W/J#3/
MB/?6MC<^&GN840?VD"E_-O,=FP4_,54@%B"0N[(R<GI7=*H50J@ #@ =J" 1
M@@'ZT ?/UO=P'P)XZMKF>29Y/$23*;J+RVD1IX3O*E0!D!FQ@<9XP*[]UTT?
M&O36A6U"IH$FS8%PI$BE<8Z?(6Q[$]LUZ'@44 >$64\=KX0T_5(X[N;1;#Q'
M>27*6!99(H7$BHXVX95&\'C'!%6/$4?AF7P#KFH:%;71@U&[LM]W>RS,UW(D
MP+X64DX5<Y;H>?[M>WT4 >8:_P"5-\2;NUTAX8]1F\)7,-N8\+ND+J8E!Z$X
M!('8#/2L+^W]/U#PWX$TFWLKM-0TS5+%+NW-D^;9H\!]QVX&>2/7GT->V44
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MS$/GIM);(#;LXQ@Y]>WO0!3UBZ;3_B1X?U#3=$FN[F;1)EC@AVJ7P4*J7;
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M^H1JI;' )!) SWP?H:Y;1+_P,FDY\1:IX/OM8D>22XG-U#+YC,Q;[S*" ,@
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MK%LEBV?]DXJ9_!?BFQU?3M>T?5-,CU,64=CJ$$\4AMYHU/#+@[@P'TSCMR"
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M6PF@NKC3EU*V7S%;S(C@;3R-K@GIT]ZRK7XH17.G:5JG]@ZA'IE]>"S:Y=D
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M)'&S+$O5R!D >YZ4 07>E:=J#J][86MRZC"M-"KD#T&14'_"-Z%_T!=._P#
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M$$;3T]>N?;K6DWC7QK_9_BM430?M?AMGDGE,4VR>,1[U"INR&P&R2QYP,=Z
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M)P<5B/?75WX*\)Z#_P (UJ\>I:-J5B+J(6+E46(X,@;&#N )XSU.>.:]MHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% "'H:S]"_P"0/!]6_P#0C6@>E9^A<Z/#
M]7_]"- &C1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1BB
MB@ Q1110 4444 %%%% !1BBB@ Q1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "'
MI6?H7&CP_5__ $(UHGI6=H?_ ""(?J__ *$: -&BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHK-U_7;#PUH\NJ:G*8[6)D5F R<LP4<?4T :5%("" 000>A%8,7
MBN"]GN(])T^^U1+:0Q2SVPC$0<=5#2.H8COMS@\'F@#?HKEKKQWIEIX5NO$4
MMK?"TM)3#<1F(++&P8*059AW(_\ U4Z/QQ8KK6G:5?V-_IUQJ2DV;72)Y<Q
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA"GFE(_-?HHX &?RQ76ZUXLT_0WF2:*[N'MX?/N!:P&3R8^?F?'3H>.O!.*
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M:?%>6XM[F.W1)(A('"L!@C<.M:-03WMK:R11W%S#$\S;8E=PI<], 'J>1TH
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M_P"!)+>VM_&*^;A6UN[N 7XW(P4[AZKG< 1P<4 <S#JC>(O!4?BJ\\:ZOH!
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M XKT>UNH+ZS@N[:19;>>-98G7HRL,@CZ@UP9M[QF^(P&GWG^EK_HW[AOW_\
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M!;!(R03@FMN@#R^TM(/%FC:O%IW@RYT.]ETZ>S>YOH%B8NZX"(<DLN223@#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYSC!H ]DJ WEJ#@W,((_VQ4U>6^-?#NCZ3>^![:WL+8)_;$<<A,2[IL@Y+G
MW$GDYZDT >GQS139\J1'QUVL#BI*Y#7+S1/ 4,E_9V$$-WJ<L<"Q1(521P&.
MY@BD@!=Q) )P!63+\2KV#P[K^I/H99]*6.6)PTBP743@89'9 <C/*XXH ]%H
MK@;_ ,;>(],2REO/"\<45_J<-G;#[8"[)(I(8KCAAM(()&/>HE\9^*Y=3UG0
MTT+3?[7L(TN5;[6YMS"PR,MMW%^",8 ]QCD ]#HKSM_B:D^B>%KRW2ULWUX2
M 2WS-Y,#(,%2P[EN!T[GMBNVT>XO;O2X9M1MH[>Z8MOCB?>HPQ (;N" #^-
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MP!@$=<GFK/AF#7=6\1:S<3^)KW[+I>MR0I;&./;+'Y2$HV%' WC&.G).2<@
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M4<\2-"KB.XD9W3(SM)8D\9QCM5!_!FARW.LW$MM)(^LQB.^#SNRRJ!@<$X7
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 !Z4R+_5_B
M?YT_M3(O]6/J?YT /HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBDR,XR,GM0 M%(&#9P0<''%+0 4444 %%%% !1110 4444
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M[IM'N=DYB$FT[ACY3P>:@^'<WV+3/$<$EHS>,[9V?5!*^XW4N&,3*>FQAC
M 'ZD ]-HKQ_PO;VVL:3X;\3CQ#86]ZDZ-<FVM&^TW$K862"4^:2V2?[O'!
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MCLEU*$SR3M;(.=K2J,L@;&"P],U%X.OKK4O"&FW=]9)97$L67A0$*.2 5!Y
M888 \@&O)CJUO<C1[DB[MI+/Q&KW6EVUC)Y-GF1\L[;26D8GL<?-@+Q0!ZN/
M&WAHZBNGKK-JUV]S]D6)6R3+C.WC^?3/'6I+?Q=H=SJ46GQ7P,\Q80EHG5)B
MN-PCD("N1GHI-<?X5MK2\USQY!;M'+=RWQFMY73!&8@ RMCHKE@".GXUE>"U
MT6Y@T/1K_0=6_P"$DTEX]\%P]QY5L4(S,K,Q0+C! '7(&,'- 'H_BR6"+PMJ
M#7.JRZ5%Y1#7T.=\/N,<Y^E5G\8:!IC6]A<ZJSW1M%N$7RG>26/@!@%4Y))'
M YZ\<&J7Q1_Y)GKPVNQ-OA509)8L !CZXK TB6*?XD^&IQ&[QKX:\L2^4Q5)
M"R$#=C . W\N] ':Q^*]#FT2#6(K])+&X<1PNB,S2.3@($ W%LY&W&>#Q1'X
MJT633+S4?MH2VLI3!<&2-T:.08^0HP#;OF7 QDY&,YKRFU;4-'T;3]=BTJ\G
MMM*\0WMQ<VB0LLGD2APL@0@$@*^?H:Z/Q$]UKWA^'6]!T*86T&JVNH21-;^5
M/?)'R[;.K<;-N>3LX&,9 .WM?$FE7EU=6L=PZW-K$)YH)H)(I%C(X;:Z@D>X
M'7CK6&/BGX,:(RC65,?DM/N$,A&Q7V'^'KGMUP0>AJG*L?B3QOIVOZ:+C[%I
M^G7*33^0T8F9]H6+YE!?&') Z$#N<5R5A:RV7[,UY;7EC/:7MO:SK+'<0-$Z
MDRLP^\!G(*\B@#TC3/'/AW5]:_LBSORUZR&2-'A=!*HZE&( 8#V)Z&I3XOT4
M3Q(URXAFE,$=T87$#2ABNP28VYR"!S@G@'/%<O<P)XHUCPDVE6UQ"VF+)+/=
MO;O%]G4PE!%\P&69F4X'0+GH1G':QU._^$<?@J;2KJ#7$,5IQ;N8?DE5O.\W
M;LP5&XG.<Y'7B@#N+WQ[X>L-7GTJ>ZE%Y;RPQ2QBW<[3+]T]/N],MT&1SS4B
M^-M$;4(;033?OKMK**<P.(7G7.8P^,9R"/<@XK&T*-X_BIXF::UN_+GM;1(;
MF2V<1R%%;> ^W;GE>_/;I7%RIJ]ZVEW5UH.LV]U9^(X[FYLK>TVVMM$&<9C"
MX\TMD,7^;DGE0>0#T71/&D.KZQKEH]G<6L&ES>4T\T953A=S,Q/W1SQGMS5V
MT\6Z5>:I;:>KSQ3W<336OGP/&LZ#!)0L!G@@XZX.:X=]-U2\G^(6B1Z=?07&
MK_O;6X>/; 0T 7!D'&<C:0,]?3-2^&8DU>*U@/@Z]TK6;2"2*6]O("(X&,90
MM"Y)W%B1P.V<G@9 &_$CQ='-X<MI-'GOT*ZK!&MW"DB0R%7PR[Q@,."/0D5V
MWC)Y(O!&O2Q2R12QZ?/(DD;E&5EC8@@CD<BO)+B'7W^&&G>$I/#&K?VIIEY"
M)&2#="Z+)D.KYP00>W3J<#FO7/%<4MYX*UJ""&1YI]/GCCB5<L6:,@# [Y(H
M YCP1XXL&TCPQH]X;XWMY8QA+N>%O*FE" LHD/WF_P#U9S6W>^.]&L)6:?[0
M+%+G[)+J C'V>*;.-K-G/7C< 5!X)%<8=*U);#X7Q_V9>E].=/MF(&_< 1A#
MNXXY_P >E5]$T.?2)-1T#4? 46JW+W<DMKJ<T$4L$J.Y8&5VY&T'D<DXP* .
MZG\>:1#K4NDB.^ENX;B&"41VK$(9/NL3V7I\W3D8SSA)?'FE0W5NLD-XMC<W
M9LH=1,:_9WF!(V@[MW4$;MNW(ZU4\.B?_A/?%C26-Y!#<FW^SW$D#(D@CCV-
MM8C'7IZ]17(^%M$O-%A@\,ZGX M]1O;>XPFLR01-"\1<L)6<C=N4$?+U..U
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MK$L[?+U P<G)XH ])HK,TFXUB>?45U2R@MHH[EELVBEWF6'LS#^$^W_ZSIT
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MK4]% #617&&4$9!P1GD<BB2..:-HY45T88*L,@_A3J* &HB1HJ(H5%&%51@
M>E((8A(9!$@D/5@HR?QI]% ##%&91*44R*" Y'(!ZC-*44L&*@L!@''(IU%
M"8&<TN*** #%)@4M% !BBBB@ HHHH *,444 %%%% !6-XJT(^)O#5[HWVHVJ
M7:>6\HCWD+GG R.:V:* (;2%K>S@A=Q(\<:HSA=H8@8SC)Q],U-110 4444
M%%%% !1BBB@ Q1BBB@ HHHH **** "BBB@ HQ110 4444 %8L'AFRM_%5QXB
M22X-]<0BWDRXV;!@@!<<8(ZUM44 %%%% &3K/AVPUZ2RDOO/)LIA<0>7,R!9
M1T? ZD<XSQR:UJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH ***,C.,\^E !1110 4444 %%%% !145O
M=6]Y%YMM/%/'DKOB<,,CJ,CO4M !1110 4444 %%,>6.,H'D52[;4#'&XX)P
M/4X!_*GT %%%% !116=9Z_I&HWTEE9ZE:SW4:[VBCE#-MSC=CN,\9'&>.M &
MC12$@#)Z54T[5M/U>!Y].O(;N&.0Q-)"X90PZC(^M %RBBB@ HK(N?%7AZSN
MY+2ZUS38+F(X>&6Z177Z@G(JWI^JZ=JT3RZ=?VUW&C;7>WE5PIQG!(/!YH N
M45A0^,O#L\DJ)JUN#%#]H8N2H,73>I( 9<G&5R,U;TK7M,UMKE+"Z$DEJ_ES
MQ,C1R1-V#(P##/;(YH TJ*** "BL^+6]-FUR?18[M&U*"%9Y;< Y5"< ^G_Z
MQ6A0 4444 %%84OC'P_#)=1R:E&&M&*W "L?*(Z[L#CH>M:>GZE8ZM91WFG7
M<-U;2?=EA<,I_$4 6J*** "BBL^^UJQTV_L+*ZE9)[^0Q6ZB-B'8 L1D# X'
M<T :%%%% !11535-2MM'TJZU*\9EMK6)I9"BEB% R< <F@"W15>PO8=2T^VO
MK8L8+F)98RRE2589&0>1P:L4 %%%9%KXETV\U^ZT2!Y6O[10TZ&%@$!Z$L1C
MGM@T :]%%% !1165XAU^T\-:8+^\CG>(S1P@0QEB&=@JY[ 9(&3QR.Y% &K1
M61'XBLI/%<OAP+.+Z*T%XQ:/"&,L%&#WY/;T-:] !1163XA\06OANPBO+R.9
MXY+B.W'E+DAG.U<\\#/>@#6HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBJD%WX')/\SD YZW\5>+;7PMI.K7\EI.^NBRM[*&WA&^*60$NQW,JME!N R
M&..@R="76/&.F:)XHN;VV*0V5D]UI]Y=)#O)5"6C=(G(/3AN.O2M&?P)'?>
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MIU_>>P_*FR?"WPG-_K;.]?@#YM3N3P.G_+2D'B+6Y?B6-$2PA&F#3_M(D:X
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M 'DOB#P]K&L/X[CL;"42SW-E<6BSH5CNO)"[E#'@Y*D?EVJ=8HM0\*:RNF^
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MV;V)(]/AEB2W\DDN9,;R6W<<(N!CUK,/@BX?0/$NE2:JFW6[F2X,JVV##YF
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MCX&20!V ZD\?F*TZX+Q=)J>A>.-'\30Z=>ZEIJ6LMC<PV41EEBWLK!PG<94
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MQE#N91@@[ADC/%+=>%-5@U3P:-+-FVGZ ACD:XG=99%,7E<!4(R!D\GD\<4
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M#MA)=^7HC[[/]X,J>@W<?-@<?2IQX2L!=:W<":ZWZT@2['F#! 78-HQQA>*
M..O[W7_^$0\(:F(M0U'31IZ3ZJEA<-'=.S1)MD!!#, 2Q*@\_2HH-?F\1ZKH
M^A:9J,E]93:4]Z)GO9;&6=Q+LPSHK-N7!RHP"<GH,5V2>#;*&+3$M[[4K<Z;
M;M:P/%<8/E-M^5N,,!L7&>F*K:A\.?#>H:;86?V:6V;3V+VMS:S-'/$Q.6(<
M<DD\G/?F@#"N[?QA9^$;.WN;H:S<V=XQOXM.NFBN)[<*2%#C:V\$J2!@L !G
MDYZ3P-J5GJOAM;BRN[ZYB$TB'[>#Y\1#',;YR<KTS4I\'Z8MI80027MN;!W>
M":*Z?S-S\L68D[\]]V:TM*TFTT:T:VM$8!Y'FD=CEI)'.6=CW))S0!PKW+^+
M;_QI'<W=[:KH^;2UAM[EXMO[HL9653ARQSC<",*..N<;0M2U&^MO!OAJ/;Y#
M^'5NMB7TMEYK@JJ@21J7)5025& <Y/ %=YJO@31-6UF3594NH+J>+R;DVMR\
M*W*8P!*%(#@#CGMP<CBJ]Y\-O#5[H>G:5):S)'IO_'I/'.RS0^NU\YP?3I^0
MH Y*_M/$EC;>%=*OO$TYN)-7>TEFL[@DF$QLP5V(!9P.Y'H<$TC'5?#5YXUT
M*/7M2N[2#0SJ5K/=7!EGMY-KC <\XRN<?3WK4\5>%;:W_P"$0TG2K"\6PM-3
M\Z9K42%HE*/F0R#G=N8'.<]ZZV+PMID=EJ5LZS2G4U*WL\DS&68;=N"V<@ 9
M  P!GC% '!Z1JD^LR^!]!U.ZN3:WFB?;)F^T,K7<H5<*S AC@;F(SSGGI2>)
MO#]I'!X3M+K6+W4KBUU]+43&[D1U1M[;"5;[ZJ5&_P"]QU'2NOU+X?>&]6T3
M3])NK)S!IJA;-UF820#C[KYSV'7T%6+CP3H%QH5MHQLFCLK:87$0AG>-UE&3
MOWJ0V[))SG/- '$7VGZAXK\4>(M(M=2%H^EI#;VBR7=P)(1Y883C:XW-N/+-
MD\ $\\W-+DD\5>+9-$UF_:Z@TW2K>:-[662!;N20'?/\I&0,  =!DGZ=%JOP
MZ\*ZU>6]W?:6'G@B6!72:1"T8Z*VUAN';G-6=7\$^'];O+2\O+#_ $JT7RX9
MH)7A=4_N$H02OL>.3ZT 9/PJ18?!C6RM*X@U"\CWRDLS8G?DD]3SR?7-,*P^
M*?'OB#1M4:X%MIUK;"W@2:2(-YBLSR@J1DYPH/;:<8R:Z?1=!TWP[9O::5:B
MVMVD:4QJQ(W,<G )X^@J+5/#.EZM?PW]Q#*E[#&8DN;>>2"38>JED()7O@]^
M: /,;2XU75-)\*K=ZGJ$<L/B&?31<Q3E6N($$H!<?=9OD W$9X)SDYKK?!<!
MTOQAXLT.">X?3[5K2:".>9I3&9(V+@,Q)P2H.,^M=$WAK2&CTZ(682/3F#VB
M1R,BQ, 1D $ G!/)]3ZU+9Z'IUAJE[J=M R7E]M^TR&5V\S;PN03C@<# XH
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M&0O'%:'BS1(-&\)O:V.N37"'7K:0"W)C6T+G)CC() '0@<XX/>@#VHLH4L6
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M>Y2.9%"[X@IY&.Q(SW]O4_[.L?\ GSM_^_2_X4U[.PAC9VM;=5 Y_=#_  H
M\FU30_#^M>+/MFH^)M$O-/.B_P!G&:34D^TK*K^8)UXP&#>A[^G%=3X6\96-
MGHT%EX@\5Z)=W\6$-Q!<_P"L'JV0.?<=>O%=CYUI"S0H$#0IO*1IDHI]@.,\
M_6F:9JMCK-H+O3KE+FW)($J9VDCK@]Z .'G\9VUIK5]>6/BCP]<V5R4*6MU=
M&,QL$"DAP&X.!QM[=17&>(KWP_IGPUU:RL_$6DSZGJ.K1ZA(ELX\M'::,G:N
M<[550?P)XKWBJ]W86=^BI>6D%RJG*K-&' /J,T >8W.LZ+KVK1:AK7BS0+=[
M.UFALEL;G<4EE7:TI9@.0 -H'OS6;H$-G%?^%#)XN\-SKHL$ULUO;H3YL;JJ
MLWWN7(4DD@ $YP><^S1HD4:QQJ%10%51T ':G4 >4>'X!X4N$TZ'QC"_AE+@
MO!;);%[A<L7V%U7A,]3Z''&:J1W5IH^IWL>E^,;FUT/4+B2XGMVTN9YHG<Y8
M1/LX!)ZGIVYYKV*LH>(+(^*O^$<VS?;OL9O<F/$?EAPG#=SD]!0!?M+B&ZLH
M+BW8M!+&KQLP()4C(R#R./7FN4\7V7_"3ZEI6@P .MM>Q7U^_:*-,E5/^TYQ
M@>@)KL:Y*3XAZ)#?:E:O!J6_3647S)9.ZP!AD,Q4'C'.?04 6M)77T\5:N;V
M]6XTE]AM4-N(S"W=0>KC'))]1CO46N^%[[4?%.F:[IVJK9S6D,ENZ26XE#1N
M025R1AL@<\UOV%]::I8P7UC/'<6LZ!XI8SD,#Z59H \ZL/AI>V.B:5I@UU94
MTS5CJ4+26V2Y#,55CN&?OMD_3 ]=34/ 4.JZEXDGO;]GM]<M8K=X8X@IA\O.
MQE8DY())Z=<>E=C10!PUKX'UEM3T*^U3Q3)=OHTDAAQ:(ID5EV?.<G+%>I_3
M/-;?AJ'68)-475;Z2\B-T3:R20K&0A&< +U4$X!/)P>V,V;O6Q:^(;#2/L%[
M*UY'(_VF.+,,00=';L3G K5Q0!R&K^";FY\4'Q!HWB"[TB\FB6&Z6.)98YU7
M.TE6XW $@'G^=7CX51[O3O/N?M-A9PR(;:XBWF:5^&E9LX+8+#&,?,WJ,=#1
M0!P$7PQ1O!X\.7>L2R06UR+K3IX8C')92 DKM)9L@;B #S@GGIB\W@%=1T2^
ML?$.M7NJSWBHANMJ0M"$;<OEA1A3NY)YR0,\ "FS_$G2X-/NKQ].U<+:7_V*
MXC-H0\?!/FD=H\ G/Z5V= 'G]WX8?0?"^L7FM>(KO5Y(]-GMX9+T*JQ(R],
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MBZMR,<. 1SQTY!^JCTK6HH RK+P]IVGZ_J6M6\16]U%8Q<-G@[ 0,#MP>?7
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M&<  6;+PII=C+/.@NI;F:V^RFXN+F2658LD[5=B2HR<\=\>@K;IKR)& 9'5
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MTF<L9$/!);+>@)]A5F?P)<M?Z3J5OXBO$U.RCECENI8DE,XDQN.T_*IX&,#
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MTLS0P!Y&F=5FACYPP;[P[XQ[UUU49]&TNZOH[ZXTVSFO(QA+B2!6D7Z,1D4
M8/AK5TT;PAX>@\1:@L5]=(L$1N6P\K8RH.?XBN,Y[^]<%XXL_%]E8>=?6VB2
M176NVTJSBZDWG$@$2,"F H4 '!]3R2:]8U71;'65@2^MXIDAF29 Z@D,I# @
M]1R!TZC@\&KLL$-P@6:))%#!@'4$ CH>>] 'G_B"P\8R&[U6:#1'CCTMX?+-
MQ)^X++F5D^3DG  )/11TR:TOAP]TWPUTAM0-K'"+&,1/"Y.(@@Y?(&&ZYQQ7
M8LJNI5E#*PP01D$5&+: 6WV80QB#;L\H*-NWTQTQ0!R/PH:(_#72%AD$BHLB
MY!S_ ,M&Z_ABNSJ&VM+:SC,=K;Q0(3DK$@4$^N!4W6@#Q:31I?%3^.$T>_'V
MNVU7S4L1-F.Y*H-R2Q[MI5R,9/<'-=7:^,?#.K^!H?/MK..T)CL[[3)2 ;/+
M;"K)C.%/L.!GC%=M;V%G:.SVUI!"S##-'&%)[\XJ7R8@Y?RTW'J=HS0!Y/H6
ME6_A7XAZ9:>#]9-YH>IK+)=:8LPFCM5"Y$JMD[06P.>3TR>TOAW1=&\5ZGXX
ML[B[E<OJSX2"]=1@(@#%%8*V&!Y(/3%>H0VMO;;_ "((HM[%F\M NXGN<=33
MUB1"2J*I/<#% #ZY'Q_#:2V&F--KJZ)=0WRS6=Y(%,:RA'&'#$ J5+#J.2*Z
MZFLBN,,H8>XS0!XK?ZC:ZCIWA>ZUNTL88H_$DL5Q<*/]&NAL?=,N[_EFYP3V
MR#VIWB 64-YXVUO3M-@U3PX^FP1W$%FVV.YNO,!W;DZ[5.6(/0_EZ1XB\.3Z
MUJ&A3PW$,,6F7?VIHWC+>:=I4*"#P,,W8]JZ!455VA5"^@'% 'A[W4^J>)->
MATW5?[1O;[PJT=G-#;&)'82/\D6!]T @ Y/)ZUTVA>(]%\3Z18VVAZ<\6OV=
ME+;*C0%'TP^65.YB,#YE4 9R<YQP<>E!%4@A0"!@8':@(JDE5 )Y.!UH \=\
M$/X<U&T\/:3>0:JWB31WCWZ?(TVVVE7AI3QL"XRW)YS@9->R4@50Q8*-QZG'
M6EH \VAU=-$\3>+=/UY)_/U*7S;!Q \B7$'DA1&N%QE<-D>Y/O7'6+2Z=H/@
M/4=2CU8:(FGRV<YL/-CEM9F=3O.S#;2%QQG@' YY]Y(!ZC-&* /%O%L&A1Z%
MX<NK"RGBTJY\5V\\K7?FL;G(;?(4D^;!Y'3G&<=*Z2:&WOO'>I:[IJJ;"+09
M+:[N5X260MN11_>*JIR>V0*Z'Q;X6D\3R:*5O5METS48]0P8MYD:/.U>HP.3
MGK72#]: /%+.ZN-$T/X<>(6L;FZTS3X9[>\$4+,]NTB[-^T#/!!!XZ?45N^*
M+RVNO#%OJ^G:+<6UA%K]M>R,MJ4DN%5@7G,> V#TR1DXSTQ7I]% 'DVJWMG:
M^-M2N=;TO7)M'UJU@%I/9BY4-A2K12)&0><Y 89Y/KBI+$2>#_&]E?3Z1J%M
MH%SHZ6EK'#$]R;-Q)N\MPNY@3D<\C/ )QFO5:* .!^%4-S#8^)&NK.ZM3<:]
M=7,2W,#1EHVVX(R.>AK;\>Z5?:YX$UG3--S]LN+9DC4-MW'KMR?4 C\:Z.B@
M#@[N1_%C>$WLK:]M)[.^CN[HS6\D1@18G#QDL!G<2$XSG.>17&?8+YOA#XXL
MUT^]^U7.KS20P_9GWR*TD95E&,D$ \^U>WT4 5[)Q)8V[@, 8U/S*0>G<'D5
M8I*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *R-=\3:3X:2V;5;B2$7,@BAV6\DN]
MST4;%/S'L.IYQTK7K@?BO&9-+\.[5W.FOVC(I;:"PWX!.#B@#I+3Q7I5YJ$-
M@AO8KF<,8ENM/N( ^T9.#(B@D#G&:VJP[2;6KG65CU'2K2WM(X#)'/%<><PE
MSMQRJ[?E)['.37,Z=XCU_P#X2N;P?J,\0U!9OM$5^@15EL\=D/\ RUSC(QQG
M=T&" =A::[87VMW^D02.;VP5&N$:-E"AP2N"1@\#M2:KKMIH]QIT%REPS7]R
M+:'R82X#D$Y;'0<=?Z9->?W$.OM\2?&;Z9J$=@4L;66.5X!*6 C;  /&"V[)
MZ\<5H6OB[5KWPYX%U598HSJUY';7L8B!WY1R2I_AYC/_ 'U[4 =?I/B#3];N
MM2MK-I#+IUQ]FN%DC*$/@'@'DCGKW^E.N=;M[77;'2'@NFGO4D=)$A+1($&3
MO?HN>W_UQGR^VL_$T_B'QY/X=UNWTUK;4%F9'M!*;AA$"$+$X5>.P)YZUKV_
MC/5=5\0^ ?(F%M9:_9W,ES;K&K%72$L"&()QN/Z<T >DJZNS*K E#A@#T. <
M'\"#^-.KS[X96-W!=^*I;G6+V]*ZU/"5G$>&*K'ASA0=V,+@';@<**Z/Q?J$
MUAH$J6GF&\NF%O!Y<;.P+?>8*H).U0S<#^&@"]I&M6&NVDESITXFACGDMV8?
MWT8JP_,=>XP:T*\I\$7-GX8^(E]X8L;>ZMM(U2 7MBMS;RQ$3(H650'49R &
MR/3K7:^.M0GTKP'KM]:MMGALI3&P."K;2 1[C.: -.SU:SOTN9(),PV\K1-*
MPVH67KM)X(!XR.,@CM5=_$%JGBJ+P\8I_M<MHUVLFT>7L5@I&<YSD^E<)XRL
MAIOPET2&SOYDBMFL4WVS#;,"R#<<@Y'\0[9ZYJWJNG7DWQ3TNT@U:X@D_L2<
M27>Q&F*^:OW<KL!SCDJ>,\9Y !Z-17DMAXG\02:!I.DF_::_N-;N=-:]++$[
MQPASU*L S;0,[3^?-=IX3B\0VDVI6FNW-O/$L@ELL7'FS)$V?ED.Q<@$<-U/
M.>E &S-JMK EX[,2+3_78&2#@-C'<X8?G65K7C"ST.\TJUGL[R:75&*6P@52
M"XP=I)8 'GN:DNO!NAWNJ:CJ,]HS7.HVOV2Z(E8"2/@= < X Y'/%<5XUT=-
M$O/ .FZ*B)]FU I;+<.S*,+QN/7% ':Z1XLL-7UF]T?RKBTU.S57EM+I0KE#
MT=<$AEYQD&M[->9^ MNK^-]<U;7<Q>*[0?8GM  L<-OG<IC[N&_O'] 16?IT
MWBSQ3:7&OZ=J=M92P7\V)9]0D\F.*-V4PO;A-F-H!+D[N<Y'2@#U:[N/LEE/
M<^4\OE1M)Y<>-SX&<#) R?<BJ'AO7(O$GAVQUF"%X8KN/S%C<@LHSWQ7)0S2
M>,-1\6++?WEI_9,SV5I%;W#1B,^6"9752-Y+9P&R,+C'4G \$SW$'_"L88KF
MX2"YTV\$\*RL(Y-BJ5)7.,@NW./Y"@#V&BO'QXANM,T_78)=3NH[>3Q>-.:Y
MDN&9K2W94)VLQ.T<$ ]!N)K9\52S^"/#FN26&L74IN'MS'%<W#R-8H[K$[B1
MRS 'DC/0@XS@T >CUSOB3Q2/#NIZ#9FR,XU:]%GY@D"^42,YQ@Y^G'UKC)K?
M6O ]AK&OP:A;&W;3))(M-6\FNE:13D3JTG. &7=C@]<]!5#Q%I-G;ZC\.M2@
MO+J[FN]5A>:>2Z>19V902^TG:#Z;0  < 8XH ]6UC4#I6C7NH" S_986F,08
M*6"C) )XS@5%X>U9M=T&RU4VK6R7<2S1QLX8[&&5)QWP1Q4?BD,?"&M;<;OL
M,^-W3_5M5+P/*D?PX\/2NX$::5;EF)X $2YH Z2BO)]16[\:>+O$NEQ:A;VY
MLX81:>;-,C1QO&&\Y%1E!^9N20>@'3BGZB)M3O;/3[C47UR\AT1I)8XY&LX
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2ZB;6G8.PZ,,Q_*>^1@YYHLO#^K:3HMSI5AX&TDVEVN+A+C67D\SC&"S1DX
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HI,TM !1110 444C,%&6( ]2:
M%HIC2QHH9I%"G@$G@T^@ HHHH **9%-'/&)(9$DC;HR,"#^(I] !112,RJ,L
M0!ZDT +13%EC8X612?0&GT %%%% !115>.^M);R6SCNH'NHE#20+("Z ]"5Z
M@&@"Q1110 4454OM4L--:V6]NX;<W4P@@$C >9(<X4>_% %NBBB@ HHK);Q-
MHJ:O'I3:E;B^D8HD6[[S@9*YZ;@#TSF@#6HHHH ***I:MJ]AH6FS:CJ=TEM9
MPX\R5^@R<#]2* +M%4)=9TZ#4[+39+I%O+U6>WAP2SJHRQ]@!W.*OT %%%%
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M72O&6OV^M^"]3UVVU6Y%Q93V<8DC(**"C_,H7!7J?_KD ]!U/QEI.F#.+J[
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M]0N/B/KFH7%C+%IFH::+);@21DY&,G&XG!R<<=CD#C,7@^S\8Z/#9>'+W2;
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MOG,'#J/XALP 3GD$_2@" ?$:&ZT'P]>6D$276MH[1I,[,D(0?O"=H+-@X48
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MD8R>:LNT<'@*5SZG*]L@5>30]1O]9T_5M8-F9M-BD%M#;EBC2N #(2PXX!
M!QN/)J3P5H%UX7\,6VC7-S%<?9B^R2-"N0S%L$'TS0!/XGU*_P!+TZ&6P2V#
M/<)'-<738BMHCDM*PW+D#&,9')%>?ZUXGE\5_"7QE]KCA\VPGEM/,@5E2959
M2C@,21D$'J:[3Q?X=U#73I,^FWUO;W&G78N5CNHC+#+P1\R@@DC.1SU].M<\
MWP[UF30O%6F3Z[;2G79_/$HM2IC8[=Q(W'C"X '3N30!H:LX3XC>".F7M;Y!
MG_KG$?\ V6NIUFZGL=$OKNV$;3P0/*@ESM)52><<XXK(OO#MW>>)?#FK_:(4
M_LF.99(]I/FF1 IP>V,9'7K6SJT<4NC7T<S[(GMY%=LXP"I!.30!YWIWCCQ4
MVF^'O$5_:Z8=#U.6*WFBMQ)YT+.=HDR3C&_MV!')/-:<GC/5$\,>,M1\NS^T
M:%>30P 1MMD1%1AN&[.3N(R"/I63X T*_P!=^'7A:*^N[;^RX#'=>5%$PDD*
M,6168L0 & )(ZXQQFM'4_A]JUR/$MG9:]%;Z7KK//)"UKNDCE9 IP^[&TX!(
MQGC (ZT +J'B;Q9<^*+?1-$CTE6N=#&HI)=*_P DF]5(.#R.<#ZY.<8-=]?\
M>:CK?B32M*715ETAH2KRQR8EWQ;]@&[KSC=G''3GC;L/">H6GBS3M;DU."46
MNE_V;)&+8J95W!M^=QVG*KQSWKG]'CU6Y^)WCZ/2M2M( S6:N)H3(R'[.!O7
M##D<C![@=,'(!HZ'XVO?%O\ 8L.F+#9/=Z<]]=O*AE\K$GEA$&X=7#\GLOJ:
MJ/X^U.VT/5DN[=3J6C:C':7TUI"TJB%B#YZQYS]W/&>#SSTK4@\ IHSZ'<^'
M[M+:[TNV:T8SQETNH6.YE?!!!W_."#P<\$&KD'A6[L(+J?3]52#5;R^%[=7+
M6NZ.7C;Y?E[@=FT ?>SGG.: ,;_A,;YM,L4LM1L=5N-5U!H;*YLH@0(5C\QM
MREP!(-I7!8<D$\ BG7.O>+](\-ZU/?:5,\EK)%]DNMD;O)"Q4.S11.WS1_,>
MH#8'3FDN_ABEUI]Z8M5>QU2?4AJ<-U9P[$MI0NWY4SR"N<DGYB<GTK6C\,ZZ
MND3I)XKFDUB62)A?FU541(WW!!"K 8.6!YR=W/   !)X-UU=?MKJYM]8MM4L
M0RBWEC0)*HV_,LJ\8;/L.".*S_'6NZ_I6K>'+'1)+./^T[IK>1[F%G"G;D'@
MCWX[XZBM3P]X671=6U;5IKB.:_U1HS.8(/)B 1<#";FYY)))).:Y[XEY;6?!
MB07<-K>'5QY4KH'V QL/NDC()V@\CMWQ0!CZGXS\6>'K/Q7I=_=65SJ>EVD5
M[:7L=ML62)VVD,F[ (/3^M;B:OXGL;?2X-0U&QFN]<NHH[5H;8J+:/RVDER"
M?F("X!)Y)SCM5V]\"-JFEZY%J&J>9J&L1I!-=16X18XD/RHB%C@<MR6)RWL!
M5[4_"8U7P_I]A+?21WNG/%-:WT: ,DL8P&VYP01D$="">E &0=6UN#Q3J?A'
M^T!+>2:9_:&FWK1*&4[BA20!=I&X#G X)[XJ/PIXGU/Q)I'AQ1<[-09YFU4>
M6H*K#E63&/E)=H\=]N372:7H#VVK2ZSJ-VEYJLENEJ9DA\I$B4EMJKEB,L23
MECVZ8J/1O"EEHGB#6]7MV8RZK*DCH1Q&0N#CZG+'ZT <M/XXU'2K?QK<7$D-
MTVFWL5M80L FTR!0H<\?+N8<D]CR*-2@OM-^*/A22^U26_3[#?-\\4:%6"(6
MQM X/& <D8ZUK'X>65U_PDT>H7<ES;:^ZO-&(PAA*_=*-SR..O<4FG^ Y[;6
MM)U.^\2ZCJ$NF120PK,D8!1PHPV%R3@<G.3QR,<@&1H.M>,];M]$URS1IK.\
MDWW5O*;=8%@8GF,J3)O3@<]<'(%9OB34-4\5_"GQ%KT6IO;VCB>.&Q6*/9Y,
M;E#O)4MO;:3PP XXZUU&C_#JWT:[,<.LZC)HJS_:(=)=E\F.3=N'.-Q4-R%S
MC.,YJ&Z^&D,L.J6%MKNHVFC:D7>;3XPA19'^\58@L 3SMSC/MQ0!V5E_QXV_
M_7-?Y58J&TM_LMI#;^;)-Y2!/,DQN; QDX &?H!4U !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 445R?Q \8)X/\/BX1X!>W$J0VZRL  68 N1W"@Y_*@#K**YBQUI=
M*MY[W6_$FG3Z9<2!M/N&VQ,4V_,&(^5L'N!TZ^VO+KND06UG<2ZG:)!>LJVT
MC3*%F)Y&TYYS[4 :%%5--U.QUBQCOM.NHKJUD)"2Q-N4X)!Y^H(K-U&:5?%F
MC1)KT-JC),7TQHU9[OY>&!SD;>O% &[16!-XX\+P2QQ2Z[8J\DYME'FCF08R
MOX$@9Z9XK?H *AFM+:XEAEFMXI)(&+1.Z F,D8)4GH<''%8)\9:<_C!O#4;N
M+I8/,:0QOPY;:JCY<$?>).<# '/.,#P;XYM(M,^S>)->A;4I-1N;>$RX0N%E
M*J,*,#T&: .^%K;K=-=+!$+AT"-*$&]E'(!/7')XJ6L;5_%>AZ#,8=3U".WD
M""1@59MB$[0S8!VC(/)P.#Z5L*ZN@=6#*1D$'((H 6BN)\2WFJ6OQ#\+6-MJ
MEQ#8ZD;@7$"JA!\I PP2I(R3SS7:]!DGB@!:*PM/\8Z%J>H16-K>EKB>%IX0
M\$D:S1@X+(S* X_W2>.>E)IWC30-5O[>RL[XO-<K(UON@D1)PAPYC=E"OC_9
M)]>E %?6/#&I:KJ3W,7B.>UA("I MC;2A!MP<-)&S<\]^]1GPWXCQ_R/6H_^
M -I_\:J];^+=(NM3CL(I;@R32O!#+]ED\F61 Q=5DV[20$;OVXS4*^-]!?5(
M+ 74H:XF:V@G:WD$$LP)!C60C:6R#T/;'6@"F?"FOF=9CXWOS*JE0_\ 9]GN
M /49\KI3_P#A&O$G_0]ZE_X 6G_QJNKJO?7UMIME->7DRPV\*[GD;H!_7Z4
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M*J2!,IV&,]3UY^48YVX;S6I?C#=6#7\!T^#2TF6'R&X#R$$9WXW?(/F(/'
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M3F*V<1E6"&1RIWD !0.ASVJCH-T]SKG@>_6PU<"UDFANH8].>&UL9&@9?*1
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M^HH YJP\%WNBZKJ<&FW-JWAO5&+S:=*K*T#.,2&)EZ C)VD8SZ5%X6\(^)]
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M_P +]$U31?"\^FZWI;6LJWLDZ;Y(Y ZLVY2-K'!!]?;'MW)&5(&,X[T >/\
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M6R@@M9Q,V]6CSD, O 8,PR#D?CP :.A>++K4?%=]X<U&ULDN8+1+K=:7/G*
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MR,^V)6*LC%@,M[@ 5%H_C/7;_4=&+:0\UCJ49:1HK*XC^Q$KN3=(Z[9%/0D
M<\C(ZWM2\(W>K>,)M3NI;<:=<Z,^E3P*S%R')8D'&.IQ_G%1^%O#7BG1H;;3
M]1\06]UIEB MN(K<I-*H&$61LX"CCIR<<G&00#F/^%F>)D\+W?B673=+33M/
MU,VEQ&'D,DJ>8$RO88W#DYSSP,<]A=ZU?ZKJVLZ9H\MDD>F0J+B29&D+S.NX
M( " H"]3R<GIQSAR?#6\F^'FI>&'U*!9+^]-TTXB)$>75RH&>>5QGCKGVK5D
M\(ZK:>)-3U;1=5M;6/5HT%[;3VAE42*NWS(R&7!QZYR>3[ '&>"?$TVA_##P
M?IUDDAN=0%V1(EH]R8TCE8L1&G+'+*.H'4]L'I;?QCKT>F6UCJ&F?9];N]1-
MA:320E(9DP6^T;"=RC8I.S.<X'&3BO:_#/4-/\+>'[+3_$ M=7T1Y3;WJ6VY
M&25LR(R$_,#QSGL.*T=2\#:AJVFV\MUK[G7[:\6]M[Y( (HV4;0@BS]S!.1G
M))R3VH K:!;ZA;_%W65U*6VGD.D6Y2:"$Q>8OF28+KD_,#D<'H!TZ4SQ_>:Q
M'XQ\&V%AJ*VMO>7DF]?)W_,B$@GD9'S=..1GGMMZ+X;U6S\3W.NZIJT%W-<6
MB6S1PVIB5-K,PV_.>/F[Y.<\]J?XL\+S:_/I%[97L=GJ&EW)GAFEA,JX*E64
MKN'7(/7M0!2_M37];FUH:)?6<*:5*;0>=;>9]IG5%=\G>-BY8+[<GGI6OX0\
M11>+/"EAKD41B6Z0DQDYVLK%6&>_*FLV/PEJ&FZOJ5[HNK16\>J;7NX9[7S
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M: $\.3O=>%])N))/,>6SA=GS]XE 2:TZBMK:WL[:.VM88X((E"QQ1(%5 .@
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M'/"ZR12*'1U.0RD9!%>5>"+Z^TJQ\5BQTF6\1_$USOD#+LC#-&K$KG<0H^;
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MEN&DRT+0@\OGY0N.Z@5-H]G#'\4M%MM<^S3ZG!X3C64RX8F8/ACSWV[N?3-
M'I$NM:7!IL>I27]N+*0 QSB0%9,]-I'WB>P'6L'Q7XD)^'.I:]X<U2 M% 9(
M+E561<@X(P>,]N>A[=J\YT35K#3?!_AF-9K6!$UN\2+4)V9H;+!DQPI +,KX
M4-QSFIK>^M5^%GC^V%S+))]ON"HN8]DK^9M"97 P6.<# ^E 'M%NQDMHG8Y+
M("?RJ6J]A)'-IUM)$ZO&\2LK*<AACJ#5B@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF2:Z"_O71=JEN^!Z#H/859JM?:A9Z99O>7]U#:VT9 >:9PJKD@#)/ R2!^-
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M< #\.]6+C3+"[O+>[N;&VFN;8DP321*SQ9Z[6(RN?:LK_A-?#PAOY9-0$/\
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M=% AWG)&X#+<]R?PK0U+3+J[O+>XM=2>U\M'CDA,8DCF#%3\RGTV\$8/S&@
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M0NI0(I,Y# ALY!Z>F3CK714 >#>(;>6\O_%'B[1[9)=)TW4Q!JFC32%8[XP
M>9*P!P""00.^W)!SM/L5Y=1ZIH%Q%:L/M-U8-+% 6 DPR<<=N2!]:AN_!V@7
MU_+>W&G*TTS*TP$CK',5Z&2,$*Y'JP-!\,V9\9+XC\B)+I+;[.)$+;W&>C<[
M<#C&!GWXQ0!Y?<QO=_L\Z%ID.%O;BXM[.., @^:+C!!QT(VG/T-1?%>;Q!_P
MCWBB?4/#4JVDCQ00ZA]KB*0P).I7$88MES@G@=5!'RUZ_'X=TF+5#J26,0N]
MQ<2<G:S?>91T5CT) R>,YP*L:CIEEJ]A)8ZC:Q75I+C?#*H96P01D'W /X4
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MQE(8_P .6VC!QG'M3-6FLM1OO&OAJYU33IKS4-17[-=WES&C6P 4LFUR&Q&
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MEJODLOGJ#@E,_>Y5AQUQ73:C8?\ "5^(O#L^D6\UNFE17'G7<ENT/DEHMBQ
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M7M.\.V0O=5G-O:[@IE\MF52>F< XSTK2K@OC*-WPPU%<%LRVXP,\_ODXXYH
MWX_%=BUU;036FI6IN9!%$]S9O&A<]%W$8!..,]:9K/C+3M%N9X)(+RZ:U1)+
MLVD7F?9D<D*7&<\X8\ G )J6-]:GU:VCU#3[)++8[EH9S.1("I3.Z-=O\7(S
MSBN(\+:??3_%7Q\@UN\C,?V-694BR^Z%]N<H0-F>,8SWS0!U\/C2QN-3M[6&
MSOY+:XN'M8[](=T!E3[RD@Y'((R0!E3SQ725X[X>U"^\._#=;FTU.YN9]2U>
M2QM%*1%8W>Z=2ZG &2 Q^8[<D=!Q5W5O%/B_P=8ZW?ZG;F33O)5K!KV6%IDF
M9T3:1%@,@W%L^V,\T >J5EZOKL>E65M=I9W=_'<3QP*+&/S2N\X#GGA1W/N*
MYW5=-UZPTO6))/$\]Q9MI3F,E8XYTG0$ED*H!M(Z]QVQUKF9M1U?P_\ ![PE
M=Z9JERDTSV*-OCC;*.J@H/E^[Z'K[T >NT5P6L:]>>%_B1:_VGJ4I\.ZC8S-
M&CHFVWGB&]OF"[B"@.!D\DU6O=7UV.7PIHIFE-[K/VBZG\R9875$0,(0ZH<8
MWKR!D[#SS0!Z-25SG@^W\06=I>6OB"\M[J5+AFMFCEWR+ ?NK(=JY8<C..:R
MX[NZ\4>,O$NE)J=W8P:1'!#$MLX0F61"YD)QDXX !XX/K0!W%%>-P^*?$?B"
MP\"2KJ-Q8S:E=3VMV;=%Q*(\@R $''0GT'IQ75>!+^_/B7Q=HEU?W%[;Z;=0
M_9Y+E@T@$B%BI.!D CB@#I=:U^TT-+<3K)-<W4GE6UK  TLS=]H)' '))( '
M6J\7BB%=9@TO4;&ZTVXN5)MC<F,I.1U561F&X==IP<=*Y75B\?Q]\/FZ<"VD
MTF=;0'/^N!)?'OMQ3/C*DLVE>'(;+G4VURW-H%^]N ;)'TXS0!Z547VF#[5]
ME\U/M&SS/+S\VW.,X],UY_I\EYXPNO%#C7+S3+S3-3:TM5BE(2"./:0[Q@@.
M'.[._/' QBJ-@T7_  MWQ-J(DN[E;;28+F)8;F3#\%L!=V"I[*<CGI0!ZG6!
MI_B=;_QCJWAX6CQOIT44C3%P1)OR0 .W&.]<)+J.I-\)(?'%MJMX-7PMXZ_:
M7:%\R;3#Y6=@7!VC SD>M":(/$?Q9\7VLFH7]BGV*S;-G,8FW>7P2PYX/..A
M/7- 'K5%>*Z%XFUO5+7PWHFI:@CF>ZOH/MDDC1K?^0P5 60@\[FXSSM&<U;\
M16^N:)H6F:<OB.>2X/B2"!'MI7WP0R L(F+$[\<$;L\8H ]?K"'B//C;_A&S
M8R(WV%KW[0SKM90ZI@ 9/4]\=*M:%HR:%8-9QWE[=(97E#WDQE==QSM#'G [
M5S<T8?XW6K<_)X?D/!QG]^HY]>M ';UBZ]K5[ICVUMIFCRZI?7&YEB698D1%
MQEG=NG4 <')-:HN8&N6MEFC,ZJ&:(,-P!Z$CKBJVK:M;Z1:>=,'DD<[(((QF
M2=\9"(.YX/L "3@ F@# T3QY::AI>L7.I6DNE7&BDC4+>5@_E87<"&'# CI2
M:5XSGN=0TBVU/35LEUJ!I]/99_,)"J&*2#:-K;3NXR.H[<\_XIT"2#X=^+27
MC;7]3B^W7L<;[BJ @!!WVJBE0>YS^%S794U2[^'L%DS,\ETE\CH 0(8X3N)Y
MX!#J/Q^E $^H>/M1TGR-4U#P\T/AN:981>_:094#'"2M'CY4/'\61D?2MWQ!
MK]WIEQ:66EZ8FI:A<!G^SM=K!MC7 +98'NR@#'//I61XCNM+\27HT6YNK9-*
MLYEGU"66555W0[EA&??#,1P-NWJ3B?Q-X3\*>+%DN]0\D7D-N&CO8YRDEL@R
MRN"#P!DGGB@#I--FO+C3X9K^T6SNG&9(%E$@C.>FX 9XQ46L7-]::>9-.M$N
MKHR1HD;N47YG"EF(!( !)/':L7P7K%Q)X)T*;7[N)-0NX@JF9U5IR2=A [LR
M[3@>M=30!Q<7BC7[CQ9?^'8=.TW[3:6J7/F-<N$?=P!]PD?6NHL;R232[.XU
M"-+.YFA1I8&?/EN5!9<]\'BN-TK_ )+AK_\ V"H/_0JY_P 0Q6.O?$+Q#H^N
M:E9:>%LX8[,WT".'A9"7:)F("L')SCG@>G !ZZSJOWF X)Y/8=333+&(O-+J
M(\9W9XQZYKR*'0;#4?'OABSOKA]8MVT2;?<7&5-VJR#87&?G&,=<YZFL^WET
M^S\'66BW'SPGQ3<6]E:/-LMPL<K%4F)!_=@\[>2>/>@#VJ*ZMY[<7$,\4D!Y
M$B."I_$<4C7ELHF)N(1Y(S+EQ^['JWI^-?/6HO;2_#SXB6BRV$D<&K0S6Z6N
M!&A,D:LT8!)"\XR/4^M=PVBZ;I7QBL;2QLH8K>_T.;[7&%R+@[\Y?/WCGJ3R
M>] '6W7BEK_P=/K?AQK.8H6V->.4C*JY5F..<$*2/48K8CU6"/2K6]U&2*P\
M^-&*7$@38Q7.WYL<CG\JX7X(BP_X5IIZ0I;"\S(;E4 \S_72!2_?H.,_A6GX
MVL;NZU?2Y]*O=/\ [3M8+@KIM^@,=Y"VS> 3]TC:!GT8YX)H [2.1)4#QNKH
M>C*<@UP-KXE\5ZG?>)[:Q;1E;1IO+C$UO)^^^4L,D2?+TQT-=#X)O+?4/!>E
M75KIYT^"2 %+7=N$0R1@'N/0^F*\P_L'4/$FI?$2'1M2E@O8M1C98DF*QW "
MG=$X!Z-@C_ZV: .RC^)44WPH/C:/3Y<A,&V)X$F_R^O]P-SGT]ZT=.O?$7VK
M1I'U#2M6TV^=EFGLK=D\O]T[JRMYC!E)4#/N*R+#QCX6N?ANMQ)86T&G1-%9
M7VF.!BTW2+$P=<=%+9Z<@5S]AH4?@KQKHO\ PA6MM=:1JMSLNM(67SUCCVY,
MZG)PH^7GW R<XH Z73M9\2ZMXX\3Z''J5A;V^D&W,<C6)=G$J%\']X!QC&>_
MM76Z*^H/ID9U-X)+G<P,MNNV.5=QV.HR<97:<9ZYKSC0]/L=?^*_Q$@DNKC:
M5LD!M;R2'_EB5;.QANP1CG.#]:].T^T%AIMK9A]XMX4B#$8SM &<=NE '(>&
M/%Z^9KJ>(]:T^$V^LS65IYK)!E55,  GGEO<\_3'4ZAK>DZ3M_M'5+*SW*67
M[1<)'D#J1N(XKR>"V\+^3\0(=?AL#J$VIW)ABN%7[0ZE!Y9C!^8Y;.-O4UF-
M=/8Q_P!D:S,;'74\+K#/<W"F:6[1MQ\B-"2,CHS8).#P,9H ]KO-<TG3X89K
MS4K2"*<;HGDF4!QQR#GD<CGH,UGW.H>?XAT,V?B*RCM+B.5_L0".U\I3*LC9
MR%7!.1P:\TMKNS?PSX0OM,\4V^D:S9:*$B6\*_9[I<)YD3;B,89 ,CI^'&I#
MJ,=SXC^&-Q<6<6F3/;W9:TSCRMT050 >0">GUQ0!Z%_PDFB_VF--_M2U^V%S
M&(?,&2XZJ/5AD<=:NWE[;:?:O=7DZ00)C<[G &3@#ZDD #N37E-C</I?BJV;
M1-035=-U#6':?1[A,7-E(S.'G1ASL!!//!!Z\UVGCZVTZ]\.I;ZE>S6$;W,9
MBO(>L$JG<CGV!'.?TZT 8_CWQ?):^'++4O#VK1J!JL%I<,BJPPQ^9&W [3C!
M['FNMTSQ'HNLR7*:9JEI=M:X\_R90VS.<$X['!Y]J\=\076I:IX6GL]3%KJ/
MD:[9XU2T3$5^NWYFV],J JL1QT':NEU1X;#XFZY-#IXNH#X5(^RPC N75V(C
MX'WBF!ZX- '=V/B;1=2OULK/489KEX?/1%)_>1YQO4]&&1U&:X*W\1:[<?#O
MQQ?MJTRWNF:A>16LXCCRB1JI5<;<>O.,\]:R_#U]')XP\$SBXN9H8[&> 1)8
M/'%:$QQA85.W)P!R23TSP*6Q<+\,/B*C9#SZG?&)<<R!U4)M'?.#C'6@#UZT
M9YM-@9I&#O"I+C&<D=>>*X;PEX\TV#3(K/Q#XAA;4Y+^YMT,Y568+,ZINV@*
MN0!C.,]J[;2I$FTBSDC8,C0(01T/ KR@VMO>?#?7_##6#2ZW=7UUY=HT#!][
MS,8Y3QPH!5M_0 =: /2]6\4:/H9D_M"\,0B022E8GD$2DX#.5!" D'!;&<'T
MK4BECGB26)UDC=0R.AR&!Z$'N*\:,=MX?\4:]I7BVPUR\MM2CA^S3V37#172
MB%8VC98V&3D$88>N<#&?6-'MX['0;&WBLS9Q0VZ*MKN+F$!1A,]R.E '":5X
MENO$?C:6"#Q;-IBQSDIHL^FHK3PH0"5D<9._!/'(!]J]*9@JEF("@9)/05Y_
MK,UEXZGT$:9:7BW=GJ,=RUU/8R1&U2,DN"SJ.6VA0HSG()&!D:^I7T?B>;6O
M"<37NGW$<2@W4EMF.:,XW[,\,,':?]Z@#)T_Q3J.J?$ZUM4E2/19]-DGMH\Y
M,^)-HEZ=#@D#/W<'OQ7^(?B[5+"ZTZUT6011)JMK;7MR.<F0D^4O&,[1ENX#
M+Z\48_#WB.U^,&D/)JL]S:PZ8P>Y&GQI&J"3_4\# R._6J?CGP7XB@T?2X;7
M6[K4$;6X9BD>GQ[HV9F)F8J,G!/?CF@#LOB1J.HZ1X76_P!.OI;:2.Z@1@BH
M?,5Y44@E@<<$],5U^.,5PWQ*T_4+KX>BP@6ZO[T36V7@A)=RLB%GPH.WH37<
M@[E##.",\C% 'G=Q?SO\4=6TR[UZZL=+ATQ+I0)UC5'+8)RPZ8[=*L?#S7->
MU3PUJTE]NO?LEW/%IU[)&$-[$N=CG& >>,C /U!-9NI^%K7Q)\3M:BU?2IY=
M-NM*2WCN6M6VK*&SE'*X##KFK_A*_P#$&BV-YX8U>PO)KK3D9-/U%;9WANX@
MN8]S 8#C@$'&>.] &'X2UQ/%NA*EEXDU"V\6Q,K7EI=7!3<0P,B+"V0$QN4%
M0".,GUUM8O43XP1Z=?ZO<VFER:)]I,0OW@3SO.*@@AA@[1TZ=ZR_%^BIXNTF
MRO+7P[?67C57@,<_V9XQ X92Q>8#8R@;L<D],#M6U<VMR/C1:ZA+8W<UE_8W
MV%[@6K&)9C+O'..F._0=,]< '2^&1 UE/<V.J2:AIUQ,SVTDDK2E0/D8!V)W
M+N4D'W[UMUBW\Q\.:7"NEZ/+=J;A4^SVH"[ [DLY]%!))K:H **** "BBB@
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M6DLC2B4[4DCD:0R;U('!#'/?TZ4EG\/+%=(O=/UC4M2UP7<7D-+J$V]HX\Y
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M9@T2DEI?,\L*!ZER!GISG..:/^$HM/+AQ:WIFFE>!8!#\XD0993S@'&2,G!
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M0%Z*BX!)].6 %4+SQ+;VEQJ$,=E>77]G1K)=- BD)N&[&"P+$+\V #P1WXH
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MA%! !^6-@>.0W0X)=8^'=:CBT9+S[;<P6=[<3)YE]_I$4+1LL:.ZL YRQ[G
MP,G'/2:3XBBU35=7T\P-!+IURMN=[@^:3&'RH'L:TKBZ$,$[Q(9Y84W&&,C>
M>^ /4]J (M*@>UTV*W:)HEB'EHKRF5M@X4LQZDC!/7ZGK5VJVGW]MJNG6]_9
MRB6VN(Q)&X&,@^QZ?2K- !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML\!4;$!(^0IPI0G.1G!R37>44 <@$EM_BC?7[VUU]D.D0VXF2W=E,@ED8J"
M<\,#^-<GXZ&HZ]'<%-"U&-Y+&)X%^R/,SE9V;;D?+"P 5FS\QR%'W>?6Z* /
M']8\,/JNM^(9UTBY.JS:E:7.DW30.HB4+ '??P%QM.03GY<8)Q6YX<LKJV\:
MRS?9)9+$FZD,MY9M#-9NSAB/-^[,CG)'4J .>,5Z)3)H8[B&2&9%>*12CHPR
M&!&"#0!S'P[$A\(1S.Q,=S=75Q!E<?NI)W=#@^H(/XUU5(B+&BHBA44850,
M#TI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HI*,T +129HR/6@!:*3(]:,CUH 6BDR/6
MC(]: %HI,CUHR/6@!:*3(]:,CUH 6BDR/6C(]: %HI,CUHR/6@!:*3(]:,CU
MH 6BDR/6C(]: %HI,CUHR/6@!:*3(]:,CUH 6BDR/6C(]: %HI,CUHR/6@!:
M*3(]:,CUH 6BDR/6C(H 6BDS10 M%)10 M%)FEH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
:**** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ibc-shattucklabs_1stamen002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibc-shattucklabs_1stamen002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH C\U?/$7\17=^%255/_(47
M_KB?YBK5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)=ZE<6VO1A;*.U6359[?YANW;5CA4<+TW$]S@8YKO(88K>"."&-8XHU"(B#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 4W_ .0I#_UR;^8JY5-_^0I#_P!<V_F*MB@!:***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BB@T 4Y!_Q,H#_ +#_ -*N
M"JDO_(0M_P#<;^E6Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% %2;_D(6WT;^56Q5.?\ Y"-K]'_E5P=* "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ H/2BB@"G<_P#(0M/^!?RJX*I7/%_9_P"\W_H)J[0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %&].+ZQ_ZZ,/\
MQTU>JA?_ /'[8'_IJ?\ T$U?% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%,DECA0O*ZH@P"S' YX% #Z*** "BBB@ HHHH **** "BBB@
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M,EW)(P6>.0]6R=Y.>FWM7L- ')ZSXFU*Q\:Z;X>L[.TE^WP23+--*R;-@Y!
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MVL1VR3+.I1#Z%LX%>/1ZAI>C^&/$MC)#']AB\5B"VC64PPP$LC*7(SB,%22
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MC6 I&Q! 5@"=QR21V [5!X5TJTMO"WA[Q)-?7,+Q:>EQ>237,CI*K098L&;
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M<V[11P2&Y+K*J2;RYPGRY X')]<4 =K>>(K@ZU=:1I%A'?7=G;I<7(DN/*5
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M76"676IK9KF5]RQ6H/EPK@#:"W+'())('7IQ0!IT444 %%%% !1110 4444
M%%%% !1110 4444 %%%% &9JW^NL/^O@?^@FM.LW5AF6P_Z^!_(UI4 %%%%
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MLMTXC@E,R@2.3C:,G[V>W44[3?$.C:R+HZ;J=K="T?9.8I0PC/O[=>>G!]*
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M.V<\4 =517-6_CC2[W2-'O[*.XN'U=F6TM5"K*[*&+@AF &T*V><>F<C+_\
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MIY&78,.APO3/>E\,^(=&T_P5X=CT/3+B.'4=T>GV&_+#EF8LQ)P!@DDD]>]
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M=\>Y0RG*EE((/&#0!KT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI8O+,1TW.Q+-[9- 'BMOX;LKSX>>*M;DN+U-1TG4;YK"9;IQY!C?<H S@DD
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M/9.?D+=5,@ !]>GO7L-% &#X76=[2>YDT6/1H9G!ALPB+(% Y:39QN)SQS@
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MB/5;:1A.UJ'8K"RA0"=NU22Q Y]\I+X*UN7P[XQT_P RR\S7;EYH/W[[8@X
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M%XATR+PPUAJ>G>=H]M):LMU"\D9#D?O4 *D/@ 8)Q[^OI-(S*BEF(50,DDX
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MOC/+*O Z#/4GBQHEKXUU&U>#Q+_9UG'' \ %FS2-<.5VB1B?NKU.T<DGMCD
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MY%@%T@1A KL(VV[0067!.>3Q7.>(/#9LK[2K,0>)6TNRT_[+#?:/<?OP2_\
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M#1LHQE@<,01Z&MCQ@C?VE=:IH=U?6FK_ &.,-:26;2VVK1[<K$588W<L,#D
MGCT]5HH \==)=.\6:Y'XIT'7+FUUN.&>/^SY)I(RQB5'MY%C8*<$;1G@CV->
MJ:1 MIHMG"MF+)(X%46RMN$( X3/MT_"KU% 'E_P^T+2=1O/$EQJN@1O>?VY
M/<6\M[8$,83MV,K.O3(8X'3\:W]6CD_X6AX?N/L5S);Q6-S$TZ6SO'&[M'M!
M8# R%;Z=\9KL:* ."TL7?AWQ1XJBU+3[JXM-3N%N[.6"W>839CVM$VT$*1L
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *&K<0VY]+A/YU>%4=7_
M ./:'_KO'_.KXH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#/UCBTB_P"N\?\ Z$*OCI6?K7_'DA])H_\ T(5HT %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %0P75O<F06]Q%*
M8VVN(W#;3Z''0UPWQ'UB]-_H?A73H[AI-8DD-R;:0)+]GC 9U5F("ELXW9X
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M64FG:5:V4MY/>20QA&N)SF20C^)CZT 9_AKQ&OB(:J5M)+8Z?J$M@RR,"69
MI+<= =WZ5N9KQ5-%OKG2/'^K67B#4M.FT_6;VX@CMG"QET1&)<=6R %P3@>G
M6K>GZIKGQ U6[LI)?[-EM]*M9HH?M4T++)-&6:8",C=@D !L@8Z<T >D:[KT
M>BG3X1%YUUJ%TMK;1EMBEB"Q+-@X "GL>U3:+J%YJ-D\E_ILFGW,<KQ/$S[U
M;:>'1L#<I'() /M7G/B#19KF7P)#K.H27]XNH-:W-U;SR0K)M20<*K#:W&"P
MYX/..*U]+2/Q5XD\4Z=>7-]#%I<D-G:Q0WDD;1+Y>[S,JW+,Q/)SPH'KD ]
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M!>V /7KS46B1WGBW0&U]_$]KI.K6VH2//((6EGMR'8+"?WH4H5( 7;SZ$\D
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M4#O@'K0!8F\&:/+>Z/=)%+ VCH4L4@D*)$",'@=<@ '/I705S]KKEY+X\O\
M0988!;0V,5W#(A)=M[LI#=ARAZ5OLP498@#U- '/2^"=&ENKN5DN1%>2^==6
MJW+B"=SU9H\X.<#/K@9IOB#P)H'B6\MKR_M72[MU*)/;2M#)M_NEE()'M[GU
MKH?,0@$..>G/6F_:(?/\CSH_.QGR]PW8]<4 8U[X/TB]?3"8YH%TPYM$MYFC
M6(^H ]N/H3ZU+J7A?3=3U!;^3[3!=;0DDEI<O 9D'17*$;@,G&>F3C%:CW,$
M4T<,DT:2R9V(S@,V.N!WI)KRVMGC2>XAB>0X19'"ECZ#/6@#-D\+:+)<:9/]
MA5)-+4I8F)VC$"D $*%('( !]JKZQX'\,Z_J*:AJFCV]Q=H-OFG*LP]&P1N'
ML<U;G\1Z5;^((=#DNXAJ$L1F$6]054%5&<GJ2PP.^#Z5=^W6GVO[)]J@^T_\
M\?,&_IG[O7I0!,B+&BHBA44855& !Z"L2X\&>'KJ[O[J;3(S/J";+IPS*9 1
M@]#QD<$C!(R#UK=J.>XAM8'GN)8X88QN>21@JJ/4D]* ,D^$]%*Z6OV1L:6N
MVRQ/(/(''3YO0 <]N.G%0OX'\,2>(!KSZ+:'4PP?S]O\8Z-CIN_VL9K4BU;3
M9H$GBU"TDB=@BR),I5F/( .>3[5,UY:K)+&US")(EWR*7&47U([#WH FK.TO
M0=*T4SG3-/M[4SMOE,28W'GK^9X]S2_V]H^QG_M:PVJBR,?M*8"M]TGGH>Q[
MTK:YI"6TERVJ6*P12F&24W"!4D'\!.<!O;K0 [^Q].^P0V/V*#[)"ZR1P[!M
M1E;<I ]F -1ZQH&D>(+=+?5].MKV)&W(L\8;:?4>E/76M*:WM[A=3LS#<OY<
M$@G7;*^<;5.<,<\8%.T_5]-U9)'TW4+6\2-MCM;S+(%/H<'B@"O/X<T>XALH
M9-.M_*L6#VJ*NU86'0J!@ BG+H&DK>7EV-/@^T7J&.Y<IDS*>,-ZCV-<EXA\
M:%/%_A6PT75[.:WO;QX;R*(I(S*%R.>2!G(R.X(S773:_H]MJ*Z=/JEG'>L5
M40/,H<EONC&>I[#J: .=U;0-5BBM_#OARQTNQ\.7,$D5Y*N5EAW<'RU'!)!/
M)SSUZ<]?!#';6\<$*A(HE"(HZ  8 K/F\2:';W;6DVL6$=RLBQ-"UR@<.WW5
M(SG)P<"M2@"I?Z5IVJ)&FH6%K=K$_F1BXA60(W]X9!P?>FRZ1IL]]%?3:?:2
M7D*[8[AX5,B#T#$9 Y/2J]IXET._O?L=GJ]E/<$%A''.K%@.I&#SCOCI4/\
MPF/AK?;J->TTFX<QPXN4/F,#@@<\\\4 6K;0-&L[6XM;72;""WN/]?%%;(J2
M_P"\ ,'KWIUEHFDZ;'+'8Z796J2J%D6"W1 X&< @#D<G\Z;JFKZ?IZF&[U*&
MSEDB9T+,-RJ."^#V&1R>/6LKX?:K>:WX$TK4M0G\^ZN$9I)-H&X[V'0<= *
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M!^51QQG)]>F*^D^!=;L]:TO4+KQ!;,EE8&P^SVUCY2B+*'Y#NR"=G)[=@.M
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M]S&7TJ*_N&M8(I7#2YV*/,=0%!!R<$G(''6KY\#WAM/%MN=9BV^(68Y^Q_\
M'N&781]_YODP.W//M5?4/AS<S2:5?:5XCN-*UBPLUL6O((%9;B$= \9.">_7
MKVX& #H_"EYK5]X<M9_$%@MCJF"LT*L",@D!A@G&1@XR<9J*_P#"MGJ'B&/6
M'N;V.06S6TL$4Q6*=#G&]>Y&YL=.M:&D::NE:>EM]HFN9,[I;B=MSRN>K'_
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MH-JC9CJ0,=?2K7B))!XP\:6/AW:E])X=C'DV^ S2!FR O=MA &.>17KQC1@
M44@= 1TI0BAMP4;O7% 'C]]XA\.:W?\ P[&D21E[6^561$(^RJ8B#&W&%.0H
MP>N*I6<FDS6^K^%_%TVJ/K3:E++]BBWJ+XF3?%)'M7&#\HSP  ,X%>VA57HH
M'?@48&<X&?6@#SK0[+3KOXL>+DN[>":58=/:,RH&.Y%))!(Y((0D^PKOKU_*
MT^YD,+S[(F;RD^\^ ?E'N>E6** /"]%U!9-6^'MW;2S)9123Q-906CB*Q#1$
M+$7(+._J2QSC. #5>9+;_A27B]HHP+M]8E=#M&YV\]2C+W/RYP?8]J]\HH \
MPL==BT'XDZ]/K9F:UU>UM&TNY2%I8Y$1"&C#*#\Q9LX[_B,ZGP=,O_"L-+CG
M25)8VG4K*A4@>:Y7KVVE:[NB@#SSQ9?S:%\3= UG4(YVT(64]L9HXFD6WG9@
M=S8!P& 4 _6N*NH;Z]M_%.HZ?IVH300>);?4'MXXI(99X$4;MG1@V<-Q@C':
MO>** /+$.@ZOX:\6ZMH.F:IY]QI,MO)=WKSLTS>6P6-1(QW$'@XZ$@<YJ!8)
M#H7PL9X)O/MYX1*/*;,0$)5MW'RX;:.:]:HH \U\2Z'J</Q 0:6CK8>);7[+
MJ,B XB,1R7)[$Q%T'J35;Q;;II7Q&75=7TO4[[0[K3DMD?3TD/V>5&8@.L9!
M((8X)SR:]3HH \MN=/M[77/A[]AT2XL+2UGNI#;"!G-JDBG;YA&=A+$9![YY
MXKU%55%"J % P .@I:* /,+JPU-O&WCO3%M;U!X@L8EL;M(6,*,+=HRSR#A<
M-CCKTI)+.[\3>"O#>A/I=Y9:E97=KYXGMV5+?R"-[A\;2"%(7!YW#W(]0HH
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M>!W()HT/X<>&_#NI"]T^WG78Q>""2X=XH&(P61"< GUY-=949N(!$\IFC$:
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M%'<GBKEG=V]_9Q7=I/'/;S('CEC;*LIZ$&@!DNF6$]F+.6RMI+4=(7B4H/\
M@.,=S2OIUC);+;/9V[6Z'*Q-$I4?08Q7+>%=4U2\\9>*M/O;^2XM=.EA2V1H
MXUVAU+')502>,5T^H:E::7 LUW-Y:NXC0!2S.QZ*J@$L3Z 4 /%A9BY2Y%I
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M[C$4\AD8B1 ,!2I.W''I_.H]/\*Z)I=Q%/9V"QM &$"EV9( WWO+4DK'GOM
MH \WTG21':^,?$"R7EQ>Z#J]]+IT+7$C*"L(^4C/S Y Q_LCWS#J$6DQ>#_
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M?$,.EW,5ZP6*2*$2+;JJ&%XY'!8<<X4]23W.?5SX9T$V"V!T33?L:R>:MO\
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M&&)'M4A0 XR6 )+M@8R3T)XY-=110!B^)= 'B#PY>:/'.EHMT@B>41;\)D9
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M;#R0%MF8C.QL_=//&,9/&*Z.F+*C2.BL"R8W 'D9]: 'T444 %%%% !1110
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MGMS[5U$,T5Q!'/!(DD4BAT=#E64C(((ZBN$\/N@^,?C!-R[_ +-9G&><;/\
MZXH [R21(8FEE=4C0%F9C@ >I-01ZC8RVSW,=Y;O GWY5E4JOU.<"N,\=>(]
M$F\/7MO,4N88;RTAD?S@D E9PRB1QG"@!6;CH<=>G!7%Q8/;_%*WEU'2[N2X
MT^"=%M%"1,ZQR9*+N.2I"Y;/7'2@#W"/4;&6\-G'>V[W002&!95+A#T;;G./
M>N4^(GB[_A'O#.H2:9JNGQ:Q;B-Q;S,KN5+ 'Y,YZ'.<&N96RTS1M>^&EQIL
M%O%)=1R)),OWIE:W!RS?Q9.#DUS.K:YIES\$M:TW6KFV'BI+B1[NVGP)_/\
M/SN"GD@(0 1P!QVH ]4.MZD/B?:Z*9$_LZ71VN]@CP?-$BK][KC!Z<=:W/[>
MT?\ M#^S_P"UK'[:6V?9OM">9NZXVYSGVKCKVZS\2=*BM)X3>-X=N?(5I ,L
M7C*^O7:3T/ /I7+27EI>_ ]M)W^7XF@<1_9%8"Z%\)@<A<AMQ;YLCL<T >N7
M&M:5:2M%<ZG90R(R(R23JI5GSL!!/5L' [X..E<G\2O&*Z!X4U1M(UO3[?7+
M9498)9$+X)&1L/?:20,>E9.F6&G:A\7M;L=7M8+N[&F64OSX*AT.6./7)4Y[
M#ZURU_J^F2?![Q#H6N,$\1Q3337-M.")GE,N])<#DC:5^8<8'I0![PA)12>I
M%9K>(M&74?[..J6@O"_E"$RC<7Z[0/[V"..M7K65)[2&:)MT<B*RMZ@C(KR*
MUNAI_BR"+1=4M=6TR\UUA<:/<(#=6,V]B\J$'.T$%OF&-OUH Z7PQXVMXEU6
M'Q+KMI'<1ZS<V=L9V2$M'&R@ #CUZ^]=7J/B'1](E\K4-2MK:7RS-LDD 81C
M@N1U"^_2O';K[%=?#'XDO"(99Y=:NBK* S.IE780>X.#CZ&K_B/5;*\\5ZG;
M(9;)KK05CBN;>!YI]25@3Y<8PRA1G!(7=[@"@#K_ !CKE[9:[X.73KXK:ZAJ
M(BG6,*RS1E<CG!/Y&G>&-8U&]^(GC32[JZDEL]/:S^RQNBCRQ)&[-@@#(SCK
MGI7!P7,;^'/A1]]?L]W&LN]"FW:H!/(' )QGIFNU\,-"/BMXXV,,R)8D?[16
M-PV/7!(!],T :/CK4;W2[+1[BSO7M@VKVD$^ I$D3R!64Y!P,'J,5HZ3XLT+
M7%O&T[4HIELL&X."NP$$AOF RI )##@XZUA?$TV[:'ID=RJO#_:UI)+&5W9B
M60-(2O<!02?:L3Q'*UMXY\3SP:6]_GPT(?LZQMMF?>Q,9(ZG8RG .<=* .SL
MO&6A:A-/#:WCO-#;_:C&;:56>+^^@*@NONN>WJ*6V\8:'>Z!'KEM>/-ITLHA
M29+>0[G+[  NW=]XXZ=:\Y\+Z@9O'_A^_1-8N[:71FM1,]@T<4<A>,E% 4;4
M7!R23_O&MCP_X?OK#QUJ&B/;LN@6UY_;-JZKA-\@8"+IT5BS<'C:OK0!UNK>
M,=%T2Y>&]N)5\H*;B2.!Y([<,1M\QU!"9R#R1QSTK<1TEC62-E=& 964Y!!Z
M$&O';JWM-+\6>(]/\1^&-6U9-3NS<V4UI'(\<R,JCRFPP4;2,9/XFO6=*@^R
MZ196_P!G2W\J!$\E&++'A0-H)Z@=,T 9#^.- 34DLFNI 6N_L0G\A_(^T8_U
M7F8V[NV,]>.M.UCQGHNAW$\-Y-/FV17N7AMWD2W5C\ID900N>O/;GI7EFI#5
M;]%67P_KD=S:>(EO'M;6Q*VT<0FSO! _>NP^8MSR3T%=);7^J^&O$OB2SO?"
MVJ:M9ZQ<"[MIK> 2(VY%7RI<\(!@#)]#VH [/6?%FF:'+Y4_VF=UA:XE6U@:
M8PQ 9+OM^ZO!QZX.,X--N?%VF16]G+:BXU WEN;F".RA,K/$,9?V'(ZXR>!D
M\5R,UUK7A#QUJ6IW7A^]U2SUJSM@3I,)F\F:%"I0J<84[C@G_&J7B.QO+3Q7
MI>O:CX-?5=+FTT6<EG9P":2R82LZG8.#\K ''&0<'ID [:+QMHUY9:;<Z=)+
M?_VD'-M%;)EV"#+D@X"[<C.2.2!U-//B^P:RL;BWM[VY>]61X+>*'$I6/AV*
ML1C!P,'G+ 8S7(:GH.GW&E:1!+X9U#1B&GN+.XT:(F736^0#>(P>7SD@ CY<
M=LB";3K[4?#/AY?%-AK":Q$9WBU/28CYUJV]0K.B X+J06&#RIS[ 'I>FZA#
MJFG0WUN)!%,NY1(A1ASCE3R#[&L.P\627OC35=".F7$<.GQPLUPVS&7#G<?F
MX4A1CC/7.*L^"WUN3PAIS>(DVZJ8SYXV@$\G!8#@,1@D#OFN:N='U*3QQXLM
MC9W:6FOZ=#!#J$04QP%8Y%8MDYSEA@8.: -M/'>F&:R:6VOH+"^D$=KJ,L:B
MWE8YVC<&)7.."P .1@FNDGD:*"218GE9%+"-,;G('09(&3[D5Y>^EZQJ_P /
M-/\  ]QH]S;7UN;:VEO&0&W2.!U/FJV?FW*@ '!RW( S7JE 'C'BGQ9>^*/A
M$^LM9WFGL-03:RRX4H)V3&5;+8 P<@#/3L:]#T[QKIU_K-YI<EM?6,UK;_:]
MU["(EE@SCS%YSCUW $>E>?7/A[7Y/A;/X7_L*[:[M;_>CJ\>R8&X:7*9/*A3
MSG'. /;=U[0M0U_Q[/,EC=16%WX=ETTW3 *(Y9#O&1G=@#@X'7B@#<M?B#I5
MQJFE64EM>6PU96:PN)A'Y<X SQM<LI(((# $Y%;'B/68_#WAO4=7E7>MI TN
MW^\0.!^)P*XKP;::S UAIM]X*LK"XL B3:MF)EE51C<@ W;FQ^&<^U=SKFCV
MWB#0[W2;S=]GNXFB<H<,,]Q[@\T <MX6T"#6_#%IKGB3.HZCJ5JMQ*[NQ2)'
M&Y4C08"84C[HR3DY-9.HW?A>T^&][]MOKSQ#HEI?+\T%R7E0F12B.Y8;MK,!
MU)QCBM7PLWB+PGH=OH&I:-=ZI]A3R[>^L9(BLL8)V AW4JP&!CD<#FN8N?!O
MB&V^#VI:$NFF?4+W4O/CAAD3*QF59,N20 <*1@$]1[X /0Y/%=K%XTA\+R6=
MVEW-;FYBG8)Y+H.N#NR2#VQ[]*KW'C6QM[*VFEB:.2[N9;:UBEEC3SC'NW/N
M+8"?*3D\D8XR0*SO'/AW4M<M]'UC0Q]EUW3YPT+2[<I'* D@89P< YQG^'C/
M>+Q7X4U%5\,W_AZ"WNKC0&9%LKA]B3Q-'Y;#/0, ,@G_ /6 ;GA7Q;9>*XK[
M[,C13V-PUM<1,ZMM8="&4D,I[$>AKDOBK)96VN>#I[Z-3;'42MQ^Z,F^/;]T
MJ 2PYZ8/6NS\.-JLUK)<ZIIMOIC2E?+LH9!(8P!R6<  L2>@X  ]ZQ?&VCZK
MJ6N>&KO3K'[2FF7GVF;,J)D8Q@9/7]* .5T>^T]_C'I]OX1F^S:9]@?^TK5@
MT,;C!,?EQ/C+ XR5' SGJ:ZR7Q[Y-]$'TF5=/DU8:0MPTH60S%MNX1D<Q[N-
MV<]\8JIJOAO5O%'CCP_K%Q:1Z79Z,[R[S*'N)R<83Y>%3@YY.<GBL"[\(>+)
MYFNIM(T^\U&WUB.]6_EOB)+B%)@Z1("A\I0H (SCC."30!VFI^+IK>;4ETK2
M9-532RBWODR8<,V"4C7:?,<*=Q&5[#)/ P+^_LM%^+]YJ4J!"_AN-MH7YYG-
MP0J@#DL<!0.3TIZZ+XST'QAJ=UH<.FW.F:RRW$RW4[*;2?:%9AA<NIQTQSQT
M[Q>(_AY=^)/%?V^\>-EBTB.VM[U)-DT5VDAD64+C &3CKW- '>Z9/>W.GQ3:
MA9I97+C+6ZS>;L]BV "?7''N:X'X@SWFA^*M+\27.AR:SH-K:R0SQ1*'>U=F
M!\T(>N0 ,]@#TKL_#;:[_8T$?B**U748U"R26TFY)2/XL;1MSZ5'>KK\.N_:
M;%+2YTYK=4>WFF:-UD#,=RD*1T(!!ZX'IR <C;^*-"T'P%K7B[PI;QWME).)
MY+57\GR7VHC#&/EQ@';CN<=:UK3QK?IXKM-(UC07T^#4HW?3Y_.#F0H,E'4?
M=;;SC)]*Y7Q5X8DT3X?>.]2FAMK:75O+E-I;,6CB"D#.2!EB22< #I763Z+K
MFNZQI=Y?):6$6F1RR0F"8S.]PZ% W*+A%!8XZDX]* *FG_$"\F\0:)8ZAI4=
ME%K*R_9X6F/VJ!DY'FQE1M# $C&?2K5OXMU?43!J.EZ-'>:%)??9?-CF/GE
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MVSC)ZT 8/Q1D6#4O!DS023^7K4;>7$NYFP#P!W-5_!"Q>(?B'K7C#3L6=@T
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MBEW+G_EMMZL>HIVI> ;V5M(OM'\0S:;K-A;"UDO/LXE6Y0D,P="1U;+=>,T
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M]!)=K<7F#-#Y[>26"[=^SINQQ0!N4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% %#6_\ D"7G_7)JMV__ ![1?[@_E576?^0+>?\ 7)OY59MO^/:+
M_<'\J ):*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG)_ GANYU
M&YOY=.+75R<SR"XE'F^S -AAVP>,5T=8^C>*-(U^ZOK?3;V"X:SF\E_+D#;C
MM4DC!Y W8STR#0!:M=&TRRTLZ7:Z?;0V!0H;9(@(RI&""O0Y[^M9=CX#\*Z;
M+;2V>@V,4EK*TT+B++(YQD@GZ#'I@8Z5JVFL:7?W4UK9ZC:7%Q!_K8H9U=D_
MW@#D55\2>)=,\*Z2^HZI<I#%D(BE@#(YZ*OO_(9)X% "1>%/#\":@D>C6*IJ
M)W7B^2N)SDGYAWY)/XU&OA/1[/P_=:/IFEV%O:SY+0F',;-QRP!!;H._85AW
M/C..'Q[91#5[/_A'9M(FNVE4J8]ZR*NXR^F,CJ!GU.*Z==?TAM&76!J=F--8
M B[,RB+DX'S9QUX^O% $^F6*Z9I-G8(VY+6!(5; &0J@9P.G2L^Z\(^&K^[D
MN[SP_I5Q<RG,DTUG&[N?<D9-7M-U6PUBS%WIUW%=0;BN^)L@,.H/H1Z5BGQU
MH:^,?^$9^UQ_;0@+9/\ RT) 6,>IQDGTQ[T :</AS0[;2YM,@T;3XM/F;=+:
MI;((G/'+(!@G@=1V%'_".Z)S_P 2?3_FB2 _Z,G,:D%4Z?=! P.@P*9%XHT.
M?5AI46J6SWQ9D$*ODEE^\H[$CN.U0-XT\,K,D3:Y8AW>2-?WPP6C +C/3@$9
MH N_V'I.ZW;^R[+-LH6 ^0G[H Y 7CY1GTI\VCZ9<7$MQ-IUI)/*@CDD>%2S
MJ#D*21D@$ X]:QXOB#X2GN[6VBU^R:6Z0R1 /PRC.26Z#[IZD=*M:/XO\/Z_
M#>3:7JL%S'9?\?#*2!&,$Y.0., \].* -(V%FUXMXUI ;E>%F,8WC@CANO0G
M\S3OL5K]L-X+:'[45V&;RQOV^F[KCVJAI/B;2=<F,5A</)((EGVO!)&3&WW7
M&]1E3V(JSJ6K6.DQ1/>S^7YKB.)%1G>1S_"JJ"S'KP : +"V\"R>8(8P^2=P
M49R>IS36LK5YGF>VA:5U"NYC!9@#D GN :PM1\8Z>GA35-9TV4W1LDE4QK#(
M625%)V2+C<G09W 8[U4\'VMU<K:ZW_;.IS0W%DBW%I>1N%:;AC*F\#:.2,*-
MI_"@#KZ3:H.0HSZXKS/_ (2)M1^(VLZ!J?B&[T2XA,<>F6\.Q5F4KN,A+*P9
MB3]TG&.,9S776>HSZ'H=G'XANVN-1DD>(&*'<]PVYB"L:9_A ) Z#.>E &\%
M Z "C R#@9%8D'C#1+C1KC55NRMM;S&WF#QLLB2AMOEE"-V_) "XR<BL[4?B
M#I-GI6LW,$=U/=:4FZXL_(9)4RNY2P8#"X_BZ4 =;25Q6L:OI]U!X6N]1U#5
M=-EGOX5ACMXI(UN)B,".0$'Y"3GD\@'%:^I>,-+TN2\$PNI([$9O9H(&D2V^
M4-\Y'?!!P,D Y.!0!O4M<]?>-M%L-3L=.>6>:XOX#<6HMX&D$J#^Z0.3SGCM
MR<"KGA_Q#I_B;36OM/:38DK0RQRQE'BD4_,K*>01Q^= &K25QOBCP[/<S:AK
M=[XJUK3K&V@W);Z;<"%51%+,S94Y8G/IP!6AX"M]1M_ ^E#5KNXNKZ2'SI9+
MA]SC>2P4GV! _"@#H\45Y)X?\81>&K[QM<:E'JEY!#K4A9X8VF%O$, %B3@*
M/0'H.E=[?^*[.TVK;6]SJ,AMOM9CM-A*PGHQWLHYP<#.3@\4 ;U%<9+\3=""
MZ2UM#?WO]JP/-:K:0;V?8#N7&<A@1C'ZXR:+OXDZ7:VLDXL;^0P6B7EQ&1'&
M\$;*6PRNZDMM!.U<GIZB@#LZ*XM]8T+4O&OA>[BANYKF]LIWL;I7*P^455FR
M,\M]WC'&?88KW'Q1LH;&[OQHNJM96-\UG>S^6@6W*L%+'YOFY/1<\<G' H [
MRBBN0\9^)=6T/4-!M--TY;A=0O5@>1I54]"VP ^H4\]A[XP =?17,7OBRX2[
MO+33-%GU"XL(EDO%65$$;,NX1J3]Y\<X''(YYK6T+6[+Q'HEIJ^G2&2TNDWH
M2,$<X(([$$$'W% &C17 7OQ*NHH]5DL?">I7D>DW+P7K"2-?+50I+#D[CR3M
M'89)&14VJ_$[3+62VBTYK*XDGLEO@;N_2U3RV^XH+ DN<'C''<C(H [FJ][?
MV>G6YN+Z[@M8 <&2>0(H/U/%<0_Q0BFM?#DVF:+=7AUU9OL\?F+&RR1@Y0Y_
MVAC/0#GGI63?:IK&L?$/PQ#J'AZUB62PGFCLKN[)VNP4.6Q&1N50R@$$$,>0
M: /4HI8YXDEBD62-U#(Z'(8'D$'N*?7!Q^)TT71=1;P_H*3:#H4DD$[?:RCC
MR^9?+0JVX+D]67H0.U+J'Q"N%UF#3]$T)]6:ZTL:G:M'<K'YJ%@,<CC@D^Y
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M4/\ *"1\S-GK7=?$;_DF_B+_ *\)?_030!TD,JS0QRJ"%=0PSUP13Z\REO\
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M,<]!6]_PK_2O^@CX@_\ !U=?_%T?\*_TO_H(^(/_  =77_Q= '*:-HU_X?\
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M1KS2[O?]GNX6ADV'#;6&#@^M7:* .>T_PJMM?65Y?:E=ZE-81&*U^T","+(
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU%4QJEB=6.E"ZB-^(?/-N&RXCR!N([#) H N4444 %,DD2*-Y)'5(T!9F8X
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M0&DVB,"5G&1PV5 X^5N!7?V.D^#O%.A)<VNDZ7>:;<DE&^QJ Q4E<C*@Y!W
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M^A$%TQO)29E&<[LMR3D@GK@G&,U>;PAH[7>D71BF\_1T*6+^>_[E3@$=><J
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M.D,AC.XJ1D*HZ?[6>PKS32+ZYTGPBNG07;6MM>^,9K2XNI7; CX.&8,K?,5
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MC^T]'L[K[.,1>;$#L'H/;VZ5+J?AS1=8M(+74=+M;B" @PH\0Q%C^[_=Z=J
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M$Q )!\EON_\  PO3N!WK0U#Q/9Z#/X)U^2]MRDFC/$WVPR+'M(B)975'(DW
M#&TY&<XXKUL0QKRJ*/H/QKF/$7A[6KS58]3T35+2"46_V=[:]M?.A8;]VX8(
M*G.,XZ[1Z4 5_AFNFIX7D&FZI:7ZO=RS2_9&S% \C;S$F<$*-W&0,]<#.*C^
M)=G<1:19>)=/A:34=!N5NT6-06DA/RS1^P*$D_[M;^AZ*VEFXGN+A+B]N=OG
M21P+"F%!"JJC. ,D\DG)//0#6- 'D2Z7XDL/$@M+F,O;^+T+WL<>"MG(K9<=
MNL!V9[L*H>/M3BEO_'&F1QS:?<&TB?9#:F634@L3?,Q(94C0<9 !X^\.E>VT
M4 >4G4;6Y^)?@&>.7]V^E38+ K]Y,+P<'D@X]>U;_P /;J&YO/%QAD##^W)F
M!'==B#(]1E6&?8^E=O10!Q?C5C:>)O!FH2LPM(]2:WDQT#RQLL9/MGC/O47B
M"_@TOXHZ!<W8E6*:PN;>-DB9PTA>(A> <' )YXP*Z_4M.M=6T^:QO(_,@E&"
M,X((.00>H((!!'((!J2UA>"UCBDG>X=%"F60 ,_N< #/T H \.U"-3\%/%D=
MM$QNY]89HU6/$D@^THRD <GY02/8&M2\DTW3_'&KKXFLM8N[36XXFL)K(SF*
M:,Q!&A9(F )[#(.<DG&:]CQ10!1T>WCM-&L[>&T-G%'$JI;%MQB&.%S[=*O4
M44 ><Z[K5CIGQ>L+BZ>58(=+DADD6!W5'9@P!V@]1S2WUK=^.?'FAW<5A<VN
MB:%(UR;F\@:)KJ8@;5C1P&VC&=Q%=%>>#;:]O)KE]7U^)I6+%(-5FC1<]E4-
M@#V%5_\ A [/_H.>)O\ P=7'_P 50!P6AP6T*MX1U[PSJMYK*7<K0RR&4VLX
M,C,D[-NV@<Y)QG@]SBM&VL;W'Q3)TZ]_TY76T/V9_P!^?)9/DX^;YN.*ZS_A
M K/_ *#GB;_P=7'_ ,51_P (%9_]!WQ-_P"#JX_^*H Y9+:]@@^%>=-U(FRC
M5+L1VT@-N3;B,^9\ORC<><]1GM5N"Q6>_P#'T>HZ1J,]E>7<&U$@D1ID"(C-
M&<#=M()X/;TKHE\&:9:Q,UQJNO2)W:;7+H ?E(*D'@W2)$:(W.L21CY2AUJ[
M('?&/-^GZ4 <0;+78?"'C33B=4U2P:R6'2YKVT8W<A9&#1D;0[!21AB.,GTK
M3M;:[;Q-X E_L^]$5EI<T=S(ULZK$[QHJJV1P<HW7IQZBN@;X?\ AYA@QZCC
M_L*W7_QRHE^'OAF7.U=0;:2IVZQ=\'T_UM '#:C8R-X1\907>FZFCW'B);JS
MV0%'<.\2QN@88<@J3LZGIQD&NA\*ZC9ZCXUEU;4-/UJRUB\M!9P_;]-:UC\M
M"795^9@6)RW+=%X[YT-0^&?AF>T*-)J=L0P9)EU:X+(V>"-[L,]NG>G:#\-M
M)T6X@NI+_5]1NH)/,BEO;^1MC<CA5(4\''(- '94444 %%%% !1110 4444
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MAP,NJG@\=":P]0UOQ'>>/[#P_I^J064%UH@O&D:U61DDWX+ $\G P >.>AH
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M/'.BZ9?M;7+W(C2=;::[6W8V\,K8PCR8P#R/IGG%+/XLBE\J'2[*_N;J2X2
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M?LUO87\T"WQL'O(U3RDF'4'Y]X /&=N,UT5>8R:)?)XOCU/0=-U'2-1DU/\
MXF W V5[;!F#2L,X#,H!&!NRW0\M79Z!KMQK,VI176E7&G26=R8569@WFI_"
MXQT!]/IS0!1\4ZC*^JZ+X;MY#&VK22?:)%)#+;QIN<*1T+?*N>V3WQ2))H]O
M\1(K&.TN_P"U(]'RDN_,7V<2 !<%OO;N^/QJKXG$]AX_\)ZODBQ)GL+AMN=I
ME4&/)[ N@&?<#O2W&FW_ /PN"SU9;*5M/&CO:M<@KM60R[P",YZ#T[B@"EX=
MMM(\2^%-0;PY%>:7/%J%PT,\SDR1W0^\Y^9LJ2<%>A'&*Z3P?XBC\5^$]/UJ
M- AN8\R(/X'!*L/P8&L7P?$_AG0_$5UJEJUA;#5+N^7?M \ECN##!P..U3_#
M+2KO2/ =A%?QF.ZG:2ZDB.?W9E<N%P>A 8 CUS0!E>(99]5^)]CH5YI?VK2_
M[-GD\J1TV2%BBF3&<Y4,R\\\G'6HM%U+PYX(T;Q6VE:-J*1Z+,HNT9][S':,
M.NYC\NW![<=NU;-U8ZB_Q5L=473Y3IT.FR6K7.Y,>8SJP^7.[&!C..OYUA:A
MX?UR>S^(<4>E2%M8*K99EC E'EB(G[WR]-W../?B@#?TOQY#J'B&RTF?2;ZP
M.H6IN;*6YV 3*O+#:"2I YP><=A69I?B?P[X?\/^(=0LM,ELDM]9DMKB)Y!F
M6Y9U4MG)"J2P]@ :'T+5Y?&O@K4QIL@MM-L98;MC+'F)WCV@8W9.".<9]LU5
MTS0]<LM+\40W?AU;Z'4M;DNELIIHB);>1AG^+ 88SS[?@ 1_$C4)=1\!7K7V
ME/;RV5_9/&P82I)F5/FB8#GABO0'KQ74:/XNEO\ Q7=>'K[1KG3KJ.U%Y"99
M$<31;MI/RD@$$@8R:XJ]\&:W!X,U;2])TVY^R3ZA;36&FSW<;-:HC*\GSERH
M4E>%!.,Y[G'6C3M3;XJQ:S_9[C3O['-FTYEC^60R"3[N[..,=.OMS0!U]%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!'<?\ 'O)_N'^50:6<Z5:G
M_IFO\JGFYA<?[)JKHY)T>TR<GREH O4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7EGCWQ;X)\4>&-0T"XUJ2VF9\)-_9]PPCE1@<C"<],<'H:]
M3J"ZNXK2VGGD)*P1F5U0;FV@$]!SV/Y4 >97DO@W5[WPO?V\FHF+0W_=;-'N
MV$J!<*N1'CAU5OPJUXFU33]:U;1=4L-4U*QN=+:4J)/#UW.CB10I)78O(QP<
M]S7<:!K=IXDT.TUBP\S[+=)OC\Q=K8R1R/J#6E0!XA+I&FS>#=;\,/X@UF2+
M4[S[9]ID\-71*$R!V& HW,2JY/ QT'6MI=7L[WXBZ9XASK :&T^P?9SX?N%#
M[CDMO)^7YCW!P/SKU6N;@\9VEW?ZA96NGZE<3Z?(([E8X5.QB,C^+G(]* .D
MKD[+3Y=5^(,_B&6'99V5G]ALF/69F;=*_L!A5'K\QZ8K6T+Q+I7B2">33+DR
MFWD\J:-T:.2)O1E8 C\JUJ ,?Q3H0\3>&KW1FN3;)=IY;RJ@8A<Y. >_%4(O
M"+1^+K#Q ^H;GM-/^P>2(0 ZYR6SG(.<?A^==/2,=JD@%L#.!U- ''Z9X*OM
M)L98;3Q#*D\FIR:B9OLR8)D!WQE<X*DG/J,=:KW7PSLKC1!:)J$\%Z-5&KK>
M0QH-ER.A6/&T+CC'XG-=5HVHRZKI<-Y-IUUI\DF[-M= "1,$CD GKC/XU'K.
MIW>FK9&TTJXU$W%TD$@A8 PHV<R'/88_6@#F+[X9P7FH:K<C7=4BCU:U2WOX
M5*8N"B;%8G;D<$Y P#GTXJS%\/K>/_A%BVJWKMX=4K;E@G[P$!<-\O3: !C'
MY\UV-% '+W'@;3[Z7Q%_:$T]U!KHC%Q"^T!-B[4*$ $$ #KGD"H-(^']GI]M
M-;ZAJNJ:S$]LUHB:A/O6*)AAE4 #J,#)R<#C%=?6!XP\41>#] DUBXLKBZMH
MG591!C* G&XY/3)'YT 8%M\*[. Z0K^(-;G@TBY6>QAEFC*Q!>B_<Y'0<\@#
M Q7=30QW$$D$R+)%(I1T89# C!!KG;_Q@FF^)M%T2XT^;=JX;R+E'4Q JNY@
M><Y]..<BM1-4=O$,ND_96_=VZW!G#C:%8E0".N25;\!G/:@#G[3X<:9:^'X]
M'-_J<L-O.L]E*\X\RS*YV^40,# )'(.<G-;6E>'H--OIM0EN;B^U*:-87N[D
MKO\ +4DA % 55R2< =3SFMBN.M?&=[=>'O$VI?V3$L^B7<]N;?[5Q*(D5BV_
M;QPQP,=A0!NZUH<6MI:;[N[M);2?SX9K5PK*VUEYR"",,>",5DWGP^T+4=#N
M-,O(YIC<7!NI+LL!/Y__ #U#  !@, 8&,<8Q6]I-Z=2T:QOR@C-S;QS% <[=
MR@XS^-2"^MCJ#6 F4W2Q"5HQU"$X!/U.?RH X7Q#X-33/ FH:?IT.J:O->21
M"ZFENO,NVB5P259B 2JYVKTR>AYS3\/Z+?RZQ!)87_C1;-A(EXVMSC9M:,@;
M$<;BX8K\V,#:>3T/IU% &!I_@S1-.\+R>&HK9Y-(<,OV::0N%#') )Y'.3UX
M)XK,A\#V7AKP[JL6@6LMW>2VDD,$=[=,XP0=L0)/RIT'&,X&3WKLJ* /(M \
M.SP6^EQZ=HWBBQU*W:%9I;K4C]GB52-YV^80XP"-H7OVZCL9OAOX7G%TKV4N
MRYN?M;(MU*JI+N#%T ;"$D#)7'''2NKXI: ,./P?H46M_P!KI9;;OR5@)$C;
M&55VKE,[20O&2.E5-$^'WACP[J37^EZ8L$Y)*_O'98R1@[%)(7.3TKIZCBGB
MG3?#*DB9QN1@1G\* (K^PM=4T^XL+V%9K6XC,<L;9PRD8(XK)@\%>'[5]->"
MR='TPLUH1<RYC+  _P 7S9  YSP,=.*W$FBE)$<B.1@D*P.,\BB66."-I)9%
MCC7JSG 'XT 8R>#]!6/58VT]98]68/>I-(\BS,.A(8D _3'0>@IWA_PGH7A:
M&2+1=.CM!+C>0S,S = 68DX&3@9P,GUK76:-HA*LBF,C<'!&,>N?2FQW,$L!
MGCGC>(9)D5P5XZ\T +/!%<V\D%Q$DL,BE'C=0RLIX((/45A+X&\.+ +<::/L
M@Q_HAFD,'!SS%NV'KZ5MQW=M+((X[B)W*!PJN"2IZ''ISUI@U&Q:\-F+RW-T
MO6$2KO'7^'.>Q_*@"O/H6EW-_8WTMG&;FP!%K(,@P@C!"XZ CCZ<58EL+2:^
M@OI+>-KJW5EBE(^9 V-P!]\"L_2;F_1M6?5[[3I(HKM_(^S''DPX!42D]'QR
M:BU3QGX?TG0KC6)=4M9;2'C,$JR%V.<(N#R3@_D?0T 6=:\-:)XB6)=8TRVO
M1"28_.3)7/7!_I6A;V\%I;1V]M#'#!$H2..-0JJHZ  =!55]=TB.QCOGU2Q6
MTD)5)VN$$;D9! ;.#T/Y4^35M-BC@DDU"T1+@$PLTR@2 #)VG//'/% %6Y\+
MZ#>7SWUUH]E/=R##3RPJ[D>F3SCVZ5+:Z#H]E93V5KI5E#:W&?.AC@54DSUW
M #!S[U2U/QEH&E^';C7)-3MI;&$E-\$@DWO_ '%P>6/I^/2M33M0MM4T^"^M
M)HY8)EW*T;AA[C(XR#Q^% &=9>#O#6FR6TEGH.G0R6I+0.ENNZ,GJ0<9SQUJ
MQ:^'=$L=0EU"TTBQ@O)L^9<16Z+(^>3E@,G-3_VMIHFN8?M]KYULN^>,2J6B
M7U89R!]:5-4T^6UANHKVWDMYG$<4J2!D=B<  C@G/'UH I#PGX=%A+8#0M.^
MQS2"62#[,FQW'\17&"?>M2&&*V@C@@C6.*-0B(@P%4#  '85R,OB>V\.6_B7
M4M4\00ZC;VLX9+:"(![7*_+"2"<DD=3COFLW4_&[+XS\(&UU2"/0=1ANY+O<
M%"YBB+ [ST )'ITH [&Z\.:'>W N+K1[":89_>26R,W)R>2/7GZUS7C'PK>>
M(/%OA:[6RL[G3=-DF-U'<./F610O"D$'&,\UU6E:SINNV0O=+O8;RV+%?-A<
M,,CJ/K4E_J-GI=J;F]G2&($*"W=CT  Y)/H.: &1:/ID&F_V;%IUHECT^S+"
MHC_[YQBI(-.L;619+>SMXI%C$2M'$JD(.0H('3VZ5FGQ9H\F@7>L6M[%<6UJ
MI,FPG<K=E9<94GC@C/-<UX"U*]\306.NQ^(;B57B+:AITEN/+5W&56-MH(V_
M5LXH [>TTZRL/,^QV=O;>8VY_)B5-Q]3@<FEAL+.WN9KF"T@BGF_ULJ1A6D_
MWB!D_C6)KGC&PT+7]*TB=96GOB[96&1@J*I)(VJ=QW;1CL#D^_,:+XYMM&UO
MQ5!XEUT^3;ZEY=KYRY*1[%)X1>%!/4C\: /1Y8HYXS'+&LB'JKC(/X5"=/LB
MBH;.W**20OE+@$]>U5=3\0:;I*P&ZG<M."T200O,SJ,98*@)P,CGIR/6F#Q-
MI#Z-#JT-XL]G.XCA>%6<R.3@*% R6SVQD8.>E &E+!#/&(YHHY$'(5U!'Y4D
MEM!+&L<D$;HOW59 0/H*RHO%FC3Z8VH1W3F 3_9L&"0/YW_/,(5W%O;%6-'U
M[3M=CG:PG+M;RF&>-XVC>)QV96 (_*@"Y]DMO-,OV>+S",%]@R1C&,_2I$BC
MB&(T5!QPHQT&/Y53U36+'1H89+V5D\^40PHD;.\CG.%55!)/!/X5G?\ "6Z=
M<:1JEY8-+/+I^Y9[?R'$L;@<!D(##/KC&.: -THC,K%5++]TD<CZ4;1_=%<-
MX"MY]6L-+\2RZIJIN)K3%W;3._D2NWS!E5N!C. 5XQBM'6/&D6E>,M+\/?8K
MJ1KN.25Y4@9P%5> H4$L<XSV H ZG:...G2EKS72?&=CX9N?$R:WJ%]<+'K4
M@0E7N#;P^7%@M@'8@)./QQG!KL]2\26.FS) 5N+J=X6N!%:1&5A$O5SC@#GC
MU[9H UZ*IZ5JMEK>EV^I:=<+/9W"[XY%!&1TZ'D'((Q[5PGB>68_%?1;"36;
MVSTRYL)9)XHKQH59U)VG@\=>WI0!Z-2UP'P[U35;S4O$%L]U/J&@6MR%T[4;
M@Y>7(RZ[N-ZJ>C8Y]36TGCG1FN-.0FX2#4IVM[.Z:+$4SCL&[9P<9 SVS0!T
MM%>;?$[Q/$W@37X;%-1)M_W+7MME8XY0Z@H6!!ZG!P".H-=C9Z_:3:L='59_
MMB627F"F%:-B5!!]<@C!P>* -BBN<@\:Z5=:+9:E;+<3"^F>WM;94 FFD0L&
M4 D 8V,<D@8'6B+QIILFF3W;Q74,L%Y]@:TEC F-P<;8P,[23N4@@XP<YQF@
M#HZ*YJW\<:2Z:P+L3V$^CA6O8+E5WHK#*D%2RL&[8)YKG+K4[F]^+?A;?::E
M8HUI=$P714*XV<, KL,]<@X(X]J /2**I:O$LVCWB-G'DL>&(((&001R#FN;
M^%DDUQ\.-)N+B:2:XF61Y99'+,[>8PR2>3T% '8T5S6N>-+#1;JZM1$]U<6E
MN+FYCCEC0QQG./OL-S':Q"CT[9&6IXULKV+3VT>UN-2DO[1[V%(MJ?NT*JV2
MY !W,!CUSTH Z>BN6B\=6%W::'+96T\TNLI(]M"2D9&P#>&+$#() P,Y^G-%
M[XZL+"WTXW4+V]W?!V6UN98X6C5#AB[,P4<X'!.2>,\D '4T5A>%/%5CXOTE
M[^Q61!%.]O+')C*2+C(R"0>"#D$CFN0^*:6D>N>#[B[$8MVU+RKDN,J\.,E6
M'\2Y&<&@#TRBO(?#NKMX>UOQIJ6EP7=QX/LH$FBA ( F"C>(=^/DQN)QQP,=
MA741_$-(M/2\U+29M/CN7A2Q:XG14N?,0OG<<! H5L[N<8XR<4 =M17GI^+&
MGIH>LWOV%IKO2)$2YM[6=94(<X1UE& RDD=MP]*MOX^O5\2S^'QX7O?[0-L+
MJSC:XB FCW;2SG.(\'MR<=L\4 =G//#;1^9/+'%'N5=TC!1DD #)[DD >YJ2
MN U/Q/I6O_#DZKJ>AFY@%W'!<V$D@_=3"94Y8=0&(/ Y':M75?%TUIKUSH^G
M:;'>7-I:K=21O="%W5MW$2[3O(V'/( R.>> #JJ9'$D6[8@7<VYL#J?4UQFO
M_$2WT?4)[&VM[:XN;>V%Q)#/>"!VRI?9&I4EFVJ2<[1T&<G@;X@B_NM/M-"L
M([BZO+$7ZQ7UQ]E)0L5V+\K9DRIR.@QUYH ["YM8+VW>WN84FA?[R.,@]Q^M
M2(@C14!)"C W,2?Q)Y--MY6GMHI6C:-G0,4;JI(S@U3UO4GTC1;O4([.>]D@
MC+I;0#+RGLH_&@"Q>6-MJ$ ANXA-$&#&-ONL1R,CH1['BK%<=9>,KU]3U?2K
MS3;8:A8V(OHTM[O>DBG(V,Q4%&#+CH>N:H6OQ$OWB\-ZA>Z$MKI&MRQVZ3FZ
M#2)-(A9?D"\H2" <@\9('&0#N[BY@L[:2XN9HX8(U+/)(P55 [DGI3XY$FB2
M2-@Z. RLIR"#T-><>.=?U'5O!OBQ-*TZTNM,M()K2:>2Y*N7"?O&1=I!"9[D
M$E3CL3W6AG_B0:=_UZQ_^@B@"W+<0P-&LLT<9D;8@=@-S>@]35#_ (2+1OL-
MY?#5+1K6RD,=S,LH*PN,95B.A&1Q6!X=NU\0>-/$-],-Z:5.NGV:,O\ JB%S
M*X_VF9L9_NJOO6;'KT1\">++X^&=.'V"^N8Y[ ,#%<,A7>[G;@D\GIS@4 =P
MVK:<EQ:6[WUNLUX"UM&9 &F &25'?CGBI[>Y@NH5FMYHYHFSAXV# X.#R/>N
M3NM;@BUSP='/IEF3J22>5.5R]NPAW;4XX!X&<]*073:+\4(].0A;+6K)YUB'
M1;F(C<P'0;D89]2OY@'94444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% #9!F-OH:I:(<Z+:'_IF*NO]QOH:H:#_P @.S_ZYT :-%%% !1110 4444
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MQ+!CU(SCKTZ# JS:SS:)XITX#^S=9TF]UF802Q86]LIW9]X8#[ZJ68'N .<
M"O4#I>GGR,V%J?(_U/[E?W?.?EXXY]*6/3+"&Z-U%8VR7#9S*L2ASGKSC- '
ME=M:Z;?:%\0;"XU*/3H9/$ 'VA=I$3EH=A8'C:7&#GJ-U9WB'4-2O/ _C>SU
M2UL9[^VBM7DU#323#<J6!!(_AD"]?;'8"O98]-L(A*([*V03$-*%B4;R#G+<
M<\^M20V=K;VWV>&VAC@((\I$ 7GKP.* /+?$/BBPA\?Z7?W&N&V\.7.FR6]I
MJ%HL4L(G\P;U9F5U&5 &<=L9ZUD76D^'HKOX>V>G2376E_VG<&)[W!,R\<C@
M93=TXP?<&O:'LK62V%L]M"UN  (F0%1CIQTJ0PQ,5)C0E?NY4<?2@#PK6D5M
M,^+EG:*NQ);9UABQA< ;B /IS]*]D\.7]IJ7AZQN+*XCN(3"B^9&VY<@ $9K
M16&)69EC0%OO$+U^M.50JA5  '  [4 ><^,8;[0/'6FZ]I=N;AM7MWTB>$KE
M/,P7A=O;((8_W15;P3I5]I6O2>#)_-DTW0)OMMM<,1^]24'RD..N&,I^JK7J
M&*3 R3@9/4T >)WZR7%E\7DA1I'9XRBH,E@$Y(QUQBM*_P!1TO7_ !]\-[FW
MEBN;3R[M3O0[=WDKMZC!^88'N,#D5ZW2      #@ 4 <+X FM6\2>-H[0@1?
MVOO" _Q&) [ >A<-S[5-XUEDT[Q)X5UF>%Y-*L[B9+MADB!I$"I*P[!?F!;M
MN]Z[6B@#SB*-9_%OC#7K6>/^R)],BM_-0?)<3!6^96Z-@$+D9Y..U;OPWP/A
MYH<.2)(+1(I$889' P00>0:ZJB@#A/&EP=+\=>#M7G@N'L8?MD$LD$+2E'DC
M78"J@GDH17-.K'2/BP/*?S+AI/)^0YE!AVKM_O?-D<=Z]@HH \G\,2W>BZWH
M.LZL+EM.N_#5M9B<QL_D7";2Z. "5)Y.3W&*KMH%E_9]U-J2:I96VK^()+[3
MKBT1TEL3Y9Q,RXR@8J>". PSCM[!10!XS?6WB&?2+#6-6M;K5+;2]8F:7[%$
M8);ZV:/RUN-B%3N&>,=1STYKN?!,&F.M[J>DZ-=Z?!=E=TE\'$UPRY&XAV)V
M@$ $]>>V*ZVB@#C?&7VVP\1>&]?BM9[FPL))X[U+=&D=%E4*) @Y8*1SC) -
M4$M96UOQCXECMKG[%=6$5M BV[^9<NB-EE3&XCY@H..<$],&O0,C.,\^E+0!
MS'P[\Q/ .C6\UO<6\]O;)#+%<0/$RN ,C# $_4<5C>*X+ZS^)GAC7(]-O+RR
MAM[FWD-I%YC([+\N1V!Z;CP.Y%>@44 >6S)<R>&/B1:IINH?:+NYG-LOV*7]
M^'B2-=GR_,-RGD< <GCFJ=W!<:?KUIXBO/"E_K>DZAI4%NUO':;[FTF3LT3X
M(!W'/OG\?6Q)&93&'4R*,E<\@>N*#-$LR0M*@E=2RH6&Y@,9('<#(_,4 9^@
M0):Z';11:9'ID>&9+.-540@L2 0O ;G)QQDGK7(^(-*.J?%71Y+C2YKK3$L)
MK>XD:V9H@S] 3C'X]!7H-% 'G7A^RU7PO=7O@ZZM]0NM"F0_V9J4:&3R$<$&
M*0CIM/0XQC';IE>"=(NM+@L]!O? $"ZE:RQI<:L\41@DB0\2!_O,^TX QP>2
M1R!ZU5>6]M('*2W4$;@9*O( 0/QH \>N--\2:?\ #K7/ Q\/ZA>W(:4VM_'L
M,5Q&\N\,Q)!#<\CD_ADCIXH=8T3QGIU\N@WEW;7&B06#>0\9,$T;LQ$F6 "X
M;[P)Z=Z] CD26-9(W5T89#*<@_C3J /%M.\/>*]*\.^&-:ATB5[_ $*]O7ET
MTR!6G@G8DE>>6 / .#['OO>*].\2^,/"UIJ,>B)!=65_#>V^D7<BDSHH(99#
MG:"VX\'H!SR2!Z75>WOK2[EGBMKJ&:2W;9,L;AC&WHV.A]C0!YU>:!J7B+P?
MJ:V'A:R\.W+^1);0,L8DEDCE63YRG 7Y0 #SR2<5=V^(M9\;^%]7N?#=Q86]
ME%<QW7FW,3%'D1!D!7.5R.#U.#D#C/H%5+[4]/TQ$?4+ZVM%<X4W$RQAC[9(
MS0 FJF4:3=^3!)<2F%@D494,Y(P -Q _,BN+\&-X@\.^ =/TJ;PQ?/J4$;J5
M$T'E[BS$9;S,XY&>*[N&X@N4WP31RITW(P8=,]O8C\ZEH \TOM#\2:-XVN=<
ML]$L]?M]4M[>.ZB>=8G@EC7;O7>" A'8?EZV=3TCQ+<:EI"W.DVNH:<MJWFV
MD-UY%O#=%]P,B_\ +2-5^4<-SD[<FO0J* /+=-\'WL_@C0_#_B+PPMQ';"0,
M]M=H)K9]P*2(VY< Y;@$]!GTIC>$?%MA'X9UA5M]9U'3HYK:ZL[R8%I()'W*
M!*1@N@"@MCDC\_5:* ,S0O[4:Q>;5H(+:XFD+BV@;>(5P,*6P-S<$D^IXX%8
M'C31]2U37/#%Q8V;3PZ=?"ZG82(N% Q@!B,FNRHH PO&-C>:IX.U?3K"$375
MW:O;QJ7"@%QMR2>PSG\*Y[6_#>NW?AWPU>:2D$&OZ&59(;F0^5(-GER*2IZ$
M<@_RR:[ZJ&G:UINK37D5A>1W#V<ODW 0Y\M_[IH XKQ'I'C#Q7X&O[*]M+&U
MO;IX1#:17)*1*KAV9WQR3C&!D=/?&G+H.HR?%:V\2B%?L":0;)@7&\2&0OT]
M,<=>OYUTNI:I8:1:FZU*\@M+<'!EG<(H^I/%5['Q'HFIW?V2QU:RN+D)O\F*
M=6?;ZX!SCWH \_O/!'B"X^&&O>'8X;=;Z_U%KF%C/\H0S+)DG'!PN,#/)%:7
MC3PG?^*(;B!M&LY)EMT_L[4/M/E3VLV#G) )*AL' ///L:]"HH \\E\/>,=!
M\3S:GX?ET[4(-0MX$ODU"1XV,T2;!(I4'&1C(]OQJ;Q%X8U77;-=/U73=/U>
M(6:F.[,I@E@NRS%F0@$A/]7C!S\N#G-=AI>KV&M6K76G7 GA61HBX!&'4X8<
MCL:NT <?I[>*-'U?0-&F-OJ.F"R\J\O6+?:/.53\Y[;20HY))+>QK5\7Z;J6
MK^%-0L=(N5M[Z6,")V8J/O E21R-P!7(Z9K:P,YQS2T ><Z=X6\2P:]+J#V>
MA6L$VC?81:VLCJL+!G8#.WGEAEL<#(P>I9<^!]>F\'>#M(#:9]IT._M[J=O.
M<)(L(( 7Y"<D'N!T]Z[C6];L/#VF-J&HR-';JZIN5"QW,0JCCU) ]*T: /-+
MCP5XGL['Q'H6C3Z4VBZQY\L;W;R>=;O*N&3"@@KG.#U'?/0]]I-M/9Z19VUR
MT;30PK&YCSM) QQGFHHM>TV?7)]%BN=VHV\8EEA"-E%/0DXQSGUK2H X[P_9
M_P#"/^,_$%I* D6JSK?VCD\2$KB1/]X$9QZ,/PJ0>#M6'A;Q7I4LUD)M:N9[
MB-U+%8O.ZJW'..Q[^U=V5#8R <'-+B@#C[[PM?76I>$KI9;<#1-QE4LW[S,>
MSY>.W7FD6U.M_$N/4U3-EHMH]NDH_CN)=I8#U"H!^+8Z@X['%-"*HPH 'M0
MZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1ONGZ5G:!_P @*S_W
M/ZFM%ONGZ5F^'_\ D VG^X?YF@#3HHHH **** "BBB@ HHHH **** "BBB@
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MAEPK/@E0P7CIM&*ZSP=I,>B7.K6<6M"^4RI-]ECCVQV98'*I\S8!QG;GC\:
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M=UYZW(#,V "@?/4@8Z]ZHWECI*_#;XA.EM9B6UU2Y2$JHS"!(I0+_=&3D 4
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MZ<CGMD9Q5NX\8:):7'E3W,J+]I%H9_LTAA$N<;#)MV Y^7KP>.M<[I%I<?\
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M6^&)]!^&WB2YD>V%_JNI6]W)% #Y,+F>(!5S@MTR6P"<]!757GAG6=>OFO\
M5+FVL9[>RGM;%;&5Y/+DE4*9BS*I! & H''J30!4T3Q_<7?B2QTG4H;&*2\L
MY+EH[>8N]FZ8)BE[9VG/;ITYJYI'BG5]>M].UC3-.@N-%O;MH<;RLT<(++YQ
MR<$97.W&<$=:R-%\"^(+34_#=Y>7&B1II4$MM)!:6[[7C<*,Y)&6;!)R  3T
M:IO#G@GQ+X;E&CVVOVY\,1S^="A@/VI%W[S$&SMVD]6.203@#B@!MW\0M4D>
M\ET?1)K^*VNF@2".UG9KA$D\MW68+Y8(8/A<DX7/? ]"5MZ*P!&1G!&"/K7"
MV/@SQ#H^J:K'I7B&*+1M3NGNGBDMMT]N[\OY3YQR>A(('IUSW2*$14&<*,#)
MS^M 'GWB;Q[J7AZYN'DBT^..&]B@CL96)N+F%BBF92K80;G( 93G:>>0*LW_
M (F\32>)O$&CZ19:8?[-M8;B*6Y:0^9O5CM(&.25P.>.O.<5G:G\.M=OK/7;
M--<LA#J.H+?I++:,TV5=66-VW_<7;@8Y^G2N@L_#>J6VO:WJTE[:R2ZC:1P(
MHB90CQ@A6/)X)8Y'; Y/6@"GIGC>YUVR\.16,$%OJ.L6KW3F96>.!$P&. 06
MRQ  R/4^^;\+A<C7_'(O#$;C^V#O,0(0G;U .2/ID_4U/#\/=3T_3/#KZ9K,
M-OJ^B1O LKP%X;B)R-RNN01]0?Z8VO"?A6Z\.WNMW=UJ,=Y)JEU]I;R[<Q!&
MQ@@?,>/\Y- &?\8,'X5:YNQC9%U_ZZI6!'*WC'XCZ%!Y#Z1/X:B^TR1W)'GW
M*R( -FPE?+XY.[OC KM_&WAN3Q=X2O="CO%LQ=; TS1>9M"L&X&X<Y [U5UO
MP?)JG]D7MKJ"V.M:6P\F]2'<KIC#1NFX$HWINH S-6\7ZS-KNK:;X?MQ)+I8
M5=C6<DJW$S1E]C.&41K@J >26]AS=AU_6-;U%-(LXDTF]AL8KR^:>,3^2\A8
M+$ & )^1B3Z=.3D5[KP/JZ>)9M>T;Q*-,N[Z)$U&-;(2Q3L@P'56;Y"![G^>
M;%SX+O(=<M-9T76S9WL=HMG=&XMQ<+=HN2&8;E(<$DY!_3B@#D?"6NZCH?A.
MQ9/L;R7?BJ2QNE*,0/,G(8H=PP1VR#U%=/JWCB?1-9\3174,,EGI.G17L00%
M9'9RPVL<D=5'.!C-5D^&DD?AE]+&N,;I=6_M:WN_LRCRY@^X;E!&X?B/PX%3
M_P#"NS>ZMJU_K6J_;CJNGBQN(EMA&J@'(*')*@'H,GW)H N1W_B/2%EU36)K
M*ZTA=/>[N# FQK>11NVI\QWJ5SR>>/>L?2/$_BBYN=(U*6T>?2+Z%I;O%LL:
MVB%=R,C[B7 Z'(YZC'2M'P_X(U'3HC:ZUXFN=:T^*!H+>VE@6,(K J2[#+.V
MTE02>A/%1^'? 5_H<D=I/XHO;[0K;BUTV6%!L'.%>3[SJ,\#@<#TQ0!RGC#4
M=8\1_# ^(?MT,>F7=U;NEAY ++%]H0(?,SG=D!CQCDC'&:]CKSF?X6W+Z%/X
M>M_$]S!H9G$]O:_9D=H,.'";R>4!&0,9SW/2O15!"*&;<0.3CK0!PFC)M^,_
MB9BF"VGVI!QU'3^AK6\<>(;CP]I%H;*)GO-0OHK&#:%)5GR<@,54G"G ) SC
M)J,^%=0B\8W_ (CL]9BCDNX$MS!+9[T5%Y'(<'.<_GTJ*_\  B:UI%];:QJ<
MT][=7$<Z7T$8A>W,>/+$8YP%.X_\#;UH R$U?QQINB^()-0@CBC@B5].O]4E
MMXFR<!A*(G*?+DD'C/ /6K'A_P 0ZM<ZQKNGQW<^II%817EA)=6JV[LS[P%P
M N5)48) /)[5-+\.Y+_PW>:9J_B34K^ZN!&%O7"JT(1@RA5 QU4$YR6QUI\7
M@"<:E=7]QXIU6>XO++[)<MMB3?@-M8;4&W;O) '?J30!S5M\0;G3M&U74[C5
M[FZN]/T_?<Z/J%HEO/#<,R!6 55S%\WJ>".3GCIO#TGB_P#MV$WRWDNDR6Y\
MYM0%JKI+U#1_9V.5/0ANG')YJQ_P@MK?7<]UKEW)JDTNG'32S1K'F$MN)(7J
MY..1@<# '.5\,^"!X<EB+Z]JVI16ZE;6&]F#)#GC(P!DXR 3T!.* .KHHHH
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M9_$6QO\ 79=*M=)UB62"_P#L-Q*MKF.%L??8@\+GCGGOTH [%55$"(H55&
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M%G=>([W0XUG%W9PI-(7C*H58D#:3UZ'IQ6K7#+'<W/Q,UF."?[)=2:!;A)0
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METX2N+J:<+]J+\#]YR?DZKT'UH [ZBBB@ HHHH **** "BBB@ HHHH ****
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MMP/;H*D\2>%K?Q&VGRO=W=G<V$_G0SVKA7&1AAR",$''2L>V\::U/X;M]?\
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M4 %%%% !1110 AZ5GZ'_ ,@:W_X%_P"A&M ]*H:)_P @B#_@7_H1H T****
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M+="76HQ'=D3$9 7:-O\ =PIQQ4 \#Z2+?0H ]WY>B'=9#SONXX&>/FP..>U
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M2;);2U0A 2S,QW,[$Y9F/=B2235NN9TOQA_:5]81MH]];VFI1/+97;J&215
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M(Q0\8 &[@X)SG.: /2**\6L]2\53^ _#7BH>*+@W4]]';R6[P(87228Q98
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MRVF?(*)Z A=VWH.H'- '=45YY\0;M6\4^&=)OY[.'2KSSR_VZ$R023*%\M7
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MASDI%RRDCJK=QT- '?4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M"'I5+2/^09#_ ,"_]"-73TJII0QIT6/5O_0C0!<HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "O+_&VBWEUK5]J&@V6LV7B&,1I!=V@!MKU<+\LP
M)VX&6!)Z ?Q=*]0HH \]TJRU*T\=>--3N=/N#%=6EMY+1QDB9XXMKJF>OS'
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M-MW,%R2H)XXZX&+NG>%HM-N-9GBU&^=]6D,LP<QXC<KMW(-G!P .<_=%;]%
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MJRQ_QID#D@YQT'/7%!O_ !AJ]QK6F:=J)-[I BMTFC\F(23^6':21&#'8Q.
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MZT^^]S,<N>^#VR.#CM7444 <_)X,TB1-,VK/#/ID7D6ES#.R2QQX V%A]Y<
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MKB(7##*Q%QN(]AUH FHHHH **.E1P7$-U$);>:.6,D@/&P89!P>10!)1110
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M7" F3:2-R*2,GIP>:\S@M-$OOA;X1&CFV?Q"MW:/#Y!!G$H<"0MU;:%5LYX
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M@T>\N)[68[I(9(Y<[D?*@C(.. >GOQW?ARUUR&UDG\17EM/?S$9CLPP@B4#
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MTMN]TR-&KR%L+'@@;MHWM[;EKOJ "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *C@_U(^I_G4E1P?ZK\3_.@"2BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BDI: "BD9E12S,%4=23@"E) QD]>E !134=9$
M#HP93T*G(-<ZOB&X?Q_#HD9M9+"739+L2)DN'21$QG.,?.>V: -^YMH+RVEM
MKF))H)4*21R+E74C!!!ZBLG3O".B:7<VEQ:VC^;9Q&&V,MQ)+Y"'J$#L0N0
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MW>B^+-(\6SZ[X?@L+R/4[6&*]MKV4QM%)$I"LK*#QACD<UU+>*_#JF0-KVF
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MVS@UKT <18>!;FSL_$>E+J$46AZNLXBLHX26M#("I*.6Q@Y+;=N 3P?6I+X
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M<>[:Y!Z[]P&.X0>M5_#<&JQ>,]&U.XT/7 ATI[6YN+K;Q,7B)P@;$: *<
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M;M,^'/@W3;37=0WVL(CL(IEMF)?Y2%!5=W.%//2@"WI>M-KMYIMQIUR'TY[
M74V4!+F3 C&>Q^63(]ATKH,5R_@'0H="\.LL-O/;+=W$MRMO,3N@1F)2/!^[
MA=OR]B6KIWW%&"$!L<$C(!^E '$_"/8/AOIVTDGS)]W(//G/7<9KE_#?A>7P
MKX0FT:'4FD8><\5REOAD+Y.=F3N()) [\"KWA2TU*R\-VMOJUW-=WB;P9IU
MD==QV;@"1NVXSR: *'C%+>#PSJ&FVMK'-?:P'@@MS_RVE=<%CGLH^8GL%^E<
MT;!M(^(WP_T21VD@T_29TB=B<-(L:H3[G:/PS6SJ7@W7[OQ)/K-EXRFLF=?+
MBB_L^&40Q\952^<9(R3WXST%:$OA$36>CM)J4\FK:4YD@U*10SLS B0,.ZL"
M05&,<8Q@4 8GAF"*7XE>-+?RDDM8;FTNEY^[.8<,<=,]_K4D"BX\5ZWXWMXP
M;.UTMK&V9>?M11C([C'5<@(#GG!]C6@W@HKHFI6=OK-[!?:G/Y]YJ**GFR'
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(.E+10
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 56@
MU&QNKF6VM[VWFGB_UD4<JLR?4 Y%4_$QU!?"NK'20QU$6<OV4)][S=AVX]\X
MQ7E;Z[I%MH'@-]$>+^WH;NVM9+=3^_ =2)HY.XRP).>XS0![31110 4444 %
M%%% &7?^)-$TN[6TU#5[&TN'7<L4]PJ,P]0"<XXJW97]GJ=JMS87<%U W26"
M0.I_$<5Y_P".+P:9\3?!U_\ 9KFY\FVU!FAM5#22 1KP%)&[KG'XT_X86JWU
M]K_BZUGACT_7)T>"QA;/DE 0QD'02,3D@?GSP =OI.LZ?K<,\VG7(GC@G>VE
M(4C;(APR\@=/7I5V1UBC:1SA%!9CZ 5YV_CR[TWP;XBU>73[8W&GZO)81QP*
M0C-O1-[GKU8DGCL/>M2V\0:VGQ ?PO>?8IXAIPU#[3# \9"EMFP@NP!W G.>
MG;B@#H]'UG3]?TN+4M+N1<6<I94E"E0VUBIQD ]0:OUX5X$UWQ%X>^&GAG48
M18MHOVTVLT!5C-(LEPZEPW1<$X"X.<9SS@=?X4N-<NOBMXQAN=5BEM+(VB>3
M]F(^1HY&54._Y<%LDX.X_P!V@#T:BL7Q3K<F@Z*;F"));N::*UMHY&PK2RN$
M7<?0%LGV!K%;6M:T?QC8:!J5W;W4.KV\S6=TEOY;0S1@%E9=QW+@@CH>W/8
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M#<!>25YXYS;^Y\:6<OA'2[[7(8+V[O)[:ZG@",LD80LK8*C$@'0?=W <$<4
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MJP\=^&-3TJ]U.SU>&2TL6VW,A#+Y7H2" <'L<8/K6HNKV#06$RW ,>H%5M6
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MZ4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445G6NO:9?:O
M=Z5:WB37MFJM<1)D^6"2 ">F>#QG- &C16+JOBS1M%O?LE]<R),(Q,XCMY)!
M%&6VAW95(1<YY8@<'TK:!! (.0: "BBB@ HHHH **S=9UW3]!MXY;Z4AII!%
M!#&I>29ST5%'+&JMGXHM+C48M.NK6\TZ]G3?##>QA?- &3M925) (R,Y'I0!
MN454O[^*PL;JZ<-(+:(RND9&[: 3T)'H?RJ/1-5AUW0[+5;='2&[A69%DQN
M(S@X[T 7Z*** "BBL+Q+XHM_#"6#7%I<SF_NTLX!#M_UK_=!W$8!P>?:@#=H
MK%CURZ&J6EG=Z+=VJW19(YVDB= P4MM.UB02%;MCBMJ@ HHHH ***KWM[;:=
M937EY,L-O"I:21N@% %BBBB@ HHHH **** "BBB@ HHI&944LQ"J!DDG  H
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M?,(]P//7 SCD5)KGQ,M-+FU$6MM!>1Z;,(;E/M82=GXW"*/:=^W/.2O(([4
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M3<8GW*P9V8$'C^]C\*ZFB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ(1$)^9SCG@5S-EXE\27WB;7=!BATO[5I4<4BL?,VS>8A8#K\OIWKN:X#PX
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M.?TS0!W@Z5574[![XV*WULUV.L E4R#C/W<YZ53U37+6RE@L([B)M2O"T=K
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M+A5N+=H_.B)QYD>>67/'K[5D>&-=T?3?!ME-8W6K:E!<7DEM;&[^>YGEWO\
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M9E.667=\VU3Z G'KQ0!T%U\1K"+4M2T^TTO5+^YL8([EUMH5(>-E+;E)8#
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M[-/<_P!HVA@MQF:03*5C'^T<\?C0!"?#FD_VK::F+)%O+.'R+>169?*C_N@
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MSUJSH_C:\US5FBL;&RFM4NY;69%O"+FU"%P))(]OW6*C&#QN'7L =K17E_\
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MTNYM;:[0)<P13(#N"R(& /KS]33$TZRCDCDCL[=9(P C+$H*@#:,'''''TH
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M "BBB@ HHHH **** "BBB@ HHHH *I7NJV>GW%G;W$RK->2^3!'W=L%CQZ
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MJ6ECIGQ"TB+1$M;6YDT2\CA\K:-S QF//KSD]\\T :?C3Q;#80VL&E:W:)J
MU.V@FMU='=D:15=2IR0<-GCD5T%UXFT*Q-R+O6;" VI43B2X1?*+?=#9/!.#
MC/I7DW]OZ%-\,]!LI)XEU:QU"T>\@F4^?#,)QYKN",J22V6/7=CO72Z%_9ES
M\7/&LD_V24"UM1N?:V$\K#\GMTS^M ':Q^)-#EOK>QCUBP>[N$$D,"W"%Y%(
MR"HSD@CFEO/$>BZ??)97FJV<%TY4"*295;+?='/0GMZUXW9M8VWPJ^'SP+;)
M)_;MJT[Y"LI5V#L>^0, ^@-63)H0UCQ3H?C&[UA+FZU2:>'3HWDV7L#%3%LV
M#YCA5&,C& ..: /5=0\6>'M*>Y2^UJQMY+4*9T>=0T>>F1U!/8=ZS=;^(.A:
M,-()NDG&J.OD/$<KY74R9 /  Z=2:YRP2SB^,.M[Q$H@T*)/WC!C&!C()/MC
M-<5H$WD^!/A??7#MY%EJTR7,AR?)S(^T-Z<8Q[8]J /H&-UEC61#E6 8'U!J
MCJMI?7GV6.SOY+)%FW3R1!"[)M;"C>K#EBI)QT'O3++7;*_U6YTZ#SO/MX(I
MWWQ,HVR9VX)'7CD=OSK3H \UT23Q#K/B+QAI7_"3WT?]F2Q1V<GDVYP60M\X
M\OYAD#TXIMAXYBT/QGXQ@\1ZPXL[.2S6V1HRWE[XBS[0@SC/4XXXR:N>!G5_
M'OCB1<[)[F!HFQ@2*J$$J>X!XR*R%A(U[XLS%3B>SB2'Y#E]MNZG;QS\Q XS
MS^% 'H=YXBTNQM[:=[AI5ND\RW6VB>=Y4P#N54!)&"#D#'-6-+U6QUK38=0T
MVY2XM9AE)$_D1U!'<'D5XOI;SZ-#X.U75;359=%;0UL)7L#,LEK.),DN(V#;
M2,#'/W>E>I^#;;3[?0 =+TJXTRSEF>1(;G=YC9/WR&)*[L9P>?7!- &;XBO;
M^#XB^$K"&_N([+4/M7VBW0@*YBC#KSC<.3SS@@?6NPEEC@A>:9UCBC4L[L<!
M0.22:X7Q9(T7Q)\&W?V:[DM[-;UKB6&UDD6,/$%3)53U((Q4_B>_N/%&AZWH
M6CV5TS2Z7/\ OI[>6!3*<!(U+J 206SSQ@>M &G8>-]$O[Z.T$LUM)- US;M
M=PM"L\2]71F ! '/KCG&*32_'&C:OJ-K96[W"O>)))9R2P,J7*H?F:-NA X/
MT.:XGP^UK/90O9?#R]CUS3K20NU]#Y4:R",KM1V/SEV ' Q@DG'?)TB'4Y_%
MO@#56T772;2*XBO1):&&&V=X2JQQQG"HBG(S@ C;R2,  ]-T[QKINJ7UO;VT
M%ZT5U))%;W9@(@F9 Q;:_P#P!L9ZXXJ&'Q_HLNIV5F5O(H[^0Q6=W+;E8+AQ
M_"C?AP2 #V)KB=%T:\AUJS3PW!JVG:;?13G4-*O[=Q#9.T;8DC=A@$L0,(3D
M$].0&> =/CL5TS0[[X<LFMV+KYVJSV<9@"JW$B3'+%L 8"]^>.: /8JR=8\0
M6NCW-A:/#/<WM^[);6UN%+R;5W,<L0H '))(IFAZ^=9N-1@?3;VQDLI_*Q=(
M%\U>=KK@]#BL+QQ-JL>KZ&EOIVHW6ELTQNWTP 7"MM&Q0^045B3D@@\=0* -
M&V\<:7=Z!!JL,5T1/=?8DM60+,9]Q4QD$@ @@]3C ZUJZ3JHU6&=_L=U:203
M-!)#=(%8, #D;2000000<&O,](T7R_!-[HFN>$=4DLSK4K&.( O$C%F26,JV
MYMN%!(Z[N-W-=?\ #^WUBTTF^M]4GO)[>.]D73I;X8G:VP-N_/.<[OO8..PZ
M4 :FJ^)+?3-2@TU;6YO+Z:WEN5@MPN1''C+$LP R2 /4FL@_$C1FLM"NX(+^
MXBUH/]E\F#<=R@DJPS][@C SS5+Q>FL3>++2 Z1?ZCH<MBZ!+"01DW)<']\Q
M9<1[1TR02>0:YCPSX=U>UTCP!976B7T)T>\G>[+!#MW;B&&&.5W-]< G X)
M.E'Q5M3;7Y7PWKS7>GN1>6@ME+P)M#;V.[;@@\#.3@\8YK=N/&6G);Z<UJ#<
MS:C;?:[> 2)&WE8!W,78 ?> Z]3['',VVD:C#JWQ'N&TVZQJ<:+9G Q/MA9/
MEYX^8]\9!]C67%H&M:5%X5UV#PV=0-II*Z7>Z7(R"2/!!\Q=V5/(^N"/? !T
M*_%72)=(TO4K:PU&XBU"\:Q"0QJSQ3@'Y&&[DG'&,C'<5H6/CW3YX-=:]M;K
M3Y]#*_;+>?8S#<NY-I1B&W=  >M9&J:9K5\GA>X&@I;^1JZWMQ;6\D?^C1A"
MH#<@.QSDD=.GN<S5O!FOZMJ'CXQP&$:DUE+ILTDJ[)&M^2I ;(!(XR,=Z )]
M0O;B_P#BSX(FN]'N+"4PWC*9&1MRF$X4E3PP[CH-W!/-:4GQ5T6.\M1A7LKF
M]-DDZ7$;2!]Q4.8L[A&2#ANO0XP159$\4:]XQ\)ZK?\ AJ33H-.-TMT6NXY"
M&>((" #RN>G?VQR8O"5AXW\.:?'X5.E6CV5M*5M]9:Z4J("V['E8W%P"0.@S
MC/') )/'7B!=8\%>*[>QTL7]C9P2V\]SYBX64)DE5/WO+)!)R,$'&2*[?1-W
M]@Z=O55?[+%N"G(!VCH<#/Y5YR_A_P 5Z5X<\5>%K31TU"SOVN9+"]%W'&%6
M8$F-U/.X$G!Q@YZBO1]&CN8M$L8KR)(KF.!$E1'WJK  '!P,T >;Z?J]WH7C
MWQ^=+\/7.ILL]K-)';,D84>0"3R?F8G)P 23]:Z.W^(,%W<>&GM]/E.FZ\"L
M5X[[1#( 28W&#\V5('/)!],TRVL-=T/QEXDOK;21?0:N8)+>5+A$6)DB"8E#
M$,!D9R@?CM65X@\-66F_"8>'KK48EU*SA%U;R1_?%R'W*T:YW<NQ4?[U '>6
M&I?;[O485BVQV<X@\S=G>VQ6.!CC&X#Z@^E<QXNU_6M.\8^%M,L(K;[/?3R[
M]\Y5I=D;$J?D.U1D'/))P,#OT?A_2SH^B6UH[!YP#)<2#_EI,Y+2-^+%C6)X
MOT'4]0UWPWK.E1V\TVDW$K/#/*8PRR)M)W!3T(':@#CK+6+[P]X]^)%WINC+
M?B'[+<3+]H$"(JPLS'.#ECDG&.<')KJ;GQ!IVIZAX*OVT:*Z&IEGM+F20;[1
MFBW' P<D@8ZCI5&#POKBZCX\N9+: _V[;1QVV)@/F6)HSN'8$MD=>!3K#PEK
M<5IX%ADCM4_L,L;O,QY_=F,;,*<YSGG'I0!I6/C.?5/$-Y865K:216=Z;*XB
M:Y*W28(!F\O:08\GCGH,Y[#L*X'4O!VH:UXAT_4[FTT^UOK'4O/34[=SYLEJ
MK-MB9=HY*E5.20!D^U=Q=&X6UE-I'$]P$/EK*Y5"W;) ) ^@- 'D_P 1-2O3
MK(\1V5[$MOX4N8S]F#*6N2PQ<<=?E1E'_??>NW\3^*WTCPG#KFFP1WJ3O (P
M6QE964 @=S\PXR/K1IGA2WB\*I8:G86%S?R0,+N3;N6:9\F1BQ4'YF)/3C-<
ME'X#\5O\*HO"%S+I+W%O,GDW(N)"IC5]X# Q=1POICZ8(!KGQ;XH7Q;<>&6T
MG2Q?R6@OK1_M3^4L6\J1(=N2P.!\HQ]*@MOB6]UX1L+Y;)1JUY>R6 @1)9D2
M5-VYL(I=E"KNP!DYQD<D;)\.Z@_Q*C\3,;06R:7]A\K>QDW%]Y8?+@#/'TY]
MJYJ+X9ZQ;>%8K6TU:WM=9L]6DU.SN4#,F7SE'&!P02#U_I0 E]\2/$&E^%]2
MO;O0=MU:744$4\]O-;0W*2' =$<;L@\%21ZY[5N6WBS5[#Q=?:5XAM;"&T73
M7U.":T=V*1HP5E?=C+#.<@ 50UOP=XI\3>$I[/6-3TY]3GGA<+ LB6T"1MNP
MH.69B<Y8^W'%:VH>%+G5/&9U6Y: 6$VCR:9-$LC>9AVW%@<8]OU]J .9\1WF
MM:UI_A'5KI;%--N]=L;B&!%<31(S@QEFW;7)!Y 48)[XS5N[\9>+))?%@TVS
MT<)H#LQ,_FEI4";]H QEB,\\#CH<Y#(_ ?BO^R](TF;7[*6QT?4(;FU=H&\R
M2.)@423! X [=>.>.;T?@K557QNAGLMOB(.(B&;]SN0Q_,-O/!SQWX]Z &P^
M-]975O"TEY9V*:5XB7]S'$7:>$F,.I9CA2#GD <>IJH_CGQ'J);4M TQKW3D
MO#"EN+%]TT2/L=Q-O #95B!MX'7)X&D?!>HRP^#E>XM5;P\%#!=Q$V%"<<#'
M SWYX]Z@L? NO:-J]W#H_B-;7P[>7#7$EG]G!EA+'+K$_P#"#D\]5XQSS0!!
M?^*?%LUYXOM]-72H4T,))'+/'(6=3%YNTKG[V.,]!Z5!/J^O:UXJ\$SVFI06
M=MJ>F27OV<VQD"/Y2DY.\;O]9@=,8[YKH!X2O%OO%UQ]M@*Z]&J(OE',!6+R
M\GGYN,'M53_A"-4B7PM+::Q!!=Z%:O9ES:EUFC9%3."PPV$!ZD9]N* .YKFO
M%7B&?2[[1=(L3"E_K%R88Y)AN6)%7<[[006., #IDC/NWP\FO+XCUTZAJ!N]
M+:4&S#VODF$Y;<BG^-0-OS="3P>M'C;P@?%EE9FVU"73M2L+@7-G=QKN\MQZ
MKW!_SZ4 4-0UWQ%H-DT&H_89+N]U6*PTNY1#M99.=\B \%0&X!&X@=,YI)]>
MUS1O$4^BWMQ;W0N-/DO+&Z^S%=C1_?1T#?,.0001Z>]*_@.ZU'0I(-=UR6^U
M@SQW,6H+ L?V>2/)CV(O&!N;([[FZ=KZ>&+RZO)=2U:^MY]0-FUG;M%;%8X%
M;[[!2Y)+$#N, 8]20#D[+Q?XH73?!^NWMS9266L7<5E-9Q6^&!DR!)O)[$9V
M@#KC)ZUHMXLO&\:SZ-<:G_9ETM[&MM:W=L%AO+;*Y,<F,F0_-WQT&.I$W_"N
MYAX8\-:-_;"?\2*]CNTF-I_K3&254C?QUY.>?:KNI>#;[6+R);_6Q-ID.H+?
MQ6_V7]ZA4[@@EW_=S_LYQP,"@# \+7FHK?\ Q NSJ,LLME=2)'YT<9#%(AM)
MVJ#QMP "!R>IYK*N]8U;7;?X:7L^IS0RZA=,9A J*I8*<-@@@D ]#D>U=I%X
M)EM=3\27-KK#QV^MHQ:V: ,(Y60(7W9!8=?EX'-4%^&SIX9\/:9'K;Q7NA3^
M;:WT=LN<<Y!1B0>#U]1T[4 +:^(-7=_'=N]V3_8^#9S;$W+^YWX(Q@\^HZ'V
MK&L+[5M:\6^"+JXU.YC:\T:2YE2)(PBOA-Q *G[V<'KCMCFM^_\ A[+<ZMJU
MU:>(;RTM=7@$=[;)&I\UU0HK[^J\=0N,],@5+'X CMX_#_V76+V"?1X&M5G5
M4W2PL "A&,#H,$#(]SS0!@P>(/%_B&Q;7- W>4M\Z);S/ MN8(Y&1@V1Y@<@
M9SD8XXQ5C5?%%_I_C:;3]5U&\TBVFN8$TN;[,C6EPI"ET=RI(<G<.HQP>W.B
MGPVMX-9O)[76M3MM*O9?/NM)B<"&1S][G&0K?Q =?7%:&I>#SJLUU#<ZO=-I
M5W,DTU@40J2I!VJV-RJ2JDCZXQF@#HYHVF@>-97B9E($D>-R^XR",_4&O"+J
M.>+X )<->SS.^IY F((1A>/D@@!B2>3DGGIBO>\8&!7$+\,]._X1ZXT*74]2
M?3Y+K[1%$'0>3\YDVK\IR-Q)R>>V: ,RY\1ZOX6\<:II]YJ,^JV<?A]]6"2Q
M(K)(CE=J;%'RD#H<GWJ?P^?&5S-H&L?;K>;3[N!7U!9[H,L@=5*F%5C&P@DX
M&3D=<GFNCN/"%A=>*CX@N);B6X:P.G/ ^PPR0DEB"NW.23GK^E4?#WP\TWPW
M<1&VO]4N+2V8M:65S<EX;=CD$JN!SACC.<9/>@"[XZUV;PUX)U75K<#SX(<1
M$C(5V(56/L"P)^E8EO:^+[.\EN)=34:;)8N'\RY6:7SPI*R1_NE SC)7E?05
MV6IZ;::QIESIU_")K2YC,<L9)&Y3[CD?45SFC_#^PT6VDA@U36)P86@@-U=>
M;]E1NHC4C:.@Y()P,4 <G;:MXBM-$\":]/K=S=3:M>6UK<VH1!$T<L;'.,9W
M#:"3GJ3@8P*U/"MA)#=^.9HM1OUE34941FFW[3Y$9#88$$CH,Y& !BM@?#_3
M?["T;1WOM0DM]'N%N;1GD0NKKG82=G(7) &,8/.<#%R'P?I]MK6JZI!<7T4F
MIKBXA6<^5NV[=X7^]CUR/:@#B4U37-0\.> '37+NVFU.3RKJ6,(2X,;$MRI^
M;CCM[&KS?V]=^(;_ ,-6NK3SOIEA"1//=FWDDDE,A\TE(FW[0%&.%ZYSGCHX
M_ ^EQ6>B6L<UXL>BR>99XEY!Z?-Q\W!(Y[$T[Q!X'TGQ%JMKJD[WMKJ%LGEI
M=6-RT$ACR24++SCD_F: +_AL:DN@6L>KW=M=ZA&&CGGMON.RL5ST'/'/'7->
M?^/+O4PWBB[T[5=1DFTNVBE@CM9###8LJ[V\P[@)F88.TAL#&>HKTVPL;;3+
M""RM(A%;P($C0'. /<]3[GK7-ZI\.?#^L7^I7=XEVQU)5%U"ETZQNRKM5RH.
M-P'3M[4 9>I:C-=>*K*TU6YO(-+FT8W47V&62,M.&&XL8_FX4C:,X))X)Q6)
M<_\ "36^@>#(KG5]2@O]3U01W3,X#^2RL0",##!%4X[-GCM4_B'08;3Q&D,N
MC>)Y+)+)(+:]T:Z=G;#,SK,=X;J5QD$?3MO:+X1%_IEN=<.IR"UOOMFG)>WC
M-<VXVJ!YCJWS'.\XR<!L4 8<UMJG_"4+X+@U2[N8K2P2Y66\U.:WGE#RON;?
M$-SE5VJ,G ZD-VK377B3^U/#_A*XUBVO+I;2>62Y%W+;)<RQRA A>/YRRKNR
MN1D\G.,5W'B?P-H/BY[:75;:0W%MD0W$,K1R*#U&Y3R/KZFF:QX \,ZYHUGI
M5YIB?9K(?Z*8F9'A]2K YYP"<YR0"<T <;J5EK>E1>&=,N/$EQ<.?$!@:2"X
M8N(61G$<A8DNR\8+=L5"GA]I]0\<:')K>MFPTV.*YMD-^Y99)(6<DO\ >8!E
MR%)QGD@GFNY;P)X>:RTRT%G(D.F7'VJV"3R*1-G.]B#\S9SRV>IJX/"^E"]U
M6[,4QEU6,17F;A\2*!@#&<# )'&.#0!YK_;.JZW'\/\ 2[BZCVZCIC7,KW,K
MHMS,$4!6*,&)&2<="2#R1Q'XAL-1T+P7!ITWB*6XGC\0PQ0O:7#AK5'(;RF)
M)+X!R-^>HKT34? ?AK5=!M=%O=,2:QM/^/=&D?=%[*^=P'MGL/04]?!7AU-'
MM=)33(UL;64311([+B0=')!RS>YR: .$U#28-+\1^*-!$MQ-I,WAS^T#!<W,
MDH$JNZ[LL21G;DC.#76_#"UAM?AOH7DIM\VTCD?DG+%1D\UM_P!@:9_;,NK&
MUW7TT'V>21G8AHO[I4G;C\*71/#^E>'+)K32+*.T@9RY1"3ENG4DGL* -*BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *I:GH^FZU;K;ZI86U["KAUCN(@ZAAT.#
MWYJ[7+^*-5O=-U_PPD%VL-G=7LD5TC*/F40NX.X],%: -8>']'$UW,--M1+>
M1^5<N(QF5,8VMZC'&/2H1X5T$064 T>R$5B_F6J>2N(6SG<@['('2IM-\0Z-
MK%E->Z=JEI=6T)(EEBE#*F!DY/;CFJ \=>&7L+Z]CU:&2"QC$LY0,2J'[K 8
MRP/8C(- %]?#^CIJ!OUTNS%X7\PSB%=Y;^]G'7D\]:O3P0W,#P7$22PR*5>.
M10RL#U!!ZBN<TCQ]X?U6PTZX^WPP2W^Q8H')#&1@IV#(&3\PZ>M:MGK^EW][
M>65K=K+<V1(N(@K;HOJ,=^WKVH N6UG;65LMM:6\,$"C"Q1(%4?0#BL\>%_#
MRP/ NA:8(I&#/&+2/:Q&<$C')&3^9J"[\9:!8V5M>7&H!8+F(S1,L3L3&,9<
M@ D+R.2 *L7OB32;"TM;F:[#Q78S;^1&TS2C&<JJ DC'.0* +!TC33=0W1TZ
MT^T0((XI?)7?&HR JG&0.3P/4T6ND:;8P206FG6EO#(,/'%"J*P]P!S68_CG
MPS'::?=OJ\"P:@2+5SG$A'WNW&.^<8[U;T+Q)I'B6">;2;L7"6\IBES&R%&]
M"& - %F+2M.@LQ9Q6%K':@[A D*A ?7;C%/73K%9$D6SMP\8 1A$N5QTP<<5
MD:WXKMM$UW2M*EM;N5[\R'?%;O(JJJ,W&T$LV0.!T!R<<9YBR\=6F@ZWXKAU
MJZNGM[6_40D*\[1H8U+?*H.Q%ZY/'- 'H)L[8RM+]GA\QB"S[!DD="3[4"TM
MP[L+>(,^=QV#+9ZY]:S;WQ-IUFMKM,]T]U UQ#':0M*SQ#&7X& /F7KC.>,F
MK>DZO8Z[ID.HZ;<+<6LPRCKD?4$'D$=P>10!;5%3.U0NXY.!C)]:1HHVD21D
M4NF0K$<KGK@]JYC6/B)X<T._O+"[N+@WEFBO+!%:R.^U@3N  Y4 9+#@9&3D
MU;/C+1GMM,GM9I+S^TT:2TCMHR[R*HRQQV Z'/?CK0!O45RLOQ'\-0Z-I6JF
MZF:TU23RK9EMW)+ X((QP001CJ>V:S+7XDIJ?BO2-,L=,OA:WEO+-(\UN5?Y
M6V !2<@!@V2?;% '?45Q6CZWX>TR?Q9>Q76H;;6\W7_VG<RI(1C;$O7'0  <
M\8[5?C\<Z6NKW>EW\-WIUY;69OVCND7YX!G+J49@<8/'7VX- '345BZ;XC74
M;^*T;3+ZT:>V-U#).(]DB J#@H[<_.O!QUKEOBC+]FO_  9<EYE6/7(BZQ!F
M+K@G&T?>/ [4 >A4M<K9>/=+N(M:>]@N],?1E$EW%>1@,(R"RN I.00#QU[4
M6?CNRN-<.CSV5U:WS6K74$;O$_G*,Y"LCD!ACH2* .IQ17#:=\4])U&P341I
MVJ0Z>]N94NI8 (W<2"/R@<\N68 =O?@TM]\1DBBUNUM],E&KZ=IQU!;::6,I
M+$."P=&8?*>HSGTH [C%+7(Z?XQF_P"$:T*XO;"5M4U5(UM[960>>YC#L^02
M%0#).>0!T)P#H:'XF35M1OM*NK1['5;$(TUL[AP48?*Z,/O*<'L".X% &]17
M.:WXHFT7Q+HNEOIOF6^JRF%+PSA5C< DJ5QG) &/4DCC'-"R\=FY/B>.?3D@
MN-!;:\0N2YFRI*D83@-C ZG/&!0!T\"V5M=2V\)A2YES/)&&&]LG&\CJ1VS^
M%37%S!:0-/<SQPPK]Z21PJCZDUR#:E;K\05ME\/Q#Q"^BM.+EIP%*AP/*W 9
MQN/WB.W2N#\1:WJOB3X%W^IZO:VZO]M5X98GWD$7>W 4K\NT?*#DDCTH ]PH
MKDM-\874_C-_#NI:,VGR26IN[1S<+(98PVT[@H^5O;)^M3^-?%DGA'3[&Z33
MFOC=7L=H(UE"$%\\C(Y/!XX^HH Z:BN"N_']_8&VL]1TFRT_591+(T-WJ $2
MQ(0%;>J-DL3P,=CGI4*_$MI])T21=.CLK[59Y;=4U"9HX8F1<Y+A#D-E=O S
MF@#T.BN#U?QUK6D2>'[63PVDE_JTTT'D)>@!&0D##%1E2-K9XX/2H4^)-QID
M.LVWB/2X[35]/:+RK>WF,B7(E(6,JV,_>.#QQUQVH ]"HKSZ#XDM:3ZNNK6+
MFUL;+[9'>VUO*D<N.&B_>*,/G&.<$'M6[9ZAXGFNEAN=-LX8Y[+SX[A)"Z03
M9'[IQP6X;.X8SM/2@#I**Y/X<ZCJNK^#K34=5GAFEN=\@**01^\;(.2>!P!C
MH!5&XU'6Q\7X[ 7=NNFIH[W(A*M]TS1JQ.#@O\O!Q@ GU- '=45P#^.M43PL
M/&/V.V;0/,):W4,;G[/OVB;=G;G^+9CI_%FNVN)'ETV26SFC5VB+12LN]0<9
M!QD9'XB@"/4M7T_2(X7U"[BMEGE6"+S#C?(QP%'J:KW7AO1K[7;76[K3X9M2
MM4V07#@DQC)/ Z=2>>O->5IJ>KZI\$].U:^EBO+F?4X)(T"%&+_;>06+$<GI
M@  <<UUX\9ZGH_B'5-/\1PV AM=).K)+9E_E0,5,;;OO'/1AC/H,X !W5%<1
MH/B7Q+J.IZ<9],$FFW:,9I%M)(&M6VAEY=B)4.=N0%.><#I6UXPUFZT#PW<:
MC:6YE>)DWD1F3RHRP#R; 06VKDX!'2@#=IDTJ00O-(2$C4LQ )P!R>!7 W/C
M+4%\%W>O:?J&FZA;QW,"VUQ%"P$L;ND;!T+95U9R>W0<<FMBXUZ^A^)5KH.8
MVL;C3)+K&SYU=7"_>STP?2@#=TO5+/6M,@U'3YO.M+A=\4FTC<,XS@\U'9ZW
M87^K:CI=O,7N].,8N4*$;-Z[EY(P<@'I7D'A3Q1XET'X7^'=>A33IM @9;:Z
MM]K^>J>:8S('SC.['RX_$UV-[XYFT;6/&D=ZD,D.BV<%S;)%&5:3>K$ACDYY
MV#/'4\4 =]17G\6N^,-*N&U#5-.DFT9+":XNWD6"(P.B%QY821V96P1@@D9!
MSUJ_HEQXHU6#0]86\M#8ZA;F:\MR@_T<.FZ/RF RQ!(#;B<\D8Z4 =@"#G!Z
M4M>>?"8WL^GZ]=7FHS73-K-RA#JF"5*C=D#T &,XXX%:/B74M?@\;>'M*TV[
M@MK+48[@2O) )"&1-PQR.WX>N>E '945Y!/XE\8CPOXGU#^V[59/#E[+""MB
M,W83!P_S848;'R@'WK3\2^)]5FMQ-::BUBLFC"_M;>S033M,1N_>Y0JD0 QD
ME<\\]J /2RZJ5!8 L<*">IQG^AI!(C2-&'4NH!90>0#TR/P/Y5Y,UYJ/B/6_
MAIJ,FJW5F^HV5Q)+'!LV"409+@,I&3O(YS@=,<YJV>LWGAVY^(VMR:C>74FG
M7*111S,A1BP"IN^7.%+= 0,9^M 'LM%<-I$/B^/7E6>ZN6TFYM"KRWC6[213
M@$AHA'P5/H<]*A^&<OB'6]"TWQ%J^O-<1W-JZ&R%NBKN\PXDW#G. 1CIR/3D
M Z>]\16UCXFTS0I(+@W&HI*\4H4>6!&,L"<]>G3U%;%<!XSM[FY^(W@J&TNS
M:2/'J \Y4#,H\N/.T'C..A(('H:PAXNUK1?"NKVDNH/>7MOXA&D6UY. 'V-L
M(+$*1N +#)!&<'!Z4 >N45YK(OC'1M-\2/=Z@L5H-,EN;(M=BXN8IHUR2"8U
M!0]^.">,9K/N[WQ)IFG:$TFOS7=QXC>UB$9 A$ $3,X1\,07^09()SD_0 ]:
MHKR^XO\ Q7X7TK5EU2^B6&ZNK:+3Y&N?M$UHLL@C=F)1=P7)*D@\C!S6G<27
M_AOQYH6DQZA>WNGZU#<1RK=2F1X7B3<'1N,9S@_RH U;GQBPU2>VT_1KS4;>
MTNDM+R>V*DPR, ?N=6"AEW$=,]\&NHKS+X5:>L6K>,91<W3F+7;F$*\Q96QM
M^9AW;WKH_%TKG4-'M%O;U?.>8FPL24FN\)QB0,OEJI8$DD \"@#JJ*\8M]9U
MR]^'/A:Y.KZA!=MXA2RDN!("T\?VAD^8_P 0P .>N#G(K0U'5]4\!7OC 1:E
M>ZK'!I<%_;+?R&4PRL[QG'^SD!B  ..U '<:SXGCT;Q%H>D26DDAU:1XTF#@
M!"JY.1U/;\ZWZ\GUC3HK/QA\.KB*_O;HSS2LS7-T\V\^4#O&XD+G/(7 Z<<<
M=SXSBU6?PM=0Z+=16^H.4$322>7O^890-_"6&5!]3^- &_17C-[K2VW@GQ0]
MO+K>D:G8M:&XTZXNY&-D2X&8I-W*."W0\XZ#BNWNIII?B?;6 N[E;6?0YW>%
M)V5=WFQJ' !X8 G##F@#KZ*\*BT_4K3X5Z;XUB\0ZO-K5JZ21K+=,T<JF?;Y
M13^+.3R<DYZXP!NW%KJ/C34_%MLNK1Z==65YY$+-+('M8D52LB!9  &^8DGK
MWZ8 !ZQ17DMSIT^O_$NSTFXU[4C97/AB.XF>SN'A$T@EV^8!D[,\' _'/.77
MK7F@>*(YM9M[FYTJ?58_LNLVMXS-"VX((9T)QMR"I(X_$T >L51UF^DTO1+[
M4(H5F>U@>81L^P-M4G&<''3TKRNUM)/$]MK>JR^)K;3+[3]7F,EPUL[3VBQO
MA4!,H&PH%^7;@Y/4U;E:V\6Z?\0&UA5:\TR2>UME+E#!$L0*.O/REVW$GN.#
MQQ0!Z'X;U9M>\,Z9J[Q"%KVVCG,8.0NY0<9_&M2O%-$G>_E\'>'[JYLHK)O#
M4=Q#'?0F6*:;*J?E#I\P49&2>_&<&M*;0-3MM%T;3],U*Q\4'3);EI+"^!1;
MI/E&%8EANCW[022!N]10!ZS17/\ @G4;+5/"=G<6$$UM!ET^SS_?A97(9#Z[
M2"/PKR[QY+'<67B_4K!EEDLKV&,W]U/B:VE4I^YMU R%&2220"2W!QF@#W L
MHSD@8&3GTH) &2<#UKS6YT#3=?\ B]J]O?H\]I)HL)> 2L(Y"9'7+ 'G&!CW
MYZU@>&]1BD\/?#K3M:N-VF7+7GF&X?Y))(F(A1R>HY. >I5?2@#T;0O$-WJ?
MBOQ)I-Q# L6ER6XADB))=9(]_P V>_3I71E@O4@?6O/? EM867Q"\>6^G)"E
ML)K-E2'&T$PDM@#@?,3Q2>-M+LM4^)7@VUO5+07$&H1RH'*^:HC3"G!R1\S<
M>YH ]":1%QN=1GID]:&=5^\P'U->-WUEI-QXHU[PQK>H66FV]O8V]MIOVV)7
M/V41XW1.Y&&#9R>N0.N*D.B:1J_C[PG:7L\NJVTFA2@R77!NE5AL9\?>SUYS
MT!H [[QQKU[X=\*3:MIRV\LL<L*[9@2I5Y%0XP1S\V?PK<N;^SLFB6ZNX(#*
MP2,2R!=[>@SU->,:A;1:5\/O&FG:>S/HMIK=O'99.0A,T)DC7/.%<E?P-6_'
M]WIEQJWC.%9+6&ZM](2*YEOFW,V59D2WCXP22,MN/)'RF@#UV[O;6P@,]Y<P
MV\(X,DT@11^)HGO;2UM3=7%U##;@ F:20*G/3D\<UY#IGB#2HO$&AOXKNK0Z
M?<>&8%LIKG#Q&7I."3P'/ /L .O%)JU[I.D7G@T0W4NG^#XUN8[:Z<"5!+_
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MN3C#+]>V<5W>OVM];?%#P]K$6FW=W:?9)K25[=%;RF9E*ELXPO7DGM^?<T4
M>07?A#7-4L/'UO!:-%+?ZC#>6'V@!4N!&P;!![$H1@X['I6WH:2WUM=W"_#B
MUTF2*TFCD6:*%6N9-N/*3;_ W.6/!X^H]$J 7UH1,1=0$0';*1(/W9]&]/QH
M X+P7X?N]$\3/_9-OJECX=>U836&HR!E@GW @0_,QQC.2#MZ<D\"]X_TS4M1
MU#PI)I]E)<I9ZQ%=7)0J/+B7J>2,]>@KL;>Y@N[>.XMIHYH)%W))&P96'J".
M"*EH \P\1>&-9\2ZOXTLULFMK?4-.MK>SNY67RY'B9F.<$L 2V,X[&M7P_\
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M:,K]U@X P0.,XZ=<U)XE\0S:#<Z(B6B3QZEJ,=B[F7:8BX)# 8.?NGN.U;]
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MH00: ->BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN)K^32]3E>2._;8J.V6) 8;@<D=3GUKK3X1\/'1O[(&C60T[?YAM5A C+>I
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M<$JW0\]SZUEZ/X-G?5+?4=5TKP[I\MM*T@&DVV'F)4K\\A .TAB2N.3CGCD
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M&0H6QR 2.V<''L*\QTS5_$WA^W\:7^AZ58W=E:>(+JXO%GF*R.@2,LL8 P"
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MHS[@<L!D\XZ]A0!Z317"Z6?&47B*UED=Y]'FM&61;Z: .)\%E9/*4<'&"#G
M)/:L_P #Z_J5YKD6FZWJ6I6^M10R->Z=>P(L<IR )(&51E1Z9Z'//6@#N];U
M:'0M$O=5N(Y9(+2)II%B +%0,G&2!T]ZDTO4(]6TBRU&%)$BNX$G1)!AE#J&
M ('?FL?Q^,_#SQ$/^H=/_P"@&N&T.\U?0[[X=(NKW$]GK-B(I;)T00Q*ENA3
M9@;@1GDECGVZ4 >N45Y)I>H^,O$_AZ#Q-I-_#:L]V\KK=W>V&.!'8-$T7E\$
M <MNSG)R.,:$!UZZ\3^)I7\0WPM="OHIXK.-$/GH85D:)C@?*02!Z9R2QQ@
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MU*)[?PQXQT:XT.'3-=32$N)/L$F+:YBB+?O4Z$-RV5;).!UYJ>70X_#U_P"
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MEH^HZK!IL;W,5S<Q--;"XMI(A<(.I0L!GUQUQSTKE/'OB^&;3[!-)NM0C/\
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MSD'(XR2#3M7TW4(_%XU/PS9ZK8:O)?HM[$T;&QO( VUI68C:#M /'S>@/WJ
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&\ ZGH5X;2R\33)X;\XS#3/LZ[ERQ8QB7.0A)YXSCCN:MGP3,UCXLM3JJ_\
M%0LY+?9O^/<,FPC[WS?+CTYY]J["B@"GI-BVF:-96#S"9K:!(3($V[]J@9QD
MXZ>M8L_A)SXX'B>SU22VDDM5MKB#RE=955MPY/*^AQU'0CK5L>(D/C5O#1M)
M5D%A]N%P6&QEWA-H'7.?7TK;H \];X89\$'PQ_;!\EKW[6\WV;YC\V_:!NP/
MF[\\<>]7=2\!3W'B637=+\0WND7-VB)J"VJ*5N0@P#AL[6 X!YQ6OXP\2_\
M")^'I-6^Q&[6.1$,8E$>-QV@Y/N1T!-;U $%G:16-E#:P[O+A0(I8Y8X[D]R
M>I/<UYVMEJ%W\8M;:QU":P5M.A4S+"LBN1U7YAC(SGCI77R>(O+\;P>&S9G]
M[8/>BY\SCY75=NW'^UUS6Y0!Q\WP^M$CT;^S-1O-.GTMYF6>+:[R^=@R[]P(
M)8C.<<=JJGX9V_V1[5-<U,0G5/[44,48K-N+#DJ21DDG.2<#GU[JB@#G-?\
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M[5LZ9X;M-*U74]1AFNI)M2</<K-)N4D# (&.,  <=A6Q33(@7<77;G&<\9H
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M6DVB37]LT(3A%+;=JEC@\+G('M5SPOX6TS0;&UDATFTM-0^RI#/)"BY) ^8
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M<>XKE/#NN6^E^+OB)J^I6L^GPVZV<DT4K!V!\M^FTD'<>@![T >H4UG5,;F
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7 ?&$A/!$<C$!(]0MF8GL-XKOZP/&'AR7Q5H;:
M6E_]B1I8Y&D$0D/R,& &2!U H WZ\XF\2>,-3%SJ/AW3FNH;?4'MTM"($BEC
MC<HY:1Y X<D$@A<#IANM=3/I.LWLENMYK%O]FCF262*WLRAE"G(4L7; R!G
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M>6SP[Q_"6! /X&KLCPVD$LS[8XT!D=L= .234&EZI9:UID&I:=.)[.X7=%*
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M::Q!>+9VLULMC=/9O%(BKAT S@*2,<B@#7HHHH **** "BBB@ HHHH ****
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M*@N+ZTLT=[FZ@@1 "S2R!0N>F<]*Y#X5D+X1FMHV_<VNHW4$29SY:+*VU1[
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M"VE?P=;W7EM#)X@MQ*DA&UH_F#9![<\_6N>\26TS:W\1=/T%$6ZFTVT86\&
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M$L[>>>X%Y Z)!&SM\KAB<+SP!6U-XHMS<VEK96M[<3W$ZQ\V<R)&F<L[.5
M"YQZG ]P 1W'C;0[74Q8S7$RG[0+5K@V\@MUF(R(S+C9N[8SUX.#3=0\=:#I
ME[);7%Q-MAG2VGN$@=H8)6QM5W PI.1],C.*\XT[2K:UN-0T#6_ U_J.I?;)
M6M;KRW:TN%DE9DD=L[4QNY."0!W/%0>,(]2U.R\6VC:)JZ7/]H(]O;V5B5@G
MB5T_?NX'[UF Z9..,#@D 'JFI^+M-TF[FMYTO)# JM<26]J\J0;ON[RH..!G
MV!!. :;K7C+2-!DG6[:Y=;55>ZDM[=Y5ME;H9"H.WCG'7'/2N+\2QW4M_>ZU
MX?M];TSQ"R1[+=K1I8-04(N%D !13\VW)8%<<^U'4=/.E^.==;7/!M_K=KK)
MAEM9+"/S45Q&%>-\LH R.I__ % 'KT$\5U;QW$$BR0RJ'1U.0RD9!!JGK&LV
MFAV:7-V7(DE2"*.-"SRR,<*JJ.I/\@3VK'L]7&BWVA^''T2XMDN+4!);==UM
M ZJ3Y6[KD!3C\*C\?R:E%I-@VG6,]T!?Q&X:UA66>&(9W/$K C=T&>P)H MQ
M>,M,DT^]N76Y@DLKE;2>VECQ*LS%0B 9P=Q=<$$@YSG'-:&EZLNJ?:4%I=6L
MMM+Y4L5R@!!VAN""0PP1R"17FMKIT@A\6V>J^$M9N]-OKJVG5))"\KILC4D-
MO+%UV[L G&,9' /4^!+?6;275K>[NKZZT:.5!IDVI(4N2NWYPVX!BH. "P!.
M#VQ0!I:YXNLM#NI+9[:[NIX;-[Z9+95)B@4X+G<R]\X R>#Q5.Z^(6BV\^C0
MQQW]TVL6YN+,VUL9 ZA=V/K[=N^!S6-XUM]9OM>NK'^Q;Z]TV?33';-9NB(9
MR3GSR64[1E<+R#SP>V7X<TG68KGX<FZT:\MQI5K<0W1?!\O=$$4D \98'W P
M3C- &X_Q9T5=/GO!IFM%+29H;]?L9'V(@X/F'.WOT!)]JWM6\5VFFW4=G##)
M?7DEN;H00/&I\H' 8EV4<G@<\X/H:X34=$UB?PI\0[6+2KMI]3OVDLTV@&9"
M$4,,XX^4]>>E37>DZUIFNZ9XCC\._P!MV]SI4-G?63A!-;RIR'4-P>I! ^N<
M8H WQ\3M%EM=$N+.VO[Q=964VH@A#-NC!+(PSPV1CTYSG'-6[/Q[IESHFI:C
M/;7EH^FW)M+FTEC!E$V0%1=I(8L64#!QS61/I.LR>)O!^H#1$ACLY;N2ZCM9
M(MENLJ;$')7<>A; /?':LJY\+^);A_%$MOI_D3?VS!JVF^;-'MN3%MRC88[<
M[.,@=1G% %U+Z2?XTV4UYIMQIK)H4Q;[0\9#+YJ'.49AQSG_  Q6I8_$O2[S
M4]-MFA>&WU,E+.X,T;;GZA716+(2,$9'?!P>*R6T_P 1^)O&5KJ%_P"'9=+L
M)=(N=/N&DNXG>,R$'("DYZ8'YG'>QX/MO&.GVEGX?U#0=/MH+/;&^JQ3HRSQ
M( !MC'S!R !EL <GT% &5\2O$/\ ;G@&YGL=/EFTS[;'%'?AE*LRRA2P7.=F
M0R[O7M@YKTG7(EGT#48GC$BO;2 H1D-\IXQ7F$GASQA:?#RZ\#PZ'%=1VY46
MNH_;8T6:,3AP"A^96 X.>.#R3@'UB6$7=E)!.N!+&4<*W3(P<&@#R7X>^-CH
M7@'PW%?Z)?Q:4^+=M4.WRDD:1@,KG<%R0-Q &:[G3/&"WNJ:]I]Y9?89=' >
M3S9@?,C()$B\#Y,#K7+6?@O5KSX?6/@74K$6]M!*GVF]2X5DDB67S,1@?-N.
M /F4 9SD]*O^*= MM:\=:+<V.H)'-,DMEJ<,3C=-:+\[*V.@#[5/_72@#M-.
MO)K[1K:]>T,$TT*R_9W<$H2,A2>F:\H\3ZSJOB#X1^,I=7LH(_L]W+#'LEWA
M#',J;1\HZ8/S=\]!7LE>8:AX2\13>#?%OA];*TD&HWT]S:3"ZQN$LH<;@5XV
M\YY.3CZT ;7AWQ;,VJ:=H%_I$EB;FP$UC*\Z.;@(!N!4?<.""!D\>F,51TGQ
M=I>D>%-2O[;18],2+67LI(99PJ^>756DD?!VC)Y.#C%32^'-7D\;^$M6%L@M
M=,L)(+G,HR'=-O [XQ3=)\.:W9Z#K-O/IVFW+:CK-Q>/9W,V8W@E;)5CL.&Z
M8X/.* .NT>^O+^WF>\LH[9DEVQF&X\Z.9-JL'5MJY!W$=.H-5/%5[/;Z4MI9
MN4OM1E6SMG SL9\Y?_@*AF_X#6=X'\+2^&%U1$1;73[JX66UT])C*+8;0&^8
M]V/.!D#'!-6+_P /R:YXH6;6;#3KK1K:V*VT4O[UC,S#<[(R[1PH Y)&6]:
M,?X8W4ME9ZCX0NV=KOP_.8%=Q@RV[$M$_P#WSQ^ JK?_ !'UBWTG7=3@\-))
M;:)?O:W1:] +(FW)0!>3\V>< #N><6Y/!M[I'Q!L=<\,V>EVFG&U-KJ%L&,/
MFKG*LH5"-P./KC'>JTW@S7)/"GC72O\ 0/.UR_FN;9C.^U%D"+A_DX("YXSG
M/XT :MGXOU)O%MCI6HZ.EK9ZI;R3V$ZW(=\1@%A(H&%.&!X) Z9/;,3XERSS
MZ?>6NFFXTJ\NOL^(DD:XC4D@3,-NW9D9(SD COP+UWX=UJX\2^$M2$5AY&EV
MLL-Y&UP^6,JHK;/DY VYYQG...M9OA[PCXS\..FA6NKZ7_PB\<S/')Y3B\2,
MON,:X^4=2-QR><CL  )>?$37(K+Q#>6VAV;V^@WCQ7)>\(+QH%SL&W[V"3S@
M#&.:WF\4SZIJD&F^'UM))S9)?3O=,P6..3_5@!>K'D^P'N*QV\#ZN^B>--/:
M[M?^)]/)-;CS'*P[P <_+[#IUI;7P7KNAZK8:KH=SIHN?[-AL-0AN@Y27R@
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MF6:HLNEFV_UD+2;"?,/S;\MQC"X]>_MEM#]GM8H/,>3RT";WQN; QDX &3[
M"N2T_P"'\5GI46B3ZM=7>A02B2*RE10>&WJC.!ED#<XXS@9.." 4Y?%&H:#X
MQU>RUBXDFL)--.H:6HA5&;8#YL6<?,X^4@>AYKL=(@O+;1[2+4;HW=ZL2B><
MJJ[WQ\Q 4  9Z<=*X^XFT_QQXOM+1]&OE_X1V_>62ZN[<I&S*I51&V?FRQ5O
MHGN,]X0""#T- 'E9\7:S!X@T53J[W,=UK3V-TL-NGV((=^R-)2@9G&%SAB-V
M03VJ:XN_%%_?^.8HO$TUK#I!#6@BM8BP/D^9M)*G*CIZGU[5JK\*M(CL[*SC
MU35TM;"\%[90K-'MMI-Q;Y?DY&6/WL^V*U8_!EK#/K\R:CJ&[7%"W +1D1X3
M8"GR<';QSG\Z ,73?$E[XCUG0='-XUKY^@QZO=O;E0\K.0H1<@[5!W$XY^Z.
MF<V/AM%);P>)8)KI[J6/7;E6FD"AG^5.2% &?H!4S_#G36MM&$>I:K!>Z1%Y
M%K?Q3(L_E=-C'9M9<<8*_P!:U?#OA>S\,B_%G<7DQO;EKF4W4WF'>0 <'\!U
MH W**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ K*\0^'=+\4Z2^FZM;>?;E@XPQ5
MD<=&4CD$?UK5I,C..] '.1>!](ATF73T:]*3.CSS/=.\LVS[JL[$DJ/[O3VY
M-7&\,Z6_B"37&AD^WR1"!W$SJK1C^%D!VL/]X&M?>I.-PSZ9K+O+C5&U;2O[
M.:P?37>07S2N?,P%^01XX)SG.>PH R]&^'GAG0-5;4=.T\PR[RZ)YSM'$Q!!
M*(3M4D$]OIBG1_#WPK%KSZTFD(+YYOM#-YK[#+U#^7NV;L\YQUYZU3L?$VL7
MVJ>,K%8[%7T?8+)BKX<LC-^\Y]@.,=ZW?"^I7&L>%=*U*Z6-;BZM8YI!&"%#
M,H)QGM0!2U+P'X;UB]O;N_T[SI+Y ER#/($EPNU24#;=P'1L9'8U)+X*\/3M
MI;2::A.EIY=GB1QY:<?*<'YEX'#9%5=(\2ROX@\16&K7%E##I]W#!;O_ *O>
M)(ED .YCEOFQQZ=*Z&[O[.PC62\NX+9&.%::0("?0$T 81^'WA0^)1XA_L2W
M_M02>:)LMC?_ ']N=N[/.<9SSUIVI> _"^KZA-?7VC6\MQ.FR9LLHE'JP! 8
MCL2,CL:Z&.2.:)98G5XW 974Y# ]"#5.YUG3++4(+"ZU"VAO+@9A@DE"N_T!
MY- $UE96VG64-G9PI!;0H$CC08"J.@%9T?A+08KV2[CTR!99)?/=1D(TG]\I
MG;N_VL9JUJ.N:5I#1KJ.HVMHTIP@GE5-W;C-+?:UI>F21QWVHVML\JLR++*%
M+*HRQ&>P ))H PI[+Q!K/B0V^I6MA#H%G<QW,#HQ>6Z*C*@@\+M?#$_[( R,
MFNKK-@\0:/<Z2^K0:I:2:='G?=+,IC7'7+=*R-1^(7AJP\-7FNIJ4-S;6ORL
ML#;F,A&53'9C[_7I0!J7?AK1+^^:]NM+M9;EU"/*T8W2*.BM_>'L<BK&H:/I
MVJQQ1W]C!<K$V^,2(#L;U7T/TK+_ .$X\-Q:?;W=SK%E L\)G57F&=J_>^N"
M"/J,5=A\1Z-<1W#P:E;S"VA6XF$3[BD;+N#$#G!'(]: )I-%TN726TJ33K5M
M/8;6M3$/+(SG[O3KS]:CM_#VC6EQ#<6^E6<4T">7%(D"AHUQC:IQP,=A4<OB
M?18=+MM2?48?L=T<6\BY;S3R<*!R> 3P.@-*OB717T-=:348&TYL!9U.023M
M QUSGC'7- %K3]+T_2HFBTZQMK2-CN9+>)8P3ZD <FN8_P"$-6_\>:GK.L:=
MI=Y83VT4%O',HE=&0GYMK)@9W'H>U-\)^(&UOQMXHCAU)[K3[5+001E0HB+"
M0N,8!SD#KS72ZIK-AHT<#7TS(9Y!%"B1M(\CX)PJJ"QX!/ H DNM+T^^ABAO
M+"UN(H2&C2:%75".A (XQ4%QX>T2[W?:='T^;?(96\RV1MSGJQR/O>_6J3>-
MO#B:+;ZPVJQ+87$OD12E6YDSC;C&0<@]1Q4NB^+M"\12W<>EZ@L[V>TSJ4="
M@8$@_,!D$#J,B@#0GTRPNHH(KBQMI8[<AH4DB5A&0, J"."/:GQ6-I#</<16
ML$<\F=\B1@,V3DY/4\UYSXH\8+=^)/!D>B:G>);W>I!)@L,D<5S'[,R@.,C^
M$D8/?->D7-S#9VTMS<2+'#$I=W8X"J!DDT 1Q:?90>=Y-G;Q^?\ ZW9$H\S_
M 'L#GKWI;:QM+(,+6U@@WXW>5&%SCUQ6+;^-M#GFNH6FG@EMK;[6\=Q;21LT
M'/[Q5(RR\'H,^U06/Q#\-ZC=Z;;6UY*3J61:R-;NL<C 9*[R,;L'IGVZ\4 =
M)+;P3D-+#'(5! +J#@'K_(?E3PH P  .O%>;R7T_B_QQXBT"6;5+&&QAMELY
MK5GC,,C!G,K\X.2% SD8';)KHX?&6D6MO:+<7-TUN\HM$U"6W80S2CY<[P,<
ML#S]TGH>E '2)$B%RB*I<[F(&-QP!D^IP!^5/KE=1^(>@Z9JUSIDS7;WEM+%
M'-'%;,Q3S.CG_8Y&6Z<CK4LGCG1X[RVB/VDV]S>_V?%>+%F%KC./+!SGJ",X
MVY!&: .DI:YK4O'&EZ5]HEN(KO[!:W"VUS?K&#!#(2!ACG) ) ) (!X)S3=>
M\1VQM]2TZT@O;R6*S,D[V)'^CAU.TEMP.X@$X7+8YQR,@'3TE<I\,I9IOAMH
M4EQ*\LS6P+.[%BQR>I/6F0ZGH^G^)?%EZBZD;JRMX)KY&8F/:$8J8E)QG:IS
MT[>] '7T5Q^F?$;2]4N]%ABL=2BAUB,M:W,T(6(N%W%"<YW#D9 (R."1S70Z
MUK%IH&C7>JW[LMK:QF20JNXX] /4]* +]%<Q9^-[";4+VQOH)]-N+2R6_D6Z
M*$& Y^<%&8<$<@\\T[3?%Z7^JV5E+I&HV@OK=[BUFG1-CHN.NUB5)!! 8#\^
M* .EHKF+?QI;7;6,MOIU]+IU]<FV@OD13&S<C<1NWA25(W%<=^A!IM[XUCM;
M>]U"/3;F?2+"5XKN]1EPNPX=E3.YU4Y#'CH<!J .IHKAM8^)$=CK,6EZ7HE[
MK$\^FC4K<VS*%FC+ #;WZ;CR.P !)%5O&?B234?"7B:WT_2)+RUM;.:*[G,J
MKY,WEY*A3]XIE6." .Q)&* /0L\9HKS[1O%#Z5X0\,Z?9Z<]Y='0(;UPTGE1
MI$D: _.01N)/ ^O3O,_Q-MI+/PS<6&DW=W_PD D^SH'1"C(.5.3USQGIWS0!
MVKVT+W*7#1AIHP0C'G;GKCTS4U<39_$6V;2]>NM3TZ:QN=%G6"XM%D$K.S ;
M A& 2Q. *NQ^*KVQ:_;Q%HKZ;;6EG]L^U13>?$4[H6VKB0?W1D'L: .IHKAM
M$^(\.J^);31Y;6W'VV%I8);2[^T!"HR4E&T;&QZ%AVS6KXV\2W/A/0EU6'3T
MO(4F1+C?,8Q"C''F'"MD D9X[T =)5>XO[.TFMX;F[@AEN7V0))(%,K=<*#U
M/L*Y^/Q>/^%@-X7G@@C5[$7EM<K<;C*,X*[=O!')ZG@9^F1JGB2&>;P?<W^@
M6TTFHZ@5M)&ER;8'.R497.67!QQCCDT =S=7=M8VSW-W<16\$8R\LKA%4>Y/
M J2.1)HDEB=7C=0RNIR&!Z$'N*\HN]8US6=.^(]MJ$=G]ELK6>#RTF=O*Q Q
M3:"N"2<DDXZ# K;\/^)=8M[SPSI5[I$,&GZE:;+:87&Z8-'"'RZ8P 0#@ D^
MOI0!WU57U.PCU*+37O(%OI4,B6QD'F,HZL%ZX]ZY_P"(VI:GI'@?4;W2I8HI
MXT ,C@DJ&(4E<=&YX/:N6\3MJL?Q6\(-##:3:H;*\"*69(<XZL>6  .> 23Q
MWR #U.BO/;+XCSRZ#,US8Q+K,.L/HS0P>9)&TR\LZA5+E0H+8 SQCWK;\,^(
M-4U/5-0L-1TR>-+?:UO?_8Y;>*X4CD;)/F5@>,9.>HH V[C5;"TOK6QN+R&*
M[NR1;P,X#R8&3M'4X%7*XKQA_P COX&_Z_I__1#5G>(/B#J.@W\GVF*QAB34
M8[5+)P7N)H&95,X97PHR3@%>W7)H ]&K(TOPOHFB7]Y?:;IEO;7=XQ:>9%^9
MR3D\GH,\X'%<]=^+=5L?$?B/2KQM-MQ9Z<-1TZ5T?$L8W;]_S_PD8.,=<^U2
M^'O&-QKVD>'9(S;#4+Z1Q>PF)E\D1@^: I;(*L47))^\#CF@#LZ*X/P=XSO?
M$FH"*2ZL$F5Y!=Z8T#Q7%H!G9RS_ #@\9(7'/:MWQ5XA;0X=.@MQ&;[4[V.R
MMO-!**S')9@""0%!.!U.!QG- &_6*WBW1%U.'3S>XGFN'M8SY3[&F7[T>_&W
M</3/8CK67;:[JL'B^?PMJ4MLT\]D;NPO8H&4, =K*Z%CRIP>",CT-8GP=2>]
M\'&ZO)89XWO[F5$:##+)YK$MG)]3VX]: /2:HZ9J]CK"7+V,WFK;3M;RG85V
MR+C<.0.F17)ZU-K!^*NAV5OJ:Q64EE<3>08-PW*5!).X9)#<>GO7,0:OK^B:
M3X[U;2I;)8=/UNYE>*ZC:0S?<RHP1L&._P V2>@QD@'L-%<#>^+M6U75[K3?
M#MM-YEI90W+L(HF)DE!9%8/(H"X SC)^;MCGK- N-4NM!LY]:LTL]3:,?:($
M<,J/TX()&#UZGK0!6NO%FC6=W<V\ES(SVI N6AMY)4@)&?G=5*KQSR1@5JVM
MW!>V<%W;2K);SQK)%(.CJPR"/J#7EVH?\)9\.]8U?5=-L$U[PS?7,E]<PJVV
MXMG;[^/[RC'H>G;K4>KZG%JEQ\.)-!OYX-'O)RL4(5?D*(0I.0>5)(QTX^AH
M ];HS7E_BSQGK>BW6MS6]U$W]G30>59PV_FH86*[C.__ "S8DM@9!XZ&GV^H
MWEK\6/%<]UJ5S)9Z7ID4XAVH1LPSE!\O ]^I[F@#TVBO.M"U+QCJLWA_6XUE
M;3KZ-9+VWF\A84CD7<K1%29,KD<-]X?W3Q70^./$,WAOP[]JM@GVF>XBM86D
M&51I'"[C[ 9/X4 =)7.3>,;.+5OL4=EJ%Q&EVMG-=P0;XH9F (5B#G'(!8 @
M'@D5EW%WJOA[Q;I.E3ZI>:C8ZVDT(EF2(26DR)N#*54 @C/!!P0/I4'PSL)H
M!K\SZE>3JNM7T1BE\O:Q$OWSA =QQZXY/% '5:EKD6G7<=J+2\NYW3S"EM%O
MV+G&6)( &?Y'T-96E^.],UFSL;ZTM;\V%]+Y,-V\($>[>4 /.1EA@9'4BNF=
M%^=PHWE<%L<X]*\_^#FU/A!I#2)N$?VABI'.1/(?SXH ]#HKRC0=0\:>(++2
MO$]G<1);SW)DN(YKQ?(^S;B#&(PGRLH ^8MG(.>#@+JFK:SI/C63PM<:[(UE
MJ\L M+TN!+8<LQB)"X+/M(0M^N,$ ]6J)K>!YTG:&-ID!"2%064'K@]17G?C
M6]O;>]O;*SUC4-UGHS3Q6]BX$J.-W[Z9V&TKA0 ,Y/S<'K574]=UTZ!X9UFZ
M75)-%FTA)]1FTEU6:*9T4B0KU9!\W X').<"@#U.LW6-6;2H;<QV%U?37$PA
MC@MMNXG!8DEF   4Y)-)X>O(;_PYIMU;WOVZ*2VC(NB,&7Y1EB.Q)SD=C6G0
M!Q,/Q$-R-5\CPQK$K:4Q2\56M\QL!D@?O?FXYXS70V&L27^KWMH-.N8K:WCB
M>*]?'E7.]<_(1UQT-<MX"B,7B[QT#WU16_- ?ZTKSZ@?%?CBU_M2\$,>FV\U
MLH<?Z,S)+DIQ@9*@]Z .]HKR&VBUM--\!:L/%&K&XU?R;:Z1Y T6Q[=F)"$8
MW@K]XY.3GVI]SK.J>$K7Q_9P:C?WR:9%:/:2WDQFEA,R$,Q8_P *D;L8]>M
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MT>?10>XKH+_2H]'\3?#JV<HT\4UT)90H7?(T#,[<=-SDG'O7?#3K);.&T%I
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ME]\/M6UC_A.;=_+LAJ]U!<V%PLN<-%C!8#)&2,_C^%;":+XK\4^'KW2?%O\
M9]G#+:M;G["3(TTA'$IW#"@$ A1SGN,5W=8NM>+-&\/N5U&Z:/8JO*4B>00H
M3@,Y4'8I(P"<9_ T 9/A.#QO"8;3Q&=)6TM(PBS6;.TET0, L&&%'<]R1Z5T
MFJZ=!K&D7FFW2Y@NX7AD'^RP(/\ .H-7\0Z9H6F1ZC?W(2TDDCC2107#%R N
M,=1S6F: /+1\*[N7PCH]K-?I_;MI,IGO ?OQ%!"\8.,X\D #W4$]<UTWB?PU
M=ZE=^&VTV&T6+2+Q;@^;*RG:J[0B@ CD'J>FT>M=8** //KKP9KB7WC".PFT
M\Z?X@@;!G9_-CE:/81P,;1DMW/ 'O5R?PUKDESX-GCFL%?101=_.^) 8Q&VS
MY?3)Y]A[UU]S<):6LUS(',<2-(P1"S$ 9. .2?855T36+3Q!HUKJUB7-K=)O
MC+KM)&<<C\* *GB_0Y?$GA/4-(@F2&:XC C>0$J&#!AG'.,BL23PSKU[XV\.
M>(;Z;3<Z=;S1W"0>8NYI 1\@(/ XZGGGI6[#XGTZXU;5],B,IN=)C22Y7RST
M=2PV]VX';U%7-(U.'6=)MM1MTF2&X3>JS(4<#W':@#SZ+X::H^G:VDFHVUK?
M7&NMK>G7-OE_)E/\+AE&1CCCKGVYZ[P[I^OPLUWXCU*WN;PH(EBLD9($4');
M!.68\9)Z8P,<YZ"B@#F_$7A^]U?7/#^H6MU#"-+N6G=9%),@9=I4>G!/-<OJ
M/PVUJ]LM8LEUNR$%[J0U&-Y+,F4N) P61@PRH P  /J!Q7<:OKD.DVEM<_9K
MJ[2XN8[=1:1^85+G 8\_='<UJ4 <OKO@NW\0ZMH.HWTQ,VFL?.$:[5N5(!*,
M.?EWJIVG(QD=ZDT3PA:Z)XFUC6(7)%^P>.')VPDX,I7_ 'V52?\ =%=)10!Q
MUOX/OKCQ%I.K:S?6EQ-I:L(9[>V:*:;<FW$K;CE1EC@<$GZ@ZOBCPU#XELK9
M#.]M=V=REW9W*#)BE3H2/X@02".X-;E% &!8Z%>#5CK6IW=O-JGV3[+%Y$+)
M#$N[<2%+$DDXR<CA0/4EG@WPS+X3T>33GOUO$:>2=7$'E$%V+,"-Q!Y/&,5T
M5% '/:QX9DU+Q%INM6NIR65Q91R0D")9 \;XW 9Z-\HP>?H:R7\ W$F@^)=*
M;5X]NN73W+O]D/[DOC< /,YX QZ<]>V]KWB&+0)M)CFMI91J5]'8HR$81W!(
M+9.<84]*V: .'D^'UQ%=6%_I7B&XTS4H+6.TN9H(59+J-!A=T;D@,!T/-==I
M]D-/L(;032SF-<--,07D.<EF( &223P!5JHYYXK:WDGGD6.&)2[NQP%4#))/
MIB@#GX?#5_8"]CT_7[B*&\GEG9)H$E\EI'+'RC@;>2?O;A5&Y^'>GG3- L]/
MO;JQ.B2F6VF3:[DG.[=N4@DDYSCKVK2O_%4-CXJT+1/LSR?VPDSPW*L-J^6F
MX@CKT(]N:Z"@#A-0^&D6H0ZQ:MK^IQV6IS_:I+>/RP!-\OS$[<D?*/E)Q6NW
MA)7\1)K+ZG=M(UFEI=1%8]ETJL6!?Y>.6.0N,].E=)7.>*/%0\-76CP-8O<_
MVI>+91LL@4)(W3=GMUZ>E &?H'P\MO#]W'Y&MZQ/IT$AEM]-GN 88F[<  D#
MJ 3@'GD\UTFM:-8^(-(N-+U*$2VLZX9<X(/4$'L0<$'U%7A1GG'?TH QK3PY
M'!J5OJ%UJ%[?W-M T$#W/E_N@V-S#8B_,=HR3GI[FF^'/#$7ALZAY.HWUV+Z
MZ>[D6Z,9"R.<L5VHN 3VZ5N44 -D4O&RABA8$;EQD>XS63X9\-V?A31TTK3Y
MKE[2-F:-9W#%-Q).#@'DDGFMBB@#C;'X9Z'IVM-?VEQJ45NTWG_V8MV19^;G
M._RO7('!..!QQ5Z_\%:=J>D7^FW=Q=R17MT+J23<HD5QC&UMORXV@#N , UT
ME!( ))P!WH Y"[^'&C7UVUS<7.IM-+:BTNF2\9#=1@$#S=N-Q'KW[YJ:S\"6
M6G6UK!8ZIK%N+>W^S*5NRV8^P(8$<=N..V*ZA6#*&4@@\@CO2/(D8!=U4$XR
MQQ0!BV?A+2M/N=*FLXY;<:7;O;V\4<A";&QG<O\ $<C.3WYK<I"0,9(&>E,\
M^+8K^:FUCA3N&"?:@#-TSPY8:1J>H:C:"87&H.'N2\I8.PZ'!Z8!QQ4<GA?3
MY-1U*^+7(GU* 6]R5G8!D (  _AQD\C'4UKO+'$ 9)%0'NQQ2F1!MRZC<,CG
MK0!A?\(=I7V+2+0&Z$.D.LEF!.V8RHVKD_Q8!(P<\$U,GA?2EU/5+]H7EEU2
M-8KQ)9"T<BJ, ;#QP,CIW/K6LLJ.F]'5D_O Y%<M#XHN+CXD1Z%!-93Z8^FR
M70DB):02+(B%20<8^8\8SS0!;\.>"-!\*R/)I5K)&[)Y8,L[R;$SDJNXG:"0
M"<=<#TJ]K6@:;XA@@AU.!I4MYEGB"RLA61<[6!4@Y&35R.]M);I[:.ZA>XC&
M7B60%U^HZBN4\?\ BR?PYI ETR[L#>I<PI+;S?.^QV"Y"A@0?F!R<T :<_@O
M1+F_GNY;>9C<2+)<0FYD\F=AC!>/=M;&U>H[<UO$ @@@$'M39A*8)! 467:=
MA<$J&QQD C(S7,^"?%*Z[X6TBYU&\M%U2]@\UH$<*3EF^ZF<XX_2@"[I_A#0
M]+N$FM+,IY<C20Q-,[Q0LW4QH250_P"Z!C)QC-6+;P[IEIKMSK4,,BZA<J$F
ME,\A#J.@*EMO';CCM5N#4+*YDECM[RWE>'_6+'*K%/J >.E2PSPW,*S02QRQ
M,,JZ,&4_0B@"KK&C:=K^F2Z=JEJES:2XW1OD<@Y!!'(/N*AMO#FCV=U;W5MI
M\,4]O!]FAD489(O[@/IWQZ\]:YG5OB#8W6A^*?[ U&T.H:1!(\;,RR"4I&)&
M*J#E@,[<] ?7OK^%/$]KK&BZ0MSJ%F=9N+"&XGM5E42 L@9CLSD#GTH MGPK
MH+:5+I;:5:O82R>:]N\89"^<[L'OGG-6M)T;3="L5LM*LH;.V4DB.%-HR>I/
MJ?>J6DW4L<^M27VNV5Y!#<ED6,*OV.,*#LD(/4<G)_\ U7-+UO2M:C=],U"V
MNPF-_DRABF<XW <C.#UH OT444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4%Y>VNG
MVKW-Y<1P0)C=)(P51DX')]20*GKA?BB+B'2-)U!8+FXL+'4HKB_BMBP<0A6!
M<%2#\A(;CN >U '2VWB71KRRN[N#48&@M#MN&)VF(XSA@>0?YTV+Q1HL]O=S
MI?Q^7:%5N-RLIC+<*"",Y/88R<CUKST_\(1JVE:YJFGRZE]DOU@M[K6/.F),
MF]0FWS,DE, D@<<#UQ!;7O\ :&B^(K'Q#J27UA!<6D5OXBTV,*\K$[D9MF03
M$VW.,CGGH: /28O$^BS6MW<K?QB*S94N"ZLAC9L;000#DY&!WR*BB\8:#-87
M]Z+\1PZ>0+OSHGC:'/3<K ,,_2O+;BZ\07NAWLK*^OVVDZM9S'4+",PRZA;J
MI+ ;?O.A9>5/7Z5:UR;0-4\#^*-5T+3KX&>P6&6]O#/YDTA8;8E$F2V.Y' X
M SS@ ](T_P 8^']5U8:78ZG'->&+SE158!DXY5B,'&>0#D=^E'_"7Z%_:,5A
M]O'G2SFVC;RG\MY1UC$F-A8>F<UPSS0OKWPQ-M($$5G.KLD6?*WP"-"W' ,G
MR@'J:C\!ZI)I^CV/@S5/#EY/KNF71;,MONA&9&;[0)3P  QYZD\#.: .\N_&
M&AV%TUO=7DD96=;=I3;RF%9&QA3*%V Y(')X/6MQF"J6.< 9X&37B^GV\-O>
MZKX;\1^%M3U/4I;R<V<K&4VMXCR&16)SLC"E@20./KQ7M!(1,\X ^IH X;1_
M%WAOP_X-TVYDUZ^O[&XNGMH;Z[C=W>0NW#':, 8(&<<"M_0_%>E^(;F\MK)K
MA;FSV>?!<V[PNH<94[7 ." :\I_L^_D^'WAVW32=162#Q3]JD@-E(&CA$DC[
MBNWIM9?SQUXKMM+L+V+XR:[J$EI<+93Z?!%%.8R$=U.2 >G% &IXJ\6/X=U'
M1;)-.N;C^TKH0F:-=RQ@ DC'4L0#@?4YXP<-O$2:)\0-?,_]IW:/I]K-!80J
M\\FXF3=LC_AZ#/0#O6GXYM[MKOPU?6UE<7<=CJBS3K;IO=4V.N=O?DBJ^GBY
M'Q0U/4I=/OX;672845V@8KO4EF3(!!8!AT)YR!F@#:;Q;ITFE:=?V*7%^-2&
MZTAMH\R2C&2<,0% '4L1CIU(%6/#OB/3_%&EB_TYWV!VBEBD7;)#(OWD=>S"
MO&]$\.:UI?AOPGJE[X8GU8:;]KM;W2YH 95620LCHK\'''3U^N/7?"L"1:=-
M)#H$.AP33%X[5(DC<K@#?($X#''3L,9YH IZMX^TO2M4O-+^QZI>7]I&DKV]
MG9M(S*W=>@('<]!TSGBG1>.]&N=!L-5LS-<K?[A!;QA1*67[X;<P5=N#DD@>
M_(S@KJHTWXQ:UFTN;A7TN G[-"9&4@G' YP<]>G3.*YJZ\!ZKI46E:V-!360
ME[>W-YHDS1N(XKA@55 V5RH4$@=\X]: .T'Q0T0^&AK1@O0BWPT^>W$0:2"8
MG!#8)&!UR"<\8YXK \9>,;_4M*T:.U\/:Q%;7>M1VMQ'.J0-.@8GRL,P/SX'
M7 QD$\U8UW3=3U#PC ;?PBEC,=5MYTLK81^8D2$$NY!"[N&& > 0/6MGQ]!?
MWJ^&GL--NKLVNKP7LRQA<I&@;=G)'/S#CZT ,T^]L?#4LVDZ%H5]->2I_:%S
MIT,T>+/<  N6?8I8J<*I.<$]*ENOB3I%OIFBZA#;7MS!JTYMHO*C&Z.49_=N
MI.=V01@ \@^V8?[.U70?B+JFO0V-QJ.FZO:0HZP,OF02Q A1M=E&T@GD'@GG
MUK%O/"NN00:!<VNGO)<+XADU>]@CEC_<1NS90%F )"L!QWSSTH VXOB*\U]%
MIX\*ZXFHS6CW4=K+'&C,%DV$9+X7UR<#'3.0#4_X6K"='MM7'A[5#IXF$%_.
M0JBRDW["I!(+8.,D#'/7/%:UQINH/\4K+5ELW.GQZ5);//O3"R-(K ;=V[HO
M4#N*Y.X\,^(9OA?KNCKH\O\ :%]JLD\</GP\1M.LH8MOQT&,9SGMCF@#L/$'
MC'^Q;N^@BTR:Z%A9?;KF3S!&BQY(VJ3]Y_E)QP/>J]WX]1+_ $:UL-(O+_\
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M11LA$K-]XR%E)).6R00?F)Z\TT^!X3=:U<KK&J)+JLT<TC))&#$\9!0QG9D
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M'Z5W7V>'YOW,?S_>^4?-]:?'&D2[8T5!UPHQ0 ZBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** $XI:\SL?&.HK\4(A=,1X;UE)+33"<_ZZ!L,V.VXEP#W 6N
MMU[Q?I_A[4[#3[J"]FN;Y9&@6V@,F[8,D#')/3@9Z\X'- &_17"2?%?18].N
MKW^S-;9+*1H[U%LCNM"#C]YS@=>Q/'-;6K>,++3+J"TA@FOKJ:V-TL4#(N(A
M_$2[*.2< =3SZ&@#H:*XM?B?H<UKH]S;6^HW,>JF58/*M\L'C!S&PSG<2N /
M<'('-7;#QSIUWI.IWT]O=V3Z9-Y%S:W"#S5<XV@ $@[MP YY)H Z;H:6O,I]
M0GN/C-HTD^CWME.ND7!9))$82KD$!=KE<@[@>G4=L5</Q8L%T[2]5;0]772K
M^8VXNC$N$DR0J[02S9(Z@8^I!% 'H-%<GIWCJWN+[5[/5-/N-)GTVW%VZ7+H
MQ: @G?\ *2!TY';BJMA\2=/O->L](>%%FOX7EM/*NXYMQ49V/M/R,1R.2.O-
M ';45Y[!\4TGT;3];_X1^^CTFZNA:R73R1CRF,A0';G)&0,GISCFM:PUW6+G
MXB:IH\UI"EA:6L,B%9LD[V?YS\N<G;C;G QU.: .LHHHH Q8/#-K;^+;KQ&M
MQ<F[N;=;=XV*^6$!!&!MSG(]>];5%% !1110 4444 %%%% !1110 4444 %%
M%% %34],LM9TZ;3]1MH[FTF $D4@RK8.1^H!_"I;.SMM/LXK2S@C@MH5"1Q1
MJ%50.P J:B@ HHHH **** "@\T44 5K+3[+3HFBL;2WM8V;>R01A 6]2 .M6
M:** "FNBR(R.H9&&&5AD$>AIU% #8XTAB2*)%2- %55& H'0 4ZBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MUS7AO7D\6:E#JFG23?V5'8I_&=KS2')4CN44#)_Z:>U=!JW_ "!K[_KWD_\
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M7AD56Z-M< X/KTKRC6]-U:^U7XCII\5P_F3Z?<P1IN7[2L('G+&>Y& #CG(
MKJO!TNA:WKZZUIVAZQ%>QVK0W%YJ<D^Z+D?N1YC$,<[B<<#'N* ._DD2&)Y9
M'5(T4LS,<  =2:Q-)\8:+K=\MG97,AGD@^TPK+ \?G19QO0L!N7)ZBKGB"66
M'PYJ<L-B+^5;60K:$9\\[3\F.^>GXUY5X=#2^./!]ZD&JRQKILUM-*]A)##
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M:AI"AB4$ C+ F0CURW(R =U+\2]&6\N+2"TU2YGM[M[*18;-L+(HS@DX !Y
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M.BM;2WDTMUE-Y.[XDC( V;1WR<YJ>QU*TU)9WLYEE2"9H'9>F]?O#WP>/PH
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MZ\%CJ-Y.MR+47046\CEHR0,C"\_ATP?2GWOC[1+ >;,;DV:RQPS7BPDPPR.
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MU1;HXD&PN\DA*#8  QP-W8 \\;>B>);B[\07_A[5;2.VU2TC6X4P2%XIX6.
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MB[5=""#D ]. <<T +K/C._MKZQT>WM1;ZO)8"]ND:SFOEM\X41X@Y)+;ANR
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ME)#M@,/+^Z$( &T=,#KSF2_\!S:QX5O-,U;79[O4KHQLVH>2J;#&^Z,+&O
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M5M$\1^#+F34M4OSK-C+]OMYI<QJ4B1PRIC"D$X)ZGN>M=1:?#W0[30KK2/\
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M #W'W=Q]-YK<T63QM=6P77;#3[3R(GW"TG\QKQ]I"@ @"-><]2<@=!FNOHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MYKMM8WAT=[:RO;87$4QN$<A6"LH*CD9#?I]* .@HK 7Q98NFNLD<K'2%9Y%
MYE4*22GJ-RNGU0UGP>,[J;2(M0_LF-HIIK:.&2&\$D4@F;8&#[1]UB PQD<]
M>,@'7T5G:3>WUXD_V^RAM9(I=B^3="=7& <YVJ0<DC! Z5HT %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44E% "T4
MF:,B@!:*3(]:,CUH 6BDR/6C(]: %HI,CUHR/6@!:*3(]:,CUH 6BDR/6C(]
M: %HI,CUHR/6@!:*3(]:"P! ]: %HI,CUHR* %HI,BC(H 6BDR*,T +129HS
M0 M%)FC- "T4F:,T +129HS]: %HI,_6C/UH 6BDS1GZT +129^M+0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
F444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ibc-shattucklabs_1stamen003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibc-shattucklabs_1stamen003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 9+((HFD;.%!)Q[412"6)9
M!T89&:9>?\>4_P#US;^5)9?\>,'_ %S7^5 $]%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2[BJ%L&0$("V6*YVGJ!SJ^*_']I!I+6_AK4=.O-5N!(L+BY5HH J[FD<@G@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 0W7
M_'K-_N-_*HM,_P"07:_]<E_E4UQ_Q[2_[A_E4.E_\@JU_P"N2_RH MT444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% $=Q_Q[R#_8/\JKZ5_P @
MFU_ZY+_*K,PS"X_V3572/^01:?\ 7)?Y4 7:*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@!DO^J;Z&JFC\Z/:?]<A5R3_ %;?2J6B\Z+9_P#7
M(4 7Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!LF=AQUQ5+
M1/\ D"6?_7(5=?[IJCH?_(#L_P#KF* -"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH :_P!TU0T+G0[/_KF*T&^Z?I6?H/\ R K/_KG0!HT4
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML[*0O';G'/;K7.:+;WL/BGPO/)IUZL,.@&RGD,# 13$QG:V?]QN1D=* .O\
M#WB&Q\3:4-1T\RB/S&B=)DV/&ZG#*R]B*@U;Q3:Z5?FQ6TO+V[6W-T\%FBNZ
M1 XW$%AW!  R367\/;.\LK/7%O;.>V:;6KNXB$JXWQNVY6'L1^/%9WCC1XM5
MU@2I8:Q::G;6A:PUG3 6(<ELPL%/3@?>&WYCRO< Z*U\7Z?>>(8-$CBN1=SZ
M>NHQED 5HB0.N>N3C'M5:S\>Z1?:"FK0I=;9+HV<-N8QYTLP.-BKG!/!/7
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ME\HS1 _/&''W"1WH I1^.PG_  D=O=::5O\ 0H1/-!;SB194*E@5<A>< Y!
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M2#S1-,4#MN&00@RHXP>ISTH ZF""&V@C@MXDBAC4*D<:A54#H !P!4E>5?\
M"?\ B#69_!<&D"RM)->CNTN/M,3.(98 0Y7#<C(8@<9P,D9->DZ2NHII5LNK
M26\FH",>>]L"(R_?:#SB@"Y17$RZQKVNZQXCL=!NK:T?1_+AB6:(.)YF3>=Y
MZJF"%&!GJ<]JL?VQJFI^)ET""[@L9[73H[N^>)!*1*Y(5%W< #:Q.1D@KTH
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M6('4]30 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 AZ&L[0/\
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M'/-=#>_#N#4[:2:\U&4:Q+?0:@U_!&$Q+"NV,!#D; "?E)/4Y)KM" 3G I:
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MXNETN:R@T^RCN;/;- SR3&.,^:<AP$&25'!^[GH<5>B\"W4/AGPYHT>KQ?\
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M^O:W?/=6K6@N+RY$CP1M]X1_+@$\9)!/RCTJ8>![<+X:4:G>[?#X ME_=XD
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M[0_^01#]6_\ 0C6CVK.T/_D$0_5__0C0!HT444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 9>M>'M+\0QVT>J6[3
MK;2B>$"9X]D@Z-\I'([>E:E%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4=1@T44
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MP": -^BFJVY Q!7(S@]JQ?%/B/\ X1FPM;HV4ETL]W%:G:X4)O;:&.>W/84
M;E%0BZ@-VUH)D-PL8D:+/S!22 <>A((_ U5T2_NM3TF&[O=.ETZX<L&M96#,
MF&(&2/4 '\: -"BH;J9K:TFG6)I6C0L$4@%L=LGBJ'AG6U\1^&[#6%@,"W<0
MD$1;<5]LX&: -6BBB@ HHHH **:[,J,57<P&0N<9]JIZ/>7E_I5O<W^GMI]U
M("9+5I1(8^2 -PX/&#^- %ZBBB@ HHK)U_7$T2TMF$8EN;NZCM+:(MM#R.>,
MG!P  6/'130!K45E:'?:I>172ZMIBV,\$[1H4F\Q)D&,2*< @'/0C/%97BWQ
MDOA[PZFKV5O'?1M>+:L#*4 .\HQ'!SA@1_6@#JJ*9(SK$[1IO<*2JYQN/89J
MEHEUJ-[H]O<:MIZZ??.#YMJLHE$?) ^8<'(P?QH T***QO%7B.U\)^&KW6KM
M2\=NF5C!P9')PJ@]LDCGMUH V:*@LKR#4+&WO;6026]Q&LL3CHRL,@_D:GH
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M+8ZS/-INDVZ?V;>[(WWN4#.-^WYRIXS[\\U+IVKZ_8>)/ OVK6I;Z#Q!9/\
M:+>2)%2,I"KAEP,YRW)).?R R-.FUO6-,N;%M(\;7NBW\#03)J'V6.16++@H
M2%PI4.#GU&,=:W3I5\]YX?N#X5\0&30(S'9YO+'!5@%(;Y_FRJA?UZ\T 9J>
M(=8M_$&BW1U>YO/M>N-8W'E+BQ:-MX"1;E!8IM'S#(SGDUG6*7EAHWQ-U*WU
MC4ENK*\N!&_GYR552K'CJ-N.,#'&*T(_!4L=O:0#P]XM\FRN_M=I'_:]H%MV
MR250"3H23R<L.Q'-:*:%/'=ZY*/"'B V^M!_M5F=1M/)+NNUG \S.XCU) [
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M"33B#&IBDCR 4+@YQ_>.1DBDN;R9='^*8DO9E%J[M;EIV'DM]G#+L.?E^?D
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M4EUR.VGGL[F1(WP)<$;2N'  !8 '.>:VKS1[;_A;>E+YM]C^R)V_X_INJR1
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MEDR>.20.>V:]4J"2\M8KN&TDN84N9@QBA9P'<#J0.IQWQ0!P/A%+>:[CO?\
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M0* .IA\1:)<60O(-8T^6U,GE"=+E"F_^[N!QGVJ5-7TV2]CLH]0M&NY8A/'
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M:RZNFDW-I=V.H2PF>W@N0@,Z#KL*L1D=P2#[54^(6@7OB7P==6&G.JWJO'/
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MCD#->B0M(\$;31B.4J"Z!MP4XY&>] 'GURNHZG\6+JPO-,T^YL%TE$,<UP6
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MSJ.3PSH$R2)+HFFNLI5I%>U0ARHPI/'.!P/2JT'C7PS<WB6D&MV4D[NZ*BR
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M_P 3N*22)]P_=[(Q(0P^A'2L'2_B>NI-<3MX?OK;3+.XN(+Z]ED39;-$F[D
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M&S;MXRP!^7(K-\>:_>>(/AMXEN["UMWTB,M;+)(Y$DVQPK2IVVA@0!U.">.
M0#U)2&4,I!!&012U4-U%9:0;N=ML,$'F.?157)_05R1\:ZC;:1H^O7^F0IH^
MJ2PIB&0M+:K+_JW?C:025! QC(^]0!W%5;'4K+4XI);&ZBN8XY&B=HF#!77J
MI]Q7&V7C'Q%JGBS5-)L="M&M]+O88+F9[H@F)QDLHP,D#DCVXR3Q3T_QTNG^
M#=3U3^Q+2SE@UE]/%K"WEQF0R*I=VV\<L23CM0!Z02 "2< 54TS4['6=/BU#
M3;F.YM)<^7-&<JV"0<?B"/PKGK3Q)JI\9S^&;FSLY)8K$7PN8Y'164L5"[2&
MP=P'?ID^U<U:>/KNR\%>%+ZQT&QA.JZJ=/-G ^Q(@99%^3@#)V9R<<GI0!Z7
M=6MO>VLMK=0I-;S(4DCD7*NIX((]*YS3O 7AS0V6:&.Y\FW;S8XKB]EDAA(Y
MRJ,Q48]<<8%9]KXTU<7?BC3;O2(9]4T:&.>&"QE9Q<"12RKEE&". 3COP*3P
MYXYEU7Q5-X>NVL)9QIRWPEL7+*AW;7C;)(W*2.0: .NTS5+'6=/CO]-NH[JU
MD+!)HSE6VDJ<'Z@BKE<!\%F#?"C1R#D$S_\ HYZ[^@ HHHH **** $==Z,N2
M,C&0<$5FZ#H%AX;T[[!IRRK;[VD"RRM(06.3RQ)Y.3]2:TZ* "N?U/P3X=UC
M5#J=[I^Z]9 C31S21%U'0-L8;NW7-=!10!7LK&TTVTCM+*VBM[>,86.) JC\
M!5BBB@ HHHH R]3\-Z-K-]97NI:=!=7-DV^WDD7)C.0>/Q ZUJ444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 (:K:=_QY+_ +S_ /H1JT:K6/%HO^\W_H1H LT444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7 :UJ-OI'QBT>XOB\4%UI,MI#)Y
M;,'F,R$(, \X%=_2%5)!(!(Z'TH \C\%/I\GA?QM<-IT&H7MOJ5],+?:#)(I
M3"X[@, P!'OBL;0M8MCX^\%7XOI6LO[.FB*):-%;6I\M?W*';DA>-Q9FQC)(
MKW:B@#Y^AOK:P^!VE30R0I>1ZX)1@+N#K.6W$>H3:>?X<=JZ'7[J.S\07E[X
M<U-I[NXO8TN_#EQ%YB7S!@#+%G[IPN[>.!LYQC%>P44 >1R>5);?%01*YDND
M=;<LN6FS!Y?R8^\/,RHQGGCK35M)U3X2A;.<"UB'VD"(_N3Y"J=_'RG=D<]Z
M]>Q1B@#R:*TMI;[XCQ:QI]])IUW=6Z'R8GWNAPI>/ RVTG/&>E16T<KZ7KNF
M:Q<7_B3PP\%NL6HK;D7,9,VWRS@;I&CSOSC(P<CG%>O44 >/W)UJW\&^,K"6
M:^UJR%BL-C?36C+<2EPP\HX7=)M+9W8_B/3FMFU:YT;Q[::U>07,FDWVB16L
M<\<+/]GD1MQ1E4$C=DG)[\5Z/10!XU>:3=:?:6-Q-:W<D-]XR&I) +9R8;?<
MWS,N,KD8;! /-=2VH'2?'_B?43IU]-$NEP,OD6S'SFC+EE4XP6PR<9[^U=Y3
M70.I4YP?2@"GH^J1:UI-MJ$,4L23H&\N9=KH>ZL.Q!R/PKQ6Z@U?46T"^DT+
M64N[+Q*L]U9P6K1VUM&)&/R+P'+9#%^>6.2!@5[G;V\5K D,*!(T 5548  J
M6@#R>RL[Y-/^*&_2]0S?22FT0VCYGW1LHV CYN?3ZU+ILNI^&]6\/ZG-HFIW
M5C-X=@L)A;6S/+;31DL0R=0#G'3J!7J=&* .$^%EI?VFB:K_ &AIUS8R3ZM<
M7"1W";6*,1@_H:Q_%6GWR^([O4_#-OK%EKXN84:)(':RU),+\TC$;%P,C=G(
MV^XKU.B@#RN2WU31O$OCR%=$U&\&LQ1O9S6\.8F_=,K!GS@$$].I[ U4TX:_
MX5?PIK2^&]0OK<:#'I=Y;0)^_MW5@P8IW'7^N.E>OT4 >>ZH-6O=6\'WD^CS
MP+%?27$T,,1?[+$8RJB0KD%B6R<=,GTR=?P];W,7CCQ;<S6L\5O=26Q@E="%
MD"1!&P?8BNKQ1B@#BO$T%[)\1?!UW#9W,ME9&[:ZECB++&9(MB9Q[YZ=.]<A
MXTTGQ#K%MXJMFT34[BXDN(_L!@9$MO(4H=Q 8;Y#@@[@Q'&,8->R44 >7V<O
MBCPSXRUF]B\+WFHZ?KQBN8O+EC5[:4(%,<F3@#WS@8[\XE\6Z)<:I="Y;3-1
MMO$-O8I]DU;2B0&E(.Z%N?N[L?>XPW4<UZ710!P4-KK,'Q&TB_OK*:94T$VM
MW=0IF,3EE<X[X.T_F*Y^VT36F^$NEZ4-'NQ?QZN)I(&"JR1BY:;<<G&-N.AZ
MG%>NT4 <7%87\7Q7O-9.GSFP?25MDF!3#R!]^T#.1QQD\9[US5SX:\0/\(]%
MT>+3;A-4MKZ.62-9(]T:K,7W [\="",&O6<48H \PEL->\.>,]7EM?"B:]8:
MS,MU%-YD<;6\NT*R/NS\ORYS_6N_D6]M_#KI'##<7T=H0L04+')($^[CLI/'
MTK0HH \T\/\ AV_TKQ$+S1](O]'TA[&4WFERSQO&\YQL$*JY"MUR>!^9K!AT
MC6-)^&'A+1+C1YVUVWU)GB@CNXTG3:TDN^-B2A^4X.[C!/'2O::QM?\ "VE>
M)5MO[0BD\VU<O;SP3-%+$3C.UU((S@9H \^(U2YT;Q+I$_AS58/$.LV4DB37
M5S!*;G;MCQN0A45/,&!QP3U/78_LC6?LWP_0:3-_Q*2OVW,L8\K$!B_O?-R<
M\=O?BNLT?PWI^B/)+;_:)KF0;7N;NX>>8KUV[W).WVZ5K4 >+77AKQE>MI]S
M>>'A=:K8:Y'=R7\E_'FXA60E5C7_ )9H%VY''W<X)S6Z?#?B%V\=:3_9L0M-
M:\V>WOC<#&YX@H39USD<DX'UKTRB@#S2PTSQ=>:[X,O;[0H+2'1XY8+@?;%=
MCNB$>\8[<9 Y/KCK2^'O!6H2^#_%V@:O;&U&JWUS<02>8KC;+C:?E)Y!4$@U
MZ510!QGA.7QN4M-/\0:9:6L5G&%DOHKH2F[VC PF/ESP22?H!GC&T3PMJJ^*
M]*UN+0T\/7.UO[8^SW"-!>?*<!8U)YW<Y(!'J37IE% '->,=/EU2VMK*3P]!
MK>G2,WVJ&214=.!M9"Q'.<]P??UY6U\,>)+-/"]N\,UW;V6K27K&6Y1GL[<J
MR1PDDYD(#Y)'I@9XKT^B@#S/6="\675SXS?3+3[,^HM:_99#=*OG)$ KKD'*
M%EW8/'7J*;H7A?7=,\5ZOJRZ#8V5E>:6L4=I:W*L8W7=\@^5068X)/ YZFO3
MJ* /-;;PIKT/@WP;I;6D'VG1]0AN+G%P-NR,M]TXY)#9Q[&NP\6Z1-K_ (1U
M72;=T2:[MGBC9_NAB.,^U;5% '#-X?U7Q,-'M]<L(K"RTS+R1I<"5KB3RVC7
M:0!A &8\X))' QS6\'Z5XZT..V\.7ATYM(L2%BU-6+2RPJ?EC\O/#8XST Z9
M(KT*B@#F?'7ANY\2Z%#%83I!J-E=Q7UF\@RGFQG(#>QR:PV\.>)?$'B6SU'7
M;73[.V73;FQFCM;EI''FA1N4E .W3MZFO0J* .&\):3XSTB&TT/4)]+.D:>%
MCBNX=_GSQ)C8I4\*<  GGC@>M5/#?AKQCX9'_"/6MUIK^'EF9X+QB_VF&)G+
M&/;T+<X#=!G//2O1** /,U\':_-X;\9:;);VL<VNWTD\+?:,K&LF =WR]5"Y
MXZYK=U#P[J6I^)_#^HSQ6HMK"TFAND$S9=IE"L$^7HNWJ2,[NV*Z^B@#S_PS
MX<\9:!+#H?\ :6GMX<M)0\%SL8W1B#;A"1]W_9+>A..V,Z[\!>)8/#&L^$]-
MN].DTB]D>2WFN"XEA#N&:,@<$ Y.[/X5ZC10!0ET_P"VZ#)IM^5;S[8P3>5D
M##+M.,_6N4@\):Q-X<TOPSJ%Q:/IMA+"6N8V;S+B*%@T:%",(3M7)#'IQUKN
MJ* .1\,>&M1T3Q1XFU&X>U>VU:X2>(1NQ=-HQA@5 YZ\&N5U;1KSP]X$U2RU
M>\T=9M9USSE:Y+-;GS9 Y5R0NS 5CN'IQ@XKUC%5[VPL]2M7M;^T@NK=\;H9
MXPZ-CID$8- '">'VUC1_$B6EU:Z#<3ZA"Q:6SNYGF41J2AD,FYC'GY<CH6'T
MJI%\/M;C\,>%M,\[3VGT;5_[1D;S7"R+YCN%'R9!^<C\.^>.^TK0M)T*%H=)
MTVTLHV.6%O"J;C[X'-:% 'G.L^ M:U/5_%]S;ZC;V::Y:0V\,L;L9(S'@$,-
MH&&&X'!R >]2:5X+U^R\86GB&:YT=?*T@Z:;.U@>-% ?>H4Y/!/4XX_NGK7H
M5% '#>&?"GB#PKX%TW0+#4+$7-I=[I+AT9EE@,A=QMQ\K88COTZC/'<T44 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  :KV
M7_'JO^\W_H1JQ5>Q_P"/4?[S?^A&@"Q1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %5['_CU'^\W_H1JQ5>R_P"/4?[S?^A&@"Q1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/Q#XEC\.1Q2W&G7UQ!))'$)+81M\[MM5=I<,3G'0&@#<HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #4-
MJ,6X^K?S-2FH[;_4#ZG^9H EHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:YO/%?B/Q!<VT\*3O%9V8N(6C<PQKDL%;! 9G/8=* .OHHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** $-1V_$(^I_F:E-1P?ZH9]3_ #H DHHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** #M4<'^J_$_P ZDJ.'_5CZG^= $E%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 &FQC:F/<TZD'2@!:*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I%Z4M(O2@!:*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ H'2B@=* "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **9'()4#J&P?[RE3^1I] !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%4]4:_2P
MD.FFU%S_  O=EO+0=R=O)^G'UH N45B^$]7NM<\-VVH7L,,4\A=6\ABT;[79
M0Z$\[6 ##V(ZUM4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ-8T[[08Q%-'+)!/$'W".6-BC#/&1D<' R,5HT %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HI** %HI*,^M "T4F1ZT9'K0 M%)D>M&1ZT +129'K1D>M "T4F1ZT9'K0
M M%)D>M&1ZT +129'K1D>M "T4F1ZT9'K0 M%)D>M&1ZT +129'K1D>M "T4
MF1ZT9'K0 M%)D>M&1ZT +129'K1D>M "T4F1ZT9'K0 M%)D>M&10 M%)FB@!
M:*** "BDR*44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
&4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ibc-shattucklabs_1stamen004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibc-shattucklabs_1stamen004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * <TAI$^[0 ZBBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5=S"+:N5R1C'\JYBVU36;;PAH31S79G\3Z3'I4;G<1'<K)L20DGY28G<Y[[
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MG9FX.:T?"VE^)Y+*5K/5;G2].749FMK74;0RRM;$KL&7(9!P^ >0"/2O1**
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  :9']S\3_.GT
MV/[GXG^= #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I%Z
M4M(.E "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>.]>+PS7.N>"?!?A35TBT[0=2V@:E$YF,KHYQ PPOE,Q[Y;V[UW7Q)::#6O
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MNJ6-DEA!+'';.%,;MN'RG&0,KDXY/KCB@#T26XA@,8ED5#(^Q QQN;DX'J<
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M [C!Y/K6U10!S@\#:"ND:;I2VTPL]-G%S:1BYD'ER D@YW9."3@'-,U+X?\
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M=9/-(5"0Y8'"D?W<'WKH;SQ%KFO:_?:5HS75M]CT^"8M;& ,TLREE)$P/RJ
M!@#.2<]JTF\ ;M$\0Z:VL3E=<G:>=_*7Y"W#!1[@ ?A4>H?#E+ZYL+^'7M3L
M-5M[=+::]LW"-<QKV<8(S[_ITP =%X;DU:3P]9G75@75 FVY$# IN!(R,>N
M<>M>?>%#XD7Q%XS&@1Z0T']LR&3[;-)NW[1G&Q2,?RZ=J],L+&'3;&*T@W&.
M,'YG;<S$G)9B>K$DDGN2:Y[3?!!TBZO[FQ\0:I!+J%P;FZ"K;E6D/4@-$=M
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG-/_ .%<:O\ ]%#\2?\ ?U?\* .>^*NI/XK^'.F_V;IU\]Y+=1S268MI#+"
MCA@PV\88XSW[5!X^T?4/B)/X7\/Z797(L[;$NH7D]N\20C"K@%@-QQNX&>W3
MFNJ'PZU<#_DH/B,_]M5_PIA^&VL$D_\ "Q/$H]O-7_"@#2M[VPC^)\VG1>&9
MTO!8*6UGRAL9!C";N_8=>HQCBNPJ"QMWM+"VMI+B2YDBB6-IY/O2$  L?<]:
MGH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2F2O[OG;Y8],[NV*Q[/X>R^';/QA)HT=K/=ZW(PMTE<QK#&RG@D*>C.YP!R
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5#<6L%W$8KB))4/\+J"*FHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4R1MB,YX"C.:?6!XSU$:9X3U&X#A)/)*1\\[CQQ^=
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M]L;;4K.6TO(5FMY5VNC#@BJ6O:AJ&G62RZ=I;:A*6P45]NT>OO7,2ZCXNU&
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M!Y!%W'S^M &Q15"TUS2K^80V>I6ES(<G;#,KG'KP:OT %%%% !1110 4444
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M?9Z9:K:V-M%;0+TCB0*/KQWKF9_!5S;>);K6M!UJ32FOA_IEO]G$T<K_ -\
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MG15+2[MK[2[6[=/+::-7*>F15V@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+D=>,_CZ910!XS8Z%XG_ .$E\&Z]=>';TW=@+A-2DFNXV:21XMH90&PL8.<
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M7.CV>FR3VN@Z=;)M+22QM<2G<"QQDX'+8Z=NO6O0_P#A"/"?_0KZ+_X+XO\
MXFC_ (0?PEG/_"+Z+_X 1?\ Q- $%CI/ARROQJ#74-S?@8%S<W"NX]<<X'X"
MF^+=+TCQ=H3Z9-JL=NV]98IX95W1.O1@,\]_SJP? WA%NOA;1#]=/B_^)I%\
M"^$5;<OA?15;U6PB'_LM &3!HMX\*1ZMXYN+N%5PRPB*WW_[Q7G!^M27WA3P
MU>6VG007:V,5C="Z06LZ+YC#J&R#D' ]_>M;_A#/"_\ T+FD_P#@''_A2_\
M"'>&/^A=TK_P#C_PH TO[0LS_P O<'_?P5@^+9DOM'2"UG@E)N(S(@E7)0-D
M]ZN?\(=X8_Z%W2O_  #C_P *4^#_  R1C_A'=*_\ X_\* +R:C8J@47EN,#I
MYJ\?K3O[2LO^?RV_[^K6>?"'AHCGP[I7_@''_A0?!_AD]?#NE?\ @''_ (4
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M  H F_M?33TU&T_[_K_C2?VSIA_YB-I_W_7_ !J'_A&]"_Z NG?^ J?X4?\
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M#  I] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 455U
M+4;72=/FOKR3RX(1EFQD^P [G->>^-]7\0VWA];I+PVCZG)]DMM/6%2P5U(W
M%NN_Z$8X[T >DQRQS('B=70]&4Y!_&GU3TJP72])L[!7+K;PK$&/5L#&:IV?
MB2SO_$E]HD"2M/9(KRR8&S)Q\H.<YY].QH V**** "H+R]MM/M)+J[F6&",9
M=V/ J>L7Q)I$^KV]BL#J#;7L5RZ/TE52<K^N?PH UX94GA26-MR.-RGU%/I
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M9,D;,B?WF X'YU@^#H9I]*@U>YU>ZOI[R(-(CN/*C;.2%4#@@\?A0!TM%%%
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MY]*\D^)-YXC?^R[%W0R7TI,>F6R[B=N"OF'^+YL>W!ZUO_$&\U*ZM=&\+Z?
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MGOR*TZR_#FDC0_#UEIPV[H8P'*]"YY8C\2:U* "BBB@ HHHH **** "BBB@
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ML@)&$!/.1@X'K70T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MLM(AAU[48]4U"-V/VH0"/@GC '3 XK8H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MVBO*/ GC35KCXDZYHFOQR0G4$34--C8G"1;1A/J4VD_[2OGDUJ^.M">U\/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$AG"&.2-22IR,8R,;O3)P> 3Q%X7UW4?&D&IVKZ=<:>+%K:.&]+8M)2<F5%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ K/L=$TW3;RZO+.T2&YNR#<2J3NE(S@L3U/)YK0
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MRH&U1_",8./?Z4 :M<A\,R#X+A(_Y[S?^AFNOKC_ (9#;X*A!_Y[S?\ H9H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXG)K6H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P"#27_&NDHH YO_ (0RW_Z#?B#_ ,&DO^-(/!=N&!&M^(>#GG593_6NEHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?1QSP;P,H5<JI3(X(/X'/!XLU#4-6\..J2:9)=&_MYX+.*_B7RXHY%<[Y&8
ML=I^Z"!D=>30!T&F>*Y=2UR_T&_T2XL;R.T%W!%)*K_:(22N<CA3G P3WK$T
M;QEH>C>!="FTS3[?3X-0DE2UM+F\6%(PK,79Y&SCI[G+ #-2/?1K\5#KBR6K
MZ=_8OV,R"]@#&42^9@+OS[9..?;FN2TK3-3TCPUX8O[.YTD:[HAN(9+&?4(_
M+N896)X=6P#RI&>X]N0#8\2>/VU[X7:]=Z7''%/;,UI>B.\#&$%@H:-E&'#
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M\+?]#+H__@=%_P#%4 ;=%8G_  F?A;_H9='_ / Z+_XJC_A,_"W_ $,NC_\
M@=%_\50!MT5B?\)GX6_Z&71__ Z+_P"*H_X3/PM_T,NC_P#@=%_\50!MT5BC
MQAX8/3Q'I'_@=%_\53AXL\.-T\0:4>,\7D?^- &Q161_PE?AW_H/Z7_X&1_X
MT#Q5X=.<:]I9P<'_ $R/_&@#7HJ.&>*Y@CG@E26&10R21L&5@>A!'45)0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !5&YT72KR<SW6F6<\Q&#)+ K
M,?Q(J]10!F?\([H?_0&T[_P%3_"C_A'-#_Z VG?^ J?X5IT4 9G_  C>A?\
M0%T[_P !4_PI/^$:T'_H":;_ . D?^%:E% &7_PC6@_] 33?_ 2/_"C_ (1K
M0?\ H":;_P" D?\ A6I10!E_\(UH/_0$TW_P$C_PH_X1K0?^@)IO_@)'_A6I
M10!E_P#"-:#_ - 33?\ P$C_ ,*/^$:T'_H":;_X"1_X5J44 9?_  C6@_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB@]*
M "BD%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 444$@#). * "B@$$9'(H
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N"^*6J-#X9O]-#30
MQ36%Q)-.B/VC;9&" 1EFQG)^Z&SU%=[5>_LK?4M.N;"[C\RVN8FAE3<1N1@0
MPR.1P3TH S/!]PESX,T65,X-E".4*\A #P0.XK;J"TM8;&S@M+=-D$$:Q1KD
MG:JC &3R>!4] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 444F0.I% "T49STHH **;
MYB>9Y>]=^-VW/./7%.H **** "BBC('>@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-"TRVUY]NA:1R62;S#)N!_WB>/0XZ4 9D$NL'Q5-I,FKLPAL8+HN+= &9I9
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% ",-RD<\^E*!@8HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
/ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ibc-shattucklabs_1stamen005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibc-shattucklabs_1stamen005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK3[BW6\2XM\@M$P ^4YP6P/QYK9N?!\NHK9V-Q"(['_A'9=-E96'[N1C#M
M/;83Z<5W%% 'CT7@;Q3<:5;:SJHGEU\:B)[FUMKX0L\(A,*A9 <!@"6'('SL
M#UJ ?#76[O4K*?[)]@CE74_M#R7OVB6-IX1&C.Q)W,<<[>*]HHH \3\7Z=KT
MOA._U'5-"@TQ;#18]/1%G20SN9X6X*]$'E\ _P!\UI:QX9\3^*)KC6Y-).E7
M$4EF8["&\59;H0NY;=*IPI^;Y2?[HZ5ZO+#%/$T4T:21MU1U!!_ T^@#DO V
MC76G)J5[>Z=-8W-[,I*SW[74KJJX5I&R5#=1\O8#/(KGM/T#Q'H?V2[CT<WD
ML.MW]T8$N8T)BF#A&RQQ_$..M>G44 <9IEIXA;6]5\3WVEQQ7$EK':6>F+<J
MS;%9F+/(!M!)<\#.,=:O^,M,U"_L+"ZTM!+>Z;?17L<!<()PN59-QX&5=L'U
MQ7244 <1I>CZQ<Z%XIO;^U%MJ.N&1X[/S%8PJ(1%&K,.-Q"@GMS6+J>E>+(?
M!_A?P_;Z3-<6$-A''K$=M<Q1R2;8U7R59F'RDYW$=1C!ZUZC10!YMXCM=6U'
M0X-,D\"076ER692&R6:+?97(WJI)W!=FTK@KR,GKTK'U7X8^)]]IJ</BB>ZU
M*26P2X+VD3F,1.A+JS'HI!?:/O$<YKV&B@#RCQ)X-U'5M;U.P71IS:ZE<02R
M7L-]LM652F]Y8-XW2 *> ,'"GUK&U#P-<2ZOXGCN? #:I<7U[++8ZB+V.)8D
M*#9SNR,$$].]>X44 >3>)?!^N:E)<6#:=/<S:A8002ZC!?M%;M(JA7>XBW L
M1C<N%.> 1P:Z#6?AY=:GI]W:Q>+]9B2ZP'BF,<L*INW;%3:,#MR3QP<BNYHH
M \93X?>(K;3KZ2_4:VMOKZW\>GO'%"MW&(]C, OR@L&'R-P/+Q_$<OF\&:K<
M6MU<G0)8]#N-62XD\,I-&A:!8@NX;6V!O,^?9N .*]CHH \GT[PUJ%CI-E+>
M^#8-0T^&^N'M](D=))K&"0#:%W-Y;_,&)!/&X8/%:_AKP-JEMI$#3:]JNE2!
MI'CTZSFC:"W1I&=8R&0Y*A@IP>V!ZUZ#10!Y+IWP_P#$OAKQ7I=Y;:W-J5I:
MV]U)(S6L*-([,C&-F)W,9"/OG)&WK5>&T\6:QHGB"/5_"E[_ &WJ=A<0B\DN
M(3%$I4[(8U#?*N<<]SR?;V*B@#RSPYIL\,ME:OX#U.QD:#R);][Y&2,F/:S;
M/,.1R> /PJKX7\%ZC!=:-:+X>/AU].M9H+S5K.:+?=%E !3[Q;)^?YQQC%>N
MT4 >9^)O"5ZMWI[WEI?^,-*BBF5[2YFB$J3-C;)_ I  9<]1NR*Q[KPEXGAT
MG3(+JPO;R^;21937>G:B(F+!F*Q3[B T8#+\R_-D-R0>?9** /-O#OPX@M=7
MOHM4M/.LX;*QM[699G3S&CB*R'"MTSCK3_B%I.KZS'-I<'AJ/4$,*?V5?Q2J
MCV,^<,SEF!&,*P*@YP0:]&HH \^\1^ ]1O\ PW>0G7-2U:>3RY?L5W+&L$C+
M*LA52J*R9VE02W :L9?#=\ZZS>6_@>"+3+A[,C0YWB7SO*+&20*C; V"H )P
MVWD<UZU10!Y1#X7ND@N-0E\%0W&G2ZHMQ%H4CQAK:-8MAD10WE;F;!*YQCWY
MJ&#PIJEAIUK>)H=_$5U2ZN;:#3KJ*.YTZ"0#$:JQ\I@Q4EES\N[CFO7:* /)
M]$\.:YX+NM,U>WT:YU%I;>\CNK6*Y5I86FF65,EV 8@*%9@3R,\\55TCPOXC
M\&PB:'1YM5GO]&:WF6"6,>1<F623#;F7*?O<9&?N].:]BHH \S\/Z+JGP]NP
MT>C7.JP7NG6<$K63J6CG@B*'(=A\K<8.<#OBGZ]=^.+K2]*M#I-V$NW>;4GT
MV2-9H(BQ*0(S.!NVX#./3CK7I-% 'DNI^&+=M2MK^3P'=W^GR:2+*'3V>(M9
M/&SXRN_:-P8?."2.?4U/IW@?Q)JMQ&VK:K/IXL](BTQ2D44YN R!IR2X;J<+
MD8)V5ZG10!YO<Z+XAN_@]<Z!<VLLVJ6[K;1EG7-Q'',I1\YQR@!Y/4&NA\=:
M;>:IHUG#90--(FIV<S*I'"),K,>?0 FNGHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?VB'_GJG_?5'GP_\]4_[Z% <K[$E%1_:(O\ GHOYU(.1F@&FMPHHHH$%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5R/BBW
MM;WQ7X<M+V!9H)$NV9&Z':BFNNKF]9A63QIX;9L_*EV,?5%III;FM%R4KQWL
M_P F</):0'38M8_X1WPY!9W!WVUM>7)BGGCSP0S$*"00<5K11>$AK\VGSZ+:
M^49[>W@DC3(W2Q&0;CNY!VD @?XT^X\":Q-8'1GO-(NM+C#1VLUW8E[FVC;&
M0ISMR,<'&>E6!X#N8=-U>UM[V-7FALTLI2#NC:W0!78CN2.W]<5UKV37O/\
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M%HHHH("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI8I: ,W^W]+(S]K&/]UO\*3_ (2#2R/^/L?]\-_A6G1B@#-'B#2S_P O:_\
M?+?X4?V_I?\ S^)^1_PK1Q1B@#-_X2'2?^?Z+]:/^$ATG_G_ (OSK3HQ0!F'
MQ%I _P"7^+\S1_PD6C@9.H0_G6G28H S/^$CT?\ Z"$'_?5'_"1Z-_T$;?\
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MZF,9M9$3RP0 #O7;SCCFLN_\#:S;:9INDKI6B^(M-M]/BMO*OOW#P2( &='
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\$6D7*174JO"MO>;B'Q@MC>HY!'ZUZ+\0+34)=4\.7UEIUS>I8WAFF2#&X*
M.F2*S@FK:W\0] U$^';ZPLK))1*\^S[S#_9)]* *F_XR?W=)_):0M\9<Y":2
M!Z;5KUBB@#R.>#XMWBK'=+8",-N/D.J,<=LYZ4V*R^*ME<RR6,5ILE !2YG\
MS;CTY]Z]>HH \H$_QE#<V^D$?0?XTHN/C&"<VVD'\!_C7JU% 'BNIWWQ0>\T
M^QU'[#$]Q*Q@CMG\MI2JDD9!Z8.:MPP_%>QN))+&UM2DG5+F?S,8SC&3[\UU
M_B49\<^#QV\ZY_\ 1)KKP!0!Y2+[XQ_] _1_T_\ BJ/M_P 8L?\ (.T?]/\
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MIP/^6GJ:(/%'Q:NK>*XB\,:68Y%#H=Q&01D?\M*]'\1#.AW'_ ?_ $(5+H@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:Z:@ Q0:*#0!S$/_ "4J[_[!47_HUZZ>N9@_Y*7=_P#8*B_]&O734 %%%%
M:Y.Z9?\ A/[%21GYCC/./*:NLKB;VWB'Q5TVX"#S3#(A;VV'C]: .VHH'2B@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#R'XYL/*\/H>]T?Z5R;@''''UKI/C?<QS76BVT98R6]P'E&TX4-C
M'/2N:EW(F5;(S6<SEKQ<I**(@P$K#MBD+ GGK48<\N.00*<,L>.M9HG$PE&S
M?9?D*&Z8)IV1C(!IN6W #\:4,VW\:9Q@6&.1S[52O<->69!(_>'_ -!-7<MG
M/:J%[N^V673[Q_\ 03312+P4J >3^-'K2%FP "*568,<X(IHD-PVY)_#-=?\
M*#GQEJISG_0X_P#T(UR3%1V KKOA.,>,-8YS_HL7_H354=S?#?Q#V*BBBK/1
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *#110!R7B$_\ %=^$
MA_MW1_\ (1KK:XWQ/<);^.?";ONV[KK.T9_Y95L-XLT2*W\^>_6WB+[ US&\
M(+8S@;P,T ;5%1Q7$,ZAH9HY 5# HP.01D'CL:D/2@!#TKBK(_\ %WM3/_4-
MC_\ 0A71/>W5U<M#8I&(HSA[B3D$]PH[D5YY;:C?CXGW:I-&+B6"*W:0Q\8W
MD9QGVH$>K#D4$XK.COI;:Y2UO0@,G$4JC"N?3V-,6]NM0D;[#Y<=LN5\Z1<E
MF']T>F>] S4S2U5T^266SC>9E:3D,5& <''2K5 !1110 4444 9NO_\ (%G^
MJ_\ H0J71^-$L/\ KWC_ /014/B XT6;ZI_Z$*R=+\9>&XM*LXWUJR5U@12I
ME&00HH ZFBL3_A,?#G3^VK+_ +^BD/C+PVHR=;L1[F84 ;E%87_":>&O^@Y8
M?]_A5RTU[2;Z,R6NHVLR X+)*#S0!HTR25(D9Y&"JHR2>@%0_P!H6?\ S]P?
M]_!_C5&X,&J:C#;AED@B'G.4<$%L_*#C\3CZ4 <E\1M2BN=%TPP)(T9U*$"0
MJ0#UZ9KT,5Y_\5Y$AT#2V=@J+J<!)/0 9/\ 2NJ7Q1H3=-6LSC_IJ*!&O162
M/$VB$X_M6S_[^BG'Q)HHZZK9_P#?T4#-":XBMXGEF=4C099F. *\V^)GB"Q2
M+1@3)^ZU".=LH1\H#C(_*NSA:'6[UKA94FLK<A8MC!D=\<D_3I7F'QI(6_TI
M0?F+QX'?&7_QH$SUNTU>SO"%BD(<KN".I5B/4 ]:N@YK-:RCO-,@W?+*J*T<
MB]48#@U#8^(=-FM(WDO[99,88&0#D<'C/K0,V:*S_P"W-*/34;7_ +^BE.M:
M;C/V^V_[^C_&@#GO&-[#I^M^&KFX8K$ET^X@9ZH1_6NFMM0MKIBL4H+@9*'A
ML?0\UY_\0M2LKJ_\.)!=0RG[;SL<'' KN=0LOM$"R1'R[F+YHY .<^A]C0!H
M YI:S;76=/FMHY/MMO\ .H;!D%3_ -J6'_/[;_\ ?P4 8>M<^.?#'L+K_P!%
MBNGKCM8U&R;QUX;(NX2JI=$G>,#Y!C)KIO[3L#_R^V__ '\% %NH;BZ@M(_,
MGD6-<XRQZGTJ$ZG8\8O;?_OX*KV,?V^1KZ<(P#D6^#D!/4>YH YVXUJR'Q$M
MI-[;5T]XS\C9W%U(XQGH177V]Y!=*6AE5]IPP'53Z$=J\ZNFC'Q?2/>N=B_+
M[X2NVU6.&QC;55/E&W!>8K_&@Y.?7 H UJ#57^T+//\ Q]0?]_!3C>VN/^/F
M'_OL4 8,'_)2KT^FE0_^C7KIJY:SFCF^)%^8W5@-+AY4Y'^L>NIH ****  U
MQMX?^+G:<,=(I#_Y#-=D:X:Y@3_A;-E/@[S;2(>>,!,]* .Y'(HH'2B@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#Q+XR)=VFLVDA\LVMZZ*I'WE*XSU[<]JQML>. V![5TGQS)$WASK_P ?
M#?S6N7D88)4<5G,Y,2[-%46X$Y)+"+/RC%3!8NHD8"DWY)Q^M-R%XQ6:T(KX
MF=>2E/IH/"Q9)#G\J>1'C[SDX]*BR#D8I 0!_.JL<[9*S1E0I9L8_NU1O"HN
M[1>HW$YQ_LFK)(/09%4+HC[;:!A_$V/RII"1I(L0'.XCMQ2 Q D$MSV %1A@
M%XI0Y/(7D4"8]EB8 ;G_ "KKOA.,>+M8 )(%K#U^K5R!&5QC'X5UWPE;/BW6
M0<Y^RP_S:G'<Z,-\9[%1116AZ 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !0:*#T- '"^,[B[MO&7A62RM#=S!KG$(<)G]WZGBM(:WXC(&?"KG
M_M[C_P :AU\9^(/A/_MZ_P#1==<.E '%QW.L0ZE)?P^#%CN)5V2R)<1!W'&,
MG//0=:O/K?B'8P'A:8''_/U%_C7344 5;&W6VLXH@I!5>03DY[_K7F]KH'B%
M/B6VHOI@73GD"F;S5)VJQ(.,YYXKU*C H S-:LY-0TN:W@95G(S$S=%8'@U>
MAB6*".,*!M4# ^E2T4 <*NN>,K1G@B\(K-&CMMD%X@W#/!QFG?\ "2^-A_S)
M?_DXG^-=Q10!PY\3^-,?\B4W_@;'_C0/$_C/'/@IO_ R/_&NXHH XC_A)_&/
M_0E2?^!<?^-+_P )1XPSC_A"I?\ P+C_ ,:[:B@#SW4O$?BB>U$-UX3DM8'D
M17G-RC!!N'. <UNZ9X1\.OI5F[Z)8,Q@0EC I).T<]*T/$8_XD<_('*\_P#
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M'U\AO\*[CX.RK/XHUMU!Q]GA'*E3U;L:I;F^&3Y]3V:BBBJ/1"BBB@ HHHH
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M_"NIIK_<;Z4 <AX M!:V5R [N9#&[%L=2@KL37+^"_\ CSE_W8O_ $ 5U!H
MY:WB23XCZB70-C38 ,_[[UT?V:'_ )Y)_P!\BN?M.?B+J1_ZAT _\?>NFH A
M-K >L,9_X"*3[';'K;Q?]\"IZ* *YL;7_GVA_P"^!7'2@#XL6G&,6\G_ * *
M[DUP;VZ?\+AAN,/O-HR?>XQM':@#O**!THH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \2^,BW-MK=AO$1MK
MV5-C _,I7:#QC^1K$=(P/OL3WP*Z3XY _;O#7_7PW\UKE'8!N.O>HDCBQ3U0
MYM@Z,V._%-+1\_.WU II;"Y*YIKXSZ?2IL<EQ^8>N]B?<5G:ZR'1;HAFSL&/
MS%6\ @ 8-9VMK_Q)KH8X*_U%-(<'[R-2W=3:Q!F;&T=O:JUPT*W]IRQY;J.?
MNTF]HK#<!G;&"!Z\5P%Q<W-Q,9Y)'+D^N,4[&E.+FSTP>0#SDCZ4T>2'Y+!?
M:L30+N6[TL&8EF5BNX]2*U0NX8/;I2M8RE=.Q8)@;[KN/3-=C\)1_P 55KF"
M3^XAZ_5JXE1@8/!KI_@;<S7>LZU+,P+F*,<#'1FJD;X765SVZBBBJ/1"BBB@
M HHHH **** "BBB@ HHHH **** ,/QCK7_"/>$-4U0$B2" ^5\N<R'Y4X_WB
M*\DTGP;<6/C6XT6]USQ!<^7ID%RY34 "LK$AADD KD<=Z]1\;>%;CQ=I5M8V
M^J#3_)NDN2_D>:6*<J/O+CGFL#1OA3'#K=UJGB75?^$AEFA6)!<6Y3R\'.0=
M[>_'O0!EWGA'R[_3X8;[Q,5GD97']H(20$)X^;VKE_&6CW^CZO:VEEJNMVXD
MMGE/VK45&2I X.<=^G6O88/ _AJUG6>WTB"&9?NR1EE8?0@TMYX)\.:BR-?:
M7'=,@PIG=G*CVR: /$O!UM>ZWJ%M;WNNZW(TL+2F.VOEX (&2=W')Z&NS\.^
M#CK-YK"7&O:_$MG="&-?MG.-BMR1D$\UV(^'/@]#N7P_9J?4*1_6ETWPL=!F
MNQH<L%G:7#B0P>5N ;:%)!SWP* /.M7\$PQ_$?1M)?6]7>":VED,LESF1" ?
MNG'&<<UTC_#S1;>=(F\5:Q%,W**;X GZ#%.U31I9OB=H$FJR07J26UPHC,("
MC:N>ASGK7?Q6=M JK#;Q1A1A0B 8_*@#S^V\"6UW<LEOXK\1LB [C]J(&<].
M5JW)\-%$;%/%'B$MM. ;SO\ E7=X'I2GI0!G:*^_2+8>8\A1 C,YRQ8<'/OF
MN5\*Q7$'C74DDO[JXCFMO/$<LFY8R9G7"CL, 5U,UE/'*TMC.(7=P9%==RMT
MSQV)'>L#1;:2T\=74,K*SC358E>G,SG^HH [$#%%%% !1110 4444 %5M1&=
M-N@?^>3?R-6:K:A_R#;K_KDW\C0!R^K:98IX)A=+2W2010D.(P"#QSG%2?#/
M_DGNDY.3Y9Y_X$:FUD9\"H!U\F+^E-^',,MOX"TJ.:-XW$9^1Q@CYCU% '4T
M444 %!HI#0!Y!9+_ ,9"71/_ #R./^^*]@KR" &W_:!G:93&LD)9&?@, G;U
MKUH7,/\ SVC/_ A0(EHJ+[3#_P ]4_[Z%+Y\7_/1/^^A0,DHIGFQ_P!]?S%'
MFI_ST7\Q0 ^J-_JUGIL)ENYEC0>Q)_(<U)>77D6<TL9#.J$JHYR<<50DL%M=
M%O6D/F7,D+M-)_>;:?T]* .>^'LXN=3\5RHP:-M48HP[C&?ZUW5><_"QE\WQ
M*<X_XF/K_LBO1-Z_WA^= AU%-WKG[P_.EW#U'YT#%/2N&^)BJVG:,&Z#58C_
M ..M7;EACJ/SKA?BBY73M#VD<ZM"/T:@#NQ2T@(]:,CUH 6BDR*,^] "UQ/P
MO_Y%V]Y_YB,__H5=KGWKA_A;_P B[??]A*X_]"H [FFO_JV^AI<^]'XT <GX
M%G6:QF*9^41*V01@A!GK76GI354+T&*4T <W:?\ )1-3_P"P?!_Z&]=+7-FV
MOK3QC=ZD+-YK2:TBA#1NN059B<@D'N.E;5I?17L EA)QT*L"K ^A!Y% %JBB
MB@!#TKB9"?\ A:]OT_X]GX_X"M=L>E<,]O&OQ>BN @\QK1U+>P5: .ZHHHH
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M#8 H 7W'^-:QH Q]1\6>'](NS:ZAJ]G;7"@,8Y90K 'H<5EKXO\ #T^LVO\
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M44 <OX5'_$^\5'UU%?\ T4E=37$^%VOFU3Q#+;/:2>9J#>8LFY3&P &WC/\
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M2$<CW%=T:Y'5 #\1]%]1$Y_\<DH WM*T6PT> 164&P8QN9BS'ZD\U-=V%O>
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M +?I?_BJZ>B@#F?^$'TK_GOJ7_@=)_C2?\(+I7_/SJ?_ ('2?XUT]% '+_\
M"":7G(NM4'TOI/\ &D/@33<_\?NK?^!\G^-=310!R,/P[T:WDE>"YU.-IFWR
M%;UQN;&,GFICX(L%Y%_JW_@<]=12,>* /,_$>A:<M@/[,\875G<B9 SM?"7"
MDX(VEAZ_I5&W\#ZC/,B1_$V69F((2,*2WT^<YKNM TVRF\*Z>DUG P>U0.&C
M!SE>_P"?ZUE:Y;2>&X-.N+2W@GMX+G(CP$D"B-_E#8P?QQ0!;B\$6ZQJKZOK
M$A Y8W9&3ZX%2CP9:CIJFK_^!C5MZ?=?;;&&Z,31&1<E&()7V)%6\T 9.B>'
M[30OM1MY+B5[EP\KW$I=B0,#D^P%:U%% !1110 4444 %%%% !112&@#CEU7
M3]-^(.L"^OK>V+VEML$L@7=R_3-;8\3Z$1QK-@?^VZ_XUSDOAO1]?^(&LG5M
M-M[SR;6V"><F[;G?G'Z5J)\/O"2?<\/V*\<XCQ0!I?\ "2:)_P!!>Q_\"%_Q
MH_X2/1/^@Q8?^!"?XUG-\/\ PHXPV@VA!XY4_P"-1_\ "N/!W_0O67_?'_UZ
M -4^(M$/_,7L?_ A/\:Y>TO+6_\ B@DUK<1SQBUE&^-@PZ1]Q6D?AOX.R/\
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MI(0\UGZY917NER1R2>7T()( SV!)K2VX&369KJ;M(G4Y.0 /S%$=RXZ-6,B
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M[TOP@U]:6<<T\]Y'&(G<@#<J@G('.,4 C0/C&]'\#?3[$W_Q=!\9W7&48?\
M;FW_ ,76Y!<^(KB%)8XM(9'4,I$TG(_[YJKJNJ^(M*LFN6L],EQT2.:3<W?
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M&$F\HI.%7/5B,CG% $FK_$+3]%$7VG3=5W2OL3_1".3ZDD5N/;7>H;1>A(H
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M:3:7,VWS)84=MO3)4$T^_P #3KDG_GD_\C53P[-%/X=T]XI$=?L\8RISSM%
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M>(6LI/%?AEXC ]P;M\LA!;'EGJ1VKL17D>AQ-'XAT.>[M4M)WDE5D#EERK
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MMY<86#.W>H));/'_ .JO9VKQWQ'-:/9:Y#8/;IJ U"<7#20L3WP-WW0<#ZT
M>A>$?ETZZQT^UR_SJXF@V<8;RWNT#.SD)=2 9))/ ;U)KC_#,-I>:UJT-S>2
M1LDH,<*SE,[F?) !]1^E=?\ \(_9G_EM=_\ @2_^- !+H-I-&T<DM\R,"&!O
M)>1_WU7#>!+:.SM_'$,.1'%=R(HSG $>!S7=:+%Y$-U#YDCK'<LJF1RQ XXR
M?K7$>#SBU\>M_P!/T_\ Z!0!J:+-%8^%_#]V2D3)90@R&15# K]PY/Y5T,*-
MJZQ37,>R!&W)$'5EE& 0QQP1W%<QX=M;;Q%X8T.VFM(I[&"U@>9I>0SJH*A?
M<'!.?I747"OI%G;?8HA]CMD"/ !R(P, K],=.XH X;Q1HEH_Q3\+@F8K*99W
M0RL5W @@@9P.?2O3@,5Y'XM\3PV?CO0=9EAS8VIEAW1OO9]S ;L8XQBNQTGX
MA^'];U*&PL;F1YY6*J&B*@D*6[^P- '645%+,D$;2RR*D:C+,QP!^-/+<9S[
MT *?NFO,?AKID,EQJXE>66.,1JD;R%E7S(U9\ ^I ^E:[_%GPB"Z'4'W+D$"
M)C@UA^ -6%@+V:6$;+Y8WM@K\R%(T7;CU)84 =H;Z725-C';R2L 5@W.H+#'
M R3SV%9>K6@MI_#196$\VJ++,6Z[S$Y/Y=*VQI,&H-9WFK6MO+?6S>9$X7_5
M'.1CGJ..?:L#6KZ677?#MG=1B*XCU3( Z2+Y<F&'ZY]Z -0C_BO5/_3I_4UJ
M:5_J[K_KZD_G6#J-X]CXQ$R0-.WV<+Y:?>YSS3K#6K^W282:+<DO,\@QZ$Y'
M:@#K**Y\>([K/_(%N_\ /X4O_"17/_0&N_RH WZ*Y_\ X22X_P"@->#\*S]+
M\>1ZQ]J^RZ3>,MM,87; P6&,T .\?C.E6@SC]^Q_\A/6[HX_XDEK_P!<A7&^
M,M7FN].AWV$UO''-R\O ^960#IZL*['1CG0;0\?ZD?RH \:\%!Q\0M<V2NF+
M>($K,D>>!_>!S^%>EYGQQ=SG'3%[#_\ $UY_\.[ WWC_ ,1$3>7L@A_Y9(^<
MC_:!Q7J1T)C_ ,O?_DM#_P#$T"1YWX=$@\::L1/,";>/+"YC4M^\DZDCG\*[
M!FN0#_I5T!_U^0?_ !-)8> [73M1N[^*_G>:Y 5A+#$RJ 20%&W@98UIMX?8
MKC[6OU^R1?\ Q- SAOA5DZUJF221&V26#'/GR]QP?PXKU6O+/A7"8=;U>,D-
MM0C( &?W\W8<5ZG0 5SWCKCP)KG_ %YR?RKH:Y_QP W@?6E/0VKC]* +/A88
M\*:2/^G2/_T$5KFLKPTH7PSI:CH+6/\ ]!%:AZ4 <WX8_P"0QXF.<_\ $Q'_
M **2NEKGK'3[_1KS5;F-8KM+VZ^T!%.QD&T#'<$_+[5LVEVEW )4#+V*L,%3
MZ$4 6**** "N(^%]VK>"(FN+H-*;R[+&23+']^_7/M7;UP=G\+--T_S1::I>
MQK)(TA#6UI(1N8MC<\)8C).,DT =O]JM_P#GO%_WV*I:O=PKHM^RSQEA;R$
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M?+"Q@2GE3[YKT#6?"<&MO82R7]]:SV081R6L@0G<,'/!]*S[7PK!HWB"SO\
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M-(V]SYZ?,?7[M7M#\#V&@ZU-JL-W>W%U-'Y;FXD5ACCT4<\"@#J!THH'2B@
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M[./Z_P"-"PU5_9!UZ:ZGI M-;QSJEG_X!'_XY44&B7"VVJ+<WJ2S:AG<Z0[
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MN'UOXF^';^6Q: W85)Q]HS#C=%U(Z^H7\JL:M\6/#EWHM_:P)>^9-;R1IF$
M9*D#O[T?5:W\K']9I?S(])M)&EM(97QN=%8X]2*FKQ^/XUQ6MM%&-%>0( G$
MX!P.,]*3_A>J@\^'I,?]?(_PH^K5OY0^L4OYCV&BO(!\=(R/^0!(..]P/\*Z
MOP=\0[;Q7=36SVOV*9 &C5Y-WFCOC@=*F=&<%>2L5&K"3M%G:451DU6VBU>#
M3&9OM,T32H-O&U2 >?QJIK7B&'24*1Q_:;S"E;6-OG*EL9P 3C\*R-#-\)#.
MM^*&[?VB/_1:5T%_?)8V^]E9V9@D:+U=CT KA="UR^TF^UF6[\-ZP_VRZ\]/
MLUOO4#8HQEBISQZ5:O?%E[+=6\UMX8UO,(8XEL^Y],/0!M:GX>D\1V(MM6N3
M'%YB2B*V 7:5((RQSGI[5T"KM4#TKS#6/BEJ&BK;M<^';Z/SIEB436Y3=D\A
M3NZ^U>@:-J]OKFDP:C:!Q#,N0LB[64]""/4$4 :%%<W>^,8K34;FSCT;6;MK
M9PDDEK:ATR5#8!W#LPI^E>,M*U2WDD9WL7CE:)H;W;%("N,_+D^HH Z&BJMK
MJ-I>LPMKF&8K]X1N&Q^56<T !&:XJVTNPTGXEHEE;1VZR:7-+)L&-S-,N2?Q
MQ7:Y%9UYH>FWVH17US:B2YB38CEF^[UP1G!&?6@#.O-^JW=O>68\R*P<RHPZ
M2MT('_ 2PSZFJOBZYBOO#MJ\?S*VH6H*GJ#YRY!KIG:&WA+.4BB09).  /Z5
M0N] TK4YH9[FS21XY%E1@2N6!R"<8SCWS0!8TK2K'1[(6FGVT=O &+>7&,#)
MZU>I ,4M !1110 5B:SX3T;Q!/'/JEDD\D:&-221A2<D5M9J*XNH;2+S+B5(
MDSC<[ #/XT ):6<%C:QVUM$L<,:A551@ "L/QV,^!]7 _P">!_F*Z('(S7-?
M$$X\ ZT0<'[.?YB@3-3P^,>'=,'_ $ZQ_P#H(K2K-\/_ /(NZ;_UZQ_^@BM*
M@85%- DZ,DJ*Z$<JPR*EHH \Q^(V@67G^&SB0DZD(^9"<(PY _(5WEEH=G83
M"6)&9E 53(Q;8,8PN>E<U\0@#<>&\_\ 043^1KMZ!!1110,PO&4,4W@[6!)&
MKC[)(<,,\[36'\.M+L5\/7 ^QVY O90,Q@\<>M;_ (O./!^L?]><G_H)K*^'
M7_(O38_Y_)?YB@#J;>T@M01!!'$#R1&H7/UQ4U%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5'/)'#$TDK!40%F8G@"I#
MTKSWXL>(1I?AX:?#(5N;TE?EZA!][\^E:4J;J34%U(J3Y(.1S'@;38?$GC^^
MU@VVVQMI&DC#$D%R?EY/YU[2.E<K\/\ 0?["\*6T4B@7$X\Z7CD%N<?@.*ZJ
MM,54YZFFRT1GAZ;A"[W>H4445SFX4444 %%%% !1110 4444 %%%% !1110
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MJ&J0MXVM8K!KMXI-.:26/37C#!@Z@;\GMN/YU<NKJ=+:1T7Q*I"DY\R$X_\
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M%4 %G/H * ./TGQQK^N0O-IOA^&YB0[69+I1@]>Y%:']N>,?^A47_P "X_\
MXJM[1[9XXI+F:!8)[DAWC4?=&. ?4@=:TJ /-_%&L^*IO#.I17/AKR(&@822
M_:$;8.YP&YKN-"7;X?TU?2UB_P#015#QK_R)6L?]>K_RK0T7_D!:?_U[1_\
MH(H OT444 %%%% '!?%X_P#%!R#UN(_YU>^&*%/ 6G@]]Y_\>-4/B\,^!G _
MY^8_YUI_#@8\":9[H?\ T(UU+_=?G^AS/_>%Z'5T445RG2%%%% !1110!6U
M_P#$MNO^N+_R-<!\'>=!U _]/"?^BDKOM1_Y!EW_ -<7_P#037!?!T8T#4,?
M\_*?^BDH ]'HHHH *X#PT0?BOXO..1%;C_QVN_K@O#"_\71\7G_9M_\ T&@3
M.]HHHH&%<KKX!\;^%?\ KK<'_P @M755RFOG_BN?"HQ_'<?^BFH ZL=****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)0!)8&XEU.:=[>2")H@N'*G<P)YX]C6HRJZE74,I[$9%+10!%]F@_P">$?\
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M4&0M%%% !1110 4444 %%%%  >E8Y_Y'%/\ L'M_Z,%;%8__ #.*_P#7@?\
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MCJQ'I4%IXET^\U)[*%G;: !-M_=EB,[0?7!'YT ;5%(",4M ' _%W_D2^/\
MGXCJ;P?HU])X1TQTUZ_C5[=2$5(B%SV&4-1?%K_D3,CG%PA_G6_X+4KX-T@$
M8/V5/Y5TR5\-'U.9?[P_0Y[6/AM-JVI->GQ%=)(T:HVZWB8G&<'[OOV%4/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*6)/3BLB*3Q#+&CE=-4LH.T[SC-.9Y-;*Q"$KIYP9'<$&7N H].G-; 4+TH
MY[4[7Q%?Z;<VB2Z;%Y\31AU,@*Y&,C%9NG>%]5M-.M[>=K.YEC0*TS7%QER.
MY^:NTQ10!S$5GK.DV-P+.'3(P=TI^:5LMCKS]*/!6KWVLZ5=SZA(CRQ7LL(*
M+M&U<<5T%[_QXW'_ %S;^5<'X-FU>STF]AM=(:0S7\\D<TLJI%@MC/<]1Z4
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M\\Q:;C_KK)_\31NU[_GEIO\ W]D_^)K6HH R=VO?\\=-_P"_TG_Q-,D?Q$0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "@
M]**0]* ,^QR=3U(]MZ ?]\BM&L_31F:^?UN"/R K0H+J?%]WY!0>E%%! W%1
MS6\-PA2:))%/574$5-11L)J^YRVI?#_PSJF[SM+A1SSOBRA_2N)U;X)PRSJV
MF:CY<?.Y+A=V/3!&*]?HK>&)JPVD8RP].6Z/"&\#>//#9 TB\G>)?NBWF.T
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ME@K32^9M&?EV'K[55M+?26O=+N=.,TCKJ;QRP2@9:0D;W&?X5(!H ]1HHHH
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M>7WVBQZ[\6[^"2:2'R[&"8.@&<I("!S7J%<)I@S\9=7/IID8_P#'J!,Z73M
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M_P#KRN/_ $*.NEKF[X_\7 T@8_Y<KC_T*.NDH **** "@]**"<#- ' _"O\
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M:13D4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 9>JZRNERP1?9IYY)RP1(5!/ R>OUJJ/$DIX_L34P?\ KFO^-)K7_(;T
MSVCN#_XZ*\TTF"]6UT8G3I;5[N1!'J+7[D,<[N5S@$@=#6U*C[1-WV"M5C1C
M'W;W7ZV/31XCD_Z VI_]^A_C0/$A[Z3J0_[8?_7KESXUU(:Z\:PL]M'=FV,"
MVSDLN<;]_3/M3KG5=4OY[&YEE@6S;4_)2&/.\;=W).>>G2K6$GU,_KE%[1_$
MZ<>(^/\ D%:E_P!^/_KT?\)'_P!0O4O^_'_UZQK;Q->'2M+N96B:2>ZFBE4#
M&57?C _X"*BBU_6K?0I=;N9;26WDMVEB@13N1OX1D'YAZU'U>93Q-)?9-T^)
M0/\ F%ZE_P" ]'_"298#^RM2_P# ?_Z]<K:>,M6>&Z1H_,<Q(T$KVKQ*K,^W
M!!/(&<YK9T%]27Q1>P:E=13NEM&081M')/;)P:<L-.*;D]B5BZ4K*,=_,FT[
M6VMH)%?2]1RTK,,0'H35L^)#VTK4C_VP_P#KTW1'9M3UP.Y8+> *">@\M>E<
MT/&]]+K4B11,;:.Z%N8OLSG(SC=YG0?2IC0G)M1Z&E3%TK\TH[^9U'_"1G!/
M]DZE_P!^/_KT#Q&<_P#()U+_ +\?_7KF[?Q7J<OB6UBC>*?3;JXDA1EA*C"@
MX(8GYCQZ5EVWCO7;%[QM6$(G2UEF6QDM7C974;@$D&5==I!)R#[5?U:9'UNC
M_*=R?$>.FE:D?^V'_P!>C_A(C_T"M2_[\?\ UZYKP;XLU/5=<&GWDJW<4MJ;
M@3"S>W\L@J-HW?>'S=?\:[_%9U(.#LS2%6G-74?Q,7_A(O\ J%:E_P!^/_KT
MG_"21B6-);*]A#NJ!I(<#).!6W@>E8WB(#[+;9_Y^X?_ $,5FS:GR3FHVW\S
M:%%)2T& 4444 %8\7_(XW/\ UX1?^C)*V*R(O^1NN?\ KQB_]&24 :]%%% !
MBBBB@ HQ110 8HQ110 F!1M![4M% #'ACD4JZ!E/!!&0:S+KPQH5ZH6XTFS<
M#_ID!_*M:BFI-;,EQB]T<G<_#7PI<Y)TM4..-CL,?K6%=_!K0I4/V>XN87/1
MBV['YUZ325K'$U8[2,Y4*;W1Y,?@]<VY_P!!\12QCW0C^3"@^#/']BA6R\2"
M5$^Z#*P)_,$?K7K&/:EP*T^N5?M6?R(>%I]-#POQ%I_CYK -K5NEY;P,'!78
MS*<C!!'S _2C1/$/BGPZ9)T\-,_VG#R2M$Y:3W+')KW,J#P0"/<4;1C&!BG]
M:BU[T$+ZO)?#-GCG_"Y]5@;%SH,0 X8;V4Y_$5:C^-T;[0=#;GJ1<CC\UKU"
M?3K&Y0K/9P2*>H>,&LFY\$^&[O\ UNC6F?\ 9C"_RH]IAGO%KYAR5UM*YP7B
M#XM:7>:+- +&Z$C#HI1A^>:W;#XK:))!"C6FH(=H!S$IQQUX8FI;KX2^%[@D
MI#/ 3_SSEZ?GFLX_!C2=V8]2OD'N5)_E3Y<*^K0N;$+HC8D^*?AF)29)[E O
M7-K)C\\5;A^(OAB;IJ00>KQ.N?S%<VWP9TQ@!_:E[CT.WFD_X4QIO_04O/R%
M'L\-_._N#VF(_D_$ZM?'WA9A_P ANU'U;%.C\=>&)6VIK=IGW?%<C_PI72_^
M@G=_]\K2?\*5TS(_XF=U_P!\K1[/#?SO[@]IB/Y/Q.U'C#P\Q &LV63_ --1
M4O\ PD^A,,?VO9?]_EKA?^%*Z9_T$[K_ +Y%'_"E=,Q_R$[O_OD4>SPW\[^X
M/:8C^3\1;WQ;I?AG5M4W3BZ@U)_/AEM&5F1]H7:PR,<@$'WJWX)U"RBGU36M
M2O[*VN-3D1OLYG7**H(!;_:.2:R;WX*0&)39:I)YFX9\U!C;WQCOTJ<?!/3L
M?\A2Y_[Y6E[/#_SO[@]I7_D_$[__ (2/1?\ H+67_?\ 7_&E_P"$BT;'_(6L
MO^_Z_P"->?GX)Z=G_D*W/_? II^"5CVU:X_[X%'LL/\ S_@'M:_\GXD'Q9U7
M3[Z/15MKV";;.Q;RY VT<=<5Z1'X@T8(N-5L@,?\]U_QKS]?@IIX;+:G<%>X
M"+S6]'\+?#JH%\N0@#J4C_\ B*,1*GR1A!WM?\1T(SYY3FK7.F&OZ01G^U++
M'_7=?\:!K^D'_F*67_?]?\:Y6;X3^&YF1F6==C;L*(QGZ_)R*F_X5=X=Q@1N
M/HD7_P 17(=1THUW23TU.R_[_K_C0=<TD==3L_\ O^O^-<G-\)O#<RJI6==K
M!LH(P3CU^3I4O_"K/#N,>6__ 'Q%_P#$4 4_'^KZ;++X<\N_M7"ZK"S;9E.!
MGJ>>E=G_ &UI9Z:E9_\ ?]?\:Y*;X1^&IVB9EF!C;<-JQC)]_DYJ0?"KPYVC
M<?\ ;.+_ .(H :M]!8:C+)]HAN<3RSI(ET/WBN"0N W4$A?FXQ3= \67D^_3
MXM.2:>$NQ,,N],;L<-CUJG??"72Y+VW-M\L .)MR(&Z@Y7"XSVYSUKHO#7@?
M2O"UY<76GM<%YT",LC+M !SP !B@#*U>;7[OQ%H5Y#H3M%923-(?,Q]Z,J.O
MU[5M#6M9[Z%(/^VG_P!:NBHH YB3Q!KJ7,4:^&Y7C;.^02_<_#'-3C6]5Q_R
M YL_[W_UJZ"B@#A;F\UR7Q;I^H?V!-Y,%M+$QW]V*D=O:MK^W-4_Z <W_?9_
M^)KH,"B@#F'\1:RMVD2^&[AHV4LTOF<*1VQMSS4_]NZGC/\ 8,_TW'_XFN@H
MH YP^(-4$BK_ &!.0026W'CIC^'WIYU_4=N?[#G_ .^F_P#B:Z"B@#R.XU#Q
M!%J2>&4$R6]U:RN%^S_O N[D9Q[]:[>#7+^&)(AH5R0JA0<MV_X#70&V@-RM
MP88S.JE5DVC< >HSZ5+0!S/_  DVI?:Q"/#MV4*%O-R=H/I]WK4O_"07^/\
MD!W'YM_\370X%&* .:'B743=>3_PCUV$V;O-).W/I]WK6%9+JUMXXU#7GTMV
M@N;9(%B7?O4@YR?DQ7H6*,4 <S'XHOGNYH6\/WJ+'C$A!VO]/EJS_;]W_P!
M:Z_(_P#Q-;M% '._\)'?"[,)T"\"! PDZ@DG&.G45(?$%R.FC79/IM/^%;V!
M10!SJ^)+MIWC.AW@50"'(.#G/'3VIEYK-S=6DL']DWB^8A3(4G&1]*Z6B@#Q
MKQ5=:OXET/5M'V,'M!&9-\!7@8<>I''M7:_#*U>P\"6-I*0SQ-(I*@@??;U
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\0?ZBS_Z^XO_ $(5LUB^(/\ 4V8_Z?(O_0J&:T/XB-JBBB@R"BBB@ K*M_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 =JC@_U0^I_G4G:HX/]4/J?YT 24444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !VJ.#_ %0^I_G4E1P?ZH?4
M_P Z )**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ /2H;7_C
MW'U/\S4QJ&T.;<?5OYF@":BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH #4%I_P >X_WF_P#0C4Y[5!:?\>P_WF_]"- $]%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 &H+/_ (]A_O-_Z$:G-5[+_CU7_>;_
M -"- %BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *KV7-J/
M]YO_ $(U.:K:><V:G_:?_P!"- %JBBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH 0U5T[_ (\E_P!]_P#T(U;/2JFF?\>*_P"^_P#Z&: +=%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 'I5/3/^/%?]]__0S5
MSM5/3/\ CQ7_ 'W_ /0S0!<HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "J>F?\ '@O^^_\ Z&:N53TS_CQ7_??_ -#- %RBBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *IZ7_QX+_OO_P"AFKE4M)_Y!ZY_
MOO\ ^AF@"[1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 !JEI
M/.G(?]M__0S5T]*I:3_R#D_WW_\ 0S0!=HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH ****  U1TC_D&I_OO_ .AFKQJAHW_(,C_WW_\ 0S0!?HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  U0T;_D%Q_P"\_P#Z
M&:O'I5'1O^07'_O/_P"AF@"_1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 (:HZ+_ ,@N/_>?_P!#-7CTJCHW_(+CQ_>?_P!#- %^BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0U1T7_ )!47^\__H1J\>E4
M-%YTF$^[_P#H1H T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@!&Z50T3_D$P_5O_0C5\]*HZ+_R"8/^!?\ H1H OT444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% "'I5'1?\ D$0?\"_]"-7CT-4=&_Y!,'_
MO_0C0!?HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $/2J.B\
MZ1 ?8_S-7CTJCHO_ "![?Z'^9H OT444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% "'I5'1?^0/;_[I_F:O'I5'1?\ D#V_^Z?YF@"_1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 (>AJAHG_('MO\ =/\ ,U?;
MH?I5#1#G1K;_ '3_ #- &A1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 (W0U0T/_ ) MK_N?U-7F^[5'0_\ D#6O^[_6@#0HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** $;[I^E4=$_Y UK_ +E7F^Z:HZ+_
M ,@:T_ZYB@"_1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -?
M[I^E4]&&-&M!_P!,Q5Q_N-]*J:/_ ,@BU_ZYB@"[1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 -?E3]*IZ/SH]I_US%7'.$8^@JII VZ1:#_
M *9"@"[1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,E_U3_0
MU7TO_D%6O_7)?Y58E_U3_0U7TO\ Y!5K_P!<E_E0!;HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** &2_ZIOH:KZ7_ ,@JU_ZY+_*IY_\ CWD_
MW3_*H=._Y!MK_P!<E_E0!:HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** (KG_ (]9?]P_RJ/3_P#D'6W_ %R7^0J2Z_X]9?\ <;^5,L>-/M_^
MN:_RH L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $5U_P >
MLW^XW\J;9?\ 'C;_ /7-?Y4MU_QZ3?[C?RI+/_CQ@_ZYK_*@">BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH AO/^/*?_ *YM_*BS_P"/*#_K
MFO\ *DO/^/*?_KFW\J++_CQ@_P"N:_RH GHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** (+S_ (\I_P#KFW\J++BQM_\ KFO\J;J'_(.NO^N3
M_P C4EK_ ,>D/^X/Y4 2T444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% %;4/\ D&W7_7)_Y&GVO_'I#_N#^5,U'_D&77_7%_Y&I+;_ (]8O]P?
MRH EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!4U3_D%7?_ %Q?^1J:V_X]HO\ ='\JAU/_ )!5W_UQ?_T$U-;_
M /'M%_N#^5 $M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"EYX9M+"UET_1X3;VOD3W=JS&6Y(Q@D%%P,Y)R6/2@#M**** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3719$*.H92,$$
M9!IU% !1110 4444 %%%% !1110 4444 %%%% !1110 4@4 D@ 9Y/O2T4 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!3U;_D#WG_7%_Y5-:?\
M><'_ %S7^50:N<:->_\ 7%_Y5/:?\></^XO\J )J*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@"CK/_(%O?\ K@_\C5FU_P"/2'_<'\JJZT<:
M)>_]<6_E5JV_X]8O]T4 2T444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% %#6EW:+>#_IDW\JMP?\>\?^Z*JZS_ ,@:\_ZY-_*K<7^J7Z4 /HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *.L#.CW8_Z9FKB#"#
MZ54U89TJY'JF*N+]T4 +1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 5-3YT^0>I7_P!"%6EZ57OAFT8?[2_^A"K Z4 +1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
=%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>ibcbankplazasecondamendm001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibcbankplazasecondamendm001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW1?*Y3. =HR,@XJ7R-6O- MXUTVZM433+R+9&TBAT^TP'*[\,I9 ^U6.<<4
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MV[B>BY[9/I4<_A^[.E:''#X7U,QV5]++<PM?1+<3EXF!E,BR 9+L,\@\'C%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 57OK&UU*REL[V!)[:9
M=LD;C(858HH SM)T'3-#25=.M%@\XAI#N+,Q P,DDG@=*T:** "BBB@ HHHH
M *K6.GVFFVY@LH$@B+M(40<;F)9C^))JS10 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%8?B_Q-;^$
M?#=SK%Q"\PBPJ1(<%V8X SV'O_.L\^(=9ANM%5[*PNK/4I?+-W9SLRQ'86Z;
M?F!VGYLCZ4 =917FZ>/->?QSJ/A?[%I,<MC ;B2YEGD6/9M5L_=)'#C\C6W:
M>+KFTT+6]2\1V<=FNES%/]'<NLR;5960G&=V\ 4 =;17#>'O$7BSQ-I[:S::
M;IMKIT@)M;>Y=S-,!G#%Q\J@_P"Z?RJK?_$]=(\&V>KZAI31ZG>7$UO%IRR\
MAXY&0[G(Z# R<=30!Z'17 Z_XM\1^#=/AU;6[+3[JPDE6.6.R+I+;[@>[$B3
MT_A_7B+QC\0K[PW!I^IZ=IT&J:1>1>?YL;.KI&-@+'@@ [U )[G!% 'H=%<@
M_B^74--T;4M!^QSVFHSI;MY[$/$[ G!"YY&,$5F_\)MKA^(4GA%;+3O/6#SA
M<%WVGY0V,8R.N* /0:*XWPKX[&NZ]J'A^_TY]/U>Q!,D>_>CJ"!N4X![@XQT
M(KLJ "BN1\)^.;;Q3KFO:="$']G7&R)E.?-CZ%O^^@?P*U@_$+QQXD\%:I;O
M;V^G7FERCS'S"ZR1*&"D%O,P<YX.._3U /3**Y#QGXQ?0O"*:KI*PW%S<()+
M9902A0+O9C@@XV ]^I%<R_CCQ>OPQ7QH&T,J>3:?9)<A?-\O[WF]<\XQ^- '
MJM%>=Z5XE\87]AHNH;M"FCO3!+/:16\PFC@>149@?,(XW9Y'8^E4?%7Q'USP
M;XP%K?V5I=Z(!&\D]O"Z2QK(7"@DN5+?NV/3G!Z=@#U*BN1N-;U>\\2Z=::-
M?Z4=.O[*2[BGDM))6 0H.TJ@@^8#VQBN9\.>-_&'B+4_$%E FB^;H\A79]GE
M'VC#,, ^8=A.ST/6@#U2BO.['XBR^(O >IZYI"6]IJ&F1O)<VEW&THPJEL J
MR=<=>V#Q5GX<>.;OQ9:ZG#K$%O:ZGI\^R:*$%5"=C\Q/((8'GL* .[HKRG1_
MB!XF\0>.YM @CTRQMGA-S;32VLDKF(@-&6 E49*L#_2C1O'/B75->\0Z9<7^
MCV<6AL^^Z-A(_G!&*\KYO&<9XR>PH ]6HKB+_5?&%IX.DU(IIZ:O:S.CVJV[
MM%<C?L3;EPRYR#G)S67X<^(M[XE\-ZFG^C:=XDTQ7DFMY82R.$)) 0N&'3:>
M>": /2Z*XM[WQG'937(N-'\B"P%UYLEE)^]D.]B@ E& H"C)SUK#\&>)O&?B
MG2+775GT]K<ZBMO<626C K%N4,ROO/(#9P1T'4]* /4**Q-?&OR2V$&AS6]N
M))&^TSSP^:(T"\87(R2<#K7 :+XF\;ZYX@\1Z-;ZGIJSZ066-FL3B=@Q4#[_
M ,N<>_6@#UJBO-M3\>ZK)KVC>$]*MX8M=NX(Y+R6Z7*6I*;V&T'E@ 3C..G7
MM-K/C+5/!7BG3++79;6\TG4LHEU'$89('! .X9(*_,/0\^W(!Z'15/5M2M]&
MTB[U*Z)$%K"TK[>I"C.![FN&\.:UXL\9Z)/X@L;RTTV$O(ME9-;^:) O'[Q\
M@\MD?+C&.] 'HM%>8VWQ&N]>^'6IZS8>78:OI0)NK:6/S%) [ D$ ^_(*D<]
M37TSQ-XPU+PGIVKP:I927U]'-)#IR::27$1(8!P_7 &,CJP'O0!ZM17F=[XH
M\1I\5[;PI%?VR6EU"TZR-:9>,;78+][!^[C--O\ Q/XGLO"FKZQ'?V]U!;PP
MW%G="P\N.96=D=2I<\Y"L"#T(]: /3J*\SB\>W>A_#*'Q5K-RMY=WX'V6V2(
M1HKG.%XY(X)))[<5I:=;>/+[P\FJ'7;&/4+B$31V)LAY*;@"$+9W9QW['UQR
M =U17D_BSQ)XLT>]\'0Q:F;8ZT(HKJ.2VC)AE_=AR 5R.7/!/7TKJ?#TVMMX
M@D$^M#5M*\N:(N+5(C%<1NH()7J""WX@T =?17#?%37=5\->%%U72+TV\T<Z
MQLAB1U<-Z[@2",=CZ_AT'A2:[NO#&G7E]>/=7%W;QW#LR(H4N@)4!0.![Y/O
M0!LT5Y7K>O\ B2U^*]GX7M]?\FQO(#<>;):Q,T0"R-C.!D?)U/8UUOA*76Y7
MNI=2U$:A83PP7%A<"W6(E'#$A@O<?+^8H Z>BN"UCX@C2OB5IOA]XL6$ZF&6
M<CCSVVE%!]@1G_KH/05)\1_%<OAB+1U%R]G:WMWY5U=QQAWAC Y*@@C//4@]
M#P: .YHKC-%_M+4YY#:>*9=0T6YM<P7D4</G0RAAD$A-I)!Z%>.>.]<5X'\5
M>(/%^FWLFH^)KFQN([F*UM3;6\&UWDSC<K)DXVYX(XS0![1165X:&JCP[9+K
M;;]2"8G; &X@G!P..1BM6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M01.T"EP1T.[&>* /&;?PUJO@;XCZ3I,$LDGAR_U!;B#()".H;"D]F /_  (
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M#:O<8Z^U?1.*,4 9'AO5IM=T@:C+:O;)+-((8Y$*OY:N55F!Z$@9_&M>BB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@],8K$N/#INK;7]0U/0I[JUUJ\A9K"+B>*)$VB3J,/N^; /3W.*LZ(VH>&_
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MJMW_ ,@\--;;F^ZDKJ0N<\#)(_[Y]JN_%QXV^'E[:;#)<7<D4-M$HRSR>8I
M ]< T =SUHJGI,$UKH]C;W)S/%;QI(<YRP4 \]^:N4 %%%% &%XB\2QZ&]G:
M0VSWNIWSF.TLT<*7(Y9BQ^ZH')/-59=?US3K[3XM5T:T6WO;D6_VBTO6D$)8
M';N5HU/)XR./IWP/$K-IWQC\,:G>873I+66T29^%CF(?OZL"H&?>N\N[VULS
M +F0*TTJQ1+@DLYZ  ?GGL 2>!0!@+XHO-8U"^L_#5G;70L)?)N+J[N#%%YG
M=%VJQ8CN< #WIUCXN:_AUBV6P$6M:4/W]E+-A&R,@K(%.5(Z';GU K!^$L;:
M;INLZ%=@IJ-EJ,C3(>ZL!M8>H.#@U#%#_:/Q6\1ZG:'_ $6QTH64[ </,?FQ
MGN0!@^E '3^"/%T/C/P^-3CMC:R+(T4L!?>48<]<#.00>G>JMOXV;4/'=]X8
MTZQBE-E;^;+<RW!0%L@%0 AS@L 3GL?2N(LKB]\$WVC7VG6CS6GB'28(?)09
M'VY8QL)] 01GU^8]JVO#FEQZ-\6GL(SN,7AY-[GK(YFR[GW9B3^- &]X/\:M
MXFO]7TZZTX:??Z9-Y4D0G\T,,E=P;:O&5(I-?\9R:;XNTKPU8VD4UW?@LTTL
MA5(0 2,@ [B0K<9&./6N6UK=X9O+#QO!$S107]Y9:F$R2UN]U)M./]EC^)(I
M+JTD@\9^!K^\0I?:E=W=U<!NJEHE")[;4"+CU!]: .FTGQ)KVJ>)-<T86VFQ
MMI)A#REY")/,4L,#'& *B\0^+==\.^#;G6KO2K5;FTN/*EA\UMCJ7"JZ-CD'
M<#R!W]*SO#]G)>?$[QTL>H75H0]ED0;/F_='KN4]/;'6J/CUK>#X.ZKI4-VU
MV^FO;VTTYYW/YB$@MW;!&?<T =-+XLU+1_$^F:1KNGVRPZIE+:[M)F8"4 91
ME8 XYZ_3WQ;O/$T\_B63P[HMO%-?00B:ZFN&(BMU/W1@<LQSTXX[URAA;P]\
M3[6;Q1=3ZC:W,?E:1?W.W%O+QN0J@"!F[-@=/KB?P])'H7Q<\46VHNL3ZLL$
M]E)(<"55!#*I/4C<./:@#IK?5-=766TF^M;%)'M6GM[J)W*2LI4,I0C*XW9Z
MGJ/0TSP)XDN_%GAJ/6+JVBMA+(ZQQQL6X4[<DGW!_*MK^TK4ZE_9ZR;[D1F1
ME09V+D#YC_#G/&>N#CH:\X^'.L1Z-\'(KM"9IUFEBBA)^],\I5$'U++^9- '
M5Z=XSM=0\=:GX:5 &M(5DCESQ(0<2#_@)*CCON]*9XF\0ZII'B#1-.LTLW35
MI6A5ID;,)49+'#?,,'IQTZ\\<)KFE:]X*LM#\0SIIQCT6?;<2VKR-+/',V)-
M^Y<')8GV)XKH?'5XG_"6^ +F!EDCEOVVL#D%751D?@<T >B+N"*'(+8Y(& 3
M]*6J-QJUI;:K9Z8[YN[H.R1KC(51DL>>!T'U(J]0 4444 %<MI/B'4;[QKK.
M@RQVHBTU8G\Y%8-()%W*,9X('!.3GT';J:X'PZZ#XP^,D+*':"S(7/) CY_F
M/SH V/'>NZCX:\,2ZMIT5O*\#H)(YT8@JS!<@AAC!(]:D2;Q3;7]F+L:9<VD
MLNR86L3I(BE3AQN<@@-MS[&L'XFZO97?P]\00Q2[A \$3R*05WF1&V@@]0,9
M^HK1\O1=)U&QU)=9N[N7_CTAA>[-P9&E9 , GC[H.?3.: +/CGQ8OA#P^;Y(
M?M%RSA(H<$[@.7)QT 0,<^PK0U/7[;3_  K<:^@,]M':FZ0+_P M%V[EQZ9X
MKG+JUOO%6N:C/92Z;+IUK%)I@2YC9\NP4RL"I'^ROX&LSP-KD.G^"=;T75V2
M[E\-B>&X08;SH%W$8!ZC *X/H* .@TG6-=O+#2M39]-N[._:,R);1NIME8=F
MW,'P>#D+50Z_XFF\=WWARV;2 D%JMVDTL$F2K-C:0'ZCU[^W2N8DTN'P?K&E
M:GX(U83V.I7B0RZ3YWFQL'S\Z<Y& ,\],=<<5HS16=U\:=32XOY;94TF(%H;
MHPG=OZ$@CL<XH [O1I=5DAN4U>.W6:*<HCVX8)(FU2& ))')(Z_PUI5A>&'L
M;>UFTBQNI;P6#8DN'.X,SEGV[OXF (S]1ZUNT %%%% %>^O8-.L+B]NG$=O;
MQM+(Y[*HR37*S^.;?2-)L-0UQX[9]5EC%G9XP\<;$#+DG'"L&8\ =.>I7XJ1
M7,WPTUM;4D2")6;!_@#J7_\ '0U97Q(FM1H/A2^1HULXM:LY3+C:J18;DGL.
ME &K'XJ^S>+K^*_U6Q71!I\-Y;S<(%WNR<N3ALE?;J.*UM3U$M_9$EAJ]A!'
M<7,9/FL#]IB/58_5CE<$5RS3Z%JOQ-NKF=[*XC_L",QF8J0%,DA;AO\ 9()]
MCZ&N;T:YLS\-O $MQ/!YL.L1*'=QE )'R,GH,;?PQ0!ZM<^(=&L[];&YU2SA
MNV95$+S*');[HQGJ>U:5>1ZC>1:7K][/IFH6NJV=UK$8O=%N1_I"7 =1YD6.
M3C:I Z8'M7KE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%)0 M%<DGCS3Y-
M(;4U:W6W-\;-&DNE4*1G+2$_ZO@$@<D@KW. Z;Q3--KEYI>DZ>U_+8JK7#?:
M!&$+<A0#G<2* .KHK*T/56U?3H[M[2:T9F=6BF(W*58KS^6:U ZMC# YY&#0
M M%-#J0"&!!Z8/6@.A&0RD9QD'O0 ZHKF%I[>2))Y(&88$L6W<ON-P(_,5)N
M&<9&:H:UJ#Z;I-S=01I//'$SQPE]N_ R0* *GAKPS;>%M'_LNQN[N2W#,R>>
M49D+$DX(49Y.><U'H/A6#P]-J,MMJ%],U_,UQ,)S&1YK=7&$&#[=/:K7AS5)
M-:T"QU&2(1-<P+*4#9VDCI5/Q=XIM?">EK?W8+HTJ1JBGDDGD_@.: *]IX&M
M;*WUB&+5M3*ZNSO=;FB.6?[S*/+PI(XX_H*(? ME;Z7I=C'J6IJ-+=FM)A*@
MDCRI7&0N" ">"/KD<5TR2*T2ON&"H.<]J<&4C(8$>QH R;#P_;V6JS:I+<W-
M[?RQB'S[DKE(QSM4*J@#/)XYK7I-RX!W#![YI@FB=2RRH5!P2&& : )**;YB
M#(+KD=>>E<UXN\1W'AVR@N+:VCN2]U%#*K2X**[A=V,>] '3US)\%6@6ZABU
M/5(;6[EEEGMHYQL<R$ENJEE!R?ND5T7G(%W,ZJ, G)QB@S1;]GFINQG;N&<>
MM &)J7A#3=3DTQG>Y@73"#:);R;%B(& <8YX '-6;;P_!!JJ:C+=WEU<1QM'
M']HEW*@;&2%  !.T<UHFY@$X@,\8F/(C+C<?PZT/=6\6?,GB3!"G<X&">@^M
M &%'X+TNUN+F2QEOK&.Z;?/!:W+1QNQ.20O\)/JN*N7?AK2+[0AHMQ9AK!0-
ML89@00<A@P.=V><YSFFW/B'3K368-*ENHQ>3JS)&S@8P0.?KGCUKEH?%OB4:
M=%=OHUH734?LEQ&MWG<AP%:,]SD].?IZ '2IX4T]KFUN+R6[OY+0AK?[7,76
M-@,;@O +<]2":LIH=NGB!]:\^X-RT/D;2XV!,YP!CUYJ+3-:DN-5O-(OH4@O
M[91*H1]RSPL2!(N>1R""#T(ZG@UL4 4)M'LYM6BU0Q[;Z*!X%F7@[&()!]>5
M!&>G/K6);> =-M;F\GAO]61[V0RW.R]9/-8]2=N/TQ6N\^J#Q'';B"U_LIK9
MG,ID/F^:&' 7^[@]>?PJ\MS;M,85GC,HZH'&[\J *ND:)IN@V0L],M([:#<6
M(7)+,>I)/)/N:OT5')<00DB6:-"!N.Y@,#.,_G0!)147VF#,8\Z/,@R@WCYA
M[>M-EO;2"XCMY;J&.>7_ %<;R ,_T'4T 2NN^-DW,NX$94\CZ53TK2;71K,V
MMF)!$9&D/F2M(2S$LQRQ)Y))_&I+Z\BLX"7N+>&1_EB\^0*K/V'_ .JL'P9X
MJ?Q!X276M2^S6G[R1'*MMC4*Q7.6/M0!);>!="M(=1AMXKJ./4BQNU%Y+B4G
MJ?O<$^HQ6D-!TXIIRR0&4Z<V^U:5V=D.TKG).3P>^>WI5ZWN(+J!9[>:.:)^
M5DC8,I^A%24 89\):4=<FUD"[74)D,;RK>2C*?W0-V /0 <5!9^!]&T^*YBL
M_M\"7,C2S"/4)QO=NK'Y^I]:V8=3L+BZ>U@OK:6X3.^))59UQZ@'(I7U&QC:
M-7O+=6D8J@:506(Z@<\F@#-B\*:5!_9WDI<QC3L_9@MU* I.<DC=\Q.3DG.<
MU>U#2+'57M'O+=96M)UN(&)(*2+T((_ET-,UC4X=+T^6:2[M;>4HWDFYD"JS
M 9 ZC/X5F^!=<NO$G@S3]7O5C6XN0Y81C"C$C*,?@!0 V[\#:)>ZK/J<JWRW
MDX"R2Q7\\9('0?*XX'I6CIGA_2]&@GBT^U$'V@[IG5F,DA]6<G<3SUS6G52'
M5-/N9I(8+^UEEBSYB),K,F.N0#Q0!GVWA+1K719='%L\MA(_F-#/.\@W;MV1
MN)(^;GCO3]2\+Z5JVH0W]Y%,]U!_J9%N9$\H^JA6 !/<CK5L:OIC20QKJ-H9
M)L^4HG7,G)'RC//((X]*H:=XMT?5==OM)M+V&2>T";BL@^=CN)5?7:%&<=,T
M 5/^$ T#[3<W(COEN;IE:>9-1G5Y"!@9(?FK3^#M$?3A8?9I5MA.;@JES*I:
M7KO9@V6((!!)." >U7K77-(OFG6TU2RN# ,RB*=6\L>K8/%/AU;3;@,8-0M)
M0J>8VR96PO\ >.#T]Z '7NFV>I:?)87L"W%K(H5XY.=P]SUS[TS5-)LM:L7L
MM0B,UL_WX_,90WL=I&1[4NGZMIVK1/+IU_;7<:-M=H)5<*?0X-<I>>,TF\?^
M']'TG5M/NK2Z:X6[B@*R2(4C++E@QP"?8?=/- '7V-C;Z;916=HA2WA7;&A<
MMM'IDDFK%%8U_<7:>)=*@AU.QAMG67S[27_73_+E3'],$F@#9HK*;Q/H"F,'
M6].'F2&%/])3YG&,J.>2,CCW%4QXQTH^+V\.">/[2D/F,Q< !RP41CU;G/%
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MSD=>A[$\UT= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD/OD5:\%W&A:IJ6G7-II^KR:M;Q%;F2^FN'%D-A#*&D)4Y; "CZ\8KTD<44
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M=V^^63'0$^@'0>Y]: ->N!\0:9XQUGQ5$BVFE'1+.43VIG<G,H7AW4<L5).
M-HXKOJR]2LM7N;A7T_5X[.(+@QM:"7)R><EA[<>U '.Q^$IM.TG4I-:\4:[J
M)N(F60Q%CY>X8/EQ(&/?@ ''IWK/\)^%Y/[>LM0@_M&#1],C9+1;QBDER[*4
M+&+ $: $X&T$DY-=-_9?B7_H9H?_  6K_P#%U/#INM*F)M?WOGJEFBC'T.:
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MLV(RLW7H2V0!SC-+XI\'W4OB"Q\0:$S13R7-NFI0*<"YA61#N(/&Y<9]<?J
M8>L:G8^%/BH$FGN_L8TE9K>S%V^);IIO+7 9L9*Y'/& 2>E=EX8\,OI<L^I7
M\TDFIW;,\B+<2-# &.=B*QQ@>N,DYZ#BN;UCP]_PD'Q.G?4M#NY]&FTG^SS.
M5 42^;O# YR !W]?:KG@^[\2:-?S>'M6TZ_O=/@E,5EJS*N6C' $@SG'HWIU
M% '<W4ZVMI-<,"5B1G('4@#-<'X,@_X3CP]_PD.N2W$C7TDH@MX[F2-+:)7*
MA0$*_-P<MU/'/%=]-$D\$D,@RDBE6'J#P:X/PO;:QX#TUM FTB\U6RCF=K&Y
ML?+)\MFW;9 [+M8$GD9!S[4 8ESJEX-*\>^&[NZFG.BP>?8W)D/FJC1EE#.,
M$E>.3R><YJYX9/AS5-/\.VUMJ5T-;,,-R[QW$K'>BJT@<,=I!Y!'O[5)<>%=
M4&B^+=3GLFEUGQ#'Y*6D#J?(785168D*>VX_SKK/"MI-%X8T>#4=/>VO+&VC
M@VRLC$,J!25*,1@\]\^U &]7FWA."'XAKJ6N:V9KBU%X]O961D9$@C7')"D
ML<\DY]J])K@?#VD:UX'OM1LK73'U/1+FY:XMOLTT:RVY;JK"1E!'3!!/3WH
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MABAV3VV[*#!)!E& :J^"D\3>&/!=GHMUX.N[F>W,C;EN[;829&<=9,\9'Y4
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M*_A_JQTNRU;3M.L3>7DNO702W1]@CB&T%V;!"J.!SUSQFO4T+%%+@*V.0#D
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MTEN"X7RH$&7//7/RKC_:JCX&O8?&'P\.EZ@[/+; Z?>['^\4XR&'4%<<]^:
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M?+\6:GJVJZKX;B%QIR0);PZHK,C*6(7) !R6Y/&,C&:]-_LRP_Y\;;_OTO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5332M/CU!]02QMEO7^]<"(>8>,?>QGI5RB
M@ HHHH **** "BBB@ HHHH :44N&*@LO0XY%.HHH **** "BBB@ HHHH *0J
MK$%E!*G(R.AI:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBN6
M\=>(=1\-:5:WFGQVLK2W4=L4N%;&7. <@\8^AH ZFBN03Q5J.F^+].\/:W:V
MK/J4;O;W-FS;04!)5E;GH.H/X5#;^(M>N_'NJ>&XQ81)9P)<).]N[&16Q@8W
MCIG&?:@#M:*Y;4?$]UX:\/ZAJ.O01.]O<"*V6T!'VG<J[<!B<')(/7&T]:2\
MN_&%GH]QJ0@TJ>5(3*-/5) P(!.T2;B&/_ 1DT =517*W>OZI#XXTS1(ULS:
MWML]R7:-MZ!,97[V"23UP,>]9^I^)?$NF2^'XKB'3HI=7N1 86B=C;9&>2'P
MQ'0XQ0!W5%9VFOJOGW46I);E4*F&:!2JR*1R"I8D$$>O<5A^&?&D?B'Q)K6E
MB,1I:,K6K$$&>+[K./4;P<$=B* .MHKD;W7]7B^(=IX=@:R%M<6INS(\+%U5
M6VE>' )/KQC/0UM^(M87P_X>O]6>%IA:0F3RU.-V.@SVH TZ*Y+2]8UV]L=(
MU)9--N[*_9#*+:-P;=6!/WMQ#X.%)(7GG':NGCN[:6ZFM8[B)[B$*98E<%D#
M=-PZC/;- $U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5P'Q> /A.R5I#&#JEN-X."O)Y%=_56[TVQU
M H;RRMKDQYV&:)7VYZXR.,T >>6,?_",?%!U\0S/>C4DVZ3J=T<F,C[T/'RJ
M3GJ ,_C@!6VU7XQZ[;SWMS9&VTV"(-;W!B,@)W'+#!&-P&/QKT.73;&>U2UE
MLK>2W082)XE**,8P!C XJO'X?T6%2L6D6"*3DA;9!S^5 'G'CFS1_!$5EI4T
M^IC0=2BNKJ0'S'*DN2,Y^9P'!/US7H$?BK0Y='358]2MVM)%!1E;)8GHH7KN
M[;<9S6G;VMO:1F.V@BA0G)6- HSZX%00Z/IMO=M=PZ=:1W+=9DA4.?\ @0&:
M .1U&>-OB]X=+'8SZ;<81R P)(.,>O7\J9\0)$3Q)X)#.JG^U@>3CMBNT?3K
M*2X^T/9V[3@@^8T2ELCISC-+<:?97<@DN+2WF=1@-)&&('U(H R?%FI-9Z6M
ME;744&HZC(MI:M(?NLQP6QWVKN;Z@#O7#>(+.;P+X@\+^(;F[LGLX NDS^3;
MF$^25.UFR[ A<$\8KU":QM+AXWFM8)&C^X7C!*_3/2EN+*UO HN;:&<+RHE0
M-C\Z .!U&_LXOC7I$DEU"L;Z-(%<N,$[R>OT&:Z#5?%6B?8M10M%J%M;VPDN
M_*99(U1FV[6QGDC<<8Z*:USHNEL<MIMF3C',"_X5-!86ELCI;VL$2O\ >$<8
M4-]<=: /*SHL?A'Q)HEYX+U<R6&JWJQSZ3YWF(R-RTB#L%49SU''/:O0[.?0
M6\5:E#:_9QKBQ1F\PA$A3'R9..1C'3VSVK1BL+."=IXK2".9L[I$C 8YZY.,
MU*L,2RM*L:"1P SA1E@.F30 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY;:* .IHK-\/ZY:>)-"M=6L=WV>X4E0XPRD$@@^X((JOXMU&^TCPKJ6HZ='
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MRU0'E>6X)["FZCX1\4W-OXEAM7LH$U.^CN8P9VR\8 5XW(7@,%'3W'>O2J*
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MTV5[/5%O Y=T#HLOF ?=."3Q[#UKT:LS6/$&E:!#'+JE[%;+(VV,-DLYR!@
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MF(0SLS*<YWY+=3TQ79:7:7%EI\<-W=M=W&6:29AC<S$DX'91G '8 "K,G$9
M!_ XH \Y\,G_ (2#XB^(Y-2 G72S%:VL3_=3Y06<+TR3WI=<5_#GQ*T5M+18
MX=6@FAN+=>$9D&0^.QYQD56OM4TW3?%ESK>C7NV[G40W=K/;3".7;P'#!3AA
M]"#45KJVFW.O-K^L7JRWT,!@M;>"UG\J $\G)7+,?ER<#ITH NZ3XK\0:_X>
MNM0N=#L1IXM;C<'F)W2(2-I'H<5+I_BRX71O"-K86-I:7&LQ$QH$)A@54WD
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M"6$$87)!*^F1S]*K:3\-[?2)M$DAUG47_L@R&!7*%2)/O C;P"../KUKMZ*
M.'N?AI9W6G:K8R:O?^5J=Z+Z<@19W@YP/DX!.W_OD>ISJV7A&+3?$MSK5GJ-
MU";O!NK1 @AF<#!<KMX8GDD$=35;7/%NHZ7XJLM"M-$CO);V)Y8)#>^7D(,L
M""AQ^9S3V\0>(/[/U+;X:_XFEJ(FBM!>!EG5V(R)-H QAN/;W% %KQ;X5A\7
MZ6FG7-]<VUN)!(X@VY<CD9W ]#6PD,JV0@:ZD:7R]OGE5#$X^]@#;GOTQ4L9
M9HU+KM8@$KG.#Z4Z@#B!\-;0:;:6W]M:H)[.ZDNK>[5HQ)&TG+]%P03D\CO4
M5U\+-/N=/O+'^V-66WO+L7DR&57#/CG.Y3G) )SGH*Z^RU2TU&XO8;642-9S
M>1-CH'VAB,^P89]\U=H XR]^'<&JV[QZIK>I7;A4%O*?*C:W*MN!38@&?J#5
MW1O!5IHVNRZPFH:C<7<T"Q3M//N$I7HS#'7'&.@]*GMO%MC<^-KSPN@/VNUM
MEG+[N&R>5QZ@%3^/M6_0 5EZWH5OKT5M'<3W$0MIUN(S P4^8O*G)!Z5J44
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MWG_9H_M+1M-CYS&I"Y]@230!F3^&;":^N[Q'O+>>[Q]H-O=R1B0A0H) . 0
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M'?A>T:V:'32#:S>= 3/(3&>3@9;A<L3MZ'OFB&_U]I=&%P^GVKRNZWL#D[G
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MX&&:!"I4E?3@_I733^$-?N)%DD\6%Y$^Z[Z9 2/IQQ21>#M=B$B+XI 24?O
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M7MM%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '*Z?XAU*X\?:CX>FCM
M!;V=NEP)D5M[AN@P3@8/UKJ'D6-&=V"HHRS,< #U-<#ID\(^->OJ94!&FP#&
MX=B/\1^=5OB-K_VKP_.NFRS/9V-_;#4;FV"R*(R277N"5^0D$8^89SS0!WMG
MJVG:A \]E?VMS"GWY(9E=5^I!XI++5]-U(2&PU"TNA$<2&"97V?7!XKR>\;P
MI8Z9K^M6VHWWB#S].V78MVCBB"F1%C5_*1=K]??:&R.F:EM=Z7_PF>K6UQKE
MDMA=^&)(WET]-D:D-R$&2794W'))/7IC  /8[/6=,U&62*QU&SNI(QET@G5R
MH]2 >*++6-,U*1X['4;2Z>,9=8)U<J/< \5Y#J4^MVVCZQHMK';:E>KH\;VF
MKZ>-K2VHD4;712>=N[&.H!Z\UL:#J7A&36;;Q!:Z]?W<]K8.)\QQI';6X&2)
M%2->C8P.3GIP* /4F8(I9CA0,DGM7!:E\0(=0\.>([CP[>V@N]+W&-I"'\Y4
M169E3(..2H/(R*[+3-4L]9TV'4-/N%N+2<9CD4$!AG!Z\]017D<6IV5MX=^)
M^GSW"1W;7U[*(GX)1@%4_B2 /7- 'J&BZ]8:A!;6XU.SFU$P(\T"3(9 =H))
M0'(Y/I4P\0Z,=2_LX:K9?;<[?(\]=Y/IC/7VZUYF_P#9]IXR\!+I;6<,LNES
ME3&5&]FB^0GURV>O4YJAX/FT"^T+2M(U0ZC+XATZ^RNG"1PRSB0GS.. !DDD
MGL<T >E^--?F\-Z!]NBBE8&9(WECA,OD*<Y<KD9QC'7J169-XMNKC6-=T^S<
M0RV5@MW:^=:,4D78K%V;([MMV\8P3D]!VM9GB.:*V\-:I+-*D<:VLF7=@ ,J
M1U- %#P3JNH:[X4LM6U%[<RW:>8$@B**@R1CECGI[5I:EKNDZ.R+J6I6MHTG
MW1-*%)'K@]O>N,\!^*-"TOX9Z2UYJUE$T%L=\9G7>"">-N<Y]JP=8N[*/X@Z
MF/%.IW^D6FHV$'V7RRH1XMI\R%SL8_>+="/Y4 >H:CK^D:1'%)J&I6MLDHS&
M990-P]1ZCWHN]?TBQM8+FYU*UC@G7=#(91B08R2OJ,<Y%>875UI%CJECIB+-
MHD;:*T:W-YOEN);=I2!!&C94,< \AF (&.*IZ)?V_P#PAOABZL/$-OIVLV=E
M.L:7F/L]P@<%XG)QCHO(.?RX /6KCQ!I%I807UQJ-M%:SIYD,K2 "1<9ROJ,
M<_2LK4-0UB7Q%HYT>[L9M)NHG,HVEV/RDK(& QM!V]QG.!UKS]=9M[/5-%U7
MQ%%=:/HUYHWD0B -Y44F\EE. 3M90"!Z8]*]%\$VUA:^&XH]*MKB#3O,=K;S
MW)+H3D.,\A3R0#VH Q4U_P 0Z1X376]6:VO!:3NEXMO$R"2'>%\Q,@'*\]1@
M@'V-=U%(DT221L'1P&5@<@@]#6#XYDCB\!>(&E("G3YUY'<H0/U(JAX2UNTL
M['0_#%W)(FLKI<,CPM&W " '+=,\'C- '47EY;:?:O<W<\<$"8W/(V ,G _7
MBN+\+^+9+[Q/XNBO=5MY=*TQK<P3%5C2-75RV6]B .3_  ]J3XAW;Z;JOA;4
MKD/_ &/:WS/>L$++&2NV-V]@2>?ZXKB[[6;![SXCWR6(U*SN4L)(T='6.10,
M%SC!*AB#QUQZ<T >IS^,-!ATR]U!=1AFBLDWS+"=[J",CY1SSV[4MIXKTJ?P
M_:ZQ-<QV\,ZI\K')#LH;8.,LW/85YC:W/VGQ9XA6'5+F_%[X:D\JX-MY:R,,
MX\M0H&T#(!Y[C)J;4M5M?[#\$:O))?MHMG!]EO)K1I(FMY3'&H?( ) PP)'N
M.O% 'J46OZ3/I+ZI%J%N]C'D/.'&U2#@@^^>W6N>\-^))M8\;:W:1:E'=Z;#
M;PRP(L6PQ,Q8,K9 .>!U[8KC[V+3K.WTS6]&@U&7P^FM)=W]S.7D\[Y<>=M;
MYMJL3DXY(SS@5TWAW4].U#XF:O=6 =H;K3[8K,('5965I,G) SQ@9[XXZ4 =
MAJ6KZ?I$227URD(<D(IR6?'7:HR3CV%<WXO\:6VE^$4U32[RWD-VZ16\X^=%
MW,%9^,_=!)P>X_"L7Q[.FF>.-&U/5'U&'1FM);9KFRDD7R92P.6V<X( 'OCV
MK(\8?V+9?#"6+28YK>VN]2CEMQ<.^^XPR%Y '^8#()Y^O0B@#6O]<N].UJQT
MK_A*IIK+59B5N6@036L:1LS ,$VMN;: 2O !^M=%I_B*QT:WCT[6_$EM=WJO
MM-PT?E\-R@?'RJV".N,UB>*M9TX?$/P/-_:5OY"M<N^UP5 >+:C$CH"<@>O/
MI6)&^D)J/B#P]XHT[5)KRZU&:>TMTEG\J]C9@T>-K!<C@9. ,#)XX /3=2\0
MZ5I$A2_O$A(4.^02$4G 9B!\HSQDX%9,OCO2X_&-OX='F/++!YIF5&*9) 11
M@<YR3GH..:Y:#5[7PYXFUW1_$NF7+P:N\<MKM@:Y69/+5##P"3MQC\3[9L-*
M--^+6B2S6,EK%-X?6VBAAB+JDGFY,8VC "COP * -O3_ !1IVF:7J&I:GXFB
MO[+^T'C2=8"%M\@$1$J#G&>I]:Z :S8&\M[3SB)[B$W$:&-AF,=6)Q@=1UQU
M%</X>M--\5:'XUTN.:&6*ZU.<J5P0 R)L<>VY20?:H/#5GX@USP3JEQJ"/%J
MHTZ72;4,2&R@96?/JSX!_P!R@#M[3Q/HM_?QV5M?QO<2J7B3!'FJ,Y*$C#@8
M/*YZ5KGI7E?@RZT/5I]$A_L?5FUW2U$<HN)9_+L2%VL?F;: =N H'.1P,''7
M^,M7CLM,&GI>+;7>H$0I(1GRD9@KR'T #<$\9(% &;X9\:2ZSXSU32YHS':-
M$MSI;, /.A4F-V]P6&X9YP:Z<ZYIRZQ)I)N#]OC@^TF#RVW&/.-PXY&>.,\\
M5Y[XLT:^\+W/AW7[.YN=0ETZ=;7[/%:(&-LP(9?D7. !QG@9J[J=]%IOQ9T_
M6YH[A[&\T1K6!HK=W+2B7?MP!D';Z_CB@#KU\3:.^C1ZLEZK64C^7&X1B7?<
M5VJN-Q;<", 9JNOC3P^UO<3_ -H@+:C=<*T3AX1WWIC<OXBO-OMJ6W@#0)YX
MKRVO+;Q"TL4;6K,"YEF;! 'S+L+<IGFK,%SI_B+P_P"-SI&H&YUW4X/-EM(X
M9(MJ(NP*BL,L2.">Y8# XH ],&OZ6=1LK#[4!<WL1FMD*,/-0#)*G&#@<XSF
MJJ>+]&DE>.*>>3;O"NEI*R2% 2P1PNUR-K<*3T-<):7TFI>,O -Q%INI)!96
M<T-Q+)9R*L<C0A=IX[' +?=YZ\'#]#@NK77; :#+>RZ3=RS23Z;?6S9L6*MF
M1)& P"3C&>=W?/ !VOA'Q3!XLT5-2@AFB5W?"R1LORB1E7D\$X4$X)P:Q_B3
MXEO]%\/7::.=M^L'GO-C(MXPP&?3+$X /N>U1_"9I+?P+::3<VMU;W=@TB3K
M/ T8RTKL-I(PW!'3UK/\?>&-8'ASQ)=VNK37"W@#M9+9J[, 5"H&^]@=>/?U
M- 'H.FS/<:59S2G=)) CL<8R2H)JOK4&J7-I'!I-W'9RR2 27+1AS&F"254\
M%B0!SP,D]JQ--UPZ%'X?T35#=W%S>Q +="UVQ(<?*C$< ]OPR<5I^*/$'_".
M:.UZMC<WLK.(XH((V8LQ]=H.%&"2<?F>* .8TK6]7\/ZQXCT[6K]M5M-,LEO
MX[IHUC< ACY;8X).TX/M4%EXCU>SLO">M7]ZTL6NW2P7%L4 2+S03%Y?&1MP
M <DYS^(FTR6U\0Z;JNC0VU]+>:E:2-?:E<V;V\9<KL4 , <#@!1T ZYSFA#I
M]_J^E^"M#EM;B.\T:]AFOF>)E2)8%8#YB,-NXQC.0?QH N>*W\7:!IDOB1-<
M5Y(KA!_9*P*871I @0-C<6PPY]<U-\0_$MUI9L+-+R^T>"7][<:G#9?:$BYP
M$)Z#)R3WPHXYJ/4O$)OM<+WOASQ#+9:?*6M88M.D*W$@Z2L3V'\(_$]@.AU'
MQ':PNNGWVD:E*]S;;S%'9--&^1S&64$9]<X% &AH,<D6AVBRZH=5<IN^VD*/
M.!.00%XQ@UI5QNA^=X)\&:+8W%A>W4LDX@,5NOFF#S&9OF.?N*.,_2NRH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** ,]]!T>1V=])L69CDL;9"2?RJQ!8V=
MM;M;V]I!%"V=T<<853GKD#BK%% %6'3;&WMY+>&RMHX),[XTB55;(P<@#!XI
M!I6G!546%J%5#&H\E>$/5>G0Y/%6Z* *]K8VEBC):6L%NK'+"&,("??%0R:9
M;"SN;>VA@MOM 8.R0K@D]21C!_&KU% %/2M,MM&TR"PM 1#$#@G&6))))QQD
MDD_C5AK>%RQ:&,EOO94<_6I** (OL\ 96$,8*\*=HX^E.$48D,HC3S#P6V\_
MG3Z* "LS7=(.MZ?]D&H7EC\X<R6C*&..QW C'^ K3HH XC_A7!_Z&SQ!_P!_
M8O\ XW3Y/ $\N/,\8^(WQR-T\1Q_Y#KM** .,;P#<.RLWC+Q(67[I,\>1]/W
M=,/P[=E53XN\0E5Z RQ8'_D.NVHH XQ_ $\B;9/&/B-E]&GB(_\ 1==#HFDR
M:/9/;R:I?:BS2%_-O75G48 V@@#CC/XFM*B@#+UG18M;%M!=OFRCD$LMOMXF
M92"@8_W01G'?CL"#.VFPOJT>HN\KR11&.*,M^[3)Y8+_ 'CP,GMP,9.;M% "
M,H92K $$8(/>DV+@C:,'@\=:=10 @1000H! QP.U!4,I5@"",$'O2T4 & **
M** "BBB@ HHHH **** "BBB@ HHHH **** ,/Q%X<.NM930ZG=Z==64C202V
M^TC++M.Y6!!X)'MD^M2:5H;V-T][>:C<ZC>LGEB6<*HC3()5%4  $@$]2=H]
M!6Q10 4444 %%%% %273H)]0@O93*TD (C3S#L4G(W;>A;!(R>@)JW110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%0W%Y:VFW[3<PP[ON^8X7/TS0!-144%U;W2EK>>*90<$QN& /X5+0 4
M444 %%%% !13)9HX(FEFD2.-!EG=@ H]234,.HV-Q*(X;RWDD/14E4D_@#0!
M9HHHH **** "BBB@ HHHH **** "BBJEGJ=AJ$EQ'9WD%P]N^R812!O+;T..
MAH MT444 %%9UIK^CW]S]FL]3M+B?YOW44RLPQUR!R/QK1H **** "BBB@ H
MHJCJ>L:?HT"3ZC=1VT;N(T9S]YCT ]Z +U%&:* "BJ=]JVGZ88A?7D-N9B1&
M)' +D#)QZ\513Q?X=D&4UJR8>9Y>1,,!\XV_7)'% &U1110 4444 %%9^HZY
MINDW5C;7UR(9K^7R;92K'S'].!QU'7%:% !1110 4449H **** "BBB@ HHH
MH **S]+UJPUK[;]@F,OV.Y>TG^0KME7&X<CG&1R.*T* "BBB@ HHHH **S]1
MUO3]*E@ANYR)YR1%#'&TLDF.I"("Q [G'%)IVN:=JLT\-I.3/;D":"2-HI(\
M]"4<!@#V.,&@#1HHIJR(Q8*RL5.& /0XS@_@1^= #J*BN+A+6WDGD#E(U+-L
M0NV!Z  D_A5+0=;L_$>BV^K6!D-K<;O+,B[2=K%3Q]0: -*BBB@ HJIJ6I6F
MDV3WE[+Y4*D#."Q8DX"J!RQ)X ')JEH7B?3/$0N1822^;:L$G@GA:*2(GD;E
M8 \@4 ;%%9MCKVG:EJ=[IUK,SW5D$-PC1,NS=G;U SG:>E:5 !16%KGB_2O#
M\_D79N9)A'YKI;6SS&-.?F;:"%'!Z^E2GQ1HW]A0ZTMZCV$Y AD0$F1B<!57
M&2Q/&,9H V**QXO%&E/::A<23M -._X_(YD*O#QN&5QDY&",9SVJ#2/&.CZU
MJ4FG6[W$5ZB>:(+JW>%W3.-RAP,B@#?HK,O->LK/4%T_$T]XR>88+>%I&5,X
MW-@84>F2,]LUIT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7GWQD@@?P(TLD"2
M/'=0[24!8 N,@?6O0:Y/X@:#JGB;05TK35M5+RI*\UQ*RA-C @ !23G\,4 <
MAK<^G6_Q-\*OI=H^BN\CBZFF@-K'<H=H"#( =LDC&,\CVKUNN'\0>&==\7W.
MF6^JKIMEI=I<+=2K:SO-+*Z@[0"T:!1R<]:Z:V_MG^WKS[2;/^R/+3[+LW>=
MO_BW]L>F/:@#2HHHH **** $9%="CJ&5A@@C((KP+2;6/4OAD^FZ7HMW-KOV
M]S:74-FZK"1-G=Y^ JX /\5>]3F58)# B/,%.Q9&*J6[ D X'O@US'@#P_JG
MAG07TS4_L;D3/+');2LV=Y)((91C'XY]J %L-<U2/4;_ $:[AMWN;#3X;D7
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MWVR..* .=@\;Z_K$OVW0=/>ZLQ=F$0-9D*\2OM9_.+@!L D#;@=.35C3-?\
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M,:!0K1O<%"=_WMV3G/TXZY]2M/#BQW\5]?ZA=:C<PPM!"TX11&K8W$!% W'
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM]Y\$!$)P<8^O&*BT"YL[SQUX9NN&@M_#81WEC*B-P<<[@,' ;'J.1Q7K=%
M'B>G7JV.@^']9CLY_P"R;#6KJ>YA2(Y@BD+^6Y0=@&SD?A73^#[V&_\ B?XI
MOK:.X^RWEO:O!*]M(BR!4P3EE'<]^O:O1:* .$^+RF7X?W$**7EDN(0B*,EB
M'#$ =^ 3] :4_9!\77NBD?DIH.TR[/E#>;NQGUV'/TKNJ* /'- %Q8^%O NJ
MM;3/::5=7*7Z"-MT(DWJ'*XSA=V<]@:L^)]-N-?;Q1JV@VTMQ:RVEHA #!;Y
MXY-[[/[P\O"Y'4Y KUJB@#R]=;M]=^*/AO4+*UOA:QV4Z2/):2(L;%<[22.W
MKTY'-5K:ZB/PS\;(!+OGO;[RD\IMS^:3Y9 QD@UZS10!P/B>W35? -IK>G2A
M;W142_MW((^:-<NA'7!&01ZXKI_#5M=0Z,DU^@2^NV:YN$!SL=^=N>^T;5_X
M#4.J>&8]7U>"]N-2U%;>(*&L(YMMO*5.077&3SCO@X%;M '$^.)[[2-<\/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;7%K%%$F$FBF3 FW#J!M#D_K5CQ!97^B^/YX--MBUIXKM_LTA7(6&9>'D/\
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M6X-/7RV>'S+:]0NY$+#!^;(^OS<"HEU.PL_'&AW?B"S@T^1O#X B:+*6\AD
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M!]XX!/3WB\?:_-H6@@VPN%GN)XH1+% SB-6=58Y (!P3C/.2, UFZ7%>Z?\
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MYF\*3V."?IC'6NDT34YM6L6N)].N;!Q*\?DW PQ"G&[Z'J* -&BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:!IEUK>I6T,UQ;QLS,P7S&*C<5'IDY]A0!NT5'!/#=6\<]O*DL,BADDC8,K
M]"".HKG/&^JZAH]AIUQ87*0^9J-O!-NC#;D=P" 3TX[X_*@#IZ*HV.LZ9J:S
M-8:C:70A.)3!,K[#[X/%5+/Q9H%^]REMJ]G(;9=\W[T *O\ >R>"ON.* -FB
MLN+Q'H<ZS-#K&GR+#$)I2ERA"1GD,W/"\CGI50>)])U71]0FTS6[2)H(V5KB
M0@"W8CY68-CC)!YX- &_16!:^(=/T[3M-AU?7]/EO)[<2>>)%19@$+-(!G 7
M )STK1TG6-.UVR%[I=Y%=VY8KYD39 8=0?0_XT 7J*;)(D4;22.J(H+,S'
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M3:WK7MOI=E#=N26GCMT5R3URP&>:KZ'H%MH?VUXA&9KV<SS&.)8ES@  *.@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% %*'5]-N)YH(-0M)9H03+&DRLT8!P=P!R,'UJ&Y\1:+:6
M"7UQJUC':2-L2=KA=C-Z YP3Q7"^+$N_"WCVVUG2X-YUZ Z:X4#Y;G_EDY]O
M7V4U/KDND^'_ !!X=T??#8?9[";RK^Y4LJK\H947.UI6QG)!QZ'.* -CQCXC
MNM-T"QU31KJUDAFNX(RQ3S!(CN!E6#8'&>QZ]JZ!=9TMY+J-=1M"]H<7"^<N
M8?\ >Y^7\:\;34-/_P"%26-G#=H7M]<5&1\(Z@W+,,K@8.WG&!CT%=7/JEAH
MWQ3UN2_G6%;O2H# ,%C-AF!"@9+'/8<T =O<ZYI-G917MSJ5I%:S'$<S3*$?
M_=.<'\*YOQ1XIGL;KPS-IE]:/IVHWZP32@!PR<DD/G '!SQ^(KB-(\1:7!HW
M@96N(+26.SF3^TYE++;D *T87(!<\=<X]#FLVSFTV7PGX0@FDCDM;3Q$Z77G
M* J*9'(WY  R,''% 'L-[KD-WX7U'4=!U"TN'@AD9)D(E0.JYP<'^O>H]&\0
M0CP9H^K:S>P0/=6D+R2RL$5I&0$X[>O KCXK2TMM8\=7^F^5#H[Z<(V:,A86
MN C;MN.#@8!/J<5B-J4>F)X#U'4;^YM=%_L46XNK7#>3<;5SNX.,@ =,\'WH
M ]EM+RVOK6.ZM)XYX)!E)8F#*P]B*JZCKVDZ0Z)J6I6MHS@LHFE5"0.IY[5B
M^ K;2+?0[@Z&]Y)837;RI-='_6DA=S)D#"Y![#D$]ZYN[UW2M!\>>);/Q6"M
MMJ<$7V69X699(=FUHAM!/4GCN<]Z ._U+6]+TB!)]0OX+:.3[AD<#?\ 3U_"
MD?7M(CAM)GU.T6*\(%LQF4"8G&-G/S=1T]:X>POXM(\;V<^I6RZ9I5SHZ0:>
M9WQ' 58EH\GA6*[2<^@'.*Y75K6*VL]/:5H!I5WXRCFLHFQL^S<AF4'_ )9D
M\^G.>] 'L5CKVD:G!//8:E:7,,'^M>*966/C/)!XK+O/$NFZGX>U&?2/$-C:
MO%'@W<N"MNS9"E@Q'7!QG]>E<C?'0!X@\>65U<I;6LUC:>?]E*[UQO5F ]5R
MF?PJI-JMW_PC?B[3]0O=/U2VM](*0ZS 0#*2KB.*0YP9/FSQZ^IH ]%;6K+2
MM L[S5=5MMCQ(/M60%F<KG*@=<\G [5B^#_$YN]"U;4M7U:TFM[;4984NT C
MB,8VA<<G@Y]2>>IKE[36[?1-:\(:GJTP71)- 2V@N-NZ.*Y.TMDC."57&?K[
MUD37D,N@WE[:Q7G]GV7BI[R\2!7BD2W(.'QP>#SCJ,=J /5H_&'AR73VOEUF
MS^S*XC9S* 0QZ+@\Y]L4[_A*]",!F75+=T%P;7]V=Q,H&2@ Y) .>*\K\17'
MABZ\#>(M3T@W<D-XUHLUY=R2?Z0ZS+\JA^6*J"21V/UKIO%-YI.AZMX;^R6M
MKI]G=-,RZK;V^[R2T:C"*HVEW 4!B#P.AH VM;^(N@:19:9=)=QW4>H7"11-
M$V5"[PKN2 <!1GCJ2,?2Y97XO?%TQM_$%M/:BR0_V8JKYD;$@B4G[V"".#ZU
MY)'?6L'A'1I"TZPZ=XP6:Y>:)@T2;W.6XZXQD=>>E==JMW'J?Q"U.VTVZ2.^
MN_"QBMU;Y'\TNS!<'!#;2#@\@<T =U;>)-'N[Y+.#4(7G<L(U!XD*_>"GHV,
M'.,XQ5&X\>>%+5F6;7K%664PD>:#AQC(X],C)Z"N+CN++6?!?A;0K,M%K=G<
MVJFW5-LEJ\6/-=Q_"-NXY.,[AZUE7USI5YX:^)30-;22R7^U, %G.%"X[GYP
MV/?.* /:@0P!!!!Y!%87BOQ3:^%-,CNKB.21IIEAB1%)!8D#D@''&33-.\5Z
M3-JUIH23,;Z2R2Z0;"%9,=CZ^U8_Q6CD?PI;2)&[K#J-O+)M4DJH;DX'/>@!
MUSXKCTOQNW]H:PL.B2Z7]ICCGC$>R3S%3C(#$D G!]371OXCTA=(AU7[=&]E
M/@0R1@OYA/0*H!+'@\ 9X-<H-4TJ^^)T%XS*T"Z(VV2:%EVDR!OXAP2F3]*X
M*TBEC\+>%M1FCU%]-TV_O4O8[%GCFB$C'8X*D,  >W8X[T >W:7K%AK5LUQI
M]RLT:.8WP"K(XZJRD J1Z$9JCJGC'P[HMQ/;ZCJUO;S01B22-B2RJ<8X')/(
MXZUF^!;?2T@O[C1K6]2RN9A)]IO7D,ES)C#-B3YL#@9/4Y],FA=-8S_&B**X
MC67_ (DK0#?$642&3?MSC .S)^AH Z*^\7Z#ITPBNM05.$+.L;M'&&QMWNH*
MIG(QN(ZU+JGB72=&)%]=%-J"1RD3R"-"<!G*@[5SW.!P?2O-%%AIOB7Q+I7B
M;3=8NS?WC3V:0-,T%S$V-L852%W# &3QVR,5<L+Y?"VO:SIOB/1IS:ZK';FV
M6")[J-P(EC:'.,G!&!G^M 'H-]XBTK3HHI)[HL)8C,GD1/,3&,9?" G;R.>G
M-9-]J]C=:_X<>U\3"!+C>\=I%'YBWRE3CYA]W&"<_P!:Y#5;A?#_ (R6^UO2
MM2BTN^TR&&)+"20BV=,YB81D=B?;T[T^[6ST[4_ D5OIKZ;;+?3RI;8=C'&X
M(1G_ +I8D$CL3CM0!UEQ\1_"%LVV;7+=6\XP$!6.'&,YP.!R/F/'7G@TO_"<
M6)\;_P#"-K#<F00>8TPMY&4L64*!@'Y<$DN?E]ZXT7FER6/C_2'@,NJ7=_.D
M,2P%FE+1JL8!QCALGKQU-6M"L[KPW\1=,@U".>9I/#T%DLL4;.ID5QNR1T P
M3DXX^M 'HVHZC9Z3837U_<);VL(S)*YX7G _4@?C68?&>@):7EU+?F&.R*"X
M$\,D;Q[ONDHRAL'L<8-5/B%=W%EX,O)[;3X[YE:,M%)%YJJN\$OL_BVXS]1G
MM7G.JW@V>,4CAUNX&I:7;^1<7=L^92"XST&T$L !@=^* /4=-\9^'M8U".PL
M-22:YDC,L:A& =1U*DC!QW .1@US/Q \6+;Z9&-'U6XANHM0BMY#% QC<[AN
MC\S85W =@PZ$>U1!RFJ^ HXK:Z4Q:?+%(ZVSA8&>)%7<<?+\RD>U<A/=7<?P
MZLO"<^EZH=9L-11IU6TD=67SF?>' P00?QH ]WK%A\6Z3<2;(WN6!C>6-Q:2
ME)D7&YHV"X<<CIG/;-;$;"2)7 8!@" P((^H/2O*_"D4]MK=G:: ]]-H\EM*
M]U9:C P;3&*Y58W91U)QM&>!GWH [T^+-$%OI<YO#Y.JNL=D_DR8E9ONC.WY
M2??%<OJ&IRZ]XRU/1A?ZO8165M$;=[.WF!\UBV7?"_,OR@ -\IYQGJ.7AFO;
MKP_X$T]=$U59M)U* WA:T<"/9NSCCYLCG(R/7D@5V&DWT8^*/B"5X;M(9+6W
MBCE:VD".T>_> VW!QD?7MF@#%%\^NZ;K5[=^)-<TIM/N9(OM$-O(J"&,*I+(
M% WDY8_Q#V Q7:6WB#3['0=)8W5W?O<VB/ 4@:2>X7:N9"BC/<$GH":XVVO!
M<^!_'4"6M^LUU/>S01O9RJTBR#:A *\Y)Z=1WJ"SOM1\,?\ "+:TVC:A>V#:
M%%IUS';P,9K>1.?N'!Y(QVZ=>F0#J[[7M)UA?#UU9>(+FWBN;T>1]F1L71&0
M8GR.!UR#CIZU?U+QCHVDRSK=S2B.WD2.XG2!WC@9L;0[ 8!Y'TR,]17,:W>M
M]D\,RMH\]E&-96[%O!:LS1P;7&^0("%8EP2.O/L:Q;>T?2=<UO1-;\)76LO?
MWLEW9W,4>^&4.<@2$D!,$#/7'/' R =SJ/C_ ,/:9?7EE/=3-=6:!YHHK>1V
M"GG(P.0!R3T [UH'Q+IAL;"ZBE>==00/:QPQEWE7&20HY  /)/3O7#V:26WC
M?QB\EG.L3:5$B-';2&-BD>UE0[><$@ #DUFZ+%K?A/3_  KJ\VBWUU!:V,]E
M?6T<69H"TFX,J'KG ''84 =VWCW0A;Z=.DEQ)'J$WV>!DMV($N<>6W'RMGL<
M=#6S%JEM-J\^F)YAN((DED.P[0&)"_-TR<'CVKF=1T@^+_!-_!=V/]DB:0SV
M88!9(BN&61P,@,6!)QV..M:/@R&];08M2U38=1U +<3;>BC: BC_ (" ?J6H
M T]2UBTTIK=)S(\URY2&&&,N[D#)P!V ZGH*QM3\96J^%-7U335FEGL8Y%>%
MX65X9%0L ZD9 Z<^E5?$<%YIWC72/$8AN+K38+::UN(X$+M!NP1($&2P. #@
M9X%8]WIUQ<:;X[U>&QND36[9(+.#R6\R5A$4WE,97<S8YQP,G% &SX)M[B_T
M[3-=DU+5O,N+&/[3;W$A:&61E#&10V=O)XVX&.U:'_"9Z5NU="MX)-("M>1_
M9FW(ISA@,?,,*3D=N:F\'))#X,T:VGAEAGM[*&&6.5"C*ZH 1@^XZ]*YWQ)X
M<U*?QU9W>G.\5GJEJUEJ<BD_(J'>I&.C$;D![9_, Z*/Q'I]_:Z88C<[-71O
MLK)&0=NW.X_W>.<FN+^'WCRU3PKIL6LWUY/>7%V]O]HDCDD42-(VQ&DQ@'&,
M#/3':M'P3X<U#P]>:A%?;FT[3'EBTL!2[&*0B1CZD_=7 '4,*YO3-*U2T^&.
MB6$NE7PO+?6DGEA%NQ8(LV\MTZ;2/Y4 =S97VF)XUUH_VO?M<Q6R/<6EQN6W
MMT7^),@#GDD@D<T?\)?INI,-.0WUI-?6\DEE+)$8_/55R6C/L"#S@^U<WJ>A
MZAJWC#Q<D-O<PQ:CHZVMO<-&RQM(%^Z6QP.<'\:U-"UK5[NTL+?4/"UU:S64
M96[N)X0R!0F"(<'<S,0!@#IGKQ0!E_#SQU:+X4T"TU2>^FO;R5X#=O$[H9FD
M8JC2?WB,?0=<5Z/=W4-C93WER_EP01M+(^,[549)_(5Y$NDZI'\-?"E@-(OE
MN;+65GGA%NVZ.-9)&+8';#+_ )%>I:^;X>'M0_LR));[[._D1OC#/@X!SQ^=
M &=IOC/3M3=$BM[V,RVAO;??#G[1".K(%))/(X.#R.*JVGQ%T&]MYKF$WAM(
M86E>Y-JXC!#!2F<??R1\ON*Y#0[+6+?Q5X;U4Z%J\<45C+#J$TQ4N[E02-N[
MA V-H '3@<5/9>&=8O/@O=:#]A:'4UF:18+D !\3B8#.<<C Z]>#TH [FP\4
MV-[KDFBR17-GJ20BX%O<H 7C)QN4J2#SVSGVK"^(%V=,U#PM??:;N-!JBQ21
M0,Y$JLC'!1?O'*@#CO[T_P )"2ZOH[H^";;06CA*SSO!&LCN<?+'MYV]22?;
MCTL^,;.\O=1\--:V<TZ6NII<SL@&(T"LN3D\\L.!0!8M?&^D7-GJD[BZMGTQ
MUCNK>>$K*K-]P!1G.X\#'6H_^$\TN.34(KBWO;>>QM/MLL3Q!F,/=E*D@@=^
M>/SKB]9\(ZUK-WXW>"Q=/MD]G<60G("7/D@AD//0]LXSQTK0CL;W4/#>L+:>
M"+;1)IM*GMG5(8UEGF==H5"N,(#SENO''>@#?M/B)H]YI\E]';ZBL \H1-):
ME1.TGW4C)X8YX/8>N.:Y_P :>*X=6\#>(88/MNFZMIJQ220B;:Z!F&T[XV*L
MI!/&3[CBG:KX:U;4/A=X>M(-/634M)-M*]A<[=LQC7:R-DX(.2>O.*BU#0-3
MUKPAK=OI_A&RT-KBU2-+91$LL\@=6)+)@!0 0,GD\\4 =+9^/;&\UB33?[.U
M.&9H6FM#/;&/[8JC)\L-CGV.*M:=XQL-4\._VU:V]XUN9Q;K&8P)&<N(\!<_
MWCW(JA-I]UXD\5Z%JDVG7-C;:4LLI^T% [R. H4!2>  23],>U+3/#S0?$G4
M_)N,Z4ICU%K8=$NG5T_(@%_KMH [2_O[?3-/N+^\?RK>WC,LK8)VJ!D\#K6%
MH_C2UU34DL)K*ZL)IK87EL+@H1/#_?!5CCMPV#S6EXC_ +3_ .$=O_[%1'U+
MR6%NKXP6_'C\^*\[TSPYJ\WB[3KZ70KNV@ETN2SN[B>X227S6'S.WS$D9X&/
M3H* .PA\:6=S>V,)LKU+'4G,5G?%0(YFQD8 .X @$AB #C/2N>\):[)I5KKE
ML(KW4ISXCNK6TMA-OD$:A?XI&^ZHZDGO[U9\(R^,["UL?#U_H5O'%8;(O[3-
MPI1X4( VH.=Q08SD8/)]*YVPT#Q'I.K:AXGT_2[U;]M:GD:R=DVW5G*0?[V
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M!TYQWJ;66\7ZSHVL1V>GMIDGD(EG')<1EYF+9D)9"=GRC:.?XB>., $P\<F
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M@C&3Q6-+X9\:6G@.?P;:Z-;7$-O<![:_-XBB6,3B0#9U#=<Y(& <9.,^PT4
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M(  W9' Z;1SV';P>=]GB^T;/.VCS/+SMW8YQGG&:DHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG;;B0M&<$%@P!'/.<5V7AB_A\3W<GB6#SA:M;QV]LK,P4]6D;;G!.Y@F<?\
M+,^M %GQ3XE/AI-.D-D;A+V]CL\B79L+G@]#GH:Z"N ^+,9FT;0HED>(OKEJ
MHD3&Y<[N1GN*Q]2O+WPM+XX@TR\NS%:V-K/ )YGF,+/N5V4L2>@S]10!ZO17
MEATQK.PN=3B\0VHAO=.G$=OI[38N66,N)-YE8AEV]>^<'K63#"V@_"[3-;BO
M[M9M4^QP7]S-.SK##O.Y@ 00,':0I'!['F@#V&^EG@T^YFM8/M%Q'$S10[MO
MF. 2%SVR>,TEA-<3Z?;37=O]FN9(E:6#?N\MR 2N1UP>,UYY=:(-'T_Q#Y.O
M(\5QI$MU'8V221)$R+\LJOYC%<GMD;O?!JHEL-2NOAK'=7MZOV[3)!/Y=PZ^
M=MMT;!P>,Y;)')Z9H ]7HKB/AGNAL/$%B))&M['7+JVMUD<L8XUVD+D\XY/Y
MT[Q!<+=_$30]#OM[:=-:S3K"?]7/,N,!_4*N3CIDCB@#M:*\;\2PSVGA_P :
M:=#=SFPT^[LWL2LK V[2,OF1@YY4!A@'@;J]1T30K30;>>"S:X9)YC._GS-(
M=Q !P6YQQGZDT 22ZM;_ &Z?3;:2*;4HK<S_ &8OCCHNXX.W)]O?%4_".O2>
M)O"]GJ\MLML\_F Q*^X+M=DZX&?NUSD-AIJ?&:^D>VMA(VE0S!F49,OFL-P_
MVL #/M7$V-G'IO@7P?K=N\XOVUQ8BYF?:(S-*"@7. IQR,<Y- 'NE%>,RP?\
M)1J/BR/4/$=GIES97S@--;L9K>!#^[:-_-4*N!DX'4G/45Z_9G-C;GS3-F-?
MWA&"_'7';- $VY=^S<-V,XSSBD+HK*I90S?=!/)^E>5>'O[#UW14U;5]1-OX
M@L]2>2ZE20+<!EE8)#@Y.PJ% 0=<<<YJ:QMK/7](\7WVK*J:U97=RBSNY\RR
M5%S%Y;<;0 ,Y7&[G.: /4:IW^IVFFBW^U3+&;B=((E)Y=V(  '?KGZ FO*M,
MADU[QCX5.LK*TE]H)FNH_-=1*PP 6 (Z@ D=*@BM;$^$M$-^D<R6?B<VB2W.
M'*0B9AM+'MP,T >S-(B;0[JI8X&3C)]*=7D6I6=KKGB_7M'N=5TJP2VBA%BE
MS:[S'#Y0)>!O,4(0=Q) ].U6?$=C<VEEH.L>&KJ:^UJVMR[NT/S7EL$PSNIQ
MD],=R3Q0!Z)J>M6&D+ ;RX2,SSI;QJ6&6=B  ![9R?0<U?!! (.0>AKR75K'
MPS?>$_!EQ8P6]U:2:Q;1O-/&I=@V?,63CJ2!N'3@=@*]7@BAAMHHK=$2!$"Q
MK& %50.  .V* %,T?FB+S$\SKLW#/Y5B:)K-YJ&O:]I]U#!&FG31QQF(DE@Z
M!\DGV8#&/7K7"^&[KPSJFCV-UJ-SY/B6UU$RW"Q.!=O<;R#'CEF0@XP.,#MB
MD\3WEY96_P 19;'<)!<V8E9.2D1AB#G'^[G]3VH ]6CFBF!,4B.!UVL#BB.:
M*7=Y<B/MX.U@<5Y2P\-6%CK&L66O1R6\^CLDEIH\2P@*"H60@$[9/G"C=C@G
MC@U2LH;.'5;V&'^SXHIO"K/Y%HW((*E#(P(WR8YW8']: /1_%VO3:!X5O]6L
M8X+B6U02;)'(!!..W^>*TM/U".[LK61Y(UFFA20QAN02H/ ZUY,FB6%I\![G
M58H6%]=:6BS3-*S%@'R!@G Q["MCQ!:1Z%:^'/'-O:K)+80Q0WP5!E[=T"EO
M7<I(Q['TH ],62-V94=6*G# './K4<UW;6Y(FN(HR%+?.X'R^O/;D5E>&+%[
M;2VNKBW6"]OY6NKA0H!#,<A3CNJ[1^%<CKF@Z5K7Q@AL]0M4E@GT1WE3)7S&
M$H W8()P/Y#TH ]"DO;6*>.WDN84FE_U<;2 ,_T'4TES>VMD$-U=0P!SM4RR
M!=Q]!GK7C;VFBWNJ>*=/\4:Y_9<UO>9@0I$'%JH7R?*=U+\8Z*>_3DYT3?Z1
M+K_B^W\4S6R3I;1K8C45!80^4>4!SR6.2%Y)[4 >J1WMK,ZI%<PNS+N55D!)
M'(S].#^1JAJ6I/+H5[<:)>:?)=1*0CS2@PHP_OD=.*\P\/&TL[;X7:C<RQPA
M4NH#(^ #OC8*"?KP/]ZJ\3Z9?^'/B>T!MIX//>:';@K]PX=?QZ$4 >OIJ5O#
M;0F^N[2&8Q!Y )@%Z#)&?X>>OTJ634+*&>."6\MTEE&8XVE4,_T&>:\MN-#T
MG5OB1X>MKVR@FBN= W3*1CS"  "<=< <>F!Z5FN-$O=0\5Z7XEUV339EU B.
M+RXO,>!<&'RV9"_  P%/X<\@'L=SJ5A9S)#=7MM!*XRJ2RJK-VX!/-6J\G\3
M*VE7^J:U ]IJMM';P1:CIM^1'<1[4!5XW]<'.!_$6QDUZM&XDC5P" P! (P?
MRH =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !115:YU"TM+FUMYYU2:[<
MQP(>KL%+''T"DY_Q% %FBL#0O$IUG7-;TM[(V[Z5)'&S^9N$F]20>G'3]:WZ
M "BBB@ J*=))8'2*4PR$860*&VGUP>M2UEZ3=ZK<W.HIJ.FK:10W!2T<3!_/
MB[.0/N_0T 4?#WA1/#WA:30H-0N'C;S=D^ LD>_))!'<$D@UJZ1I[:5I-M8O
M>7%XT*;3<7+[I)/<FKM% !1110 45SMMXBO+C7=?TW^SD5M,BADA)G_U^\.>
M>/E^Y[U;\+ZQ+K_AJQU::!('NX_-$:,6"J2=HR0.<8S[YH NZA/-!8W#V\4D
MDRQDHL8!8GMC/'YUYQ8:5K>G6MS;6L/B:**[F>XN/+:S#M*YRQ5L94>U>H$9
MI-B^@_*@#SB;1X9?"<_AT>"M36SF^9W%Q#YK29SYA<L27SW.?3IQ4>EZ?JVF
MV%S;MI7B*[GGB\C[5=7EO))%%_<3.0!Z\'/X#'I809ZFJ&JS:E!':G3+**Z9
M[E$G$DFSRXCG<X]2..* /.WT"]?PE:^&QHWB%+*VE62-UNK42?*=P&<= >>F
M?>K@L-5_MK4M6_LC7OM&H6PMI5-Q:E54# VC'!'/KU-=S;:SI]YJ]YI=O.LE
MW9HCSJO(3?G )]?E/'N*N%@P<1E&=>V>_OZ4 >4R^%)9='TO3SH7B%)-+)^R
M7L=];I/&">5##C'X58N_#T]WIUG;_P#".Z[%=VDQGCU&._A%T7888LY)SD #
MIT4#M6_I_B;6]<\)76HZ3I5J^I1WDENEM).0A5'VD[B!GC/I_2NQQ0!YYX=L
MM3\.W5]<6^A:S<2WK*\S7M_$^6  SU'/'^1Q6W<:OK]Q;R1+X<N8BZE1(ES#
MN7W&21^8-=.[I&,NX4$XR3BAV"(69@ .Y.!0!P'A:RU?PGI TNST34;BT5BT
M:W5W QCR22 5"\$DGG-9VG>%9],UB2^MM!U987F,_P#9YU2/[*),YW>6.N"
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M.IVL(;$C H'.["$!@2WRDD#H,>M %2+X>>'8]*U'3#;2RVNH2^=.LL[O\_\
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MSHFV"+KYDK<(N/=B/PS0 S2/#&FZ)=7UQ9K/YM\X>X,L[2;VYYPQ//-4],\
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M 3/HNFRZFNI/9Q&^5#&MQCYPI&, ^E5?^$2\/_V<^G_V/9FSDD\UH#$"A?\
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MZ):Z@EE/?;)'F^SJYB?RO-QG9YN-F[VSFD/B_0UU(6!OOWQN/LF[RG\KSO\
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M"LZ_1B,BKM>:?$/Q</[+@31KV_BD34HH'N+:-EA<[OF3S,8..G!Z@CU%>ET
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M)]:GGU+5?$.N^'='%_:+#/H,=X#=M)LN)F(#8\MT+,!DCDXY.*]!7PEHB#4
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M\01VFMV^I-++%%;#[8TY?!3EMS*00, 8P,=C6]I'A#0-2U?Q5/<6@D:RU-C
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MBBB@ HHHH **** "BBB@ HHHH **** $P,YQS1@9SCFEHH *3:O]T<>U+10
M@4#H!1M7&,#%+10 FU?0?E0% Z "EHH 3 HVCC@<4M% "  '( %  '0 4M%
M"8&<XYH  Z "EHH **** #&:*** "BBB@ Q1BBB@ Q1BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1110 4444 %(5!ZC.*6B@ Z4444 %%%% !1110 4444 %%%% !1110 4444
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MO+:\0O:W$4Z@X+1.& /X5F^*M2N]&\,ZAJ=EY!ELX6GV3(65PH)(X(P??]*
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MN1>W1#*I5@ D9R!DYRV.V/<5R]LB0^"?AW;K!*DUOJL4L\?DL&C5=WF,1C(
M++D].17LM)0 H.17A_B6\NKJVUTII]];W=OJR3#3[>T;RG170^?(X7YRV.!G
MTP.]>X"B@#RV-XI];^(EXME<QB\TZ 0M+;NK2GR65@H(SG)0$>O:L_0I;[0+
MCPAK-Y8W\VFIHS6,JQ6[NUM-OR2R 9YPJ].U>PTM '%_#H2B+Q$TEC=6BSZU
M<7$2SP-'N1MN",CV-6O'-G8WUE817DM];.+L/;7EFC,UM*%8JY"@\=1SQSVK
MJJ0$-G!!P<'% 'D5Y_;DVD^'M2U2UDN!I^O^9+=6]HRO/ !@3M$HW#/3IV'J
M*I:A;7VJ:3\2#;Z7J :^DMY;9'M74RJI7)''7'..OMUKVNB@#SV"*/7_ !AX
M5O\ 38',.D6TWVJX:-HPN^/8L7S 9;.21_#CWKC["WO1X-AU*ST^?4$T_P 2
M7$UQ;6[,)&C(925V\Y&[M_+->P:SIUWJ-K%'9:I<:;-'*)!+"JMN !^5@P((
MY_04:%I%IH6EIIUFS.L;,SLY!9W8[F9L=R230!YKJ43WMA'XC\.^&-0B^R:A
M;74ZW6X7%ZL>\,H5B3A01@]^PXK5UV^D\5^!_$4VF^';ZV:>T"E[BV$<]RX/
M "C)8*,\GUP.]>CT4 9GA_4#J>B6MRUK<6Q:-04GC*-G R0#SC.>H&<>E<MX
MI2YM/B1X8U86%W<VD4-S"[6T)D(=E^4''3/J<#WKO*89HA*(C(@D(R$W#)'T
MH \OLHKO2_!6O>%=1TV\N=3FENEMPEN[I=B4DK)O VJ,MSD@KBO0]"T]])\/
M:;ITD@E>TM8H&<#&XJH4G]*T** .,NIKC3OB=)=MIM_/:SZ3%")[>W9T5EED
M9@2.A"G..IZ $D \'%IVII\-M,M&TC4_M46OBY>'[#+O6,.6+8V],$?Y!KV^
MB@#R,Z7)HWB+6K34_!,WB!=2O7O+2\CA5U ?&(Y"V @!'?\ 6O5;*(P6%O"T
M<4;1QJI2(81< #"^WI4]% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ\CBT^:YCU"_?S@J,R!BX0@]@5/&.#DUD"#3CI/PP0Q6NQ9 9QM7 .P;MW_
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MUC3[J.XM3(V%Z@.&YZ;2<COB@!UGXZT^]TK4KY;*^C.G77V.:W=8_-,NX*%
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M-",5+C'0$@]?2@#1Q2<#O7.Z]XOMM%U)--2%;B]:W-R4:XCA"Q@X'S.1DDY
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M>QX:,YY9L84]!@;N3Z<T =Q1BN-B\?1WFB^'[FSL2U[KK%+:VEEVJFT'>6<
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MVT\-Q7,%G+</'<3M</YS _O&^\1@#K^7%;5>>1>)-8A\>:_%>BW73M,M(IB
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M9$J^ZYY]O;- 'JMKJ^G7UY/:6UY#+<P?ZV)&RT?^\.U7(XTBC5(T5$48"J,
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MIJ$T<UXJ 321KM5F[D#L* +5%%% !1110 4444 %%%% !1110 4444 %%%%
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M5LWP%PXD5APX?JV>"2>>:BU'POK6LVNF7U_=V(UO3;XW4'E(WD;>GE9/S8(
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M06%SYA48SC(P"0,<^M4=8N+37+.]DFOYAJ7VD/IUPEC< V:#&!P.3USZYYH
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MCD66"Y339BT4B]&'R4 =?JGA_3M3TPZ?-"AMP5(0#&TK@C'ITK#DUC6=7O\
M5UT.6TB33'\C]_$9&GE"AR."-J_-C//-8L?B6YN8H[._U*[-N,!I;71KA)9E
M'8DY ]\"H?[6AL]8U&\T::_MDU0A[B&;2+A]DF-N]"%'. .#D<4 6(O'&JZO
M=>&?[&MK1(M8BF#"X#%H'CR&S@CC(JE+XS\60^&];U1DTTOH-X\%U@/BY"[2
M=@S\I^;K3;;^S-.U3P]+8/J26FCI*AC?29V>8R9W$MCCDYZ55ECAF\/>)M+:
M[U+;KETUP91H4^(-VT, ,\_=% '57OB+7[GQ?#H6F?88X[K2S>QS7",VPA@O
MS $9Z^M8B>-_$O\ PCUGK\J::+9+W[#=0A6+RGS#&74] .^,'ZT^WOX8/%MM
MK[/J<C0:;]@$(T2<!_F#;\YXZ=*R_LT!\)'03<ZH?]/^W?:!H<P /F;]N,^I
MQF@#I];\4:U+K>J:=H,+F33(XP0ML)1+(R[@A)8;1CO[U''XA\57_B*STF&"
MPL9;C2_M;K.C,T#@A2IP>>36'J3>;XCEUK2-0US3;BZC5+Q?[%DD67:,!@"/
ME;'UJW:7L5GXFM=85]8D,-B;,12Z-,S-DAMS-GU'3% %_2O&FI:KIVAVG[B'
M5=1FGB:8+E%$).]U4]=P& /6K=_KWB'1-,$%_!!/?3WPMK26!2?,0C.]DXYP
M#QG'2N173[=="M[5+K68=1L;N2ZM+^/1I?W;.264KSD')%7+SR-3T,VE_>^(
M9=4$ZSQZ@FER)Y3+P-J@8 Z_G0!:O?%?C#1]"UBYNK),6;(UM=7-OY0G4G!4
MQAC@CUJ^VJ^+1XK71/M6F!KJR-W#((6_T<*0",9^;.ZL"X6?4M O++5-5UF\
MO+D*INO[#D5%13G"H.^<<FM:35$_X2ZUUPQZL7ALVM!$-'EPP)!W$Y]5H +;
MQQJDGA+2V>.-]7O+^6Q$D48*Y1RI<*2.H'3-0ZAXG\8Z3X>U>ZNX%7[-)";2
MXN;=4,JNV&5D5C@CUK-33;*3PT=-*Z\9X[Q[VUNX=)>-[:1F+'&<YY-.N8;C
M4- N-/O[GQ%=3SE ]TVE$*JJVX*$!'4]2>: .@CU;Q%%XJNM#O-1MB)]+:\@
MDAMP#;L"!CG[WKS5SX5?;)?!-G<WEZ;GSE+*&0*4.]LY(ZYX/M6*]TTOBR+7
M'L=;9H[$V3PC3B 5)SNSN]:L>#]1?PMIIT^2S\07ENI_<%]/V^6N2<<<GKU-
M %OQ?_R4_P #<=6O"<9[1K5+XD0I8:SX:UBP(CU5;]8%VKS*C<,I^@Y_&H]>
MNYM9\1:7K$$&L6DNFB00K_9#2!MX ).2/2DMY8I=?AUG6;77]2O+4'[*ITTQ
MQPDYRP4=^>I)H ;J_C+6],U(.+JWFA.J):-:00AT2%F" O+V?)Z5'%JNIZ#J
MOCC4Y]2:[&GE-L3PJH?*94#G@ FL:719'M[BTCD\2I:O?B_@C_LT'RI=V[DG
MEN>G85JR0[]4U>XFTGQ'-8ZK$J75F;-0&8+MW9)R/7B@#>T6X\72ZW$E^C2Z
M5<Q,)7D2-?+<C@IC.Y>>AKHK?PU9PQ6$2O(8;.5Y@A"_O)6;=N8XX^8DX7 R
M>G %<+X/@O-/U&SM[L>)KVVBREJMW;*L< [$D')P..:]2WK'&\C'Y5R20,]*
M ./TJY-A\5=;T=% @O;&+4@%X"N&\MS]6^7_ +YK3\6:A=6%O8_9[X6B2W(2
M9TC\R=EVL=L2;6W,2 .AXR?>JWAO3II_$.L>)KF-HOM_EPVL3J598(P<,P/(
M+$DX(! QGFK/B3PNVNWFF7UMJEQIU[I\C-%-"H?Y67:PVM\O([D&@#AK?QEX
MENO"]O=6]Z@NH_$*Z6S7-JJ-,A*XWJ,A#R0=H_(U?/C+5O#5YXLMM9NX]2&E
MVL5S;R+ (?FDX"$ GC<5&>O6KQ^&AB@D@M->N8XFU1=45)84DVRKSUX)R<$Y
M/8<#G-Z?P'%>ZWK=]?7[S0:O:"UFMQ$%V!0 I#9SD8)_&@#%N;;58O'_ (%N
M-1U5KSSDNF:,Q(BQR?9R3LVJ#MYQAB3QUKK_ !=KA\-^%-0U=(Q(]O'E%/0L
M2%7/MDC/M6'8> ;JVU'1KRZ\3W]W_9#.+9'BC4!&0)M) YXX)//ICK74ZMI5
MIK>DW.F7T?F6MPFR10<''J#Z@\T <K8#QA)J\,<EQ<C3)[5EDN)UM0\,W)5X
MQ'N#*>F&S]:S_"VOZ]J6N/X;U+4534M*N'DO+A$CVWD'\ 1=O')&XC&,8Y)^
M78T7P/+I,3))XAU&\,2,EBT^UOL8(*[ER#E@#C)[<8I)/ $!30VM]4N;:YT@
M,(KF*./S)-W7>2O.<G/J22>30!S(U7QIJ">+9K+7XHET2YE6&(V,;&8(N[:3
MV''7KD]:U+3Q1JVH>*?"<2W*PV6L:4]U+ L2G;)LSD,<G&3T]N]9GA[P_?ZM
MKOC&"34;JRTV[U%Q+;BV ^TQ$8)5V&0",C(KLIO"$#^(M-UB"\EMSIUNUM;6
MZ(OEJA7!ZC/IW[4 <YX7O?%VJZ9=ZO>:] ;6$W4*0)9J&9D9@KEO;'3T SDU
M1L/$GB;4=#\$W,>K)'/JTLD-T6MD8-C>=P&!@@+T'&<>^>RT?PI_8WAZ[TB'
M5+F1;AY'$TB)N0N<M@  'DD\CO6?9_#Z*QM] @AU>\\O19'DMP4C^<L3G=QS
MP2.,=: ,*/Q1XBL]%\:1/>B\O-'N42"Z-NH*QMC+%% !VKEOP]*U-#U#4[KQ
MM]DL=<;5-!6Q2YEG*QMME8X$>]0.H&['49]*J^(?"D^E:3K<]J^I:C)K5U"U
MV+=$WP*&!,B* "V ,;>^>>]/\*IJ0URU:QU/7;S33O\ M8U.S6! -IV[,JK%
MMV.F1@'/:@#H/&6MSZ'HT4ML42>YNX;1)9/NQ>8P!<_09-9=]>:MHOB2+21J
M,\]IJ-C-)#/,L;2031 $D84 J01P0>?;BNEUS0[+Q#I4FG7Z,T+D,"C;61@<
MAE/8@UG)X5R\ES<ZK=W.HFV:UBO)$C#1(V,[5"A<DC))!H X?3-?\306?@K5
MKS6FN5UBY6VGM1 BIM;.&SC.X8SUQVXKUAA\A^E<</A["NF:%8C6+WR]%N!/
M;MLCR2/NAOEY Y_.NLO();FSEA@N7MI'&%F159D]P&!'YB@#@_@JBK\-+3YU
M??-*2!GY?FZ'W_QKD=!UN\TB'6+3176*RO\ Q*UK9,755488N%<@J,A4 X.,
M^M=YH?P[70M+.E0>(=6.G'<?LZF./DGGYU3?S[&M.^\#>'[[PPGAYK%8M/C(
M:)8B5:-A_$&Z[N3R<YR<T <I<:GXK\.6\T6I744=O>WMK:V;2W"SS6RR-MD8
MMM7=C&06'USBM#7KC5O!FCZY>)K7VJ$PQM8PW;AI86+JCN6(Y4%U/((''XZ<
M?@#2&T*YTO4)+O43=(B375W.7F8(24PW\."20!ZFIK7P1I,&F7=A</>7\=W%
MY$KWMRTK^7V52?N@=>,<@>E '.AO%>EF_N[R],&E'3Y9MS7B7,ZRH"^^/,8&
M".-N,>F*S(=2\4)I_@N]/B.1Y=:*PSH]M&8T#1Y# 8!W#!Y)P2>@ Q76V7P^
MTFRL9[476HSK+:M9HUQ<^88(6&&2/(PH( [=A4R^"+!+;1;<7E\8]'</: NG
M!' S\O( XH Y'6KC45\)?$#2K[49;]-/"+!+,JA]KQ*^#M !QN]*E-[KWA:[
M\,SR:R^H6.H1&.:TDA10FV+>#'MY'W<<D_K76MX,T^4ZU]IN+RX36% NTDD
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M).6,T8[GIQTZ5Z77*>-]&O\ Q!IZZ=!8075JV&D$NH26X)# @$(AW#C/48-
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MO+&FUHH)"Z+CH Q )XQUH O4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 U>13J:GW:=0 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MPC1H[>:2)(ED QOP?FXZ@&O8MI[DFC:* /*YM+U&Z.M!O#6M[-9*_:B;R$'
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 444&@ HHHH **** "B@44 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%(SJBEG8*HZDG I: "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** &1_=I]-3[M.H **** "BBB@ HHHH **** "BBB@
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M<)=0F/=_=/9OP.#^% '->&?#L6L>%[/5-7O+VYU+4K>.X>X6Z>,Q;P&"Q[2
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M.#UY&,@'>T5QFL>-[C2KB'3WL;)=4: W$D4M]MC1-Q50'V9+'!XV@#'6JO\
MPLF26+0)+;0+EQJ[R1*CRJC)(NX;<'J,A?FZ8.>2,4 =[41NK=;E;8SQBX92
MRQ%QN*CJ0.N*Y&S\>,=&U*?4M+>VU*QO!8FRCE\SS96V^6%; &&+#GMUK 6Y
MNK?XR0WFL6-I8.NBRR2/;S>:KJ'^\254Y &.G:@#U+-13W,%J@>XFCA0D*&D
M<*"3T'/>N'L?B3#<ZGIL,EI$+34>(Y8IR[P<97S5V@+GV)P?SKG?'>M7'B+P
MYHVIPZ9 -+DU:(6]R\N9MH; ;;MX#$'OG &>O !Z_5:34+.&0QRW<"..JM(
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M89W#.<\=.@XJKX6\4ZI8)X3TK4=-2*RU*T$=M,T^Z8LD8.74*  1TYZ8SZ4
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M^]ZDG SP.V<5D:UX9\07FA>.;*'1K@RZKJ$4]H3)$ Z!U))^?CA>_J*]AHH
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MA\O)SGN!CWI\OA[6V\0^)[Y$T\V^J626T -PX9616 +#R\ '<>A.,#K7:44
M<!HL?B+PM;>%O#['2GC :&Y2-Y9)74<[T^50 ,\[O8<UW]%% ')>-] U?7WT
M1=-6Q\NPU&*_D-S.Z%C'G" *C=<GGMZ&G^-/#5]K]II]UIEU%:ZOILXN;9I
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M%%% !1110 4444 %%%% #(_NT^F1_=I] !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 >=>([C6/^%L:%;0+9/$UK.UNLS/@?*-[, .O! ]C5BSU
M^2S\/7FI>&M&L#H%A)-^Z20I),$/SN@"X'.[ /7';-7]6T#5[KQ_I6O6RV)M
M+"&2$I).ZN^\8)X0@8],\^U5;/PAJVDZ/JGA_3[FT;2KUI##-,6\VV60'>NP
M+A\$Y!W+UYH KW4UIJ_Q%\%:M:Y$=Q875PC8 +*T:8#?0-T[&JNF:S;^%O\
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MU,@ ? W!3D ]\4ZD7(4;CDXY-+0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 ,C^[3Z9'TI] !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 ,C^[3Z9'TI] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 ,CZ4^F1]*?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M #(^E/ID?2GT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M'&<@_7%25'&, _[U24 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45
MC:[KZZ1<:=9Q0+/>ZA,8K>)Y?+4[5+,2V#C@=,$DD5%%XKT^*UC?5G32[AY)
M(O(N)!DLAPVT_P 0[@^A' H WJ*QY/%.AQ6<%V=3@:"<LL31G?YA4X; &2<'
MKZ43^*=$M[>WG?486BN$,D31Y?<@X+?*#\H]>E &Q16?;:YIE[<26]M>12RI
M$LY5#G,;#(8?W@?49K.;QQX<3R=VI*/.C,J9B?E Q4M]W@9&,T =#14<$\5S
M D\$B2Q2*&1T;*L#W!K$T;Q79ZUKVLZ5 I633)%1F)_UF<AB![,K+^% &_15
M.TU2QOK:6XM;N&6&)F21U<81EZAO0COFLY_&7AY%1O[4A?>GF*(@TA*?WL*#
M\OOTH W:*S(O$.DSP7DT5]&Z62[KC;DF,8W9(ZXQR#WJJWC+P^EPT#ZE'&ZA
M2WF*RJNX;ERQ&!D'UH W:*J0:G9W5_=6,-PKW5J$,T0SE PRI^A /2L^3Q?H
M46[=?@A;AK4E(G?]ZO+)P#DB@#;HK*L?$FD:C=):VMXKSR([K&4920AVMU Y
M!(R.M5'\;>'XWV/?D-YABQY$A^<$@K]WKE6&/8T =!16//JUW=6-I>:#;6U]
M!/EC+-.855,$@_=8G)XQBLOPYXMO=6T6#7-1T^UL=*EMGG\];LR-&58#:RE%
MZC<<C/3'<4 =915#3M9L=5,JVDCEXL;XY87B=0>AVN <'L<8X-8\?B'4=7N=
M2&@VMG/!ITYMG>XE9#-,H!=%PIV@9QN.>>V.: .GHKF+#QYHM]86-S_IB/=Q
M/(D*V<LK#8VUP=BD94\'\/6IT\:Z%+,\4=S<,4:-686<VU3( 4RVS W9&.>]
M '045C1>*=(FLK6[BGEDCNV=8$2VE,C["0V(PN[ P<G'\Z@C\::'/+#%#-=2
MRS(\B)'83LQ"/L?("<8;@@\CCU% '045S'B;Q+<:9H-CJFEQP3I=S0QJ+@.F
M1*0%..HZY((S6UJ&IV^D:<U[?NR1)M#M'$SX)( X4$]30!=HK/@UJRGBN9-T
M\*6R>9*;FWDAVKSS\ZC(^4]/2H3XCTXZ78:A%(\T.H;?LJQ(2\I*EL >NT$G
M.,8- &M16*_BO24FMH=]T\MS ;B)([*9R4! )PJ'&"0"#R,CUK3L[N&_LX;N
MV8O#,H=&*E20?8X(_&@">BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** &1]*?4<?0_6I* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0ZYX4DC)&2.3C-=LL\+[=LJ-OSMPP.['7%9GB#78]"T:[U 1?:C:@-)"D@#
M9 SS]: ,7Q9IVK:KX7T^"VTUI+N.\@G>%9T^1(W#8+,0"<#''?VYI_B*+6O$
M.D7NGQ:1);0O&@'GSQAW;S%/!1VV@*K<]22,=#75+*C.8]Z^8!ED#9(K)TW7
MCJ'B/5]'^R^6=-\K?+YF0_F*67 QZ Y_K0!CKI6J7>FRZ8;&ZM;.YN$,\EU?
M"YEV9^?&XL-I"J,?[3''K1'AO48])N=%O=--_IL>H--:20W"1W$41RP9#\H5
MU<\<CY217<RWUI!.D$MU!'-)C9&\@#-GI@=3T-8OACQ7;>(K:3<(+:\CGEA:
MU%P'?Y&*EN@.#C/2@#FGT'7WO]'DU.'4;TVUA<037-C>)#(6>52@)WIDA$&[
MMDCK7=Z7]I_LNV%W#Y,X0!H_,W[?0%NYQC/O56_UN"UTZYO+;9>K:DFX2"0%
MT4?>P!U8#G;Q6E%*DT*2Q.'C=0RLIR"#T(H ?1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% $<?0_P"]4E1QG(/^\:DH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &'XJ
ML-4U/25M-,^RMOE7[0ES(R+)$,DIE5)Y. >.1D5YM]EU!O!*6>KVL=I#+X@?
M_38=Y>R_>NQE&0-OS#:K=,-D^E>RT4 >9:1?VB?#]-(U2ZNM/\^2>&WN["!]
M]XB-_K1A6PTG7GEN2.M8OBC3;ZY@T%;Z.2RN[7179+F&V=O/ERBBV>-!@*R]
M5QW(Z9S[/10!Y_XCN9Y6\"&YLY(;HW\,T\,4+,L/[HAAD#  9@*J>+="\1R>
M(]-OH5M)XI-:MG1TAEDD@C17"[\' 098G&.6ZUZ710!R+M)_PMB)_LMV8/[(
M:#[0+=_*#F0/MWXVYV@]_;K5;Q-#/?P:7XHTG2;A]4TN[(2":+RY98F)CD7G
MH"&W ^@SWKMZ* //?%6F)HWA#0K"-=SQ:I:RRF-"=Q\S?(^!VR2?QKT*BB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"./H?]ZI*BBZ'
M_>-2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!'&, _[Q
MJ2HX^A_WJDH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@".
M/H?]ZI*CCZ'_ 'JDH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@".(8!_WC4E11'.?]XU+0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% $47?_ 'C4M11=_P#>-2T %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!'&I#/D=3Q4E%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
, !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>ibcbankplazasecondamendm002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibcbankplazasecondamendm002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZFFH64EV]HEW URG+0K("Z_5<YJ*VUG2[V58K74K.>1AE4BG5B1] :\]TIM
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI7C!9@!@9/TJQ;:%I5D&%MIUM&&A$#;8QS&"3L/MECQ[UH44 51IMAY]O/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY]KK_P #I_\ XN@#JZ*Y7_A7WAT=+:Z_\#I__BZ7_A7_ (=_Y\[D_P#;]/\
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M00Q8E60R<\L><]AQ7>QZC:Q1(DE_!(ZJ SM(H+'UP.E %^BJ?]JV/_/W;?\
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M)9AO!5B-Q7/ '4GIVK8M_%NN#1?$[0PMJ%UI<T2VY:S:*1XW56+-%D$E58G
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M *\XO_010!5'P\\)@8&B6_YM_C4G_"!>%?\ H!VG_?)KHJ* .=_X0+PK_P!
M.T_[YH_X0/PK_P! .T_[YKHJ* .:;X?^%&.3HEM^&1_6F_\ "N_"1_Y@EO\
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M%O\ H7-)_P# ./\ PK=HH PO^$*\+#IX<TD?2SC_ ,*/^$+\+_\ 0O:7_P"
MB?X5NT4 8?\ PA?A?_H7M+_\!$_PIO\ PA/A;_H7=+_\!4_PK>HH PO^$*\*
M_P#0MZ2/I9Q_X5SEAX4\/2^.]8M7T+33!%;0,D9MDPI);)Z5Z!7+:9_R477/
M^O2W_FU %K_A"/"O_0NZ9_X"I_A1_P (/X5_Z%W2_P#P%3_"M^B@#!_X0CPO
M_P!"_IO_ ("I_A2?\(1X6'3P]IO_ (#)_A6_10!@_P#"$^%_^@!IO_@*G^%
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M;TG_ , H_P#"C_A"_"XZ>'=*'TM$_P *W:* ,/\ X0OPO_T+VE_^ B?X4?\
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M<G YK)73]6\"Z_I(MM6NM1T74KPVT]M=X:2*23<XD1@!QG<3_G&7IVR3PO\
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M+@@9Y!R< <X]<55T'Q'K%KXJT[P[XTTY/[3*R&QU.V/[J?Y?FR.,' _EP.M
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M&?\ H/Z;_P"!*?XU?_LC3_\ GQM?^_*T?V1I_P#SXVO_ 'Z6@"A_PF?AD?\
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M4)5N?O*0>GI6E8^,?"6GV,%E8WT4=O @CCC1&.U1T[4 7?\ A);W_H4]=_\
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MC>E]_P" <G_Q- '5T5RG_"P-&]+[_P  Y/\ XFC_ (3_ $;TOO\ P#D_^)H
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MO=32UU3[3>QI%,WV*7!5,[<#''WC0!O^(?#FG^*-/6SU S^6C^8C03-&5<9
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MV$O_ ,33O^$[TWO9ZJ/^W"3_  H ZBBN9_X3C3?^??4O_ "3_"C_ (3C3?\
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M_E3)C'#"\K1E@BEB$3<QQZ <D^PKS/5;ZZT_Q,S:W+J,%G<:G&;#5+.[=H
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MQ(]_;_8;FQO;"18[BUNE =-PRIX)&",X^E;%_?VVF64EW>2B*",?,Q!/7@
M<DDX  Y).*X^--2TBSU_Q&EDTVM:H$>#3T +I$F$0$=V&_<W/?&: -I/%&GR
M^,&\-1(\ETELT\DB@;$P0-A/][Y@?QK=VK_='Y5X[H&H&#XM:9&-$UB!CHYA
MD-W"BRNS3%FG?#8VDDY/J>E>R4 -V+_='Y4NU?[H_*EHH 3:O]T?E1@>@I:*
M $P/048'H*6B@!I1<?='Y5S&F*/^%A:X,#'V6W./Q:NI/2N7TW_DHFN?]>EO
M_-J .GVK_='Y4;5_NC\J6B@!-B_W1^5&U?[H_*EHH 3:O]T?E1M7^Z/RI:*
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M4SR,CMFN(TF'5],^)]U;W]['J$5_I_G)*(!&\ C<*$XS\IW$^YH O1>,Y/\
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MSH YO_A.](_YY:C_ . ,O^%)_P )YH__ #RU'_P!E_PKI=@]_P Z/+7T'Y4
M<S_PGVB_W-1_\ )?_B:S-=\0^'/$.G-87C:RENQ!=8+69"V.Q(7IFNY\L?Y
MK$\4ZQ-X<T.;5DMEN8;8;IHS)L;;T^7Y2"<D<'% &+_PDWA@WEE>2VVHS7=E
M&T4%Q)8S%U# !N=O).!S]?6LZPN_"MEK%[JJ'79KB^79<B>WF=)E V@,I7!
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M-I>VJ>$M=2"^)-RGDMB4GJ3\_4]SWJ?4]4TW6K);/4?"^MS6H(/D&W(0XZ9
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MVI?]_P"'_P"*I1XDUTC_ )$[4O\ P(@_^+H ZJBN6_X2+7?^A1U+_O\ P?\
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M[>\5?]"9+_X,8O\ "C^WO%?_ $)DO_@RB_PH ZZBN1_M[Q7_ -"9+_X,HO\
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M_P!"6NFKF?'AV^#=2/I&/_0EH Z*/^'Z5)4<?\/N*DH **** "BBB@ HHHH
M**** . \0>*KX^,QX=L;^VT]XC;.#+%YCW/F/@A02!M48)[GV )KI8]5NK'P
M\;W68 MU&S(T5NI/F-O*)L&2<O\ +@9/WJY3QZOAS7IVTV_N%LM3L+FW9+KS
M%CECC=ERR,>PYSZ$ U%H$7B_7=(T356NK"9K7SMAO%=1/SMCFPO?9G&?[V:
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M#T% ',_V]XF_Z$]__!A%1_;WB;_H3W_\&$5=-@>@HP/04 <S_;WB7OX/D_\
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MZDH_]DKHL#_)I<4 <W_:WBD]/#%ICWU0#_VG49U3QCGCPSI^/^PI_P#:ZZC
M]*3 ]* .8_M3QC_T+>G_ /@S/_QN@:IXP[^'-/'_ '$C_P#&ZZBB@#C;T^(]
M0""[\*:5,(W61=^H$X93N4_ZOL0#4LEUXJEQYGA;2WQP-VH9Q_Y#KK:* .32
M]\5QQF-/"VF*C=574< _AY=,^T^*UC=(O"^F1;Q@E-0Q_P"TZZ^B@#BK(>*+
M'3_L2^&=.DB.XN'U$?.6.22!%CG-6I+_ ,6RKMD\,::Z^C:CD?\ HNNKHH Y
M&.Z\4PMNB\*:4C=,KJ&#_P"BZE&H^+PQ(\-:<">I_M(\_P#D.NIHH Y8:AXL
M5F8>&]-#-]XC43D_7]W0E_XKC0(GAO350=%&HD#_ -%UU-% ')QWGBJ$DP^%
M]+3/7;J&,_\ D.I/[4\8_P#0MZ?_ .#,_P#QNNHHH Y?^U/&/_0MZ?\ ^#,_
M_&Z/[4\9?]"SI_\ X-/_ +7744F!Z"@#F/[4\8_]"UIX_P"XF?\ XW3AJ7C
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M_P#0N:>?^XD?_C==-1B@#ESJGC'/'AO3_P#P9G_XW2_VGXQ_Z%S3Q[_VF?\
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M>+#0 />\F_\ C=)]I\;_ //AX?\ _ R;_P"-UU&*,4 <M]H\<_\ /AX>_P#
MN;_XW2_:/'(ZV/A[_P "YO\ XW7448H Y?[3XW_Y\?#_ /X&3?\ QNC[3XW_
M .?'P_\ ^!DW_P ;KJ,44 <O]I\;_P#/AX?_ / R;_XW2_:?&XZZ=H/_ (&3
M?_&ZZ?%&* .7^U>-STT[0?\ P,F_^-T&X\:C)-AH(8\#_3)O_C==1BC% &!X
M6TR^TG39(M0,!N)KF6=A Q9%WL6QD@$]?2M^BB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<VEQ"%:-UE'W96)&T@\$XYSQF@#7U3XA:1I=[%:?9M1NY9[47< L[8R^=&2
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M17T1BNX[6))D)!PX4 ]"1U% '$>-]!O--TNZ\36^M:C_ &Y%<(ULL<I\D[I
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MPH!.!C.2>E5?#7ACQ=H44&B2:MI\F@VTF8ID5Q=F,'<(S_",],Y)QG'MWM%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3+:V2?/FA$^_GL<]O;I56R\#>%].N8[BTT*RBFCD\Q'$>2K>HST]O3M7044
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MNT"7Q/X9N]&BO$M!<A5>5H?,PH(/ W+SP.<ULPK(L$:S.CRA0'9%V@GN0,G
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 44W:WF9W<>E.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF;YB .G7.>*IR^-O$UOI%A/-H,$=W-JRZ<RSF2%9@Q&V2,,N0K#/WNA'0]
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MU=1/+$_E_NR%ZC=Z\C@>M '-GPQXDT_7+;5](O-/662QCL[ZWN=[1G9]UTP
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MSZA:-'IFKM:&$6H'VJ,2!#DY.SKQCGKSTKLU\'R-JF@:E<:O-<76CI*J.\*
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M;Z"';MF"H54Y(W+@'L1F@#'_ .$IU*Y3P7:W-[]ABU>Q^T75^JH"T@B#;%W
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MMR/+16W.OW<Y[=: .>CF\5:GX^UK3K;7H[>QTZ6TFV&U5BZ.&8Q9[ C.6Y/
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MY/<DUW & !0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD;/;"^4,^QKB=(L6TJY;2-;TT0:HVCSK#J=A.WEWT8VLS.>&$@(4Y[[CV(H
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M=5**ZJ#\S&0DCTP3WK>T=9;SQKHNFZK=![S0]'59&9\LUW,F"03U(1&/XYH
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M >O5: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** //+'PS+J'Q(\4W^HV=
M]#8W<4,4$BSM$LP5 C@[&Y!P,9[>E='>^"/#U_/:S3:> UK;_98Q%(\:^3_S
MS(4@,OL<BL[3O%DP\8^(M)U>YL(+331;^3,?W6XR*6PQ9B"<8'&.AKIKW4[#
M3;87-]>V]K 2 ))I0BDGH,DT 8EIX \.6#V#6EG-";"5IK8)=2X1FQN/WN<@
M 8/&.*N7'A;2[O4[K4)DN&N+JW-K,1<R!6B.?EVAL#J2.."2:UXI8YXDEB=9
M(W4,KH<A@>A![BJDFLZ9#J2:;)J-HE\XRMLTRB1A[+G- &1'X$T&+3;+3DBN
MA:64XN;>/[;+B.0<@CYNQY Z#)]:G/@[1C)JTGE7 ?5U"WI%U(/- XQ][C@D
M<8X.*NS:]I%N6$^J649640L'G48<]%//7VJG/XOT6V\2QZ#+?P+>O$9"K2 ;
M3N4*AS_$V[@=<#Z4 <AXE\)%-2T]4\.7&JZ1967V>W^RWYCN(V+#AF9@67
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M=Z=86+V16"P<R6WE3/&R,>IW*0Q)ZDD\GFHO^$ \+_8M0LQI,0M[]Q)/&&8
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ML'?(94QCU/!KT+^S; AP;*VQ(<O^Z7YN_/'-/6RM%\K;;0CR<^7B,?)GT]*
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M1@#[H .,D\Y&2:]"^&^I6^I> =',$YF,%M'!*Q!X=5 (R>N/:NJ"@= /2@
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ML@].>17I5(0#U - 'B^OZ@\L&K6DVG2:+>3Z'"(X;2U9GNF,;'RBV"%1#\I
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;"6Y%M=2%A_HC9QN;U3G.X>W3- '<T5RVJ>,AI_AK4]>AT][JRM&Q"Z2J!<
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MEQU8%AC/'4]L'GKV75++XE:3*-)MY]6FTB='6"?]V2'7#/(5!Q@?W2<D 9H
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MR6$D2/O488@$'N" "/K5^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9O=Z9<>? DK1%MC+AEZC# 'O6A0!YQI_AG6;?3=4T_5-"TW4+2^U>2ZDA2?
M,3H<[ 0-I5E3'.3D],9KI/!6B7>@:$UE<L^W[1(]O$\QE,$1/RIN[X'\^_6M
M"+7M-FU^70TG8ZC%#Y[PF-AB/(&[)&",L.A_E6G0!QGB;1-=A\4V7B?PVMM/
M=I;FRNK6Z<JLD);?E3V8$?R].9K[3]?U:RM].U.*![6]E<ZB()!B&'&%A0D
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MY)"!F+! 3R0N<9/7';I6Y5/2=3M]9TFUU*UW_9[J)98]XP=I&1D5<H ****
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M&!-+&FU7;N0.U<S)X$1+WPY+9W_E1Z+))*%D@#M<-(?G+,"H!/)X'4_A784
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M:)[,6AC\D;0!R&ZYSNR?TH XZP\7>(;_ .'&CZU*]RQENY%U"YL;='EBA5G
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9$<.OR]CV/O7/76L:GX7LO$>DV]_.]O!J]M;17$\I9K:&90S'>>1CIGG!.:
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MK96$TP(@:Z88)'?&1D#OR.HYK-^'FNWOB7P/I^K:@8S=3F3?Y:[5^61E''T
MH VM5TJSUK3Y;#4(C-:R\21AV7</0E2#CVJO'X;TN+4+*^6!_M-E#Y%NYGD.
MQ,8Q@M@_CUP/2KU[=PV%C/>7#;(((VED;T4#)_E7/>!_%,WB?3+IKVT^QZC:
M73P7%J>L?.5'_?) SZ@T 2Z;X#\,Z1J\FJ6&E107;Y^=6;"9ZE5SA3SVQ5[3
M_#FDZ9I]S86MF!:W3,\\4CM(LA88;.XGKWIL_BK0+5E6;6M/1FF\@ W"Y\SC
MY>O!Y'YBIK77=*O=2N-.M=1M9KVW_P!=!'*"Z<X.1['@^E &=HO@7PYX>:Z;
M3--2$W2&.4EV<E#U4;B<#V%+#X'\.6^F_8(=-1( ZR)B1]\;K]UD<G<I&3C!
M&,GUJ\OB+1GU=M)75+0Z@O6W\T;\XSC'KCM44GBOP_$T:R:U8*9)C F;A?FD
M&,J.>2,C/IF@"SIFC66D"4VL;^;,09II96EEE(&!N=B6.!TR>*;J>A:=K$UK
M+?0O)):/YD#+,\>Q_P"\-I'/O4>MZ_INAVP:_P!3M+%Y01"UP<@D=]N02!QG
M'YUSW@3Q@-4\'Z?J&NZC:I>7L\J1ABL>_$C !5[X ']: -\>%]&%UJ-R;,/+
MJ2".\,DCN)E P 021P.!QP*IZ?X$\-:5:7=M8Z6D$5Y'Y4^R5]SI_=W;L@'N
M >>]3-XS\-+IW]H'7+#['YIA$WG#:7'.T>^.?IS6A?ZOI^EVJ7-]>0P0N0$=
MV^^2,X'KQSQVH KMX:T>3P\- DL4DTL($%O(S,  <@ DYX/3GCM4%AX.\/:9
MI5UIEII4$=G=<3Q'+>9]223_ (587Q)HC06<XU:R,=Z<6S><O[X@X.WGG'?T
M[U0O/'7ARTT&ZUE-4M[FTMV\MC;N')?'"C'<]J +4&@66D1R7.FV9DO([<Q0
M>?.[D*!D1AG)VKD#@<52\-6>KW%W-KGB"SM[/49H5MDMH9-XBC5F;ENA+%NW
M& />M70M:L_$&D0:C92I)'(HW;&R%; )7/MG%3:H+TZ9<#3F1;PH1"T@RH;U
M([T 37-M'=VLMM,&,4JE'"L5)!X/(((_"LF3PAH4V@1:')8*^FPL&BA:1SL(
M.00V=PZGOWQ7.2WGBF/QQ;^'O[=MBDM@UYYW]GC((<+MQO\ ?K3AX@U;1O%U
MK:>(-5M([#^S[B>9O*6-25F"HY))(RI'R@]3CF@#83P#X5C6\5-%ME%Y$(;C
M&[YU!!QUX.0"2.21D\U8A\'Z%;-IC061B.F;OL82:11%N.6P W.<G.<YZ'BK
M@US2SI"ZJM_;M8, 5N%<%#DX&".^>,>O%2:;JMAK%N;C3KR&ZB5BC-$X;:PZ
M@^A]C0!F3:!;:7-J.MZ18//K,T3'#W<@$[ ?*K;FVX[#L.V*/#FGZ@KW.KZS
M#;PZI>K&KPP<K"B [4W?Q'+,2??'0 UE^/M;U?0GT233;F...]U"*RF62,-@
M.3\P[YX^E=C&&6-0[;W  9L8R?7% &'X>\.0Z'=ZI<Q0PPF_G\UHX69AG)^8
MEOXCGG& . /4V];\.Z3XCM$MM7L8[N)&WH'R"I]01@BDA\1Z-<ZF=-AU.V>\
MRRB)9!DE?O >I'<#I35\3Z&VI_V:NJVAO/,,7E>8,[QU3_>]NM "'POHIT>W
MTG^SH5LK=@\,:Y4QN#D,K Y#9)^8'/)YILOA71I],N=/FM6DM[IP]P&GD+S$
M8 WONW-P .3V%2S>(](M]273I=0@6[:18A$3R7(R%^N.<4/XCT:/5!IKZG;+
M>EQ&(3(,[R,A?][';K0 P>&=*&HV>H>1(;NSA\B"4W$A*)C&/O<_CUJ.U\):
M-9PWL,$%PD=]N-ROVR8^86QN8Y?[QQR>N.*VZJZAJ-GI5J;J_N8[> ,%WR'
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M]\#G_?'I72:GKVE:-);1ZC?P6SW+B.%9'P78G' _$<]!F@"_'&D4:QQHJ1H
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M#IQ7K^@2++X>TUUSM-K'C((_A'8UH%5)R0#VZ4M 'E@?1M.\;^.GUWR$>[2
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M?I9723&-3;,7 P1NPQ;) ()'<D=W^-]&U*^N/#^OV.BIJ#:=O\_2;@I\R2*
M<<E=RX]^V,XJIK&C:OJWA O9^%;33IUO[>XCT^(QB5D1@2Q884,<\#L ?7
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M-+/<1P"0,H$6XCG#'DGD#MZD54^'VG:OHHU?3]0TQX8I-0GNHKDRHRR*[#:
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M9>3>:CM6W4SQJLV5W-)G.$0#UYZ<$D4#XH:8='EU!;"]?R+T6-Q''L?RI"0
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MC3[RMC@/TX&1[]*K:/\ $2YU36K*Q&E;DO4<JT8F'V=@NX+*7C P>F5SSZT
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MYY+I69(HVX5<*02Q/N, $\T =!8:C9:I T]A=PW,*N8S)"X9=PZC(JU7 ?"
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MY)ZXSP,UHVGAO64U[0M2NKFP;^SK-[658E<>9N Y&<XQM'4G//3MU]% '/\
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M%E VRC:5.3N(&,@$9P1PRY\'26EYHG]E7.H(;>]DN[J;[2JI-O93)YJ@9<L
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MY<R'C/S 8YQZ?E3+GP/I5SHMIIBRWL"6MRMTEQ#<%9VE"E=S2=2<$C/TZ8H
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MLXQAMY.[(P,<XH Y;QOH:67@WQ/;2ZO=74'D+=VEG+/(6MP/E.7+$R*6YPW
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MSPWKT=UJD6CSQVUI8P1*4'ELP\Q$&1AL8W=\#O5.^N?#<]O\.[S39;0SKJ$
MF?<OFC(R_F=\[QDD]_K0!Z1XXUR]\-^$+[5["*"2>V52%GSMP6 Z#D]?45K6
M5_#<VR,TT/FB)9)45A\F1GD=A]:YGXK<_#+6\?\ /)/_ $8M<XF@Z99>,O!\
MGAZ*)+B:&5M1\IRPD@,8R9>N<L< GJ3[< 'IRWUH\#3I=0-"APT@D!4'W/3N
M*;>W]KI]C+>W=Q'#;1+O>1V 4#ZUYE9Z(VGZYJ/@!+0G2KZY35(Y @VI;;@9
M(S_P)%0=3ALUW7C*-&\#:\K(I TZX(!'3$;8H P;OQW+)=^$Y=,%JVGZS)MF
M\W)EB^4-C@X!P>^:ZC5+NY;0KJYT66RENEC)A:=_W)8?WB#TZ]Z\F"Z9J&D_
M#*T!MIT,B1W,2,#SY*Y5P._J#ZU9N[+3[?PY\3K""&!;2";S8H5 V1N8E.5'
M0'<.W3% 'JT-X(=-MIM1N+6*5XU\QEDQ&7(R=I/4=<>U6D=9(U=&#(PRK*<@
MCU%>67=C/]E\/:AIM[IEQ>V.A1J^F7P'EW$+*,LC'H<J!GZ9P#SW?A*[MK[P
MCI-Q96CVEJUK&(K=R28U P%R>2!CKW'- &%8^,-4UO1[O7-'M+*>RMVE LY7
M9;APF1DD A6.,A<'C'//'8/>VL4"3RW$<44@!5I&"@Y&>]>2:GI-G!I]QX[\
M&:I_9%\%:6[L6=3',RGYHV4' ;(/'(STQG-+JVHRWOCFR/B'4DT&"ZT:)[9I
MK>*2/>W,J%I5(4YX/0D!0>V0#UR2YMXH!/)/&D1QB1G 4YZ<T/<V\=N+AYXE
MA(!$A<!<'ISTKR;3YM&\/^(/#MIJ-V\OAZ+3IX;"\OP/):?S3EMWW<&/A2>-
MI&.#5F Z-8ZUX8LK),^$A-<B*6;YX7NNJ$,>",EPISR<XZ T >H"Y@:#SQ/&
M8<9\P.-OY]*$N8)9GBCFC>1/OHK E?J.U>-^*[*TATWQYY(C.D(]K+ $QLBN
MCCS/+]&P1G'K6Y+96^C_ !%$F@QQ1W-SX=GD6->6EE#J49_[Q)/4\G!H ZCQ
M1XCET<Z<ME+8R23:A!:SQ2MEU21PI*@$<X/>NEKQ&/4O#=QX&\,74MS8_P!L
M1:M;273R,JSK+YP,S/GGW)/'3VKVF:Z@M[5[J:9$@1-[2$_*%ZYS0!S>M^-+
M;1O%^C:$Z%C?-MED XB+9$0)]696&/8UTTDT<(4RR(@8A1N8#)/0?6O*-?T'
M7]=\(ZGJYETZ+[4RZK#(0_G1+&NZ)0?N@A!CZLQ[TGB[5;#Q;X0\%ZOY<1:X
MUFU209!:,G=YB9Z@9 ],X!]* /4O[0LA&TGVRW\M6VLWFK@'T)SUIUS>6MG;
M&YNKF&" =997"J/Q/%>53^'?#Z^(_'=M_9]FMO;:;#+'#M 2)S$^6"]%;A>1
MSS[FLZ:\$?\ P@!OM6&FZ:VBA8[PQ1RHMQM4$-YBE5.T8SU&2..: /:%N;=E
MB99XBLO^K(<8?OQZT0W,%S&9()XY4!P61PP'XBO'M2T/P]'9>#[*PNA>63:[
ML-S/@B4$$R*A4#Y&88P/ES[<U#J<R:0?'EKHX$>G0WMBUQ! N D3*//VJ!T.
M,'IQ0!Z'%XEEN/'L.DV]U87&FR6,L^Z%MTBR(Z*0Q!Q_$>U;Z:G82S1PQWML
M\LH9HT652S@'!(&><$$&O/OM?A:]^*%FUK<:;+;W.B312JI3RY 71@I[$[=W
M'H*YNST309/!/@NXDMK87%QJZPR2AMKO&6D!4L#G;@*,=/SH ]GM;ZSOD9[2
MZ@N$1BK-#('"D=0<=Z;;:G87AE%K?6TYB)$@BE5MA'7.#Q7D6K0G3[CXF6&@
MPK#MMK)DMK1 /E*_O2JC_9)S@=ZU[)?!^H7#:G::N^HRMI<D,L9$(AAMP-V)
ME5%"X.,9YS[#@ ]%BU73IIXX(K^UDED3>D:3*69?4#/(]ZSM)\6Z/K6JWVGV
M5[!+-:.$(653YGR@DJ <D#."?4&O*;&RTVPT'X::A;0P17<]_&LUP,;W!!!!
M;KCMCH.E=%X0U71= USQHVI7-M9O'J<LH#X#"+ Y ZXY'3KD4 >H55;4K%+X
M6+7ML+QAD6YE7S"/7;G-26MW;W]I#=VDR36\RAXY$.0RGH17E/AS5_#]]X<M
M=-U_?+XCMM3:=[0!EN)+H2DJV!UX(&>@ ]!P >HMJNG)?BQ>_M5O&QBW,RB0
M_P# <YI)]5TVV\WS]0M8O**B3S)E786^Z#D\9[>M>':UJNG/;^?I]U;V$4?B
M))I+*5MUT'#@--(Q.47(P% P/7M6LVF:#J/B+XG7,UK8SI%:0R6\A52$9H'+
M,IZ E@#D<Y^M 'L$E[:0C,MS"@V;_FD ^7U^GO1%>VL]H+N&YADMBI83)("F
M/7<.,5Y1:6.DZOKOPZ%[%:W+2:*QE$FUO-98H]H?^]@[N#WS63;2-!X(OXH%
M4Z7:^,#]LA1<JMF&!((Z!,X]NM 'L@US26L9KY-3LWM(/];,DZLB?4@X%0^'
MO$6G^)M,2^T^9'1N2F]2Z#)QN )VD@9P:Y._C@N?B&+O2)DDCDT:7^T3 0T;
MK_RQW$<%CEL=\#TK0^%US8W'P_TI;2:WDEB@5+@1,"R/Z-CH?K0!+IGBB2/Q
M'XDLM;O;&WM=/G@CMY&(B!$D>_!+-RW3\CQ727FHV.GP+/>WEO;1,<+)-*J*
M3UP"37FES:>&)_&GCL^)$LB-MMY9N"-X7[.,F,'G.1U7G/%8]A.-'U#0;;Q7
M=3Z9;R: D,,\L<;*K[COC;S$;:2NW/3H : /:HY$EC62-U=&&593D$>QIU<_
MX+L]/T_PQ;VNE/=O8(S^0]U]YUW$[AP/E/5>.F*Z"@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#);PSHSZB]^^G0M<O(LK.P)RXZ,0>,C'!QQ3;KPKH-
M]J$U_=:19S7<T9BDF>(%F4C!!/TXSZ<5!>^./#&G-.MWK=I&T$HAD&_)5SGY
M>._!SZ=ZGMO%6A7NLMH]MJEM+J"IO,*-DXQG@]"<'IUH +WPIH&H6UK;7>C6
M4L%I_J(VA&V,>@'I[=*DU#P[HVJV<%G?Z7:7%M!CR8GB!6/''R^G''%1S^*=
M$M]2^P2W\:W'FK"1AMHD(R$+XVACZ$YIGB+Q#INC6SQWFHFSGDA>1&2,R,BK
MU? 4X )')&* +%]X?T?4M-CTZ\TRUFLX@!'"T0VIC@;1V_"HY?#&AS6-O9/I
M5H;:V!$$8B $6>NW'3/?'6N(\,>);G4?"'A"ZU+Q,MIJ%Y>/O1X@S7JB9D\L
M =.JC(Z<5H:UXC-]XU?PW#JEYIL<-EYIFM[<LQF9]HSE"-BCG/ .>O% '4S^
M&M%N+6VMI-,MO)M01;JJ!?*!Z[2.5SWQUI\^@:3<Z;%ITNG6S6<6/*BV !/]
MW'3\*P_">KPVWA2>\U'Q1%K$<$[))?\ E>6 >/DP.IR1TZYK9L?$NCZE'=O;
M7T9%G_Q\B0&-H>,Y8, 0,=S0 -X;T5]-73GTNT:R#^9Y#1 H6QC<1W/N:DO]
M!TK5(88KVP@F2 $1;EYC!QG:>HZ#IZ5Q\WB_[?\ $SPY8:7J4KZ?<P7#SP&$
MHK80E&!902"0>02.*[J\O;;3K.:[NYDAMX5+R2.<!0* %M+2WL;6.UM84A@C
M&U(T& HK*E\'^&YYKJ6;0]/DDNW#SLT"DR,#G)X]>?>I;;Q-H]U!=S1WJ*EF
MN^X$JM&T2D9!96 (& ><4W2/%6AZ]</;Z7J4-U+'&LK*F<A6Z'D4 .'AC0@E
MT@TBR"76/M""%=LN#D;AC!Q[TV\\*:!?P6L%WH]E-%:']PC1#;'[ >GMTI=4
M\3Z-HMQY%_>K%*(O.90C/LCSC<VT':N>YP*COO%_A[39C#>:M;0R"#[3AF_Y
M9Y #?CD8]>U %[3=)T_1[<V^FV4%I$6+%(8PH)]3CJ:Y&S\$_:_'GB'5]:TV
MTGL[[R/LP9][+Y:;"&&.C<''(XYK83Q[X6D^Q[-;M3]L($&"?F)) SQ\O((Y
MQTJ]JGB/2=%?;J%V(3LWM\C-L7.-S%0=H]S@=?2@"74M"TK6+1+74M/MKJ!#
ME(Y8P0OT]/PIDGAW1I?LGF:59-]C&+;,"_N1_L<?+T'2JEYXT\.6$_DW.KVZ
M2&(3!<EBR'&",#G.X8QUJPOB71GT)-;34(FTY\!9UR0Q)V@ 8SG/&,9H F;1
M-*>_DOVTZU-Y*AC><Q#>RD8*ENI&.U0'PMH#6D5J=%T\V\3F2.(VZ[48]6 Q
M@'CK7.>%_$_]J>+O$H_M26;2[6&"2-;B(1?9R=Y=2"JD8Q_%SQ^-=#I?BK1M
M8O&L[*\WW C\T1O&T9>/.-Z[@-R^XR* +::/IL>I?VBEA;+?;=GVD1#S-N,8
MW=<57'A?0%L)+$:+IXM)'$CP"V38SC^(C&"?>N3UWQI!=:[X<AT/6'*3:HL$
M\:PG9<1D')5V7# $ ':3]ZO0J ,N[\-Z'?R027>CV$[P*$B:6W1C&HZ 9' '
MI4FH:'I6K20R:CIMG=O#_JVGA5RGTR..E1ZOXATS0_+%].RO("4CBB>5V ZG
M:@)P,\G&!4$?B_09;FPMX]11I-0&ZT(1MLW^ZV,9XZ9XH T;'3K+3(#!86D%
MK$3N*01A 3ZX%4I?"V@327$DNB:<[W+;YV:V0F1LYRQQR<\U+_;VF_8;F\^T
M$6]M*T,KF-A\X.TJ!C+'/'&<G@56LO%NB7]C>7D5Z$ALCBY\^-HFA/;<K $9
M^E %@>'-%6]^VKI-B+K<'\X0+NW 8!SCJ!2Q:!H\%\U]%I=FEVTAE:985#ES
MU;.,Y.3S5!/&_AYK2\N7OS!'9X,XN(7B= >AV,H;![$"EL_''AS4-1?3[/5(
MYKI8?.V(K'<N,G:<?,0.H&2/2@!=7\,VUSIFK+I=O9V>HZA"T<ESY(S(3_?(
MY(/]:YW2/!4ZZC:SW6@^'=+^QS+(L^G(QEEV^AP-H/?.[@D>];OA/QA:>+%O
M'MHY8UAG>- \+KN1<#))&,DD\9R/2G:K=Q+XMT:U_MY[25Q(W]GK%N^UC'=L
M?+MP30!:'A7P^+)K(:)I_P!E:02M#]F387QC<1C&<=ZE/AW13>B].DV1N@5;
MSC N_*C"G.,\  #TK+_X6)X3+Q*-9A)DG-N"$? ?T8X^4>YP#70W=U#8VDMU
M<,5AB4N[!2V .IP,F@!D-A:6]W<74-K#'<7.WSI40!I,# W'J<#UI+_3K+5+
M8VU_:074!.3',@=2?H:S!XQT V^FW']H+Y.I2>79R>6^V5MVW ..#GUQ1J'C
M'0M*NYK:^O3;R0RQPMOB?;OD&5 ;&#Q[\=Z +R:+I<>EMIB:?:K8,"&MA$HC
M(/;;C%0#PQH0BMHAHU@([9BT"BW7$1)R2HQP?I7/WGB?1M9U#1)K#Q1);(-0
M: 0Q1,5O'& 8R2.G3GIS4UCX[L-5U37=/'VBTCTY0GGO X.<-N;I@ 8&,\F@
M#H)-#TF;4UU.73+-[]<;;EH%,@QT^;&>*LW=G;W]K):W<$<]O(,/%*H96'N#
MUKEM+\5:+HGA[1TU+Q+]N-TK"&]EB*F< GDC'&!QD^E:FF^+]"U73KR_M+]3
M;61(N7D1H_*P,\A@#TH C_X0;PG_ -"UI'_@''_A6C?Z'I6JK"NH:99W:P_Z
MH3P*^SZ9'%9T'C709]3M]-%W)'>W #0PS6TD;.IZ,-RC@^M:]_?VVF64EW=R
M^7#'C)P222<  #DDG@ <F@"*XT72[NZM[JYTZTFN+<8AEDA5FC'HI(X_"JS^
M%M DAMX7T33VBM]WDH;9,1[NNT8XSWJG/XZT"VL+R\FNIDCLG6.Z5K:020EN
MA9-NX Y'.,<UHPZ]I]QJ,5C%*[S2VHO$(C;88B<!MV-H^F<T 27>BZ7?VD=I
M>:=:7%M%CRX9859$QTP","JE_P"'+.^N]*D,-M'%IS^9$BVZ[E(QM"-_ N0,
M@#G &<9!9:>+]$OKRVM8;L^9=AC;,\3HDX7[VQB &Q[&A/%VBOJ,-D+IA)-.
MUO$[0N(Y)5^\BN1M)ZC@]10!IWMA::E:M:WUK#<V[_>BF0.I_ U6_P"$>T4[
M\Z18'?$L+?Z.G**<A3QT!Q@5GMXXT!-&NM6-U-]CM;DVEP_V:3,4HQD,NW(Z
M@9QCFFIXNAD\;2^'5M;K,-N)'E^SN069L#! P%Z_,>/0\&@#:L=-L=,A,5A9
MP6L;')6&,(">F3BF3Z1IMU>K>7&GVLMTJ%%FDA5G"^F2,XK.M_&6A76H6]E%
M>GS;HLMNS1.L<Y4X8(Y&UL>QKDOBAXSBLO#%['I&J7=OJ$%PD/F6\+;"^1N0
MR;2H(4DX!!R/PH [R'1=*MS;F'3;.,VR[8"L"@Q#T7CC\*:F@:.D,D*Z58B*
M0@N@MTVL1G!(QSC)_.I]01Y-.N4CFDA<QMB2/&Y3CJ,@C/X5Y_\ #_XAZ9/X
M:T6SUG6#)K%V74M*K'<QD;:I?&T'&W SZ4 =U=:%I-]%;Q7>F64\=L<PI+ K
M"/\ W01Q^%2R:;8RW2W4EE;/<*-HE:)2X'H#C-9^G^+-'U.34X[:>4OIG_'V
MKP2(8^O]X#/W3TJ_:7D.L:5%=V<LBPW,6^*7858!APP##CUY% $4>A:1%8RV
M,>EV26DH D@6!0C@=,C&#3[31=+L&W6>G6ENVSR\Q0JIV_W>!T]JX?P?X_TF
MWT>UL]9UQI[^6[GB6:56(/[YPFY@-JY & <<8[5U^H^)M+TJ>6"YDF,D,0FF
M$-O)+Y2'.&8JIV]#U]#0!9L-&TS2WF?3].M+1ICNE,$*H7/O@<U%#X>T6!V>
M'2+"-VD$I9;9 2XZ-TZ^]8VH^.[&UU_0],MHIKI=3#2B>&%W3RQ&S J5'S'(
M7(&< DG'%<YH/C:UT+7?$MIXAUNXE2&_$5L9D+E$V]]BX5<D<X H ],DB2:)
MHI45XV&&5AD$>A%4+;1;'2[>Y71[&RL9I@3NB@5 7QP6P!GFKTDT<4#3L<QJ
MI<E06X SP!U_"N57XG>#WEBC&KK^]D\H,89 JMG&&)7"\^N* +OAS1M4M7>_
MU^]@O=6>)8#)!'L1(U). /4DY)XZ#CBM^2-)8VCD571@596&00>H(K$U7QCH
MFC37$=[=.IME1[AHX'D6$.<+O900N?>H=4\=^'-&N9+:^U#RYD@%P5$+MF,X
M^9<+\W7MGH?0T ::Z%I$9B*:58J83NB(MT&PYSD<<<^E!T/26\[.EV1\\YES
M;I^\.<Y;CGGGFN;L?'%MK5QKUKY=[8VUE&H2Z-K('7=&6+D8^7C!4$9-7=$U
M_2[7PQI4HU6[U-+K<EO.\+O-<$$Y.T+GC![=!0!JW/A[1;Q(4N=(L)DA $2R
M6Z,$ Y &1P*T5540*JA548  P *Q8O%NC3Z>E[#=/)&]P;142%S)YP!)CV8W
M!@ 21CH*O:9JMKK%HUS9M(8UD:)A)$T;*RG!!5@".: (9/#VBRWZ7TFD6+W:
M'*SM;H7!]0<9JS>:;8ZBJ+>V=O<A#E1/$K[?ID<5PR>,+;P]XU\50:WJERUI
M"+9[>,QM)Y2LC,^ B\*"1R?;)KK+GQ)IMM%9NLDEPU['YMM';1-(\B8!+  =
M "#D^M %ZXT^RO+=;>ZM+>>!,%8Y8PRC' P",43Z=975C]BN+.WEM,!?(>,,
MF!T&TC%8+_$+PO':V=RVICRKQ6,#"&0[MN<C[O#<$;3SG''(JPWC/1!:1727
M$TL<EM]K'DVTCLL/]]E525'7KCH?2@#1.BZ6;)+(Z;9FT1MRP&!=BGU"XQGD
MTJZ1IJ7$5PNGVBSQ*%CD$*AD &  <9 QQ7/W'CJU_M[1K&R@GNK74(GG^TQ0
M.ZE O&W').2,\<9K1N_%NC6+SBXGF6.WE$4TXMY#%&YP,,X7:.HSSQWH NG0
M]),KRG2[(R.=SN;=,L<YR3CGGFK%Q:6]U;FWN;>*: XS'(@93CIP>*F!# $$
M$'D$5E:KIE]J&H6;0:I<65I$DGG);E0\KG9LY*G@ /\ F* +PLK1;/[&+6$6
MNW9Y C&S;Z;>F*K#0-&$0B&DV C#;PGV9,!O7&.OO7#>$$UWQ!HNI71\0WPO
M+74YH(0Y3RV6-AA7&S.#R"1S1X9\<V6D_P!NVVOZO<2O#KD]M$\J-)Y<0**F
MXJN$!.<$X!.?0T =X^BZ7)+-*^FV;23#$KM I,@_VCCGH.M*VD::UDMDVGVA
MM5.X0&%=@/KMQBJ.L>*M,T.21+MIV,,8FG,$#R"",YP[E1P.#[\5J03PW]G'
M/;RAX)XP\<B'[RD9!!^E $,FCZ9-Y'FZ=:/]G $.Z!3Y8'0+QQ^%+%I.G0/.
M\5A:QM.")F2%09 >H;CG/O7*?#N\U#4#XADO]1N;O[)J\]C"LI7"QIMQT R>
M>373:IK5II(A6?S9)IR1#!!$TDDA R<*/0=3TH >FBZ7''Y::;9K'M9=JP*!
MAOO#&.A[^M1_\(_HWE)%_9%AY:,65?LR84G&2!CKP/RK/'C?0Y+"TN[:::Y^
MURO#!#! S2NZ EEV8R" "3G%3Q>+-*N--AO+>26;SIVMXX$C/FF52=R;#R",
M$G/  STH T(=,L+>[DNH;*VCN9<B29(E#ODY.2!D\BFQ:/ID$$T$.G6<<,W^
MMC2!0LG^\,<_C6>/%VE/IPO(S<R;KAK58%MW\UIESN0(1G(P<]N*M:)K^G^(
M+:6;3Y6;R)3#-'(A1XI!U5E/((H ?_86D>7%'_9=CLA):)?LZ80GDE1CCH.G
MI27NCVMU#=B."VBGNDV23FW1RP[9!&&QVSD=.*N7-S#9VLUS<.(X84:21ST5
M0,D_D*Q]+\7:7JUY#:P&XCDN(/M-OY\#1B>+^\A(Y'(]#STH T].L(-+TZWL
M;8$0P($7.,_4XXIWV"S%Z;T6D NR-IG\L;\>F[&:R;'Q=IVHWMI;P)=;;U7:
MVG:$B*8)UPW^.,U=UG7++0K2.XOG<"698(D1"S22-]U5 [G% $KZ5I\CRO)8
M6K-*0TA:%27(Z$\<D=J8VBZ4[3LVF63-<?ZXF!29.<_-QSR >>]9$_C[0+33
M)[^[GGMX;>Y^R3B2W?=%+C.U@ <<$<].>M0_\+'\.EKN-)KIY[<*WD"TD\R5
M6Z,BD98=>?QZ4 ;D6AZ3!+%+#I=E')%_JW2W0%.IX(''4_G4MMI=A91R1VEC
M;01R_P"L6*)5#_4 <U1@\4Z5<Z':ZO;S/-;W9VVZI&3)*V2-H3KG@Y],$].:
MH-\0?#L6G37UQ=2P107/V2X62W?=!+Z. #M'N>/>@#H+2PM+",QV=K!;1DY*
MPQA 3ZX%+;6EM9Q>5:V\4$>2VR) HR>IP*Q]&\9:/KNH75C9RS+/;1B5UG@:
M+,9Z.-P&5]ZY'Q+XI-]K_@^32KC4HK2ZU((7 ,<-S&#S[L,XQG@@]Z /0Y].
MLKFXCN+BSMY9XO\ 5R21*S)]"1D4^ZLK6^B$5W;0W$8.[9*@<9]<&L>]\8Z3
M87#I<-.L$<ZVTMWY1\B.4_PL_P!< GH"<$YK(\?>)H[3PQK45C+?+=VL.6N+
M)21!(>5#-V[9'8'G&: .U4!0   !P *6J&AF1M TTS2O-*;6(O(YRSG:,D^Y
MJ_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !112&@#RRYOM'DUGXEM*T+NUDB
M^8I7+IY 1D5NYWX&/[Q'>J^F3V,2_"P*\",D4@;& 5)@*'/IE^/<UZW2T >4
M02E/AWKWA?5XI9-<,MS&D/EG==O)(6CEC!ZKEAS_  XYQBI-/U"3PCXIU*T\
M0Q74KWVGVD=G<0P/.)C'%M>/Y03G>6/X\]J]3I#0!XAI,4B_#OX?1R1312VN
MN)+(CPNI$?FNQ?D?=PZG=TYZUW,5U$/C'<DE@AT:. 2%2$,@F9BF[IG# XKM
MJ;YB>9Y>]?,QNVYYQZXH \4>&\_X1B]O(;:\E@L_%DM]<PVQ=)7MB3\Z;<$]
M<@@]L]JN:I8V.N^$]>U+PEINIRW%Q!$)Y[R6=GN KJQC59"=WRJ>1_NC.>/8
MJ* /*_\ A(;/Q'\2/!NH:?!>&WCANHY6:TD41NT8&TG&."0"1P,CFNC^(UO?
M2:1IEU9PRW$5CJEM=W4$*[GDA1LD =\'!Q[5V%+0!YQJUU:ZQXD;6M'F1H;/
M1KF*YNV!$3E\>5'G'S$,') Z9]36Y\.K2&W\":*1;I%<+:+')\FUP<DD'OU)
M./4UU=% 'D_CF^\S6/$VE&WN;:XGTQ%M3:6Q>343M?(9P#M121D<=\DCBI/"
MLL3^(O!DCQ2 1>&_(W20,H24; 1DCCA7P>XZ9S7JAI* /$;6/R?A/>Q&W<3C
M7%E$0B/F%1.K;@N,D;0?P%:>K2V.G^.M>'B*WUF73M92$V<UB\_ES*(PK1%8
MB,GKP<]_7GUK< P7(W$9 SS3J /-[&&SLO'GAV..S>SMK31956.7<WV<LRE4
M+G^+;GC.>O:N6T=K_3M-T75'MKN33-/U^[>Y@BA9G577$<@3&=HRW/\ M5[A
M2T >.ZF;CQ/?>.4T:"^1K_3K<6TDEG(@F\O=O4%@,;A\HSC.>.E+966FZ[I\
MLFAZ-KD.NQZ?.AEO[FX M6:-EVC>2&+,> ![G! %>PT4 >,_VK'>:9X!MDT[
M54N=)NX$O$-A+^ZV1E6S\O))7(QGC.:]0TCQ!::U=:A;6\5S')8R^5*)X2F3
MS@KGJIP>:UJJVMA!:3W$\8<S7#!I)'<L3CH.>@&> ..OJ: /-_&D LOB);ZG
MJ]IJT^BSV MEETUY5,$@<M\_ED$@@_YQ4FIZ38:SX?TWPOI&G2Z-,Q>^M7G1
MPUH%8D/GL['^'.0"2>F*],+H'"%EWD$A<\D4Z@#R,:G>W_@K0[F#2YOM/AW4
M8I+^SBB;,J+N4O'_ '\YW9]<U=\32R^*?"VJ7V@:#<KB6VGE:2%K>>],;@E5
MQACM4=?7[O(KT^B@#QS4!H][X+U[4=*T;4X'&ER13W6I2RF1"2I$0\PG<.IR
M.!QZUJVHMO$$/@--*A9KC3S'<7$IA9!#$L6'4DCJS%<#OUZ<UW'B71CXA\/W
M>DBY^S+=)Y;R"/>0IZX&1S5G2+%]-TBTL7F\\VT2Q"39MW!1@<9/8"@#C?A?
M(]G;ZQH]S:W4-W#J,\S^9"P3:S?+A\;3G!Z&K/BB=8OB)X-=ED*QO=!RB%@G
MF1A$S@< MQDUVU,66-I&C5U+IC<H/(STR* /$V7_ (M?XNB-O*9KC7GD@3R&
M+.IEC8,!C.-JL<^U>VQNLL:R(<JP# XQP:=10!Y!/X1UA],UC1+9)(K70KIK
M[2) >9)3MD0 8Z*#(OIEQ_=K1\1H[_#Z&;4[9UO-6U"WN[BW6-G*KYB':<#(
MVQ*H.?[M>G44 >>>/WB75?!TD,3F-=6CN9&BA8@)C!8X''4=:- G.D>/?&4=
M[;7,:W4L5Q'+Y+&/RQ&<L6Z=2!CKD].N/0Z* /$--D_XI[X;QO!.KV6H'[2K
MP.#%@GEN.!R.>E7]35'O?BFL\-TT,T%NT7EH1O*1D-M)&#AL9KV"LW7=%MO$
M&EM874D\2%UD62"38Z,IRK ].".X(H X'PMK%GJ_BW3[_6+N4ZNEH;.V46$T
M$;$Y9R6<8+$#IP.#UXK>^)%G>3Z'8WEI:2WBZ??QW=Q;0NRR2Q!65@I4@Y^;
M/X5I6/AJ6&X@N-2UJ_U1[:0O )_+14." <(J[CM.,MGUP*Z"@#S*TU;1+72]
M2URS\-:@MM<PBUD-XLK37,A. FTECL )RWX#.,51T33KKPTNM^"&BDE-]9G[
M%J4<,FQ7>-@(7;G;M.XKSC&>YKUE)$D+!'5MIVM@YP?0T-(B,JLZJ6.%!.,G
MVH \E\(PVFH0:9IDGAC58=;T] DL]TTH@MF"[?,4EB,G PH'?T&:T/"&K7=O
MI^G>%;_PW>-JNG2B,7$UMFW"JQ_?"0]/ESC'4\=Z],HH \3U2.[L?"_CCPZN
ME:G->7.K/=Q&.U9D:)WC*D,.#]TC Y]NN.HO6FG^(%\!9WR)J^A)!;3&V?8C
MY<D.<?(1N&<]*]$HH \B\&Q6DZ:1I%YX5U4:WIC());AY!;P%./-!+;<X'
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M7#9( R,X'2O5J* /+[HRV@T/^S_"]]IVDW-Q.9Q9VF;M!L4(6(R8RYW9;.[
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M_-\MTTAC9%7<!@J!E0!T(#=ZVSI&M^(KK1!KUE!:+I-RMT\L4_F"YE12%V#
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M\O3=)ABU?3$M(H+:<JL+!60#E0, .23CM@#G( -W3?&\]SKFE:=?:++81ZK
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MUOK6C;2(I&W12@H$=-V,\CH<#\.H@U?PQXHUC3[/4WU"T@\06=RMS!"FXVR
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MX22/9+N7 DR,'('K7&:I_P EJT'_ +!<_P#Z%0!V6FZE9ZO8I>V$ZSV[DA7
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MJ=GK%_)I/BFYL-(U"=I[FQ2W1FW-][9(?N9]0,C\!756VHW4VN7MC)ID\-M
MJ-%>,P*3D@$@#J,9Q^!K2H 9%$D,*11C"(H51UP!P*\\_P"%:7PTAK5==C2Y
M76O[9@F6S^5)/[I4OR,\]>U>C57^W6YNYK1)%>YAC65X5/S!6R%/XE3^5 '.
M^'O"E_I&MZMJ%]K7]H+J00RQ-:K'EE4+G@],# &/KD\UGGX8:3_PB+: DDBK
M]L^U1SY)>/#DJH.<\(2G7N3U-=1H6I7.K:3%>7>FSZ;,Y8&VG(+KAB,GZXS^
M-:5 &#JVC:A>2)'97EI%8FV:WFL[FU,T;@]#@,N,#COD5:\.Z+%X=\/V6DPR
MR2QVT>P/(>6.23]!DG [# K4HH X]/!EU9+JMGI>J+;:7J<C22V[0%WA+C$G
ME/N&W<.F0<'I2ZCX,FFU?PY=:;>6]G;:$K+;V[V[2;@RA""V\=@/Q]:Z^B@"
MOJ%G'J.FW5C-GRKF)X7QUPP(/\ZX>W\ :M#IWA^T?Q!#*-&NEGB+66 55=H3
MAQVSDDGDUZ!6'XG\1'PY:VDXL);O[3=1VH"2*NUG. 3G^GZ4 85S\/%U/5/$
MMQJEZD]MK:1+Y44!1H#$,1L&W')&.>.3[<5I^'/#FJZ8ZR:SXAFUAX5*6VZ!
M8A$IZDXY=B !DGCG'4UTU% &/K^C7.K+8/9ZB;"XLKH7"2B(2!OD="I!(X(<
MU3M/#=R_B.#7=7O8;J[MH&@MU@MS$J!L;F.68DG'J, FMR^OK;3+"XOKR80V
MUO&9)9""=J@9)XY/T%9,GB98_&T'AMK-]\UHUTMQO&W .,8Z]: .8C^&=]#H
MD&G)XED_T'4%OM/9K12+<AF8@C/SY+D\GMP*OOX!N)K'Q!:7&O331ZQL=V:W
M0,D@"@MQ@$?(.,# ]>M=M10!Q&I^!]4N=1LM7L/$\UGK4,)M[B\%JC"XC+9
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M4(& 7 SMW=L9(/;!J77PW62UT<V6MWEEJ6E0_9H+Z)%W-#C 1EZ'Z_SKNJ*
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M=.GO;R6S71Q,D#3L%1B"?E (P*K6.GZM9?#SPK/HJ7=]"8X[J^LEOWCEF0Q
M8C8G(4'!V+@=.*[T>%],_MF^U4I*UU?0^1<%I6*O'@ +MZ #';U-9\'@#0[3
M3H+*U-_;K;NSPRQ7TJR(6 ! ;=TPH&.G'KS0!/X(NK6[\+P26=U?7,/FR@&_
M),\9\QLQODDY7[O)Z 5QL=[?ZSX)\1^)FU&^M=2LKBY>W2*=ECA$/W8S']T@
M@?-N!)S]*](TO2[31[%;2SC*1!F<EF+,[,<LS,>2Q)))-9%SX'T2ZOKBY>.Y
M1+IM]S;17+I!.WJ\8(#'@9]>^: .%M[.7Q9\15:YO+W39;GPU;SRFQF\M@Q<
M$KNY. 3V]*IW5WJ%SX+\+)J=TUW/;>+8[87+')F5'D4-GOT(S[5Z;J7A+2M3
MU%-1<75M>K$(3/9W+P,T><[#L(R,TM[X2T6_LK&SFLRMM82B:VBAE>)8Y!T;
MY2,GD]?4T <H+O58O'_C&VLKZ9WCTI)K2*XF)BBE*D@@$X49K,T9=2UBY\)F
MSN-=#&%FUMI)YTC8[.&#$X.7R1L."#Z5V.M>%+<P:YJ&F6HEUC4;-[=OM%PY
MCD!& I4G:!Z8%<IHG@N>WN;1K+2-8T:>*2)I9)M6$D)",,@*K,7W ,,$ #=0
M!EZYK.HV\-QJVF:A>W4::\$-\]RT<:C<%^SI""0Z@=6(&3G&:W_#VF6[_%CQ
MJH>X3;':[62X<$%XCD]>>O&<X[8K9G^&?A6X^TB2PDVW$_V@J+B0!),Y)09^
M0G'./I6J?">C?VR^L+;.E^\(A:9)Y%)4+M' ;&0#@-U'K0!P&CZY?3^$/!FG
MW-_= :O>SPW5WYI,Q57D(4/U&XA5R.0,XJ7Q//J>B3^*M*M-0OOL7]B_VE!(
M9V,EK)O*[%<G=M;:3C/'-=HG@K08] &B):R"R27SH@9W9X9,YW(Y)93GG@]S
MZF@>#=(.F7MC*+J=;X*MW--<N\LRKT5G)SC'&!C@F@#CM$>[T_Q7X.!UK4KK
M^UM+DENX;J<NF5C5E8#H.21^'/7-3^&+J[L_$VGZ9KXU*#56$SPSB\::UU!,
M$YQNPK <@8X [9Q76IX/T>._T^]$4YETZW^S6N;B0B./!!&,\Y!P<YZ#TINE
M^#M(TB[@N+873FVC\NU2XNI)DME(P1&&)VY Q]..E &-X\N;BUUWP>;>YGA$
MVK)%*L<K*LB$9*L <$<=ZP-=NKR*#XDK;ZG?1BR^SRVY2Z?,1:(,P4YX!)/
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M/. .?854?PCHDFJW.J&S87URI2:=)Y%9U(Q@X;IC''M0!Y/I%D\W@'P7JO\
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MP)15+ ,2 03A<G&1TKE+#7/$E]XRUC0!<Z4BZ=##()OL4A,AD7.-OG<8^IH
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M+>V8+,TC;#&3T!5L')[<<]J -RBLJQ\2Z+J>H36%CJ5M<74*"22*-\E5/?\
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MTJT\9>-7N=3LX5EOHVC:2=5#@(02"3SSZ4GB/Q197VI:%<+%';VIO9X[?6Y
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MD=-O7FO9J* /,KBZTF+Q5H"VZVLV-!N5,$)7,@(1E3CUP^!]:YG2-1MG\1>
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M8.J^,=(T9IS>/.(+9UCN+A(&>*%FQ@,P'!Y'TR,]:9J'C71=,FNTGEG9;+RS
M=R10.Z6X<94L0.XYXS@=:X**QDT;7M;TC6?"%SK8U&]DN[.[BB#Q2;^0LA)
M0 @<GWXZ9A\466M7\/B?3)M"O2R6\9L5T]-EO(H4 NYR#(PVX"G)  PM 'IN
MJ>)=.TB26.X,[M# ;F80PM)Y47/SM@<#@^YP>.*XW4/%$=K\3-)N(M0O;C2K
M[23/%;0;Y%E<M\I6,#).!GIQR>.:<+[5-$\9W^I2^'=2O=,UZ"#8L$2M+!(B
M%=DBEL $9.<XY^M2P6FI/\2](U&XTN2W@ATF2&7R8B8X7+%E0$#!(7 )'&:
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M 2>-E*LO/&>F/QJ"WNO$,6CW-['X2AL;B8I!%8PF*1@,G=*[ J"H'1.I(]^
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MFO(9/-TU[:1)#<6D*,MQ8N"-JR;G^8=02$'..U '0>*],TO5O#MU;:W,T6F
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M:#7&M'OPS;VM PC*[CMQGGIBM&@ HHHH **** "BBB@ HHHH **** "BBB@
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MU33S)]FD9E7S%VG*L5/'U% $7AK0CH-A<1R3^?<W=U+>7,@7:K22')VCG '
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MZIK\,M[>-%ND6V(BB2-MX"(&'S$]6/48'85VL?F")!*5,F!N*C )[X'I3Z*
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M!MVT'YF) YSTZ8R:6T\'ZVWBK2==U;7X+N33H7A$<=EY8<,N"Q.\_,>I[<#
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MLG@BSDT_6K)]1U%HM8E,MT2T>[) !"G9P, #\* -[3KAKO3+2Y< --"DA Z
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M#,<G8V, >V/?KS5F7X?Z9):Z; +W45-A=K>K*9@\DLRX"M(SJ2V , <#'X4
M0^#Y]2M_$OB70[W4I]0AL'MWMYK@+Y@$J,Q!( !P1QQ5SQ9JT]G=:)I=O.;=
MM5O/(>X7&Z- I8[<\!C@ '!Z^N*NZ;X<@TS7M4UB.\NY9]2V><DK*4&S(4*
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M/!XQ@#L*[RS^&^E64NERQZAJ[2Z9N%L[W>2J$8V8Q@+CT ]\TQOAKIC>&YM
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MN8I/$"VAF#A;3RBS+Y*IU8@#E\8ST)J*^O==N=*\<W">(=0BDT6\=K78RJ"
MH.UL+R,#@# R2>:ZM_A=X>D@:W9M0^SBY^U0PK=LJ6[DY/E@8QD^N2.Q%77\
M!Z1)8ZQ9N]V8=7E$MV/-Y9@<\''';\J ,R*ZN/%GB6ZTR74;NQBL;"WG"6<I
MB:264%B^>I5< 8Y'S<YZ59^%0*_#C3 S%B'N 2>_[^2KEWX'TB[O;2]9[R*[
MMK;[+Y\%PT;R1?W7*XS^G7Z5I:!H%CX:TI--TY95MD9F59)6?!)R<9Z#/84
M9_CX ?#_ ,0$ <V,I/\ WR:SSJDVB?!^VU2V5#<6NCQ21;QD!O*7!_6NEUG2
M8-<TF?3;J25+>X79*(FVEE[C..A]J;#HEG%H*Z+(K3V(@^S;)3G,>W;M)&.W
M'K0!PVDVWC)+RUOI]3ABTRXM&$O^G_:'D?8762,-&%4\<@<8SQQ63H.I:W_P
MC7@K7YM=OYY[_4EL[B"5P8GC9Y!R,9+#;U)_D*['1OAQHNA&0VD^H,2C)#YU
MR7%NK##>6", D=\$^]3Q^!-*@TG2],BFO$M=,N/M-JHE&5DR2"3CG!)Z^M '
M%:_J>J17D^KZ=J>HSK%K45N9EFV6J1%E0PB/.'8'@MM[]:??#5]0UWXAPKXB
MU6WCTN&">U2*8*%8Q,^.!PN1C QGOG%=3=_#/P]>"X607RQS7)NO+2[=4CE)
MR749P"?7\L5;7P/I:'6"DU\IU>-([L_:"2RJ,* 3R/E)7KT- '(16AUCQ;X'
MU&ZO+T7-_H[S3&*Y= &$49^4 _*"6.<=:].O/.^Q3_9V59_+;RV;H&QP3^-<
M_-X%T>>/1D=KW_B41F*U9+ED;8<#:Q7!(PH'TK>O[*'4=.N;&X#&"YB:&0*<
M':P(.#]#0!Y?INI2QVFK:5K$FKVNMC1[AKBTO9S-#.=H_>Q-DC'!X&!R?0U%
MX6.HZ5IW@&YCU>[>'4";>:T8CR0GEL1A<9!&.N>3^5=]_P (A8N'\^YO;AS:
MM9I)--N,<3?>"\8!.!D\G@<U&G@K38K?1K=)KQ8]';?: 2CY3[\<\$CGL: .
M.O+_ %!=;L]3M=4O[E&UZ.TDG2XVVAB:3885AR0Q4=7P.>034]C_ ,C-\4O^
MN$'_ *3O6Z_PS\.NK(1?A/M)NHT6]D412%MQ* 'C)_'TJ\O@S3EN-8F2XO4?
M5U5+HK-U &!CCC"Y7Z$]^: +/A#_ )$K0?\ L'6__HM:VJJ:7I\6DZ9;Z? \
MCPV\8CC,ARP4< 9]AQ5N@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#-M
M;O4I=<U"VN-.$-A"L9MKKS0QG)'SC;U7:>.>M:5>7ZS"!J_Q&199P%T>*=<3
MN-KB.5L@YX&0.!Q[53\/6$>FWGPYOK::Z%QJ-LZ7;/.["9?L^\*03C (& *
M.X\<^);GPEX7GUFWLH[L0L@D1YC'@,P4$84YY(XXKHQR :\)\0"Q\0?!;4/$
M5VJR:Z;H&X<L=\,GGA?*P3E5"$ *?8]>:W;TIXF\5>*-'U/5;*QG@"):_:K<
ML\,.P'S(F\Q0#DDDX)Z9XP  >M45Y-IVE6NM?$06%Y?W6HV+^&[>0OYTD8N#
MN4>80#D9P&QZUCVL30>#/ FO"YNFU2?68;9[A[AV)B+R+Y>"<;<*!CZ^IH ]
MQK-O;G5(M5T^&SL(I[&4O]KG:8(8  -N%_BR<UY5=:3:WK_$V6<SL]@OFVQ\
M]_W;B%F# 9ZY'7TR.]=#*3)XE^&]V\LC3S6\PD)D/SC[,6R1G!.2>?>@#H-2
MUW5'UJ[TK0K2UGN+*V2XF%S(5#ERVV-<=#\I.3P,CCTZ&V>62UB>>+R9F0%X
M]V[8V.1GO@\9KA++P[HMU\1?$MO+I=FT9LK5B/)7Y6;S=Q''!.!R.>E9OANP
MD+GP%J"&3^RKW[6TQ4XGML[XR3TR6(!'HK#WH ]2HJ.=UCMI9'<HBH2SCJH
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MM=/6X\%:CX92"&XN;J-#]F 4S6I0F7=_>  !YY!]Z .B\*>()M7TBZN]2-O
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M%.)YEEWDK_>VH,$CUQZUZ9I6E1Z1#);6TC_9-^Z& XQ .Z+_ +.>0#TS@<8
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ML8X# ^E>@T4 >4RI/K/P\TKPFVG74&NVTEK \;Q-M@\IU!F+XV[2BD@@G.[
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M,\]_4T <QK5B+/XC>!(K2TG^Q:?#<QLZ0NR1*T6Q 6 P,D8Y-<[J,,US\/\
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MX\MIA+DG?@8 QCUQVYH ZC7_ ![8Z%<W47D-="R0/>>7/&K1@C("JS N<8)
MZ COQ4EQXUA:'SM*TV[U.)+6.\G:':GEQ.NY>&(+.5Y"C\2.*Y^;0==TKQ9J
M=Y9^'++6;#5 LX%S)$DEK-M"D$G.5X[9]O>RNG>*_#GB:YOM.TVWU6UU&U@%
MRBSK!Y5Q&FS<H8X"$#H!G\N0"[%XMO[KQU9:;!ILYTZ?2S>*VY [[GC 8@D;
M0H)&.I)Z<53T'Q#H6EP:_-::?>V\YU<P26\TBM)/=/@!4^8J,DXZX &?I:CT
MOQ!;^.-+U:>V2]4Z6UG=31R+&L4C2JY(!Y*@# P,G S7.CP9K]S_ &Q=K:?9
MKI-?36+%)I4*SA?X&VL=I^OM[X .QM_%Q6_GTS4M+GL]2CMS<Q6ZRI(+B,=2
MC9 R#U!Q^-9VF?$:'4CHTHT74(+'59#!%=R[ HEYPN <D':?FQCZ\U-<:7J&
ML:]!KMQIDMH;&QFAAMF>)I9I) ,_,K%0HQ@9(Y)Z5AV.A:]9>#O!^GMHL[W.
MEWZW%RBSP\(N_H2^#G>,?0YQQD [#Q9X@E\,:#+JR:=)?1P$&9(Y I1.[<@Y
M ./Y]JK0^+'?Q;:Z%)IX1;JS^UPW0N%974 9 &,YR?RYK>O[.'4=/N;*X7=!
M<1-%(OJK @_H:\RC^'&KKX8TQA=!/$-A<HL=RK#*VRDH%!]-C%\>IQ[4 ;.K
M:OI^JOX8N=1TBY<2ZMMLIHK@>6KJ6".Q!!(8 L!@\#D^N1J7B+6M;T/QQ;WV
MEF"ULH9HD=+E3Y+)%O&<<DDD'(X' ]<]#XHT:[*^%[71],DFMM,U"&=PDD:B
M.*-&7 W,,GYAT]#63=Z%XD1/&UA!I<4UMK!=[><7*J27B"8VGT(!.<<9QDX%
M %GP7XI=-/\ "VBW&D7EO%=:;&EK>2%=LSQP@L H.0, D$XSZ5J^.->U/0;+
M3GTVU29KJ_@MG9I NT,XX&0?O<C/;.:RK?2=;MG\!K_9$KC2(C%>,)X@$_<^
M3D?-EA_%P.GOQ6OX[TO4=3T>S.EVRW-S::A;W8A:0)O$;9(!/ - '+R:K?:/
M\2-;NXM!GNKE])@E>WMIE(&"VYBS8';& "3CIZ:NI^(-#U,>#M3N-*N;@W]S
M&;"7?L%M(V/O -R1SV(X-31Z9K?_  E.K:O<:<H6XTE+9(X9U8M*NXD#..,M
M@$XZ=JR$\*:X- \$69LAYNC7<<UU^^3&U<_=YY//M0!T5KXQDOM2DBL]*DGL
MH;\V$UPLR[HW'!8Q]=N[C.??%,^)5M%/\/\ 6))$S)!;M+$X.&1AT((Y%9,W
MAG4;KQ9;:K;Z4=*OTO2UQ?VURHAN;8,<!XPV6=EQG(Z\YZ"NC\;:?>ZMX0U+
M3=/@$US=Q&)0SA N>Y)H N>&[>&U\-Z='!&J)]GC8@=R5!)^I-<_K7Q%T_2)
M=0(B6XM].D6*[87"K(&.,A$/+XW#/3OZ5<AE\11:'9V%MI(@N5CBA>XDN$9(
MP,!F '+$#.!BL1=&\6:#XGUAM(T_3=0TW5;@W*R74VPVTA4!BPQEER.@YX'(
MH OZK\0([&VO+VVTR:YTZS@AFEN7?R0PE&0(PP^<A<$\CKBK.I>,VM[^]LM-
MTUK^XLK5;J>/SUB8JP) 0$$L<#GMR!U-<OXA\'>*-5&M6\T%CJ7VBWCCL;N>
M79]F 3YPL>TA69AU&.O)XQ5C7O#>MZ]9 W.@0V^L1QHMEJ-C>A7MSMY$CG#,
MH/8 ]3CUH V-=^(5GHTU^JVRW$>G%1=DW4<;@D XC1CER 03T] 2<XZVSNH;
MZR@O+=MT,\:RQL1C*L,@X^AKSK^P/%NA>(-1.FV-CJEEJDJ7#3S3^2UO,  Q
M;'+*2,[1U'''.>VMWUF+5XK66WMY--6T!:[#XD:8$ C9T QDT :M%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !115'4M8L=(2(WLQ0S/LB1(VD>0XSA54%CQSP.*
M+U%5--U2RUBR2\T^Y2XMV) =>Q'4$'D$>AYJW0 4444 %%%% !115=K^U744
MT]IE%V\33+%W**0"?S84 6***,@4 %%9;^(=-37X=#,S_;YHC*B>4VTH!DG=
MC;^M:E !116?K6M6/A_2Y-1U&1TMHRH9DC9R,G X )ZF@#0HIJR(VW##YAN
M[D?Y-.H ***JZEJ-KI&GS7]](8K:%=TCA&;:/4A03B@"U17/CQMH1@BN#/=+
M;R[=DSV$ZQG<0%.XIC!R.<]ZZ"@ HHK)D\1Z?'XEA\/LTWV^6)IE7RF";1WW
M$8/X9H UJ*** "BBB@ HIKND:%W9551DLQP!3J "BBLK5_$5AHEYIMK>&42Z
MC.+>WV1E@7..IZ#KW]_2@#5HHHH ***1F"J68@ #))/2@!:*** "BBB@ HHH
MH **** "BBB@ HI&944L[!549))P *%8,H92"I&01T- "T444 %%%% !167'
MKUG+XCFT)1,+V*W%RVZ,A2A. 0QZ\^GH:U* "BBB@ HHHH **** "BFR2QPI
MOD=47(&YC@<G _6G4 %%%5KN]AL[>>5RS^3'YCI&-S[>>=HY['\C0!9HJEI&
MJ6^M:3:ZE:%_L]S&)(]XP<'U%7: "BFB1#*T0=3(H#%<\@'.#CTX/Y&G4 %%
M9-UXBT^UU'3+)FDD;4B1;21KNC;"EOO=.@K5% "T444 %%%% !1110 44SSH
MA,(?,3S2I<)N&XKG&<>G(I] !1110 444R6:*")I9I$CC499W8 #ZDT /HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *X7Q':ZI9_$C1-?BL9[W38[62UE6W0.\+,2=^.N#P,CT/X]U67
MJ^FWNIJ+>'4WLK1E*S>1'^^;_=D)^3C_ &2?0B@#D/A?/)?7GBS48X'@L+G5
M6,,;\,' ^<D>_P OXY]*]#K#NO#BIX7&B:)=R:.J*JQ36ZY:/!!/7J3SDGU-
M;2*515+%B!C<>I]Z '4444 %%%% #7=8T9W8*JC))Z 5XCJVOP1>(M*\<Q27
M?FM>M'-$;>4(FGD^6IR1LYP9.HR9!Z5Z;XU%U-H$EE:PZA)]KS#*;&&.1PA4
M@\.R@9Z9YK&UC4[K6?#-SHTOA?7XQ<0>2\B6D& ",$JOG<>W/% &EXBU:^L=
M>\,BRNT^Q7]T8)X]@8.NPL&#=1T_6N,\5>(=9N- ^(%K_:$D2Z7-"D#Q*JL8
MY/O(2!TYZC!XZU+<6FISZ#I-B+#Q2EWI$JR6=[]CMBP 7: ZF;#<$CM[Y[P#
M0W>Q\16UQI7BZ<ZV4,SO;VV59<$-_K.N0?08.,<"@#1N+75?^$X\-066HJMP
MVD3;KFXA5RB;D^ZJ[03T SZY.>E+I'CK5;O1--M)I83JU[JTNG?:1%A0D?+2
M;.F<8 &<9.?:F6G]J6VMZ=JDNF>);F:RMGM@)+&V&]&()SMF&.@QCT[U3M-'
M:WT62P?0_$[RK?'4+6Z6UMU>WGSG</WI!'L: -O5/$&M^'KO5M)EOEO'32)=
M2L;R6!=X,>=R2! %/LV!Z<FL^77?&%G\-W\43:M9.TUO:S0Q+9X,>]@K#.<'
M(8'./7 JO.VMWL.HF_\ #VO7%_>VC6!NQ# BQ0,?F"1^8<$YR26/..PQ1?+J
MMUX"M_"J^&]?$42I$9S%!N:-""G'F8!X&?I[\ &U-:WTOQ>FBCUF[B4Z+YJ
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M%,W,:] ZXVY X!QT Z]:N#P4L7B2QUBVU&6,V=N\$<3H'W;\EF9B<EBQW9H
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MKVW<+(ID8LX(  P2>@ 'IQQ5D^!+!I-*F>_U!Y].N6NA*\BLT\I !:0E3G@
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MY]Z>(ULIYH42/S564@,R[2,C:"!TSU!P*V_$/B*]T'6Y;34]5U'3[)TB%EJ
MM8GMV;'S"9MA(8L.V!@YXZUKCP!8C1FTW^T]3V_;_P"T$G$D:R1S9W94A ,9
M)."#UJ74?!J:FDMM<:QJ$EA<[/M5K(8V6;: !\Q7<N=H)P?IB@#J*\ZL+:X'
MCOQONU.\DCCM;9O+<H58-'*=OW<@#MMQ[YKT6N=G\(VTFNWVKQZAJ$$U]"L,
M\4,B>6P52JM@J>0&/4X]J .!\.ZCKFB:%X!<:IOM-1F2U>S$"!!&5.#N(W[N
MYYQ[5;UWQ)K5E=7MY::G<W'V?5$MQ]GA3['%"SJOEN64%I>3G83C(Z<UTX\
MV)T_1+(:EJ:QZ+*);5MT6[<.@;]WR ./QYS4-U\,]+NX;N!M3U=+>YNS>B&.
MY4)%,6W%E&WU[-D#MSS0!0\+Q7)^+/C(2:C=R);BS 1]A#*T3$*?EX"ECC;C
MWS74^+Q+_P (;K+0W$UO(EE*ZRPMA@54G@]LXQ^/&*@LO"-GI_B2;7(+R_\
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M(@B D19D3#G;R,'H,=\YSQVFE_#G1M(OVGM+C41:F7SETYKDFU23((81]R"
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M-\HZ'E.6SDY.>OIQ6>WPTT>30+'27O-2/]GRF2RO!,JW%OG&0K*H&..X/Z#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?B7;Q7'P[UKS4W>7;-(O/1AT-<AJ.CV;>(OAM8P^;!%+#=-)Y$K*V?L\9(W
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MLBS$/& &7/ .02!C/&>.*J6U\=/T;2=%FNY%TJ3Q)<V,KN^28DD8I&6/\+,
M#ZC(Z4 >@6'B&:[\9:IH,MI'&ME!',LRREBX<G&1M&.GO705Y[X9L;+3_BUX
MFAL8TCB^QVS&-/NJQSD =O7'O7H5 %#6]5@T/1+W5+CF*UA:4KG&X@<*/<G
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M.L_"V@:>R-::+80LBE59+=00#U&<=Z2;PIX?G@B@?1K'R89#)'&L"JJN?X@
M.OO37\6Z%'J'V%]003?:!:YV-L\X_P#+/?C;N]LYJ2_\3:-IDSPWE_'$T>WS
M3@E8=V-OF,!A,Y&-Q&<T 6-2T?3-8MUM]2L+:[B4Y5)HPP4^V>E%SHNEWFFK
MIUSIUK+9* %MVA4HH'3"XP,>U9EOXML[CQ=<: D5QYL,"2&3R'VDL2.NW&W
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M&=IC<#TROXX-0VT&N^(_AIJ^IO;20:O-8"PBCS\S+%D28'8NWF#'L*]5Q28
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M/X<8R<9YKU;%-WH2P##*_>&>GUH Y[P"DD7@/1(9H9898K1$>.6-D92!@\,
M:Z.D5E=0RL&5AD$'((I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .<O
MO&-G9_;Y([*^N[73VV7ES;(K)"PY8'+!FV@Y;:#BL+Q7KCWNN^%K"UL[J\TN
M^F:=FMWC"7:B)F502XR!PQ#8! '7I3;.QUG0K3Q!H1TRYOTOY[B>QN82@CQ*
M.4D+$;2"2<\Y[9Z5&^A7^B7'@FU@L+F]AT1'-U-"!CYXS'E03D_,<X'04 =K
MHNE0Z/IJVENUSY6YI%2XE\QH]QSL!R>!T R?J:Q+OQ/>I\0(?#BZ3<O:R6+3
MO-&\>>9$0/\ ?!"+EL_Q$D8'&3UE<9JD&J6GQ/T_5;;2I;RSETU[*22-U40G
MS5<L<GT' [T 8/@OQ?;:+I"V5[!JDL3ZK/;?;FC,D4;&4A%9V.XD\<@'KR:Z
MW5?&=CI+WQ>VNYX;#;]KGA";(20#CYF!8@$$A0<9KB+?2];G\"162:%?"\_M
MW[7Y,@1#Y8E\W.68 ?+QUZ\5=DTO6=&\5:L%\)6VM66JW'VFVN7,8-O(5 99
M"02%!';\,YH ]*@GBN;>.>"19(95#HZG(92,@C\*P=?\8V?A[5K#39['4+BX
MOUD-N+6)7WE!DK]X'/3MCGD@9(V[**2"QMX93&9(XU5S$FQ,@8.U>P]!VK@_
M&L\MO\3? LL-K)=2#[=B&)E5F!B4'!8@<#)Y(Z4 :=K\1--GT?4;V:RO[>?3
MID@N;)XQYRNY 4#G!!)ZY'X58_X3:VBAUC[5IU]!<Z1$L]U;X1V\M@6#*0VT
M\ YYSP:Y[4="\3N_B'6M-M);6]U*>UC6U2YC68V\7#GS 2J,P)Z'CUS5(>'=
M;MY?%8LO"OV:VU?2UMH$2[A+!PCK\^6Y8EP2<GH>6- %_5OB>YL[672-$U,Q
MW%Y;0+=74(BC=9>?W>X_.< CL!USTST^G^*X[[Q+/H,FEZA9WL-N+D_:1%L9
M"0,J5=L\G''3O7/^(M$UK5/!'AV.#33_ &AI]W:W$UF9TW8C!# -G:?7KT_*
ME\:6%UJ<F@7MA-]@UDW/V-T$@9EBE0^8IQP2H&_N!M)YH [#1]436=-COH[>
M>".0G8LX4,P!P&X)X/4>U&K:M;:-:+<7.]C)(L,,48!>61CA44' R3ZD#N2!
M5JVMHK.UAMH$"0PH(T4= H& *Y[QII6IW]MIEYHX5[W3;Y+M878*)E 963)X
M!(8]<4 )-XWL[4ZE#=:?J$%YI]O]KDM'6,R/#WD0ARK =#\V013+#Q[IU_J6
ME68L=1MQJL1ELYYXE6.7"AF7[V<@'TP>Q(P:Q=7TC4?$=WJ.N1:3=PM_8TVG
M6MK.R)+))(3EB-V HXZG)YXX&6MH>M-J'P^F_LF8)H\#QWN9H?W9,2Q\?/\
M-RI/&>/?B@#T:N;/C& :KJ^F_P!F:A]JTR$3NG[H>=&>C1YDY''?&.G7BNDK
MBO%?A2\U7Q5I.I6$OE(\,EAJ+=VMF&['Y@CZL#0!IZ?XKLM:TG2+RWM+QH=7
M=HHER@9  Q+/A^!A#T)/08S7'^#_ !E;:'X=BAO;74I86U2:U-X%!BC9IFV!
MF9@2,8Y ('?FMSPMX1N?#NNZK+P^EQ,[:7 FT&,2[7E ' 'S*%&<< ^M<W<^
M&?$<WPY72ET287RZN;KRC/#S&93)G._'0XQZ^W- '=7WB@07E[:V.EWNI26
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M\B#!^7))S[5GZ?X8U71/$%VMG!/<:-K$&[41)+&DD=PP(:1 #CG/(''IG %
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M9B[MTR68\#/ 'KP :>F^-GN_$5KI-[H]Q8"]M3<V<TLJMYJCE@RCE..1GGU
MKC_B'KUQKWAFRN[323_9#ZA$(KZ2<!VQ(1D1X^Z2.#G/M723Z!JMUXQ\.:D]
MELM;33Y+>Y/FH2C.N.!GG'K[U@77A/Q>W@NW\*_8K2Y2QNXW@OC=!!)$KY4%
M-I((!Q^'?N >LU2U?48])TFZOY066",L%'5V[*/<G 'UJVA8HI=0K$<@'(!^
MM<WXETZ\UO4-.TZ33_/T3S#)?'S57?@?(N,Y(#88_P"Z.O- &%X O=4L/$.N
M>']>FWW\C+J<3'HRR@;U49^ZC#;6G=^.FM]1UNQ@T'4+F;2$22?8\8!1E+;A
M\WH.!U.>G6LG5_!4VC^*="UCPCI,:FV:07J_:-GFQ, -OS$Y/WB/?%6X-'UE
M=?\ &&HG36":K:PQVR&:/)9(V0AL'C[V?H#0!<L/':7NIZ1$VE7-OI^KH397
MD[JN]PN[:4SD CH>YZ#!!-.;XG:?'?0>7#%/ITMP+83Q7:&8/NV[C!][9D=<
MY]JKQZ%KL=MX%4::F_10$NPTJ$ "+RB5YY./F'I3/#.A^,O"\+^'[6+3I=)%
MPSP:@TA$D<;,68&/!W-R<=L^HH MWOQ&EM#K++X=O9(-'F5+N3S8QM0@'<.>
M3S]T$\=2*UK[Q*UPPLM&TW^U+F2T6Z:-YQ#&(GR%RQ!Y;!P #T.2.,\Y=^'-
M<N=*\;6PTX+)K$NZU_?IC&P)\W/'W<_C4NG:+XHT#6K:_L+*WNK>ZTVWM;VW
MEN C12Q*55@V""O/N>30!C_#[Q5'X?\  >@17-C=3'4;^:W1H2IVR&1L*<D$
MD_E[UO-\1+T6FK%?#-PUYH[DW\!NHPL404L'#_Q$J,[0.QYZ9PM,\%>([30/
M"UC/90F73-9-].8[A2/+W$\9QS\QX]NO.*UCX=UHS^/773@JZW"([3_2$))\
MMH\GT'.[Z>] &KJGCNVMOLL=BEI-<3V8O0EY?):A8V'RC)!^=NPQC@Y(XS6C
M^(OVM=!:PT2ZN?[86;RU\U$*21 [D.>O(Z\#!SSTK+B\-^*]!N-(U30K:SDF
M&F1:??6-S-P#&/E97'7G/^3QLRZ/X@NO$GAC4+Q;64Z=]HDNI$?:N95*A(UQ
MDA1CDXS]: ,+6_B%K$GA)KNSTD6=ZFJ_V;<H]R&\EPR\*0OS;@<9QQSUKTFS
MDN);.)[J!8+AE!DB63>$/<!L#/UP*\TO?!^OWF@:U MI"EQ+K_\ :MLC3C$J
M9'RDC[IP*]+LVN6LXFO$BCN2N9$B8LJGT!(&?KB@#-U[7)M)>SM[33WO;R\=
MEB3?Y<:[5+,SO@[1@>AR:P'^(\*:5IEY_9-S(U[?G3RD,J,%F!*D*V?FR5.#
M@ ]RM6O&&DZMJ6J:++:6D-_IT#RF[L9I_*25BH$;-P=P4YX(/7H:YNT\+^);
M6+3+>32K7R[+7WU$M;W*A3$Q?A5(&/O\#/;G% '1V'CRW>'Q VK64NF2Z&5-
MS&TBR_(P)0@KP20.G8]ZQKBYO[WXF>$KF_T&*Q,D=SY=PMP)79?*8A'&T;2,
MYP"1R>:34O!FK:[>>-[>YB2WM=82W%G/O7@P]-P'."><]<5;@L/&-_KOAR^U
M'3=-@33/-6;9>,3(6CV%QA.!SD+STY(H [ZO+KO6M:UK4/'VDZA96;:=86:J
M(VF),8,4CJX&S#LQ"DY*[<#&<5ZC7G]SX9UZ'Q'XON+2"TFL]=MHT5WG*M&R
MPM'MVX]6!SG@#N: *?@7Q5<V6C^$M)N=&FBLKZV\F"^:93ND52V/+&2 0."2
M/I6K>?$%M/NHWN]*,&GR:A_9Z2RW&V=FSM\P1;>8\]]V<<XJK;>%=;M=/\%6
MXAM7;17W71\\C/R%/D^7GKGG'3%8.H>!_%][8W,,EOI<UV-5%V+^:<F6>,-E
M4^[\BJ,\9^@]0#LO#^LZ[?\ B[7K*\M+1+2RECC#1W3,4S'O& 4&[.X9R5Q[
MXYZVN5T;3=;L/&6LW4]O:-I^HF&;SDF.Y'2)4*A,<\KG.>GKVZELE3@X..#0
M!QH\=3KJNG07.CFWM-1O'M+=Y+@"?*DC>T)7A"5.#N/&#CD5CVUE:F;XEVQM
MXO(9@YCVC:6-N&)QZ[N?K5:V\(^+%72WN;+2Y[ZPU/[7/>M<D27P^?!)V':%
M#XQSTX QSNKH>LP3^,IOLD$@U=0;54GYR(A'AL@ >O4T ;OA#_D2M!_[!UO_
M .BUK:K)\,6US8^%]+L[R'R;BVM8X)$#!AE%"Y!'8XS6M0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 45Y_=>+_%1_M_[#HNGR#1IR)"UPW[U BOM7C.
M_!SS@=ADT7WQ NCIL6IVEO;6NGRZ;]LBFO#N,\O)\A%5@=PP<GG'I0!Z!17G
MTOCK7+T^'UT;2+.236;"2Y19YR/+=%!() Z<X'K[5'9ZQXNC\1Z^;E]-D^Q:
M?;3-;8=%0E96VJ06YR""W.0!TH ]%HK@-'\<:W>2^&;F]TFUAT[6P8U:.4M(
MD@0L"1TVG!P,DXZG/%-_X6#J%Y''J&D:5+?Z>UX;?RH;.=I#$&*M*) /+/(S
MM].^: /0:Q=8T?1Y=1L]?U)S%-I@8PSM<-&D0;AB>0.1P<UA:?XG\3ZAXBU"
MRCTFP-EIUT8;B83MN(V!AM7'+<_3G'O5'2_&=[X@T6\G$^E,HLIVNK4QNDMB
MZIPLBEB77.X$A1]* ._M+JWO;6*ZM9DF@E4/'(ARK ]"#44&IV-U?7-E;W<,
MMU:[?/B1P6CW#(W#MFO.?"GB+6-(\/\ @J"XL[,:;J CLTVR,TP^0E7/10#C
MIR0/TT9/%%W9:OXV6#2M.6XT>VBN3*,JUP#&S_.P&20H % 'H%8UKX5T:S\1
M76OPV2_VG<C$D[,6/0#@$X7@#I7-6WC37K?4=!.LZ3:0:=K1$4#0S%I(9" 5
M#YX^;G&/Z5WU !17+7FOZK=:IK%CH5M;2RZ3$AD6XSF>5UWK&N" ORX^8D\G
MI1'K^JZEJK:596]K:7EO917-V+HF3RY) <1 *1G&#ENG3@YH ZFBO.I/B-J$
MUII+6FF6RW5WJ3Z7<0S3$B&=<CJ!]W.#GK@]*DB\5>,9?$C>'?[+T==06P%V
MSFXD\M?GV^F3QV]3UXH ]!HK@])\>7FLV^F64=G#;:U=7%Q;3I)N:.W, S(V
M."W5<#/\77@U#K'CW4]"L->@N;6SEU728XIP5W)%<0N0H<+DE2&.""?QH ]"
MHKAG\1>*[;0Q?ZA9Z/8B:Z0+-).3';6Y0DO("PW," -H(SFL+4_%/B#4_#@>
M&[M;6:WUZ+3YI(K9P+A28RI"LP9!\W(Y)QP0#0!ZM17#ZGXIUD:G?Z5I<4,E
MYIL,;3N;&659I'4L$4*WR#&/F)/7IQ74Z/>W-]HMI=WUFUE<R1!IK=SS&W<4
M 7Z*X-_&.KS>&9O%UC#:2Z-"SM]C,;>?)$DA1I!)NV@X4MMVG@=:>WBGQ)?^
M*KG2=(L-.>"&""Z\^>1P?*<\K@?QD9([#!ZT =S16-XCUE](MK1+=(WO;ZZ2
MTMED)"!VS\S8YP "<#KC'>LBZ\1:]H>GZF^KV%M/)%+#!I\T!,:7CRD* 5+,
M4VL0"2>: .PHKD'U_6M*\1V6C:I]@F.I0RO:7$$;1*LD8!,;*68D8_B&/I7.
MZ?\ $#Q/>>'=!UW^S]*-MJ=Z+$PAW#[V=D5\]  5Y')]^> #U&BN"M?%NNP7
M?BK3=2CTY[S1[1;N&6W1Q&ZE"VUE+9SQC(-4[#QGXJ6R\-ZOJ%GIDFF:O-#;
MR);!Q+"TAPKY+$8)[8XZ9/6@#TFBO.W\<ZO9ZU8V]V-/87.KC3Y+6W1G:!&S
ML9I@Q0/QDH0#@^U5=0\=>*;;3O$E_#9:5]GT.],+L_F$S+\ORJ >&&[.3QR.
M.] 'IU%<I-XHN[7Q9I-G<QP1Z3JMN7MIRIW^< #Y3<X'!R#WZ>];.AW\^J:?
M]NE$8BFD=K8*I!,.XA&.3U8 -VZT :5%><^*_'NJ^'GU27R;%5L98Q%9L#+-
M<Q$C=)N1OW0^;C<O;WK=N=:UC4-6U:PT06:/IL$;'[3&SF:612RH,,H48 YY
MY/3B@#J<U3T[5K#5DG>PNH[A;>9K>4QG(61<97]1^=<;:WOB2X^)EK;75U;V
MT1T47+V7E%Q&QD0.NX.-S9!P_0#MU)BT[QE<P:;JIDLK);X^(GTBW%O&41Y#
MM_>/DY)Y8GD9P![T >AT5R4NN:SIWBB#0KW['*=1@D>PNXX'15DC&621=YSQ
MR""*P].\;^(Y+#PMJU]!I@L-9NTM'AA5_-0ONVN&+8QE>1@X]3G@ ])HK'\4
MZE=Z1X7U+4K$0FXM+=YU6925.T9(X(/05S%WXL\2:7IUA-?6ED\^K30QV<-G
M&\CPJ4+R%P2 Y  P 1U/I0!W]%>?0^+?$EG$MKJ.G 375]!9Z==3P^5YH?)=
MY(@Y(V!2< C=QC%%QXB\0:7JFO:5/>VETVGZ0=2AN/LI1BP)^1@&((^7'&#S
MZT >@U0TS6M.UG[5_9]TLXM9VMYBH(V2+U7D<]>U<?:^,M5FN_ ^];7R]?MW
M:Y01G]VRQA\H=W&2V,'/2J4'C#6+?P_XIOH[.VDN=.UEK3-M:M@1@J&E9 26
M(!)//Z4 =_JNKV&B6)O=2NH[:V#!3)(>,DX JZ*\VU?Q9=I\.=2UJWO-'UN"
MWEB$<K6YVRJ2@(DCW?*X8[OIC@5J37VIVOQ)O$FU*+^S+?25NS";<G:ID8-C
M#?>PG4@^@% ':T5P&E^+_$>HSZ)=PZ3YVG:BP,Z):R(;6-L;&\UCM?&><*/:
MK/Q9O=0T[X=ZC=:?=FVD4HCLJY9D9PI /\/WNO\ ^N@#MJ*Y8:OJUSK\F@6E
MQ9BZM+9;BYNY+5BA+DA$5/,!!P,D[C].>+/A/Q%)K]G>+=0I#?V%U)9W21DE
M-ZG[RD]B.: .@J*YMH;NVEM[B))8)5*/&XRK*>H(KBKGQ;>IXWGT:6]M=.*2
MQK:P7=LVV]C;:799=P 8?, ,=<=>T=WXOUBVT3QA=8LFGT2X*0'R6VNFU6PP
MW]?FQD$?2@#>TCP1X;T&^-[IND007."!)RQ7/7;N)V_ABM&XUK3K;5[729KI
M$O[M6:" YRX4$DC\ :YB#Q#K&OWBZ=I5Q:6=Q!IL%Y<220F3?)*,K&J[AA>.
M3R?F'UK$UR37+CQI\/7NH+2TUEX[[S$+&2*-O* )X.2,<XS[9[T >HBBN;\'
M:YJ&LVFIIJ<=NMWI^HRV3O;@JDFP*0P!)(X8<9/2J.M>)M577=1TK2(E\VRM
M8Y2SV4EP'D?<57Y&&T87J<YS[4 =E17GNI>,_$.C:7HVO:KIT5II4SB/4[<P
MLT]J22H8'=@J3@_=R 0.2:O7GBC6-(\.65W?06[WVIWJVUI'#"Q$2ODJ7 =B
MYV*20I&3Q[T =I17 2>--:TTWZZEIZ^49H(-.NFMG@6:24[2&1F)^7KP1D ]
M*M:OJ7BSP_H^MW4TEA=16EI]IMKMH"FYP26C:,/G&,8;(_&@#M:I:IJECHVG
M2ZAJ-PMO:18\R5LX7)"CI[D"N>?7]5D\2Z/ID3VL<.HZ;)<LYA9GCD4+@CYL
M$98'!';KS7':'JVMP?"/5]9>YL[N5)[B4I=6Q;<WF$L3\V.O(&,"@#UU'61%
M=&#(PRK \$4ZN1FUG4=6\37>@:3=PV+V%M%///)!YI=GR0@7( &!DGKSQC%<
M\_CW7YWTBVAAL8+Q]7DTJ^62)RGF( =Z?-G:0P..O;/>@#T^BN3\':MK%U?Z
M[I6M307%QIETL:W$,?EB1'0,,KDXX/K2^*M8U&RU&SL[6Z@LHIHV83&'[1++
M(",1I"#N(QDE@#C':@#JZ*\PM?B%KNIV7@^6Q@TX2:XTT4PE1\1/'D%A\W3O
MCVQGG(NVGC/5K33K^TU#[+<ZM!J\>DV\L:%(Y7DVE79<\8!)(!YQC/>@#LEU
MO37UMM&6[C.HK%YQ@&=P3.,^G<5H5YK8P:C;_&V"/4KV*\E&@MMEC@\KY?.Z
M$;B,YSR,<8^IZWQ)JUS8-IUC8>6+[4KG[/%)*NY(@%9V8C(SA5.!GJ10!>M=
M8T^]U.\TZVN1)=V84W$84C9NSMYQCG:>E6KJYAL[66YN)!'#$I9W/10.IKR6
M/5;KPAXR\9:IJMVNHW-M8V@0K$(O,WL%7(' P2 ?;FNF2^\4&34+?4+4RZ7+
M82R?:7A2%HI=OW !(VY<9P>OJ30!OKXKT-[73+H:@GDZI((K-RK#S7)P ...
M?7%;0KR?P[J]WI/@/P L"V+17M[':R?:8R64,SG<A!&&P"!P>2*WF\9:AI>N
M^(],UC[*'M+9;O3?)A8&>,D@@Y8Y8-L7C'?\ #NJ*X35=?\ $4FKC1-. 6]M
M;".YNI8+99 \K9 0!W&U,J><D\CTYJ77B'QK<:AHFF1VUCIE]J5G.TD<R&3[
M/)'CYMP8@J<C QQGDGI0!Z-2$X&3VKA(/$.K:%XQN+#Q-J$+6,M@;JT:. (I
M9 #*H/4D#) ]/>NJT Z@VA6;ZK)OOI(P\OR!-I/.W ],X_"@!=(UO3M=@GFT
MVY$\<$S6\C;&7;(H!(Y Z9%:->*:3JNO:!X=\3ZUIUQ9K9V?B&<S6TL)9Y]S
MHI&[/RC!'0$UU?C'Q+KFDWFIM9W=M#'8VJW,%NMO]H>XQDN9<',2 +@-QDD\
MG&* /0*BN;B*TMI+B=]D4:EG;&<"N"U?QG?6^L0V[7=OI$4MC'-:2W=N6@N9
MF!)C:3("@<#C!YSGL>^+,UOEEVL4R1G.#CUH AT[4+75=/AO[&836TZ[HY "
M-P]>>:M5X]H>M^)?#/P[\/:W_H4VC1I'#-9K&WF^6S;1)YF< Y(XQCGJ>VW/
MXH\5:FVI76@632"QOWM([0Q(8YQ&VURTA<,I/)&!@8'7- 'HU%<!J'B/Q'?W
M>KQZ':S++IKI%' (8W2:38KD2,S@@?-M^7W.3G K/KOC._UC4;".?3],:WTR
M&]V/;&5XF;.Y"=V"<J1NZ8[9YH ](I,Y..]8?@W6I?$7@_2]6G4+-<0@R #
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MA]W.?IW%4?!.AW>L^#_"[WVHP2:;9I%<PP0PE7:1/NAWW$$*>P R0,].?1R
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MWV6Z:6U/DSINW [%<%6'0')XXK9T/1H]%LY8A)YL]Q.]S<3;=OF2N<L<=AV
MYP .3UK4HH Y/7/!]QXA6ZL[_4XI--GN4G6)K4F: +MRL<F_Y<E>NW^(U1U;
MX?7.H-KL-OK[VMCK++)/ +4.RN%"\/N'RG R,=NO6NZHH XF?P%<Q:C8:EI&
MORZ??V]FME,_V=9$N(U& 60D<CUR>@JPW@J;^W?#VI+JQ<Z.)B1/!O>X>48D
M9F# #V ''N.*ZZB@#!\->'[C09-6>>_CNAJ%Z]Z0EN8_+9@ 1]YLC"C]:H:M
MX/OI_%/]OZ-K\NEW,D(AN(S;B:.8+G:2I(P1GK_]?/6T4 <W_P (O)++:QWN
MH?;K"""1&M[F(L997SND9MV.[ +MP QQVQBQ_#B9_"$?A^\UUY5M)UN-/NH[
M<I);.N=O5SN R<#@X[],=]10!QLO@N_U;0+NQU[Q!/>74R(L<\,0A6!D;<KJ
MH/+9P22>PQBE3P5>W>DWEGKGB&XU*6>S:SCE$"Q")&^\VT$[F.!R?3ZUV-%
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MX4M8H'97D2)2S$LP_O,W3T4?AJV6CVUAJ6H7\+3F:_9&F$DI905&!M!^[^%
M&A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4457%]:&\-H+F$W(&3$'&X#Z=: +%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 &N%U+0--N_&6F'2K:**\L;MKW4+Q/O@,IQ
M$S=27+ [2>%7L"*[JL0>$/#ZZA]O&EP?:S+YYE())DSG=SWR!S[4 ;8Z4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 44F:;YL?F^5O7S,9V9YQZXH ?111
M0 4444 %%1O<0QR+&\L:NWW5+ $_05)0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% 'GOC-)K#69]8N]*BU?1!:+#<I'AKFQ(+$R1@],AU)(P?E
M!Z"E?7[R+68=.L=2N&L)-*MKBUECL#.<NS("Y'13M!R<=3S747GAJRO+NYN3
M)=PR7:".X\BX9!*H& ",\<$C(P>:A?PC8&[>YAGO;9VMDM ()R@6),[5'H!D
M^_- %*SU'6?$,>IW>EWUO;QV]U);6T4D&0YC.&+L>1ELC@<#'6JLWB#6/^$>
MU/Q)'- MM933[;/R@=\4,A5LMG(<A6([#C@UN+X9L8[B66"2[@28JTT,5PRI
M(0 ,D>I  .,9QS39_"FF7#SAQ<?9[B7SYK43,(9'R#DK[D D#@]QR<@'+W'C
M'5K8:S:S,JN'?^S+L0@J2J)(T;C.-V&R/4 ]Q5^YU'Q%&_B1[;4;5FTIE,44
M]N DB^4LA#$'(/) (]JW)?#.F7%C?V5Q$\\%[<?:95D<G#_+@J>V-JX^E03^
M#],NI[V2X>\ECO9!+<0&X81R$   @8X  &.G'- "ZKXB%EX0&L)&_G3P(;>%
M4,C-(X&U0HY/)YQV!KE?"&KMIGAWQ)I*7%R\FC>;<6\US"RR20N&D5BKA23N
M#@\ 5W5WI-O>7EA=2-*KV,C20JC[5R5*G([_ "DC\35._P#"FEZCJ4^HS).M
MU/:-92O'.ZAH6S\I7..Y/3K0!S[>+]0?2].M?W46L?;H[/43M&V(B6.-RH/]
M[S%*YZAL]JFTC6=6U'7=1LFNYP+:_D@4K89B$:J&&Z3H&YQC/IQ6S=^$]*N_
M-=HYDGE>!Y9XY6$CM"<QDGN0?SP,TEMX5LK6YGFBN;[$]R;N2,W!V-+P<X_
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MKB2.0RE5*JK93&T*SC QG>2<G! !NZ7<7FH:6DVHV<-M),N?)BG\T!2.,MM
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+2S%Y$NY<7*9VX0Y^]NXP1W'K4ECX<DT^;7)K?49$EU60S;Q$N8'V[05SD'
M X(ZBGWOAFUU'4='U"\EDENM,SA^ )L@?? _V@K@=B!0!F7EY?1_$G0K?[5<
M);75C</+:%AL#KMP>!R?F/4GVKKZQ[K01=>*=/UPW+*UE#)"L(0$,'QDD_@*
MV* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
LH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>ibcbankplazasecondamendm003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibcbankplazasecondamendm003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M S?HA'>@#T:HVGB1"[2(J@X)+ #/I7%Z_P"*/$2:-.+'PKJD,\DGD1S 1RE
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBP-#IFGVUG&QRRP1A=Q]3CK5ZB@#+N?#>BWFFQZ=<Z7:RV44AE2!HP45SG+
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHUD /4 C-34 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKMT#"T$)GU.!C A_N<]?>K,5CKZSO<W7A_5KFY^R-:1S/=VP9$;J>#R>.IH
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MM[>Y,<-QCCYU'7/?D9R?6K5YX*L;Z>]\^]OC97LJ2W%@'00.5"@#&W<!A%R
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MAII<$&EPQZGJ^S39Q/;AKA6PPZ=5/ '&!@?C5U_ UG))KSMJ6IDZVFRZ!D3
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MK8LO V@V>F75@UJ]W%=((YVNY6E=T'W5W$Y '8#&#SUJ:U\+65IN87%]+/\
M9S;1SS7!=XHSC(0GIG YZG ]* /,=%U76QH7@;Q%-KNH7$^H:H+&>"20>4T;
M.Z<KCD_)G)R<GZ5IZO<2>)_"_CC4)[^ZC?3Y+BTM[:*9D1(XU_C08#%^<[@<
M=L8KJT^'>BQ:5IVFQRWRVVG7)NK51<',<F<YSCL<D?[QIVH_#W0=2OKVZD6[
MB-\N+J.WN6CCF.#\S*#@GG/UH W=$_Y .G?]>L7_ *"*O56L+&'3;""RM_,\
MF% B>9(SM@>I8DFK- !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &+XH\3
MV/A/2!J-^3Y9E2%5'4LQ_H,GZ"MD$,H8$$'D$5POB.SN/%.J:E9QV"W=E9VS
MVB[I551<R("7YZ[590/0LU9GAW49]5^$FK:;?RS0ZGH\,UI<>7*4D5H@2AR#
MGH ,]\'WH ].HKQE-+,=Q\/G74=2WZS9^3>M]K?]Y'Y"'8!G"CG'&#WSGFF2
M:C>>&O#_ (ZLM.N9TM[+4((X7=VD:!)-H<@DYZ>] 'M-%>5MHDMC%J4R^([0
MVMWIDKQV6G^:N_RQN64.9&((X!(P#G!ZU0T.U%A9_#W5UO+PW=[+Y,[27+%9
M%,;83:3C&0,8]>Y- 'HOC'Q#+X6\-7.L167VL6^-T?F[, G&<X/<C\ZVK>7S
M[:*;&WS$#8],C->)ZV+3Q'\(-5\0Z@S-K8N&\T><P\AA-L6+;G  3'R^O/6M
MZ/0X-8^(UQI]U=7XLY-$@G>&.[=06WX['@< X&!F@#U*BO"].GO!X3\(^(FU
M"\DU,ZS'I_F/,2/(W.NS;T/ ZD9]ZUYX;KQ;JOBF*?5[33[JQO#'$TWFK);0
MI@K(F)% !P23CG/.1@4 >NU3N]3L["XLX+F8)+>2^3 N"2[;2V..G"GD\?F*
M\T_LR/6O$NMPW>I7ES%_8MM<,8IY(E>3#'>%SE1P#MZ<\@UC6L,&LCX8WFI+
MYTTZ3V\SR.3O1 =N>>OOWH ]PHKD_B0N/AUK#1RRQM%!O1HI&0@@CN#R/;O7
M&0:+&WC'P]8&^U'[-JNC&2]3[9)^^( (YSE1TX7' QTSD ]=**QR>?QI=HQ7
MD5O<!/!UOI,]]?/CQ%)96T*RX:X1';$3R'HGJ>3QC!J33M"N/$&@>+]$,WDW
M-K?EK)(+IW2"3RPVU6.#MR2#QW/ H ]8" '.:Q/$&N76C76DQ0V23QW]ZEHT
MC3;/++ G.-ISPIKG_!UVGBF?3-3,4L']CVAMI(>0!<MA9%([[508_P"NE6_B
M%;"[B\.6[2RQ+)K<*EXGVN/DDZ'M0!V6*3%>)>(I-0\%7WB?3]!N+LZ<=/@E
M8O*\OV1WE"'!))&4W'KGH>PKJ?"&AG2_$D5]!KVF2VU]:-BRL(G"3;2#YW,C
M<C(!/?..M 'H7E*#D<?2G8%<%\1;IQJ7AO3I[N&UTV]GF6Y>X0M$Q"?(KX9<
M@DGC< >.N,5B7OA*S@\+:OI\>O/=74=RLEB+.-E%M*_*P(-[94\?+G@')]:
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M2WMQ>2:7:-<W*&.:4Q M(I&"&/<8XJE$S^&8KVYUC6IKJR9D\AKA5,BL<C8
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MYQL$>W=NSVQ[]*RM>\3Z/?>%K^>'7[G2XX)Q;S74=K)YD$@()4HRY&1QT[T
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M$& H'  '84^LGPO-+<>$=%GGD>662P@=W=B69C&I))/4DUK4 %%%% !1110
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M Z#(_.N8O[ZRGTCXC-$CF>ZDVQ'[.X:4>4J#''(WAOY]Z]<5E<95@P]0<TM
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***0G
M)YX]* .+^(VKZM::2;3P^^-2$;7DA!Y2"+YF/_ CA0.^2*UO^$LT]?!L?B<K
M,]DT"SL(4WNH/7@>G.?3!K,TO2H_$E[JVJ:I::E:R3/]ECADDEMS]F4<#"L-
MP8EV]LX[5R^BVVJ:?X*\5^&&T74GM46X&EL\+?OHWR OJ#DY^A/I0!U"?$K2
M&EL4-EJJ+J$'FV;M:_+.VT'RUP<EN<>F>^.:M6OCS29]'U/49DN[,:9+Y-S!
M<QA95?C V@G.20!SS7-1Z9J<TOPX*Z9=@:7!B]+Q[?)/E+'SGW!Z=N:IZAX2
MUO5;;QO'%8M')?7D%S9"?;MG$9R1UP,X[^M '3P_$73VGO;:YL+V"[MK<W7D
M QRF6('!92CE<CN"1BC2OB+I^JWFE0C3M3MHM44_9;B>$"-W R5R#G\<8-9=
MK;:E/HNH>5X&M=%8V4D;)"L1DGE9=H5-N,*,Y)8^V.]5+?1M:AT3P%:_V7=K
M+IMP&O"NS]TH4J>_.=W;/'OB@!/B;XI-UX.U-=-L=2DMX91%_:=O*$B60, P
MX8,RCE<XV[OPKH7\=6UE.^DIIFJW=_;64=QY<,&1*I Y4D_7DX'&!D\5QMUH
MGBRU^'>H^"(?#\MWLE80:@MQ&$EB,OF;B"<[LG&/KZ<]-I=KJD'CVXU6;2+N
M.V718K8$E#NE4[BHPQ]<9Z9'IS0!<MOB1I%R-+D2TU$6FHR)!%=O"%B65L_(
MQ+9SQC@$9[]:DUOQ_INBW%PK6UQ=06;!;N>W:,B%CCC:6#,1D9V@XS]17)/H
MFN/X!\*:=_8MV+O3]5CN+B/*?+&C,20=V#D,,?0TY_#VHZ+XMUE'\&67B"VU
M2Y>[MKR58_W+-U1RX.%!]/PSG  .HN_B)IEOJ%U91:?JUW-;0K<,+:V#!HF&
M[>"6'&/7'4 9JCJ7C^9K_P +C2-.N;BRU=C)YJF,-(H0DQA6888$KDD@<8&:
M6&QU.+Q9KUP^E2K;R:5%:P/$JA)70-D(N[('S8&?2N?LO#_B'3](\ R+HLTT
M^DRW'VJ 2(I3?PIR3C'.>* /7 <@$@CV/:N/U;Q-J,7CRR\/0Z3<O:2V[RRS
M1RQJTJX RN6!4*2,G(;T'&3JZ#KMUJM]JEI=Z8;&2QE"#,ZR"13DAN!\N0,X
M/."/6L3Q#8:M'\1]#UFRTR2]M8;66"4I(J^66/!.3T^F: .9\"^-(=#T86M]
M::E+#+JTL!OBNZ*-G?"AG8Y/J<9QGUKK];^(&G:+>74+6UQ<QV147LT+1X@W
M8(&UF#.<$$[0<5Q1\-Z^/AX-/&C71O!KGVOR@4R8M^[.=V.E:9TG7M"\6:T\
M'A2#7++5;A;B&XFFC4P,PPP;<"< ^G84 >C+?PS::M_;;KF!XA+'Y(R9%(R-
MH]Q7%VWQ8T>Y6TN/[.U:+3[B7R3?2VX$,4F2 K$$^G;/4>^.VL89+?3[>&;R
M_-CB57\I=JY YVCL*\=\+6-[XE^$D7AVWTZ8+<7C*UX^WRDC$V]G'S9R,$ 8
MZ^W- '>ZIX]M-+O+I9-.OI+*RG2WN[U GEQ.X7 P6#-]Y<D#\ZKZE\18++7+
MS1[?0M7O;VU*;TMX000QP&SGA>G)QUKE?%.A^)]977H;C0;B_N/M@?3[AKJ,
M0PVZLI C0MQ(0""<9.3SV/3^'K+51\1];U6\TJ:UMKVT@5'9T90Z !ER#[^F
M.#0!DS^)Y=9\'>))/$.A:DNG0SRQN+>6$L@1PNP$,#D$9).1UP2,5T=]XML]
M%AM[.VLKFZ=+);@QK*@,<6"%R78;F.T@ 9)P:YRZT[Q GA/Q=HRZ#/(UW=7,
MEM*DT>)1-(2,#/  .3GZ4EYI6O:;X@MM:M?#4>L6UYI\-O<V4SQ));RH.#EL
MC&">F?Y4 =)#X\T[4$TP:3#-?3ZC!)<0Q*R1D*G# EB!NSQ@9Z$]!FMS2M2_
MM31;?45MIX?.C\P02 "1?8CUKA];T&YO;:TM=0\/-)*())HKW1RL3V,Q)*HI
M++D8P,]R,D#/'8>&K?5+/PQ8PZU-]HU*.+]^ZG)9O3/<XP,^M '-'XI6 M7O
M'T76$LX;LVES.T *V[ A?FPQSR>BY_45KZ7XQ@U#6+C3)M-O["XCMOM<:W2*
MIFBSC< "2#GL>1WKBFTG7AX"UZP30;PW=_K+7,<1:,$1-(K[B=V.B8QZD5MZ
MGIVO7?CYM:T_3Y8470Y+6*:5H_EN&)=<C<<@' /!&?;F@#3T_P <Q7^H:7:'
M2[N#^U8))[-Y&3YU4;L, Q*DCGFG:;XV@U#2-9OGL+FU;297AG@F*[RZC.!@
MGKG ]37):9HGB5-:\,ZO)X91+NU,T=_//?*TLS.FTR,V#\@Y(7G&<  8)UYM
M"M]1^)<=W87ZO87%JEWJ%O&=R2O&^(&)'&20?^_1H [A;@I8BXNU6 K'OE7=
MN$?&3SWQZUQL/Q-T^XOK*"*&-H=0<Q6<HND)9_X!(@RT88X )!QGD#I78ZA9
MKJ&F7=DYVK<0O$3Z!E(_K7#>%X/'.E65IH5WIMFMG880:C'<*S31(<A5C/0L
MHVY;&,YZT :-CX^CU!KFTBTNX35H+L6C:?)*@DSC)?J?D S\WH*;KOQ&T[1+
MJ\B\M;A;%E6Z*W,:N"0"0B$Y<@$9Z?B0:QKG1/$L>L67BZRTJ4:X\[Q7MGYT
M(1K7C:A;=@D8!#<DG.< * @T?Q!I7B34YK;PM9ZK9ZM(+I'NI8U>TE90&5^N
M0"/X<].": .EO?&<2F8:383ZI]GM5O+@PL%$<;#<H&>2[+DA?0=LBI;3Q=!>
M:Y;:7%9W >ZL/M\#R84%.!M(/*MDXKGY+#Q5X9\6W=]I>EPZQ::E;01RXF2W
M\J6)-H;'92,G '?MCF>^TOQ-:^,])UN&R@U-QI\EI=%9E@6-F?<",Y)4=. 3
M@>O4 CU3Q[>/;:%)INFNHU#5/L<ADD7<I20AE';YMI&>P/KTN:U\1]/T6:YB
M>%97LE5KM!=1*Z%AG:BELNPXSCCGJ>E<['X=\6PZ%I2/ID;W&G:ZU\\$-T@%
MQ&7=\@DX&"W )SR/>IVT;Q)HWBG4;J+PQ8ZU:ZLR7!,LZ*;27;AE+,,E1CL.
MF._% 'I%C>P:C86]]:OOM[B-98FQC<K#(/Y&N6L_'\%Y?:>G]FW,=GJ4\EO9
MW+, 79,Y)0\JIP<'G\*Z6U@N(-)AMV>,W"0A"Z(%3<!C(7L,]J\I_P"$:\87
M$F@WUQH,+ZM8WZS7E[)?)YERN6X4C.V, \K[C"]: .@N?BDEM!J<Y\.:F8=,
MN?)O'W1?NA\HR<,03DGA2>F21FM;6_$"WBWVDZ=IC:LR68GN5$HC5$<'8N3S
MO8 D#C@<D5R]]X;UZY\*^,[&/1)5NM7U$SV^9X>8R5QN._C&P_\ ?0]\7K72
M_$VA:Y?7=CI"WMMK%I;B6.2[2)K2:./80>H88ZE<]/S +_PD.?A=HQ/I-_Z.
M>G:S\1]-TF:[VK%<06,PAN2MTBR@\9V1DY<+D9Z<YQG!JU\.]'U'0/ ^GZ7J
MD"0W5OO!5) _#.6&2.,_-CC/3K6'9Z7XP\,:UJ]EHVFV=WI>I7;7<5W+<!#;
M/(!NW+U8 @' ';WX -2Y\?PV.LSV%[9B"(VC75C=-/F.] QA4X^\<].3]>*O
M2^)[F/\ LVT&D2-K%]"T_P!A,Z@0HN,EW[=0. >3[9KGO$_A_7O$0NA):W$<
MVDHCZ/<I-%NGN 03*PR OW1@$ 8+'K@".XL_&;WFC^*(M'B;6+:W>RO+"6Z0
M+,AP?,1@2J_-R0>>W(H 9K>M07^H>$/$*Z3J"W:WTUN;4QD2Y\IP5 ) (W8^
M;ICN.:V[;Q\DFB:G>W&C7T-YIUT+6:P7;))O8@*05XP=V<].#C/&:UU9^)KO
M5?#EW>:=YK07K75P(98PEJC1F,1@D@N1G<3CUQV%8MYH/BV0>*)+&PEMGO\
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M2]<@DA^<32&!X)RS9:,A3A I4=<_+[G(!V5A/-<Z?;7%Q;FWFEB5Y(2<F-B
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M9U663>5+<G!],\_B:XNTUGQ+::IXUO))+&Z.F!-L3;T4(L9D 7KCACDXR3W
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M&ZE71QD,#P01W%>6^&?$=Y!X:\+^'])&+R73#=S2?9_.,<0;:,+N4$EL]3P
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MSOI<%GYD$TT21/Y^0H1@LC J2<YZC%/'B+QG T\DNE/]E%A)*T\]LB"&95+
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MHS%XF//F#@9PWTXY]JR=.\#>)[?4?"MS/J&D*FA*\(CBAD.^-E"LV21ER![
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M3RK&<QHYSMP,+D@<[>V:>/!U_P"5XL0W]M_Q/P5&(6_< H4_O?-P?;FNSHH
MXVVC\1Z=XAT#3DU"&XL(K/9?1I:[?NJP63><XR0@VY_O'&.ESQAX<O=?&E3:
M?>Q6UUIUXMTGGQEXW(!&" 0>_P#.NFHH \TO_AQK-]8ZW:R:_;NFI74=V=UI
MC$B[2>C=/E  ],YR:U]3\&76NZ[?7FHW-J+6[TO^SFACC8LHSOWAB>H<G''0
M#O7:44 >>P>#?%4MQH3ZCXAL9$T>;=%LLSND7;M&\[ASCCCUSS77:Y::I=VL
M(TF^BM+B*82,9HMZ2H 048 C@Y'/;%:E% 'GDOPYN'T6]6&]M;74[C48M20P
M0$6\,J8P%0G)!YR3Z]*E;X>76I:KJ5YKFK)=+J5@+2XCBM]FPA@P*')P 0.H
M)]Z[ZB@#B])\->)K>#R]7U^&_%K$Z62+#Y09BA16E(Y. 2,#USR:IP> -0M_
M"GA_1$U.T/\ 9%\+P2M;L1*59F"XW<??;/X5Z!10!2U>UGOM'O+.WDCBEGA:
M)7D4LJ[AC. 1GKZUQ\?@?68;#PW'#KENESH8>.-VM"T<J,H4;DW?>4#@Y[UW
MM% 'G?\ PK6]_LRXB_X2%Q?+J;:E9WBVX#12-G=N /S;L\]!P..U:T/AOQ##
M9><WB03ZRTL;/<R6H$1B3=B/RU(&#N))SD_@*ZZB@#SR^^&]S<:1J-K;:A:6
MT^IWJ7=T4M6\H%""HC3?QR,DDG.3TK1A\*:O!XAUW5UU.R\W5+:.'8;5L1LB
MA0WW^1C/'TKLJ* .%3P1JBZ;X8M#JEF?[#F616^S-^]"C: ?GXX)S4R^$-27
M5_%.H#4;3=KD"PJOV=OW.U=BG[WS?*3GID^G2NTHH \]7X=7UKIFB-IVMK9Z
MSI41MUO$M]R30DD[&0GGGW]?P[#1=.GTVQ*7=Z][>2OYMQ.PVAG( ^51PJ@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !115
M=+^SEO'LX[N![J,;GA60%U'J5Z@4 6**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ -<-J&FQ:;\0-"O(])M8[>>:=!<V[8G>9XV8F7*\I@/Q
MD\X/'2NYK,L_#^EV%])>VUH%N)&9B[.S;2QRVT$D+D]<8H TZ*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **8TB*ZHSJ&;.U2>3CTI] !1
M110 4444 %%%-5@ZAE(*D9!'0T .HHHH **** "BBB@ HHHH **ADN[>%]DL
M\2-Z,X!I\<J3+OC=77U4Y% #Z**C$\1E,0E0R#JFX9_*@"2BBB@ HHHH **K
MRW]I#<+;RW4$<S8VQM( QR<# Z\GBK% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>-8Y"L\BB95Z"0!L/_P+-1S>$M#GN)IY+(EYF#2CSG"N0 !E0V", #&,8&*
M,CQ#;B3XE^#GVQG;'?,Q9020(TQCW!.?SIWC74+N&72(--O[N*:74$M[B&R,
M)D*/'(P_U@(!R@QG'&:VM1\-Z3J][#>WUJ9;F!2L4@E=2@/7&TC&>_K4#>#]
M!>)8VLB0LQG!\^3=YFT+NW;LYV@#KTH PM9U_5M(\+6L<'VV;5[F5_)6XME:
M54C)8B18QMP<*FX#'[P'WJ+Q!XDO_*L=9M+JY@T&2R6:2XM(TE:W=CD-+&P+
M%, CY<$$-GVZVRT'3=.N%GM8&2549 QE=N"<GJ3GD#\A5+_A#- $?EK8LL97
M8R+/(%9=Q;:P#89<DG!XY- &5'?ZM>>,[^SBNM4^R6\T6QX8[?R$5HU<K)N'
MF'/(&/7K7:5@R^#M#GO7O'MIO.DE\V0BZE"NW^TH;!'&,$8QQC%;U !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MLTZ^6L<_WU VY_'.?<XJS'X$T](HH9+W49HEL6T^1))@1/"<X#X4<C<<;<4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
G%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>ibcbankplazasecondamendm004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibcbankplazasecondamendm004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV2W@LVO+<71Z0F5=YXS]W.>E>;>$K_4=)&N1Z/H\&MA]29W?3;B.&V3,:$!
MW&>Q ).0,]:R;HVQBU&6>.%?$"^+8S"'VM<*I=-@'?;M!QVP* /4#XL\.+<F
MV.OZ6)P_EF(WD>[=G&,9SG/:M)[NWCN8K9YXEN)0S1Q,X#.!U('4XR,_6O/?
MA[8ZC)I;3(FDFR_M"Y+"2V9IR!*V?FW8SZ<>E<]I=WKLWQ3L=0U_3K^VENHK
ME!$\BI';P * 5.[/ R6/!)/ H ]9@UW2+J:XAM]4LI9;<$SI'<(S1 ==P!XQ
M[TVP\1:)JLY@T[5["[F"[C';W*2,!ZX!Z5Y3I%UX<U;49;G2)+&PM+#3KFVL
MK<.HN;TE#N>0?>P O ;)/)I?#$[KJW@1WU+2+PB$Q):V2!9X@UN<F4Y8M@#!
MZ<\T >IV?B70=1N5MK'6M.N;ALD10W2.QQUX!S1'XET*6_\ L$>M:<]YO,?V
M=;I#)N'5=N<Y]J\7\-W7EZ1X,\R^TJY":FGEV-NNV[4EG7<[ G*C=N(P,C'-
M3RS,EG<;M2TEDB\0O(NGJ@%[*PNNBMDD>OW>@H ]I75]-;43IRZA:F^ R;83
M+Y@'7[N<U#+XBT2"_%A+K%A'>%@HMWN4$F3T&W.<UY''+ /'$M[YUCO7Q08_
ML0 ^V,>(]X?KY?\ $5QC@C-;.B7'A"W\"RV?B(6CZA'-)]OMW.;F2?S#T .\
ML3C!'\J /3Y[JWM?+^T3Q1>8XCC\QPN]ST49ZD^E5_[:TO\ M+^S?[2L_M__
M #Z^>OF],_=SGI7D'C2ZU^?QAI=]>Z/J*V%EJMLFGQ*R%)?GR223DN^  #T[
MGK4>F"2UUF"ZOKFPNM2?Q"R2:8]LHNHV,A_>"56W$!<'&"F.* /:A>6QO#9B
MXB^U!/,,.\;PF<;MO7&>,U/7(Z?I-IIOQ&NI;=6\VZT\S32.Y9F8S'N>P& !
MV %==0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBU6>Z"6,H4I,4;!#?=/3(!X_,>M1-XETA-273GN]MXT?FB%HG#%/[W3I[]*
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M>7Z9+*!SGCUH UZ*YRX\=^'[2&YFN+FZCAM9/*GD:PN L;>A.S /(_,5:O\
MQ3I&EZ/'JU[-/!8R $2M:2_*"<#<-N5R2,9 SF@#9HKG;CQSH-I+;17$]Y'+
M<@F!&T^X#2@#)VC9SQZ5/;>+='NY9HH9;HS0Q><T3V4Z/LSC<%* L,GL#0!M
MT5S,/Q!\,3VL=VNI,MK))Y:7$MM+'$6]-[*%S^-:.L^(]*T"&WEU*Y:*.YD$
M4++"\@=SR -H/)[>M &K169#K]A/>P6@%W'-.6$8GLIH@Q )(W.@&< GKVJ"
M^\4Z;974EJ@NKRYB(\V*RMWG:+/]_:"%^AY]J -JBLE?$ND/HLFL1W1EL8]W
MF21Q.YCV_>W* 67'?(X[U4@\<:!<06UQ%<W)M[E@L4YL9Q&Q+;1\Y3 Y.,DT
M =#116?K.MZ?X?L&OM3F>&U4@-(L+R!<^NT' ]S0!H455T_4+?5+&*\M#(T$
MHW(SQ-&6'8X8 X]\5:H **** "BN<7QQHS:?JUZ#=>3I<ABN?]%?<K 9^[C.
M/<@ =ZWX)DN((YHR=DBAUSZ$9H DHHI"<#- "T5EZ'X@L?$,%U-8&4I;7+VL
MGFQE"'7&1@\]Q6I0 4444 %%9-[XBL;#Q!IVBS"?[7J&\PXB.S"+N.6Z=!T&
M3R,XS5^]O(-/L9[RZ?R[>",R2/M)VJ!DG Y/X4 3T5@GQCHPOTL2]Z+N2/S4
M@.G7&]DZ;@-F<5J:=J-KJMDEY9NSP.64%HV0Y5BK JP!!!!'([4 6J*** "B
MBB@ HIJ2))NV.K;3M;!S@^AK+U[Q'8^'(;:6^$Y%Q.L$?E1%OF8X&3T'XGZ4
M :U%%% !1110 4444 %%%% !1110 449 &2:9%+'/$DL,B21N RNC A@>X(Z
MT /HHK*T_7[74M8U'2XH;F.XT_9YIFCV*P<M@KZCY#STZ4 :M%-=TBC:21E1
M%!9F8X  ZDFLV77[6+Q%;Z(T=Q]IN(6FCD\O]T0N,C=W/(Z9ZB@#4HK-US6H
M=!TTWT]O=7$8=4*6L7F/\QQG'I6E0 4452U?5K/0]+GU*_D\NV@&7;&>^!^I
MH NT4@8,H92"",@BEH **** "BBL?Q+XDL_"VDMJ5]%<26ZLJMY"!B,G SD@
M#DB@#8HHHH **** "BHY)X8I(HY)45Y6*QJ3@N0"2!Z\ G\*DH **** "BBB
M@ HK!UGQ1%I=^+""PN]1O%@^TRP6@4M'#G&X[F&>> !DFM>SN5O+.&Y1)465
M X25"CKD9P0>0: )Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *X7XA_\ (6\&?]AN+^1KNJY[Q+X:E\076ES)?BU.G7*W48\G?N<=
M,_,./;]: .=\7^%;O6?%<FJZ1=-;ZW86,#V3YPI/F3;E;L0P./P]":70/%<'
MBKQ'HDAC-OJ%M!>0WMH_#0R Q9X]#SC_ !!KK(M+O4\02:D^H(T4D*PFW%O@
M *6((;=G.6-0?\(KIZ>,5\31!H[TV[02A?NR@XP3[C&/I0!NUY!>HNCZGXW\
M+R(I36$2[L$8[5,D["(_E(R_]\UZ_7/ZSX4MM9\2:)K,DFR72W=@NS/F;AP"
M<\8(ST- '(^$-4DU[1="\/3J?M&GSNFHJ>0!:E0@]\LT1_X"U:%[#'<_&J&"
M9 \4GAYT=3T93,0171:/X7L]&UO6=5@),VJ2K)("H&S Z#ZDD_C4,GAF=_&T
M?B4:@H>.V^R"W\C@Q;MQYW?>SW_2@#*UR-(OB=X+CC4*B07JJHZ "-<"HOB%
MX>M=:&C:81Y OM29GEC&")!;2[7XZD%5_*MO4_#EQJ'BC3-;345A.G"18H?(
MW!@X ?<=WH.,8Q[U9U?1I]3U'2[J.\6%;"<SK&8=^]BK)R=PP,,?QH XO3_$
M%VL(\+>(V UNROK3R9G_ .7V+[0F)%R.3C@]^OO4FK7%_;?&N-].T]+Z8^'\
M&)IQ" OGGG)!]N/>NLUOPO8:Y?:9?S*$O-.N$GAF4?-@')0^Q_0\U4G\+7C^
M,6\20ZLD=Q]D^QK$UKN41[M_/S@DY[_I0!GWFCW7BCPCKEKJ<":/?7\OD[@^
MX85AY66XW \#CKDCK61I'B74K/7-'T#QOI317L<V+#4H3F*>3:R<XZ$J^/J1
MD"NHN?"MS?P:@+[5WDGNQ$J2I %%NJ/O&Q22,YYW'G('7 I\GAFXU#4+"YUG
M44O(]/F\^VCCM_*_> 8#.=QW$<G@*.>G% '&W+^(/A]JVL:E%9KK7AC4+J2[
MN!$1YMLQ/SY]0,8],*.5YKT/P_<V-YX=TZ?3"WV%K=/(W=0@& #[C&*R(_"=
M]!;:E:6^O3"TOYII7CD@5S#YC%F$9SQ]X]0W/-;VEZ;;:/I=MIUFA2WMHQ'&
M"<G ]?>@#DOB;:SPZ/9>(K.-GN]$NDN\*.6BSB1?I@Y/L#7-KXFMM*^)L_B)
MI$&AZM UJDROP\D,:/O/MR4'OFO5;VSBU"PN+.==T,\;1./56&#_ #KE1\.M
M+_X1?1M"DE=X=+NDNE?: 9&!)(8>C;CG\* ,;Q?:W%M\%-3>\&+VY5;JX'I)
M),K%?^ Y"CV450^(6HZ]-\+KV*[T&*VM3%!NG6^$A \Q,?+M&<G Z]Z[WQ7X
M??Q1H,VD?;/LL-Q@2L(M[$ @C'(QR/>JOB#PK/XA\)?V!<:F(T<(LTR6_+A6
M#+@;N.5&>M &%XR:X7QMX#-K'%),)+G:DLA13^[7.6 )''L:ZC3!J4^L7D^J
MV%K 8D6.UDA<R91N7&XJIZJO&.PK,U+P?J&I:CHU^^N^7<Z4K>4RVBD,S#:S
M,-W< <5?B\/WK7T=]>:U-<W$,3QPCR42.-F/+A1_%CCDGJ: /'=/U2];X;:?
MX>GMH;+2M5O9;=M6F?>L?[PM@H,;3D8!)QP3].P^*%D-+\(^%;"U^<6NJ6L,
M7F'&=L;@9(^@KIM/\!Z?9^#[CPQ//+>6$NX@RJH="QSD$#J#R..*J7WP\.HZ
M-8:7=^(=1EAL)EF@=EC,@900N6*\X![T :,$OB)]?@_M:QTV*QCMY'CD@G,O
M^D%D5 2RJ5)5G P.<GVK!^#I\WPE>7,S;KV?49WNB1\WF9&<GOZ_C73R:!<W
M-_9SWFLW-Q#;2>:+;RHU1W .TMA<G!.1SU ]*K#PE]BU*[O=%U.XTTWC^9<0
M(BR1.YZN%8?*Q]0<>H- '(.LJ?$7QS96DCQVTVC^;-CI'.4 4@>I4DYJW\/F
MUN;PEX;M9=/LGT:1&\R596>3 #E=R%0%^8#D$]O6NE@\'V]GH]_9VM[<+=ZA
MDW>H2X>>7/!Y(P..  ,#TJ_X=T1/#NAVVDPW$D\-LNV-I  V,YYQP>M &K7'
M?%7_ ))GK7_7-/\ T8M:'AZQU*UU?7)KN\O)[.>XW6J71'[OEMP3!.$Y4#..
MAX[F?Q7H#>)_#]QI'VLVL5QM$CB/>2H(.!R,<@<T 3^'/^17TC_KRA_] %<!
MXM\6Z[H\NN7EM?EDT^>%8K:W@22%4)7=Y[LN0S;L!5;(],<UU">$]0DTZWTR
M[\0S2:?"L:&&*V2(R(F/D9N25(&".]9VI?#.'4?[:A_MS4(;+59OM,EHA4HL
MW!W<C)&0.,@<#K@8 *.J:KXG?Q?XCTRSUQ+:VLK!;R(FS1V3OM&>N<8R<_3O
M3]+\4:GXB@\,Z4EXUI=:AI[7E[=1*OF!5^4! 5*@LV3TX XK<@\$I#J%_?/J
MUY//>V(LI7E"$[0,!N!][]/:JP^'5JFGZ1!!JM];W6D[EM;R'8) C=4;C##Z
MB@#D-)MY[3PK\3;>YNGNIHY+A6G=0&D/E'D@<9KJ8=3NM6UVV\,VE_+I\=MI
M45W-/;A#*[-@!!O4@*!R2!GD#CG,]O\ #V&VTW6K-=:U)QK!)N9)/+9CD88C
MY>I&1^/ %6YO!RF[L-1M=3N+?5;.V^R?:PBMYT7]UTQ@\\\8YH Y#4?%OB6U
MTY(5OHDOK'74TR>4VZE;I'Y5RO\ #QC(7'7M6RESK::_IWA"ZUR9KIK.6^N=
M1@@C1W'F;410P8+CN<'@"M"]\!VM[IEO9MJ%TKQWPU"6XPA>:<'(9LC  Z8
M QBK'B#P>FMZG8:I!J5UIVI6:E$N;8+ED/56!!!'7'U[T 8WPI22+3/$4<TQ
MFE77KI7E*A2Y 3+8' SUP*U_%MY=P2:;;VVH26D=Q*ZRK:1B2ZEPAVK$I5AU
MP68@ #N*L^%_"MOX6@O8K>]N[D7=RURYN65B';J00!UP,Y]*37O"L6MZC8:B
MFH7EA>66]8YK4KDJXPP(8$=J //T\9>)IO!VCWL5\L5XVN#3)?-@0^:I)P7
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M[E?V;##CH" <$<5-9ZWK</@[68KK78EO++67T];Z:++M&"G"JJG,AW$ 8/\
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MNN1*!@-N(] !C&,>_-6]#\'PZ)K%UJ@U74KNYNHT2;[3*&#[00"0 .F3CL*
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MRT.OWQT"6SU"YLX('EN#9PF3;.ZE8@<>@+/@]]E=Y%"D$*0Q*%CC4*JCL ,
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MFZ3>7S(9!;0/,47JVU2<?I7GUQJFK6'@O3O&D>JSW,LI@FNK1BOD%)6"F-5
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(S%-OE=F9/[H8G('TQ72T4 5M/L8-,TZVL+5"EO;1+%&I).%48')Z\"K-%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC,AW$$G<,<@'&>M7_ FI7^L>+_$>G1WE[J7A;8RPW$\KMM8D#:LA.X@@OW[
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MX4KX+_Y\)/\ O\W^->A44 >>GX+>"_\ GPE_&=J/^%*^"^^GO_W];_&O0J*
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M?;G5+:2:QEC20L,C#%<<B@#I***S]8UO3?#^GM?:K=QVUNIQN?N?0 <D^PH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC(W]X'<.OI7H"-O16]1FN(\8E?$6OZ7X.1B8I2+[40!G_1T;Y5/^\X _"NX
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[8^$(M+EV:9JVHV>G[S(+")D\I23D@$H6 /H#WXQ4?\ PE6I#_F4-;_\@_\
MQRF_\)A>_P#0HZ]_W[B_^.4 6V\':7)XS'BEUD:^6$1*I(V @8WXQ][!(ZU7
MN?!%E/JEY=QWU_;07[!KVS@D"Q7!'4GC(SCG!&:9_P )?>?]"CK_ /W[B_\
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M%<M_PD6O?]"5>_C=V_\ \71_PD6O?]"5>_\ @9;_ /Q5 '545RO_  D.N_\
M0EWW_@5;_P#Q='_"0Z[_ -"7??\ @5;_ /Q= '4E@.M&X5RP\1:\/^9+OO\
MP+MQ_P"STO\ PD.O'_F2[S_P,M__ (J@#J,BC(KE_P#A(-?_ .A+N_\ P,M_
M_BJ/^$@U_P#Z$RZ_\#+?_P"*H ZC(]:4$'H<US":_KS2HK>$;J)68 M]K@.!
MZX#5TJ9QSG_"@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%(3@9H!R,\$>HH 6BBB@ HHHH **** "F
M-'N(.<8.1@4^B@!BQA0 .@I2@)ZFG44 ,\L>I_2G;1Z4M% ";11M%+10 F!1
M@4M9/B3Q'8>%=%DU74F?R$95"Q@%W8G  !(R>_T!H U<"C%<*NH^./$VZ32[
M6W\/V&0T4]ZHEGE&/[@X4?6J.KOXT\$Z8^MW7B6UUJVA*^=:7%FL!;)  1DR
M=V3WH ](Q[T8]Z;"YEACD:-HRRABC=5R.A]Z?0 F/>C JEK&J0:+HUYJ=S_J
M;6%I6 ."<#H/<]/QIFA7-]>:3%<ZBMND\N6V6^[:J]AEN2??&#VH T-HHVBE
MHH :5R>WY4N*6B@!,>]&*6N0O+V^U/XD6FE6=Y+!9Z;;?:[T1$8D=SM2-O;&
M6Q^/7% '6E,D'/0TN*6B@!,48]Z6B@!IX('K2!AD]/QXK.\0ZHNBZ%>:BT;R
MBVB:38A )QZ9KB=#MO&6L^'+*XO=?72K9HS*TB(LDSAB2,D_*H (Z4 >D<>E
M+MKSOP9<:S<:_</#K%WJ6@1QE/.O(E0R3 X^0@ E1W->BT )BC%+10 F/>C'
MO2T4 )CWH(SWI:* &[?<_G2@8[TM% "8]Z",CK2T4 -">IS2[12T4 -VCW_.
MC8/?\Z=10 FT4;12T4 )M%)L'O\ G3J* $VCW_.C:*6B@!I3..<4H&*6B@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=HWROL+?=4E,[>I';FK/ACP'H%AX?TQ;G0["2]2V3SI);96<N5^;)(SU)ZT
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MJKILTB)%=!E+$.0%8Q]5Z]ZV?$/BNWT'4=/LV$3O<%I)R\P3[/ H^:4YZC/
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M!%;-;101Q0D8VHN <]>!C\ZYJR\#76FPBSL?$NHV^GI_JX$2/<@[C>5S3_\
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MG_"%7W_0WZ[_ -_A_A0!UF]?4?G1O7U'YUR?_"%7O_0WZ[_W^'^%'_"%7O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !115/5-2@TC3Y;VY69HH\96&)I'.3@8502:
M+E%<9JGC>^@UJQTG3?#ES<W5[$9H6N)TA3: "22-Q''9@#G'K4UYKNOZ'I$V
MIZY;Z6D4>T+!:RN[RNQPJ L  22/7OZ4 =;17(VGCH782./P_K3W2J#<0I;8
M$)Z$;G*AL'^[FMS0M<LO$.EQZC8.[0.2N'4JRL#@J0>X- &E17)7WC">[U2;
M1_"UDFIWUN<7,TC[+>V]F;JS?[*_T-:7AM?$/V1Y?$-Q8O*Y_=QVD+($'N6.
M2?P&/>@#;HHHH ***Y=/'NC3>-QX4B:22^VL3(F#&&4%BA.<[@ >U '44444
M %%%% !1D$D9Y%9VO:HFB:#?ZF^,6L#R@'^(@<#\3@?C6?X-T=](\.VPN@QU
M"X437DC.6+2MRW.>@)(XXH W7N(8YHH9)HUEESY:,P!? R<#O@5)5#4M%T_5
MVMWO;??);L7AE5V1XB>I5E((Z=C5U%"(J DA0 -Q)/XD\F@!U%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %'2BJ]_91:EIUU8SEA#<PO"Y4X.U
M@0<>^#0!-YB?WU_.FF>)71&E0/)G8I89;'7'K7G.KZ#I%K\4/"-E#IEFEL;6
MZ#1"%=K;4XR,<X]ZU)[#2] \4>'K"VT52)9KI[.<3[%MI&C9G4(!T8#'MDT
M=H\B1H7=@J@9+,< 4(ZR(KHP96&0P.01ZUY9<ZEJ>O\ @GQW_:]M:/%9W%U#
M'ME+^4T<:;0H*#@'+;L@Y)X%;4_C2WT&QTO2X$M'NAI\4[K/<>2JIM "@A6^
M8X.!C ZD],@'=T5RVC^+[C7;71+JQT6=[:_\P74C2!?L13'##'S9.<=*ZF@
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MZ:0 2SLJAY,=,[0!@9/0=Z *4WB6\NKZ]LM$T>6\DLW$<LT\@ABWYY4$_,Q
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^S;'_GRM_P#OT/\ "C^S;'_GRM_^_2_X4 <U#\0O!-O$L4&OZ9%&O1$8*!^
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M1\2?!Y^[X@LC]')_D*Z,6-H.EK /I&*7[':_\^\7_? H YL_$GP@/^8]9_\
M?1_PI/\ A9G@X<?V]:_AN_PKIOL=K_S[0_\ ? H^RV__ #PB_P"^!0!S/_"R
MO"'_ $&[;_Q[_"C_ (65X0_Z#EM_X]_A73_9H/\ GC'_ -\BC[-!_P \8_\
MOD4 <+HGBCX>^'XIX]+U&T@$\IEE.7+.Q/<D9^@[5J?\+(\(_P#0<MO_ ![_
M  KIOLT'_/&/_OD4GV6W_P">$?\ WR* .:_X63X0_P"@Y;?^/?X4G_"RO"'_
M $&[?\F_PKIOLEO_ ,\(_P#OD4OV>#_GC'_WR* .8/Q+\(?]!N#_ +Y;_"D_
MX65X3/W=7C;Z1N?Z5U/D0_\ /)/^^11Y$7_/)/\ OD4 <M_PLKPK_P!!5?\
MOT_^%'_"R?"O_057_OT_^%=5Y,7_ #R3_OD4>3%_SR3_ +Y% '*_\+)\*_\
M057_ +]/_A2CXD^%3_S%!^$+G^E=3Y,7_/)/^^12&WA/6*,_\!% ',?\+'\*
M_P#03/\ WXD_^)H_X6/X7_Z"+'_MWD_^)KI_L\(Z0Q_]\BCR(O\ GDG_ 'R*
M .8_X6/X6_Z"+?\ @/)_\31_PL?PO_T$&_\  >3_ .)KI_(A_P">2?\ ?(I?
M)B_YY)_WR* .9C^(?AJ:>*&/4/GD8*H:&1<D].JUU"MN%-\F+_GFG_?(I] !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !115.6QA>_6\*L9T0HI#'&#B@"Y1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,8I%DC\1:,CJ0RLNC1@@CH0<5-!X%\>6D[SVOBO2X)G!#21Z4B,V3DY('/-
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MBC<0Q?#C6%DE5&>(*@8XW'>O ]:/AE/"_P -]'"NK[("KA3G:=QX..AK!NO
MOCV_14O/&&GW"J<J)M+1P#[9JUH7@[QCI&HPO)XGLC8AP\T%OIJ1>9[<?SH
MU?AO+X8E\/W#>%89HK+[4_F+,#NWX'J3QC;BNQJ*WM;>TB\JV@BACR3LC0*,
MGJ<"I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *0C-+10 W8O]T?E2[%_NC\J6B@!-B_W1^5(4';
MCZ4ZB@!NQ?0'\*-B_P!T?E3J* &^6OH/RHV+Z#\J=10 W8OH/RI=H%+10 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4^M=MJ4>GZ=\0+S5WL('EMM#>Z+B)=Y97/.<9SM&,^G% '9S7,%L 9YXX@>
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M2RP #<G<9'][<.?;WKT&?X:^&)?#;Z1'I-G&QA\M;H0@RJV.'W_>)SSU]NE
M'7JP90RD$$9!'>EJMI]J;+3;6T+[S!"D6[&,[0!G]*LT %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB2*XW%2,_+MV\]>N>U>CT4 >?Z]X,U1/B'9^,M$%K--%'Y<]I/(8_,^5DR&
M/\)';^$=:Z+3=*O+C4;K5=9BMDFN+=;5+:%C(L48)+ N0-Q8MSP!A1[UO4E
M'G7ASPCXA\ W-]!HJVFJZ1<R>8D%Q.8)8FP!G=M8'@ >^ >*T?$^C^)M7\)Z
ME8?Z'<7.H$((A+Y<=J@]&*YD)(YSCKQC'/:T4 >/7OPUUC4O >E:9)9VD&MZ
M9*$@NX[KCRB2Q).W/!/"^O.>HKTCPW'KMOIJ6NO&VEN($5!=02,WG\<EE*C:
M>GKGGI6S10!YMJ/@SQ!J'Q+M_%D::?%'9GRX[>2X8F9 & 8D(=N0W3G&.];L
MMAXMGUV34F.DHD5G)!9VXFD(25V4[W;8-V O3 _#.:ZNEH \]N?A\M_X%ETJ
M?3-/&K."#=M,6+29R9M^S.2<G;CH<9J*X\%^);OX8CPA<3::\BA(UN_/DX1'
M#J-NST&WKT_*O1Z* /+M6^'6OZ_X:T+P[=W>FVMCIRJ))HB\LDA5=H(!50!@
MGC/\JZ%=(U_2;W5/L=O8ZGI5R8EALKF=D9 L*1G+%6!!V],>^>:["L[5]<L=
M$TBYU.\E/V:V($AC4N020N,#ODB@#SJ]\,:KX+\&WLVC:M::=J5W?_:'2-,H
MV<[+>$$')S@#CGGH*](B;4?[%@9X87U PIYD;R%$WX&[Y@I[Y[5:C9)XHY0,
MJP#KN7!&1Z'H:DH \N\+>"_%'A/PYJ&A10Z9>+J!<FZ-TZ"$L@3E/+);IG@B
MNOU?PRGBGPG_ &3KD4*3%!AX&+B.0# =20#^'N1S7144 <!J7PV36_A[IF@7
MEPL5]I\8$-S&,@,!@^^T\?IZ5IV:>-&L$TVY338)401MJD<Q<MCC<L)0#=WY
M;&>W:NLHH Y6ZC\366O:G?OJUBFAI8$VZ7*A1'.!]YR #MR"3ST/M6GX8OK_
M %+0+>ZU*.)+ERP)B5E1U#$*ZAN0& !P>>:UB P(8 @\$&EH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8\D98\\9X'H: *FHZ]K]AK'B?2'U:87,-M%=:01!$3)N.W81L^;+LJU=\/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1^.+CQ/X;U.R@GO(1#.EY$7VX"C*XS_='IT[YKOMZ_WA1O7^^M '#>'/#?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#T
M/]*P-?\ "ECXAN;&:_\ /;[(Y8)&Y57SV8=Q7044 0QQ;(PH 4  <#&/I6!J
M/@7P]JM_+>WFG>9<2D%V\^1<\8Z*P%=+10!Q_P#PK3PI_P! H_\ @3-_\71_
MPK+PG_T"?_)F;_XNNPHH Y _#/PH?^80/_ F7_XJD_X5CX3_ .@2/_ F7_XJ
MNPHH X__ (5EX3_Z!(_\"9?_ (JC_A6/A+_H$#_P)E_^*KL** .._P"%8^$?
M^@/GV^T2_P#Q5'_"L_!__0"'_?\ D_\ BJ[&B@#CO^%9>#SUT%?QFD_^*H_X
M5CX._P"@#'_W^D_^*KL:* .._P"%8^#_ /H Q_\ ?Z3_ .*H_P"%8^#O^@#'
M_P!_I/\ XJNQHH X[_A6/@[_ * ,?_?Z3_XJC_A6/@[_ * ,?_?Z3_XJNQHH
M X[_ (5CX._Z ,?_ '^D_P#BJ?\ \*R\'8_Y D7_ 'V_^-==10!R/_"LO!W_
M $!(O^^W_P :/^%9>#O^@)%_WV_^-==10!R/_"LO!W_0$B_[[?\ QH_X5EX.
M_P"@)%_WV_\ C7744 <C_P *R\'?] 2+_OM_\:/^%8>#O^@+%_W\?_&NNHH
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M\0W]I:3+/'$+2"-I)%^ZSE9!G!YXP">M4[G3[I]>OM2M=&\86<&H,&O;2!8
MDW8\^9D9'<<\GF@!2^LCQM\0+S1M2M[,6\%I<2.T F,FV LJKD@ 'G)Y[8J]
M_P )%XKUF7PLFF:C9VC:QITDT@DMMPC=%7+#GG)/ [=\U5CMKR"[UZ>W\/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3&3.<!<GUI]% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /-=<N8%^.OAM6GC
M!2QE5@7'!(? /N<\5H>*7MX_BAX'9FB64F\5B2 V#%A0?Q) ]\UV+6%F\_G-
M:0-+G.\Q@MGUSBG26=M+,LTEO"\JXVNR L,=,&@#QMKVQLOAEXTT5[R$WUO>
MW.^/.#CS5 /XGIZ\^E6I]4T^S\10CQ#?7%KI.H:'!%:7,>#&ZA?WB9"GJ6S^
M ]J]:>RMI0XDMH7#D%]R [B.A/K2M:6[QI&UO$8XR"BE!A2/0=J .0T0^$[!
MO#EC'"Z7ACF_LK[5$S3>7DEB&Q\H*\@'!P<8[5VM5KJT%PAVL(Y0C+'*%!9,
M]Q7,_P#"(:SG_D<]6_[YB_\ B* .N+ =3CZUYKHUQ%X-^(7B--:F2VL]8E6Y
ML[V4@1L1G<A?L1NX!]#ZBMS_ (1#6/\ H<]7'_ (O_B:9+X*U2>,QS>,-4D0
M]5>.(@_@5H K^,O$NEZAX+U^"QN%N8EL9 ]U$RF%7(PJ;\\L<\ 9Z<XR,X.F
M#1M/U_X<FV^Q6\TVFR^>8]JL^85V[L=<MNQGOFNC;P-J+0?9SXLU(P_\\S%#
MM_+9BD'@&\#(P\4Z@&C&$(@@RH]ODXH X,W-M;^%KJZL3NTBS\7/-<"T /EV
M^?E8#!& =I''85NRWWAR32/%>KZ->W%T]SIK)<7ER^R*1]I5$&0N7P#T'<#O
M701>!+Z!&2+Q7J,:/]Y4AA /U 2@^!+\VXMSXLU$PCD1F&':/PVXH UO!=U;
M7'@K13!<12!+&!'*.#M81KD''0CTKS[PU>: _C[QO)J.L16T4ES#Y+C4C;B3
MA]V"KKNQQZXS[UUL/@?4;="D'B_5(D)R5CBB49]>%JN?AS.22?$U\2?^G>'_
M .(H I:U>>'-7\&)X>@ECG3S(].TV9IU423(H D5L\A,\GN00,Y&<";6[BX\
M":_HDLPF\16%P&U +*&:[A5QN=>N1L&"HZ8Y SBNTC\#ZC#&L<7C#5D1>BHD
M0 ^@VTJ>"=20G;XRU=<DDX6(9/K]V@#DKQ]'\26FIZAX5N-3U+5Y=+D@DE+%
M1$F.(V& "QY  ST)["MK2=>\.>(8]-72[(RZM;V+P,@C9#9)Y>&5CC'W@% [
MD\=ZTX_ ^H1 B/QAJZ!B6(18AD^O"TB>!KZ)G:/Q?K",YRQ41 L?4_+S0!Q&
MD^(=,3P=X&M/M!:>RU2/[2J1LWDG;*,-@<$YX'4@$]C6GHFH65I8_$73KN9(
MKEK^^G,4G'[ME 5CV )( SUS72+X$O$)*^+=8!+%R0(A\W3/W>N.]/\ ^$)U
M#G_BL=;Y]X__ (F@#C_LSCX4>%O$U@0]WH(6XPA!+Q9VRIGMQU_W35WQ3;7,
M'@C3]6FM[E$FU6/4]42$XD2-LXS[H/+'_ ,UT?\ PA6HXQ_PF6MX_P!Z/_XF
MC_A"M1/7QEK9^IC_ /B: (/!1\/76J:CJ6@W-]?&=(Q=7D[,59A]U?F RP'7
MT!'K5&6(^&/BS=Z[J+^7I.JV:P+=NV$AE7;A')^Z"%X)XYK3C\#7L2!(_%^L
MH@Z*OE #_P <I6\$7[H4?QAK3*1@@F/!'_?- &=XA:W\9^*?#=MI$Z75MIMW
M]NN[N%MT4>S!5-PX+,>P.0*B\,:MIL?Q)\=3OJ%JL3?8V#F9<$)$P8@Y['KZ
M5JQ>![^",1P^,-8C1>BJ(@!^&VHSX NCU\5:GGD<QP]^O\'?O0!PDMQI<O[/
M[6\E[;,YNQP'&]";K)P.N=F3],]JZ&77=&T?Q?XBA\531FSU.WA-E,\1=)K?
M:044J#W/XDYK9C^']U#_ *KQ5J<?(;Y8H1SZ_=]S^=2/X'U&0H9/&&K.4.5+
M)$=I]1\O% '%W5SIEAXK,?B$:CHFE7>DPP6.R4A4B4',3$ GG.2#WZ]JL6NG
M>&QXY\+:6+1/L8TVX6*VOU!D.YR4W*><D%B ><'UKK)? U_. )O%^KR '< R
MQ'!]?NTX^"=0/_,XZUGUS%_\30!UT:1PQ)%$BQQHH5$1<!0.@ ["G9%<?_P@
M]_W\9:X1_O1__$T?\(1?C[OC+71_P./_ .)H [#(HW#W_*N//@C4#_S.6N?]
M]1__ !-'_"#W_P#T.>N_]]1__$T =AD49'^17'_\(/?]_&6N8^L?_P 31_P@
MU[_T.&N_]]Q__$T =AD?Y%+7'?\ "#7O_0X:[_WW'_\ $TG_  @U]V\9:Z/^
MVB?_ !- '945QW_"#7W?QCKW_?U/_B:/^$&N_P#H;]?_ ._R?_$T =C17'?\
M(-=_]#?KW_?Y/_B:/^$&N_\ H;]>_P"_R?\ Q- '8T5QW_""W/?Q=KW_ '^7
M_P")I?\ A!KG_H;-?_\  A?_ (F@#K\TM<?_ ,(+/_T->OG_ +>%_P#B:/\
MA!9_^AJU[_P(7_XF@#L,T5QI\!2L<GQ5KW_@0O\ \30/ 4@'_(TZ_P#^!7_U
MJ .RS1FN._X0)_\ H:=?_P# O_ZU+_P@;_\ 0TZ__P"!?_UJ .O) ZTM<E!X
M(D@N8IAXFUQ]C!BCW65;V(QTKJU7:#G'- #J*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *:"V\@CY>QIU% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 445!)>6T5W#://&MQ,K-'$6^9PN,D#VR* )Z*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@!#TKRNRO+B?XIZ-?7NGZE#=W4%RK1SQA1%'\
MNQ5YQM49)/=F/J /5:KO8VLE[%>/!&US$K)'*5!9%;&0#VS@4 6!THHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIC31K*L1D02,,A2>3^
M%/H **** "BBB@ HI&8*"20 .232*X=0RD,I&00<@B@!U%%% !1110 4444
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MYQWK;H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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7 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Apr. 30, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Shattuck Labs, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-2575858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">500 W. 5th Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 1200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Austin<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">78701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">900-4690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">STTK<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,680,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001680367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 90,419<span></span>
</td>
<td class="nump">$ 54,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">23,873<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,334<span></span>
</td>
<td class="nump">4,410<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">93,753<span></span>
</td>
<td class="nump">82,475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">5,353<span></span>
</td>
<td class="nump">6,114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent', window );">Investment in related party</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,015<span></span>
</td>
<td class="nump">1,437<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">102,121<span></span>
</td>
<td class="nump">91,026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,253<span></span>
</td>
<td class="nump">2,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">2,996<span></span>
</td>
<td class="nump">4,951<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,249<span></span>
</td>
<td class="nump">7,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">2,037<span></span>
</td>
<td class="nump">1,584<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">6,286<span></span>
</td>
<td class="nump">8,636<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 5)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value: 300,000,000 shares authorized; 75,581,787 shares issued and outstanding at March&#160;31, 2026 and 63,279,843 shares issued and outstanding at December&#160;31, 2025</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">541,124<span></span>
</td>
<td class="nump">512,906<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(445,296)<span></span>
</td>
<td class="num">(430,529)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">95,835<span></span>
</td>
<td class="nump">82,390<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 102,121<span></span>
</td>
<td class="nump">$ 91,026<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities and Other Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS - Parenthetical - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">75,581,787<span></span>
</td>
<td class="nump">63,279,843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">75,581,787<span></span>
</td>
<td class="nump">63,279,843<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList', window );">Revenue from Contract with Customer, Product and Service [Extensible List]</a></td>
<td class="text">License [Member]<span></span>
</td>
<td class="text">License [Member]<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">10,946<span></span>
</td>
<td class="nump">9,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">4,599<span></span>
</td>
<td class="nump">4,470<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Expense from operations</a></td>
<td class="nump">15,545<span></span>
</td>
<td class="nump">14,389<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(15,545)<span></span>
</td>
<td class="num">(14,389)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">779<span></span>
</td>
<td class="nump">689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">778<span></span>
</td>
<td class="nump">687<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(14,767)<span></span>
</td>
<td class="num">(13,702)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on investments</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (14,773)<span></span>
</td>
<td class="num">$ (13,704)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share &#8211; basic (in dollars per share)</a></td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share &#8211; diluted (in dollars per share)</a></td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding &#8211; basic (in shares)</a></td>
<td class="nump">112,234,551<span></span>
</td>
<td class="nump">50,965,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding &#8211; diluted (in shares)</a></td>
<td class="nump">112,234,551<span></span>
</td>
<td class="nump">50,965,815<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock warrants</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Pre-Funded Warrants</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Common stock warrants</div>
</th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Common stock warrants</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,714,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="nump">$ 79,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 461,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">$ (381,720)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options and purchases pursuant to employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options and purchases pursuant to employee stock purchase plan</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Issuance of common stock upon settlement of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,403)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of restricted stock units</a></td>
<td class="num">(65)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(13,702)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,702)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,899,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2025</a></td>
<td class="nump">67,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">463,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(395,422)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,279,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2025</a></td>
<td class="nump">82,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">512,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="num">(430,529)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from sale of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from sale of common stock, net of offering costs</a></td>
<td class="nump">20,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_StockIssuedDuringPeriodSharesWarrantExercises', window );">Exercise of common stock warrants into common stock and pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,928,891<span></span>
</td>
<td class="nump">153,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_StockIssuedDuringPeriodValueWarrantExercises', window );">Exercise of common stock warrants into common stock and pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options and purchases pursuant to employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options and purchases pursuant to employee stock purchase plan</a></td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Issuance of common stock upon settlement of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56,040)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of restricted stock units</a></td>
<td class="num">(262)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(262)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">2,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(14,767)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,767)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,581,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2026</a></td>
<td class="nump">$ 95,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 541,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (445,296)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_StockIssuedDuringPeriodSharesWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrant Exercises</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_StockIssuedDuringPeriodSharesWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_StockIssuedDuringPeriodValueWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Warrant Exercises</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_StockIssuedDuringPeriodValueWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (14,767)<span></span>
</td>
<td class="num">$ (13,702)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">2,415<span></span>
</td>
<td class="nump">1,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">891<span></span>
</td>
<td class="nump">936<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash operating lease expense</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net amortization of investments</a></td>
<td class="num">(48)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,076<span></span>
</td>
<td class="nump">723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(32)<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(911)<span></span>
</td>
<td class="num">(886)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(1,955)<span></span>
</td>
<td class="num">(716)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Non-current operating lease liabilities</a></td>
<td class="num">(225)<span></span>
</td>
<td class="num">(240)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(13,424)<span></span>
</td>
<td class="num">(12,032)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Maturities of investments</a></td>
<td class="nump">23,915<span></span>
</td>
<td class="nump">15,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="num">(67)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">23,848<span></span>
</td>
<td class="nump">15,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock, net of offering costs</a></td>
<td class="nump">20,562<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of common stock warrants</a></td>
<td class="nump">5,444<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from the exercises of stock options and purchases pursuant to employee stock purchase plan</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(262)<span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">25,803<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase in cash and cash equivalents</a></td>
<td class="nump">36,227<span></span>
</td>
<td class="nump">3,511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">54,192<span></span>
</td>
<td class="nump">57,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">90,419<span></span>
</td>
<td class="nump">60,898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of non-cash financial activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain on investments</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Unpaid amounts related to purchase of property and equipment</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_IncreaseDecreaseInOperatingLeasesRightOfUseAssetsLiability', window );">Changes in lease balances resulting from lease modification</a></td>
<td class="nump">$ 678<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_IncreaseDecreaseInOperatingLeasesRightOfUseAssetsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Leases, Right of Use Assets (Liability)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_IncreaseDecreaseInOperatingLeasesRightOfUseAssetsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Description of Business</a></td>
<td class="text">Organization and Description of Business <div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Shattuck Labs, Inc. (the &#8220;Company&#8221;) was incorporated in 2016 in the State of Delaware and is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. Shattuck is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease and other inflammatory and immune-mediated diseases. Shattuck&#8217;s expertise in protein engineering and the development of novel tumor necrosis factor receptor agonist and antagonist therapeutics come together in its lead program, SL-325, which it believes could be a first-in-class death receptor 3 ("DR3") antagonist antibody designed to achieve best-in-class clinical remission rates due to a more complete and durable blockade of the clinically validated tumor necrosis factor like ligand 1A ("TL1A")/DR3 pathway.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of $445.3 million as of March&#160;31, 2026. The Company anticipates incurring additional losses and negative cash flows from operations until such time, if ever, that it can generate significant sales of its product candidates currently in development, and is highly dependent on its ability to find additional sources of funding in the form of licensing of its technology, collaboration agreements and/or public and private debt and equity financings. Adequate additional funding may not be available to the Company on acceptable terms, or at all. The failure to raise funds as and when needed could have a negative impact on the Company&#8217;s financial condition and ability to pursue its clinical operations, research and development and commercialization of its product candidates. Management believes that the Company&#8217;s cash and cash equivalents of $90.4 million as of March&#160;31, 2026 are sufficient to fund projected operations of the Company for at least the next twelve months following the date these financial statements are issued. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Global Economic Considerations</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The global macroeconomic environment is uncertain and could be negatively affected by, among other things, inflation, slower growth or recession, changes in trade policies, including tariffs or other trade restrictions or the threat of such actions, instability, or volatility in the global capital and credit markets, supply chain weaknesses, financial institution instability, changes to fiscal and monetary policy or government budget dynamics, and instability in the geopolitical environment. Such challenges have caused, and may continue to cause, recession fears, high interest rates, foreign exchange volatility, and inflationary pressures. At this time, the Company is unable to quantify the potential effects of this economic instability on its future operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text">Basis of Presentation and Summary of Significant Accounting Policies <div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Condensed Financial Statements </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying interim financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company&#8217;s financial position, its results of operations, statements of changes in stockholders&#8217; equity and cash flows for the interim periods presented. Operating results for interim periods presented are not necessarily indicative of the results that may be expected for the year ending December 31, 2026. The interim financial statements presented herein do not contain all required disclosures under GAAP for annual financial statements. The accompanying unaudited interim condensed financial statements should be read in conjunction with the annual audited financial statements and related notes in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2025.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition, the accrual of research and development expenses, and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates, if any, are recorded in the period in which they become known and actual results could differ from management&#8217;s estimates.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received upon the sale of an asset or paid upon the transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. Fair value measurements are classified and disclosed in one of the following categories: </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level&#160;1: Observable inputs such as quoted prices in active markets for identical assets the reporting entity has the ability to access as of the measurement date; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level&#160;2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level&#160;3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are classified based on the lowest level of input that is significant to the measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of the assets and liabilities and their placement within the fair value hierarchy levels. The determination of the fair values takes into account the market for its financial assets and liabilities, the associated credit risk and other factors as required. The Company considers active markets as those in which transactions for the assets or liabilities occur with sufficient frequency and volume to provide pricing information on an ongoing basis. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that the carrying amounts of the Company&#8217;s financial instruments, including short-term investments and accounts payable, approximate fair value due to the short-term nature of those instruments.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risk </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and short-term investments. The Company maintains its cash and cash equivalents at an accredited financial institution in amounts that exceed federally-insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company&#8217;s short term investments consist of U.S. Treasury securities that management believes protects the Company from risk of default and impairment of value. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is highly dependent on a limited number of contract development and manufacturing organizations (&#8220;CDMOs&#8221;) to supply drug products for its research and development activities of its programs, including nonclinical studies. The Company is highly dependent on a single CDMO for the supply of cGMP drug product for its clinical trials. These programs could be adversely affected by a significant interruption in the supply of such drug products. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is highly dependent on a limited number of contract research organizations (&#8220;CROs&#8221;) and third-party service providers to manage and support its clinical trials. These programs could be adversely affected by a significant disruption in services provided by these CROs and third parties.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all demand deposits with financial institutions and all highly liquid investments with original maturities of 90 days or less at the date of purchase to be cash and cash equivalents. Cash and cash equivalents consisted of $1.6&#160;million held in operating accounts and $88.9 million held in money market funds as of March&#160;31, 2026, and $1.9&#160;million held in operating accounts and $52.3&#160;million held in money market funds as of December&#160;31, 2025. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company's short-term investments consist of highly-rated U.S. Treasury securities and have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices. Management determines the appropriate classification of its investment securities at the time of purchase. The Company may hold securities with stated maturities greater than one year. All available-for-sale securities are considered available to support current operations and are classified as current assets. Credit impairments for available-for-sale securities are recorded through an allowance rather than a direct write-down of the security and are recorded through a charge to the statements of operations and comprehensive loss. Unrealized gains or losses not related to credit impairments are recorded in accumulated other comprehensive income, a component of stockholders&#8217; equity, until realized. The Company reviews available-for-sale debt securities for impairments related to credit losses and other factors each quarter. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a long-term related party investment in preferred stock of a privately held company. The investment is accounted for under Accounting Standards Codification ("ASC") 321, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in Equity Securities</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and is classified as a long-term asset in the accompanying balance sheet as it is not expected to be liquidated within one year. For investments that do not have a readily determinable fair value, the Company applies the measurement alternative, whereby the investment is carried at cost, adjusted for observable price changes in orderly transactions for identical or similar securities of the same issuer and impairment losses, if any. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets include prepaid expenses for general business purposes and services used in research projects, which are stated at cost and amortized on a straight-line basis over the related period of benefit. Supplies and materials that have multiple applications for alternative future use are expensed as they are consumed.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life of the asset. Expenditures for repairs and maintenance that do not extend the estimated useful life or improve an asset are expensed as incurred. Upon retirement or sale, the cost and related accumulated depreciation and amortization of assets disposed of are removed from the accounts, and any resulting gain or loss is included in the statement of operations and comprehensive loss.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation periods are as follows:</span></div><div style="margin-top:6pt;text-align:center;text-indent:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.333%"><tr><td style="width:1.0%"></td><td style="width:62.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.862%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Office equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;to&#160;10 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Lab equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Shorter&#160;of&#160;lease&#160;term&#160;or 15 years</span></div></td></tr></table></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstance indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable and the carrying amount exceeds the projected discounted future cash flows arising from these assets. There were no impairments of long-lived assets for the three months ended March&#160;31, 2026 and 2025.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception. Right-of-use (&#8220;ROU&#8221;) assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. The classification of the Company's leases as operating or finance leases, along with the initial measurement and recognition of the associated ROU assets and lease liabilities, are performed at the lease commencement date. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. As the Company's leases do not provide an implicit rate, the Company </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. The ROU asset is based on the measurement of the lease liability and also includes any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company's operating leases is recognized on a straight-line basis over the lease term. Operating lease ROU assets and long-term operating lease liabilities are presented separately and operating lease liabilities payable in the next 12 months are recorded in accrued expenses and other current liabilities. The Company has elected to not apply the recognition requirement of ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> of the Financial Accounting Standards Board (&#8220;FASB&#8221;) to leases with a term of 12 months or less for all classes of assets.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments and Contingencies</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows ASC 450-20, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to report accounting for contingencies. Certain conditions may exist as of the date the condensed financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company&#8217;s condensed financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue is recognized in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;). Arrangements with collaborators may include licenses to intellectual property, research and development services, manufacturing services for clinical and commercial supply, and participation on joint steering committees. The Company evaluates the promised goods or services in the contract to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, the Company considers the stage of development of the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property and whether the promised goods or services are integral to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Upon the amendment of an existing agreement, the Company evaluates whether the amendment represents a modification to an existing contract that would be recorded through a cumulative catch-up to revenue, prospective modification, or a separate contract. If it is determined that it is a separate contract, the Company will evaluate the necessary revenue recognition through the five-step process described below. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">When the Company concludes that a contract should be accounted for as a combined performance obligation and recognized over time, the Company must then determine the period over which revenue should be recognized and the method by which to measure revenue. The Company generally recognizes revenue using a cost-based input method. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes collaboration revenue in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services when its customer or collaborator obtains control of </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">promised goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the following five steps are performed: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.73pt">identify the contract(s) with a customer;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.96pt">identify the performance obligations in the contract; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">iii.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.19pt">determine the transaction price; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">iv.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.73pt">allocate the transaction price to the performance obligations within the contract; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">v.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">recognize revenue when (or as) the entity satisfies a performance obligation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company only applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company&#8217;s arrangements may consist of a license of, or options to license, the Company&#8217;s intellectual property and research, development and manufacturing services. The Company may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i)&#160;the customer can benefit from on its own or together with other readily available resources and (ii)&#160;are separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most-likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes variable consideration in the transaction price to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations that consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company&#8217;s accompanying balance sheet. Deferred revenues expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability. Deferred revenues not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as non-current liabilities. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Company&#8217;s collaboration revenue arrangements may include the following: </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Up-front License Fees: If a license is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, up-front fees allocated to the </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Milestone Payments: At the inception of an agreement that includes research and development milestone payments, the Company evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company first estimates the amount of the milestone payment that the Company could receive using either the expected value or the most-likely amount approach. The Company primarily uses the most-likely amount approach as that approach is generally most predictive for milestone payments with a binary outcome. The Company then considers whether any portion of that estimated amount is subject to the variable consideration constraint (that is, whether it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty). The Company updates the estimate of variable consideration included in the transaction price at each reporting date which includes updating the assessment of the likely amount of consideration and the application of the constraint to reflect current facts and circumstances. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Royalties: For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not granted a development and commercialization license nor recognized any revenue related to sales-based royalties or milestone payments based on the level of sales. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and Development Services: The Company will record costs associated with development and process optimization activities as research and development expenses in the statements of operations and comprehensive loss consistent with ASC 730, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> The Company considered the guidance in ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 808&#8221;) and will recognize the payments received from these agreements as revenue when the related costs are incurred. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">License Revenue: License revenue is generated from granting third parties rights to certain of the Company&#8217;s intellectual property, including research, development, and commercialization of specified product candidates. The Company evaluates each licensing arrangement to determine whether the license is distinct from other promised goods or services and whether the arrangement includes multiple performance obligations. If an arrangement includes multiple performance obligations, the transaction price is allocated to each performance obligation based on relative standalone selling prices. Upfront payments, including nonrefundable license fees, are recognized as revenue when the underlying performance obligation is satisfied. Milestone payments that are contingent on the occurrence of a future event are included in the transaction price only when it is probable that a significant reversal of cumulative revenue will not occur. Sales-based royalties, including milestone payments based on a level of sales, are recognized as revenue when the subsequent sales occur.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company may also enter into arrangements that include non-cash consideration, such as equity instruments. In such cases, the Company measures the transaction price at the estimated fair value of the non-cash consideration received at contract inception and recognizes revenue when the performance obligation is satisfied.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred, and include salaries, stock-based compensation and other personnel-related costs, equipment and supplies, depreciation, nonclinical studies, clinical trials and manufacturing development activities. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of the Company&#8217;s ongoing research and development activities are conducted by third-party service providers, including CROs and CDMOs. The Company accrues for expenses resulting from obligations under agreements with CROs, CDMOs and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with CROs, CDMOs and other outside </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through an evaluation of the progress or stage of completion of the services. In the event advance payments are made to a CRO, CDMO or outside service provider, the payments will be recorded as a prepaid asset which will be amortized as the contracted services are performed. As actual costs become known, the Company adjusts its accruals and prepaid assets accordingly. Inputs, such as the services performed, the number of patients enrolled or the study duration, may vary from the Company&#8217;s estimates, resulting in adjustments to research and development expenses in future periods. The Company makes significant judgments and estimates in determining the accrual and/or prepaid balance in each reporting period and changes in these estimates may result in material changes to the Company&#8217;s accruals that could materially affect the Company&#8217;s results of operations. </span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants and Pre-Funded Warrants</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s common stock warrants and pre-funded warrants are classified as a component of permanent stockholders&#8217; equity within additional paid-in capital. The common stock warrants and pre-funded warrants are equity classified because they, (i) are freestanding financial instruments, (ii) are immediately exercisable, (iii) do not embody an obligation for the Company to repurchase its shares, (iv) permit the holders to receive a fixed number of shares of common stock upon exercise, (v) are indexed to the Company&#8217;s common stock and, (vi) meet the equity classification criteria. In addition, such common stock warrants and pre-funded warrants do not provide any guarantee of value or return. </span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the cost of stock-based awards issued to employees and nonemployees as compensation expense on a straight-line basis over the vesting period of the award, net of estimated forfeitures. Forfeiture estimates are based on historical cancellation data. The Company uses the Black-Scholes option pricing model to determine the grant-date fair value of stock options. The fair values of restricted stock units (&#8220;RSUs&#8221;) are based on the fair value of the Company&#8217;s common stock on the date of the grant. The Company also grants stock options that vest upon achievement of certain market-based conditions. The Company uses the Monte Carlo pricing model to estimate the fair value of options that have market-based conditions. The Company adjusts expense for forfeitures in the periods they occur.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statements and the tax bases of assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in tax rates on deferred tax assets and liabilities will be recognized in the period that includes the enactment date. Additionally, any changes in income tax laws are immediately recognized in the year of enactment.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is established against the deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. The deferred tax assets and liabilities are classified as noncurrent along with the related valuation allowance. Due to a lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on the technical merits, as the largest amount of benefits that is more likely than not to be realized upon the ultimate settlement. The Company&#8217;s policy is to recognize interest and penalties related to the unrecognized tax benefits as a component of income tax expense.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Basic shares outstanding includes the weighted average effect of the Company&#8217;s outstanding 38,448,034 pre-funded warrants as of March&#160;31, 2026, the exercise of which requires nominal consideration for the delivery of an equal number of shares of common stock. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock or convertible notes, if any, </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">stock options and unvested shares of restricted stock, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding as they would be anti-dilutive:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.484%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">As of March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">47,487,573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13,064,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,458,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">589,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">527,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">61,141,875&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,986,287&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Comprehensive Income (Loss) </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Other comprehensive income (loss) is comprised of unrealized gains and losses on short-term investments.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in this update are intended to enhance the transparency and decision usefulness of income tax disclosures primarily through changes to the rate reconciliation and income taxes paid information. This update is effective for annual periods beginning after December 15, 2024, and may be applied prospectively or retrospectively. The Company has retrospectively adopted this ASU in the financial statements for the year ending December&#160;31, 2025. </span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (&#8220;ASU 2024-03&#8221;), which is intended to provide more detailed information about specified categories of expenses (employee compensation, depreciation, and amortization) included in certain expense captions presented on the statement of operations. The guidance in this ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either, (i) prospectively to financial statements issued for periods after the effective date of this ASU or, (ii) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its financial statements and disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text">Investments <div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the Company&#8217;s investments by major security type (amounts in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.613%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2026</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Gain</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">88,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">88,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">88,860&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">88,860&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.613%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">23,867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">23,873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market fund</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">52,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">52,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">76,137&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">76,143&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company's money market funds are calculated using level 1 inputs and the Company's U.S. government securities are valued using level 2 inputs. U.S. government securities outstanding as of December&#160;31, 2025 matured in January 2026. There were no impairments of U.S. government securities or money market funds for the three months ended March&#160;31, 2026 and the year ended</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2025.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a related party investment in a private company&#8217;s preferred stock. The Company did not identify any impairment indicators or observable price changes for this investment as of March&#160;31, 2026. The Company had no other investments held at March&#160;31, 2026 other than those included in the table above.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/940-320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph b<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">Accrued Expenses and Other Current Liabilities<div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following (amounts in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.925%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development contract costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,057&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,111&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">852&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Compensation and related benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,996&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,951&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain office space, laboratory facilities, and equipment. These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain of these leases also include renewal options at the election of the Company to renew or extend the lease. These optional periods have not been considered in the determination of the ROU assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options. The Company performed evaluations of its contracts and determined it has operating leases. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In February 2026, the Company entered into an amendment to extend the term of its lease for the Austin, Texas office location. The amendment extended the non-cancelable lease term to December 31, 2029 and increased the total contractual lease payments due over the revised lease term. In accordance with ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, the Company remeasured the existing lease liability as of the modification date and as a result, recorded an increase to the ROU asset and liability of approximately $0.7&#160;million during the three months ended March 31, 2026.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There have been no other material changes in the Company's operating leases as compared to the operating leases disclosed in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2025.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may become involved in various legal actions arising in the ordinary course of business. As of March&#160;31, 2026, the Company was not aware of any existing, pending, or threatened legal actions that would have a material impact on the financial position, results of operations, or cash flows of the Company.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Contractual obligations represent future cash commitments and liabilities under agreements with third parties, and exclude contingent liabilities for which the Company cannot reasonably predict future payment. The Company&#8217;s contractual obligations result primarily from obligations for various CDMOs and CROs, which include potential payments that may be required under its agreements. The contracts also contain variable costs and milestones that are hard to predict, as they are based on such things as patients enrolled and clinical trial sites. The timing of payments and actual amounts paid under CDMO and CRO agreements may be different depending on the timing of receipt of goods or services or changes to agreed-upon terms or amounts for some obligations. Such agreements are cancellable upon written notice by the Company and, therefore, are not long-term liabilities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party License Revenue<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Related Party License Revenue</a></td>
<td class="text">Related Party License Revenue<div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In August 2025, the Company granted Kayak Therapeutics, Inc. ("Kayak") an exclusive license (the "Kayak Agreement") to its oncology-focused TRIM7 program. Pursuant to the Kayak Agreement, as the upfront consideration, the Company received preferred stock in Kayak with a fair market value of $1.0&#160;million and recognized that consideration as license revenue. The Company also subleases certain lab space, office space, and lab equipment to Kayak for one year for total consideration of $0.3&#160;million. In November 2025, an officer of the Company was elected to the board of directors of Kayak and as a result, Kayak became a related party. Payments received pursuant to the sublease for the three months ended March&#160;31, 2026 were $0.1&#160;million and recorded as a reduction to research and development expenses. </span></div>Pursuant to the Kayak Agreement, the Company is also eligible to receive future payments contingent upon the achievement of specified development, regulatory, and commercial milestones of up to $86.0 million, and tiered royalties on net sales of any commercialized products subject to the Kayak Agreement in the low single digits. Such future payments are considered variable consideration and will be recognized as revenue only when the underlying contingencies are resolved and it is probable that a significant reversal of revenue will not occur.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text">Equity<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue up to 300,000,000</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">shares of common stock and 10,000,000 shares of preferred stock, all with a par value of $0.0001 per share. The holders of the Company&#8217;s common stock are entitled to one vote per share on all matters submitted to a vote of stockholders. The Company&#8217;s common stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking fund provisions. Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of the Company&#8217;s common stock will receive ratably any dividends declared by the Company&#8217;s board of directors (the &#8220;Board&#8221;) out of funds legally available. In the event of the Company&#8217;s liquidation, dissolution or winding-up, the holders of the Company&#8217;s common stock will be entitled to share ratably in all assets remaining after payment of or provision for any liabilities. As of the periods presented, no common stock dividends had been declared by the Board. As of March&#160;31, 2026, none of the 10,000,000 shares of preferred stock were outstanding, and the Company has no present plans to issue any shares of preferred stock.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Company sold 4,651,163 shares of common stock through an underwritten public offering, and concurrently completed a private placement of 3,100,823 pre-funded warrants. The purchase price per share of common stock was $6.45, and the purchase price per pre-funded warrant was $6.4499, which was the purchase price per share of common stock minus the $0.0001 per share exercise price of the pre-funded warrant. Each pre-funded warrant may be exercised for one share of common stock, is immediately exercisable, does not expire, and is subject to a beneficial ownership limitation of 9.99% on a post-exercise basis. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In August 2025, the Company issued and sold 15,225,158 shares of common stock, pre-funded warrants to purchase up to 37,410,188 shares of common stock, and accompanying common stock warrants to purchase up to 52,635,346 shares of common stock or pre-funded warrants in a private placement offering with certain institutional accredited investors. The purchase price of each share of common stock and accompanying common stock warrant was $0.8677, and the purchase price of each pre-funded warrant and accompanying common stock warrant was $0.8676, which was the purchase price per share of common stock and accompanying common stock warrant, minus the $0.0001 per share exercise price of the pre-funded warrants. Each pre-funded warrant may be exercised for one share of common stock, is immediately exercisable, does not expire, and is subject to a beneficial ownership </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">limitations of up to 9.99% on a post-exercise basis.  Two beneficial owners of 10% or more of our common stock participated in the private placement offering with the same terms as all other participants in the offering. Together, the beneficial owners purchased 8,963,785 pre-funded warrants in lieu of common stock and received accompanying common stock warrants to purchase an additional 8,963,785 shares of common stock.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2026, 6,929,032 pre-funded warrants were exercised and as of March&#160;31, 2026, 38,448,034 pre-funded warrants remain outstanding.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Each common stock warrant has an exercise price of $1.0846 and is exercisable at any time after the date of issuance for one share of common stock or pre-funded warrant in lieu thereof. The common stock warrants will expire on the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Company&#8217;s Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2026, 5,019,719 common stock warrants were exercised for gross proceeds of $5.4 million in exchange for 4,866,055 pre-funded warrants with an exercise price of $0.0001 and 153,664 shares of common stock. As of March&#160;31, 2026, 47,487,573 common stock warrants remain outstanding.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In January 2026, the Company entered into a sales agreement (the &#8220;Sales Agreement&#8221;) with Leerink Partners, LLC (the &#8220;Sales Agent&#8221;), pursuant to which it may offer and sell up to $75.0 million of shares of its common stock from time to time through an at the market offering facility (the &#8220;ATM Facility&#8221;). The Sales Agent is generally entitled to compensation at a commission equal to up to 3% of the aggregate gross sales price per share sold under the Sales Agreement. For the three months ended March 31, 2026, the Company sold 5,000,000 shares of common stock for $4.28 per share for gross proceeds of $21.4&#160;million through the ATM Facility.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation and Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation and Employee Benefit Plans</a></td>
<td class="text">Stock-Based Compensation and Employee Benefit Plans<div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Equity Incentive Plan</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company adopted the 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;) which, as of the adoption date, replaced the 2016 Stock Incentive Plan. Under the 2020 Plan, the share reserve automatically increases on January 1st of each year beginning in 2021 and ending with a final increase on January 1, 2030 in an amount equal to 4% of the Company&#8217;s outstanding shares of common stock on December 31st of the preceding calendar year. The Board may provide that there will be no increase in the share reserve for any such year or that the increase in the share reserve may be smaller than would otherwise occur. On January 1, 2026, the share reserve automatically increased by 2,531,194 shares. As of March&#160;31, 2026, there were 1,559,581 shares available for future grants. The 2020 Plan permits the granting of options, stock appreciation rights, restricted stock units (&#8220;RSUs&#8221;), performance stock and performance cash awards. The terms of the agreements under the 2020 Plan are determined by the Board. The Company&#8217;s awards generally vest over four years and have a term of 10 years. Periodically, the Company also grants awards that vest based on the Company's stock achieving certain closing share prices for a specified number of consecutive trading days.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Employee Stock Purchase Plan (the &#8220;2020 ESPP&#8221;) became effective in October 2020. Eligible employees may purchase shares of common stock under the 2020 ESPP at 85% of the lower of the fair market value of the Company&#8217;s common stock as of the first or the last day of each offering period. Employees are limited to contributing 15% of the employee&#8217;s eligible compensation and may not purchase more than $25,000 of stock during any calendar year or more than 2,000 shares during any one purchase period. The 2020 ESPP share reserve automatically increases on January 1st of each calendar year, for ten years, commencing on January 1, 2021, in an amount equal to 1% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year. The Board may act prior to January 1st of a given year to provide that there will be no January 1st increase of the share reserve for such year or that the increase in the share reserve for such year will be a smaller number of shares of common stock than would otherwise occur pursuant to the preceding sentence. The Board elected not to increase the share reserve for the ESPP on January 1, 2026. As of March&#160;31, 2026, there were 1,660,870 shares available for future purchases. There were 30,916 and 6,859 shares issued under the Company&#8217;s 2020 ESPP during the three months ended March&#160;31, 2026 and 2025, respectively, in each case for aggregate proceeds of less than $0.1&#160;million.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Stock-Based Compensation Expense</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following expense categories of its accompanying unaudited interim condensed statements of operations and comprehensive loss (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.153%"><tr><td style="width:1.0%"></td><td style="width:58.134%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.044%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.044%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.702%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,036&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">687&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,415&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,721&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes option activity under the 2020 Plan for the three months ended March&#160;31, 2026:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:48.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.886%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.023%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.023%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Exercise&#160;Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Remaining&#160;Life</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December&#160;31, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,648,715&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.06</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,642,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.75</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(38,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.86</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(188,616)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Balance at March&#160;31, 2026</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13,064,499&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.05&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.89</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,106,588&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.95&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.29</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at the end of the period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,096,229&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.76&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.67</span></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Options granted during the three months ended March&#160;31, 2026 and 2025 had weighted-average grant-date fair values of $4.02 and $0.96 per share, respectively. As of March&#160;31, 2026, the unrecognized compensation cost for options issued was $24.6 million and will be recognized over an estimated weighted-average amortization period of 1.69 years. The total intrinsic value of options exercised during the three months ended March&#160;31, 2026 was $0.2 million. There were no options exercised during the three months ended March 31, 2025. The aggregate intrinsic value of options outstanding and exercisable as of March&#160;31, 2026 was $11.7 million.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes employee RSU activity for the three months ended March&#160;31, 2026:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.455%"><tr><td style="width:1.0%"></td><td style="width:67.780%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.080%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.081%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Awards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December&#160;31, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">481,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8.15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">316,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(206,513)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(861)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8.67</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Balance at March&#160;31, 2026</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">589,803&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.49&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized $0.4&#160;million and $0.3 million</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of stock-based compensation cost related to RSUs for the three months ended March&#160;31, 2026 and 2025, respectively. As of March&#160;31, 2026, the unrecognized compensation cost for RSUs issued was $3.5 million and will be recognized over an estimated weighted-average amortization period of 2.60 years. The fair values of RSUs are based on the fair value of the Company&#8217;s common stock on the date of the grant.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Stock Options and Shares Issued</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation by measuring and recognizing as compensation expense the fair value of all share-based payment awards made to employees, including employee stock options and restricted stock awards. The Company uses the Black-Scholes option pricing model to estimate the fair value of employee stock options that only have service or performance conditions. The inputs to the Black-Scholes option  pricing model require a number of management estimates such as the expected term, volatility, risk-free interest rate and dividend yield. The fair value of stock options was determined using the methods and assumptions discussed below.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The expected term of employee stock options with service-based vesting is determined using the &#8220;simplified&#8221; method, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company&#8217;s lack of sufficient historical data.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The expected stock price volatility assumption is based on the historical volatilities of the common stock of a peer group of publicly traded companies as well as the historical volatility of the Company&#8217;s common stock since the Company began trading subsequent to the Company&#8217;s initial public offering (&#8220;IPO&#8221;) in October 2020 over the period corresponding to the expected life as of the grant date. The historical volatility data was computed using the daily closing prices during the equivalent period of the calculated expected term of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of the Company&#8217;s stock price becomes available, or until circumstances change, such that the identified entities are no longer comparable companies. In the latter case, other suitable, similar entities whose share prices are publicly available would be utilized in the calculation.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the expected term. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The expected dividend yield is 0% because the Company has not historically paid, and does not expect, for the foreseeable future, to pay dividends on its common stock. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Prior to the Company&#8217;s IPO, the Board periodically estimated the fair value of the Company&#8217;s common stock considering, among other things, contemporaneous valuations of its common stock prepared by an unrelated third-party valuation firm. Subsequent to the Company&#8217;s IPO, options are issued with a strike price no less than the market price on date of grant.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of options calculated using the Black-Scholes option pricing model granted under the Company&#8217;s 2020 Plan were estimated using the following weighted-average assumptions:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.673%"><tr><td style="width:1.0%"></td><td style="width:59.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.175%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2020 Plan</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Expected term - years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.00</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">110.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of shares issued calculated using the Black-Scholes option pricing model under the Company&#8217;s 2020 ESPP were estimated using the following weighted-average assumptions:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.352%"><tr><td style="width:1.0%"></td><td style="width:59.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.711%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2020 ESPP</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Expected term - years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.50</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.50</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">109.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">107.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment Reporting<div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has one reportable and operating segment, which is engaged in the business of drug discovery and development. The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) is the Company&#8217;s chief executive officer. The CODM uses the Company&#8217;s net loss to monitor actual results versus the budget in assessing segment performance and the allocation of resources. The measure of segment assets is reported on the balance sheets as total assets. Accounting policies for segment reporting are the same as the accounting policies disclosed in Note 2.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information about the Company&#8217;s single reportable segment and the significant expenses reviewed by the CODM, including a reconciliation to net loss (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:60.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.680%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.681%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">SL-325</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other research and development</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2,3</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development non-equity compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development equity compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total research and development</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,946&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9,919&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative non-equity compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative equity compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other general and administrative including legal and accounting fees, facilities, insurance, travel and depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total general and administrative</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,599&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,470&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Expense from operations</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15,545&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14,389&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(15,545)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(14,389)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other Income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">778</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net Loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(14,767)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(13,702)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">1 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Expenses for SL-325 that were incurred prior to it being nominated a product candidate are included in &#8220;other research and development&#8221;. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"> Other research and development expense includes technical operations expense of $1.9 million and $2.4 million, research activities for other pipeline compounds and facility expenses of $1.9 million and $1.3 million and depreciation expense of $0.9 million and $0.9 million for the three months ended March 31, 2026 and 2025, respectively.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">3</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Other research and development expense includes a gain of $0.7 million due to a change in estimate and expense of $2.0 million for the three months ended March 31, 2026 and 2025, respectively, related to SL-172154 which was discontinued in October 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2026 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=sttk_ArunthathyNirmaliniLiniPanditeM.B.Ch.B.Member', window );">Arunthathy Nirmalini (Lini) Pandite, M.B.Ch.B., [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2026, Arunthathy Nirmalini (Lini) Pandite, M.B.Ch.B., the Company's Chief Medical Officer, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act (a &#8220;10b5-1 Plan&#8221;). Dr. Pandite&#8217;s 10b5-1 Plan provides for the potential sale of up to 83,514 shares of the Company&#8217;s common stock and will expire on the earlier of June 30, 2027 or the date when all shares under Dr. Pandite&#8217;s 10b5-1 Plan are sold.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Arunthathy Nirmalini (Lini) Pandite, M.B.Ch.B.,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Medical Officer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">February 2, 2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">June 30, 2027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">513 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">83,514<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=sttk_AbhinavShuklaPhDMember', window );">Abhinav Shukla, PhD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2026, Abhinav Shukla, PhD., the Company's Chief Technical Officer, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. Dr. Shukla&#8217;s 10b5-1 Plan provides for the potential exercise of stock options to purchase up to 168,659 shares of the Company's common stock and subsequent sale of a portion of the exercised options to cover the exercise price and estimated income taxes associated with the exercise. The 10b5-1 Plan will expire on the earlier of January 29, 2027 or the date when all shares under Dr. Shuckla&#8217;s 10b5-1 Plan are exercised.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Abhinav Shukla, PhD.,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Technical Officer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">February 2, 2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">January 29, 2027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">361 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">168,659<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=sttk_ArunthathyNirmaliniLiniPanditeM.B.Ch.B.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=sttk_ArunthathyNirmaliniLiniPanditeM.B.Ch.B.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=sttk_AbhinavShuklaPhDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=sttk_AbhinavShuklaPhDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Unaudited Interim Condensed Financial Statements</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Condensed Financial Statements </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying interim financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company&#8217;s financial position, its results of operations, statements of changes in stockholders&#8217; equity and cash flows for the interim periods presented. Operating results for interim periods presented are not necessarily indicative of the results that may be expected for the year ending December 31, 2026. The interim financial statements presented herein do not contain all required disclosures under GAAP for annual financial statements. The accompanying unaudited interim condensed financial statements should be read in conjunction with the annual audited financial statements and related notes in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2025.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition, the accrual of research and development expenses, and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates, if any, are recorded in the period in which they become known and actual results could differ from management&#8217;s estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received upon the sale of an asset or paid upon the transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. Fair value measurements are classified and disclosed in one of the following categories: </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level&#160;1: Observable inputs such as quoted prices in active markets for identical assets the reporting entity has the ability to access as of the measurement date; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level&#160;2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level&#160;3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are classified based on the lowest level of input that is significant to the measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of the assets and liabilities and their placement within the fair value hierarchy levels. The determination of the fair values takes into account the market for its financial assets and liabilities, the associated credit risk and other factors as required. The Company considers active markets as those in which transactions for the assets or liabilities occur with sufficient frequency and volume to provide pricing information on an ongoing basis. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that the carrying amounts of the Company&#8217;s financial instruments, including short-term investments and accounts payable, approximate fair value due to the short-term nature of those instruments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Risk</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risk </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and short-term investments. The Company maintains its cash and cash equivalents at an accredited financial institution in amounts that exceed federally-insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company&#8217;s short term investments consist of U.S. Treasury securities that management believes protects the Company from risk of default and impairment of value. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is highly dependent on a limited number of contract development and manufacturing organizations (&#8220;CDMOs&#8221;) to supply drug products for its research and development activities of its programs, including nonclinical studies. The Company is highly dependent on a single CDMO for the supply of cGMP drug product for its clinical trials. These programs could be adversely affected by a significant interruption in the supply of such drug products. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is highly dependent on a limited number of contract research organizations (&#8220;CROs&#8221;) and third-party service providers to manage and support its clinical trials. These programs could be adversely affected by a significant disruption in services provided by these CROs and third parties.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents </span></div>The Company considers all demand deposits with financial institutions and all highly liquid investments with original maturities of 90 days or less at the date of purchase to be cash and cash equivalents.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company's short-term investments consist of highly-rated U.S. Treasury securities and have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices. Management determines the appropriate classification of its investment securities at the time of purchase. The Company may hold securities with stated maturities greater than one year. All available-for-sale securities are considered available to support current operations and are classified as current assets. Credit impairments for available-for-sale securities are recorded through an allowance rather than a direct write-down of the security and are recorded through a charge to the statements of operations and comprehensive loss. Unrealized gains or losses not related to credit impairments are recorded in accumulated other comprehensive income, a component of stockholders&#8217; equity, until realized. The Company reviews available-for-sale debt securities for impairments related to credit losses and other factors each quarter. </span></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a long-term related party investment in preferred stock of a privately held company. The investment is accounted for under Accounting Standards Codification ("ASC") 321, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in Equity Securities</span> and is classified as a long-term asset in the accompanying balance sheet as it is not expected to be liquidated within one year. For investments that do not have a readily determinable fair value, the Company applies the measurement alternative, whereby the investment is carried at cost, adjusted for observable price changes in orderly transactions for identical or similar securities of the same issuer and impairment losses, if any.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_PrepaidExpenseAndOtherAssetsPolicyPolicyTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets include prepaid expenses for general business purposes and services used in research projects, which are stated at cost and amortized on a straight-line basis over the related period of benefit. Supplies and materials that have multiple applications for alternative future use are expensed as they are consumed.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life of the asset. Expenditures for repairs and maintenance that do not extend the estimated useful life or improve an asset are expensed as incurred. Upon retirement or sale, the cost and related accumulated depreciation and amortization of assets disposed of are removed from the accounts, and any resulting gain or loss is included in the statement of operations and comprehensive loss.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation periods are as follows:</span></div><div style="margin-top:6pt;text-align:center;text-indent:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.333%"><tr><td style="width:1.0%"></td><td style="width:62.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.862%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Office equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;to&#160;10 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Lab equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Shorter&#160;of&#160;lease&#160;term&#160;or 15 years</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div>Long-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstance indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable and the carrying amount exceeds the projected discounted future cash flows arising from these assets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception. Right-of-use (&#8220;ROU&#8221;) assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. The classification of the Company's leases as operating or finance leases, along with the initial measurement and recognition of the associated ROU assets and lease liabilities, are performed at the lease commencement date. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. As the Company's leases do not provide an implicit rate, the Company </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. The ROU asset is based on the measurement of the lease liability and also includes any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company's operating leases is recognized on a straight-line basis over the lease term. Operating lease ROU assets and long-term operating lease liabilities are presented separately and operating lease liabilities payable in the next 12 months are recorded in accrued expenses and other current liabilities. The Company has elected to not apply the recognition requirement of ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> of the Financial Accounting Standards Board (&#8220;FASB&#8221;) to leases with a term of 12 months or less for all classes of assets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments and Contingencies</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows ASC 450-20, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to report accounting for contingencies. Certain conditions may exist as of the date the condensed financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company&#8217;s condensed financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue is recognized in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;). Arrangements with collaborators may include licenses to intellectual property, research and development services, manufacturing services for clinical and commercial supply, and participation on joint steering committees. The Company evaluates the promised goods or services in the contract to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, the Company considers the stage of development of the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property and whether the promised goods or services are integral to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Upon the amendment of an existing agreement, the Company evaluates whether the amendment represents a modification to an existing contract that would be recorded through a cumulative catch-up to revenue, prospective modification, or a separate contract. If it is determined that it is a separate contract, the Company will evaluate the necessary revenue recognition through the five-step process described below. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">When the Company concludes that a contract should be accounted for as a combined performance obligation and recognized over time, the Company must then determine the period over which revenue should be recognized and the method by which to measure revenue. The Company generally recognizes revenue using a cost-based input method. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes collaboration revenue in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services when its customer or collaborator obtains control of </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">promised goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the following five steps are performed: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.73pt">identify the contract(s) with a customer;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.96pt">identify the performance obligations in the contract; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">iii.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.19pt">determine the transaction price; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">iv.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.73pt">allocate the transaction price to the performance obligations within the contract; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">v.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">recognize revenue when (or as) the entity satisfies a performance obligation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company only applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company&#8217;s arrangements may consist of a license of, or options to license, the Company&#8217;s intellectual property and research, development and manufacturing services. The Company may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i)&#160;the customer can benefit from on its own or together with other readily available resources and (ii)&#160;are separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most-likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes variable consideration in the transaction price to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations that consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company&#8217;s accompanying balance sheet. Deferred revenues expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability. Deferred revenues not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as non-current liabilities. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Company&#8217;s collaboration revenue arrangements may include the following: </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Up-front License Fees: If a license is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, up-front fees allocated to the </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Milestone Payments: At the inception of an agreement that includes research and development milestone payments, the Company evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company first estimates the amount of the milestone payment that the Company could receive using either the expected value or the most-likely amount approach. The Company primarily uses the most-likely amount approach as that approach is generally most predictive for milestone payments with a binary outcome. The Company then considers whether any portion of that estimated amount is subject to the variable consideration constraint (that is, whether it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty). The Company updates the estimate of variable consideration included in the transaction price at each reporting date which includes updating the assessment of the likely amount of consideration and the application of the constraint to reflect current facts and circumstances. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Royalties: For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not granted a development and commercialization license nor recognized any revenue related to sales-based royalties or milestone payments based on the level of sales. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and Development Services: The Company will record costs associated with development and process optimization activities as research and development expenses in the statements of operations and comprehensive loss consistent with ASC 730, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> The Company considered the guidance in ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 808&#8221;) and will recognize the payments received from these agreements as revenue when the related costs are incurred. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">License Revenue: License revenue is generated from granting third parties rights to certain of the Company&#8217;s intellectual property, including research, development, and commercialization of specified product candidates. The Company evaluates each licensing arrangement to determine whether the license is distinct from other promised goods or services and whether the arrangement includes multiple performance obligations. If an arrangement includes multiple performance obligations, the transaction price is allocated to each performance obligation based on relative standalone selling prices. Upfront payments, including nonrefundable license fees, are recognized as revenue when the underlying performance obligation is satisfied. Milestone payments that are contingent on the occurrence of a future event are included in the transaction price only when it is probable that a significant reversal of cumulative revenue will not occur. Sales-based royalties, including milestone payments based on a level of sales, are recognized as revenue when the subsequent sales occur.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company may also enter into arrangements that include non-cash consideration, such as equity instruments. In such cases, the Company measures the transaction price at the estimated fair value of the non-cash consideration received at contract inception and recognizes revenue when the performance obligation is satisfied.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred, and include salaries, stock-based compensation and other personnel-related costs, equipment and supplies, depreciation, nonclinical studies, clinical trials and manufacturing development activities. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of the Company&#8217;s ongoing research and development activities are conducted by third-party service providers, including CROs and CDMOs. The Company accrues for expenses resulting from obligations under agreements with CROs, CDMOs and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with CROs, CDMOs and other outside </span></div>service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through an evaluation of the progress or stage of completion of the services. In the event advance payments are made to a CRO, CDMO or outside service provider, the payments will be recorded as a prepaid asset which will be amortized as the contracted services are performed. As actual costs become known, the Company adjusts its accruals and prepaid assets accordingly. Inputs, such as the services performed, the number of patients enrolled or the study duration, may vary from the Company&#8217;s estimates, resulting in adjustments to research and development expenses in future periods. The Company makes significant judgments and estimates in determining the accrual and/or prepaid balance in each reporting period and changes in these estimates may result in material changes to the Company&#8217;s accruals that could materially affect the Company&#8217;s results of operations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_WarrantsPolicyTextBlock', window );">Common Stock Warrants and Pre-Funded Warrants</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants and Pre-Funded Warrants</span></div>The Company&#8217;s common stock warrants and pre-funded warrants are classified as a component of permanent stockholders&#8217; equity within additional paid-in capital. The common stock warrants and pre-funded warrants are equity classified because they, (i) are freestanding financial instruments, (ii) are immediately exercisable, (iii) do not embody an obligation for the Company to repurchase its shares, (iv) permit the holders to receive a fixed number of shares of common stock upon exercise, (v) are indexed to the Company&#8217;s common stock and, (vi) meet the equity classification criteria. In addition, such common stock warrants and pre-funded warrants do not provide any guarantee of value or return.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the cost of stock-based awards issued to employees and nonemployees as compensation expense on a straight-line basis over the vesting period of the award, net of estimated forfeitures. Forfeiture estimates are based on historical cancellation data. The Company uses the Black-Scholes option pricing model to determine the grant-date fair value of stock options. The fair values of restricted stock units (&#8220;RSUs&#8221;) are based on the fair value of the Company&#8217;s common stock on the date of the grant. The Company also grants stock options that vest upon achievement of certain market-based conditions. The Company uses the Monte Carlo pricing model to estimate the fair value of options that have market-based conditions. The Company adjusts expense for forfeitures in the periods they occur.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statements and the tax bases of assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in tax rates on deferred tax assets and liabilities will be recognized in the period that includes the enactment date. Additionally, any changes in income tax laws are immediately recognized in the year of enactment.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is established against the deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. The deferred tax assets and liabilities are classified as noncurrent along with the related valuation allowance. Due to a lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on the technical merits, as the largest amount of benefits that is more likely than not to be realized upon the ultimate settlement. The Company&#8217;s policy is to recognize interest and penalties related to the unrecognized tax benefits as a component of income tax expense.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Basic shares outstanding includes the weighted average effect of the Company&#8217;s outstanding 38,448,034 pre-funded warrants as of March&#160;31, 2026, the exercise of which requires nominal consideration for the delivery of an equal number of shares of common stock. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock or convertible notes, if any, </span></div>stock options and unvested shares of restricted stock, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Comprehensive Income (Loss) </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Other comprehensive income (loss) is comprised of unrealized gains and losses on short-term investments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements/Recently Issued Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in this update are intended to enhance the transparency and decision usefulness of income tax disclosures primarily through changes to the rate reconciliation and income taxes paid information. This update is effective for annual periods beginning after December 15, 2024, and may be applied prospectively or retrospectively. The Company has retrospectively adopted this ASU in the financial statements for the year ending December&#160;31, 2025. </span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (&#8220;ASU 2024-03&#8221;), which is intended to provide more detailed information about specified categories of expenses (employee compensation, depreciation, and amortization) included in certain expense captions presented on the statement of operations. The guidance in this ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either, (i) prospectively to financial statements issued for periods after the effective date of this ASU or, (ii) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its financial statements and disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_PrepaidExpenseAndOtherAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expense and Other Assets Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_PrepaidExpenseAndOtherAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_WarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_WarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 450<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477850/954-450-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment depreciation periods</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation periods are as follows:</span></div><div style="margin-top:6pt;text-align:center;text-indent:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.333%"><tr><td style="width:1.0%"></td><td style="width:62.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.862%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Office equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;to&#160;10 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Lab equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Shorter&#160;of&#160;lease&#160;term&#160;or 15 years</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of antidilutive securities excluded from computation of net loss per share</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding as they would be anti-dilutive:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.484%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">As of March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">47,487,573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13,064,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,458,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">589,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">527,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">61,141,875&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,986,287&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Investments</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the Company&#8217;s investments by major security type (amounts in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.613%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2026</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Gain</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">88,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">88,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">88,860&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">88,860&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.613%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">23,867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">23,873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market fund</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">52,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">52,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">76,137&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">76,143&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following (amounts in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.925%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development contract costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,057&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,111&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">852&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Compensation and related benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,996&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,951&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation and Employee Benefit Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation expense</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following expense categories of its accompanying unaudited interim condensed statements of operations and comprehensive loss (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.153%"><tr><td style="width:1.0%"></td><td style="width:58.134%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.044%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.044%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.702%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,036&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">687&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,415&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,721&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of option activity</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes option activity under the 2020 Plan for the three months ended March&#160;31, 2026:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:48.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.886%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.023%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.023%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Exercise&#160;Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Remaining&#160;Life</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December&#160;31, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,648,715&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.06</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,642,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.75</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(38,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.86</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(188,616)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Balance at March&#160;31, 2026</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13,064,499&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.05&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.89</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,106,588&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.95&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.29</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at the end of the period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,096,229&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.76&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.67</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock', window );">Schedule of RSU activity</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes employee RSU activity for the three months ended March&#160;31, 2026:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.455%"><tr><td style="width:1.0%"></td><td style="width:67.780%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.080%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.081%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Awards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December&#160;31, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">481,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8.15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">316,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(206,513)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(861)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8.67</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Balance at March&#160;31, 2026</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">589,803&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.49&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of valuation assumptions</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of options calculated using the Black-Scholes option pricing model granted under the Company&#8217;s 2020 Plan were estimated using the following weighted-average assumptions:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.673%"><tr><td style="width:1.0%"></td><td style="width:59.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.175%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2020 Plan</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Expected term - years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.00</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">110.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of shares issued calculated using the Black-Scholes option pricing model under the Company&#8217;s 2020 ESPP were estimated using the following weighted-average assumptions:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.352%"><tr><td style="width:1.0%"></td><td style="width:59.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.711%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2020 ESPP</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Expected term - years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.50</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.50</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">109.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">107.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information about the Company&#8217;s single reportable segment and the significant expenses reviewed by the CODM, including a reconciliation to net loss (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:60.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.680%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.681%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">SL-325</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other research and development</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2,3</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development non-equity compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development equity compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total research and development</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,946&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9,919&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative non-equity compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative equity compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other general and administrative including legal and accounting fees, facilities, insurance, travel and depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total general and administrative</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,599&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,470&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Expense from operations</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15,545&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14,389&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(15,545)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(14,389)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other Income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">778</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net Loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(14,767)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(13,702)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">1 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Expenses for SL-325 that were incurred prior to it being nominated a product candidate are included in &#8220;other research and development&#8221;. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"> Other research and development expense includes technical operations expense of $1.9 million and $2.4 million, research activities for other pipeline compounds and facility expenses of $1.9 million and $1.3 million and depreciation expense of $0.9 million and $0.9 million for the three months ended March 31, 2026 and 2025, respectively.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">3</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Other research and development expense includes a gain of $0.7 million due to a change in estimate and expense of $2.0 million for the three months ended March 31, 2026 and 2025, respectively, related to SL-172154 which was discontinued in October 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Description of Business (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 445,296<span></span>
</td>
<td class="nump">$ 430,529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="nump">$ 90,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 90,419<span></span>
</td>
<td class="nump">$ 54,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sttk_PreFundedWarrantsMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares)</a></td>
<td class="nump">38,448,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,823<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=sttk_OperatingAccountMember', window );">Operating Account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 88,900<span></span>
</td>
<td class="nump">$ 52,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sttk_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sttk_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=sttk_OperatingAccountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=sttk_OperatingAccountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Schedule of property and equipment depreciation and amortization periods (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment depreciation and amortization periods</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment depreciation and amortization periods</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment depreciation and amortization periods</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sttk_LaboratoryEquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment depreciation and amortization periods</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment depreciation and amortization periods</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sttk_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sttk_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Schedule of anti-dilutive securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net loss per share (in shares)</a></td>
<td class="nump">61,141,875<span></span>
</td>
<td class="nump">8,986,287<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net loss per share (in shares)</a></td>
<td class="nump">47,487,573<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net loss per share (in shares)</a></td>
<td class="nump">13,064,499<span></span>
</td>
<td class="nump">8,458,834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net loss per share (in shares)</a></td>
<td class="nump">589,803<span></span>
</td>
<td class="nump">527,453<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Schedule of Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAbstract', window );"><strong>Debt Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">$ 88,860<span></span>
</td>
<td class="nump">$ 76,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax', window );">Gross Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total Fair Value</a></td>
<td class="nump">88,860<span></span>
</td>
<td class="nump">76,143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market fund | Cash equivalents:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAbstract', window );"><strong>Debt Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">88,860<span></span>
</td>
<td class="nump">52,270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax', window );">Gross Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total Fair Value</a></td>
<td class="nump">$ 88,860<span></span>
</td>
<td class="nump">52,270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. government securities | Investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAbstract', window );"><strong>Debt Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax', window );">Gross Unrealized Gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,873<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain (loss) in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=sttk_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=sttk_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal', window );">Investment impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding accrued interest, of credit loss expense (reversal of expense) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) with previously recorded allowance and not intended to be sold and not more likely than not will be required to sell before recovery of amortized cost basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_AccruedResearchAndDevelopmentContractCostsCurrent', window );">Research and development contract costs</a></td>
<td class="nump">$ 1,057<span></span>
</td>
<td class="nump">$ 1,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">852<span></span>
</td>
<td class="nump">837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and related benefits</a></td>
<td class="nump">752<span></span>
</td>
<td class="nump">2,767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">335<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 2,996<span></span>
</td>
<td class="nump">$ 4,951<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities and Other Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_AccruedResearchAndDevelopmentContractCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Development Contract Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_AccruedResearchAndDevelopmentContractCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_IncreaseDecreaseInOperatingLeasesRightOfUseAssetsLiability', window );">Changes in lease balances resulting from lease modification</a></td>
<td class="nump">$ 678<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_IncreaseDecreaseInOperatingLeasesRightOfUseAssetsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Leases, Right of Use Assets (Liability)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_IncreaseDecreaseInOperatingLeasesRightOfUseAssetsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party License Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License and collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sttk_KayakAgreementMember', window );">Kayak Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License and collaboration revenue</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_SubleaseAgreementConsideration', window );">Sublease consideration</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sttk_KayakAgreementMember', window );">Kayak Agreement | Kayak Agreement, Contingent Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Account receivable</a></td>
<td class="nump">$ 86,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_SubleaseAgreementConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sublease Agreement, Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_SubleaseAgreementConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sttk_KayakAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sttk_KayakAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sttk_KayakAgreementContingentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sttk_KayakAgreementContingentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($) </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_CommonStockNumberOfVotesPerCommonShare', window );">Common stock, number of votes per common share | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from sale of common stock, net of offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,562,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sttk_PreFundedWarrantsMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,823<span></span>
</td>
<td class="nump">38,448,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_ClassOfWarrantOrRightWarrantsExercised', window );">Common stock warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,929,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants or rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,866,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sttk_PreFundedWarrantsMember', window );">Pre-Funded Warrants | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_StockIssuedDuringPeriodSharesWarrantExercises', window );">Exercise of common stock warrants into common stock and pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,928,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sttk_CommonStockWarrantsMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,487,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_ClassOfWarrantOrRightWarrantsExercised', window );">Common stock warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,019,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sttk_CommonStockWarrantsMember', window );">Common stock warrants | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_StockIssuedDuringPeriodSharesWarrantExercises', window );">Exercise of common stock warrants into common stock and pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sttk_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from sale of common stock, net of offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,651,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of preferred stock (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_ClassOfWarrantOrRightPriceOfPreFundedWarrants', window );">Price of pre-funded warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.4499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of securities called by each warrant or right (in share per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise', window );">Pre-funded warrants, ownership limitation post-exercise</a></td>
<td class="nump">0.0999<span></span>
</td>
<td class="nump">0.0999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of preferred stock (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.8677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Preferred stock sold (in shares)</a></td>
<td class="nump">15,225,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of preferred stock (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.8676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of securities called by each warrant or right (in share per share)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Preferred stock sold (in shares)</a></td>
<td class="nump">37,410,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Pre-Funded Warrants | Beneficial Owners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Preferred stock sold (in shares)</a></td>
<td class="nump">8,963,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.0846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of securities called by each warrant or right (in share per share)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Preferred stock sold (in shares)</a></td>
<td class="nump">52,635,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sttk_AtTheMarketOfferingMember', window );">At The Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of preferred stock (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Preferred stock sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_SaleOfStockMaximumAggregateSalesPrice', window );">Sale of stock maximum aggregate sales price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_SaleOfStockCommissionPercentage', window );">Sale of stock commission</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, proceeds received | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Pre-Funded Warrants, Ownership Limitation Post-Exercise</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_ClassOfWarrantOrRightPriceOfPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Price of Pre-Funded Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_ClassOfWarrantOrRightPriceOfPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_ClassOfWarrantOrRightWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_ClassOfWarrantOrRightWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_CommonStockNumberOfVotesPerCommonShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Number Of Votes Per Common Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_CommonStockNumberOfVotesPerCommonShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_SaleOfStockCommissionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Commission Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_SaleOfStockCommissionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_SaleOfStockMaximumAggregateSalesPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock Maximum Aggregate Sales Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_SaleOfStockMaximumAggregateSalesPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_StockIssuedDuringPeriodSharesWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrant Exercises</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_StockIssuedDuringPeriodSharesWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sttk_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sttk_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sttk_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sttk_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sttk_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sttk_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sttk_BeneficialOwnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sttk_BeneficialOwnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sttk_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sttk_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation and Employee Benefit Plans - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 01, 2026 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.02<span></span>
</td>
<td class="nump">$ 0.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,415<span></span>
</td>
<td class="nump">1,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sttk_A2020StockIncentivePlanMember', window );">2020 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage', window );">Increase in number of shares authorized, percentage of capital stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,559,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance', window );">Common stock, additional capital shares reserved for future issuance (in shares) | shares</a></td>
<td class="nump">2,531,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock-based compensation, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based compensation, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sttk_A2020EmployeeStockPurchasePlanMember', window );">2020 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage', window );">Increase in number of shares authorized, percentage of capital stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance', window );">Common stock, additional capital shares reserved for future issuance (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,660,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock in percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Contribution limit in percentage of employee's eligible compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue', window );">Maximum value of shares per employee during any calendar year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Maximum number of shares per employee during any one purchase period (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm', window );">Annual increase in number of shares authorized, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock issued under ESPP (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,916<span></span>
</td>
<td class="nump">6,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Additional Capital Shares Reserved for Future Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase In Number of Shares Authorized, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized, Annual Increase Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Maximum Shares Per Employee, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sttk_A2020StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sttk_A2020StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sttk_A2020EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sttk_A2020EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation and Employee Benefit Plans - Schedule of stock-based compensation expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 2,415<span></span>
</td>
<td class="nump">$ 1,721<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">1,036<span></span>
</td>
<td class="nump">687<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 1,379<span></span>
</td>
<td class="nump">$ 1,034<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation and Employee Benefit Plans - Schedule of option activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, beginning balance (in shares)</a></td>
<td class="nump">8,648,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, granted (in shares)</a></td>
<td class="nump">4,642,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options, granted (in shares)</a></td>
<td class="num">(38,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options, granted (in shares)</a></td>
<td class="num">(188,616)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, ending balance (in shares)</a></td>
<td class="nump">13,064,499<span></span>
</td>
<td class="nump">8,648,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options, vested and expected to vest (in shares)</a></td>
<td class="nump">7,106,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options, exercisable (in shares)</a></td>
<td class="nump">5,096,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise&#160;Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted (in dollars per share)</a></td>
<td class="nump">4.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised (in dollars per share)</a></td>
<td class="nump">0.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, forfeited (in dollars per share)</a></td>
<td class="nump">7.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, ending balance (in dollars per share)</a></td>
<td class="nump">5.05<span></span>
</td>
<td class="nump">$ 5.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, vested and expected to vest (in dollars per share)</a></td>
<td class="nump">3.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable (in dollars per share)</a></td>
<td class="nump">$ 6.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining&#160;Life (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted&#160;average remaining contract life, outstanding</a></td>
<td class="text">7 years 10 months 20 days<span></span>
</td>
<td class="text">7 years 21 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted&#160;average remaining contract life, vested and expected to vest</a></td>
<td class="text">9 years 3 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contract life, exercisable</a></td>
<td class="text">5 years 8 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation and Employee Benefit Plans - Schedule of restricted stock activity (Details) - Restricted Stock Units<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2026 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Awards, beginning balance (in shares) | shares</a></td>
<td class="nump">481,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">316,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Released (in shares) | shares</a></td>
<td class="num">(206,513)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(861)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Awards, ending balance (in shares) | shares</a></td>
<td class="nump">589,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 8.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">4.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Released (in dollars per share) | $ / shares</a></td>
<td class="nump">7.69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">8.67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.49<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation and Employee Benefit Plans - Schedule of 2020 Plan option valuation assumptions (Details) - Stock options<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">2020 Stock Incentive Plan | Black-Scholes Option Pricing Model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term - years</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">110.40%<span></span>
</td>
<td class="nump">101.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.80%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sttk_A2020StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sttk_A2020StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=sttk_BlackScholesOptionPricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=sttk_BlackScholesOptionPricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation and Employee Benefit Plans - Schedule of 2020 ESPP valuation assumptions (Details) - Employee Stock - 2020 Employee Stock Purchase Plan - Black-Scholes Option Pricing Model<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term - years</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">109.70%<span></span>
</td>
<td class="nump">107.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.92%<span></span>
</td>
<td class="nump">4.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sttk_A2020EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sttk_A2020EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=sttk_BlackScholesOptionPricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=sttk_BlackScholesOptionPricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">10,946<span></span>
</td>
<td class="nump">9,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">4,599<span></span>
</td>
<td class="nump">4,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Expense from operations</a></td>
<td class="nump">15,545<span></span>
</td>
<td class="nump">14,389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(15,545)<span></span>
</td>
<td class="num">(14,389)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(14,767)<span></span>
</td>
<td class="num">(13,702)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">891<span></span>
</td>
<td class="nump">936<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=sttk_ReportableSegmentMember', window );">Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">10,946<span></span>
</td>
<td class="nump">9,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_ResearchAndDevelopmentNonEquityCompensation', window );">Research and development non-equity compensation</a></td>
<td class="nump">2,382<span></span>
</td>
<td class="nump">2,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_ResearchAndDevelopmentEquityCompensation', window );">Research and development equity compensation</a></td>
<td class="nump">1,036<span></span>
</td>
<td class="nump">687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_GeneralAndAdministrativeNonEquityCompensation', window );">General and administrative non-equity compensation</a></td>
<td class="nump">1,427<span></span>
</td>
<td class="nump">1,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_GeneralAndAdministrativeEquityCompensation', window );">General and administrative equity compensation</a></td>
<td class="nump">1,379<span></span>
</td>
<td class="nump">1,033<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Other general and administrative including legal and accounting fees, facilities, insurance, travel and depreciation</a></td>
<td class="nump">1,793<span></span>
</td>
<td class="nump">2,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">4,599<span></span>
</td>
<td class="nump">4,470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Expense from operations</a></td>
<td class="nump">15,545<span></span>
</td>
<td class="nump">14,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(15,545)<span></span>
</td>
<td class="num">(14,389)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense</a></td>
<td class="nump">778<span></span>
</td>
<td class="nump">687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(14,767)<span></span>
</td>
<td class="num">(13,702)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=sttk_ReportableSegmentMember', window );">Reportable Segment | SL-325</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">2,861<span></span>
</td>
<td class="nump">2,229<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=sttk_ReportableSegmentMember', window );">Reportable Segment | Other Research And Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">4,667<span></span>
</td>
<td class="nump">4,606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_OtherResearchAndDevelopmentExpenseTechnicalOperations', window );">Other research and development expense (income), technical operations</a></td>
<td class="nump">1,900<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Other research and development expense</a></td>
<td class="nump">1,900<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">900<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=sttk_ReportableSegmentMember', window );">Reportable Segment | Other Research And Development, SL-172154</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_OtherResearchAndDevelopmentExpenseTechnicalOperations', window );">Other research and development expense (income), technical operations</a></td>
<td class="num">$ (700)<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_GeneralAndAdministrativeEquityCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General And Administrative Equity Compensation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_GeneralAndAdministrativeEquityCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_GeneralAndAdministrativeNonEquityCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General And Administrative Non-Equity Compensation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_GeneralAndAdministrativeNonEquityCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_OtherResearchAndDevelopmentExpenseTechnicalOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Research And Development Expense, Technical Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_OtherResearchAndDevelopmentExpenseTechnicalOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_ResearchAndDevelopmentEquityCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Equity Compensation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_ResearchAndDevelopmentEquityCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_ResearchAndDevelopmentNonEquityCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Non-Equity Compensation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_ResearchAndDevelopmentNonEquityCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=sttk_ReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=sttk_ReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sttk_SL325Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sttk_SL325Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sttk_OtherResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sttk_OtherResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sttk_OtherResearchAndDevelopmentSL172154Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sttk_OtherResearchAndDevelopmentSL172154Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>108</ContextCount>
  <ElementCount>237</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>42</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="sttk-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sttk-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - CONDENSED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS</Role>
      <ShortName>CONDENSED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sttk-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - CONDENSED BALANCE SHEETS - Parenthetical</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED BALANCE SHEETS - Parenthetical</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sttk-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sttk-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sttk-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - CONDENSED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sttk-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/OrganizationandDescriptionofBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sttk-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sttk-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sttk-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sttk-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sttk-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Related Party License Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/RelatedPartyLicenseRevenue</Role>
      <ShortName>Related Party License Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sttk-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sttk-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Stock-Based Compensation and Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlans</Role>
      <ShortName>Stock-Based Compensation and Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sttk-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sttk-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sttk-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="sttk-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="sttk-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/Investments</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="sttk-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilities</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="sttk-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Stock-Based Compensation and Employee Benefit Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansTables</Role>
      <ShortName>Stock-Based Compensation and Employee Benefit Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlans</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="sttk-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/SegmentReporting</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="sttk-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Organization and Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/OrganizationandDescriptionofBusinessDetails</Role>
      <ShortName>Organization and Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/OrganizationandDescriptionofBusiness</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="sttk-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="sttk-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of property and equipment depreciation and amortization periods (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Schedule of property and equipment depreciation and amortization periods (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="sttk-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of anti-dilutive securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Schedule of anti-dilutive securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="sttk-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Investments - Schedule of Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/InvestmentsScheduleofInvestmentsDetails</Role>
      <ShortName>Investments - Schedule of Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="sttk-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/InvestmentsNarrativeDetails</Role>
      <ShortName>Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="sttk-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="sttk-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/CommitmentsandContingencies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="sttk-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Related Party License Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/RelatedPartyLicenseRevenueDetails</Role>
      <ShortName>Related Party License Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/RelatedPartyLicenseRevenue</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="sttk-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/Equity</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="sttk-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Stock-Based Compensation and Employee Benefit Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation and Employee Benefit Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="sttk-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Stock-Based Compensation and Employee Benefit Plans - Schedule of stock-based compensation expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofstockbasedcompensationexpenseDetails</Role>
      <ShortName>Stock-Based Compensation and Employee Benefit Plans - Schedule of stock-based compensation expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="sttk-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Stock-Based Compensation and Employee Benefit Plans - Schedule of option activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofoptionactivityDetails</Role>
      <ShortName>Stock-Based Compensation and Employee Benefit Plans - Schedule of option activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="sttk-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Stock-Based Compensation and Employee Benefit Plans - Schedule of restricted stock activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofrestrictedstockactivityDetails</Role>
      <ShortName>Stock-Based Compensation and Employee Benefit Plans - Schedule of restricted stock activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="sttk-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Stock-Based Compensation and Employee Benefit Plans - Schedule of 2020 Plan option valuation assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020PlanoptionvaluationassumptionsDetails</Role>
      <ShortName>Stock-Based Compensation and Employee Benefit Plans - Schedule of 2020 Plan option valuation assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="sttk-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Stock-Based Compensation and Employee Benefit Plans - Schedule of 2020 ESPP valuation assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020ESPPvaluationassumptionsDetails</Role>
      <ShortName>Stock-Based Compensation and Employee Benefit Plans - Schedule of 2020 ESPP valuation assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="sttk-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Segment Reporting (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/SegmentReportingDetails</Role>
      <ShortName>Segment Reporting (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/SegmentReportingTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="sttk-20260331.htm">sttk-20260331.htm</File>
    <File>sttk-20260331.xsd</File>
    <File>sttk-20260331_cal.xml</File>
    <File>sttk-20260331_def.xml</File>
    <File>sttk-20260331_lab.xml</File>
    <File>sttk-20260331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="388">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="19">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>67
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "sttk-20260331.htm": {
   "nsprefix": "sttk",
   "nsuri": "http://www.shattucklabs.com/20260331",
   "dts": {
    "inline": {
     "local": [
      "sttk-20260331.htm"
     ]
    },
    "schema": {
     "local": [
      "sttk-20260331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "sttk-20260331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sttk-20260331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "sttk-20260331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sttk-20260331_pre.xml"
     ]
    }
   },
   "keyStandard": 214,
   "keyCustom": 23,
   "axisStandard": 19,
   "axisCustom": 0,
   "memberStandard": 20,
   "memberCustom": 19,
   "hidden": {
    "total": 9,
    "http://fasb.org/us-gaap/2025": 2,
    "http://xbrl.sec.gov/dei/2025": 5,
    "http://xbrl.sec.gov/ecd/2025": 2
   },
   "contextCount": 108,
   "entityCount": 1,
   "segmentCount": 42,
   "elementCount": 456,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 388,
    "http://xbrl.sec.gov/dei/2025": 30,
    "http://xbrl.sec.gov/ecd/2025": 19
   },
   "report": {
    "R1": {
     "role": "http://www.shattucklabs.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS",
     "longName": "9952151 - Statement - CONDENSED BALANCE SHEETS",
     "shortName": "CONDENSED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETSParenthetical",
     "longName": "9952152 - Statement - CONDENSED BALANCE SHEETS - Parenthetical",
     "shortName": "CONDENSED BALANCE SHEETS - Parenthetical",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "longName": "9952153 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "shortName": "CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentIncomeInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
     "longName": "9952154 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY",
     "shortName": "CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-22",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-22",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
     "longName": "9952155 - Statement - CONDENSED STATEMENTS OF CASH FLOWS",
     "shortName": "CONDENSED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.shattucklabs.com/role/OrganizationandDescriptionofBusiness",
     "longName": "9952156 - Disclosure - Organization and Description of Business",
     "shortName": "Organization and Description of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies",
     "longName": "9952157 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.shattucklabs.com/role/Investments",
     "longName": "9952158 - Disclosure - Investments",
     "shortName": "Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilities",
     "longName": "9952159 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.shattucklabs.com/role/CommitmentsandContingencies",
     "longName": "9952160 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.shattucklabs.com/role/RelatedPartyLicenseRevenue",
     "longName": "9952161 - Disclosure - Related Party License Revenue",
     "shortName": "Related Party License Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.shattucklabs.com/role/Equity",
     "longName": "9952162 - Disclosure - Equity",
     "shortName": "Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlans",
     "longName": "9952163 - Disclosure - Stock-Based Compensation and Employee Benefit Plans",
     "shortName": "Stock-Based Compensation and Employee Benefit Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.shattucklabs.com/role/SegmentReporting",
     "longName": "9952164 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:NonRule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:NonRule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9955511 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables",
     "longName": "9955512 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.shattucklabs.com/role/InvestmentsTables",
     "longName": "9955513 - Disclosure - Investments (Tables)",
     "shortName": "Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables",
     "longName": "9955514 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansTables",
     "longName": "9955515 - Disclosure - Stock-Based Compensation and Employee Benefit Plans (Tables)",
     "shortName": "Stock-Based Compensation and Employee Benefit Plans (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.shattucklabs.com/role/SegmentReportingTables",
     "longName": "9955516 - Disclosure - Segment Reporting (Tables)",
     "shortName": "Segment Reporting (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.shattucklabs.com/role/OrganizationandDescriptionofBusinessDetails",
     "longName": "9955517 - Disclosure - Organization and Description of Business (Details)",
     "shortName": "Organization and Description of Business (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
     "longName": "9955518 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-36",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails",
     "longName": "9955519 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of property and equipment depreciation and amortization periods (Details)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Schedule of property and equipment depreciation and amortization periods (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-40",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-40",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails",
     "longName": "9955520 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of anti-dilutive securities (Details)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Schedule of anti-dilutive securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.shattucklabs.com/role/InvestmentsScheduleofInvestmentsDetails",
     "longName": "9955521 - Disclosure - Investments - Schedule of Investments (Details)",
     "shortName": "Investments - Schedule of Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.shattucklabs.com/role/InvestmentsNarrativeDetails",
     "longName": "9955522 - Disclosure - Investments - Narrative (Details)",
     "shortName": "Investments - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
     "longName": "9955523 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "sttk:AccruedResearchAndDevelopmentContractCostsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "sttk:AccruedResearchAndDevelopmentContractCostsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.shattucklabs.com/role/CommitmentsandContingenciesDetails",
     "longName": "9955524 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sttk:IncreaseDecreaseInOperatingLeasesRightOfUseAssetsLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R31": {
     "role": "http://www.shattucklabs.com/role/RelatedPartyLicenseRevenueDetails",
     "longName": "9955525 - Disclosure - Related Party License Revenue (Details)",
     "shortName": "Related Party License Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-56",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.shattucklabs.com/role/EquityDetails",
     "longName": "9955526 - Disclosure - Equity (Details)",
     "shortName": "Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansNarrativeDetails",
     "longName": "9955527 - Disclosure - Stock-Based Compensation and Employee Benefit Plans - Narrative (Details)",
     "shortName": "Stock-Based Compensation and Employee Benefit Plans - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofstockbasedcompensationexpenseDetails",
     "longName": "9955528 - Disclosure - Stock-Based Compensation and Employee Benefit Plans - Schedule of stock-based compensation expense (Details)",
     "shortName": "Stock-Based Compensation and Employee Benefit Plans - Schedule of stock-based compensation expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-84",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofoptionactivityDetails",
     "longName": "9955529 - Disclosure - Stock-Based Compensation and Employee Benefit Plans - Schedule of option activity (Details)",
     "shortName": "Stock-Based Compensation and Employee Benefit Plans - Schedule of option activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofrestrictedstockactivityDetails",
     "longName": "9955530 - Disclosure - Stock-Based Compensation and Employee Benefit Plans - Schedule of restricted stock activity (Details)",
     "shortName": "Stock-Based Compensation and Employee Benefit Plans - Schedule of restricted stock activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-89",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-89",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020PlanoptionvaluationassumptionsDetails",
     "longName": "9955531 - Disclosure - Stock-Based Compensation and Employee Benefit Plans - Schedule of 2020 Plan option valuation assumptions (Details)",
     "shortName": "Stock-Based Compensation and Employee Benefit Plans - Schedule of 2020 Plan option valuation assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-88",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-93",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020ESPPvaluationassumptionsDetails",
     "longName": "9955532 - Disclosure - Stock-Based Compensation and Employee Benefit Plans - Schedule of 2020 ESPP valuation assumptions (Details)",
     "shortName": "Stock-Based Compensation and Employee Benefit Plans - Schedule of 2020 ESPP valuation assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-95",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-95",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.shattucklabs.com/role/SegmentReportingDetails",
     "longName": "9955533 - Disclosure - Segment Reporting (Details)",
     "shortName": "Segment Reporting (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20260331.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "sttk_A2020EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "A2020EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020ESPPvaluationassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Employee Stock Purchase Plan",
        "label": "2020 Employee Stock Purchase Plan [Member]",
        "documentation": "2020 Employee Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "sttk_A2020StockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "A2020StockIncentivePlanMember",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020PlanoptionvaluationassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Stock Incentive Plan",
        "label": "2020 Stock Incentive Plan [Member]",
        "documentation": "2020 Stock Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "sttk_AbhinavShuklaPhDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "AbhinavShuklaPhDMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Abhinav Shukla, PhD [Member]",
        "documentation": "Abhinav Shukla, PhD"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses and Other Current Liabilities",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r41",
      "r44",
      "r962"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r710"
     ]
    },
    "us-gaap_AccountsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNet",
     "crdr": "debit",
     "presentation": [
      "http://www.shattucklabs.com/role/RelatedPartyLicenseRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Account receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r592",
      "r645",
      "r723",
      "r992",
      "r993"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net amortization of investments",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities",
        "label": "Accrued Liabilities and Other Liabilities, Current",
        "documentation": "Accrued Liabilities and Other Liabilities, Current"
       }
      }
     },
     "auth_ref": []
    },
    "sttk_AccruedResearchAndDevelopmentContractCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "AccruedResearchAndDevelopmentContractCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development contract costs",
        "label": "Accrued Research And Development Contract Costs, Current",
        "documentation": "Accrued Research And Development Contract Costs, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r54",
      "r105",
      "r510",
      "r548",
      "r549",
      "r970"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive (Loss) Income",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r6",
      "r13",
      "r421",
      "r424",
      "r463",
      "r544",
      "r545",
      "r839",
      "r840",
      "r841",
      "r893",
      "r894",
      "r895",
      "r896"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r710",
      "r1026"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r561",
      "r893",
      "r894",
      "r895",
      "r896",
      "r971",
      "r1029"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Taxes paid related to net share settlement of restricted stock units",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r739",
      "r749",
      "r759",
      "r791"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r742",
      "r752",
      "r762",
      "r794"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r743",
      "r753",
      "r763",
      "r787",
      "r795",
      "r799",
      "r807"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofstockbasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total stock-based compensation",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r366",
      "r375"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.shattucklabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from computation of net loss per share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.shattucklabs.com/role/RelatedPartyLicenseRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "sttk_ArunthathyNirmaliniLiniPanditeM.B.Ch.B.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "ArunthathyNirmaliniLiniPanditeM.B.Ch.B.Member",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arunthathy Nirmalini (Lini) Pandite, M.B.Ch.B., [Member]",
        "documentation": "Arunthathy Nirmalini (Lini) Pandite, M.B.Ch.B.,"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r82",
      "r101",
      "r127",
      "r128",
      "r129",
      "r161",
      "r174",
      "r192",
      "r196",
      "r237",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r399",
      "r401",
      "r447",
      "r501",
      "r502",
      "r507",
      "r597",
      "r675",
      "r676",
      "r683",
      "r710",
      "r717",
      "r718",
      "r730",
      "r928",
      "r929",
      "r981"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r106",
      "r127",
      "r128",
      "r129",
      "r237",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r399",
      "r401",
      "r447",
      "r710",
      "r928",
      "r929",
      "r981"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sttk_AtTheMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "AtTheMarketOfferingMember",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At The Market Offering",
        "label": "At The Market Offering [Member]",
        "documentation": "At The Market Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020PlanoptionvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofrestrictedstockactivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsScheduleofInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position Location, Balance [Axis]",
        "label": "Statement of Financial Position Location, Balance [Axis]",
        "documentation": "Information by location in statement of financial position where disaggregated cumulative balance is reported."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r403",
      "r405",
      "r406",
      "r407",
      "r408",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r446",
      "r695",
      "r696",
      "r819",
      "r995"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsScheduleofInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position Location, Balance [Domain]",
        "label": "Statement of Financial Position Location, Balance [Domain]",
        "documentation": "Location in statement of financial position where disaggregated cumulative balance is reported."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r403",
      "r405",
      "r406",
      "r407",
      "r408",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r446",
      "r695",
      "r696",
      "r819",
      "r995"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Unaudited Interim Condensed Financial Statements",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "sttk_BeneficialOwnersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "BeneficialOwnersMember",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Beneficial Owners",
        "label": "Beneficial Owners [Member]",
        "documentation": "Beneficial Owners"
       }
      }
     },
     "auth_ref": []
    },
    "sttk_BlackScholesOptionPricingModelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "BlackScholesOptionPricingModelMember",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020PlanoptionvaluationassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Black-Scholes Option Pricing Model",
        "label": "Black-Scholes Option Pricing Model [Member]",
        "documentation": "Black-Scholes Option Pricing Model"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unpaid amounts related to purchase of property and equipment",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r20"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r99",
      "r654"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Axis]",
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsLineItems",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Line Items]",
        "label": "Cash and Cash Equivalents [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.shattucklabs.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents, and short-term investments",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r59",
      "r126"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase in cash and cash equivalents",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r59"
     ]
    },
    "us-gaap_CashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashEquivalentsMember",
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsScheduleofInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents:",
        "label": "Cash Equivalents [Member]",
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.shattucklabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r102",
      "r103",
      "r104",
      "r127",
      "r129",
      "r152",
      "r153",
      "r155",
      "r157",
      "r163",
      "r164",
      "r237",
      "r272",
      "r274",
      "r275",
      "r276",
      "r279",
      "r280",
      "r285",
      "r286",
      "r288",
      "r289",
      "r291",
      "r293",
      "r296",
      "r297",
      "r300",
      "r303",
      "r310",
      "r447",
      "r556",
      "r557",
      "r558",
      "r559",
      "r561",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r584",
      "r605",
      "r623",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r817",
      "r890",
      "r891",
      "r897"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r163",
      "r288",
      "r296",
      "r297",
      "r298",
      "r300",
      "r303",
      "r308",
      "r310",
      "r419",
      "r556",
      "r557",
      "r558",
      "r559",
      "r684",
      "r817",
      "r889",
      "r890"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Axis]",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Domain]",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price of warrants or rights (in dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r130",
      "r311"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of securities called by each warrant or right (in share per share)",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of securities called by warrants or rights (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, outstanding (in shares)",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "sttk_ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded warrants, ownership limitation post-exercise",
        "label": "Class of Warrant or Right, Pre-Funded Warrants, Ownership Limitation Post-Exercise",
        "documentation": "Class of Warrant or Right, Pre-Funded Warrants, Ownership Limitation Post-Exercise"
       }
      }
     },
     "auth_ref": []
    },
    "sttk_ClassOfWarrantOrRightPriceOfPreFundedWarrants": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "ClassOfWarrantOrRightPriceOfPreFundedWarrants",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price of pre-funded warrants (in dollars per share)",
        "label": "Class of Warrant or Right, Price of Pre-Funded Warrants",
        "documentation": "Class of Warrant or Right, Price of Pre-Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "sttk_ClassOfWarrantOrRightWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "ClassOfWarrantOrRightWarrantsExercised",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock warrants exercised (in shares)",
        "label": "Class Of Warrant Or Right, Warrants Exercised",
        "documentation": "Class Of Warrant Or Right, Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/RelatedPartyLicenseRevenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party License Revenue",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r396",
      "r397"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.shattucklabs.com/role/RelatedPartyLicenseRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 5)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r75",
      "r508",
      "r583"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r266",
      "r267",
      "r646",
      "r923",
      "r925"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r647"
     ]
    },
    "sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "CommonStockAdditionalCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, additional capital shares reserved for future issuance (in shares)",
        "label": "Common Stock, Additional Capital Shares Reserved for Future Issuance",
        "documentation": "Common Stock, Additional Capital Shares Reserved for Future Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares reserved for future issuance (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r720",
      "r721",
      "r722",
      "r724",
      "r725",
      "r726",
      "r727",
      "r893",
      "r894",
      "r896",
      "r971",
      "r1025",
      "r1029"
     ]
    },
    "sttk_CommonStockNumberOfVotesPerCommonShare": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "CommonStockNumberOfVotesPerCommonShare",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, number of votes per common share",
        "label": "Common Stock, Number Of Votes Per Common Share",
        "documentation": "Common Stock, Number Of Votes Per Common Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETSParenthetical",
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETSParenthetical",
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r584"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r48",
      "r584",
      "r603",
      "r1029",
      "r1030"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.0001 par value: 300,000,000 shares authorized; 75,581,787 shares issued and outstanding at March\u00a031, 2026 and 63,279,843 shares issued and outstanding at December\u00a031, 2025",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r286",
      "r292",
      "r509",
      "r710"
     ]
    },
    "sttk_CommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "CommonStockWarrantsMember",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock warrants",
        "label": "Common Stock Warrants [Member]",
        "documentation": "Common Stock Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r111",
      "r113",
      "r118",
      "r499",
      "r518",
      "r519"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Comprehensive Income (Loss)",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r445"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails",
      "http://www.shattucklabs.com/role/RelatedPartyLicenseRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r127",
      "r132",
      "r133",
      "r281",
      "r298",
      "r464",
      "r481",
      "r506",
      "r655",
      "r656",
      "r657",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r966",
      "r967",
      "r968",
      "r969"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.shattucklabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAbstract",
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsScheduleofInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities [Abstract]",
        "label": "Debt Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/InvestmentsScheduleofInvestmentsDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsScheduleofInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gain",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss), before Tax",
        "documentation": "Amount, before tax, of unrealized gain (loss) in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r909",
      "r910"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/InvestmentsScheduleofInvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsScheduleofInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss",
        "documentation": "Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/InvestmentsScheduleofInvestmentsDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsScheduleofInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Fair Value",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest",
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal",
     "crdr": "debit",
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment impairment",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest, Allowance for Credit Loss, Not to Sell before Recovery, Credit Loss, Previously Recorded, Expense (Reversal)",
        "documentation": "Amount, excluding accrued interest, of credit loss expense (reversal of expense) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) with previously recorded allowance and not intended to be sold and not more likely than not will be required to sell before recovery of amortized cost basis."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r248"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest, Current",
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "sttk_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrentMember",
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsScheduleofInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments:",
        "label": "Debt Securities, Available-For-Sale Excluding Accrued Interest, Current [Member]",
        "documentation": "Debt Securities, Available-For-Sale Excluding Accrued Interest, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in related party",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest, Noncurrent",
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsScheduleofInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Investments",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
      "http://www.shattucklabs.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r28",
      "r121",
      "r658",
      "r659",
      "r661",
      "r663"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation and Employee Benefit Plans",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r330",
      "r361",
      "r362",
      "r364",
      "r688"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.shattucklabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.shattucklabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.shattucklabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.shattucklabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.shattucklabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.shattucklabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share \u2013 basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r119",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r150",
      "r152",
      "r155",
      "r156",
      "r157",
      "r160",
      "r284",
      "r365",
      "r390",
      "r395",
      "r433",
      "r434",
      "r500",
      "r520",
      "r665"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share \u2013 diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r119",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r152",
      "r155",
      "r156",
      "r157",
      "r160",
      "r284",
      "r365",
      "r390",
      "r395",
      "r433",
      "r434",
      "r500",
      "r520",
      "r665"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r159"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation and related benefits",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average amortization period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r960"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020ESPPvaluationassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020PlanoptionvaluationassumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.shattucklabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.shattucklabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.shattucklabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.shattucklabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.shattucklabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.shattucklabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.shattucklabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.shattucklabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.shattucklabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.shattucklabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.shattucklabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.shattucklabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.shattucklabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.shattucklabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.shattucklabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.shattucklabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.shattucklabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r92",
      "r93",
      "r94",
      "r115",
      "r116",
      "r117",
      "r134",
      "r135",
      "r136",
      "r138",
      "r145",
      "r147",
      "r149",
      "r162",
      "r238",
      "r239",
      "r259",
      "r283",
      "r312",
      "r365",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r391",
      "r394",
      "r395",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r432",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r463",
      "r516",
      "r544",
      "r545",
      "r546",
      "r561",
      "r623"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r739",
      "r749",
      "r759",
      "r791"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r736",
      "r746",
      "r756",
      "r788"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsScheduleofInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r282",
      "r308",
      "r419",
      "r430",
      "r441",
      "r446",
      "r449",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r505",
      "r517",
      "r681",
      "r698",
      "r699",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r711",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r917",
      "r918",
      "r919",
      "r920",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r743",
      "r753",
      "r763",
      "r795"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r743",
      "r753",
      "r763",
      "r795"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r743",
      "r753",
      "r763",
      "r795"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r743",
      "r753",
      "r763",
      "r795"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r743",
      "r753",
      "r763",
      "r795"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "sttk_GeneralAndAdministrativeEquityCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "GeneralAndAdministrativeEquityCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.shattucklabs.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative equity compensation",
        "label": "General And Administrative Equity Compensation",
        "documentation": "General And Administrative Equity Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.shattucklabs.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r607"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofstockbasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "sttk_GeneralAndAdministrativeNonEquityCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "GeneralAndAdministrativeNonEquityCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.shattucklabs.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative non-equity compensation",
        "label": "General And Administrative Non-Equity Compensation",
        "documentation": "General And Administrative Non-Equity Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofstockbasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r262",
      "r263",
      "r404",
      "r409",
      "r410",
      "r418",
      "r438",
      "r439",
      "r440",
      "r448",
      "r449",
      "r450",
      "r541",
      "r543",
      "r608",
      "r650",
      "r652",
      "r690",
      "r691",
      "r696",
      "r697",
      "r700",
      "r708",
      "r964",
      "r965",
      "r996"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofstockbasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r263",
      "r404",
      "r409",
      "r410",
      "r418",
      "r438",
      "r439",
      "r440",
      "r448",
      "r449",
      "r450",
      "r541",
      "r543",
      "r608",
      "r650",
      "r652",
      "r690",
      "r691",
      "r696",
      "r697",
      "r700",
      "r708",
      "r964",
      "r965",
      "r996"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r555"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r820",
      "r885"
     ]
    },
    "sttk_IncreaseDecreaseInOperatingLeasesRightOfUseAssetsLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "IncreaseDecreaseInOperatingLeasesRightOfUseAssetsLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
      "http://www.shattucklabs.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in lease balances resulting from lease modification",
        "label": "Increase (Decrease) In Operating Leases, Right of Use Assets (Liability)",
        "documentation": "Increase (Decrease) In Operating Leases, Right of Use Assets (Liability)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r743",
      "r753",
      "r763",
      "r787",
      "r795",
      "r799",
      "r807"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r735",
      "r811"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r735",
      "r811"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r735",
      "r811"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r177",
      "r196",
      "r675",
      "r842"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r521",
      "r551",
      "r552",
      "r553",
      "r554",
      "r629",
      "r630"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/Investments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r91",
      "r204",
      "r206",
      "r442",
      "r443",
      "r990"
     ]
    },
    "sttk_KayakAgreementContingentMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "KayakAgreementContingentMilestonesMember",
     "presentation": [
      "http://www.shattucklabs.com/role/RelatedPartyLicenseRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kayak Agreement, Contingent Milestones",
        "label": "Kayak Agreement, Contingent Milestones [Member]",
        "documentation": "Kayak Agreement, Contingent Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "sttk_KayakAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "KayakAgreementMember",
     "presentation": [
      "http://www.shattucklabs.com/role/RelatedPartyLicenseRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kayak Agreement",
        "label": "Kayak Agreement [Member]",
        "documentation": "Kayak Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "sttk_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab equipment",
        "label": "Laboratory Equipment [Member]",
        "documentation": "Laboratory Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r462"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r127",
      "r128",
      "r129",
      "r237",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r400",
      "r401",
      "r402",
      "r447",
      "r582",
      "r669",
      "r683",
      "r730",
      "r928",
      "r981",
      "r982"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r76",
      "r512",
      "r710",
      "r717",
      "r718",
      "r889",
      "r892",
      "r921",
      "r980"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r98",
      "r127",
      "r128",
      "r129",
      "r237",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r400",
      "r401",
      "r402",
      "r447",
      "r710",
      "r928",
      "r981",
      "r982"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.shattucklabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r169",
      "r268",
      "r269",
      "r270",
      "r271",
      "r325",
      "r356",
      "r357",
      "r358",
      "r376",
      "r437",
      "r497",
      "r540",
      "r542",
      "r550",
      "r574",
      "r575",
      "r628",
      "r631",
      "r632",
      "r633",
      "r634",
      "r641",
      "r642",
      "r643",
      "r644",
      "r648",
      "r649",
      "r680",
      "r684",
      "r687",
      "r690",
      "r692",
      "r693",
      "r701",
      "r702",
      "r706",
      "r707",
      "r713",
      "r930",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r169",
      "r268",
      "r269",
      "r270",
      "r271",
      "r325",
      "r356",
      "r357",
      "r358",
      "r376",
      "r437",
      "r497",
      "r540",
      "r542",
      "r550",
      "r574",
      "r575",
      "r628",
      "r631",
      "r632",
      "r633",
      "r634",
      "r641",
      "r642",
      "r643",
      "r644",
      "r648",
      "r649",
      "r680",
      "r684",
      "r687",
      "r690",
      "r692",
      "r693",
      "r701",
      "r702",
      "r706",
      "r713",
      "r930",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.shattucklabs.com/role/InvestmentsScheduleofInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money Market Funds",
        "netLabel": "Money market fund",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r932",
      "r933"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.shattucklabs.com/role/OrganizationandDescriptionofBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization and Description of Business",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r166",
      "r666",
      "r667"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r61"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operations:",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.shattucklabs.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net Loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r61",
      "r77",
      "r94",
      "r96",
      "r110",
      "r112",
      "r117",
      "r127",
      "r128",
      "r129",
      "r131",
      "r137",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r148",
      "r149",
      "r154",
      "r237",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r284",
      "r287",
      "r290",
      "r294",
      "r365",
      "r390",
      "r395",
      "r434",
      "r447",
      "r515",
      "r604",
      "r621",
      "r622",
      "r660",
      "r662",
      "r664",
      "r728",
      "r928"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Adopted Accounting Pronouncements/Recently Issued Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r743",
      "r753",
      "r763",
      "r787",
      "r795"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.shattucklabs.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r900"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.shattucklabs.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r671",
      "r679",
      "r900"
     ]
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office equipment",
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "sttk_OperatingAccountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "OperatingAccountMember",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Account",
        "label": "Operating Account [Member]",
        "documentation": "Operating Account"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.shattucklabs.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Expense from operations",
        "terseLabel": "Expense from operations",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.shattucklabs.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "terseLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r660",
      "r664",
      "r670",
      "r899",
      "r901",
      "r902",
      "r903",
      "r904"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash operating lease expense",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r828",
      "r887"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized loss on investments",
        "verboseLabel": "Unrealized gain (loss) on investments",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r516"
     ]
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.shattucklabs.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other general and administrative including legal and accounting fees, facilities, insurance, travel and depreciation",
        "label": "Other General and Administrative Expense",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r1028"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.shattucklabs.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other expense",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r694"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.shattucklabs.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other research and development expense",
        "label": "Other Research and Development Expense",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "sttk_OtherResearchAndDevelopmentExpenseTechnicalOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "OtherResearchAndDevelopmentExpenseTechnicalOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.shattucklabs.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other research and development expense (income), technical operations",
        "label": "Other Research And Development Expense, Technical Operations",
        "documentation": "Other Research And Development Expense, Technical Operations"
       }
      }
     },
     "auth_ref": []
    },
    "sttk_OtherResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "OtherResearchAndDevelopmentMember",
     "presentation": [
      "http://www.shattucklabs.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Research And Development",
        "label": "Other Research And Development [Member]",
        "documentation": "Other Research And Development"
       }
      }
     },
     "auth_ref": []
    },
    "sttk_OtherResearchAndDevelopmentSL172154Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "OtherResearchAndDevelopmentSL172154Member",
     "presentation": [
      "http://www.shattucklabs.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Research And Development, SL-172154",
        "label": "Other Research And Development, SL-172154 [Member]",
        "documentation": "Other Research And Development, SL-172154"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r741",
      "r751",
      "r761",
      "r793"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r744",
      "r754",
      "r764",
      "r796"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r744",
      "r754",
      "r764",
      "r796"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of investments",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r122",
      "r205"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020PlanoptionvaluationassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020PlanoptionvaluationassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "sttk_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded Warrants",
        "label": "Pre-Funded Warrants [Member]",
        "documentation": "Pre-Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r296"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r584"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r584",
      "r603",
      "r1029",
      "r1030"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "sttk_PrepaidExpenseAndOtherAssetsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "PrepaidExpenseAndOtherAssetsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid Expenses and Other Current Assets",
        "label": "Prepaid Expense and Other Assets Policy [Policy Text Block]",
        "documentation": "Prepaid Expense and Other Assets Policy"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of common stock, net of offering costs",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the exercises of stock options and purchases pursuant to employee stock purchase plan",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r10"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of warrants",
        "label": "Proceeds from Issuance of Warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturities of investments",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r123",
      "r905"
     ]
    },
    "us-gaap_ProceedsFromStockPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockPlans",
     "crdr": "debit",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from ESPP",
        "label": "Proceeds from Stock Plans",
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of common stock warrants",
        "label": "Proceeds from Warrant Exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.shattucklabs.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r199",
      "r498",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r653",
      "r659",
      "r662",
      "r664",
      "r685",
      "r686",
      "r712",
      "r713",
      "r714",
      "r716",
      "r719",
      "r818",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r926",
      "r927",
      "r994",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.shattucklabs.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r199",
      "r498",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r653",
      "r659",
      "r662",
      "r664",
      "r685",
      "r686",
      "r712",
      "r713",
      "r714",
      "r716",
      "r719",
      "r818",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r926",
      "r927",
      "r994",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r462"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r462",
      "r504",
      "r514",
      "r710"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r86",
      "r87",
      "r513"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of property and equipment depreciation periods",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r462"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment depreciation and amortization periods",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r169",
      "r268",
      "r269",
      "r270",
      "r271",
      "r324",
      "r325",
      "r356",
      "r357",
      "r358",
      "r364",
      "r376",
      "r437",
      "r471",
      "r480",
      "r497",
      "r540",
      "r542",
      "r550",
      "r574",
      "r575",
      "r628",
      "r631",
      "r632",
      "r633",
      "r634",
      "r641",
      "r642",
      "r643",
      "r644",
      "r648",
      "r649",
      "r680",
      "r684",
      "r687",
      "r690",
      "r692",
      "r693",
      "r701",
      "r702",
      "r706",
      "r707",
      "r713",
      "r722",
      "r924",
      "r930",
      "r974",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r169",
      "r268",
      "r269",
      "r270",
      "r271",
      "r324",
      "r325",
      "r356",
      "r357",
      "r358",
      "r364",
      "r376",
      "r437",
      "r471",
      "r480",
      "r497",
      "r540",
      "r542",
      "r550",
      "r574",
      "r575",
      "r628",
      "r631",
      "r632",
      "r633",
      "r634",
      "r641",
      "r642",
      "r643",
      "r644",
      "r648",
      "r649",
      "r680",
      "r684",
      "r687",
      "r690",
      "r692",
      "r693",
      "r701",
      "r702",
      "r706",
      "r707",
      "r713",
      "r722",
      "r924",
      "r930",
      "r974",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988"
     ]
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable",
     "presentation": [
      "http://www.shattucklabs.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r736",
      "r746",
      "r756",
      "r788"
     ]
    },
    "sttk_ReportableSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "ReportableSegmentMember",
     "presentation": [
      "http://www.shattucklabs.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable Segment",
        "label": "Reportable Segment [Member]",
        "documentation": "Reportable Segment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails",
      "http://www.shattucklabs.com/role/RelatedPartyLicenseRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r127",
      "r132",
      "r133",
      "r281",
      "r298",
      "r464",
      "r481",
      "r506",
      "r655",
      "r656",
      "r657",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r966",
      "r967",
      "r968",
      "r969"
     ]
    },
    "sttk_ResearchAndDevelopmentEquityCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "ResearchAndDevelopmentEquityCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.shattucklabs.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development equity compensation",
        "label": "Research and Development Equity Compensation",
        "documentation": "Research and Development Equity Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.shattucklabs.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r650",
      "r660",
      "r661",
      "r675",
      "r989"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofstockbasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Costs",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "sttk_ResearchAndDevelopmentNonEquityCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "ResearchAndDevelopmentNonEquityCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.shattucklabs.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development non-equity compensation",
        "label": "Research and Development Non-Equity Compensation",
        "documentation": "Research and Development Non-Equity Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r737",
      "r747",
      "r757",
      "r789"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r738",
      "r748",
      "r758",
      "r790"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r745",
      "r755",
      "r765",
      "r797"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Domain]",
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested restricted stock units",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r898",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofrestrictedstockactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS",
      "http://www.shattucklabs.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r68",
      "r511",
      "r547",
      "r549",
      "r560",
      "r585",
      "r710"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93",
      "r94",
      "r134",
      "r135",
      "r136",
      "r138",
      "r145",
      "r147",
      "r149",
      "r238",
      "r239",
      "r259",
      "r283",
      "r365",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r391",
      "r394",
      "r395",
      "r420",
      "r422",
      "r423",
      "r425",
      "r432",
      "r457",
      "r458",
      "r544",
      "r546",
      "r561",
      "r1029"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.shattucklabs.com/role/RelatedPartyLicenseRevenueDetails",
      "http://www.shattucklabs.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "verboseLabel": "License and collaboration revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r161",
      "r175",
      "r176",
      "r190",
      "r196",
      "r199",
      "r201",
      "r202",
      "r321",
      "r322",
      "r323",
      "r498",
      "r660",
      "r664"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r651"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer, Product and Service [Extensible List]",
        "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]",
        "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer."
       }
      }
     },
     "auth_ref": [
      "r685",
      "r686"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "sttk_SL325Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "SL325Member",
     "presentation": [
      "http://www.shattucklabs.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SL-325",
        "label": "SL-325 [Member]",
        "documentation": "SL-325"
       }
      }
     },
     "auth_ref": []
    },
    "sttk_SaleOfStockCommissionPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "SaleOfStockCommissionPercentage",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock commission",
        "label": "Sale of Stock, Commission Percentage",
        "documentation": "Sale of Stock, Commission Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, proceeds received",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "sttk_SaleOfStockMaximumAggregateSalesPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "SaleOfStockMaximumAggregateSalesPrice",
     "crdr": "credit",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock maximum aggregate sales price",
        "label": "Sale Of Stock Maximum Aggregate Sales Price",
        "documentation": "Sale Of Stock Maximum Aggregate Sales Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock sold (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of preferred stock (in dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of accrued expenses",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of antidilutive securities excluded from computation of net loss per share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsScheduleofInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]",
        "label": "Cash and Cash Equivalent [Table]",
        "documentation": "Disclosure of information about cash and cash equivalent by type. Excludes restricted cash and cash equivalent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.shattucklabs.com/role/RelatedPartyLicenseRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of RSU activity",
        "label": "Share-Based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block]",
        "documentation": "Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r462"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020PlanoptionvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofrestrictedstockactivityDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofstockbasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r329",
      "r331",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r364"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of option activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r9",
      "r69"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of valuation assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock, Class of Stock [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r66",
      "r67",
      "r68",
      "r102",
      "r103",
      "r104",
      "r163",
      "r296",
      "r297",
      "r298",
      "r300",
      "r303",
      "r308",
      "r310",
      "r419",
      "r556",
      "r557",
      "r558",
      "r559",
      "r684",
      "r817",
      "r889",
      "r890"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.shattucklabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.shattucklabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.shattucklabs.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r81",
      "r82",
      "r161",
      "r171",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r196",
      "r197",
      "r198",
      "r202",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r264",
      "r265",
      "r392",
      "r393",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r672",
      "r675",
      "r676",
      "r682",
      "r715",
      "r994",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/SegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r161",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r186",
      "r188",
      "r189",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r202",
      "r671",
      "r673",
      "r674",
      "r675",
      "r677",
      "r678",
      "r679"
     ]
    },
    "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems",
     "presentation": [
      "http://www.shattucklabs.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual increase in number of shares authorized, term",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase In Number of Shares Authorized, Term",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase In Number of Shares Authorized, Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation, vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofrestrictedstockactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofrestrictedstockactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofrestrictedstockactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofrestrictedstockactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofrestrictedstockactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Awards, beginning balance (in shares)",
        "periodEndLabel": "Awards, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofrestrictedstockactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofrestrictedstockactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofrestrictedstockactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofrestrictedstockactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock upon settlement of restricted stock units (in shares)",
        "negatedTerseLabel": "Released (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofrestrictedstockactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Released (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020PlanoptionvaluationassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividends",
        "verboseLabel": "Expected dividends",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020PlanoptionvaluationassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020PlanoptionvaluationassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in number of shares authorized, percentage of capital stock outstanding",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized, Annual Increase Percentage",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized, Annual Increase Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020PlanoptionvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofrestrictedstockactivityDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofstockbasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r329",
      "r331",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r364"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contribution limit in percentage of employee's eligible compensation",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum number of shares per employee during any one purchase period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee",
        "documentation": "The highest quantity of shares an employee can purchase under the plan per period."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue",
     "crdr": "credit",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum value of shares per employee during any calendar year",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Shares Per Employee, Value",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Shares Per Employee, Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining\u00a0Life (Years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, exercisable (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intrinsic value of options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Options, granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant date fair value (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options, beginning balance (in shares)",
        "periodEndLabel": "Options, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r336"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, beginning balance (in dollars per share)",
        "periodEndLabel": "Weighted average exercise price, ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r336"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise\u00a0Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, vested and expected to vest (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, vested and expected to vest (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020PlanoptionvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofrestrictedstockactivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r334",
      "r353",
      "r354",
      "r355",
      "r356",
      "r359",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation, expiration period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020PlanoptionvaluationassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term - years",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contract life, exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted\u00a0average remaining contract life, outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted\u00a0average remaining contract life, vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price of common stock in percent",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Taxes paid related to net share settlement of restricted stock units (in shares)",
        "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.shattucklabs.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r81",
      "r82",
      "r95",
      "r161",
      "r171",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r196",
      "r197",
      "r198",
      "r202",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r261",
      "r264",
      "r265",
      "r392",
      "r393",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r672",
      "r675",
      "r676",
      "r682",
      "r715",
      "r994",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r102",
      "r103",
      "r104",
      "r127",
      "r129",
      "r152",
      "r153",
      "r155",
      "r157",
      "r163",
      "r164",
      "r237",
      "r272",
      "r274",
      "r275",
      "r276",
      "r279",
      "r280",
      "r285",
      "r286",
      "r288",
      "r289",
      "r291",
      "r293",
      "r296",
      "r297",
      "r300",
      "r303",
      "r310",
      "r447",
      "r556",
      "r557",
      "r558",
      "r559",
      "r561",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r584",
      "r605",
      "r623",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r817",
      "r890",
      "r891",
      "r897"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r48",
      "r51",
      "r52",
      "r92",
      "r93",
      "r94",
      "r115",
      "r116",
      "r117",
      "r134",
      "r135",
      "r136",
      "r138",
      "r145",
      "r147",
      "r149",
      "r162",
      "r238",
      "r239",
      "r259",
      "r283",
      "r312",
      "r365",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r391",
      "r394",
      "r395",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r432",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r463",
      "r516",
      "r544",
      "r545",
      "r546",
      "r561",
      "r623"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r162",
      "r285",
      "r286",
      "r288",
      "r291",
      "r458",
      "r498",
      "r551",
      "r562",
      "r573",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r584",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r593",
      "r594",
      "r595",
      "r596",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r606",
      "r607",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r623",
      "r662",
      "r664",
      "r723",
      "r1027"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r162",
      "r203",
      "r285",
      "r286",
      "r288",
      "r291",
      "r458",
      "r498",
      "r551",
      "r562",
      "r573",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r584",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r593",
      "r594",
      "r595",
      "r596",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r606",
      "r607",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r623",
      "r662",
      "r664",
      "r723",
      "r1027"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r740",
      "r750",
      "r760",
      "r792"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issued under ESPP (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r47",
      "r48",
      "r68"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of common stock, net of offering costs (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r47",
      "r48",
      "r68",
      "r556",
      "r623",
      "r636"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options and purchases pursuant to employee stock purchase plan (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r47",
      "r48",
      "r68"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleofoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options, granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r47",
      "r48",
      "r68",
      "r340"
     ]
    },
    "sttk_StockIssuedDuringPeriodSharesWarrantExercises": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "StockIssuedDuringPeriodSharesWarrantExercises",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of common stock warrants into common stock and pre-funded warrants (in shares)",
        "label": "Stock Issued During Period, Shares, Warrant Exercises",
        "documentation": "Stock Issued During Period, Shares, Warrant Exercises"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of common stock, net of offering costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r47",
      "r48",
      "r68",
      "r561",
      "r623",
      "r636",
      "r729"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options and purchases pursuant to employee stock purchase plan",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r47",
      "r48",
      "r68"
     ]
    },
    "sttk_StockIssuedDuringPeriodValueWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "StockIssuedDuringPeriodValueWarrantExercises",
     "crdr": "credit",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of common stock warrants into common stock and pre-funded warrants",
        "label": "Stock Issued During Period, Value, Warrant Exercises",
        "documentation": "Stock Issued During Period, Value, Warrant Exercises"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS",
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r51",
      "r52",
      "r62",
      "r586",
      "r603",
      "r624",
      "r625",
      "r710",
      "r730",
      "r889",
      "r891",
      "r892",
      "r921",
      "r980",
      "r1029"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/Equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r295",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r312",
      "r419",
      "r431",
      "r626",
      "r627",
      "r640"
     ]
    },
    "sttk_SubleaseAgreementConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "SubleaseAgreementConsideration",
     "crdr": "credit",
     "presentation": [
      "http://www.shattucklabs.com/role/RelatedPartyLicenseRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublease consideration",
        "label": "Sublease Agreement, Consideration",
        "documentation": "Sublease Agreement, Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.shattucklabs.com/role/RelatedPartyLicenseRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublease income",
        "label": "Sublease Income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r709"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosures of non-cash financial activities:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.shattucklabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsScheduleofInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r282",
      "r308",
      "r419",
      "r430",
      "r441",
      "r446",
      "r449",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r505",
      "r517",
      "r698",
      "r699",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r711",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r917",
      "r918",
      "r919",
      "r920",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.shattucklabs.com/role/RelatedPartyLicenseRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsScheduleofInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. government securities",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae)."
       }
      }
     },
     "auth_ref": [
      "r932",
      "r933",
      "r991"
     ]
    },
    "sttk_UnderwrittenPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "UnderwrittenPublicOfferingMember",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwritten Public Offering",
        "label": "Underwritten Public Offering [Member]",
        "documentation": "Underwritten Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrealizedGainLossOnInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain on investments",
        "label": "Unrealized Gain (Loss) on Investments",
        "documentation": "Amount of unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r85",
      "r165",
      "r167",
      "r168",
      "r169",
      "r501",
      "r503",
      "r668"
     ]
    },
    "us-gaap_ValuationTechniqueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationTechniqueAxis",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020PlanoptionvaluationassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Approach and Technique [Axis]",
        "label": "Valuation Approach and Technique [Axis]",
        "documentation": "Information by valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r436",
      "r690",
      "r693",
      "r701",
      "r975"
     ]
    },
    "us-gaap_ValuationTechniqueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationTechniqueDomain",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationandEmployeeBenefitPlansScheduleof2020PlanoptionvaluationassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Approach and Technique [Domain]",
        "label": "Valuation Approach and Technique [Domain]",
        "documentation": "Valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r436",
      "r690",
      "r693",
      "r701",
      "r975"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock warrants",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r720",
      "r721",
      "r724",
      "r725",
      "r726",
      "r727"
     ]
    },
    "sttk_WarrantsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.shattucklabs.com/20260331",
     "localname": "WarrantsPolicyTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock Warrants and Pre-Funded Warrants",
        "label": "Warrants [Policy Text Block]",
        "documentation": "Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares outstanding \u2013 diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r157"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares outstanding \u2013 basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r157"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/942-320/tableOfContent"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-2"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEE",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEE",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEE",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-4"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "181",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-181"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "SubTopic": "310",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/940-320/tableOfContent"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>68
<FILENAME>0001628280-26-031661-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-26-031661-xbrl.zip
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M=&#?\,Z!RN[E-C20F<I>^XW_9*9/EMP]U\:6\:>?J'@SF?;S3AO;)G?%:V^
M1C"#:>O\I0$K:R_AG<?6>[D-A!34N$]JW)-LS&V49QUJ? =T^+ZB^+W<QK *
M<GR'28M>;N-S863NJ^\:%G?=._&(^)2;6SZU'0_;CLD?CU-DY#8@ET<<[8F/
M<A>;P[,_-XZM^YIW[=QQY]'0XK+N[K*AMC([,Y!#.M@/K]9KN0L:OG="V(]
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M2%L0PT]C [Z)9/6BU?(B]Z6JKAC8CH$.FVE 7=_3D&IQ5E>'Q-*AI]$6N6%
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M0C[B*OC"##XC4YJVZV.MYV!H^T$#$>76<'\>*:=UCY73F@6G[8_3FN3:>PY
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M'E@B1)8H;()O/20V^11)GAP/!M,74J BJ8D7LHF[8GY @>7-L4PR9&B86',
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MRLUZ[\NGY$K[0?.ZUV,E8+:UL9.-%BK8XKC8HKD'ME!+_5:S7.^IN6:+'9E
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MS181F6I3<!1Q8$#!XN4B38K'1^EC_)SFLC?80YQD0>(TZ",D;IZR65"#D61
M\;O(JB_6\R2?3I>*&L>PB!-6+,J@Y9,P*(JL&75M,["]#Y8YQY.FHD5AT/HG
M%F8.SD0!6!,G:.=!4 X:^: -)&+F$>3H+)6E14T9Q/[B*T )L@!6P'SB('4
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MD6ZD2M9YBL&7<#Y'@38%75CYOM.ADQIS5K9 D0S3I?%T(BKI0,.YO357CO3
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M OT"2WGA>H0L$:<GJPWRH^"9</%>Z,;6K7,GJ$1X*D3 I8(@#[-*6U?@@KW
M,=]X??6WY<2Q2*ALN)2YP\_"F4=1ZWLON2UL,<ZM6I4HJU=;7F+A^<$JIW#T
MZD[AK_=AZJ,_(Z*9AP=YJ[83YTN.86NH<=#WP982AP\/ENXEL:X!BF5U$.\.
M]YM0&7:83TC"HT^')3X'UB<QC71CBYT[:*I/HXLE6K5 # <NU47!?QOT@B>B
M3HNO5O4F7*8QG(QM@3BFZF_B,A#+=,)\!]E#^8F"GPDR]GR&G1S4]F%P KZ[
M6*PVH:M1;"0713ZMNCQDLP)/NBE0PYW@A6(#"/[2Y#@X''")0=OC,I@L+[]]
ML,;]KOV(/0RU\KCZ!ED*/U-+19Y<(K& Q5"_% F=GUY<D:=?R3X _,HB=+VY
MQ]1@N=BK@/<H6QOBU$]L^%]NR$'Z4Q>,)) 3*O2S[ 7P=&>YC,*?8"\F D3"
M+WOW:)T/<E;L9[D"($#ZW\]!/B\:7^/I7,W_CL4E23N=*-5FZS"S2'IG%^U6
M79 ?;LJG8TDC/,1UG3ZZ;/6TFEE 79(N(3VB.S[PRB(/65>VDDBUDC4%%@4N
M$@SUN!#EA5+,%[[CLFF8J:GL>9>LA:_%,HP2"X[\$^@"J],^_T\MQ[*FJ9I.
MP:U/_BB-NB^@A&^("T^'@#Y%(>@">!A=.?QO7ABQL05D@:U =Z%_QS=_YT38
MZ =4<4,13VDF11ZUD$K2 ($#Y@NHQ%F81F@"S:TI]IB*&)3[95T74_[]]T"4
M:*0X]]BHBA()%:H4B398'-1]:EM$8"!+0/61^C&7158CVS#$*$[&'-B1-2-B
MI?8,6"[X)VBDR9E)MA2@M%C)#/!(>M\,\2WG?G@?%^S!K1JCY V_JME.O1.>
M[72:;N8'PVZ[FOI2.IV2MVGN(#1V$(DEL";:N_,4F\N9'6>%J(/I&Z4!.CG.
M#2A__H+TD+R(.S\SY_0G>X$S%;+(=W6A,KN_]6:W.4$%1C;**<.!6F)?]$RO
M3QK,.8])]Y+.:G>)T@>;0N%BX%RM.8IK\QNX&B6-/WS\\TI&6ZZO8#.\2N74
M+L,$>U%1NE7YT]+U=N4YH1.2G16OVG#AT%O&_W2D,B#O@KH[Z/U  R).PD#(
M=SADI$1D5\ASL:4_NJ(/I^1P +O%*1TLG#L9)$O8)BU5!%'H^V3 NM8,Z 1#
M?U9"4AQDH)!+! V&&@@$LMXDV<)\M*KI;NEX:I]X9NK(3.*0IP*&]5Q0SLX5
M4MDH;9&]"HQKX2T3_->;$'U[N!-LZ 4OC?Y=F6#H_N$;W/-TB0\!]X@^5\O"
MNXQ1U1H7W+*^X8D8*V,("'3IV*>C9]U'7I*0_9>@;SA=Y8@3]D=J-:+&?9L>
M@=3JAR"PR!LT"/R0?;V38PR5#G</E?HRE@5*^3**\#;Q+M;&2?L5H<I^.4XJ
MJYVLK]1[_@4N+P!3"0$3 AR-M$^8M%\9)NUOT%_/+^H_!]9E>I/&";D">3OP
M!@X=C^D_G97S@V!#X Q3H'40<^!-MJPW9_31V5OT<$F"QW!90-=\H&_P8?P5
MZU+Q$GP96!(E71C@_FY6Y_-PEJ(D^G[]^<\1B*H07KQH65_!@$T=CMC@DPH/
M4K(,>!$$=)#%U!PV(O/N/0@+-*,+^ %H-?-C22\YUAPG9$FH"D)H0?FRDPL^
M&%;[X(JN)96A"Z#4[#_AW1_@"D *11DZ"/C@\/^[)G29X7\/P+1KU4&?*O^;
M"VIGX4U X])(*^1."8]0W5;$"\M'%TGGQ)A RL6<@3-5P#D??B;]#Q_J6#->
M'I\P"EI03NR/DG.JHES&>@YUVA3Q^";7K4GF@_FNJE,=8E2C#D%*GBH%U_X*
M[SB*QUSCJ#!\5 Q3HR]%(>S,OY^&J)3A>RZH_AG#4<SE(95B2/QG\ 9A6T74
M#& 1I6\S B\PC;J[72%7"!YHMZL8K2=\=1L@.8#0JTY_A*=?EP@MTC0'UOBH
MW)271SF!FG9851E4#'%O"ZYU'.)ZC?X!3;-18IJ4Z4F+4H#9XZ%-0Z='9%0P
MGV/3*F<K"H/?LUL/SI<.%^@W7L+=SSV1.W5TY6\0-BN,5BP<T%G E 9POF&O
MPN_3)2Y@-XH;KZ<X!0UR3;M"N^TOD501'@Z]'E9(4TL2'2\=[#14'%&X<GS&
M-@+3#_1$#(^+59@DVQ^)7%!F2)RQF3FKN!D5O?'#>PNC.3X:P3=>HBS1XGV0
M.9IEKPQG("?< \Q(^3Y[&EH-.+&2]; #<&_N;P6_G8QS?X4&MK[PF<(K \;B
M2!2E*Q(D']C<E%[+[@:L'-Z ,?$@H3<@^A2;ZOPV6@N:P.%LED:M,NM5N,C;
MV;R#[C':O*-=;=YO:)/<ACY<0_P[:-!D]1?XCVLMWDF%U3DI6[S\M/U,VTFE
M:3M98]I.CD)6?B\(NS2Y#2,VA,  C>-42*%3*W-B<)]%O+;:KP+^#:LPPH#N
M\AL]X%*_>;OJ( W(UFNWSR[@'W:;_Z\"F>U5P:#Q?:!(F=$92R,>)=*![_"K
M\A,.<XT=L-;K;]'*]E7P3T#Q@,B4O@G8?%OZ)%]%1$M^V*[!.[Z*OB5H;]+,
MX.RIY0UVUU?;[;L@@Y5V60TE)^&DR[9D^>R78+/3^;/C(Z5OP8PW8H8FW8%:
MQ.A>XK-,J3V!.Y#BVVZ=/!=CWR"KP<^XFO\7/".&3<N/>.L&&9['8H:D> ^6
M<2R"JF/IGUV M54^ EQ>=@YHUB#5P8,3/ FP7!88YZ(M.OQEM/<,75477S7.
MRN.4DGE<2S1^EAC>L:BX4$:"Y3<-@PD.#HT)F1IRZ4?H*T9H*_U <P51)=$<
MN?-B%;_3OV:6 DM&&+%79[GT5US&M*IGOSS8:J(BD#)=MPNID.FCK&LPSRA8
MS05!=PA7Z,9(#3ZE@?-Q1/V\"K>1 BSXA6[[_6_X,?U[Y_U;7#A^E=$V*3.'
M[U-(I.3"4IW#G;3>JU[H>V TN#*:XH+"Q&27//A[CP[E/%WN>1;3/.LPY:F#
M\9@"9=%5)!:.%] 58&Y*6<&4'8RR6R</E^KCC+"J3'GBFE0-F$QA"-?&Q'UN
M9=EE() CY?:+MT+'O#:3^@2:Z"HCR^W177OM :*[5@D >4+'K4.'>^I0#F48
MG&P7P9JI%"X(%6582]\)XLQ(7"LB3JAL!7A>%Y\!J?;RX0#@[C565)7W/=EP
M_W3MG_$(W8]4"/25.)"T-^R&/MER](I!!B.LEQ\..G9G6 [46346HJQ-Q3@=
M.;DJ<[-,ISZX92'FFS1EP#9ESYA/_OS2%ZC],E!:H(^9CGOLR#3#]B:3QP>Q
M=S7_IX,IC^0JXJJL.H;?XL"P<]7N -N,NQ4'!N1\CEH"BU?YE5*;+U.0;51T
M2."XAGE0.%N,<.YEC0XW(8HC6O;5G*T_7,0ZDV^"*:9^N4$W8_:*#94W_X#=
M=-<:=%6W2INZFH.<_$2+D)_&%?OKM&E__<FD8H><<KZ7Z9"M+VX!_CS_Y+ ;
M7DO)O\N"9KEWM67Y:=RIVGNGUIPW=J<KI7G;2NF7;KAE_>[ :55<O<P^JP>Y
M9%#LRMY['8JR\3/0^ \.YMU_6^%:\]_=T>CO=&N,_DJ:L-'Z]A8+X7I<?2H/
M XU&L %#(:WXGTLO$MI<-[L")' +!7C#^P!LPEMO"289N! ZPU-[I@&=PT$X
MJ\!25VHI7_1*OM*L,+YK?7#GW>SDP(N<M"H8[A_D(6&Y6G*NJ6[JQ-ZIE<_7
M)G[)[N%([WJSH(8)-EF&AF#7I$]/8FOA<_ =+BWFE^VJ[SK@Y78&=A?VU!F,
MM[40["I%2-ZCDJ9[A0J'_><\";#W>R.[#U9S9[S#27#MCD3>YV1 3MT?[' V
MS=%XU,,9TOC086]@]_KE_NDZ0S*L,AKB_,P"TSQDNY(C>+JY)XC!\4UE:Q(B
M%^ L#ZKQQ8$!851M@<%2!&JN:F6^U:4]P+H9'LY6ZU">=SP<E=L':JTUM?D*
MM?W8.Q\=<.=CN?,RP>UMQ6VU??O!QMZF4SB8L3<YI+$7/[*UM]>I/**UUVT?
M@[77E.)7E^+W3[D4?UV^]Y&SZ]7'F?D41OW(KJ[%^%E<BVYG#]?"^GX?EOD-
MM]YI_X/G;#&+AVF45P)4:#_SEDZ2M9!M,E:H=@QKSKA@&@NM?%^VN>GGZ5DJ
M0O\:3)?P1N#7V*4H+UAIMMW=BHT!QT>T%[M _6-[,NS9HW$YRE1G%/J>2"LU
MMJ[7V]'0QDYFU_6D[7A2!]A;>X#5]O8)1=<_[M#KNG.2:%07-:Z74TH\*3FT
M<\*E"X[TT)YT)W:[5X:%K:1XRK1D%I4L9CU0HJR_R5T\=.2\B_[SV.[WQW "
M_>U.@'.59K;IA$B83.5*[XE&]@459O=>SL1H4^#_4,Y$=TA5\N,J!U]:LX;)
MBQE^0A;!QEQ.-1,FB,,%#Q@4(S2%/1R%_7;\F([":!='H3KLH14<-3F%<]6O
M5J7#*.?/CH1JY>JUP<QPP0O+!K1EQQT8W7[P%X=[\,@HX?)8)Y[)SC WC!E[
M89'ZB;<L?X:M\<I*K"I.^$J:M5-L<(-O?_N"4L"6W7SX0-3;RP0[&6:S%)XR
M6W&4U)F+9$4KS4(8KL""6.V<^DZ ;=+\MF[A;6_BMP:@ +8UID!JKDQ0^JM3
MBBQOH0D?J HZ=:K@,=7A^.QB8+<[$WO4*1ON=62?5X@H.6ZB,*;2Z9D0;KQS
MPTM^Z^6:]Z_RP=A?]%E*K$Q8EHO?>]T)XIA5J#?5<.%1:Q=U4^XC^O93V_6B
MKRCW=[W'7AL+",;#H=T>;&G(<_WEP=3??B>RA_KKK4F<[E$SVUE;LEA3[<'^
M@URMVL/NEX;#P@8]>SBL(-0:U^& -5JCO;*Z#S ]>^ L]4=V?SRR!Z.*JHUJ
M:7/2QN?G_)CZ=6A>LN-&MV?GZB"_T6>ZLT971!(3?Q$8I/A!C;\8C+"M+U\^
M5/[<^*F=:ZJ3_?T<0*:H!UL  @R</7J81KUJ><X\E?GC?SH_O46ZN+R!C=V
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M*NT::GR9U/C\*[Q60UN9^+YX\]/BG3?_!SN#WE;PRY,6:-!KG]@4_<WQ"0S
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M7/.KBJ VU2>;(U>#8\S'=X:8CY]4S+U]??GX)DY[0&H?'B6UCY#:1P_/9;\
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M_C$.9+\"7PV'GQZ5<ENKRO[) 5OP+N S\C*!%,#+F'HA!?Q@!3?<YX_CS9=
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MM':1@$CFFXK%OU)4O03A =>JC ND-/Q)_4V"J "A391#R@ W2\K#7^%706*
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MMB[__&,RY*ZPZZO1N#?J3 :V# XA*^<<YX!U":9B"N&!K&]#%]I0N0SLNEJ
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M9U&T@IW>.Y$;R\&1'\5,+*; ^G)LY "!^QT"[@<CPZ-\+:72LM&4V358.#2
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M&*W;4<V2BI]/&_B[9),BL7V"XT>^OT9]PU.,3\E8O3+LTC26U[WK< L2;T#
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M%DO289V1Z++/] 9CA^KBNUW:E/@Y=;WBGT<1-\U[\)U8U-6)OM;%_:>7 '>
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M<XSXF^P4A)I+\,9PA9CBJ<]7((!PV'?D*VA:%]^&]+>S#R!XA>P#K#0%0OX
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MX*# 166VWT;3O/8+$DSPW\)ZL8+DM5Z0(.>G-]R"3E[#!8GE.T6B7I*/Q7V
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MXN\($E%.H]NCJZ/.7/RCV;?G8U*&1:,]F6,"'\RY?^_ T?Q:8^".T=_5$O7
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MWG^'V6T32)_!#*(0]"(I( 3#W&M#/-A$BLBV?@U/9_Q7!--'TWLT)AR#J:_
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MGP!#2UJN(4V:H1+S_T['D]FX^.AG=5^?JSVQ<\B!H@X! 6'\:;"4A=S'>3K
M?=SD.Y0=&SC8O?SS'OOG:DVAZ@RZ68;^T4<EC@<3_\G77P?6SZ?PC]Y67^;&
MG;D\*SEHQX#VT8F&7'E.J9&L0$%Q69F>#)N/SX@&RG?>EEA77/N^&H_/ONK!
M,%7OI1&KAU$2&YWXR<"/[]7RP4_.0QS?*]MLS *-B09:,>N=L@%3GIG:N; _
M;@H?Q<(-5.V\^Q&!W"-?1N.QC$ \ S"0N&;8.'BR%^ _ /"X2;._KALLO_>V
M1>M-?:@]T(BDK[ *3E/$3/8]KLV%%"4J PS&P 2.@#.:F\"082SW*<-UE0'_
M_G*)V._CMUUZ-T1W;S"NPD548IQ59FMDU..GZ=65KK]7X=,@KHMA8'6,EJVM
MIJ-)2A=5PX&-L]&'E/B>Q*GK=3H),!P_)%N[O@Y9WY^IYT,YG63J!_%*CR_/
M1B[]+Y'C:UPCHBOT?ETU%PNI - :P+# RD!OI,]>Q+P94N=1:2^]FP[]>6A^
M4>-Q!A%2;2*<=0[")%!L(<X^_[0!=JB^$CEYL9*^R&Z!OO2>:):GZ1"U,JG@
M'=-TBLWAX!1V,G<Z>#V:HYT9RF_YY;,!>2Q0H$[PHQ]/ZH&=>->,L?FGS2?A
M&K$7.FS4!?>13B-EXL#*(<4#&[#G)!0D^N10!4"=$XX2; W-7=S</_)M._'4
M?^YMM%ON,U'G<770R:N]\6^;(7D=0 KK@,&!8<<T"<L5TFN*BIJ??_C8_7 &
MJO)JM\"QB%^KD?_^JZ[_])-TH&N-E 028'B$1HVQ#%ING<_M4C<C>0+LR&B*
M0YV:O3L6ZB!Q !LN(C F@/+4 NZ9P5 1QFQ#E\I'=K"^O).<1?]'.&^_#=KS
M>?N=#+CCN>I=M7^$\_:+$!4"AG@'@N;$(!L'!\SMGI[6>?M#\&*3T@]YWGZ&
MB4$F@6": HD( EQ@2CFG1HAV%>LG<]Z^M07:GK=OJ[X"WN.:"&KR*J+\'EW=
MQFUU9#&0S%L@#=2:,2BER5T1U K8$;A1,%.;WQ8E"-,T.);V$N>$AHK&$8*,
M %):#1QR1%CNC-0'Z=9TU#/:16F2TP)K5XE>;5C>.NE5N*ZKZ-Q/OL<_315!
MUVD?P?GKVMO![2/U555/!O]O]NWUK$QH?*1]SERP>[ ]6L0"F795+VX070P3
M]-&L,OQZI4V&@XQI8!WV0&B,@$(A .N=\X0YX67NC=7MJ/+MK:Y]UUWTNB@]
ML]%IB1XH",$1J2V$G.6.\]MB.]0.:V:.K-]DS6B*ONRSKA7IY^^?XR/N(IX%
MN;SB0!N# /:*(6H=%RIW.-@"UO&32CGI4)4U2X$$PGKIXP,6(JIM$ MEFEK
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M"?_//E2IF/[;2O09)VIE&08PJ!""HX&;P^X.[P#^*1"UD"D+Q/S[^0ZKNM/
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M'B:6BMMZ7?/R3H8J<"CF5L:FX26" ](% 2 G$%,B#2>Y>^@NOO]I^W%[6Z+
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M8BYX;6S<O7MSY#:2+_K_?@K<V8@]=H1@\_V8?9R0N]6^BNV6=-6R?>9VW'"
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MLYAG\4'Q9&QADCHQ#D/+C%UJ&9%-()Y@E(IF\[]B9X55P3[P)UIVAX9_^]?
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M2H'Y@EV4X X=>$M8"Q;P,>G4H_X>4'HM?-]C(D\@^1Y]10-<T!7]VOSI $B
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M5AI%MNU&%BB/19RTYN6C9X2[#M*RLMD'2^,CS6E3<$'0HB.@,Q^HI^,"#=A
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MLZ&Z8>N8:L5\AQZ%P5S(1,/6#1]OJ6'KA'+T-FP=(_P6&K9.*$2P8>O4"/#
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M3Z7/]'5MRM;"*#1=3*E'(R>A5N"#VJ# R&L^0?5%)2*;:!7*%#-8?2J"&;1
MR8W>>UDY12Q42/.:][1RBH$6RB@M:&\6Q6@>2RTZ@J76+:$\X>^2\9KE518W
M*84'0:(H\7$8> 1;3I+8MIDXMF>"83>UL+I8\FO6TT7/?=IET3*'Z)8[":A-
M/3,H>!QX$_/RZL<&SC_/^>]GN!%!,3ZF5BVKQ,'4P^CR>)=:%3Z*:ZF7HN0B
MT;9F:/.^V7GJ_::QP/B&U,<^L0@.(L]BWMZA'DF(8QHP;S]/4[/;[CA &Q:
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M8.9^?E_29H5XQ\^XM'QB^YX77B*Q[60XO'"P38H#SV&*=5.';4&<U'>%&O>
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MG9.6MW5^_EB+&L7,,)JM9%N(AAKZ:,  NJ7UNLSG4#O BIFW+84Z@1F; G6
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M@=Z//< !W$[2UT Z-A)W#P;YT*!$RM'LLLI;DMWQ_O67I*0J54DE<;%(V=G
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M0)953Y1<ETQFF"JY>JHJMN'3LT5<.T9IF#HHX.U[LS )75?*7Z,+H?7LJ/\
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M0X1/7^A0D2G]T7<Z*W)"TVD-A;[JZ:W(FN/37'49^.E^5Y'+JAI$*>[O!2S
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M//)K[]XREPRJ+*]D6' 9 NC7R\O;7=K[  ?Y\(H$0Y:#+'IY 1/:.39HOH[
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MEB73;3V.U^5N3)!($;O<]6WAVN_8N4@(1C&F!/E>%MM!&,=.(I4OO1[*IAT
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MI*IHK.L!/9-9(^?FN>NI!L:*9P;O=H,S.MGDK&TI2#,4AXF'[,!.2)X'3)6
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M5V*UFL/4*,MAOE0-?)KUKIZS_GK^5@U<./# ZEA/\3:.:^[RY7_P,/XSWO#
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MR6"H/)CI^XE1<^+7@[+;NFV+=23+?I*B%$<^PD[BQ-B+*'9 +4#UHVC<'SK
MXZ =MPA9#/[>1H*:;[BT#E]::M"UUEY*FHROND-0[ZGQS3DCVT<W_[1G^VA#
M\)6R?70S^'2VCW9(\+Z-PL:[>[CG(3%9?]C)]PQ&=CDXZZYXX 4I!_/SM#K
M%BE3:E8XO>)JW0IG"1JV*YQ_\)5<5[^R)QNXWXK[P=E_4M_U$/8CVR.V0\,
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MT.N%<LSR[B  9!B40B))GZ]R77YY>GBH7CA>=5/>I9L/V^KR<9-N_E7!4N4
M2QH^'"_O[RM1Y]%F8PEO[$S2EG7YL'WBH_3:8N0V>8N3@*N70P4@*B(!^2L
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MJQ)3OOF_\I\SAK;U5+<!N;V-AG<(2Y;I&]U0N0/BM;<)&$#=8<NW8H?N<)P
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MW3+%4*#>$]QIT;!:/'9=5 0JNX+073VH,:9!IAH;8I[BK&*=3 2.'E9@Q/Q
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M%'J2IV^D%>@8OQ^JV>=)]NINYWD:D*(.;U--VMP3GH(-:_!^ZG6#$MOE5^U
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MRF,<H"AS$Q1'@<.KR1P[\TGFR?5$5 -O6!-W^/0!H'829EMO=O5454+^!7*
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M"^'=]@$7Y?'-/ Q]%'O$14[HT2SU(M>-0#7X2P -&S-#\-8>_H5P0UE?6QR
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M?[_Y_/&'M[6=WOGAY(?+D=<3[W[XO9K<_C"Y]3_\O1[]5GW3/UP/]"34HSL
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MKX<;<$:& 84$ L[[>"[V5!/M,^!AZ^+-<%%\FK&]8(O QY=;/QCLH)YI!DS
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MY!%@W+F)$ !C0:",%N&S3P#*17LC2&9_AZ[3LU\?6BU@U]S"\BY6!$9 (H.
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MU,\ED@Z]]7 V-^Y[M9'\0TP#:7T '$H9^2$0P]RU#'L)*@1+1VAZ%VA:B[T
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M$0%/!+]5PGH?:=$W^EKHJ>\<PEY[6AR#WWWW(UN-G\R*(L TBP=ARB20\;^
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M^[E[R&F6;H?GB]9<JBH =7O:'U[@#-,8"$GI@=54,X^UC__O="TK1V'RC.^
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M5K)P@ S++$D(F+NXP:>J,D04H 9[)J&4CN1^L;>PDH2V[]VL[HQS,8H8:*G
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MIM(4$5VS8M)A8;!D//L[/GLIZGD >F:,=:"% C#UV.3[V<^2$$L;P@Z&.'=
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MT'=4"GL8H<V ^)H2ZIVKJU1,/IZ!GU\NO]2#@7=O'MYI>[OZLQL!IF9 (R@
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M+)WJP6P(4!M%K7VJWT/9?IG7+PF@;U,:#)[I&B\&([0RHFT?[$U#.V1>-Q-
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M'ZW>J&5I#B%RHLR2M@5%"HI\@5$UOCU%7G),3@W'U%^PJG>[S9ISW)$Y"O(
M6N_8/ @87AI[NR!4@+%LM%2F300MD(#4=SZ3H1;78C%Z*]ICT==H(U[$98;U
MM!\C<,:,3"JX!S[^+,D>6K0/B AKMKU[+Z3) $@7783K+$()DV4ZW(-]4]5D
MF?25O60Z?9)8M.CVB?8CYHAC":!UV;BC8*&C #O2XWS((930(=2*!,/K8<MC
M%*A5G,;ZTL?8\CAWCDU:]"L3JUXY:M4+8DV(90/V+?-]Z!O$]#E(5 "!96*L
MIVE:TN&?1S.Y>14=A[F 9,Q[LI$=SP0V@([5D$GCKJ$4)*8=G5:=.7KSSJ*
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M/C.QJJ5&L[HEUH18+F#?,-^'OD%,GS$-"@"P;(SU-$T+&/[Y--/K5\$XK,^
MC'E/+K*3F8(&P+$:<FW=-9!BB6T'LZKWCMZLLZB8H!:U>6@W@TONPDKKE"98
MGFD,]>Q^HVU<:%TVJ1ET8\!%Q+&D%)<A$Q0]35#6-GT?,D(-%X#.QLWPJ<]0
M$)Q!J,^"5^W\?0] ?Q.7LEJJ-;8NY68#NK]IT?@\O=?V5!<@OKZ/NS;+@?]#
M'B"BJ9:)11[5@'?,[B&WJ0HFM 6J<]KG@ILQQN/+NL4=Q8+9,M=M!G.B,]E!
M&S/<Y0-*,Y4"\[7-'_@^T-8J8/.$ Y8P106@'TI8BF$]BF2)<7CGT'0*;OL6
M\%O _W"FOY& ]S<-\-TA%9D]887T8V'(?,.'P"V])'4Y3;*LX9.[R^793,MS
MJ.B+3+N<:5]F9K4&ZT0-="K-,"$</OUDAO0GJ6:[13$W$Z"/Q3%VL$7RNF70
MJE?[%DBNUAI;)&\TDH--0_*9H]TB-?'Y>9[QM25+T?P9GC9F0:3O9PK9.).<
M6-)J++6![_&@'[2E80[)O^ZH#=E;424$R(,/_$ Z5]P']-I'_W@J(,FF>NT[
MK2*JI_D9])[MIL "&U;8^<A=_C$1_):)_!S  _G"5T_1J]\(MD_>OK<QUS>-
M7E_V6,X>Y0LFX"O<NV;H*<["Y]Y+0WQ\1D)B(:$[58UF 3=2Z6D.P'X!3<8Q
M-X:Q1_S@OJ3*.IL!!_UL(WN *' [-;JU\!M3RQ.NLG\S#NI;AF:);X\+[&^?
MOFV?OOUP1KR1CN8+/'W[L0;<$8)@FI4#B?$)%QXM\#D#=.;Q^_01V8C16PS(
M79K3AN0V06N/:DZ./GT6D//G7NXXQA)OC@904;.I,[<2WGE:%ZH @0&'!9<5
MT+H 87T,$PT38@>3.]%+#XF]>D=OFX1]FR:ZD2#>N*=L'0CL0P5N9P&PR*RG
M#&"U)\]S A=<7,R3H11#AL%Q0@?Y 7J5.]<L3H4<,R@=1=)YU'2.[\#C9\D<
M+%N>Y92<S.'L6[*IU/;\;,N=M1BRE>_-3E;EO@KM:RDRL[K*E[QJZWY&ZOZ>
M&K!B'W:EVR(-84I:5(SH6#_HZ&7>_9VO7K5U7W;C:39+U7+]2_:=1J74J*_W
MAM[G;6>5P^??>*H86*S7;+[Q/+BW/<\MSJ.8*A,GM0;1OE1T([;%,\"B#9S)
M?^C8[9&'!?M' #9LY_@P7I4_>,NC?K=;@PW+_GSXZO2JK>EIBWA>V\RYC"^5
M@RR!;8L'!">E_>J7H%RS+LLCT_X]M+6-M;B!6?/7T/\TXBPD'Z?.S:5+1[ZF
M<7AH"GOY*2)\-7(Z& QW9PX:Y:G6_;?HMAVXO^1R8/^"S/\!4$L#!!0    (
M ,4VIUS?I5W'= 8  ,\E   >    <W5B+6-E<G1X<V5C=&EO;CDP-F]F=&AE
M<V$N:'1M[5IM4^,V$/[>7[$-4PYF$F,[Y(4DQTPNA"DS5[@CN;GV4T>VY5C%
ML5Q))J2_OBO9)D (%ZX<S1TP#(.]TJYV5\^NM.M>I*;Q82^B)#C\J?=SK09'
MW,^F-%'@"TH4#2"3+)G YX#*"ZC5BE$#GLX%FT0*7-MMPF<N+M@ER>F*J9@>
MEGQZ>_ES;\\(Z7D\F!_V G8)+'A;8<V&8WN4NM0[</9;U"-AVVWNT[K7JMM^
MZ-,_G0I.Q>'Y'*GF,7U;F;*D%E$MO]-R4]6=L4!%'<>V?ZF8<8>]D"<*A0F<
MG/^[S(.(";+QN%)\VK$MNYVJRLJ)2],5O5(U$K-)TC&&**:69)_'7'2V;//3
MU91:2*8LGG?>C-F42CBE,SCG4Y*\J4HJ6)B/D>P?BGJ@2N9Q5NB(+&*6T%)G
MI]E"18=7$?.8@KIK.2NUO+%,'[U!Q;.NT]4.&0S/QR?')X/^^.3L%#Y\.A]]
MZI^.87P&F[QJIPV?K)$UL& T')B5._6&787^"/I'9Q_&PZ/O1I52@0.["6?'
M,/YU"*/^^;O^Z7!4._O]_? /Z _&FN+:MKLF7EHHN7BC>-IIXJ/1E"4!:MFI
M-]-OBHC]>Q4]2<#G24)]Q7@",Z8B4!&%CQD1:/AX#N<TY4(!$H^YF()CUSX"
M#V$4$:4R_P+>$T]6X23Q+=C1,[>WVJYK=P=\FI)D;IZ<[BZ$7!C&*2Z3!T!1
MYP!^(\*/MK><IMVM.U43%TM;KFF& 6X33S!4GR2RMF0#9RT;P".%/I7MB820
MQ6B':[./J)\)IABR)TD PRL_(LF$8NZ83IF4VD7XJT<&F&@@HH*B+V[:/7=7
M:?8J4.)'VE]Z2(9&%Q)AA2)Y&#(?GTI:X2_#TIL#DA0+<1U52#,A,X*&41P6
M"-=>:W4+@*,B)."I3GTW1^=C-(0*(2,B/))063N[BND<^K[2% VA*M*)F:3'
M>50:2L0D7"1\AC::T.VM1KN[!+7#GB)>3$NO>5R@CC5T7DQ223OE/]V R30F
M\PY+C!_,I.YM?#;0:9=:;Y_$1?@Q^,S)1<(\:%MVJZESIL)\IX)2<)%.+9-.
M]U2P3*M;S7I[)=6VG)6TA[@>[%M.TUV+[9Y9<;YJM(M$?[^MU"OEA)0$ 1Y;
M.FYZ!4X9FW(SQ#1<-@U/*^L>#IX)4PU4=<?9O7,**<SRPVH\1L 403K,8HS8
M/D(YUB'D.JP(^G?&!-5G2P/X41'NG?H.V06,S$YC)]B]1NDB"%T'H *JSD%]
M'W%XT-7AZ1X[FRVV9\#UBM%7C*["J/L2,<H2/ --B0$>'KD483H/LSR=EP F
M3)^Y4D&EQFI5DTD< TY#P21&),L4P2NK9E;($I+X^CTR#)AAK<\-."J+<ZAS
M/' 9F7<SO?4(^*Z^&7Y'T&Y8#7LU?K\6VT[+LNNM)V>[_^B040XH]UW=[/.'
M065K2%76PM_7#GW:@);OA4U$^!$BU)Q0\5(SSZ\TK=LWFO\2ZDRYY&N-L<3H
M^:WS;G[/Z?WIHO[F;HOMK?U65YJ_<"0L&),YRH21'PG*/"I6!>$O(^9IL5L$
M;EV7P+$@><P"*"WSPWACDSWP=$;63M05WH)C34^_]<($ ?WF63U0/]"%S8C1
M$*\5>,50[)+"65Z&^%(%;7V5;MKMKTPJ%LZ_B9:&68<IE.2OH?=.*AB>U%(\
MJM%KY8L:S.Z:]4/W=OWP42Z^KSS_FIY?T_-K>KY.S_TD$)JAA7Q9'&]*7G@9
MF7E#C?^2DO+Q=3'A!2;E125%UT^([_,L4;J)OSDY^LX%?Y/N]TLEHUN=W/^U
MOZDK;R$7=,*U-XNVEI]7X9@$C^K78282)B,:Z/!*X[GN0^D]D+?$;M3G'NJ%
M%:TPW#[(-^&JY&TZ?+K]B9-3+NGM"GQ[S:K[+<XHW=,%19\C1V$^.?'F(&A(
M!4U\3=$*X-)1>+Z);U;^JC"+*#X+F)) -]NT?707@(2*BKO=Q2KRG1 1Q%2:
ME6NV$YI0@5A9K$#K$N.:,S+1XD%F?E1(M]:)(XV-:(:?\O*4V(>R3XHHQ=@0
MYS9$^\_028JBA@IM9+[Z*;HKQ@>+EF=$].["@:G@ETQWN]$G]W7-M5]GF/.T
M2P4MRL+(:M78Q68MNJ7K-(T%,"7UFL,0LA3?Z$53J9:=L\YW0#>_(\(M;0K/
M'4%CHJ\U2U\6+4XR^1%C,045XW&FEJ=\JX^1BK_Y!U5[YD.N?P%02P$"% ,4
M    " #%-J=</']QVW$!  #/!@  '               @ $     :6)C+7-H
M871T=6-K;&%B<U\Q<W1A;65N+FAT;5!+ 0(4 Q0    ( ,4VIUQ;$/FG9P$
M )X%   <              "  :L!  !I8F-B86YK<&QA>F%S96-O;F1A;65N
M9&TN:'1M4$L! A0#%     @ Q3:G7&Z9(F6L]   #.@) !$
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M,GAC9F]X<3$N:'1M4$L! A0#%     @ Q3:G7-^E7<=T!@  SR4  !X
M         ( !FV@" '-U8BUC97)T>'-E8W1I;VXY,#9O9G1H97-A+FAT;5!+
4!08     "P +  (#  !+;P(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>sttk-20260331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:sttk="http://www.shattucklabs.com/20260331"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sttk-20260331.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sttk:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sttk:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sttk:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sttk:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">sttk:OperatingAccountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">sttk:OperatingAccountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sttk:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sttk:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">sttk:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sttk:KayakAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2025-08-31</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sttk:KayakAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sttk:KayakAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sttk:KayakAgreementContingentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sttk:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sttk:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sttk:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2025-08-31</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sttk:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2025-08-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sttk:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2025-08-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sttk:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sttk:BeneficialOwnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sttk:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2025-08-31</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sttk:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sttk:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sttk:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sttk:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sttk:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sttk:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-01-01</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sttk:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sttk:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sttk:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sttk:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sttk:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sttk:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sttk:SL325Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sttk:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sttk:SL325Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sttk:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sttk:OtherResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sttk:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sttk:OtherResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sttk:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sttk:OtherResearchAndDevelopmentSL172154Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sttk:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sttk:OtherResearchAndDevelopmentSL172154Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sttk:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">sttk:ArunthathyNirmaliniLiniPanditeM.B.Ch.B.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">sttk:ArunthathyNirmaliniLiniPanditeM.B.Ch.B.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">sttk:AbhinavShuklaPhDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">sttk:AbhinavShuklaPhDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="vote">
        <measure>sttk:vote</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>sttk:segment</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-26">0001680367</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-27">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-28">2026</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-29">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-30">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="c-5" id="f-79">http://fasb.org/us-gaap/2025#LicenseMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="c-1" id="f-80">http://fasb.org/us-gaap/2025#LicenseMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <ecd:TrdArrDuration contextRef="c-105" id="f-479">P513D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-107" id="f-480">P361D</ecd:TrdArrDuration>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2026-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-39593</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">Shattuck Labs, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">81-2575858</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">500 W. 5th Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-10">Suite 1200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Austin</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">78701</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">512</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">900-4690</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">STTK</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-19">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-20">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-21">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-22">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-23">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-24">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="0" id="f-25" unitRef="shares">76680517</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-31" unitRef="usd">90419000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-32" unitRef="usd">54192000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-3" decimals="-3" id="f-33" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-4" decimals="-3" id="f-34" unitRef="usd">23873000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-35" unitRef="usd">3334000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-36" unitRef="usd">4410000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-37" unitRef="usd">93753000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-38" unitRef="usd">82475000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-39" unitRef="usd">5353000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-40" unitRef="usd">6114000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent contextRef="c-3" decimals="-3" id="f-41" unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent contextRef="c-4" decimals="-3" id="f-42" unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-3" decimals="-3" id="f-43" unitRef="usd">2015000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-44" unitRef="usd">1437000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-45" unitRef="usd">102121000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-46" unitRef="usd">91026000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-47" unitRef="usd">1253000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-48" unitRef="usd">2101000</us-gaap:AccountsPayableCurrent>
    <sttk:AccruedLiabilitiesAndOtherLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-49" unitRef="usd">2996000</sttk:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <sttk:AccruedLiabilitiesAndOtherLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-50" unitRef="usd">4951000</sttk:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-51" unitRef="usd">4249000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-52" unitRef="usd">7052000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-53" unitRef="usd">2037000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-54" unitRef="usd">1584000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-55" unitRef="usd">6286000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-56" unitRef="usd">8636000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-57" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-58" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-59"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-60"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-61" unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-62" unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="INF" id="f-63" unitRef="shares">75581787</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-64" unitRef="shares">75581787</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-65" unitRef="shares">63279843</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-66" unitRef="shares">63279843</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-3" id="f-67" unitRef="usd">7000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-68" unitRef="usd">7000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-3" decimals="-3" id="f-69" unitRef="usd">541124000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-3" id="f-70" unitRef="usd">512906000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="-3" id="f-71" unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-72" unitRef="usd">6000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-73" unitRef="usd">-445296000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-74" unitRef="usd">-430529000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-75" unitRef="usd">95835000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-76" unitRef="usd">82390000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-77" unitRef="usd">102121000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-78" unitRef="usd">91026000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-81" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-3" id="f-82" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-83" unitRef="usd">10946000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-5" decimals="-3" id="f-84" unitRef="usd">9919000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-85" unitRef="usd">4599000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-5" decimals="-3" id="f-86" unitRef="usd">4470000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-87" unitRef="usd">15545000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-5" decimals="-3" id="f-88" unitRef="usd">14389000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-89" unitRef="usd">-15545000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="-3" id="f-90" unitRef="usd">-14389000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest contextRef="c-1" decimals="-3" id="f-91" unitRef="usd">779000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-5" decimals="-3" id="f-92" unitRef="usd">689000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-93" unitRef="usd">-1000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-94" unitRef="usd">-2000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-95" unitRef="usd">778000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-96" unitRef="usd">687000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-97" unitRef="usd">-14767000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-98" unitRef="usd">-13702000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-99" unitRef="usd">-6000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-5" decimals="-3" id="f-100" unitRef="usd">-2000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-101" unitRef="usd">-14773000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-5" decimals="-3" id="f-102" unitRef="usd">-13704000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-103"
      unitRef="usdPerShare">-0.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-104"
      unitRef="usdPerShare">-0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-105"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-106"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-107" unitRef="shares">112234551</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-108" unitRef="shares">112234551</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="0" id="f-109" unitRef="shares">50965815</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="0" id="f-110" unitRef="shares">50965815</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding contextRef="c-6" decimals="INF" id="f-111" unitRef="shares">63279843</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="-3" id="f-112" unitRef="usd">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-7" decimals="-3" id="f-113" unitRef="usd">512906000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-114" unitRef="usd">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-3" id="f-115" unitRef="usd">-430529000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-116" unitRef="usd">82390000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-10"
      decimals="INF"
      id="f-117"
      unitRef="shares">5000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-11" decimals="-3" id="f-118" unitRef="usd">20562000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-1" decimals="-3" id="f-119" unitRef="usd">20562000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <sttk:StockIssuedDuringPeriodSharesWarrantExercises
      contextRef="c-12"
      decimals="INF"
      id="f-120"
      unitRef="shares">6928891</sttk:StockIssuedDuringPeriodSharesWarrantExercises>
    <sttk:StockIssuedDuringPeriodSharesWarrantExercises
      contextRef="c-13"
      decimals="INF"
      id="f-121"
      unitRef="shares">153664</sttk:StockIssuedDuringPeriodSharesWarrantExercises>
    <sttk:StockIssuedDuringPeriodValueWarrantExercises contextRef="c-14" decimals="-3" id="f-122" unitRef="usd">5444000</sttk:StockIssuedDuringPeriodValueWarrantExercises>
    <sttk:StockIssuedDuringPeriodValueWarrantExercises contextRef="c-15" decimals="-3" id="f-123" unitRef="usd">5444000</sttk:StockIssuedDuringPeriodValueWarrantExercises>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-10"
      decimals="INF"
      id="f-124"
      unitRef="shares">68916</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-11" decimals="-3" id="f-125" unitRef="usd">59000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-1" decimals="-3" id="f-126" unitRef="usd">59000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-10"
      decimals="INF"
      id="f-127"
      unitRef="shares">206513</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="c-10"
      decimals="INF"
      id="f-128"
      unitRef="shares">56040</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-11" decimals="-3" id="f-129" unitRef="usd">262000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-130" unitRef="usd">262000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-16" decimals="-3" id="f-131" unitRef="usd">-6000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-132" unitRef="usd">-6000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-11" decimals="-3" id="f-133" unitRef="usd">2415000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-134" unitRef="usd">2415000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-17" decimals="-3" id="f-135" unitRef="usd">-14767000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-136" unitRef="usd">-14767000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c-18"
      decimals="INF"
      id="f-137"
      unitRef="shares">75581787</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-138" unitRef="usd">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-139" unitRef="usd">541124000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-140" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-141" unitRef="usd">-445296000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-142" unitRef="usd">95835000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c-22"
      decimals="INF"
      id="f-143"
      unitRef="shares">47714708</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-144" unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-145" unitRef="usd">461339000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-146" unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-147" unitRef="usd">-381720000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-148" unitRef="usd">79626000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-27"
      decimals="INF"
      id="f-149"
      unitRef="shares">6859</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-28" decimals="-3" id="f-150" unitRef="usd">8000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-5" decimals="-3" id="f-151" unitRef="usd">8000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-27"
      decimals="INF"
      id="f-152"
      unitRef="shares">232076</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="c-27"
      decimals="INF"
      id="f-153"
      unitRef="shares">54403</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-28" decimals="-3" id="f-154" unitRef="usd">65000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-5" decimals="-3" id="f-155" unitRef="usd">65000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-28" decimals="-3" id="f-156" unitRef="usd">1721000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-5" decimals="-3" id="f-157" unitRef="usd">1721000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-29" decimals="-3" id="f-158" unitRef="usd">-2000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-5" decimals="-3" id="f-159" unitRef="usd">-2000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-30" decimals="-3" id="f-160" unitRef="usd">-13702000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-161" unitRef="usd">-13702000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c-31"
      decimals="INF"
      id="f-162"
      unitRef="shares">47899240</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-163" unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-3" id="f-164" unitRef="usd">463003000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-3" id="f-165" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-3" id="f-166" unitRef="usd">-395422000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="-3" id="f-167" unitRef="usd">67586000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-168" unitRef="usd">-14767000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-169" unitRef="usd">-13702000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-170" unitRef="usd">2415000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-5" decimals="-3" id="f-171" unitRef="usd">1721000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-172" unitRef="usd">891000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-5" decimals="-3" id="f-173" unitRef="usd">936000</us-gaap:Depreciation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="-3" id="f-174" unitRef="usd">132000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-5" decimals="-3" id="f-175" unitRef="usd">118000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-1" decimals="-3" id="f-176" unitRef="usd">48000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-5" decimals="-3" id="f-177" unitRef="usd">2000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-178" unitRef="usd">-1076000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-5" decimals="-3" id="f-179" unitRef="usd">-723000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-1" decimals="-3" id="f-180" unitRef="usd">32000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-5" decimals="-3" id="f-181" unitRef="usd">-16000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-182" unitRef="usd">-911000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-5" decimals="-3" id="f-183" unitRef="usd">-886000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-3" id="f-184" unitRef="usd">-1955000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-5" decimals="-3" id="f-185" unitRef="usd">-716000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-186" unitRef="usd">-225000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-5" decimals="-3" id="f-187" unitRef="usd">-240000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-188" unitRef="usd">-13424000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-5" decimals="-3" id="f-189" unitRef="usd">-12032000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-1" decimals="-3" id="f-190" unitRef="usd">23915000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-5" decimals="-3" id="f-191" unitRef="usd">15600000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="-3" id="f-192" unitRef="usd">67000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-5" decimals="-3" id="f-193" unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-194" unitRef="usd">23848000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-5" decimals="-3" id="f-195" unitRef="usd">15600000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-196" unitRef="usd">20562000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-5" decimals="-3" id="f-197" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c-1" decimals="-3" id="f-198" unitRef="usd">5444000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c-5" decimals="-3" id="f-199" unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-1" decimals="-3" id="f-200" unitRef="usd">59000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-5" decimals="-3" id="f-201" unitRef="usd">8000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-202" unitRef="usd">262000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-5" decimals="-3" id="f-203" unitRef="usd">65000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-204" unitRef="usd">25803000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-5" decimals="-3" id="f-205" unitRef="usd">-57000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-206" unitRef="usd">36227000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-5" decimals="-3" id="f-207" unitRef="usd">3511000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-208" unitRef="usd">54192000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-26" decimals="-3" id="f-209" unitRef="usd">57387000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-210" unitRef="usd">90419000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-35" decimals="-3" id="f-211" unitRef="usd">60898000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-1" decimals="-3" id="f-212" unitRef="usd">6000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-5" decimals="-3" id="f-213" unitRef="usd">0</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-214" unitRef="usd">63000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-5" decimals="-3" id="f-215" unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <sttk:IncreaseDecreaseInOperatingLeasesRightOfUseAssetsLiability contextRef="c-1" decimals="-3" id="f-216" unitRef="usd">678000</sttk:IncreaseDecreaseInOperatingLeasesRightOfUseAssetsLiability>
    <sttk:IncreaseDecreaseInOperatingLeasesRightOfUseAssetsLiability contextRef="c-5" decimals="-3" id="f-217" unitRef="usd">0</sttk:IncreaseDecreaseInOperatingLeasesRightOfUseAssetsLiability>
    <us-gaap:NatureOfOperations contextRef="c-1" id="f-218">Organization and Description of Business &lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shattuck Labs, Inc. (the &#x201c;Company&#x201d;) was incorporated in 2016 in the State of Delaware and is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. Shattuck is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease and other inflammatory and immune-mediated diseases. Shattuck&#x2019;s expertise in protein engineering and the development of novel tumor necrosis factor receptor agonist and antagonist therapeutics come together in its lead program, SL-325, which it believes could be a first-in-class death receptor 3 ("DR3") antagonist antibody designed to achieve best-in-class clinical remission rates due to a more complete and durable blockade of the clinically validated tumor necrosis factor like ligand 1A ("TL1A")/DR3 pathway.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of $445.3 million as of March&#160;31, 2026. The Company anticipates incurring additional losses and negative cash flows from operations until such time, if ever, that it can generate significant sales of its product candidates currently in development, and is highly dependent on its ability to find additional sources of funding in the form of licensing of its technology, collaboration agreements and/or public and private debt and equity financings. Adequate additional funding may not be available to the Company on acceptable terms, or at all. The failure to raise funds as and when needed could have a negative impact on the Company&#x2019;s financial condition and ability to pursue its clinical operations, research and development and commercialization of its product candidates. Management believes that the Company&#x2019;s cash and cash equivalents of $90.4 million as of March&#160;31, 2026 are sufficient to fund projected operations of the Company for at least the next twelve months following the date these financial statements are issued. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Global Economic Considerations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The global macroeconomic environment is uncertain and could be negatively affected by, among other things, inflation, slower growth or recession, changes in trade policies, including tariffs or other trade restrictions or the threat of such actions, instability, or volatility in the global capital and credit markets, supply chain weaknesses, financial institution instability, changes to fiscal and monetary policy or government budget dynamics, and instability in the geopolitical environment. Such challenges have caused, and may continue to cause, recession fears, high interest rates, foreign exchange volatility, and inflationary pressures. At this time, the Company is unable to quantify the potential effects of this economic instability on its future operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-5" id="f-219" unitRef="usd">-445300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-3" decimals="-5" id="f-220" unitRef="usd">90400000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-221">Basis of Presentation and Summary of Significant Accounting Policies &lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim condensed financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Condensed Financial Statements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, the accompanying interim financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company&#x2019;s financial position, its results of operations, statements of changes in stockholders&#x2019; equity and cash flows for the interim periods presented. Operating results for interim periods presented are not necessarily indicative of the results that may be expected for the year ending December 31, 2026. The interim financial statements presented herein do not contain all required disclosures under GAAP for annual financial statements. The accompanying unaudited interim condensed financial statements should be read in conjunction with the annual audited financial statements and related notes in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition, the accrual of research and development expenses, and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates, if any, are recorded in the period in which they become known and actual results could differ from management&#x2019;s estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received upon the sale of an asset or paid upon the transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. Fair value measurements are classified and disclosed in one of the following categories: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Level&#160;1: Observable inputs such as quoted prices in active markets for identical assets the reporting entity has the ability to access as of the measurement date; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Level&#160;2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Level&#160;3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value measurements are classified based on the lowest level of input that is significant to the measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of the assets and liabilities and their placement within the fair value hierarchy levels. The determination of the fair values takes into account the market for its financial assets and liabilities, the associated credit risk and other factors as required. The Company considers active markets as those in which transactions for the assets or liabilities occur with sufficient frequency and volume to provide pricing information on an ongoing basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management believes that the carrying amounts of the Company&#x2019;s financial instruments, including short-term investments and accounts payable, approximate fair value due to the short-term nature of those instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Risk &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and short-term investments. The Company maintains its cash and cash equivalents at an accredited financial institution in amounts that exceed federally-insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company&#x2019;s short term investments consist of U.S. Treasury securities that management believes protects the Company from risk of default and impairment of value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is highly dependent on a limited number of contract development and manufacturing organizations (&#x201c;CDMOs&#x201d;) to supply drug products for its research and development activities of its programs, including nonclinical studies. The Company is highly dependent on a single CDMO for the supply of cGMP drug product for its clinical trials. These programs could be adversely affected by a significant interruption in the supply of such drug products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is highly dependent on a limited number of contract research organizations (&#x201c;CROs&#x201d;) and third-party service providers to manage and support its clinical trials. These programs could be adversely affected by a significant disruption in services provided by these CROs and third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all demand deposits with financial institutions and all highly liquid investments with original maturities of 90 days or less at the date of purchase to be cash and cash equivalents. Cash and cash equivalents consisted of $1.6&#160;million held in operating accounts and $88.9 million held in money market funds as of March&#160;31, 2026, and $1.9&#160;million held in operating accounts and $52.3&#160;million held in money market funds as of December&#160;31, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's short-term investments consist of highly-rated U.S. Treasury securities and have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices. Management determines the appropriate classification of its investment securities at the time of purchase. The Company may hold securities with stated maturities greater than one year. All available-for-sale securities are considered available to support current operations and are classified as current assets. Credit impairments for available-for-sale securities are recorded through an allowance rather than a direct write-down of the security and are recorded through a charge to the statements of operations and comprehensive loss. Unrealized gains or losses not related to credit impairments are recorded in accumulated other comprehensive income, a component of stockholders&#x2019; equity, until realized. The Company reviews available-for-sale debt securities for impairments related to credit losses and other factors each quarter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a long-term related party investment in preferred stock of a privately held company. The investment is accounted for under Accounting Standards Codification ("ASC") 321, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments in Equity Securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and is classified as a long-term asset in the accompanying balance sheet as it is not expected to be liquidated within one year. For investments that do not have a readily determinable fair value, the Company applies the measurement alternative, whereby the investment is carried at cost, adjusted for observable price changes in orderly transactions for identical or similar securities of the same issuer and impairment losses, if any. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets include prepaid expenses for general business purposes and services used in research projects, which are stated at cost and amortized on a straight-line basis over the related period of benefit. Supplies and materials that have multiple applications for alternative future use are expensed as they are consumed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost, net of accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life of the asset. Expenditures for repairs and maintenance that do not extend the estimated useful life or improve an asset are expensed as incurred. Upon retirement or sale, the cost and related accumulated depreciation and amortization of assets disposed of are removed from the accounts, and any resulting gain or loss is included in the statement of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation periods are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.333%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.938%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.862%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5&#160;to&#160;10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shorter&#160;of&#160;lease&#160;term&#160;or 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstance indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable and the carrying amount exceeds the projected discounted future cash flows arising from these assets. There were no impairments of long-lived assets for the three months ended March&#160;31, 2026 and 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is a lease at inception. Right-of-use (&#x201c;ROU&#x201d;) assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. The classification of the Company's leases as operating or finance leases, along with the initial measurement and recognition of the associated ROU assets and lease liabilities, are performed at the lease commencement date. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. As the Company's leases do not provide an implicit rate, the Company &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. The ROU asset is based on the measurement of the lease liability and also includes any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company's operating leases is recognized on a straight-line basis over the lease term. Operating lease ROU assets and long-term operating lease liabilities are presented separately and operating lease liabilities payable in the next 12 months are recorded in accrued expenses and other current liabilities. The Company has elected to not apply the recognition requirement of ASC 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) to leases with a term of 12 months or less for all classes of assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows ASC 450-20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to report accounting for contingencies. Certain conditions may exist as of the date the condensed financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company&#x2019;s condensed financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration revenue is recognized in accordance with ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 606&#x201d;). Arrangements with collaborators may include licenses to intellectual property, research and development services, manufacturing services for clinical and commercial supply, and participation on joint steering committees. The Company evaluates the promised goods or services in the contract to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, the Company considers the stage of development of the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property and whether the promised goods or services are integral to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the amendment of an existing agreement, the Company evaluates whether the amendment represents a modification to an existing contract that would be recorded through a cumulative catch-up to revenue, prospective modification, or a separate contract. If it is determined that it is a separate contract, the Company will evaluate the necessary revenue recognition through the five-step process described below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When the Company concludes that a contract should be accounted for as a combined performance obligation and recognized over time, the Company must then determine the period over which revenue should be recognized and the method by which to measure revenue. The Company generally recognizes revenue using a cost-based input method. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes collaboration revenue in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services when its customer or collaborator obtains control of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;promised goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the following five steps are performed: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;i.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.73pt"&gt;identify the contract(s) with a customer;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.96pt"&gt;identify the performance obligations in the contract; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.19pt"&gt;determine the transaction price; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iv.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.73pt"&gt;allocate the transaction price to the performance obligations within the contract; and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;v.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt"&gt;recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company only applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company&#x2019;s arrangements may consist of a license of, or options to license, the Company&#x2019;s intellectual property and research, development and manufacturing services. The Company may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i)&#160;the customer can benefit from on its own or together with other readily available resources and (ii)&#160;are separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most-likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes variable consideration in the transaction price to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations that consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company&#x2019;s accompanying balance sheet. Deferred revenues expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability. Deferred revenues not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as non-current liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Company&#x2019;s collaboration revenue arrangements may include the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Up-front License Fees: If a license is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, up-front fees allocated to the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Milestone Payments: At the inception of an agreement that includes research and development milestone payments, the Company evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company first estimates the amount of the milestone payment that the Company could receive using either the expected value or the most-likely amount approach. The Company primarily uses the most-likely amount approach as that approach is generally most predictive for milestone payments with a binary outcome. The Company then considers whether any portion of that estimated amount is subject to the variable consideration constraint (that is, whether it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty). The Company updates the estimate of variable consideration included in the transaction price at each reporting date which includes updating the assessment of the likely amount of consideration and the application of the constraint to reflect current facts and circumstances. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalties: For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Company has not granted a development and commercialization license nor recognized any revenue related to sales-based royalties or milestone payments based on the level of sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and Development Services: The Company will record costs associated with development and process optimization activities as research and development expenses in the statements of operations and comprehensive loss consistent with ASC 730, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company considered the guidance in ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 808&#x201d;) and will recognize the payments received from these agreements as revenue when the related costs are incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License Revenue: License revenue is generated from granting third parties rights to certain of the Company&#x2019;s intellectual property, including research, development, and commercialization of specified product candidates. The Company evaluates each licensing arrangement to determine whether the license is distinct from other promised goods or services and whether the arrangement includes multiple performance obligations. If an arrangement includes multiple performance obligations, the transaction price is allocated to each performance obligation based on relative standalone selling prices. Upfront payments, including nonrefundable license fees, are recognized as revenue when the underlying performance obligation is satisfied. Milestone payments that are contingent on the occurrence of a future event are included in the transaction price only when it is probable that a significant reversal of cumulative revenue will not occur. Sales-based royalties, including milestone payments based on a level of sales, are recognized as revenue when the subsequent sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may also enter into arrangements that include non-cash consideration, such as equity instruments. In such cases, the Company measures the transaction price at the estimated fair value of the non-cash consideration received at contract inception and recognizes revenue when the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred, and include salaries, stock-based compensation and other personnel-related costs, equipment and supplies, depreciation, nonclinical studies, clinical trials and manufacturing development activities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A substantial portion of the Company&#x2019;s ongoing research and development activities are conducted by third-party service providers, including CROs and CDMOs. The Company accrues for expenses resulting from obligations under agreements with CROs, CDMOs and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with CROs, CDMOs and other outside &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through an evaluation of the progress or stage of completion of the services. In the event advance payments are made to a CRO, CDMO or outside service provider, the payments will be recorded as a prepaid asset which will be amortized as the contracted services are performed. As actual costs become known, the Company adjusts its accruals and prepaid assets accordingly. Inputs, such as the services performed, the number of patients enrolled or the study duration, may vary from the Company&#x2019;s estimates, resulting in adjustments to research and development expenses in future periods. The Company makes significant judgments and estimates in determining the accrual and/or prepaid balance in each reporting period and changes in these estimates may result in material changes to the Company&#x2019;s accruals that could materially affect the Company&#x2019;s results of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock Warrants and Pre-Funded Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s common stock warrants and pre-funded warrants are classified as a component of permanent stockholders&#x2019; equity within additional paid-in capital. The common stock warrants and pre-funded warrants are equity classified because they, (i) are freestanding financial instruments, (ii) are immediately exercisable, (iii) do not embody an obligation for the Company to repurchase its shares, (iv) permit the holders to receive a fixed number of shares of common stock upon exercise, (v) are indexed to the Company&#x2019;s common stock and, (vi) meet the equity classification criteria. In addition, such common stock warrants and pre-funded warrants do not provide any guarantee of value or return. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes the cost of stock-based awards issued to employees and nonemployees as compensation expense on a straight-line basis over the vesting period of the award, net of estimated forfeitures. Forfeiture estimates are based on historical cancellation data. The Company uses the Black-Scholes option pricing model to determine the grant-date fair value of stock options. The fair values of restricted stock units (&#x201c;RSUs&#x201d;) are based on the fair value of the Company&#x2019;s common stock on the date of the grant. The Company also grants stock options that vest upon achievement of certain market-based conditions. The Company uses the Monte Carlo pricing model to estimate the fair value of options that have market-based conditions. The Company adjusts expense for forfeitures in the periods they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statements and the tax bases of assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in tax rates on deferred tax assets and liabilities will be recognized in the period that includes the enactment date. Additionally, any changes in income tax laws are immediately recognized in the year of enactment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A valuation allowance is established against the deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. The deferred tax assets and liabilities are classified as noncurrent along with the related valuation allowance. Due to a lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on the technical merits, as the largest amount of benefits that is more likely than not to be realized upon the ultimate settlement. The Company&#x2019;s policy is to recognize interest and penalties related to the unrecognized tax benefits as a component of income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Basic shares outstanding includes the weighted average effect of the Company&#x2019;s outstanding 38,448,034 pre-funded warrants as of March&#160;31, 2026, the exercise of which requires nominal consideration for the delivery of an equal number of shares of common stock. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock or convertible notes, if any, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;stock options and unvested shares of restricted stock, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding as they would be anti-dilutive:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.092%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.484%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47,487,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,064,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,458,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;589,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;527,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;61,141,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,986,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Comprehensive Income (Loss) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Other comprehensive income (loss) is comprised of unrealized gains and losses on short-term investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in this update are intended to enhance the transparency and decision usefulness of income tax disclosures primarily through changes to the rate reconciliation and income taxes paid information. This update is effective for annual periods beginning after December 15, 2024, and may be applied prospectively or retrospectively. The Company has retrospectively adopted this ASU in the financial statements for the year ending December&#160;31, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (&#x201c;ASU 2024-03&#x201d;), which is intended to provide more detailed information about specified categories of expenses (employee compensation, depreciation, and amortization) included in certain expense captions presented on the statement of operations. The guidance in this ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either, (i) prospectively to financial statements issued for periods after the effective date of this ASU or, (ii) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-222">&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim condensed financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Condensed Financial Statements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, the accompanying interim financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company&#x2019;s financial position, its results of operations, statements of changes in stockholders&#x2019; equity and cash flows for the interim periods presented. Operating results for interim periods presented are not necessarily indicative of the results that may be expected for the year ending December 31, 2026. The interim financial statements presented herein do not contain all required disclosures under GAAP for annual financial statements. The accompanying unaudited interim condensed financial statements should be read in conjunction with the annual audited financial statements and related notes in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-223">&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition, the accrual of research and development expenses, and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates, if any, are recorded in the period in which they become known and actual results could differ from management&#x2019;s estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-224">&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received upon the sale of an asset or paid upon the transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. Fair value measurements are classified and disclosed in one of the following categories: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Level&#160;1: Observable inputs such as quoted prices in active markets for identical assets the reporting entity has the ability to access as of the measurement date; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Level&#160;2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Level&#160;3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value measurements are classified based on the lowest level of input that is significant to the measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of the assets and liabilities and their placement within the fair value hierarchy levels. The determination of the fair values takes into account the market for its financial assets and liabilities, the associated credit risk and other factors as required. The Company considers active markets as those in which transactions for the assets or liabilities occur with sufficient frequency and volume to provide pricing information on an ongoing basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management believes that the carrying amounts of the Company&#x2019;s financial instruments, including short-term investments and accounts payable, approximate fair value due to the short-term nature of those instruments.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-225">&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Risk &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and short-term investments. The Company maintains its cash and cash equivalents at an accredited financial institution in amounts that exceed federally-insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company&#x2019;s short term investments consist of U.S. Treasury securities that management believes protects the Company from risk of default and impairment of value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is highly dependent on a limited number of contract development and manufacturing organizations (&#x201c;CDMOs&#x201d;) to supply drug products for its research and development activities of its programs, including nonclinical studies. The Company is highly dependent on a single CDMO for the supply of cGMP drug product for its clinical trials. These programs could be adversely affected by a significant interruption in the supply of such drug products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is highly dependent on a limited number of contract research organizations (&#x201c;CROs&#x201d;) and third-party service providers to manage and support its clinical trials. These programs could be adversely affected by a significant disruption in services provided by these CROs and third parties.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy contextRef="c-1" id="f-226">&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents &lt;/span&gt;&lt;/div&gt;The Company considers all demand deposits with financial institutions and all highly liquid investments with original maturities of 90 days or less at the date of purchase to be cash and cash equivalents.</us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-36" decimals="-5" id="f-227" unitRef="usd">1600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-37" decimals="-5" id="f-228" unitRef="usd">88900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-38" decimals="-5" id="f-229" unitRef="usd">1900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-39" decimals="-5" id="f-230" unitRef="usd">52300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InvestmentPolicyTextBlock contextRef="c-1" id="f-231">&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's short-term investments consist of highly-rated U.S. Treasury securities and have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices. Management determines the appropriate classification of its investment securities at the time of purchase. The Company may hold securities with stated maturities greater than one year. All available-for-sale securities are considered available to support current operations and are classified as current assets. Credit impairments for available-for-sale securities are recorded through an allowance rather than a direct write-down of the security and are recorded through a charge to the statements of operations and comprehensive loss. Unrealized gains or losses not related to credit impairments are recorded in accumulated other comprehensive income, a component of stockholders&#x2019; equity, until realized. The Company reviews available-for-sale debt securities for impairments related to credit losses and other factors each quarter. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a long-term related party investment in preferred stock of a privately held company. The investment is accounted for under Accounting Standards Codification ("ASC") 321, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments in Equity Securities&lt;/span&gt; and is classified as a long-term asset in the accompanying balance sheet as it is not expected to be liquidated within one year. For investments that do not have a readily determinable fair value, the Company applies the measurement alternative, whereby the investment is carried at cost, adjusted for observable price changes in orderly transactions for identical or similar securities of the same issuer and impairment losses, if any.</us-gaap:InvestmentPolicyTextBlock>
    <sttk:PrepaidExpenseAndOtherAssetsPolicyPolicyTextBlock contextRef="c-1" id="f-232">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets include prepaid expenses for general business purposes and services used in research projects, which are stated at cost and amortized on a straight-line basis over the related period of benefit. Supplies and materials that have multiple applications for alternative future use are expensed as they are consumed.&lt;/span&gt;&lt;/div&gt;</sttk:PrepaidExpenseAndOtherAssetsPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-233">&lt;div style="margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost, net of accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life of the asset. Expenditures for repairs and maintenance that do not extend the estimated useful life or improve an asset are expensed as incurred. Upon retirement or sale, the cost and related accumulated depreciation and amortization of assets disposed of are removed from the accounts, and any resulting gain or loss is included in the statement of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation periods are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.333%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.938%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.862%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5&#160;to&#160;10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shorter&#160;of&#160;lease&#160;term&#160;or 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-234">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation periods are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.333%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.938%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.862%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5&#160;to&#160;10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shorter&#160;of&#160;lease&#160;term&#160;or 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-40" id="f-235">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-41" id="f-236">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-42" id="f-237">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-43" id="f-238">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-44" id="f-239">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock contextRef="c-1" id="f-240">&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;Long-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstance indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable and the carrying amount exceeds the projected discounted future cash flows arising from these assets.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-241">&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is a lease at inception. Right-of-use (&#x201c;ROU&#x201d;) assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. The classification of the Company's leases as operating or finance leases, along with the initial measurement and recognition of the associated ROU assets and lease liabilities, are performed at the lease commencement date. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. As the Company's leases do not provide an implicit rate, the Company &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. The ROU asset is based on the measurement of the lease liability and also includes any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company's operating leases is recognized on a straight-line basis over the lease term. Operating lease ROU assets and long-term operating lease liabilities are presented separately and operating lease liabilities payable in the next 12 months are recorded in accrued expenses and other current liabilities. The Company has elected to not apply the recognition requirement of ASC 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) to leases with a term of 12 months or less for all classes of assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="c-1" id="f-242">&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows ASC 450-20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to report accounting for contingencies. Certain conditions may exist as of the date the condensed financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company&#x2019;s condensed financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-243">&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration revenue is recognized in accordance with ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 606&#x201d;). Arrangements with collaborators may include licenses to intellectual property, research and development services, manufacturing services for clinical and commercial supply, and participation on joint steering committees. The Company evaluates the promised goods or services in the contract to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, the Company considers the stage of development of the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property and whether the promised goods or services are integral to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the amendment of an existing agreement, the Company evaluates whether the amendment represents a modification to an existing contract that would be recorded through a cumulative catch-up to revenue, prospective modification, or a separate contract. If it is determined that it is a separate contract, the Company will evaluate the necessary revenue recognition through the five-step process described below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When the Company concludes that a contract should be accounted for as a combined performance obligation and recognized over time, the Company must then determine the period over which revenue should be recognized and the method by which to measure revenue. The Company generally recognizes revenue using a cost-based input method. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes collaboration revenue in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services when its customer or collaborator obtains control of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;promised goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the following five steps are performed: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;i.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.73pt"&gt;identify the contract(s) with a customer;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.96pt"&gt;identify the performance obligations in the contract; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.19pt"&gt;determine the transaction price; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iv.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.73pt"&gt;allocate the transaction price to the performance obligations within the contract; and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;v.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt"&gt;recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company only applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company&#x2019;s arrangements may consist of a license of, or options to license, the Company&#x2019;s intellectual property and research, development and manufacturing services. The Company may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i)&#160;the customer can benefit from on its own or together with other readily available resources and (ii)&#160;are separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most-likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes variable consideration in the transaction price to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations that consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company&#x2019;s accompanying balance sheet. Deferred revenues expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability. Deferred revenues not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as non-current liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Company&#x2019;s collaboration revenue arrangements may include the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Up-front License Fees: If a license is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, up-front fees allocated to the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Milestone Payments: At the inception of an agreement that includes research and development milestone payments, the Company evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company first estimates the amount of the milestone payment that the Company could receive using either the expected value or the most-likely amount approach. The Company primarily uses the most-likely amount approach as that approach is generally most predictive for milestone payments with a binary outcome. The Company then considers whether any portion of that estimated amount is subject to the variable consideration constraint (that is, whether it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty). The Company updates the estimate of variable consideration included in the transaction price at each reporting date which includes updating the assessment of the likely amount of consideration and the application of the constraint to reflect current facts and circumstances. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalties: For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Company has not granted a development and commercialization license nor recognized any revenue related to sales-based royalties or milestone payments based on the level of sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and Development Services: The Company will record costs associated with development and process optimization activities as research and development expenses in the statements of operations and comprehensive loss consistent with ASC 730, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company considered the guidance in ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 808&#x201d;) and will recognize the payments received from these agreements as revenue when the related costs are incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License Revenue: License revenue is generated from granting third parties rights to certain of the Company&#x2019;s intellectual property, including research, development, and commercialization of specified product candidates. The Company evaluates each licensing arrangement to determine whether the license is distinct from other promised goods or services and whether the arrangement includes multiple performance obligations. If an arrangement includes multiple performance obligations, the transaction price is allocated to each performance obligation based on relative standalone selling prices. Upfront payments, including nonrefundable license fees, are recognized as revenue when the underlying performance obligation is satisfied. Milestone payments that are contingent on the occurrence of a future event are included in the transaction price only when it is probable that a significant reversal of cumulative revenue will not occur. Sales-based royalties, including milestone payments based on a level of sales, are recognized as revenue when the subsequent sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may also enter into arrangements that include non-cash consideration, such as equity instruments. In such cases, the Company measures the transaction price at the estimated fair value of the non-cash consideration received at contract inception and recognizes revenue when the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-244">&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred, and include salaries, stock-based compensation and other personnel-related costs, equipment and supplies, depreciation, nonclinical studies, clinical trials and manufacturing development activities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A substantial portion of the Company&#x2019;s ongoing research and development activities are conducted by third-party service providers, including CROs and CDMOs. The Company accrues for expenses resulting from obligations under agreements with CROs, CDMOs and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with CROs, CDMOs and other outside &lt;/span&gt;&lt;/div&gt;service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through an evaluation of the progress or stage of completion of the services. In the event advance payments are made to a CRO, CDMO or outside service provider, the payments will be recorded as a prepaid asset which will be amortized as the contracted services are performed. As actual costs become known, the Company adjusts its accruals and prepaid assets accordingly. Inputs, such as the services performed, the number of patients enrolled or the study duration, may vary from the Company&#x2019;s estimates, resulting in adjustments to research and development expenses in future periods. The Company makes significant judgments and estimates in determining the accrual and/or prepaid balance in each reporting period and changes in these estimates may result in material changes to the Company&#x2019;s accruals that could materially affect the Company&#x2019;s results of operations.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <sttk:WarrantsPolicyTextBlock contextRef="c-1" id="f-245">&lt;div style="margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock Warrants and Pre-Funded Warrants&lt;/span&gt;&lt;/div&gt;The Company&#x2019;s common stock warrants and pre-funded warrants are classified as a component of permanent stockholders&#x2019; equity within additional paid-in capital. The common stock warrants and pre-funded warrants are equity classified because they, (i) are freestanding financial instruments, (ii) are immediately exercisable, (iii) do not embody an obligation for the Company to repurchase its shares, (iv) permit the holders to receive a fixed number of shares of common stock upon exercise, (v) are indexed to the Company&#x2019;s common stock and, (vi) meet the equity classification criteria. In addition, such common stock warrants and pre-funded warrants do not provide any guarantee of value or return.</sttk:WarrantsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-246">&lt;div style="margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes the cost of stock-based awards issued to employees and nonemployees as compensation expense on a straight-line basis over the vesting period of the award, net of estimated forfeitures. Forfeiture estimates are based on historical cancellation data. The Company uses the Black-Scholes option pricing model to determine the grant-date fair value of stock options. The fair values of restricted stock units (&#x201c;RSUs&#x201d;) are based on the fair value of the Company&#x2019;s common stock on the date of the grant. The Company also grants stock options that vest upon achievement of certain market-based conditions. The Company uses the Monte Carlo pricing model to estimate the fair value of options that have market-based conditions. The Company adjusts expense for forfeitures in the periods they occur.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-247">&lt;div style="margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statements and the tax bases of assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in tax rates on deferred tax assets and liabilities will be recognized in the period that includes the enactment date. Additionally, any changes in income tax laws are immediately recognized in the year of enactment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A valuation allowance is established against the deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. The deferred tax assets and liabilities are classified as noncurrent along with the related valuation allowance. Due to a lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on the technical merits, as the largest amount of benefits that is more likely than not to be realized upon the ultimate settlement. The Company&#x2019;s policy is to recognize interest and penalties related to the unrecognized tax benefits as a component of income tax expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-248">&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Basic shares outstanding includes the weighted average effect of the Company&#x2019;s outstanding 38,448,034 pre-funded warrants as of March&#160;31, 2026, the exercise of which requires nominal consideration for the delivery of an equal number of shares of common stock. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock or convertible notes, if any, &lt;/span&gt;&lt;/div&gt;stock options and unvested shares of restricted stock, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-45"
      decimals="INF"
      id="f-249"
      unitRef="shares">38448034</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-250">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding as they would be anti-dilutive:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.092%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.484%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47,487,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,064,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,458,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;589,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;527,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;61,141,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,986,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-46" decimals="0" id="f-251" unitRef="shares">47487573</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-47" decimals="0" id="f-252" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-48" decimals="0" id="f-253" unitRef="shares">13064499</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-49" decimals="0" id="f-254" unitRef="shares">8458834</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-50" decimals="0" id="f-255" unitRef="shares">589803</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-51" decimals="0" id="f-256" unitRef="shares">527453</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-257" unitRef="shares">61141875</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-5" decimals="0" id="f-258" unitRef="shares">8986287</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c-1" id="f-259">&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Comprehensive Income (Loss) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Other comprehensive income (loss) is comprised of unrealized gains and losses on short-term investments.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-260">&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in this update are intended to enhance the transparency and decision usefulness of income tax disclosures primarily through changes to the rate reconciliation and income taxes paid information. This update is effective for annual periods beginning after December 15, 2024, and may be applied prospectively or retrospectively. The Company has retrospectively adopted this ASU in the financial statements for the year ending December&#160;31, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (&#x201c;ASU 2024-03&#x201d;), which is intended to provide more detailed information about specified categories of expenses (employee compensation, depreciation, and amortization) included in certain expense captions presented on the statement of operations. The guidance in this ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either, (i) prospectively to financial statements issued for periods after the effective date of this ASU or, (ii) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="c-1" id="f-261">Investments &lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the Company&#x2019;s investments by major security type (amounts in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.611%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.611%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Gain&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market fund&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;88,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;88,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;88,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;88,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.611%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.611%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market fund&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's money market funds are calculated using level 1 inputs and the Company's U.S. government securities are valued using level 2 inputs. U.S. government securities outstanding as of December&#160;31, 2025 matured in January 2026. There were no impairments of U.S. government securities or money market funds for the three months ended March&#160;31, 2026 and the year ended&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a related party investment in a private company&#x2019;s preferred stock. The Company did not identify any impairment indicators or observable price changes for this investment as of March&#160;31, 2026. The Company had no other investments held at March&#160;31, 2026 other than those included in the table above.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="c-1" id="f-262">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the Company&#x2019;s investments by major security type (amounts in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.611%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.611%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Gain&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market fund&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;88,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;88,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;88,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;88,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.611%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.611%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market fund&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-52" decimals="-3" id="f-263" unitRef="usd">88860000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax contextRef="c-52" decimals="-3" id="f-264" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-52" decimals="-3" id="f-265" unitRef="usd">88860000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-3" decimals="-3" id="f-266" unitRef="usd">88860000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax contextRef="c-3" decimals="-3" id="f-267" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-3" decimals="-3" id="f-268" unitRef="usd">88860000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-53" decimals="-3" id="f-269" unitRef="usd">23867000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax contextRef="c-53" decimals="-3" id="f-270" unitRef="usd">6000</us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-53" decimals="-3" id="f-271" unitRef="usd">23873000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-54" decimals="-3" id="f-272" unitRef="usd">52270000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax contextRef="c-54" decimals="-3" id="f-273" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-54" decimals="-3" id="f-274" unitRef="usd">52270000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-4" decimals="-3" id="f-275" unitRef="usd">76137000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax contextRef="c-4" decimals="-3" id="f-276" unitRef="usd">6000</us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-4" decimals="-3" id="f-277" unitRef="usd">76143000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal contextRef="c-1" decimals="INF" id="f-278" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal contextRef="c-55" decimals="INF" id="f-279" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c-1" id="f-280">Accrued Expenses and Other Current Liabilities&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following (amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development contract costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation and related benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-281">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following (amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development contract costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation and related benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <sttk:AccruedResearchAndDevelopmentContractCostsCurrent contextRef="c-3" decimals="-3" id="f-282" unitRef="usd">1057000</sttk:AccruedResearchAndDevelopmentContractCostsCurrent>
    <sttk:AccruedResearchAndDevelopmentContractCostsCurrent contextRef="c-4" decimals="-3" id="f-283" unitRef="usd">1111000</sttk:AccruedResearchAndDevelopmentContractCostsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-284" unitRef="usd">852000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-285" unitRef="usd">837000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-286" unitRef="usd">752000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-287" unitRef="usd">2767000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-288" unitRef="usd">335000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-289" unitRef="usd">236000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <sttk:AccruedLiabilitiesAndOtherLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-290" unitRef="usd">2996000</sttk:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <sttk:AccruedLiabilitiesAndOtherLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-291" unitRef="usd">4951000</sttk:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-292">Commitments and Contingencies &lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Leases &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases certain office space, laboratory facilities, and equipment. These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain of these leases also include renewal options at the election of the Company to renew or extend the lease. These optional periods have not been considered in the determination of the ROU assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options. The Company performed evaluations of its contracts and determined it has operating leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2026, the Company entered into an amendment to extend the term of its lease for the Austin, Texas office location. The amendment extended the non-cancelable lease term to December 31, 2029 and increased the total contractual lease payments due over the revised lease term. In accordance with ASC 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company remeasured the existing lease liability as of the modification date and as a result, recorded an increase to the ROU asset and liability of approximately $0.7&#160;million during the three months ended March 31, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no other material changes in the Company's operating leases as compared to the operating leases disclosed in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may become involved in various legal actions arising in the ordinary course of business. As of March&#160;31, 2026, the Company was not aware of any existing, pending, or threatened legal actions that would have a material impact on the financial position, results of operations, or cash flows of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contractual Obligations &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contractual obligations represent future cash commitments and liabilities under agreements with third parties, and exclude contingent liabilities for which the Company cannot reasonably predict future payment. The Company&#x2019;s contractual obligations result primarily from obligations for various CDMOs and CROs, which include potential payments that may be required under its agreements. The contracts also contain variable costs and milestones that are hard to predict, as they are based on such things as patients enrolled and clinical trial sites. The timing of payments and actual amounts paid under CDMO and CRO agreements may be different depending on the timing of receipt of goods or services or changes to agreed-upon terms or amounts for some obligations. Such agreements are cancellable upon written notice by the Company and, therefore, are not long-term liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <sttk:IncreaseDecreaseInOperatingLeasesRightOfUseAssetsLiability contextRef="c-1" decimals="-5" id="f-293" unitRef="usd">700000</sttk:IncreaseDecreaseInOperatingLeasesRightOfUseAssetsLiability>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-294">Related Party License Revenue&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2025, the Company granted Kayak Therapeutics, Inc. ("Kayak") an exclusive license (the "Kayak Agreement") to its oncology-focused TRIM7 program. Pursuant to the Kayak Agreement, as the upfront consideration, the Company received preferred stock in Kayak with a fair market value of $1.0&#160;million and recognized that consideration as license revenue. The Company also subleases certain lab space, office space, and lab equipment to Kayak for one year for total consideration of $0.3&#160;million. In November 2025, an officer of the Company was elected to the board of directors of Kayak and as a result, Kayak became a related party. Payments received pursuant to the sublease for the three months ended March&#160;31, 2026 were $0.1&#160;million and recorded as a reduction to research and development expenses. &lt;/span&gt;&lt;/div&gt;Pursuant to the Kayak Agreement, the Company is also eligible to receive future payments contingent upon the achievement of specified development, regulatory, and commercial milestones of up to $86.0 million, and tiered royalties on net sales of any commercialized products subject to the Kayak Agreement in the low single digits. Such future payments are considered variable consideration and will be recognized as revenue only when the underlying contingencies are resolved and it is probable that a significant reversal of revenue will not occur.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-56" decimals="-5" id="f-295" unitRef="usd">1000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sttk:SubleaseAgreementConsideration contextRef="c-56" decimals="-5" id="f-296" unitRef="usd">300000</sttk:SubleaseAgreementConsideration>
    <us-gaap:SubleaseIncome contextRef="c-57" decimals="-5" id="f-297" unitRef="usd">100000</us-gaap:SubleaseIncome>
    <us-gaap:AccountsReceivableNet contextRef="c-58" decimals="-5" id="f-298" unitRef="usd">86000000.0</us-gaap:AccountsReceivableNet>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-299">Equity&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is authorized to issue up to 300,000,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;shares of common stock and 10,000,000 shares of preferred stock, all with a par value of $0.0001 per share. The holders of the Company&#x2019;s common stock are entitled to one vote per share on all matters submitted to a vote of stockholders. The Company&#x2019;s common stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking fund provisions. Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of the Company&#x2019;s common stock will receive ratably any dividends declared by the Company&#x2019;s board of directors (the &#x201c;Board&#x201d;) out of funds legally available. In the event of the Company&#x2019;s liquidation, dissolution or winding-up, the holders of the Company&#x2019;s common stock will be entitled to share ratably in all assets remaining after payment of or provision for any liabilities. As of the periods presented, no common stock dividends had been declared by the Board. As of March&#160;31, 2026, none of the 10,000,000 shares of preferred stock were outstanding, and the Company has no present plans to issue any shares of preferred stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the Company sold 4,651,163 shares of common stock through an underwritten public offering, and concurrently completed a private placement of 3,100,823 pre-funded warrants. The purchase price per share of common stock was $6.45, and the purchase price per pre-funded warrant was $6.4499, which was the purchase price per share of common stock minus the $0.0001 per share exercise price of the pre-funded warrant. Each pre-funded warrant may be exercised for one share of common stock, is immediately exercisable, does not expire, and is subject to a beneficial ownership limitation of 9.99% on a post-exercise basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2025, the Company issued and sold 15,225,158 shares of common stock, pre-funded warrants to purchase up to 37,410,188 shares of common stock, and accompanying common stock warrants to purchase up to 52,635,346 shares of common stock or pre-funded warrants in a private placement offering with certain institutional accredited investors. The purchase price of each share of common stock and accompanying common stock warrant was $0.8677, and the purchase price of each pre-funded warrant and accompanying common stock warrant was $0.8676, which was the purchase price per share of common stock and accompanying common stock warrant, minus the $0.0001 per share exercise price of the pre-funded warrants. Each pre-funded warrant may be exercised for one share of common stock, is immediately exercisable, does not expire, and is subject to a beneficial ownership &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;limitations of up to 9.99% on a post-exercise basis.  Two beneficial owners of 10% or more of our common stock participated in the private placement offering with the same terms as all other participants in the offering. Together, the beneficial owners purchased 8,963,785 pre-funded warrants in lieu of common stock and received accompanying common stock warrants to purchase an additional 8,963,785 shares of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2026, 6,929,032 pre-funded warrants were exercised and as of March&#160;31, 2026, 38,448,034 pre-funded warrants remain outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each common stock warrant has an exercise price of $1.0846 and is exercisable at any time after the date of issuance for one share of common stock or pre-funded warrant in lieu thereof. The common stock warrants will expire on the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Company&#x2019;s Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2026, 5,019,719 common stock warrants were exercised for gross proceeds of $5.4 million in exchange for 4,866,055 pre-funded warrants with an exercise price of $0.0001 and 153,664 shares of common stock. As of March&#160;31, 2026, 47,487,573 common stock warrants remain outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2026, the Company entered into a sales agreement (the &#x201c;Sales Agreement&#x201d;) with Leerink Partners, LLC (the &#x201c;Sales Agent&#x201d;), pursuant to which it may offer and sell up to $75.0 million of shares of its common stock from time to time through an at the market offering facility (the &#x201c;ATM Facility&#x201d;). The Sales Agent is generally entitled to compensation at a commission equal to up to 3% of the aggregate gross sales price per share sold under the Sales Agreement. For the three months ended March 31, 2026, the Company sold 5,000,000 shares of common stock for $4.28 per share for gross proceeds of $21.4&#160;million through the ATM Facility.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-300" unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-301" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-302"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-303"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <sttk:CommonStockNumberOfVotesPerCommonShare contextRef="c-3" decimals="INF" id="f-304" unitRef="vote">1</sttk:CommonStockNumberOfVotesPerCommonShare>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-305" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-306" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-59" decimals="INF" id="f-307" unitRef="usd">4651163</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-60"
      decimals="INF"
      id="f-308"
      unitRef="shares">3100823</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-61"
      decimals="INF"
      id="f-309"
      unitRef="usdPerShare">6.45</us-gaap:SaleOfStockPricePerShare>
    <sttk:ClassOfWarrantOrRightPriceOfPreFundedWarrants
      contextRef="c-62"
      decimals="INF"
      id="f-310"
      unitRef="usdPerShare">6.4499</sttk:ClassOfWarrantOrRightPriceOfPreFundedWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-62"
      decimals="INF"
      id="f-311"
      unitRef="usdPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-62"
      decimals="INF"
      id="f-312"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <sttk:ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise
      contextRef="c-62"
      decimals="INF"
      id="f-313"
      unitRef="number">0.0999</sttk:ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-63"
      decimals="INF"
      id="f-314"
      unitRef="shares">15225158</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-64"
      decimals="INF"
      id="f-315"
      unitRef="shares">37410188</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-65"
      decimals="INF"
      id="f-316"
      unitRef="shares">52635346</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-66"
      decimals="INF"
      id="f-317"
      unitRef="usdPerShare">0.8677</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-67"
      decimals="INF"
      id="f-318"
      unitRef="usdPerShare">0.8676</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-67"
      decimals="INF"
      id="f-319"
      unitRef="usdPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-67"
      decimals="INF"
      id="f-320"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <sttk:ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise
      contextRef="c-68"
      decimals="INF"
      id="f-321"
      unitRef="number">0.0999</sttk:ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-69"
      decimals="INF"
      id="f-322"
      unitRef="shares">8963785</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-69"
      decimals="INF"
      id="f-323"
      unitRef="shares">8963785</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <sttk:ClassOfWarrantOrRightWarrantsExercised
      contextRef="c-70"
      decimals="INF"
      id="f-324"
      unitRef="shares">6929032</sttk:ClassOfWarrantOrRightWarrantsExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-45"
      decimals="INF"
      id="f-325"
      unitRef="shares">38448034</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-71"
      decimals="INF"
      id="f-326"
      unitRef="usdPerShare">1.0846</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-71"
      decimals="INF"
      id="f-327"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <sttk:ClassOfWarrantOrRightWarrantsExercised
      contextRef="c-15"
      decimals="INF"
      id="f-328"
      unitRef="shares">5019719</sttk:ClassOfWarrantOrRightWarrantsExercised>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c-15" decimals="-5" id="f-329" unitRef="usd">5400000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-45"
      decimals="INF"
      id="f-330"
      unitRef="shares">4866055</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-45"
      decimals="INF"
      id="f-331"
      unitRef="usdPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <sttk:StockIssuedDuringPeriodSharesWarrantExercises
      contextRef="c-13"
      decimals="INF"
      id="f-332"
      unitRef="shares">153664</sttk:StockIssuedDuringPeriodSharesWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-72"
      decimals="INF"
      id="f-333"
      unitRef="shares">47487573</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sttk:SaleOfStockMaximumAggregateSalesPrice contextRef="c-73" decimals="-5" id="f-334" unitRef="usd">75000000.0</sttk:SaleOfStockMaximumAggregateSalesPrice>
    <sttk:SaleOfStockCommissionPercentage
      contextRef="c-73"
      decimals="INF"
      id="f-335"
      unitRef="number">0.03</sttk:SaleOfStockCommissionPercentage>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-74"
      decimals="INF"
      id="f-336"
      unitRef="shares">5000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-75"
      decimals="INF"
      id="f-337"
      unitRef="usdPerShare">4.28</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-74" decimals="-5" id="f-338" unitRef="usd">21400000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-339">Stock-Based Compensation and Employee Benefit Plans&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, the Company adopted the 2020 Stock Incentive Plan (the &#x201c;2020 Plan&#x201d;) which, as of the adoption date, replaced the 2016 Stock Incentive Plan. Under the 2020 Plan, the share reserve automatically increases on January 1st of each year beginning in 2021 and ending with a final increase on January 1, 2030 in an amount equal to 4% of the Company&#x2019;s outstanding shares of common stock on December 31st of the preceding calendar year. The Board may provide that there will be no increase in the share reserve for any such year or that the increase in the share reserve may be smaller than would otherwise occur. On January 1, 2026, the share reserve automatically increased by 2,531,194 shares. As of March&#160;31, 2026, there were 1,559,581 shares available for future grants. The 2020 Plan permits the granting of options, stock appreciation rights, restricted stock units (&#x201c;RSUs&#x201d;), performance stock and performance cash awards. The terms of the agreements under the 2020 Plan are determined by the Board. The Company&#x2019;s awards generally vest over four years and have a term of 10 years. Periodically, the Company also grants awards that vest based on the Company's stock achieving certain closing share prices for a specified number of consecutive trading days.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2020 Employee Stock Purchase Plan (the &#x201c;2020 ESPP&#x201d;) became effective in October 2020. Eligible employees may purchase shares of common stock under the 2020 ESPP at 85% of the lower of the fair market value of the Company&#x2019;s common stock as of the first or the last day of each offering period. Employees are limited to contributing 15% of the employee&#x2019;s eligible compensation and may not purchase more than $25,000 of stock during any calendar year or more than 2,000 shares during any one purchase period. The 2020 ESPP share reserve automatically increases on January 1st of each calendar year, for ten years, commencing on January 1, 2021, in an amount equal to 1% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year. The Board may act prior to January 1st of a given year to provide that there will be no January 1st increase of the share reserve for such year or that the increase in the share reserve for such year will be a smaller number of shares of common stock than would otherwise occur pursuant to the preceding sentence. The Board elected not to increase the share reserve for the ESPP on January 1, 2026. As of March&#160;31, 2026, there were 1,660,870 shares available for future purchases. There were 30,916 and 6,859 shares issued under the Company&#x2019;s 2020 ESPP during the three months ended March&#160;31, 2026 and 2025, respectively, in each case for aggregate proceeds of less than $0.1&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense in the following expense categories of its accompanying unaudited interim condensed statements of operations and comprehensive loss (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.134%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.044%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.376%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.044%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.702%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes option activity under the 2020 Plan for the three months ended March&#160;31, 2026:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.375%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.886%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise&#160;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Remaining&#160;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at December&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,648,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.06&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,642,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(38,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(188,616)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at March&#160;31, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,064,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.89&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,106,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.29&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercisable at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,096,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.67&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted during the three months ended March&#160;31, 2026 and 2025 had weighted-average grant-date fair values of $4.02 and $0.96 per share, respectively. As of March&#160;31, 2026, the unrecognized compensation cost for options issued was $24.6 million and will be recognized over an estimated weighted-average amortization period of 1.69 years. The total intrinsic value of options exercised during the three months ended March&#160;31, 2026 was $0.2 million. There were no options exercised during the three months ended March 31, 2025. The aggregate intrinsic value of options outstanding and exercisable as of March&#160;31, 2026 was $11.7 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes employee RSU activity for the three months ended March&#160;31, 2026:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.455%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.780%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.080%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.559%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Grant Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at December&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;481,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;316,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(206,513)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(861)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.67&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at March&#160;31, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;589,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized $0.4&#160;million and $0.3 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of stock-based compensation cost related to RSUs for the three months ended March&#160;31, 2026 and 2025, respectively. As of March&#160;31, 2026, the unrecognized compensation cost for RSUs issued was $3.5 million and will be recognized over an estimated weighted-average amortization period of 2.60 years. The fair values of RSUs are based on the fair value of the Company&#x2019;s common stock on the date of the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Stock Options and Shares Issued&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for stock-based compensation by measuring and recognizing as compensation expense the fair value of all share-based payment awards made to employees, including employee stock options and restricted stock awards. The Company uses the Black-Scholes option pricing model to estimate the fair value of employee stock options that only have service or performance conditions. The inputs to the Black-Scholes option  pricing model require a number of management estimates such as the expected term, volatility, risk-free interest rate and dividend yield. The fair value of stock options was determined using the methods and assumptions discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;The expected term of employee stock options with service-based vesting is determined using the &#x201c;simplified&#x201d; method, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company&#x2019;s lack of sufficient historical data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;The expected stock price volatility assumption is based on the historical volatilities of the common stock of a peer group of publicly traded companies as well as the historical volatility of the Company&#x2019;s common stock since the Company began trading subsequent to the Company&#x2019;s initial public offering (&#x201c;IPO&#x201d;) in October 2020 over the period corresponding to the expected life as of the grant date. The historical volatility data was computed using the daily closing prices during the equivalent period of the calculated expected term of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of the Company&#x2019;s stock price becomes available, or until circumstances change, such that the identified entities are no longer comparable companies. In the latter case, other suitable, similar entities whose share prices are publicly available would be utilized in the calculation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the expected term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;The expected dividend yield is 0% because the Company has not historically paid, and does not expect, for the foreseeable future, to pay dividends on its common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Prior to the Company&#x2019;s IPO, the Board periodically estimated the fair value of the Company&#x2019;s common stock considering, among other things, contemporaneous valuations of its common stock prepared by an unrelated third-party valuation firm. Subsequent to the Company&#x2019;s IPO, options are issued with a strike price no less than the market price on date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant-date fair value of options calculated using the Black-Scholes option pricing model granted under the Company&#x2019;s 2020 Plan were estimated using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.673%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.444%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.174%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.175%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2020 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term - years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;110.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;101.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant-date fair value of shares issued calculated using the Black-Scholes option pricing model under the Company&#x2019;s 2020 ESPP were estimated using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.352%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.720%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.711%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.035%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2020 ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term - years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;109.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;107.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage
      contextRef="c-76"
      decimals="INF"
      id="f-340"
      unitRef="number">0.04</sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage>
    <sttk:CommonStockAdditionalCapitalSharesReservedForFutureIssuance
      contextRef="c-77"
      decimals="INF"
      id="f-341"
      unitRef="shares">2531194</sttk:CommonStockAdditionalCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-78"
      decimals="INF"
      id="f-342"
      unitRef="shares">1559581</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-79" id="f-343">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-79" id="f-344">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c-80"
      decimals="INF"
      id="f-345"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="c-81"
      decimals="INF"
      id="f-346"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue contextRef="c-80" decimals="-3" id="f-347" unitRef="usd">25000000</sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
      contextRef="c-80"
      decimals="INF"
      id="f-348"
      unitRef="shares">2000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
    <sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm contextRef="c-80" id="f-349">P10Y</sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm>
    <sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage
      contextRef="c-81"
      decimals="INF"
      id="f-350"
      unitRef="number">0.01</sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage>
    <sttk:CommonStockAdditionalCapitalSharesReservedForFutureIssuance
      contextRef="c-82"
      decimals="INF"
      id="f-351"
      unitRef="shares">1660870</sttk:CommonStockAdditionalCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-82"
      decimals="INF"
      id="f-352"
      unitRef="shares">30916</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-83"
      decimals="INF"
      id="f-353"
      unitRef="shares">6859</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ProceedsFromStockPlans contextRef="c-82" decimals="-5" id="f-354" unitRef="usd">100000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans contextRef="c-83" decimals="-5" id="f-355" unitRef="usd">100000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-356">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense in the following expense categories of its accompanying unaudited interim condensed statements of operations and comprehensive loss (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.134%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.044%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.376%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.044%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.702%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-84" decimals="-3" id="f-357" unitRef="usd">1036000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-85" decimals="-3" id="f-358" unitRef="usd">687000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-86" decimals="-3" id="f-359" unitRef="usd">1379000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-87" decimals="-3" id="f-360" unitRef="usd">1034000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-361" unitRef="usd">2415000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-5" decimals="-3" id="f-362" unitRef="usd">1721000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-363">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes option activity under the 2020 Plan for the three months ended March&#160;31, 2026:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.375%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.886%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise&#160;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Remaining&#160;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at December&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,648,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.06&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,642,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(38,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(188,616)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at March&#160;31, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,064,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.89&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,106,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.29&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercisable at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,096,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.67&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="INF" id="f-364" unitRef="shares">8648715</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-365"
      unitRef="usdPerShare">5.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-55" id="f-366">P7Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-367" unitRef="shares">4642400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-368"
      unitRef="usdPerShare">4.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-369" unitRef="shares">38000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-370"
      unitRef="usdPerShare">0.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="INF" id="f-371" unitRef="shares">188616</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-372"
      unitRef="usdPerShare">7.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-3" decimals="INF" id="f-373" unitRef="shares">13064499</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-374"
      unitRef="usdPerShare">5.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-375">P7Y10M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="c-3" decimals="INF" id="f-376" unitRef="shares">7106588</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-377"
      unitRef="usdPerShare">3.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-378">P9Y3M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-3" decimals="INF" id="f-379" unitRef="shares">5096229</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-380"
      unitRef="usdPerShare">6.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-381">P5Y8M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-382"
      unitRef="usdPerShare">4.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-5"
      decimals="2"
      id="f-383"
      unitRef="usdPerShare">0.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-3" decimals="-5" id="f-384" unitRef="usd">24600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-88" id="f-385">P1Y8M8D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-5" id="f-386" unitRef="usd">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-5" decimals="-5" id="f-387" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-3" decimals="-5" id="f-388" unitRef="usd">11700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock contextRef="c-1" id="f-389">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes employee RSU activity for the three months ended March&#160;31, 2026:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.455%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.780%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.080%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.559%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Grant Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at December&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;481,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;316,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(206,513)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(861)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.67&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at March&#160;31, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;589,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-89"
      decimals="INF"
      id="f-390"
      unitRef="shares">481177</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-89"
      decimals="2"
      id="f-391"
      unitRef="usdPerShare">8.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-90"
      decimals="INF"
      id="f-392"
      unitRef="shares">316000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-90"
      decimals="2"
      id="f-393"
      unitRef="usdPerShare">4.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-90"
      decimals="INF"
      id="f-394"
      unitRef="shares">206513</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-90"
      decimals="2"
      id="f-395"
      unitRef="usdPerShare">7.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-90"
      decimals="INF"
      id="f-396"
      unitRef="shares">861</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-90"
      decimals="2"
      id="f-397"
      unitRef="usdPerShare">8.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-91"
      decimals="INF"
      id="f-398"
      unitRef="shares">589803</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-91"
      decimals="2"
      id="f-399"
      unitRef="usdPerShare">6.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-90" decimals="-5" id="f-400" unitRef="usd">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-92" decimals="-5" id="f-401" unitRef="usd">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-91" decimals="-5" id="f-402" unitRef="usd">3500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-90" id="f-403">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-88"
      decimals="INF"
      id="f-404"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-405">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant-date fair value of options calculated using the Black-Scholes option pricing model granted under the Company&#x2019;s 2020 Plan were estimated using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.673%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.444%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.174%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.175%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2020 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term - years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;110.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;101.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant-date fair value of shares issued calculated using the Black-Scholes option pricing model under the Company&#x2019;s 2020 ESPP were estimated using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.352%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.720%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.711%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.035%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2020 ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term - years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;109.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;107.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-93" id="f-406">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-94" id="f-407">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-93" decimals="3" id="f-408" unitRef="number">1.104</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-94" decimals="3" id="f-409" unitRef="number">1.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-93" decimals="3" id="f-410" unitRef="number">0.038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-94" decimals="3" id="f-411" unitRef="number">0.044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-93" decimals="3" id="f-412" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-94" decimals="3" id="f-413" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-95" id="f-414">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-96" id="f-415">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-95" decimals="3" id="f-416" unitRef="number">1.097</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-96" decimals="3" id="f-417" unitRef="number">1.078</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-95" decimals="4" id="f-418" unitRef="number">0.0392</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-96" decimals="4" id="f-419" unitRef="number">0.0470</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-95" decimals="3" id="f-420" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-96" decimals="3" id="f-421" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-422">Segment Reporting&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has one reportable and operating segment, which is engaged in the business of drug discovery and development. The Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;) is the Company&#x2019;s chief executive officer. The CODM uses the Company&#x2019;s net loss to monitor actual results versus the budget in assessing segment performance and the allocation of resources. The measure of segment assets is reported on the balance sheets as total assets. Accounting policies for segment reporting are the same as the accounting policies disclosed in Note 2.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth information about the Company&#x2019;s single reportable segment and the significant expenses reviewed by the CODM, including a reconciliation to net loss (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.697%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.680%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.442%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.681%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SL-325&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;2,3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development non-equity compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development equity compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative expenses:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative non-equity compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative equity compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other general and administrative including legal and accounting fees, facilities, insurance, travel and depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expense from operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(15,545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(14,389)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;778&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net Loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(14,767)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(13,702)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expenses for SL-325 that were incurred prior to it being nominated a product candidate are included in &#x201c;other research and development&#x201d;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Other research and development expense includes technical operations expense of $1.9 million and $2.4 million, research activities for other pipeline compounds and facility expenses of $1.9 million and $1.3 million and depreciation expense of $0.9 million and $0.9 million for the three months ended March 31, 2026 and 2025, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other research and development expense includes a gain of $0.7 million due to a change in estimate and expense of $2.0 million for the three months ended March 31, 2026 and 2025, respectively, related to SL-172154 which was discontinued in October 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-423"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-424"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-425">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth information about the Company&#x2019;s single reportable segment and the significant expenses reviewed by the CODM, including a reconciliation to net loss (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.697%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.680%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.442%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.681%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SL-325&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;2,3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development non-equity compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development equity compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative expenses:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative non-equity compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative equity compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other general and administrative including legal and accounting fees, facilities, insurance, travel and depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expense from operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(15,545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(14,389)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;778&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net Loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(14,767)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(13,702)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expenses for SL-325 that were incurred prior to it being nominated a product candidate are included in &#x201c;other research and development&#x201d;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Other research and development expense includes technical operations expense of $1.9 million and $2.4 million, research activities for other pipeline compounds and facility expenses of $1.9 million and $1.3 million and depreciation expense of $0.9 million and $0.9 million for the three months ended March 31, 2026 and 2025, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other research and development expense includes a gain of $0.7 million due to a change in estimate and expense of $2.0 million for the three months ended March 31, 2026 and 2025, respectively, related to SL-172154 which was discontinued in October 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-97" decimals="-3" id="f-426" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-98" decimals="-3" id="f-427" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-99" decimals="-3" id="f-428" unitRef="usd">2861000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-100" decimals="-3" id="f-429" unitRef="usd">2229000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-101" decimals="-3" id="f-430" unitRef="usd">4667000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-102" decimals="-3" id="f-431" unitRef="usd">4606000</us-gaap:ResearchAndDevelopmentExpense>
    <sttk:ResearchAndDevelopmentNonEquityCompensation contextRef="c-97" decimals="-3" id="f-432" unitRef="usd">2382000</sttk:ResearchAndDevelopmentNonEquityCompensation>
    <sttk:ResearchAndDevelopmentNonEquityCompensation contextRef="c-98" decimals="-3" id="f-433" unitRef="usd">2397000</sttk:ResearchAndDevelopmentNonEquityCompensation>
    <sttk:ResearchAndDevelopmentEquityCompensation contextRef="c-97" decimals="-3" id="f-434" unitRef="usd">1036000</sttk:ResearchAndDevelopmentEquityCompensation>
    <sttk:ResearchAndDevelopmentEquityCompensation contextRef="c-98" decimals="-3" id="f-435" unitRef="usd">687000</sttk:ResearchAndDevelopmentEquityCompensation>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-97" decimals="-3" id="f-436" unitRef="usd">10946000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-98" decimals="-3" id="f-437" unitRef="usd">9919000</us-gaap:ResearchAndDevelopmentExpense>
    <sttk:GeneralAndAdministrativeNonEquityCompensation contextRef="c-97" decimals="-3" id="f-438" unitRef="usd">1427000</sttk:GeneralAndAdministrativeNonEquityCompensation>
    <sttk:GeneralAndAdministrativeNonEquityCompensation contextRef="c-98" decimals="-3" id="f-439" unitRef="usd">1353000</sttk:GeneralAndAdministrativeNonEquityCompensation>
    <sttk:GeneralAndAdministrativeEquityCompensation contextRef="c-97" decimals="-3" id="f-440" unitRef="usd">1379000</sttk:GeneralAndAdministrativeEquityCompensation>
    <sttk:GeneralAndAdministrativeEquityCompensation contextRef="c-98" decimals="-3" id="f-441" unitRef="usd">1033000</sttk:GeneralAndAdministrativeEquityCompensation>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="c-97" decimals="-3" id="f-442" unitRef="usd">1793000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="c-98" decimals="-3" id="f-443" unitRef="usd">2084000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-97" decimals="-3" id="f-444" unitRef="usd">4599000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-98" decimals="-3" id="f-445" unitRef="usd">4470000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-97" decimals="-3" id="f-446" unitRef="usd">15545000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-98" decimals="-3" id="f-447" unitRef="usd">14389000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-97" decimals="-3" id="f-448" unitRef="usd">-15545000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-98" decimals="-3" id="f-449" unitRef="usd">-14389000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-97" decimals="-3" id="f-450" unitRef="usd">778000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-98" decimals="-3" id="f-451" unitRef="usd">687000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c-97" decimals="-3" id="f-452" unitRef="usd">-14767000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-98" decimals="-3" id="f-453" unitRef="usd">-13702000</us-gaap:NetIncomeLoss>
    <sttk:OtherResearchAndDevelopmentExpenseTechnicalOperations contextRef="c-101" decimals="-5" id="f-454" unitRef="usd">1900000</sttk:OtherResearchAndDevelopmentExpenseTechnicalOperations>
    <sttk:OtherResearchAndDevelopmentExpenseTechnicalOperations contextRef="c-102" decimals="-5" id="f-455" unitRef="usd">2400000</sttk:OtherResearchAndDevelopmentExpenseTechnicalOperations>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c-101" decimals="-5" id="f-456" unitRef="usd">1900000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c-102" decimals="-5" id="f-457" unitRef="usd">1300000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:Depreciation contextRef="c-101" decimals="-5" id="f-458" unitRef="usd">900000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-102" decimals="-5" id="f-459" unitRef="usd">900000</us-gaap:Depreciation>
    <sttk:OtherResearchAndDevelopmentExpenseTechnicalOperations contextRef="c-103" decimals="-3" id="f-460" unitRef="usd">-700000</sttk:OtherResearchAndDevelopmentExpenseTechnicalOperations>
    <sttk:OtherResearchAndDevelopmentExpenseTechnicalOperations contextRef="c-104" decimals="-3" id="f-461" unitRef="usd">2000000.0</sttk:OtherResearchAndDevelopmentExpenseTechnicalOperations>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-105" id="f-462">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 2, 2026, Arunthathy Nirmalini (Lini) Pandite, M.B.Ch.B., the Company's Chief Medical Officer, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act (a &#x201c;10b5-1 Plan&#x201d;). Dr. Pandite&#x2019;s 10b5-1 Plan provides for the potential sale of up to 83,514 shares of the Company&#x2019;s common stock and will expire on the earlier of June 30, 2027 or the date when all shares under Dr. Pandite&#x2019;s 10b5-1 Plan are sold.&lt;/span&gt;&lt;/div&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrAdoptionDate contextRef="c-105" id="f-463">February 2, 2026</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName contextRef="c-105" id="f-464">Arunthathy Nirmalini (Lini) Pandite, M.B.Ch.B.,</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-105" id="f-465">Chief Medical Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-105" id="f-466">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-106"
      decimals="INF"
      id="f-467"
      unitRef="shares">83514</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate contextRef="c-105" id="f-468">June 30, 2027</ecd:TrdArrExpirationDate>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-107" id="f-469">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 2, 2026, Abhinav Shukla, PhD., the Company's Chief Technical Officer, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. Dr. Shukla&#x2019;s 10b5-1 Plan provides for the potential exercise of stock options to purchase up to 168,659 shares of the Company's common stock and subsequent sale of a portion of the exercised options to cover the exercise price and estimated income taxes associated with the exercise. The 10b5-1 Plan will expire on the earlier of January 29, 2027 or the date when all shares under Dr. Shuckla&#x2019;s 10b5-1 Plan are exercised.&lt;/span&gt;&lt;/div&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrAdoptionDate contextRef="c-107" id="f-470">February 2, 2026</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName contextRef="c-107" id="f-471">Abhinav Shukla, PhD.,</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-107" id="f-472">Chief Technical Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-107" id="f-473">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-108"
      decimals="INF"
      id="f-474"
      unitRef="shares">168659</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate contextRef="c-107" id="f-475">January 29, 2027</ecd:TrdArrExpirationDate>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-1" id="f-476">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-1" id="f-477">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-1" id="f-478">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
